<SEC-DOCUMENT>0001728117-25-000021.txt : 20250313
<SEC-HEADER>0001728117-25-000021.hdr.sgml : 20250313
<ACCEPTANCE-DATETIME>20250313160137
ACCESSION NUMBER:		0001728117-25-000021
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250313
DATE AS OF CHANGE:		20250313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gossamer Bio, Inc.
		CENTRAL INDEX KEY:			0001728117
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				475461709
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38796
		FILM NUMBER:		25735631

	BUSINESS ADDRESS:	
		STREET 1:		3115 MERRYFIELD ROW
		STREET 2:		SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 684-1300

	MAIL ADDRESS:	
		STREET 1:		3115 MERRYFIELD ROW
		STREET 2:		SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>goss-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:27c0f11b-cb15-486e-948f-a34ff077e64b,g:c382099f-c004-46d4-b3a3-9983a179ddc5,d:23ab80a59eff4535a15f3b4d8b987e4a-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:goss="http://www.gossamerbio.com/20241231" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>goss-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001728117</ix:nonNumeric><ix:nonNumeric contextRef="c-20" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-196">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="c-49" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-390">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-431">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-432">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-116" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-580">0.0616095</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-186" decimals="2" name="goss:ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" scale="-2" id="f-947">33</ix:nonFraction><ix:nonNumeric contextRef="c-235" name="goss:LesseeOperatingLeaseExtensionTerm" id="f-982">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="goss-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>goss:segment</xbrli:measure></xbrli:unit><xbrli:unit id="security"><xbrli:measure>goss:security</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>goss:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="tradingday"><xbrli:measure>goss:tradingDay</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>goss:vote</xbrli:measure></xbrli:unit><xbrli:unit id="day"><xbrli:measure>goss:day</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="month"><xbrli:measure>goss:month</xbrli:measure></xbrli:unit><xbrli:unit id="performanceobligation"><xbrli:measure>goss:performanceObligation</xbrli:measure></xbrli:unit><xbrli:unit id="license"><xbrli:measure>goss:license</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:RevenueFromContractsWithCollaboratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:RevenueFromContractsWithCollaboratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:RevenueFromContractsWithCollaboratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-02</xbrli:startDate><xbrli:endDate>2019-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">goss:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">goss:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-03</xbrli:startDate><xbrli:endDate>2024-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:OneHundredThirtyPercentApplicableConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:OneHundredThirtyPercentApplicableConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:NinetyEightPercentApplicableConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:NinetyEightPercentApplicableConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-02</xbrli:startDate><xbrli:endDate>2017-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentTerminatedProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentTerminatedProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentTerminatedProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-15</xbrli:startDate><xbrli:endDate>2022-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-15</xbrli:startDate><xbrli:endDate>2022-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-24</xbrli:startDate><xbrli:endDate>2023-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:OfficerDirectorEmployeeOrConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-24</xbrli:startDate><xbrli:endDate>2023-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-03</xbrli:startDate><xbrli:endDate>2015-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-04</xbrli:startDate><xbrli:endDate>2018-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-21</xbrli:startDate><xbrli:endDate>2018-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-06</xbrli:startDate><xbrli:endDate>2018-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandTwentyThreeEquityInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandTwentyThreeEquityInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:LeaseAgreementEnteredInJuly2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:LeaseAgreementEnteredInJuly2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-09</xbrli:startDate><xbrli:endDate>2024-07-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:NonCancelableLeaseAgreementEnteredInAugust2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:LeaseAgreementEnteredInJuly2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-03</xbrli:startDate><xbrli:endDate>2024-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:USLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ROWLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:USLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ROWLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHCommercialExpensesSubjectToReimbursementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDCommercialExpensesSubjectToReimbursementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:EffectsOfExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">goss:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">goss:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001728117</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">goss:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">__________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">__________________________________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:24.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:24.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission&#160;file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-38796</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">__________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">GOSSAMER BIO, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">__________________________________________________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">47-5461709</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">3115 Merryfield Row, Suite 120</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">684-1300</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">GOSS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746; No&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.    <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b).      &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric>&#160;&#160;No &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of June 28, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">197.4</ix:nonFraction>&#160;million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Select Market of $0.90 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of March&#160;6, 2025, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">227,221,261</ix:nonFraction> shares of common stock ($0.0001 par value) outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" continuedAt="f-31-1" escape="true"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div></ix:nonNumeric><div style="margin-top:6pt"><ix:continuation id="f-31-1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Certain sections of the registrant&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of this fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span></ix:continuation><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_13">Item&#160;1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_16">Item&#160;1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_16">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_19">Item&#160;1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_19">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_22">Item&#160;1C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_22">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_22">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_25">Item&#160;2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_25">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_28">Item&#160;3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_28">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_31">Item&#160;4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_31">76</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_37">Item&#160;5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_37">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_40">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_40">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_43">Item&#160;7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_43">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_64">Item&#160;7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_64">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_64">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_67">Item&#160;8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_67">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_70">Item&#160;9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_70">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_70">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_73">Item&#160;9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_73">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_73">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_76">Item&#160;9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_76">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_76">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_76">Item&#160;9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_79">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_76">89</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_82">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_85">Item&#160;10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_85">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_85">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_88">Item&#160;11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_88">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_88">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_91">Item&#160;12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_91">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_91">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_94">Item&#160;13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_94">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_94">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_97">Item&#160;14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_97">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_97">91</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_100">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_103">Item&#160;15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_103">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_103">92</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_106">Item&#160;16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_106">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_106">92</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_175">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS AND MARKET DATA</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report on Form 10-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Section 27A of the Securities Act of 1933, as amended, or the Securities Act. All statements other than statements of historical facts contained in this annual report, including statements regarding our future results of operations and financial position, business strategies and plans, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned preclinical studies and planned clinical trials for seralutinib, our and Chiesi&#8217;s performance under our collaboration agreement, the timing and likelihood of regulatory filings and approvals for seralutinib, timing and likelihood of success, plans and objectives of management for future operations and future results of seralutinib, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This annual report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this annual report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, &#8220;Risk Factors.&#8221; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this annual report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report also contains industry, market and competitive position data from our own internal estimates and research, as well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this report is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in in Part I, Item 1A, &#8220;Risk Factors.&#8221; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a website at www.gossamerbio.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the Securities and Exchange Commission, or SEC, are available free of charge through our website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website does not constitute a part of this report or our other filings with the SEC.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_13"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with interstitial lung disease, or PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. We intend to maintain a scientifically rigorous and inclusive corporate culture where employees strive to bring improved therapeutic options to patients.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Team</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our founders and management team have held senior positions at leading biopharmaceutical companies and possess substantial experience and expertise across the spectrum of drug development and commercialization.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Faheem Hasnain is our Co-Founder and has served as our Chief Executive Officer since November 2020 and as our Chairman since our inception. Mr. Hasnain also served as our Chief Executive Officer from our inception through July 2018 and our Executive Chairman from July 2018 through June 2019. Prior to co-founding Gossamer Bio, Mr. Hasnain served as President, CEO and as a Director of Receptos, Inc. from November 2010 to August 2015. Receptos was a public company formed in 2009 focused on developing treatments in immunology and metabolic disorders and was purchased by Celgene Corporation in August 2015. Previously, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company's acquisition by Abbott Laboratories in April 2010.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bryan Giraudo, our Chief Financial Officer and Chief Operating Officer, has extensive biotechnology and medical technology finance experience, having previously served as Senior Managing Director at Leerink Partners and Managing Director at Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated. Richard Aranda, M.D., our Chief Medical Officer, is an experienced clinician and drug developer with previous experience at Bristol Myers Squibb Company, Novo-Nordisk, Inc., Receptos and Celegene Corporation. Bob Smith, our Chief Commercial Officer, has over 30 years of experience in pharmaceuticals, with a strong focus on PAH and rare disease. Prior to Gossamer, Mr. Smith was the National Sales Lead in charge of preparing for the commercial launch of sotatercept for the treatment of PAH in the US at Merck &amp; Co., or Merck. Previously until 2018, Mr. Smith was the Senior Vice President of Sales and an Executive Leadership Team member at Actelion Pharmaceuticals US, Inc., where he spearheaded two successful PAH drug launches, Opsumit (macitentan) and Uptravi (selexipag). Christian Waage, our Executive Vice President, Technical Operations &amp; Administration, has meaningful management biotechnology experience, having previously held various positions at Receptos, most recently as Managing Director after its acquisition by Celgene, and at Ardea Biosciences, Inc. as Vice President, General Counsel. Caryn Peterson, our Executive Vice President, Regulatory Affairs, has considerable experience and regulatory expertise as a Managing Director of Development &amp; Strategic Consulting Associates, as well as management positions leading regulatory affairs at Syndax Pharmaceuticals and FeRx Incorporated.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of PH. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. Critical components of our business strategy include:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Complete the ongoing Phase 3 PROSERA Study of seralutinib in PAH and pursue regulatory approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced the registrational Phase 3 PROSERA Study in PAH in the fourth quarter of 2023. We expect to report topline data from the PROSERA study in the fourth quarter of 2025. If the clinical trial is successful, we will seek marketing approval for seralutinib in the United States.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Increase the impact of seralutinib by expanding development into PH indications of high unmet need. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that not only does seralutinib offer potential as a therapeutic option for the treatment of PAH but also for the treatment of other rare PH indications of high unmet need, including PH-ILD. To that end, we expect to activate clinical sites for a global registrational Phase 3 for the treatment of PH-ILD in the second half of 2025. Additionally, we will continue to evaluate other potential related indications of high unmet need for further development of seralutinib.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Leverage the clinical development and commercialization expertise of our world-class team. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive management team and key scientific leaders have successfully discovered, developed and commercialized pharmaceuticals at both large and small biopharmaceutical companies. Additionally, we have built experienced PH development and commercialization teams, with key team members selected from the leadership of companies such as Actelion, Johnson &amp; Johnson, Merck and United Therapeutics.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Build our operational capabilities to successfully commercialize seralutinib for PH, if approved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we obtain regulatory approvals for seralutinib, we intend to build in-house sales and marketing capabilities to commercialize seralutinib in the United States, as part of our global collaboration and license agreement, or collaboration agreement, with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc., or collectively, Chiesi. Both PAH and PH-ILD patients are often treated by cardiologists and pulmonologists at national or regional centers of excellence. These concentrations of patients could allow us to commercialize seralutinib with a relatively small commercial footprint, if approved.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seralutinib (PDGFR, CSF1R and c-KIT Inhibitor)</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor, currently being evaluated in a Phase 3 clinical trial for the treatment of PAH. We believe that seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, &#945; and &#946;, as well as the CSF1R and c-KIT pathways, inhibited and reversed cellular overgrowth in lung blood vessels in multiple animal PAH models. In December 2022, we announced positive topline results from the 24-week Phase 2 TORREY trial in 86 PAH patients. In this well-treated patient population, the seralutinib arm demonstrated a statistically significant, placebo-adjusted improvement of 14.3% in its primary efficacy endpoint, pulmonary vascular resistance, or PVR. Seralutinib has been generally well tolerated in all completed clinical trials.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We dosed the first patient in our registrational Phase 3 PROSERA Study in PAH in the fourth quarter of 2023. We expect to report topline data from the PROSERA study in the fourth quarter of 2025. In addition to PAH, we believe that seralutinib holds potential as a therapeutic option for the treatment of PH-ILD, and to that end, we expect to activate clinical sites for a global registrational Phase 3 for the treatment of PH-ILD in the second half of 2025. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we entered into a collaboration agreement with Chiesi. Under the collaboration agreement, we will jointly develop seralutinib with Chiesi. We will lead global development of seralutinib in PAH and PH-ILD and will lead potential commercialization for PAH and PH-ILD in the United States, with both parties contributing 50%of commercial efforts, including performing 50% of the commercialization activities. Chiesi will lead global development in any additional indications and will lead potential commercialization in the United States in any additional indications. Chiesi will also have the exclusive right to commercialize seralutinib outside of the United States. We in-licensed seralutinib from Pulmokine, Inc. The United States Food and Drug Administration, or FDA, the European Commission, or EC, and the Pharmaceuticals and Medical Devices Agency, or PMDA, of Japan have granted seralutinib orphan drug designation for the treatment of patients with PAH.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the current development plan for seralutinib in PH:</span></div><div style="margin-top:10pt;text-indent:36pt"><img src="goss-20241231_g1.jpg" alt="Graph - pipeline - 2024.jpg" style="height:194px;margin-bottom:5pt;vertical-align:text-bottom;width:636px"/></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mechanism of Action in PAH</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAH is driven by abnormal cellular proliferation within and around the small blood vessels of the lung that carry blood from the right side of the heart to the lungs. Functional and structural changes in the pulmonary vasculature, known as vascular remodeling, can lead to smooth muscle cell proliferation and migration from the middle layer of the blood vessel into the inner layer. This can result in the development of plexiform and neointimal lesions that can obstruct blood flow. The obstruction of blood flow in the pulmonary vessels can also predispose patients to thrombosis, or blood clots, within these small pulmonary vessels that further blocks blood flow. This progressive obstruction of blood flow from the right side of the heart to the lungs can cause the right ventricle to fail, thus leading to severe breathlessness, reduced exercise tolerance and death. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib was designed to inhibit multiple kinases that play a role in the pathology of PAH, including PDGFR&#945;/&#946;, CSF1R and c-KIT. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PDGFR is a tyrosine kinase receptor which, when activated by its agonist, induces cellular proliferation. PDGF expression is known to be particularly important to stimulating smooth muscle cell proliferation in PAH patients. PDGFRs and their ligands are both upregulated in PAH. Upregulated PDGFR signaling results in endothelial cell and fibroblast dysfunction and the proliferation and migration of smooth muscle cells. This effect results in the overgrowth and occlusion of blood vessels in the lung. Kinase inhibitors with activity against the PDGFR pathway have shown the ability to reverse PAH in animal models.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhaled seralutinib is designed to act on both isoforms of the PDGFR, &#945; and &#946;. Data from preclinical animal models and human lung histology from PAH patients suggests that it is important to inhibit both of these isoforms of the PDGF receptor. PDGFR&#945; is highly expressed in pulmonary arteriole vascular smooth muscle cells, or PAVSMCs. Inhibiting PDGFR&#945; may help reduce the abnormal cell proliferation of PAVSMCs that results in blood vessel thickening. PDGFR&#946; is more highly expressed in fibroblasts and myofibroblasts that are involved with the abnormal cell proliferation within the blood vessel that leads to the obstruction of the pulmonary arterioles. We believe inhibiting PDGFR&#946; is therefore important in decreasing the abnormal cell proliferation of these cell types.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The c-KIT pathway was also identified as an important growth factor involved in pulmonary vascular remodeling, particularly in the cells implicated in perivascular inflammation. An analysis of lung and pulmonary arteriole samples has also shown increased gene expression of c-KIT in idiopathic PAH. C-KIT positive endothelial cells may also secrete PDGF, and perivascular c-KIT positive mast cells have been shown to secrete pro-inflammatory cytokines and tryptase that further contribute to the inflammatory process in PAH. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mechanistic validation of a PDGFR and c-KIT kinase inhibitor has been observed in clinical trials of imatinib (Gleevec), an oral tyrosine kinase inhibitor with known activity against the PDGFR and c-KIT pathways, which demonstrated proof-of-concept in humans in a Phase 3 clinical trial in PAH. In preclinical models, as compared to imatinib, seralutinib was a more potent inhibitor of the PDGFR&#945; isoform, and seralutinib was a ten-fold more potent inhibitor of the PDGFR&#946; isoform and c-KIT. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macrophages have also been identified as one of the most important inflammatory cells in the development and exacerbation of PAH. Macrophages, which express the CSF1 receptor, are now recognized to play an important role in PAH pathology. Activated CSF1R positive macrophages accumulate around pulmonary arterioles in PAH, which have been shown in vivo in PAH patients with positron emission tomography. Additionally, macrophage activity in PAH is associated with bone morphogenetic protein receptor type II, or BMPR2, levels. The decrease in BMPR2 characteristic of PAH results in induction of granulocyte-macrophage colony-stimulating factor, or GM-CSF, and macrophage recruitment. Notably, in the BMPR2 knock out mouse, there is significant pulmonary inflammation due to activation of tissue macrophages.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, inflammatory macrophages secrete PDGF and stimulate pulmonary artery smooth muscle cell migration and proliferation, accelerating the feedback loop of inflammation, hyperproliferation and fibrosis that characterize PAH.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior PDGF Pathway Development in PAH - The IMPRES Phase 3 Clinical Trial of Imatinib</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IMPRES trial was a Phase 3 clinical trial conducted by Novartis of imatinib (Gleevec) in patients with PAH. Imatinib has known activity against multiple tyrosine kinases, including the PDGFR, c-KIT receptors and Abelson murine leukemia viral oncogene homolog 1, or c-ABL. The trial met its primary endpoint, improvement in 6-minute walk distance, or 6MWD, versus placebo at week 24.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, systemic adverse events such as bleeding and poor tolerability and frequent drug discontinuation led to a high drop-out rate within the active arm of the trial. Subdural hematomas occurred in eight patients who were also being administered oral anticoagulants during the trial. Novartis withdrew its supplemental regulatory applications in PAH in 2013 and, to our knowledge, did not pursue further development of imatinib in the indication. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of PAH (WHO Group 1 Pulmonary Hypertension)</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAH, classified as World Health Organization, or WHO, Group 1 Pulmonary Hypertension, is a rare disease that is characterized by abnormally high blood pressure in the blood vessels carrying deoxygenated blood from the right side of the heart to the lungs and is progressive and often fatal. Symptoms include shortness of breath at rest or with minimal exertion. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other symptoms include fatigue, chest pain, dizzy spells and fainting. The progressive nature of this disease causes the right side of the heart to work much harder and eventually weaken or fail.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients are often evaluated by functional class, which categorizes patients by their ability to carry out physical activity and their symptom severity. Worsening symptoms, and thus higher numbered functional classes, are associated with higher mortality. The four functional classes established by the WHO are detailed below in Table 1.</span></div><div style="margin-top:10pt;text-align:center;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table 1. PAH Functional Classes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.944%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Functional<br/>Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class&#160;I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with PAH, but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class&#160;II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with PAH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with PAH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class&#160;IV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with PAH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.</span></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, recent medical society guidelines have identified intermediate and high-risk categories of PAH based on several variables including signs of right heart failure, rate of symptom progression, functional class, 6MWD, maximum oxygen consumption and NT-proBNP, which is a biomarker for heart failure and measures of right heart function. One of these risk categorization tools, the REVEAL 2.0 Risk Score, was utilized in the completed Phase 2 TORREY Study.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple PAH-specific treatments have been introduced in the past two decades, however PAH continues to have a high morbidity and mortality. Based on REVEAL registry data, newly diagnosed functional class III and IV patients have 5-year survival rates of 60% and 44%, respectively, while rates for previously diagnosed patients were even lower at 57% and 27%, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of PAH Market </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAH most commonly affects women between the ages of 30 and 60. The true incidence and prevalence of PAH are unknown. The estimated PAH patient population in the US is about 50,000 patients, and the estimated patient population in the EU is over 70,000 patients. The number of diagnosed PAH patients continues to increase, and we believe this increase is likely due to enhanced awareness and diagnosis of the disease. Worldwide branded drug sales for PAH and PH-ILD therapies totaled over $7 billion in 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment Paradigm in PAH</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently approved PAH therapies consist of three classes of vasodilators and one activin ligand trap therapy. The three classes of vasodilatory therapy are PDE5 inhibitors (and guanylate cyclase stimulators), ERAs, and prostanoids (and prostacyclin receptor agonists). PDE5 inhibitors are often used in combination with ERAs as an early treatment strategy. In patients who fail to respond to combination therapy of an ERA and a PDE5 inhibitor, it is common practice to add a prostanoid. Prostanoids are also commonly used to treat patients with evidence of right heart failure. The recent introduction of an activin ligand trap therapy (sotatercept) to the market has provided patients with an additional treatment option. While some existing treatments have led to significant improvements in time to clinical worsening and other composite endpoints in PAH patients, there are no cures. The effects of approved PAH therapies, while capable of improving blood flow through the lungs, may eventually be overtaken by the worsening cellular proliferation and arterial remodeling underlying the condition, given the progressive nature of the disease. We believe an agent with the ability to safely reverse pathological remodeling could provide utility across functional classes and risk categories.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of PH-ILD (WHO Group 3 Pulmonary Hypertension)</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that seralutinib has potential as a therapeutic treatment for PH-ILD, a subtype of WHO Group 3 Pulmonary Hypertension. PH-ILD is a collection of progressive and often fatal forms of PH that affect the small airways of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lungs. PH-ILD includes PH related to idiopathic pulmonary fibrosis and PH related connective tissue disease-associated interstitial lung disease, amongst other diseases. These diseases are characterized by pulmonary vascular pathology associated with PH, in addition to thickening and scarring of the lung interstitium from interstitial lung disease. While the prevalence of PH-ILD is unknown, we believe PH-ILD is at least as prevalent as PAH. Patients living with PH-ILD generally have a poor disease prognosis and have an increased mortality rate, as compared to PAH patients. There is only one FDA-approved treatment for PH-ILD, and there are no approved therapies in the EU.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seralutinib Product Differentiation </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib is an inhaled kinase inhibitor designed to build on the evidence of efficacy seen in trials of imatinib while overcoming imatinib&#8217;s observed systemic safety and tolerability issues and improving on imatinib's kinase inhibitory profile. Seralutinib is designed to have a differentiated selectivity profile as compared to imatinib with increased potency against the PDGFR&#945; isoform, ten-fold higher potency against the PDGFR&#946; isoform and c-KIT, and no activity against c-ABL or the tyrosine kinase, LCK. Additionally, seralutinib is multiple orders of magnitude more potent against CSF1R, as compared to imatinib. We believe seralutinib has the potential to be a therapeutic option for PH that may provide a:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;differentiated, anti-proliferative mechanism that addresses the underlying mechanisms of both PAH and PH-ILD;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;more tolerable safety profile than systemic imatinib; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;convenient, simple and portable inhalation delivery system.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Preclinical Program</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib inhibits both PGDFR &#945; and &#946;, and it inhibited and reversed cell overgrowth in lung blood vessels in a PAH rat model, which replicates many features of human PAH, including the abnormal cell proliferation that can block the small vessels of the lung. Seralutinib substantially reduced the occlusive lesions in the small lung blood vessels in this model. Additionally, seralutinib demonstrated a statistically significant reduction in right ventricular systolic pressure as compared to placebo.&#160;&#160;&#160;&#160;In a separate rat model of PAH, the SU5416 hypoxia model, seralutinib demonstrated a statistically significant reduction in circulating plasma NT-proBNP as compared to placebo, while the difference between imatinib and placebo was not significant for this PAH biomarker. Seralutinib also restored rat lung BMPR2 expression to healthy levels, which was a statistically significant improvement as compared to placebo and imatinib. Irregularities in BMPR2 expression have been linked to PAH. In a separate rat model of PAH, the SU5416 hypoxia model, seralutinib demonstrated a statistically significant reduction in circulating plasma NT-proBNP as compared to placebo, while the difference between imatinib and placebo was not significant for this PAH biomarker. Seralutinib also restored rat lung BMPR2 expression to healthy levels, which was a statistically significant improvement as compared to placebo and imatinib. Irregularities in BMPR2 expression have been linked to PAH.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development History of Seralutinib</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Completed Phase 1a Studies</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed Phase 1a SAD and MAD double-blind, placebo-controlled, randomized studies of orally inhaled seralutinib in 82 healthy adult volunteers. We assessed pharmacokinetics, or PK, parameters and safety. Seralutinib was well-tolerated, and there were no dose-limiting toxicities. No serious adverse events, or SAEs, were reported, and no reported adverse events, or AEs, led to study drug discontinuation. The most common AEs were throat irritation and cough, which were mild in severity and similar in incidence to placebo. Following single and multiple oral inhalations, seralutinib was rapidly absorbed into and cleared from the systemic circulation. Seralutinib exposure increased in a dose-proportional manner following single and multiple dose administration.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Completed Phase 1b PAH Clinical Trial</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced topline results from the completed Phase 1b randomized, double-blind, placebo-controlled, multi-center trial of seralutinib in functional class II and III PAH patients. Eight patients completed the two-week blinded portion of the trial. Enrollment for this trial was temporarily paused due to the COVID-19 pandemic but was reopened in the third quarter of 2020. The primary outcome of this 2-week trial was safety and tolerability. Seralutinib was generally well tolerated in PAH patients, and all eight patients completed the 2-week study. There were no SAEs, and the most frequently reported AEs were mild-to-moderate cough and mild headache. Systemic PK was characterized by low systemic exposure and rapid drug clearance in PAH patients, which was consistent with PK data from the Phase 1a studies in healthy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">volunteers. Target engagement in PAH patients was demonstrated via whole blood CSF1R stabilization assay across all tested dose levels. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the two-week Phase 1b trial, two PAH patients were able to enroll and complete a six-month open label extension trial of seralutinib. Both patients were able to titrate up to the maximum allowed dose, 90 mg twice daily. No SAEs were reported during the extension trial. Both patients demonstrated a decrease in NT-proBNP levels from baseline, and both patients demonstrated an increase in 6MWD from baseline. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Completed Phase 2 PAH Clinical Trial (TORREY Study)</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we announced positive topline results from the completed Phase 2 TORREY Study, a randomized, double-blind, placebo-controlled, multi-center clinical trial in PAH patients. We enrolled 86 functional class II and III PAH patients who were not meeting treatment goal despite background PAH treatment. 57% of enrolled patients were on triple background PAH therapy, and 40% were on double background PAH therapy. Patients on the active arm received seralutinib at doses starting at 60 mg twice daily, and they titrated up to 90 mg twice daily. While the protocol allowed for down-titration to 45 mg twice daily as necessary, the substantial majority of patients on the seralutinib arm were able to achieve and maintain 90 mg twice daily. Patients remained on their background PAH therapies throughout the trial.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib demonstrated a statistically significant improvement on the primary endpoint, change from baseline in PVR over a 24-week treatment period. A mean improvement in PVR between the placebo and seralutinib arms of 96.1 dynes &#215; seconds/cm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (p = 0.0310), equating to a placebo-adjusted improvement of 14.3%, was observed in the study. The p-value is the probability that the difference between two data sets was due to chance. The smaller the p-value, the more likely the differences are not due to chance alone. In general, if the p-value is less than or equal to 0.05, the outcome is considered statistically significant. Improvements in PVR favored the seralutinib arm across all pre-specified patient sub-groups. The key secondary endpoint in the TORREY Study was change from baseline to week 24 in 6MWD. An observed mean difference in 6MWD between placebo and seralutinib of 6.5 meters numerically favored the seralutinib arm. Changes in 6MWD also favored seralutinib in the majority of pre-specified sub-groups. The trial was neither powered nor designed for statistical significance in 6MWD. </span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enhanced effects for both PVR and 6MWD were observed in patients with more severe baseline disease, as defined by WHO functional class, or FC, and REVEAL 2.0 Risk Scores. In FC III patients, a 21% placebo-adjusted reduction in PVR (p = 0.0427) and 37-meter placebo-adjusted improvement in 6MWD (p = 0.0476) were observed for the seralutinib arm. In patients with a baseline REVEAL 2.0 Risk Score of 6 or greater, seralutinib demonstrated a 23% placebo-adjusted reduction in PVR (p = 0.0134) and a placebo-adjusted 22-meter improvement in 6MWD (p = 0.2482).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib treatment resulted in a statistically significant reduction in NT-proBNP, a biomarker of right heart stress, as early as 12 weeks, increasing to a placebo-adjusted 408.3 ng/L mean difference at Week 24 (p = 0.0012). This biomarker change was accompanied by clinically relevant and statistically significant changes for seralutinib vs. placebo in key assessments of right heart structure and function, including right atrium area, right ventricle free wall strain and pulmonary artery compliance.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib was generally well tolerated in the TORREY study, with treatment emergent adverse events, or TEAEs, reported in 36 (86%) and 41 (93%) of the patients in the placebo and seralutinib arms, respectively. The vast majority of TEAEs reported in the study were mild to moderate in severity. In the seralutinib arm, there was one SAE related to study drug reported, while no SAEs related to study drug were reported in the placebo arm. The most frequently reported TEAE in the study was cough, reported in 16 (38%) and 19 (43%) of the patients in the placebo and seralutinib arms, respectively. Of the 19 patients reporting cough in the seralutinib arm, 17 experienced mild cough, while 2 experienced moderate cough. The most frequently reported TEAEs in the IMPRES Phase 3 study of imatinib in PAH, including nausea, peripheral edema, diarrhea, and vomiting, were observed at substantially lower frequency in the TORREY study, and reported cases were generally well balanced between the seralutinib and placebo arms. No cases of subdural hematoma were reported in the study.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Ongoing TORREY Open-Label Extension Clinical Trial in PAH</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the 24-week blinded portion of the Phase 2 TORREY Study, 73 of the 80 (91%) completing patients elected to rollover into an ongoing open-label extension trial. In the TORREY open-label continued-seralutinib group treated for 72 weeks continued improvement was noted in PVR and 6MWD, as compared to TORREY baseline. Consistent with completed clinical trials, seralutinib has been generally well tolerated as of December 31, 2024, in the ongoing open-label extension study.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Ongoing PROSERA Phase 3 PAH Clinical Trial</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we commenced the registrational Phase 3 PROSERA Study, a randomized, double-blind, placebo-controlled, global clinical trial in PAH patients, after receiving input from global regulatory authorities, including the FDA and European Medicines Agency, or EMA. We are enrolling approximately 350 Functional Class II and III PAH patients on stable background therapy. Patients will be randomized in a 1:1 fashion to 90 mg twice daily seralutinib or placebo, and patients will receive blinded therapy for up to 48 weeks. Patients will remain on their background PAH therapies throughout the trial. The primary endpoint of the PROSERA trial is change from baseline in 6MWD at Week 24. A key secondary endpoint is time to first clinical worsening while on blinded therapy, up to 48 weeks. In addition to secondary and exploratory endpoints, safety and tolerability will also be evaluated in the Phase 3 PROSERA Study. We expect to report topline data from the PROSERA study in the fourth quarter of 2025. If the clinical trial is successful, we will seek marketing approval for seralutinib in the United States.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Planned Phase 3 Clinical Trial in PH-ILD</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to activate clinical sites for a global registrational Phase 3 for the treatment of PH-ILD in the second half of 2025. The planned Phase 3 clinical trial will be a registrational, randomized, double-blind, placebo-controlled, global clinical trial in PH-ILD patients. We have discussed the protocol design with global regulatory authorities and this will inform the final design of the Phase 3 clinical trial. The primary endpoint of the trial will be change in 6MWD from baseline.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. We face potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects or more convenient than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we do. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, convenience, cost, level of promotional activity devoted to them and intellectual property protection.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to face competition for seralutinib from existing products and products in development. Seralutinib is a PDGFR, CSF1R and c-KIT inhibitor initially targeted for PAH and PH-ILD patients. We expect competition within the PAH indication will include prostanoids / prostacyclin receptor agonists, including Orenitram (United Therapeutics), Uptravi (Janssen), Tyvaso (United Therapeutics), and Remodulin (United Therapeutics), and activin ligand traps, including Winrevair (Merck). We also may face some competition from products used in Functional Class I and II patients, such as the oral PDE5 inhibitors, including Revatio (Pfizer Inc.) and Adcirca (United Therapeutics); the sGC stimulator Adempas (Bayer AG); and oral ERAs, including Tracleer (Janssen), Letairis (Gilead Sciences, Inc.) and Opsumit (Janssen); and combination PDE5 inhibitor / ERA therapies, such as Opsynvi (Janssen). We believe that, if approved, seralutinib could be used alongside all classes of approved therapies. PAH is also an active indication for investigational drugs, and we may face competition in the future from CS1 (Cereno Scientific), L606 (Liquidia / Pharmosa Biopharm Inc.), treprostinil palmitil (Insmed), ralinepag (United Therapeutics), and REGN13335 (Regeneron Pharmaceuticals, Inc.). Additionally, although not approved for the treatment of PAH, we may face competition from formulations of imatinib, including the one in development from Tenax Therapeutics and Inhibikase Therapeutics.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to face competition from Tyvaso (United Therapeutics) within the PH-ILD indication, as it is the only approved therapy for PH-ILD in the United States. There are no approved therapies for PH-ILD in the EU. PH-ILD is also an active indication for investigational drugs, and we may face competition in the future from L606 (Liquidia / Pharmosa Biopharm Inc.), sirolimus (OrphAI Therapeutics), treprostinil palmitil (Insmed, Inc.), MK-5475 (Merck), and mosliciguat (Pulmovant, Inc.).</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be other earlier stage clinical programs that, if approved, would compete with seralutinib. Many of our competitors have substantially greater financial, technical and human resources than we have. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields. Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pulmokine </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a license agreement, or the Pulmokine Agreement, with Pulmokine, Inc., under which we were granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine, including intellectual property rights co-owned by Pulmokine and Gilead Sciences, to develop and commercialize seralutinib and certain backup compounds for the treatment, prevention and diagnosis of any and all disease or conditions. On November 26, 2024, Pulmokine became a wholly-owned subsidiary of XOMA Royalty Corporation. We also have the right to sublicense our rights under the Pulmokine Agreement, subject to certain conditions. We are required to use commercially reasonable efforts to develop and commercialize at least one licensed product in the United States and in at least two countries in the European Union.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Pulmokine Agreement, we made an upfront payment of $5.5&#160;million and milestone payments of $5.0 million and are obligated to make future development and regulatory milestone payments of up to $48&#160;million, which includes a payment of $5.0 million due upon the initiation of a Phase 3 clinical trial in a second indication, commercial milestone payments of up to $45 million, and sales milestone payments of up to $190 million. In January 2024, the Company made a payment of $10.0 million in connection with the initiation of the Phase 3 clinical trial of seralutinib. We are also obligated to pay tiered royalties on sales for each licensed product, at percentages ranging from the mid-single digits to the high single-digits. In addition, if we choose to sublicense or assign to any third parties our rights under the Pulmokine Agreement with respect to a licensed product, or our seralutinib operating subsidiary undergoes a change of control, we must pay to Pulmokine a specified percentage of all revenue to be received in connection with such transaction.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our royalty obligations and the Pulmokine Agreement will expire on a licensed product-by-licensed product and country-by-country basis on the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product or specified regulatory exclusivity for the licensed product in such country. The Pulmokine Agreement may be terminated in its entirety either by Pulmokine or by us in the event of an uncured material breach by the other party, in the event the other party is subject to specified bankruptcy, insolvency or similar circumstances, or in the event of a force majeure event under certain circumstances. The agreement may be terminated by Pulmokine if we commence a legal action challenging the validity or enforceability of any licensed patents. We may terminate the agreement, either in its entirety or on a product-by-product basis, in the event of potential safety or efficacy concerns affecting a licensed product.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property rights co-owned by Pulmokine and Gilead Sciences are subject to a license agreement, or the Gilead Agreement, between Pulmokine and Gilead Sciences. Under the Gilead Agreement, Pulmokine is required to use commercially reasonable efforts to develop and commercialize at least one licensed product, which obligation can be satisfied through our development efforts required under the Pulmokine Agreement, and to pay Gilead Sciences future regulatory milestone payments and royalties. Upon termination of the Gilead Agreement for any reason, our sublicense under the Pulmokine Agreement will survive provided that we did not cause a material breach that was the basis for such termination and we agree to be bound by the terms of the Gilead Agreement.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon termination of the Pulmokine Agreement for any reason, all rights and licenses granted to us under the agreement will terminate and revert to Pulmokine, and in the event of certain termination events, we would grant Pulmokine worldwide rights to the terminated program.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chiesi</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, we, GB002, Inc., our wholly-owned subsidiary, and Gossamer Bio 002 Ltd., our indirect wholly-owned subsidiary, entered into a collaboration agreement with Chiesi. The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds, or Licensed Products, in the United States and the rest of the world, or the ROW Territory, for the treatment of PAH and PH-ILD and other indications, as may be permitted under the collaboration agreement.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the collaboration agreement, we granted exclusive, sublicensable (with our consent required in the United States for third party sublicenses) licenses to Chiesi under intellectual property rights controlled by us relating to Licensed Products, for the worldwide development, manufacture and commercialization of seralutinib and Licensed Products for therapeutic, prophylactic and diagnostic uses in humans and animals. The licenses granted to Chiesi are subject to retained rights of our Company for the worldwide development and manufacture of seralutinib and Licensed Products, commercialization of Licensed Products in the United States, and performance of our obligations and exercise of our rights that may be set forth in the global development plan and U.S. commercialization plan, in each case in accordance with the collaboration agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chiesi granted us a non-exclusive, sublicensable (with Chiesi&#8217;s consent required in the US Territory for third party sublicenses) licenses under certain practiced intellectual property rights relating to seralutinib and Licensed Products and arising intellectual property rights, in each case as controlled by Chiesi, for the worldwide development and manufacture of seralutinib and Licensed Product and a co-exclusive license (with Chiesi) to commercialize seralutinib and Licensed Products in the US Territory.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to use commercially reasonable efforts to conduct development and commercialization activities in relation to seralutinib and Licensed Products, under the global development plan and U.S. commercialization plan in accordance with the timelines therein. We will continue to lead global development of seralutinib in PAH and PH-ILD, and we and Chiesi will equally share the costs for the activities included in the global development plan for all Licensed Products, with the exception of the PROSERA Phase 3 study, which we will be solely responsible for conducting at our own cost and expense. With respect to each country in the ROW Territory, such obligation to equally share such development costs shall end when regulatory approval is received for a Licensed Product in such country. With respect to United States, the development costs incurred following regulatory approval shall continue to be shared equally. We will lead commercialization for PAH and PH-ILD in the United States, with both parties contributing 50 percent of commercial efforts, including performing 50 percent of the commercialization activities. Chiesi will lead commercialization in the United States in additional indications, and Chiesi will have the exclusive right to commercialize Licensed Products in the ROW Territory. Chiesi further agreed to use commercially reasonable efforts to commercialize Licensed Product in certain specified countries in the ROW Territory following receipt of regulatory approvals. Generally, we will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products for the United States for PAH and PH-ILD, and, subject to any of our existing obligations of to third party manufacturers, Chiesi will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products in the ROW Territory, in each case in accordance with the collaboration agreement.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the collaboration agreement, neither party nor its affiliates is permitted to develop or commercialize any compound or product throughout the term whose primary mechanism of action is inhibition of a tyrosine kinase for the treatment of PAH or PH-ILD in the United States or ROW Territory, subject to certain restrictions for the EU and UK.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration and as reimbursement for our development costs, Chiesi agreed to pay us $160.0 million. Additionally, we will be eligible to receive up to $146.0 million in regulatory milestones and $180.0 million in sales milestones. In the United States, the parties agreed to share commercial profits and losses equally. In the ROW Territory, Chiesi will pay us an escalating mid-to-high teens percentage royalty, subject to standard deductions, on net sales of Licensed Product for PAH and additional indications on a Licensed Product-by-Licensed Product and country-by-country basis with such payment obligations beginning on the first commercial sale of Licensed Product in such country and expiring on a country-by-country basis on the latest of (a) the expiration of a valid claim to our patent right in such country, (b) the expiration of regulatory exclusivity, and (c) the date that is 10 years after the first commercial sale of such Licensed Product in such country.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we granted to Chiesi an option to purchase directly from us, on one or more occasions, up to an aggregate number of shares of our common stock such that immediately following such issuance, Chiesi&#8217;s beneficial ownership of our common stock shall not exceed 9.9% of the total number of issued and outstanding shares of our common stock, or the Equity Option. The Equity Option shall be exercisable by Chiesi, in whole or in part, at any time prior to the earliest to occur of the date on which (a) the last patient is last dosed in either (i) the PROSERA Phase 3 study for PAH or (ii) a Phase 3 clinical trial for the PH-ILD Indication, (b) any third party commences a tender offer or exchange offer for more than 50% of the outstanding shares of our common stock, and (c) we publicly announces our intent to consummate a GB002 change of control. The purchase price of each share of our common stock subject to the Equity Option shall be equal to 107.5% of the daily volume-weighted average per share price of our common stock on The Nasdaq Stock Market over the 30-trading day period ending on and including the last trading day prior to the date on which Chiesi delivers an exercise notice to us; provided that such purchase price shall be no less than $1.63 per share. The shares of our common stock to be issued will be issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering, pursuant to the terms of a stock issuance agreement to be entered into between us and Chiesi in connection with each such exercise of the Equity Option.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement will remain in force until no Licensed Products are being developed or commercialized in the United States and in the ROW Territory, on a country-by-country basis, until no royalty terms are in effect for all countries. Either party may terminate the collaboration agreement for the other party&#8217;s material breach, subject to a specified notice and cure periods, or due to an insolvency event of the other party. In lieu of termination upon a party&#8217;s material breach due to non-payment of development costs within a specified time the non-breaching party may elect an alternative remedy which may involve modifications to their performance and payment obligations. We have the right to terminate by providing written notice in the event Chiesi or its affiliates or sublicensee brings a patent challenge and Chiesi </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">does not take certain steps to withdraw from or cease supporting such challenge. Chiesi may terminate the collaboration agreement for any reason upon prior written notice to us, subject to a notice period.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on multiple third-party manufacturers for the manufacture of seralutinib for preclinical and clinical testing. We intend to rely on third-party contract manufacturers for commercial manufacturing if seralutinib receives marketing approval. Typically, there are multiple sources for all of the materials required for the manufacture of seralutinib. Our manufacturing strategy enables us to more efficiently direct financial resources to the research, development and commercialization of seralutinib rather than diverting resources to internally develop manufacturing facilities. As seralutinib advances through development, we expect to enter into longer-term commercial supply agreements with key suppliers and manufacturers to fulfill and secure our production needs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seralutinib</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, with respect to seralutinib, we have exclusively licensed two issued U.S. patents owned by Pulmokine, which are not due to expire before 2037, excluding any additional term for patent term extension; one pending U.S. Patent application, which, if issued, is not due to expire before 2037, excluding any additional term for patent term extension; and a number of patents and pending applications in other jurisdictions, including issued patents in Mexico, Russia, Australia, India, Japan, South Korea, and New Zealand, and pending applications in, Brazil, Canada, China, the European Patent Convention, and New Zealand, which, if issued, are not due to expire before 2037, excluding any additional term for patent term extension. These patents and patent applications are directed to method of use claims.&#160; We have also exclusively licensed four issued U.S. patents co-owned by Pulmokine and Gilead Sciences, Inc., which are not due to expire before 2034, excluding any additional term for patent term extension; two pending U.S. patent applications which, if issued, are not due to expire before 2034, excluding any additional term for patent term extension; and a number of patents and pending patent applications in other jurisdictions, including issued patents in Australia, Canada, China, the European Patent Convention, Japan, and Hong Kong. These patents and patent applications are directed to seralutinib compound, formulation and method of use claims.&#160; We also own a pending patent application, which, if issued, is not due to expire before 2042, directed to forms of seralutinib, and a pending application, which, if issued, is not due to expire before 2043, directed to combination treatment with seralutinib.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process before it may be legally marketed in the United States.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib is subject to regulation as a combination product, which means that it is composed of both a drug product and device product. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a Center that will have primary jurisdiction over its regulation based on a determination of the combination product&#8217;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of seralutinib, the primary mode of action is attributable to the drug component of the product, which means that the FDA&#8217;s Center for Drug Evaluation and Research has primary jurisdiction over the premarket development, review and approval. Accordingly, we plan to investigate seralutinib through the Investigational New Drug, or IND, framework and seek approval through the NDA pathway. We do not anticipate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the FDA will require a separate medical device authorization for the device, but this could change during the course of its review of any marketing application that we may submit.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Drug Development Process</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">completion of certain preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory Practice, or GLP, regulations and other applicable regulations;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or GCP, regulations to establish the safety and efficacy of the proposed drug for its intended use;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">submission to the FDA of an NDA;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current GMP, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and potential inspection of selected clinical investigation sites to assess compliance with GCPs; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. An IND is a request for allowance from the FDA to administer an investigational drug product to humans. The sponsor will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the clinical trial lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements, and trials may not begin or continue under the IND until the FDA notifies the sponsor that the hold has been lifted. Submission of an IND therefore may or may not result in FDA allowance to begin a clinical trial.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations, which among other things, include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical Trials must be conducted under protocols </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND as well as any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, an independent IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The product candidate is initially introduced into healthy human volunteers and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The product candidate is further evaluated for dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and/or for the sponsor and the FDA to reach agreement on the next phase of development.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Combination Products in the United States</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain products may be comprised of components, such as drug components and device components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a drug, or device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, or device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any investigational drug, or device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA component for combination products, although it does not preclude consultations by the lead center with other components of FDA. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A combination product with a drug primary mode of action generally would be reviewed and approved pursuant to the drug approval processes under the FDCA. In reviewing the NDA application for such a product, however, FDA reviewers in the drug center could consult with their counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the Quality System, regulations applicable to medical devices.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NDA Review and Approval Process</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of product development, including results from preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA conducts a preliminary review of an NDA within the first 60 days after submission, before accepting the application for filing, to determine whether it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after it the application is submitted. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data or other significant and time consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA or, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct additional clinical or non-clinical testing, including Phase 4 testing, to further assess a drug&#8217;s safety and effectiveness after NDA approval, and may require additional testing and surveillance programs to monitor the safety of approved products. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS, and the FDA will not approve the application without an approved REMS. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers. However, competitors, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if an orphan designated product receives marketing approval for a disease or condition broader than what is designated, it may not be entitled to orphan exclusivity. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may seek approval of its product candidate under programs designed to expedite FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. For example, the FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, a product candidate is eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during development. With regard to a fast track product, the FDA may also consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any NDA for a product candidate submitted to the FDA for approval, including for a product candidate with a fast track designation or breakthrough designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review. An NDA is eligible for priority review if the product candidate is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, depending on the design of the applicable clinical trials, a product candidate may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will generally require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials and may require that such confirmatory trials be underway prior to granting accelerated approval. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval on an expedited basis if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product or if the sponsor fails to conduct such trials in a timely manner.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any drug products manufactured or distributed pursuant to FDA approvals will be subject to pervasive and continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Exclusivity</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA alternatively provides three years of non-patent exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to an existing period of regulatory exclusivity or patent term if a sponsor conducts clinical trials in children in response to a written request from the FDA. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Coverage and Reimbursement</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for seralutinib can be subject to challenge, reduction or denial by third-party payors.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. A third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider seralutinib to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Reform</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, or ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things: (1)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; (2)&#160;created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected; (3)&#160;established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in certain government healthcare programs; (4)&#160;expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; (5)&#160;expanded the eligibility criteria for Medicaid programs; (6)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; (7)&#160;established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (8)&#160;established a Center for Medicare and Medicaid Innovation at the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs. Since its enactment, there have been judicial and political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in aggregate reductions of Medicare payments to providers, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new manufacturer discounting program (which began in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Fraud and Abuse Laws and Compliance Requirements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws include anti-kickback and false claims laws and regulations, and transparency laws and regulations.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. Similar to the federal Anti-Kickback Statute, A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician providers including physician assistants and nurse practitioners, and teaching hospitals, and applicable manufacturers and applicable group </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchasing organizations to report annually to CMS ownership and investment interests held by physicians (as defined by statute) and their immediate family members.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar state, local and foreign laws and regulations may also restrict business practices in the biopharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. These laws and regulations may differ from one another in significant ways, thus further complicating compliance efforts. For instance, in the EU, many EU member states have adopted specific anti-gift statutes that further limit commercial practices for medicinal products, in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted national &#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on pharmaceutical companies. Certain countries also mandate implementation of commercial compliance programs, or require disclosure of marketing expenditures and pricing information.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure compliance with applicable healthcare laws and regulations can involve substantial costs. Violations of healthcare laws can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. and foreign healthcare programs, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Data Privacy and Security Laws</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state and federal laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, and federal and state consumer protection laws and regulations that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, we need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, or MA, commercial sales and distribution of our products. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-clinical studies and clinical trials</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the U.S., the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application, or CTA, much like the IND prior to the commencement of human clinical trials. Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on GCP as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the EU Clinical Trials Directive required a separate CTA to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical trial development may proceed. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practices , or GMP. Other national and EU-wide regulatory requirements may also apply.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Authorization</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market a medicinal product in the EU, we must obtain a MA. To obtain regulatory approval of an investigational medicinal product under EU regulatory systems, we must submit a MA application, or MAA. The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Centralized MAs&#8221; are issued by the EC through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the EU. The centralized procedure is mandatory for certain types of products, such as: (i) medicinal products derived from biotechnology medicinal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, (ii) designated orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs, and (iv) medicinal products containing a new active substance indicated for the treatment certain diseases, such as HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the above described procedures, before granting the MA, the regulatory authorities make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure the maximum timeframe for the evaluation of a MAA by the EMA is 210 days. In exceptional cases, the CHMP might perform an accelerated review of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIority MEdicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. In March 2016, the EMA launched an initiative, the PRIME scheme, a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.  </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;standard&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data and marketing exclusivity</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, new products authorized for marketing, or reference products, generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product was first authorized in the EU. During the additional two&#8209;year period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until 10 years have elapsed from the initial MA of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product candidate for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity is granted.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan designation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product may be designated as orphan if its sponsor can establish that (1) the product is intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition (2) either (a) such condition affects not more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return in the EU to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the EU or, if such method exists, the product will be of significant benefit to those affected by that condition. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, an application for designation as an orphan product can be made any time prior to the filing of an MAA. Orphan designation entitles a party to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of a MA, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the regulatory authorities cannot accept another MAA, or grant a MA, or accept an application to extend a MA for a similar product for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The orphan exclusivity period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example because the product is sufficiently profitable not to justify market exclusivity, or where the prevalence of the condition has increased above the threshold. Granting of an authorization for another similar orphan medicinal product can happen at any time if: (i) the second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior, (ii) inability of the applicant to supply sufficient quantities of the orphan medicinal product or (iii) where the applicant consents to a second orphan medicinal product application. A company may voluntarily remove a product from the orphan register.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the member states. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, or QPPV, who is responsible for establishment and maintenance of that system, and oversees the safety </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profiles of medicinal products and any emerging safety concerns. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new MAA must include a risk management plan, or RMP describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.  </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Regulation of Combination Products in the EU</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU regulates medical devices and medicinal products separately, through different legislative instruments, and the applicable requirements will vary depending on the type of drug-device combination product. EU guidance has been published to help manufacturers select the right regulatory framework.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug-delivery products intended to administer a medicinal product where the medicinal product and the device form a single integral product are regulated as medicinal products in the EU. The EMA is responsible for evaluating the quality, safety and efficacy of MAAs submitted through the centralized procedure, including the safety and performance of the medical device in relation to its use with the medicinal product. The EMA or the EU member state national competent authority will assess the product in accordance with the rules for medicinal products described above but the device part must comply with the Medical Devices Regulation (including the general safety and performance requirements provided in Annex I). MAA must include &#8211; where available &#8211; the results of the assessment of the conformity of the device part with the Medical Devices Regulation contained in the manufacturer&#8217;s EU declaration of conformity of the device or the relevant certificate issued by a notified body. If the MAA does not include the results of the conformity assessment and where for the conformity assessment of the device, if used separately, the involvement of a notified body is required, the competent authority must require the applicant to provide a notified body opinion on the conformity of the device.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By contrast, in case of drug-delivery products intended to administer a medicinal product where the device and the medicinal product do not form a single integral product (but are e.g. co-packaged), the medicinal product is regulated in accordance with the rules for medicinal products described above while the device part is regulated as a medical device and will have to comply with all the requirements set forth by the Medical Devices Regulation. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The characteristics of non-integral devices used for the administration of medicinal products may impact the quality, safety and efficacy profile of the medicinal products. To the extent that administration devices are co-packaged with the medicinal product or, in exceptional cases, where the use of a specific type of administration device is specifically provided for in the product information of the medicinal product, additional information may need to be provided in the MAA for the medicinal product on the characteristics of the medical device(s) that may impact on the quality, safety and/or efficacy of the medicinal product.  </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements regarding quality documentation for medicinal products when used with a medical device, including single integral products, co-packaged and referenced products, are outlined in the EMA guideline of July 22, 2021, which became applicable as of January 1, 2022.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned EU rules are generally applicable in the EEA.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Brexit and the Regulatory Framework in the United Kingdom</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the end of the Brexit transition period on January 1, 2021, and the implementation of the Windsor Framework on January 1, 2025, the United Kingdom, or UK, has not generally been directly subject to EU laws with respect to medicinal products. It is currently unclear to what extent the government of the UK will seek to align its regulations with the EU. The EU laws that have been transposed into UK law through secondary legislation remain applicable in Great Britain (England, Scotland and Wales), or GB, however, new legislation such as the (EU) CTR is not applicable in GB. Whilst the EU-UK Trade and Cooperation Agreement, or TCA, includes the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, it does not contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.  </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK Medicines and Medical Devices Act 2021 has introduced delegated powers in favor of the Secretary of State or an &#8216;appropriate authority&#8217; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, has been the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland Protocol, different rules  applied in Northern Ireland than in GB; broadly, Northern Ireland continued to follow the EU regulatory regime. However, on January 1, 2025, a new arrangement called the &#8220;Windsor Framework&#8221; came into effect and reintegrated Northern Ireland under the regulatory authority of the MHRA with respect to medicinal products. The Windsor Framework removes EU licensing processes, and EU labelling and serialization requirements in relation to Northern Ireland, and introduces a UK-wide licensing process for medicinal products.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MAs in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA holder opted-out. Under the terms of the Windsor Framework, these MAs became valid for the whole of the UK from January 1, 2025. In order to use the centralized procedure to obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, since Brexit, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures. Applications are governed by the Human Medicines Regulations (SI 2012/1916), as amended, and are made electronically through the MHRA Submissions Portal. The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicinal products that will benefit patients, including a 150-day assessment (subject to clock-stops) and a rolling review procedure. In addition, an international recognition procedure, or IRP, has been in place since January 1, 2024, whereby the MHRA will have regard to decisions on the approval of MAs made by the EMA and certain other regulators when determining an application for a new UK MA. Pursuant to the IRP, the MHRA will take into account the expertise and decision-making of trusted regulatory partners (i.e. the regulators in Australia, Canada, Switzerland, Singapore, Japan, the U.S. and the EU). The MHRA will conduct a targeted assessment of IRP applications but retain the authority to reject applications if the evidence provided is considered insufficiently robust. The IRP allows medicinal products approved by such trusted regulatory partners that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update an MA in the UK. Applications should be decided within a maximum of 60 days if there are no major objections identified that cannot be resolved within such 60-day period and the approval from the trusted regulatory partner selected has been granted within the previous 2 years or if there are such major objections identified or such approval has not been granted within the previous 2 years within 110 days. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals. In the UK, the initial duration of an MA is five years and following renewal will be valid for an unlimited period unless the MHRA decides on justified grounds relating to pharmacovigilance, to proceed with only one additional 5-year renewal. Any authorization which is not followed by the actual placing of the medicinal product on the market in the UK within 3 years shall cease to be in force.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pre-MA orphan designation in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market, i.e., the prevalence of the condition in the UK, rather than the EU, must not be more than five in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in the UK.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK regulatory framework in relation to clinical trials is derived from the now-repealed EU Clinical Trials Directive (as implemented into UK law, through the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended). The extent to which the regulation of clinical trials in the UK will mirror the (EU) CTR in the long term is not yet certain, however, on December 12, 2024, the UK government introduced a legislative proposal - the Medicines for Human Use (Clinical Trials) Amendment Regulations 2024 - that, if implemented, will replace the current regulatory framework for clinical trials in the UK. The legislative proposal aims to provide a more flexible regime to make it easier to conduct clinical trials in the UK, increase the transparency of clinical trials conducted in the UK and make clinical trials more patient centered. The UK government has provided the legislative proposal to the UK Parliament for its review and approval. Once the legislative proposal is approved (with or without amendment), it will be adopted into UK law which is expected in early 2026.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Data Privacy and Security Laws</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to laws and regulations in non-U.S. countries governing data privacy and the protection of personal data, including health-related data. Laws and regulations in the EU and other jurisdictions apply broadly to the collection, use, storage, disclosure, processing and security of personal data, and have generally become more stringent over time. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. Our employees are a team of highly dedicated, passionate individuals who pride themselves on a culture of respect, humility, transparency, inclusion, dedication, collaboration and fun. Our ultimate goal is to enhance and extend the lives of patients.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our philosophy is to offer a comprehensive compensation and benefits package to support our greatest assets, our people, and our human capital resources objectives include, as applicable, identifying, attracting, retaining and motivating our highly qualified management and our clinical, scientific and other employees and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and motivate personnel through the granting of stock-based and cash-based compensation awards, in order to align our interests and the interests of our stockholders with those of our employees and consultants.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;6, 2025, we had 144 full-time employees and 1 part-time employee. Of those 145 employees, 30, or 21%, have a Ph.D. or M.D., and 84, or 58%, are women. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the state of Delaware on October 26, 2015 under the name FSG, Bio, Inc. and changed our name to Gossamer Bio, Inc. in 2017. Our principal executive offices are located at 3115 Merryfield Row, Suite 120, San Diego, California 92121, and our telephone number is (858) 684-1300.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internet address is www.gossamerbio.com. Our investor relations website is located at http://ir.gossamerbio.com. We make available free of charge on our investor relations website under &#8220;filings&#8221; our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, our directors&#8217; and officers&#8217; Section 16 reports and any amendments to those reports as soon as reasonably practicable after filing or furnishing such materials to the US Securities and Exchange Commission, or SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov. We use our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor such website, in addition to following our press releases, SEC filings and public conference calls and webcasts. Information relating to our corporate governance is also included on our investor relations website. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing. Further, our references to the URLs for these websites are intended to be inactive textual references only.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_16"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, together with the other information contained in this annual report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations or financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in this Item 1A. </span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">We have a limited operating history, a history of losses and expect to incur additional losses in the future.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We will require substantial additional financing to achieve our goals.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We depend heavily on the ability to successfully advance seralutinib through clinical development. </span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our business may be adversely affected by difficulties or delays in enrolling patients in our current or planned clinical trials or the commencement or completion, or termination or suspension, of our current or planned clinical trials.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We operate in a highly regulated industry and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize seralutinib.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We are dependent on third parties to conduct our pre-clinical and clinical trials.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our business activities could be adversely affected by a global pandemic and other epidemic diseases.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We are dependent on third parties to manufacture seralutinib.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may not be successful in entering into or maintaining collaborations, licenses and other similar arrangements, including the maintenance of our collaboration with Chiesi.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f approved, the success of seralutinib will depend on meeting ongoing regulatory obligations, market acceptance and adequate coverage by governmental authorities and insurers.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our results of operations may fluctuate significantly.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our business relies on our ability to attract, retain and motivate highly qualified management, clinical and scientific personnel.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of seralutinib.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our business relies on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We must comply with our license agreements or we could lose our license rights to seralutinib.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our stock price is volatile, and investors may incur substantial losses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We have been involved in securities class action litigation and could be subject in the future to securities class action litigation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a relatively limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biopharmaceutical company with a relatively limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2017, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring and in-licensing product candidates and conducting preclinical studies and clinical trials. Seralutinib is in active clinical development. We have not yet demonstrated an ability to successfully complete any clinical trials beyond Phase 2, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since our inception. If seralutinib is not successfully developed and approved, we may never generate any revenue. Our net losses were $56.5 million and $179.8 million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $1,268.6 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Seralutinib will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for and potentially commercialize seralutinib and seek to identify, assess, acquire, in-license or develop additional product candidates.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of seralutinib, obtaining regulatory approval for seralutinib and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates beyond seralutinib or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our seralutinib development program, commercialization efforts or other operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to remain high in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of seralutinib, continue research and development, and seek regulatory approval for seralutinib. In addition, as seralutinib progresses through development and toward commercialization, we will need to make milestone payments to Pulmokine from whom we have in-licensed seralutinib. Furthermore, if and to the extent we seek to acquire or in-license additional product candidates in the future, we may be required to make significant upfront payments, milestone payments, and/or licensing payments. If we obtain regulatory approval for seralutinib, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of seralutinib. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operations for at least the next 12 months from the date this annual report is filed with the SEC. In particular, we expect that these funds will allow us to complete our registrational Phase 3 clinical trial in PAH for seralutinib. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the type, number, scope, progress, expansions, results, costs and timing of, our clinical trials and preclinical studies of seralutinib or product candidates we may choose to pursue in the future;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of manufacturing for seralutinib, including commercial manufacturing if seralutinib is approved;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs, timing and outcome of regulatory review of seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs associated with hiring additional personnel and consultants as our clinical activities increase;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and amount of the milestone or other payments we must make to Pulmokine from whom we have in-licensed seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of establishing or securing sales and marketing capabilities if seralutinib is approved;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for seralutinib, if approved;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs associated with any products or technologies that we may in-license or acquire.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials and preclinical studies is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, seralutinib, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all, including as a result of financial and credit market deterioration or instability, market-wide liquidity shortages, geopolitical events or otherwise. In addition, we may seek additional capital due to favorable market conditions or liquidity or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the notes.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we have sold $200.0 million in aggregate principal amount of 5.00% convertible senior notes due 2027 and have approximately $88.3 million of other liabilities, including trade payables. We may also incur additional indebtedness or liabilities to meet our future financing needs. Our indebtedness and liabilities could have significant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negative consequences for our stockholders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limiting our ability to obtain additional financing;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">making it more difficult or expensive for a third party to acquire us;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the notes; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including the notes, and our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain, financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or seralutinib</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings or other capital sources including potentially collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Regulatory Approval of Seralutinib</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend entirely on the success of </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">seralutinib</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, which is currently in Phase 3 clinical development. If we are unable to advance seralutinib in clinical development, obtain regulatory approval and ultimately commercialize seralutinib, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our only product candidate is currently in Phase 3 clinical development. We are conducting an open-label extension of our Phase 2 clinical trial of seralutinib in PAH which commenced in 2020, and we commenced a registrational Phase 3 clinical trial of seralutinib in PAH in the fourth quarter of 2023. We expect to activate clinical sites for a global registrational Phase 3 for the treatment of PH-ILD in the second half of 2025. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assumptions about why seralutinib is worthy of future development and potential approval in PAH, or any additional indications including PH-ILD, are based in part on data collected by other companies. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of seralutinib. The success of seralutinib will depend on several factors, including the following:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful enrollment in clinical trials and completion of clinical trials and preclinical studies with favorable results;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authority acceptance of our proposed design of future clinical trials and allowance to proceed with such clinical trials under INDs by the FDA or under similar applications by comparable regulatory authorities;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">receipt of marketing approvals from applicable regulatory authorities, including NDAs from the FDA and maintaining such approvals;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of seralutinib, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining an acceptable safety profile of seralutinib following any approval; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining and growing an organization of people who can develop seralutinib and our technology.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib is subject to regulation as a combination product, which means that it is composed of both a drug product and device product. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. Seralutinib, will therefore require review and coordination by FDA&#8217;s drug and device centers prior to approval, which may delay approval. Under FDA regulations, combination products are subject to current good manufacturing practice, or cGMP, requirements applicable to both drugs and devices, including the Quality System regulation currently applicable to medical devices in the United States. The EU regulates medical devices and medicinal products separately, through different legislative instruments, and the applicable requirements will vary depending on the type of drug-device combination product. Problems associated with the device component of seralutinib may delay or prevent approval. If the manufacturer of the device products make modifications, or if we elect to change a device component or develop our own proprietary device component, we will need to perform validation testing and obtain FDA and other regulatory authorization or certification prior to using the modified device component. If the FDA, any other regulatory authority or notified body fails to authorize or certify use of those modified devices in combination with seralutinib or take significant enforcement action against the manufacturer of the device component, we would not be able to market or may have to suspend marketing seralutinib in certain jurisdictions.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of seralutinib, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for seralutinib in clinical trials or in obtaining marketing approval thereafter. Given our current stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a treatment sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize seralutinib, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. In addition, some of our assumptions about why seralutinib is worthy of future development and potential approval are based on data collected by other companies. Seralutinib may not have favorable results in its Phase 3 clinical trial in PAH or the anticipated Phase 3 clinical trial in PH-ILD, or receive regulatory approval on a timely basis, if at all.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, seralutinib may unexpectedly fail. The historical failure rate for product candidates in our industry is high.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results from preclinical studies or clinical trials of seralutinib or a competitor&#8217;s product candidate in the same class may not predict the results of later clinical trials of seralutinib, and interim, topline or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many product candidates fail in clinical trials despite very promising early results. For example, our decision to advance seralutinib as a potential treatment for PAH is based in part on the efficacy of imatinib (Gleevec), a tyrosine kinase inhibitor with known activity against PDGF and marketed for oncology indications, observed by Novartis in a Phase 3 clinical trial; however, we may not observe similar efficacy in our Phase 3 clinical trial of seralutinib. Moreover, these and any future preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of seralutinib in PAH and other indications including PH-ILD, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of seralutinib, we must conduct extensive clinical studies to demonstrate the safety and efficacy of seralutinib in humans. For example, we are currently conducting a registrational Phase 3 clinical trial of seralutinib in PAH patients. In addition, before we can initiate clinical development for our product candidates, and in some cases, before we can pursue clinical development of a product candidate for a new potential indication, we must submit the results of preclinical studies to the FDA along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND, and we are also required to submit regulatory filings to foreign regulatory authorities for clinical trials outside of the United States.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether our ongoing or planned trials will begin on time or be completed on schedule, if at all. The commencement, data readouts and completion of clinical trials can be delayed for a number of reasons including delays related to:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies, including the doses and endpoints of our ongoing and planned Phase 3 clinical trial of seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining approval or positive opinion from one or more institutional review boards, or IRBs or ethics committees;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">IRBs refusing to approve, suspending or terminating a trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of a trial;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes to clinical trial protocol;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing sufficient quantities of seralutinib or obtaining sufficient quantities of combination therapies for use in clinical trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up, including subjects failing to remain in our trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects choosing an alternative treatment for PAH or other indications including PH-ILD for which we are developing seralutinib, or participating in competing clinical trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lack of adequate funding to continue a clinical trial;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects experiencing severe or unexpected drug-related adverse effects;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a facility manufacturing seralutinib or any of its components, including the device component of orally inhaled </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seralutinib</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of cGMP or similar foreign regulations or other applicable requirements, or infections or cross-contaminations of seralutinib in the manufacturing process;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements; third-party contractors not performing data collection or analysis in a timely or accurate manner; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such delays or regulatory feedback on our trial designs could also significantly increase the costs of our clinical trials, including our Phase 3 clinical trial of seralutinib. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs or ethics committees for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application concerned for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as contract research organizations, or CROs, may impact our developments plans. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is currently unclear to what extent UK will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from the now-repealed EU Clinical Trials Directive (as implemented into UK law, through the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended). The extent to which the regulation of clinical trials in the UK will mirror the (EU) CTR in the long term is not yet certain, however, on December 12, 2024, the UK government introduced a legislative proposal - the Medicines for Human Use (Clinical Trials) Amendment Regulations 2024 - that, if implemented, will replace the current regulatory framework for clinical trials in the UK. The legislative proposal aims to provide a more flexible regime to make it easier to conduct clinical trials in the UK, increase the transparency of clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials conducted in the UK and make clinical trials more patient centered. The UK government has provided the legislative proposal to the UK Parliament for its review and approval. Once the legislative proposal is approved (with or without amendment), it will be adopted into UK law which is expected in early 2026. Under the terms of the Protocol on Ireland/Northern Ireland, provisions of the (EU) CTR which relate to the manufacture and import of investigational medicinal products and auxiliary medicinal products apply in Northern Ireland. A decision by the UK government not to closely align its regulations with the new approach that has been adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries. Clinical trial submissions in the UK will not be able to be bundled with those of EU member states within the EMA CTIS, adding further complexity, cost and potential risk to future clinical and development activity in the UK.  </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may also be impacted.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials in foreign countries, as we currently and may continue to do for seralutinib, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks, including war, relevant to such foreign countries. For example, we are currently conducting our registrational Phase 3 study of seralutinib in PAH at sites outside the United States.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trial of seralutinib, the commercial prospects of seralutinib will be harmed, and our ability to generate product revenues from seralutinib will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down development and approval process for seralutinib and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of seralutinib. We may make formulation or manufacturing changes to seralutinib, in which case we may need to conduct additional preclinical studies to bridge our modified seralutinib to an earlier version. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize seralutinib and our competitors may be able to bring products to market before we do, and the commercial viability of seralutinib could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for seralutinib if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as may be required by the FDA or similar regulatory authorities outside the United States. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators and associated staff with the appropriate competencies and experience, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of subjects for each of our clinical trials. Potential subjects for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. For example, a limited number of patients are affected by PAH and other indications including PH-ILD, which are our target indication for seralutinib, and we have encountered difficulties enrolling patients in our previous clinical trials of seralutinib in PAH patients. We also may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our Phase 3 trial of seralutinib and monitoring such subjects adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. For example, PAH is a rare disease with limited patient pools from which to draw for our registrational Phase 3 trial. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient populations in PAH, if they are unwilling to enroll in a clinical trial with a placebo-controlled design or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of patients, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of seralutinib may be delayed. Our inability to enroll a sufficient number of subjects for our Phase 3 trial of seralutinib or any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of seralutinib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon seralutinib, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with seralutinib&#8217;s use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by seralutinib could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. For example, based upon the benefit / risk profile and in response to serious adverse events observed, we decided to terminate the Phase 1b/2 study for GB5121. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if seralutinib is associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon its development or limit its development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for seralutinib if approved. We may also be required to modify our study plans based on findings in our ongoing clinical trials. For example, although we believe seralutinib has been generally well tolerated in completed clinical trials, future clinical trials, including our Phase 3 trial of seralutinib in PAH patients may reveal adverse events inconsistent with the safety findings observed to date. For example, in 2013, results from a Phase 3 clinical trial in PAH of imatinib (Gleevec) showed statistically significant improvement in its primary efficacy endpoint, but systemic toxicities were also observed. Although we have not observed the systemic toxicities associated with imatinib, we cannot be certain that seralutinib will not exhibit similar or other toxicities in a larger Phase 3 clinical trial. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that as we test seralutinib in our Phase 3 trial in PAH, or as the use of seralutinib becomes more widespread if it receives regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if seralutinib receives marketing approval, and we or others later identify undesirable side effects caused by seralutinib, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may withdraw, suspend or limit approvals of seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to recall a product or change the way seralutinib is administered to patients;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients, or similar risk management measures;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to change the way seralutinib is distributed or administered, conduct additional clinical trials or change the labeling of seralutinib or be required to conduct additional post-marketing studies or surveillance;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of seralutinib may decrease significantly or seralutinib could become less competitive; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reputation may suffer.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of seralutinib, if approved, and could significantly harm our business, results of operations and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have completed Phase 2 clinical trials for multiple product candidates including seralutinib, we have not, as an organization, completed later-stage clinical trials or submitted an NDA, and we may be unable to do so for seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to successfully complete a pivotal clinical trial in order to obtain FDA or comparable foreign regulatory approval to market seralutinib. Carrying out later-stage clinical trials and the submission of a successful NDA or other comparable foreign regulatory submission is a complicated process. As an organization, we have completed four Phase 2 clinical trials, including a Phase 2 clinical trial of seralutinib, and are conducting a Phase 3 clinical trial of seralutinib in PAH. We have not yet completed any pivotal clinical trials for seralutinib or previous product candidates. We also have limited experience as a company in preparing, submitting marketing applications and have not previously submitted an NDA or other comparable foreign application for any product candidate. We may also conduct a number of clinical trials for seralutinib in parallel over the next several years, which may be a difficult process to manage with our limited resources and which may divert the attention of management. In addition, we have had limited interactions with the FDA and cannot be certain our Phase 3 clinical trial of seralutinib will be sufficient to support an NDA submission, even if we believe the results are sufficiently positive. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of seralutinib. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of seralutinib. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in submitting NDAs or other comparable foreign regulatory submissions for and commercializing seralutinib.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seralutinib is subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of seralutinib are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market seralutinib in foreign jurisdictions until we receive regulatory approval from the FDA and similarly, we are not permitted to market seralutinib until we receive foreign regulatory authorities&#8217; approval. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA and foreign regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize seralutinib in the United States or abroad, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that seralutinib is safe and effective for its intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for seralutinib are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for seralutinib either prior to or post-approval, or may object to elements of our clinical development program.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable foreign regulatory authorities could delay, limit or deny approval of seralutinib for many reasons, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to demonstrate that seralutinib&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may not agree that the data collected from clinical trials of seralutinib are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may disagree regarding the formulation, labeling and/or the specifications of seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may find deficiencies in the manufacturing processes or facilities of our third-party manufacturers with which we contract for clinical and commercial supplies; or the approval policies;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#8217; clinical data insufficient for approval; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market seralutinib, which would significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we eventually complete clinical trials and receive approval of an NDA or foreign marketing application for seralutinib, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS or similar risk management measures, which may be required to ensure safe use of the drug after approval. The FDA or the comparable foreign regulatory authority also may approve seralutinib for a more limited indication or patient population than we originally requested, and the FDA or comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of seralutinib and would materially adversely impact our business and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek an accelerated approval for seralutinib. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that seralutinib has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, confirmatory studies to verity and describe the drug&#8217;s predicted clinical benefit. If such confirmatory studies fail to verify the drug&#8217;s predicted clinical benefit or of the sponsor fails to conduct such studies in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. In addition, the Food and Drug Omnibus Reform Act of 2022, among other things, provided FDA statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we decide to submit an application seeking accelerated approval, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for seralutinib would result in a longer time period to commercialization of seralutinib, if any, could increase the cost of development of seralutinib and could harm our competitive position in the marketplace.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in the EU, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, marketing authorizations may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to the introduction of specific procedures. This may arise when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This type of marketing authorization is close to a conditional marketing authorization as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a marketing authorization. However, unlike a conditional marketing authorization, the applicant does not have to provide the missing data and will never have to. Although a marketing authorization &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the marketing authorization may be withdrawn where the risk-benefit ratio is no longer favorable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain or maintain orphan drug designations for seralutinib, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EC grants orphan designation based on the EMA&#8217;s Committee for Orphan Medicinal Products&#8217; opinion to promote the development of products (1) that are intended for the diagnosis, prevention or treatment that is life-threatening or chronically debilitating, and (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment, and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. We have received orphan drug designation in the United States and the EU for seralutinib for treatment of PAH and may seek additional orphan designations for seralutinib in the future. There can be no assurance that we will be able to maintain or obtain such designations.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. Upon grant of a marketing authorization in the EU, orphan medicinal products are entitled to ten years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. This period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the orphan designation criteria, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently conducting, and may in the future conduct, certain of our clinical trials for seralutinib outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting, and may in the future conduct, one or more of our clinical trials for seralutinib outside the United States. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, for such clinical trials not subject to an IND, the FDA will not accept the data as support for an application for marketing approval unless the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary.  Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in seralutinib not receiving approval for commercialization in the applicable jurisdiction. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additional foreign regulatory requirements;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign exchange fluctuations;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cultural differences in medical practice and clinical research;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diminished protection of intellectual property in some countries; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data or cause us not to proceed into further clinical development.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary or topline or data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between topline, preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of seralutinib, the approvability or commercialization of seralutinib and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding seralutinib or our business. If the topline, preliminary or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, seralutinib may be harmed, which could harm our business, results of operations, prospects or financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages, staffing limitations or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and foreign regulatory authorities to review and clear or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.  For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.  </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. If a prolonged government shutdown occurs, or if staffing or funding shortages or renewed global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to risks arising from pandemic and epidemic diseases.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future pandemic or epidemic disease outbreaks, and any supply chain disruptions or staffing shortages, could disrupt the manufacture or shipment of supplies of seralutinib for use in our research and clinical trials, delay, limit or prevent our employees and CROs from continuing or timely advancing research and development activities, impede our clinical trial initiation and recruitment and the ability of subjects to continue in clinical trials, impact the results of the clinical trial based on participants contracting the disease or otherwise increasing the number of observed adverse events, impede testing, monitoring, data collection and analysis and other related activities, any of which could delay our clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations. Any future pandemic or future epidemic disease outbreaks could also potentially further affect the business of the FDA or other regulatory authorities, which could result in delays in meetings related to planned clinical trials or other regulatory matters.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct many of our clinical trials and preclinical studies. Any failure by a third party to conduct the clinical trials according to GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on third parties to conduct our clinical trials and preclinical studies, including our ongoing and potential future clinical trials for seralutinib. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for seralutinib. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP or similar regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or foreign regulatory authorities conclude that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA or similar foreign applications we submit by the FDA or foreign regulatory authorities. Any such delay or rejection could prevent us from commercializing seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third parties terminate or their services are delayed, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical and preclinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties for the manufacture of seralutinib for clinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of seralutinib or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of seralutinib and related raw materials for clinical and preclinical development, as well as for commercial manufacture if seralutinib receives marketing approval. The facilities used by third-party manufacturers to manufacture seralutinib must be approved by the FDA or foreign regulatory authorities for the manufacture of seralutinib pursuant to inspections that will be conducted after we submit an NDA to the FDA or similar applications to foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP or similar requirements for manufacture of drug products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the manufacturing of high potency compounds, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of seralutinib or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market seralutinib, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of seralutinib, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our or a third party&#8217;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms and comply with cGMP or similar requirements outside of the United States could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an inability to initiate or continue clinical trials of </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seralutinib</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or any future product candidates under development;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay in submitting regulatory applications, or receiving marketing approvals, for seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to cease development or to recall batches of seralutinib; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the event of approval to market and commercialize seralutinib, an inability to meet commercial demands for seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we do not have long-term commitments or supply agreements with all of our third-party manufacturers. We may be unable to establish any supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of timely obtaining sufficient quantities of seralutinib or such quantities at an acceptable cost. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">breach of the manufacturing agreement by the third party;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to manufacture seralutinib according to our specifications;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to manufacture seralutinib according to our schedule or at all;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP or similar foreign regulations and that might be capable of manufacturing for us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of seralutinib. Further, our third-party manufacturers may experience manufacturing or shipping difficulties due to resource constraints or as a result of natural disasters, labor disputes, unstable political environments, or public health epidemics. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers, and we may be unable to replace them on a timely basis or at all.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of seralutinib may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into, and may in the future seek to enter into, collaborations, licenses and other similar arrangements and we may not realize the benefits of such relationships, or may not be successful in entering into such relationships</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, we entered into the collaboration agreement with Chiesi for the development and commercialization of seralutinib around the world, and we may in the future seek to enter into other collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize such product candidates or manufacturing constraints. For additional information regarding our collaboration with Chiesi, see the section titled &#8220;Business&#8212;License and Collaboration Agreements&#8221; included in this Form 10-K.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in our efforts to establish or maintain collaborations, including our collaboration with Chiesi, because third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time consuming and complex. Further, in connection with any such collaborations, we may have to relinquish valuable rights to our future revenue streams, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following the entry into our collaboration with Chiesi or any other strategic transaction or license, we will achieve an economic benefit that justifies such transaction. If we are successful in our efforts to establish any additional collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of seralutinib is delayed, the safety of seralutinib is questioned or sales of seralutinib, if approved, are unsatisfactory. In addition, our collaboration with Chiesi and any potential future collaborations may be terminable by Chiesi or our other strategic partners in certain circumstances, and we may not be able to adequately protect our rights under these agreements. Furthermore, our strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of seralutinib. For example, under the Chiesi collaboration, Chiesi received such rights and may not conduct development and commercialization activities in the same manner as we do. Any termination of the collaboration with Chiesi or of any other collaborations we enter into in the future, or any delay in entering into collaborations related to seralutinib, could delay the development and commercialization of seralutinib and reduce its competitiveness if it reaches the market, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we currently rely on other third parties to manufacture seralutinib and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Seralutinib</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for seralutinib, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, seralutinib, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with seralutinib, when and if it is approved.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following potential approval of seralutinib, the FDA or foreign regulatory authorities may impose significant restrictions on its indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA or foreign regulatory authorities may also require a REMS or similar risk management measures as a condition of approval of seralutinib, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves seralutinib, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for seralutinib will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs or similar requirements and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with seralutinib, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the marketing or manufacturing of seralutinib, withdrawal of seralutinib from the market or voluntary or mandatory product recalls;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizure or detention, or refusal to permit the import or export of seralutinib; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize seralutinib and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of seralutinib. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection,  revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before 2026. The revisions may however have a significant impact on the biopharmaceutical industry in the long term. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of seralutinib will depend upon the degree of its market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib may not be commercially successful. Even if seralutinib receives regulatory approval, it may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seralutinib will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of seralutinib will depend on a number of factors, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">demonstration of clinical efficacy and safety compared to other more-established products;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the indications for which seralutinib is approved;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any FDA- or foreign regulatory authorities- approved labeling;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the pricing and cost-effectiveness of seralutinib, as well as the cost of treatment with seralutinib in relation to alternative treatments and therapies;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with seralutinib in the absence of sufficient third-party coverage and adequate reimbursement;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any restrictions on the use of seralutinib, and the prevalence and severity of any adverse effects;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential product liability claims;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of market introduction of seralutinib as well as competitive drugs;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the effectiveness of our or any of our potential future collaborators&#8217; sales and marketing strategies; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unfavorable publicity relating to seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If seralutinib is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from seralutinib and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of seralutinib may require significant resources and may never be successful.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as seralutinib would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of seralutinib, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of seralutinib, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for seralutinib could limit our ability to market seralutinib and decrease our ability to generate revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as seralutinib, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for seralutinib by third-party payors will have an effect on our ability to successfully commercialize seralutinib. Even if we obtain coverage for seralutinib by a third-party payor, the resulting reimbursement payment rates may not be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for seralutinib, and any reimbursement that may become available may be decreased or eliminated in the future.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider seralutinib as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with seralutinib, pricing of existing drugs may limit the amount we will be able to charge for seralutinib. These payors may deny or revoke the reimbursement status of seralutinib or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize seralutinib and may not be able to obtain a satisfactory financial return on seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of seralutinib to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for seralutinib. Accordingly, in markets outside the United States, the reimbursement for seralutinib may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for seralutinib. We expect to experience pricing pressures in connection with the sale of seralutinib due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize seralutinib may be adversely affected.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with seralutinib. Seralutinib, if approved, will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the fields of PAH and other PH indications including PH-ILD. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to face competition for seralutinib from existing products and products in development. Seralutinib is a PDGFR, CSF1R and c-KIT inhibitor initially targeted for PAH and PH-ILD patients. We expect competition within the PAH indication will include prostanoids / prostacyclin receptor agonists, including Orenitram (United Therapeutics), Uptravi (Janssen), Tyvaso (United Therapeutics), and Remodulin (United Therapeutics), and activin ligand traps, including Winrevair (Merck). We also may face some competition from products used in Functional Class I and II patients, such as the oral PDE5 inhibitors, including Revatio (Pfizer Inc.) and Adcirca (United Therapeutics); the sGC stimulator Adempas (Bayer AG); and oral ERAs, including Tracleer (Janssen), Letairis (Gilead Sciences, Inc.) and Opsumit (Janssen); and combination PDE5 inhibitor / ERA therapies, such as Opsynvi (Janssen). We believe that, if approved, seralutinib could be used alongside all classes of approved therapies. PAH is also an active indication for investigational drugs, and we may face competition in the future from CS1 (Cereno Scientific), L606 (Liquidia / Pharmosa Biopharm Inc.), treprostinil palmitil (Insmed), ralinepag (United Therapeutics), and REGN13335 (Regeneron Pharmaceuticals, Inc.). Additionally, although not approved for the treatment of PAH, we may face competition from formulations of imatinib, including the one in development from Tenax Therapeutics and Inhibikase Therapeutics.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to face competition from Tyvaso (United Therapeutics) within the PH-ILD indication, as it is the only approved therapy for PH-ILD in the United States. There are no approved therapies for PH-ILD in the EU. PH-ILD is also an active indication for investigational drugs, and we may face competition in the future from L606 (Liquidia / Pharmosa Biopharm Inc.), sirolimus (OrphAI Therapeutics), treprostinil palmitil (Insmed, Inc.), MK-5475 (Merck), and mosliciguat (Pulmovant, Inc.).</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be other earlier stage clinical programs that, if approved, would compete with seralutinib. Many of our competitors have substantially greater financial, technical and human resources than we have. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields. Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for seralutinib are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The precise incidence and prevalence for all the conditions we aim to address with seralutinib are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with seralutinib, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market of seralutinib will ultimately depend upon, among other things, the diagnosis criteria included in the final label for seralutinib, the availability of alternative treatments and the safety, convenience, cost and efficacy of seralutinib relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with seralutinib or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for seralutinib, because our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell seralutinib, we may not be able to generate product revenue.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have started to build a commercial infrastructure, we have no formal internal sales, marketing or distribution capabilities, nor have we commercialized a product. If seralutinib ultimately receives regulatory approval, we, in collaboration with Chiesi, must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize seralutinib in the United States, which will be expensive and time consuming, or collaborate with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of seralutinib. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute seralutinib. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market seralutinib effectively. If we are not successful in commercializing seralutinib, either on our own in partnership with Chiesi or through arrangements with one or more third parties, we may not be able to generate any future product revenue, and we would incur significant additional losses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future profitability may depend, in part, on Chiesi's ability to operate in foreign markets, where they would be subject to additional regulatory burdens and other risks and uncertainties.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future profitability may depend, in part, on Chiesi's ability to develop and commercialize seralutinib in foreign markets and pay us royalties on commercial sales. Chiesi is not permitted to market or promote seralutinib before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for seralutinib. To obtain separate regulatory approval in many other countries, Chiesi must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of seralutinib. If we obtain regulatory approval of seralutinib and Chiesi ultimately commercializes seralutinib in foreign markets, we and Chiesi would be subject to additional risks and uncertainties, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">different regulatory requirements for approval of drugs in foreign countries;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced protection for intellectual property rights;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the existence of additional third-party patent rights of potential relevance to our business;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">new or unexpected changes in tariffs (including recent U.S. tariffs imposed or threatened to be imposed on other countries and any retaliatory actions taken by such countries), trade barriers and regulatory requirements;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign reimbursement, pricing and insurance regimes;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workforce uncertainty in countries where labor unrest is common;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, health epidemics, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Industry</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may fluctuate significantly, which makes our future results of operations difficult to predict and could cause our results of operations to fall below expectations or any guidance we may provide.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual results of operations may fluctuate significantly, which makes it difficult for us to predict our future results of operations. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to seralutinib, which may change from time to time;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">coverage and reimbursement policies with respect to seralutinib, if approved, and potential future drugs that compete with seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of manufacturing seralutinib, which may vary depending on the quantity of production and the terms of our agreements with third-party manufacturers;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and amount of the milestone or other payments we must make to Pulmokine and other third parties from whom we have in-licensed seralutinib, including payments due upon a change in control of our subsidiaries as well as timing and amount of the milestone or other payments we receive from Chiesi;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of demand for any approved products, which may vary significantly;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and success or failure of preclinical studies or clinical trials for seralutinib or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual results of operations. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or results of operations fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. The loss of services of any of these personnel could delay or prevent the successful development of seralutinib, initiation or completion of our clinical trials or the commercialization of seralutinib. Executive leadership transitions can be inherently difficult to manage and, as a result, we may experience disruption or have difficulty in maintaining or developing our business. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the increasingly intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has experienced a high rate of turnover for all personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had 144 full-time employees as of March&#160;6, 2025. As we continue development and pursue the potential commercialization of seralutinib, as well as function as a public company, we may need to expand our financial, development, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. If our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize seralutinib and to compete effectively will depend, in part, on our ability to manage any future growth effectively. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various federal, state and foreign healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable federal, state and foreign fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal false claims laws, including the civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to payments and other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers, or by the patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our consulting and advisory board arrangements with physicians and other healthcare providers, some of whom receive stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:9pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to governmental regulation and other legal obligations related to privacy, data protection and information security. Actual or perceived failures to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. Compliance with these data privacy and security requirements is rigorous and time-intensive and may increase our cost of doing business. Despite our efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm for actual or perceived failures to comply with such requirements, which could materially and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations and business grow, we may be subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and regulations promulgated thereunder, or collectively, HIPAA, imposes requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. Further, we may also be subject to other state laws governing the privacy, processing and protection of personal information. By way of example, California enacted the California Consumer Privacy Act, as amended by the California Privacy Rights Act, or collectively, the CCPA, requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Additional compliance investment and potential business process changes may also be required.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For example, in Europe, the General Data Protection Regulation, or GDPR, went into effect in May 2018, and imposes stringent requirements for controllers and processors of personal data. The GDPR allows EU and EEA member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain.  Case law from the Court of Justice of the European Union, or CJEU, states that reliance on the standard contractual clauses, or SCCs - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework, or DPF, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of 2021, we have also been subject to the United Kingdom&#8217;s data protection regime, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the United Kingdom Government), as a data transfer mechanism from the United Kingdom to U.S. entities self-certified under the DPF. Other foreign jurisdictions, such as China and Russia, are increasingly implementing or developing their own privacy regimes with complex and onerous compliance obligations and robust regulatory enforcement powers. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize seralutinib and may affect the prices we may set.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2010, the ACA was enacted in the United States. Among the provisions of the ACA of importance to seralutinib, the ACA: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the Public Health program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020, through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was enacted into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and the list of the subsequent 15 drugs that will be subject to negotiation, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize seralutinib, if approved.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for seralutinib, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, similar political, economic and regulatory developments may affect our or Chiesi's ability to profitably commercialize, or co-commercialize, seralutinib, if approved. For instance, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e. oncology and advanced therapy medicinal products as of 2025, orphan medicinal products as of 2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical trials of seralutinib and will face an even greater risk if we commercialize seralutinib. For example, we may be sued if seralutinib allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in seralutinib, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of seralutinib. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs to defend the related litigation;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant negative financial impact;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize seralutinib; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a decline in our stock price.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold approximately $10 million in aggregate product liability insurance coverage. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of seralutinib. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of seralutinib. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, Chiesi and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, Chiesi and any of our potential future collaborators are successful in commercializing seralutinib, the FDA and foreign regulatory authorities would require that we, Chiesi and any of our potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We, Chiesi and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we, Chiesi or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of seralutinib or delay in approval or clearance of future products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, including cGMP and similar requirements, (3) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (4) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies, similar to our approach in in-licensing seralutinib. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for seralutinib, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or seralutinib, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to seralutinib, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to seralutinib could have a material adverse effect on our financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we own issued patents in the United States and foreign countries, we cannot be certain that the claims in our U.S. pending patent applications and patent applications in foreign countries and jurisdictions will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries and jurisdictions, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting seralutinib by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">countries and jurisdictions other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is also expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensor in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize seralutinib may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights for seralutinib from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights for seralutinib. Additionally, our license agreement for seralutinib includes sublicenses from a third party, and we must rely on Pulmokine's compliance with its obligations under its original license agreement.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into an exclusive license agreement with Pulmokine, Inc. to obtain an exclusive license to certain intellectual property rights to develop and commercialize </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seralutinib</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This license agreement imposes, and we expect that any future license agreements where we in-license intellectual property, will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Additionally, our existing license agreement with Pulmokine includes sublicenses from a third party who is not the original licensor of the seralutinib intellectual property. Under this agreement, we must rely on Pulmokine to comply with its obligations under the primary license agreements under which it obtained rights in the applicable intellectual property, where we do not have a relationship with the original licensor of such rights. If Pulmokine fails to comply with its obligations under the upstream license agreement, the original third-party licensor may have the right to terminate the original license, which may terminate our license. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses from third parties to advance our research or allow commercialization of seralutinib, and we cannot provide any assurances that third-party patents do not exist which might be enforced against seralutinib in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the seralutinib, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our right to sublicense patents and other rights to third parties;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of seralutinib, and what activities satisfy those diligence obligations;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our right to transfer or assign the license; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize seralutinib, which would have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our license agreement with Pulmokine may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreement with Pulmokine with respect to any licensed product, we may be required to pay to Pulmokine, as applicable, a specified percentage of all revenue to be received in connection with such transaction.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect seralutinib or which effectively prevent others from commercializing competitive product candidates.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether seralutinib will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may not cover seralutinib or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter parties review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our predecessors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which we, our predecessors or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize seralutinib and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of seralutinib. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize seralutinib.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for seralutinib may be dependent on third parties.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position with respect to seralutinib. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the license agreement with Pulmokine, Gilead Sciences and Rensselaer the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering seralutinib, our ability to develop and commercialize seralutinib may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell seralutinib, which could prevent or delay new product introductions. Our business strategy depends on the successful development of seralutinib, which is a licensed technologies, into a commercial product. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell seralutinib.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the intellectual property rights we have licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work on seralutinib was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in seralutinib pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may be able to develop products that are similar to seralutinib but that are not covered by the claims of the patents that we own or license;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent application that we own or license;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors or predecessors might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import seralutinib and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing seralutinib. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the biopharmaceutical industry expands and more patents are issued, the risk increases that seralutinib may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of seralutinib, and we cannot be certain that we were the first to file a patent application related to seralutinib or related technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that seralutinib may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">result in costly litigation that may cause negative publicity;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cause development delays;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prevent us from commercializing seralutinib until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subject us to significant liability to third parties; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although no third party has asserted a claim of patent infringement against us as of the date of this annual report on Form 10-K, others may hold proprietary rights that could prevent seralutinib from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to seralutinib or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop seralutinib. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign seralutinib or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing seralutinib, which could harm our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can, because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at seralutinib, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on seralutinib. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize seralutinib or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivation or interference proceedings provoked by third parties or brought by us or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring seralutinib to market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1) file any patent application related to seralutinib or (2) invent any of the inventions claimed in our patents or patent applications.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a Unitary Patent and Unified Patent Court (UPC) system were implemented in Europe on June 1, 2023. This new regime may present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, by default automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect seralutinib.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on seralutinib for an adequate amount of time.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering seralutinib are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of seralutinib, patents protecting seralutinib might expire before or shortly after seralutinib is commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension for seralutinib, our business may be materially harmed.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of seralutinib, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of seralutinib. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have issued patents pending patent applications in the United States and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with seralutinib, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of seralutinib. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active, liquid and orderly market for our common stock may not be maintained.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock only began trading on the Nasdaq Global Select Market, or Nasdaq, in February 2019, and we can provide no assurance that we will be able to maintain an active trading market for our common stock. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to be volatile. Since the shares were sold in our initial public offering, or IPO, in February 2019 at a price of $16.00 per share, the price per share of our common stock has ranged as low as $0.45 and as high as $27.15 through March&#160;6, 2025. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price at which they paid. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to enroll subjects in our ongoing and planned clinical trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of our clinical trials and preclinical studies, and the results of trials of our competitors or those of other companies in our market sector;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory approval of seralutinib, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success or failure of our efforts to acquire, license or develop additional product candidates;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">innovations or new products developed by us or our competitors;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing, supply or distribution delays or shortages;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any changes to our relationship with Chiesi or any manufacturers, suppliers, licensors, future collaborators or other strategic partners;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">achievement of expected product sales and profitability;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">trading volume of our common stock;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an inability to obtain additional funding;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of our stock by insiders and stockholders;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions other events or factors, many of which are beyond our control, such as health pandemics, the military conflict between Russia and Ukraine and Israel and Hamas, inflation and interest changes and financial institution instability;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additions or departures of key personnel; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to meet the continued listing requirements of the Nasdaq could result in a delisting of our common stock.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to satisfy the continued listing requirements of the Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and greater than 5% stockholders, in the aggregate, own approximately 20.0% of our outstanding common stock as of March&#160;6, 2025. As a result, such persons or their appointees to our board of directors, acting together, have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, and our amended and restated bylaws provide that the federal district courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this exclusive forum provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our amended and restated bylaws also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history, do not expect to become profitable in the near future, and may never achieve profitability. To the extent that we continue to generate losses for tax purposes, such losses will carry forward to offset future taxable income, if any, until such losses are used to offset taxable income (if ever) or expire (if at all). As of December&#160;31, 2024, we had federal and state net operating loss carryforwards, or NOLs, of approximately $398.1 million and $3.3 million, respectively. Our state NOLs that are subject to expiration will begin to expire in 2036, unless previously utilized. Our federal NOLs are not subject to expiration but may only be used to offset 80% of our taxable income. As of December&#160;31, 2024, the Company has foreign NOLs of approximately $113.0 million. The foreign NOLs can be carried forward indefinitely. As of December&#160;31, 2024, we also had orphan drug credit and federal research tax credit carryforwards of approximately $48.2 million and California research tax credits of $13.2 million. The federal research tax credit carryforwards begin to expire in 2038. The California research tax credit carryforward does not expire and can be carried forward indefinitely until utilized.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NOLs and credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOLs and credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders (or groups of stockholders) in excess of 50 percentage points over a rolling three-year period. Similar rules may apply under state and foreign tax laws. In connection with our IPO in February 2019, we experienced an ownership change for purposes of Section 382 and 383 of the Code. We also experienced an ownership change in July 2023. Consequently, our federal NOLs and tax credits generated through July 2023 will be subject to annual limitations. Our NOLs are not expected to expire unused as a result of such annual limitations, assuming we otherwise have taxable income or income tax liabilities in future periods; however, we expect that some or all of the federal credits generated through July 2023 will expire prior to utilization. If additional ownership changes occur in the future as a result of changes in our stock ownership, many of which are outside our control, the NOL and credit carryforwards could be subject to further annual limitations. If we earn taxable income, such annual limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been involved in securities class action litigation and could be subject in the future to securities class action litigation.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. On April 3, 2020, we, certain of our executive officers and directors, and the underwriters of our IPO were named as defendants in a purported securities class action lawsuit. The complaint, as amended, was filed on behalf of all investors who purchased our securities pursuant to or traceable to our February 8, 2019 IPO, and alleged that we, and such executive officers and directors and the underwriters of our IPO, made false and/or misleading statements and failed to disclose material adverse facts about our business, operations and prospects. On September 30, 2022, the court entered a judgment approving the class action settlement in which we agreed to pay approximately $2.4 million, in exchange for customary releases and settlement terms. This lawsuit and any future lawsuits to which we may become a party are subject to inherent uncertainties and may be expensive and time-consuming to investigate, defend and resolve, and may divert our management&#8217;s attention and financial and other resources. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of future litigation, and we may not prevail. Any litigation to which we are a party may result in an onerous or unfavorable judgment that may not be reversed upon appeal, or in payments of substantial monetary damages or fines, or we may decide to settle this or other lawsuits on similarly unfavorable terms, which could adversely affect our business, financial condition, results of operations or stock price. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a smaller reporting company within the meaning of the Securities Act, and if we decide to take advantage of certain exemptions from various reporting requirements applicable to smaller reporting companies, our common stock could be less attractive to investors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company. For so long as we qualify as a smaller reporting company, we will have the option to take advantage of certain exemptions from various reporting and other requirements that are applicable to other public companies that are not smaller reporting companies, including, but not limited to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. In addition, for as long as we are deemed neither a large accelerated filer nor accelerated filer, we may continue to use the exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain a smaller reporting company and non-accelerated filer until we have a public float of $700 million or more as of the last business day of our most recently completed second fiscal quarter and annual revenues of less than $100 million, or a public float of $250 million or more as of the last business day of our most recently completed second fiscal quarter and annual revenues of $100 million or more. We will need to reassess, as of June 30, 2025, whether we will continue to qualify as a smaller reporting company and a non-accelerated filer for filings beyond the fiscal year ending December 31, 2025. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance for certain costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology, or IT, systems, or those of any of our CROs, manufacturers, other contractors or consultants or Chiesi or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our seralutinib development program, which could materially affect our results.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on IT systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, clinical trial data, and personal information, or collectively, Confidential Information, of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our cybersecurity program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and Confidential Information. Despite the implementation of security measures as part of our cybersecurity program, our IT systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to attack and damage from computer viruses and malware (e.g., ransomware), misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, cybersecurity threats, unauthorized </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">access, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon IT systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, Chiesi and certain of our service providers are from time to time subject to cyberattacks and security incidents, including but not limited to persistent brute force attempts and password spraying, targeted spearphishing and smishing (text message phishing), email phishing including malware attempts, and third-party vendor cybersecurity incidents and related data breaches. . While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access Confidential Information, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. The loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We could also incur liability and the further development and commercialization of seralutinib could be delayed.  In addition, we also rely on third parties to manufacture seralutinib, so similar events relating to their computer systems could also have a material adverse effect on our business. Some of the federal, state and foreign government requirements under data privacy and security laws include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our service providers or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. Further, our insurance coverage may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems. To the extent that any disruption or security breach were to result in violations of privacy and security laws, we could also be subject to significant fines, penalties or liabilities, which could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce seralutinib. Our ability to obtain clinical supplies of seralutinib could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions and adverse developments with respect to financial institutions and associated liquidity risk could adversely affect our business, financial condition and stock price.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The global credit and financial markets are currently, and have from time to time experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the ongoing conflict between Russia and Ukraine and Israel and Hamas, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. Additionally, any adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term working capital needs, and create additional market and economic uncertainty. For example, in 2023 the closures of Silicon Valley Bank, or SVB, and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation, or FDIC created bank-specific and broader financial institution liquidity risk and concerns. There can be no assurance that future credit and financial market instability and a deterioration in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions. If the equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, financial institutions, manufacturers and other partners may be adversely affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell seralutinib abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact our ability to continue activities at clinical trial sites within regions covered by such sanctions. For example, as a result of the military conflict between Russia and Ukraine, the United States and its European allies have recently announced the imposition of sanctions on certain industry sectors and parties in Russia and the regions of Donetsk and Luhansk in Ukraine, as well as enhanced export controls on certain products and industries. These and any additional sanctions and export controls, as well as any economic countermeasures by the governments of Russia or other jurisdictions, could adversely impact our ability to continue activities at clinical trial sites within regions covered by such sanctions or directly or indirectly disrupt our supply chain. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that apply to us. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations applicable to public companies have increased and may continue to increase our legal and financial compliance costs and to make some activities more time consuming and costly. If these requirements divert </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations make it more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. If these analysts cease coverage of our company, the trading price for our stock would be negatively impacted. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of Sarbanes-Oxley, our management is required to annually report upon the effectiveness of our internal control over financial reporting. However, as a smaller reporting company and a non-accelerated filer and in accordance with new SEC rules effective in 2020, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 for as long as we are not deemed an &#8220;accelerated filer&#8221; or &#8220;large accelerated filer. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have determined that our internal control over financial reporting was effective as of December&#160;31, 2024, we cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws may materially adversely affect our financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances, including in the United States or Ireland, could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business operations and financial performance. We are currently unable to predict whether such changes will occur and, if such changes do occur, the ultimate impact on our business. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes may materially and adversely impact our business, financial condition, results of operations and cash flows.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_19"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="margin-top:10pt;text-indent:72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity.</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-36" escape="true"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity governance program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-38" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-37">Our cybersecurity governance program includes reporting channels to the executive management team and an internal Cybersecurity Oversight Committee, as well as governance processes which communicate cybersecurity risks to departments across the organization, including legal, strategic, operational, and financial areas.</ix:nonNumeric></ix:nonNumeric> This encourages consideration of cybersecurity oversight, accountability and diligence across the organization.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key elements of our cybersecurity governance program includes but are not limited to the following:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Processes to assess cybersecurity risk, designed to help identify material risks from cybersecurity threats to critical systems and information;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a security team principally responsible for coordinating and managing (1) cybersecurity risk evaluation processes, (2) implementation of cybersecurity controls, and (3) response to cybersecurity incidents;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of the organization&#8217;s cybersecurity processes;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cybersecurity awareness training of employees, including incident response personnel including third party providers, and senior management; </span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a cybersecurity incident response plan which includes procedures for responding to cybersecurity incidents; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-39">a <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-40">third-party risk management</ix:nonNumeric> process for key service providers based on our assessment of their criticality to our operations and respective risk profile.</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-41">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, which have materially affected us, including our operations, business strategy, results of operations, or financial condition.</ix:nonNumeric> We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect the organization, including operations, business strategy, results of operations, or financial condition. See &#8220;Risk Factors - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or Chiesi or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our seralutinib development program, which could materially affect our results.&#8221;</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-42" continuedAt="f-42-1" escape="true"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Governance</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-43" escape="true">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated oversight of cybersecurity risks, including oversight of management&#8217;s implementation of the cybersecurity governance program.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-46" continuedAt="f-46-1" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-45" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-44" escape="true">The <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-47">Audit Committee</ix:nonNumeric> receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-48">The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-42-1" continuedAt="f-42-2"><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-46-1"> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-49" continuedAt="f-49-1" escape="true">Assessment and management of material risks from cybersecurity threats are performed by the Executive Director, Information Security, Risk &amp; Compliance and the Vice President, IT and Facilities, reporting to the Executive Vice President, Technical Operations and Administration. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-50" escape="true">Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions</ix:nonNumeric>, in addition to holding active technical cybersecurity certifications and maintaining active membership in cybersecurity professional organizations, as well as local groups, to support knowledge share and ongoing cybersecurity professional development.</ix:nonNumeric></ix:continuation><ix:continuation id="f-49-1" continuedAt="f-49-2"> </ix:continuation></span></div></ix:continuation><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-49-2"><ix:continuation id="f-42-2">Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us and alerts and reports produced by security tools deployed in our IT environment.</ix:continuation></ix:continuation>  </span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_25"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in San Diego, California, where we currently lease approximately 18,421 square feet of office space. We use our corporate headquarters primarily for corporate, research, development, clinical, regulatory, manufacturing and quality functions. Our lease for this facility expires in October 2029. We believe that our facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_28"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_31"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_37"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;GOSS.&#8221;</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Common Stock</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;6, 2025, there were 227,221,261 shares of our common stock outstanding held by approximately 34 holders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;12 of Part III of this Annual Report on Form&#160;10-K for information about our equity compensation plans which is incorporated by reference herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock performance graph compares our total stock return with the total return for (i)&#160;the Nasdaq Composite Index and the (ii)&#160;the Nasdaq Biotechnology Index for the period from February 8, 2019 (the date our common stock commenced trading on the Nasdaq Global Select Market) through December&#160;31, 2024. The figures represented below assume an investment of $100 in our common stock at the closing price of $17.94 on February 8, 2019 and in the Nasdaq Composite Index and the Nasdaq Biotechnology Index on February 8, 2019 and the reinvestment of dividends into shares of common stock. The comparisons in the graph are not intended to forecast or be indicative of possible future performance of our common stock.</span></div><div style="margin-top:10pt"><img src="goss-20241231_g2.jpg" alt="Graph - stock comparison - 2024.jpg" style="height:412px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Repurchases of Equity Securities</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_40"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_43"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this annual report. This discussion and analysis contains forward-looking statements based upon our current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; or in other parts of this annual report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of PH, including PAH and PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with PH. In May 2024, we entered into the collaboration agreement for seralutinib with Chiesi. In December 2022, we announced positive topline results from the Phase 2 TORREY Study in PAH patients. In the fourth quarter of 2023, we initiated the registrational Phase 3 PROSERA Study in PAH. We expect to report topline data from the PROSERA study in the fourth quarter of 2025. In addition to PAH, we believe that seralutinib holds potential as a therapeutic for the treatment of PH-ILD. We expect to activate clinical sites for a global registrational Phase 3 for the treatment of PH-ILD in the second half of 2025. We have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. Our employees are a team of highly dedicated, passionate individuals who pride themselves on a culture of respect, humility, transparency, inclusion, dedication, collaboration and fun. Our ultimate goal is to enhance and extend the lives of patients.</span></div><div style="margin-top:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in October 2015 and commenced operations in 2017. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring and in-licensing our product candidates and conducting preclinical studies and clinical trials. We have funded our operations primarily through equity financings and the collaboration agreement. We raised $1,401.1 million from October 2017 through December&#160;31, 2024&#160;through the sale of Series A and Series B convertible preferred stock,&#160;issuance of convertible notes,&#160;proceeds from our IPO, completed in February 2019, proceeds from 2027 Notes (as defined below), issuance of common stock in May 2020 and July 2022, issuance of common stock and accompanying warrants in July 2023 and entry into the collaboration agreement in May 2024. As of December&#160;31, 2024, we had $294.5&#160;million in cash, cash equivalents and marketable securities.</span></div><div style="margin-top:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since our inception and expect to continue to incur significant operating losses for the foreseeable future. For the years ended December&#160;31, 2024 and 2023, our net loss was $56.5 million and $179.8 million, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $1,268.6 million. We expect to incur expenses and operating losses for the foreseeable future as we continue our development of and seek regulatory approvals for seralutinib, including the conduct of ongoing and planned clinical trials and other research and development activities; and as we hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company. In addition, as seralutinib progresses through development and toward commercialization, we will need to make milestone payments to Pulmokine from whom we have in-licensed seralutinib. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending in particular on the timing of our clinical trials and preclinical studies and our expenditures on other research and development activities.</span></div><div style="margin-top:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, we announced a strategic global partnership with Chiesi. Under the terms of the collaboration agreement, we granted Chiesi exclusive licenses for the worldwide development, manufacture and commercialization of seralutinib and licensed products and an Equity Option to purchase our common stock. The total potential transaction value includes the one-time $160.0 million development cost reimbursement payment for licenses, research and development funding, and certain regulatory and commercial milestones. We and Chiesi share equally in the costs of ongoing global seralutinib clinical development and the costs of commercialization in the United States, with the exception of the PROSERA Phase 3 study, for which we bear all costs. We are also eligible for double-digit royalties in the mid-to-high teens percentage on tiers of annual net sales outside of the U.S. and to an equal share of profits and losses from the commercialization of seralutinib and licensed products in the U.S. .  For additional information regarding the collaboration agreement, as well as our license agreement with Pulmokine, see the section titled &#8220;Business&#8212;License and Collaboration Agreements&#8221; in this annual report. </span></div><div style="margin-top:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain regulatory approval for seralutinib, which we expect will take a number of years. If we obtain regulatory approval for seralutinib, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate substantial product revenues to support our cost structure, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional capital when needed, we could be forced to delay, limit, reduce or terminate seralutinib development or future commercialization efforts or grant additional rights to develop and market seralutinib even if we would otherwise prefer to retain such right.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have generated all of our revenue from our collaboration agreement with Chiesi. Our revenue consists of a one-time development cost reimbursement payment for licenses and ongoing cost-sharing payments for performance of research and development services classified as revenue from contracts with collaborators.</span></div><div style="margin-top:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of license fees and other upfront payments, other funded research and development agreements, milestone payments, product sales, other third-party funding, US profit/loss share and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of performance of research and development services, the timing of our achievement of regulatory and commercialization milestones, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized. If we are unable to fund our development costs or we are unable to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues and our results of operations and financial position would be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses relate primarily to preclinical and clinical development of seralutinib, as well as our discontinued clinical product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include or could include:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in research and development efforts;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">external research and development expenses incurred under agreements with contract research organizations, or CROs, investigative sites and consultants to conduct our clinical trials and preclinical and non-clinical studies;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laboratory supplies;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs related to manufacturing our product candidates for clinical trials and preclinical studies, including fees paid to third-party manufacturers;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs related to compliance with regulatory requirements; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance, equipment and other supplies.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct research and development expenses consist principally of external costs, such as fees paid to CROs, investigative sites and consultants in connection with our clinical trials, preclinical and non-clinical studies, and costs related to manufacturing clinical trial materials. We deploy our personnel and facility related resources across all of our research and development activities. We track external costs and personnel expense on a program-by-program basis and allocate common expenses, such as facility related resources, to each program based on the personnel resources allocated to such program. Stock-based compensation and personnel and common expenses not attributable to a specific program are considered unallocated research and development expenses. We categorize Terminated Programs as any research and development expenses attributable to our clinical stage product candidates that were terminated prior to December 31, 2023. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur research and development expenses for the foreseeable future as we continue the development of seralutinib. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of seralutinib due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to how much funding to direct to seralutinib on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments and our ongoing assessments as to seralutinib's commercial potential. We will need to raise substantial additional capital in the future.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical development costs may vary significantly based on factors such as:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">per patient trial costs;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of trials required for approval;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of sites included in the trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the countries in which the trials are conducted;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients that participate in the trials;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of doses that patients receive;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential additional safety monitoring requested by regulatory agencies;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the duration of patient participation in the trials and follow-up;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost and timing of manufacturing seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs incurred as a result of health epidemics and pandemics, including the COVID-19 pandemic, and clinical site staff shortages, including clinical trial delays;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the phase 3 stage of development for seralutinib; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and safety profile of seralutinib.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In process research and development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In process research and development, or IPR&amp;D, expenses include IPR&amp;D acquired as part of an asset acquisition or in-license for which there is no alternative future use, are expensed as incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance and other administrative functions. Other significant costs include facility-related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services and insurance costs.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur general and administrative expenses for the foreseeable future to support our current infrastructure and continued costs of operating as a public company. These expenses will likely include audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists of (1) interest income on our cash, cash equivalents and marketable securities, (2) investment accretion, (3) interest expense related to our Credit Facility, prior to its termination and the 2027 Notes, (4) research and development tax credit and (5) other miscellaneous income (expense).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax provision from income taxes is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenue, expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions (See Note 2 to our consolidated financial statements).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our licensing and other agreements are collaborative arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. For arrangements that we determine are collaborations, we identify each unit of account, and then determine whether a customer relationship exists for that unit of account. If we determine a performance obligation within the collaborative arrangement to be with a customer, we apply our revenue recognition accounting policy. If a portion of a distinct bundle of goods or services within the collaborative arrangement is not with a customer, we apply recognition and measurement based on an analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational and consistently applied accounting policy election. To the extent the arrangement is within the scope of Accounting Standards Codification, or ASC, Topic 808, we assess whether aspects of the arrangement between us and the collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC Topic 606, Revenue from Contracts with Customers (ASC 606).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers, or Topic 606, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price, reduced by a consideration payable to a customer, that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. We utilize key assumptions to determine a stand-alone selling price for performance obligations, which may include forecasted revenues or costs, expected development timelines, discount rates and probabilities of technical and regulatory success.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_55"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Years Ended December&#160;31, 2024 and 2023</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our selected statements of operations data for the years ended December&#160;31, 2024 and 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024 vs 2023 Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sale of licenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from contracts with collaborators</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,701&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,701&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In process research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,000)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174,620&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183,759&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,139)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,919)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(183,759)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,517)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,511)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,994&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,284&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,942&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,817)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,528)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,817)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, our revenue was $114.7 million. Our revenue is generated from our ongoing collaboration with Chiesi and consists of a one-time development cost reimbursement payment for the licenses and ongoing cost-sharing payments for performance of research and development and pre-commercial services.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $138.5 million for the year ended December&#160;31, 2024, compared to $135.3 million for the year ended December&#160;31, 2023, for an increase of $3.2 million, which was primarily attributable to an increase of $36.1 million of costs associated with clinical trials for seralutinib, offset by a decrease of $32.9 million of costs associated with preclinical studies and clinical trials for terminated programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows our research and development expenses by program for the years ended December&#160;31, 2024 and 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terminated programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In process research and development expenses</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no IPR&amp;D expenses for the year ended December&#160;31, 2024. IPR&amp;D expenses for the year ended December&#160;31, 2023 were $10.0 million, which was attributable to a milestone obligation incurred upon the initiation of the Phase 3 clinical trial of seralutinib in the fourth quarter of 2023 and paid to Pulmokine in 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $36.1 million for the year ended December&#160;31, 2024, compared to $38.5 million for the year ended December&#160;31, 2023, for a decrease of $2.3 million, which was primarily attributable to a $2.2 million decrease in stock-based compensation expense, a decrease of $0.8 million in legal expense, a decrease of $0.6 million in insurance costs, offset by an increase of $0.6 million in professional services expense and an increase of $0.4 million in travel costs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $4.3 million for the year ended December&#160;31, 2024, compared to other income, net of $3.9 million for the year ended December&#160;31, 2023, for an increase of $0.3 million, which was primarily attributable to a $3.2 million increase in investment accretion and a $2.0 million decrease in interest expense, offset by a $3.6 million decrease in other income primarily related to $2.8 million of employee retention credit under the CARES Act and $1.0 million of Ireland Corporate R&amp;D tax credit.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the tax expense was $0.9 million, which was primarily attributable to the treatment of the Chiesi income and a partial release of the valuation allowance. There was no provision for income taxes for the year ended December&#160;31, 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Years Ended December&#160;31, 2023 and 2022</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of our financial condition and results of operations for the year ended December&#160;31, 2023 and the comparison of 2023 and 2022 results included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1728117/000172811724000019/goss-20231231.htm">Annual Report on Form 10-K</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2023 is incorporated by reference into this MD&amp;A.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial operating losses since our inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December&#160;31, 2024 and 2023, we had an accumulated deficit of $1,268.6 million and $1,212.0 million, respectively.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We may also use cash on hand to repurchase 2027 Notes through open-market transactions, including through a Rule 10b5-1 trading plan to facilitate open-market repurchases, or otherwise, from time to time.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreement with Pulmokine, we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under the agreement. As of December&#160;31, 2024, we were </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to estimate the timing or likelihood of achieving the milestones or making future product sales. Other contractual obligations include future payments under the 2027 Notes and existing operating leases.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception through the year ended December&#160;31, 2024, our operations have been financed primarily by proceeds of $1,401.1 million from the sale of Series A and Series B convertible preferred stock, proceeds from our IPO, proceeds from the 2027 Notes, proceeds from issuance of common stock in May 2020 and July 2022, proceeds from issuance of common stock and accompanying warrants in July 2023 and the collaboration agreement with Chiesi.&#160;As of December&#160;31, 2024, we had cash, cash equivalents and marketable securities of $294.5&#160;million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to capital preservation and liquidity.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2020, we filed a registration statement on Form S-3, or the 2020 Shelf Registration Statement, covering the offering from time to time of common stock, preferred stock, debt securities, warrants and units, which registration statement became automatically effective on April 10, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, we issued $200.0 million aggregate principal amount 5.00% convertible senior notes due 2027 in a registered public offering, or the 2027 Notes. The interest rate on the 2027 Notes is fixed at 5.00% per annum. Interest is payable semi-annually in arrears on June 1 and December 1 of each year commencing on December 1, 2020. The total net proceeds from the 2027 Notes, after deducting the underwriting discounts and commissions and other offering costs, were approximately $193.6 million. Concurrent with the registered underwritten public offering of the 2027 Notes, we completed an underwritten public offering of 9,433,963 shares of our common stock. We received net proceeds of $117.1 million, after deducting underwriting discounts and commissions and other offering costs. Our concurrent offerings of 2027 Notes and common stock were registered pursuant to the 2020 Shelf Registration Statement.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we completed a private placement of 16,649,365 shares of our common stock. The aggregate gross proceeds for the private placement were approximately $120.1 million, before deducting offering expenses. On August 9, 2022, we filed a registration statement on Form S-3 registering the resale of the shares of common stock issued in the private placement, which became automatically effective on August 9, 2022.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2023, we completed a private placement of 129,869,440 shares of our common stock and 32,467,360 accompanying warrants. The aggregate gross proceeds for the private placement were $212.1 million, before deducting offering expenses. On August 18, 2023, we filed a registration statement on Form S-3 registering the resale of the shares of common stock and shares of common stock issuable upon the exercise of warrants issued in the private placement, which was declared effective on August 28, 2023.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, we entered into the collaboration agreement with Chiesi. In consideration and as reimbursement for our development costs, Chiesi paid us an up-front, nonrefundable payment of $160.0&#160;million. In addition, we and Chiesi share equally in the costs of ongoing global seralutinib clinical development, with the exception of the PROSERA Phase 3 study, and the costs of commercialization in the United States. For the year ended on December&#160;31, 2024, we received cost-sharing payments from Chiesi in the amount of $7.8&#160;million.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about our long-term borrowings is presented in Note 5 &#8220;Indebtedness&#8221; and operating leases is presented in Note 11 "Commitments and Contingencies" to the Notes to Consolidated Financial Statements included in Part II, Item 8, of this Form 10-K, herein by this reference.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for each of the years shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,488)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,864)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,494)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, operating activities used approximately $3.5 million of cash, primarily resulting from a net loss of $56.5 million and changes in amortization of premium on investments, net of accretion of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discount, of $13.1 million, reduced by stock-based compensation expense of $20.6 million and changes in contract liabilities of $55.9 million.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, operating activities used approximately $159.2 million of cash, primarily resulting from a net loss of $179.8 million and changes in accrued research and development expenses of $7.8 million, changes in amortization of premium on investments of $9.5 million, reduced by stock-based compensation expense of $28.5 million and in process research and development expense of $10.0 million.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, operating activities used approximately $187.0 million of cash, primarily resulting from a net loss of $229.4 million and payments against operating lease liabilities of $2.7 million, partially reduced by stock-based compensation expense of $42.6 million and amortization of operating lease right-of-use assets of $2.6 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, investing activities provided approximately $29.0 million of cash, primarily resulting from the maturities of marketable securities of $523.8 million, offset by purchases of marketable securities of $494.8 million.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, investing activities used approximately $111.0 million of cash, primarily resulting from the purchases of marketable securities of $441.7 million, offset by the maturities of marketable securities of $330.7 million.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, investing activities used approximately $1.0 million of cash, primarily resulting from the purchase of marketable securities of $238.0 million and the purchase of property and equipment of $0.4 million, partially offset by maturities of marketable securities of $237.5 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, financing activities used $11.5 million of cash, resulting from the principal repayment of long-term debt of $12.6 million, reduced by the proceeds from the issuance of equity option pursuant to stock purchase agreement with Chiesi of $0.5 million and the proceeds from issuance of common stock pursuant to the ESPP of $0.6 million.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, financing activities provided $190.2 million of cash, primarily resulting from proceeds from the issuance of common stock and warrants in a private offering of $201.3 million, reduced by the principal repayments of long-term debt of $11.6 million.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, financing activities provided $117.1 million of cash, primarily resulting from proceeds from the purchase of shares pursuant to our 2019 Employee Stock Purchase Plan, or ESPP, of $1.2 million, proceeds from the private offering of $119.9 million, and proceeds from the exercise of stock options of $1.7 million, partially offset by the principal repayments of long-term debt of $5.8 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations through at least the next 12 months from the date these consolidated financial statements were available to be issued. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing seralutinib in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the type, number, scope, progress, enrollment pace, expansions, results, costs and timing of, our preclinical studies and clinical trials of seralutinib which we are pursuing or may choose to pursue in the future;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of manufacturing for seralutinib;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs, timing and outcome of regulatory review of seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs associated with hiring additional personnel and consultants to continue the development and potential commercialization of seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and amount of the milestone or other payments we must make to Pulmokine from whom we have in-licensed seralutinib;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of establishing or securing sales and marketing capabilities if seralutinib is approved;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs associated with any products or technologies that we may in-license or acquire; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any delays and cost increases that result from epidemic diseases.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial product revenues to support our cost structure, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional capital when needed, we could be forced to delay, limit, reduce or terminate seralutinib development or future commercialization efforts or grant rights to develop and market seralutinib even if we would otherwise prefer to develop and market seralutinib ourselves.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_61"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to our consolidated financial statements included elsewhere in this annual report.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_64"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. As of December&#160;31, 2024 our cash and cash equivalents consisted of cash, money market funds and commercial paper, and our marketable securities consisted of commercial paper, corporate debt securities and U.S. Treasury and agency securities. We do not believe that we have a material exposure to interest rate risk. A 100 basis points change in interest rates would not have a significant impact on the total value of our portfolio.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in foreign currency exchange rates associated with our foreign operations where we conduct business in local currencies. We also contract with vendors that are located outside of the United States and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. We do not currently hedge our foreign currency exchange rate risk. As of December&#160;31, 2024 and 2023, we had minimal assets and liabilities denominated in foreign currencies and an immediate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change of 10% in the exchange rate of the foreign currencies would result in a net impact of approximately $0.1 million in our consolidated balance sheets and consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. Inflationary factors, such as increases in the cost of our materials, supplies, and overhead costs may adversely affect our operating results. Although we do not believe that inflation had a material effect on our business, financial condition or results of operations during the periods presented, we may experience adverse effects if inflation rates increase. Significant adverse changes in inflation and prices in the future could result in material losses.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_67"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements required pursuant to this item are incorporated by reference herein from the applicable information included in Item&#160;15 of this annual report and are presented beginning on page&#160;F-1.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_70"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_73"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this annual report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2024 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in its 2013 Internal Control&#160;&#8212; Integrated Framework. Based on this assessment, our management has concluded that our&#160;internal control over financial reporting was effective as of December&#160;31, 2024.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_76"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2024, none of our officers or directors <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-51"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-52">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-54">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non Rule 10b5-1 trading arrangement."</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_79"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_85"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission in connection with our 2025 Annual Meeting of Stockholders, or the Definitive Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December&#160;31, 2024, under the headings &#8220;Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Our Executive Officers,&#8221; and, if applicable, &#8220;Delinquent Section 16(a) Reports,&#8221; and is incorporated herein by reference.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at www.gossamerbio.com. The Code of Business Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section&#160;406 of the Sarbanes-Oxley Act of 2002 and Item&#160;406 of Regulation S-K. In addition, we intend to promptly disclose (1)&#160;the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2)&#160;the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future. Information contained in our website does not constitute a part of this report or our other filings with the SEC.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-55">adopted</ix:nonNumeric> a policy on insider trading and procedures that govern the purchase, sale, and/or other dispositions of our securities by our directors, officers, employees and other covered persons that are designed to promote compliance with insider trading laws, rules and regulations, and the NASDAQ listing rules, as applicable. A copy of our policy on insider trading is filed as Exhibit 19.1 to this annual report on Form 10-K. It is our policy to comply with U.S. insider trading laws and regulations, including with respect to transactions in our own securities.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_88"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the section headed &#8220;Executive Compensation and Other Information&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_91"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the section headed &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 201(d) of Regulation S-K will be set forth in the section headed "Executive Compensation and Other Information" in our Proxy Statement and is incorporated herein by reference.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_94"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the section headed &#8220;Certain Relationships and Related Person Transactions,&#8221; &#8220;Board Independence&#8221; and &#8220;Board Committees and Independence&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_97"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in the section headed &#8220;Independent Registered Public Accounting Firm's Fees&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_103"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">All Financial statements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of Gossamer Bio, Inc., together with the report thereon of Ernst &amp; Young LLP, an independent registered public accounting firm, are included in this annual report on Form 10-K beginning on page F-1.</span></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Financial statement schedules</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or notes thereto.</span></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Exhibits</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of exhibits is set form on the Exhibit Index immediately preceding the signature page of this annual report on Form 10-K and is incorporated herein by reference.</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_106"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10&#8211;K Summary.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gossamer Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:91.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_112">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">; Ernst &amp; Young LLP, San Diego, CA</span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-56">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_112">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_115">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_115">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_118">Consolidated Statements of&#160;Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_118">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_121">Consolidated Statements&#160;of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_121">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_124">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_124">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_127">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i23ab80a59eff4535a15f3b4d8b987e4a_127">7</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Gossamer Bio, Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Gossamer Bio, Inc. (the Company) as of December&#160;31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December&#160;31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2024, in conformity with U.S. generally accepted accounting principles. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accrued Research and Development Expenses</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2024, the Company accrued $10.4 million for research and development expenses. As described in Note 2 of the consolidated financial statements, the Company records accruals for estimated research and development costs, comprising payments due for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs are accrued as patients enter and progress through the trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing management&#8217;s accounting for accrued research and development expenses is especially challenging as evaluating the progress or stage of completion of the activities under the Company&#8217;s research and development agreements is dependent upon a high volume of data from third-party service providers and internal clinical personnel, which is tracked in spreadsheets and other end user computing programs. </span></div><div><span><br/></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test the completeness of the Company&#8217;s accrued research and development expenses, among other procedures, we obtained supporting evidence of the research and development activities performed for significant clinical trials. We corroborated the status of significant research and development activities through meetings with accounting and clinical project managers. To verify the appropriate measurement of accrued research and development costs, we compared the costs for a sample of transactions against the related invoices and contracts, and confirmed amounts incurred to-date with third-party service providers. We also examined a sample of subsequent payments to evaluate the completeness of the accrued research and development expenses. </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Initial accounting for the Chiesi Collaboration Agreement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As more fully described in Note 12 to the consolidated financial statements, the Company entered into a global collaboration agreement with Chiesi Farmaceutici S.P.A and Chiesi USA, Inc. (collectively, &#8220;Chiesi&#8221;), which granted exclusive licenses to develop and commercialize products that contain or incorporate seralutinib for the treatment of pulmonary hypertension. The Company determined the transaction price was equal to the up-front fee reduced by the fair value of the Equity Option and the transaction price was allocated to the performance obligations based on the relative stand-alone selling price estimated for each performance obligation. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the Company&#8217;s initial accounting for the Chiesi collaboration agreement was complex and required the Company to apply significant judgement related to the estimation of the standalone selling price of each identified performance obligation. The estimates of the standalone selling price for the performance obligations relating to the licenses reflect management&#8217;s assumptions, which included forecasted revenues, expected development timelines, discount rates and probabilities of technical and regulatory success. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test the standalone selling price of each identified performance obligation, our audit procedures included, among others, evaluating the projected discounted cash flow assumptions used by the Company in developing the estimates of standalone selling price of the licenses by comparing the significant assumptions described above to current industry trends using available information from other similar companies within the same industry and other relevant factors. We involved our valuation professionals to assist in the assessment of the estimation methodology and the significant assumptions used in determining the estimated standalone selling price of these performance obligations. We also performed a sensitivity analysis of the significant assumptions to evaluate the change in the estimated standalone selling price of these performance obligations resulting from the changes in the assumptions. Further, we assessed the resulting impact from the sensitivity analysis on the allocation of transaction price to each performance obligation as well as revenue recognized during the period.</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-57">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-58">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;13, 2025</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOSSAMER BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and par value amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-59">46,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-60">32,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">248,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">264,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivable from contracts with collaborators</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">10,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">309,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">306,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-69">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-70">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-71">5,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-72">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-73">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-74">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-75">315,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-76">311,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">2,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">5,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-79">10,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-80">7,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">11,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">17,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">15,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">45,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">51,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:LongTermConvertibleSeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-89">197,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:LongTermConvertibleSeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-90">196,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="f-91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="f-92">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">4,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-94">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">38,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-97">285,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-98">249,147</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-99"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-100"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-101"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-102">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-104">700,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2024 and December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-106">226,604,138</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2024, and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-108">225,409,315</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-109">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-110">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-111">1,296,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-112">1,275,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-113">1,268,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-114">1,212,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-115">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-116">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">29,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-118">62,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-119">315,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-120">311,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_118"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOSSAMER BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from sale of licenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-121">90,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from contracts with collaborators</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-124">24,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-127">114,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-130">138,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-131">135,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-132">170,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" scale="3" id="f-135">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">36,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">38,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-138">47,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-139">174,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-140">183,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-141">218,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">59,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-143">183,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">218,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-145">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-146">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-147">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-148">11,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-149">13,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-150">13,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-151">14,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">15,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">4,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">3,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">10,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-157">55,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">179,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-159">229,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-160">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">56,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">179,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">229,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-166">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-167">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-168">544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized income (loss) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-169">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-170">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-171">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-172">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-173">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-174">619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-175">54,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-176">179,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-177">229,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-178"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-179">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-180"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-181">1.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-182"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-183">2.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-184"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-185">226,228,016</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-186"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-187">152,621,669</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-188"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-189">84,574,869</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOSSAMER BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>stockholders<br/>equity</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-190">75,752,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-191">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">932,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">811,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-194">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">121,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-196">Cumulative-effect adjustment from change in accounting principle (See Note 2)</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">53,527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-198">8,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">44,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with a private offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-200">184</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-201">16,649,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-202">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-203">119,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-204">119,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="goss:StockIssuedDuringPeriodSharesVestingOfRestrictedStock" format="ixt:num-dot-decimal" scale="0" id="f-205">662,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-206">270,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-207">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-208">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-209">42,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">42,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-211">157,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-212">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-213">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for restricted stock units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-214">929,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">229,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">229,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-217">619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-218">619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-219">94,423,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-220">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">1,044,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">1,032,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-223">574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">12,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock and warrants in connection with a private offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-225">10,779</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-226">129,869,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-227">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-228">201,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-229">201,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="goss:StockIssuedDuringPeriodSharesVestingOfRestrictedStock" format="ixt:num-dot-decimal" scale="0" id="f-230">55,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-231">28,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-232">28,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-233">336,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-234">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-235">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for restricted stock units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-236">724,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-237">179,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">179,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-239">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-240">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-241">225,409,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-242">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">1,275,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">1,212,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-245">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">62,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-247">20,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-248">20,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-249">767,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-250">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-251">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for restricted stock units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-252">427,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant of equity option pursuant to Chiesi Collaboration Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="goss:AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" scale="3" id="f-253">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" scale="3" id="f-254">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-255">56,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-256">56,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-257">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-258">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-259">226,604,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-260">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">1,296,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">1,268,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">29,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOSSAMER BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">56,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-266">179,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-267">229,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-268">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-269">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-270">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-271">20,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-272">28,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-273">42,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In process research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:num-dot-decimal" scale="3" id="f-275">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" scale="3" id="f-276">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-277">3,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-278">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-279">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of long-term debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-280">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-281">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-282">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of premium on investments, net of accretion of discounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-283">13,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-284">9,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-285">1,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-286">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-287">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from contracts with collaborators</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="f-289">5,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:fixed-zero" scale="3" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-292">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-293">3,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-294">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-295">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-296">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-297">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-298">3,386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="goss:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-299">2,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="goss:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-300">2,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-301">1,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-302">3,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-303">1,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-304">10,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-305">835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-306">1,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-307">2,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-308">7,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" scale="3" id="f-309">579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-310">1,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-311">3,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-312">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-313">55,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="f-316">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="f-317">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="f-318">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-319">3,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-320">159,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-321">187,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development asset acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" scale="3" id="f-324">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-325">494,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-326">441,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-327">238,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:ProceedsFromMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-328">523,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="goss:ProceedsFromMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-329">330,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="goss:ProceedsFromMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-330">237,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-333">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-334">29,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-335">110,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-336">1,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and warrants in a private offering, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-338">201,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-339">119,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-340">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-341">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="f-342">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-345">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of equity option pursuant to stock purchase agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-346">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-349">12,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-350">11,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-351">5,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-352">11,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-353">190,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-354">117,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-355">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-356">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-357">517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-358">13,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-359">79,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-360">71,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-361">32,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-362">111,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-363">183,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, at the end of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-364">46,074</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-365">32,109</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-366">111,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-367">10,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-368">12,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-369">12,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-370">5,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-372">3,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in unrealized gain (loss) on marketable securities, net</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" scale="3" id="f-373">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" scale="3" id="f-374">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" scale="3" id="f-375">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-378">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gossamer Bio, Inc. Notes to Consolidated Financial Statements</span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_130"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-379" continuedAt="f-379-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-379-1"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gossamer Bio, Inc. (including its subsidiaries, referred to as "we," "us," "our,", or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension ("PH') including pulmonary arterial hypertension ("PAH") and PH associated with interstitial lung disease ("PH-ILD").  The Company was incorporated in the state of Delaware on October&#160;25, 2015 (originally as FSG Bio, Inc.) and is based in San Diego, California.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Gossamer Bio, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant operating losses since its inception. As of December&#160;31, 2024, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-380">1,268.6</ix:nonFraction> million. From the Company&#8217;s inception through the year ended December&#160;31, 2024, the Company has funded its operations primarily through equity financings, convertible senior notes and the Chiesi Collaboration Agreement (as defined in Note 12 below).</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the Company will need to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Management believes that it has sufficient working capital on hand to fund operations through at least the next 12 months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span></div></ix:continuation><div id="i23ab80a59eff4535a15f3b4d8b987e4a_133"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Note 2&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-381" continuedAt="f-381-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-381-1" continuedAt="f-381-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-382" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-383" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued research and development expenses, stand-alone selling price of performance obligations and estimated collaboration expenses associated with the Company&#8217;s collaboration and license agreement. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-384" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-385">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-386" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-381-2" continuedAt="f-381-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-387" continuedAt="f-387-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-387-1">The Company considers securities with original maturities of greater than 90&#160;days to be marketable securities. The Company has the ability, if necessary, to liquidate any of its marketable securities to meet its liquidity needs in the next 12&#160;months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying consolidated balance sheets which reflects management&#8217;s intention to use the proceeds from sales of these securities to fund our operations, as necessary. The Company&#8217;s marketable securities consist of U.S. Treasury and agency securities, commercial paper and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operation and comprehensive loss. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</ix:continuation> The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December&#160;31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" id="f-388" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury and agency securities and commercial paper with maturities less than three months and in money market funds that invest in U.S. Treasury and agency securities.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s available for sale securities are also invested in U.S. Treasury and agency securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-389" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, which consists mainly of lab equipment and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:f-390">two</span> to <ix:nonNumeric contextRef="c-50" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-391">seven years</ix:nonNumeric>, using the straight-line method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-392" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASU 2020-06, the Company accounted for the 2027 Notes as a liability and equity component. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component was not re-measured as long as it continued to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (&#8220;debt discount&#8221;) was amortized to interest expense over the term of the 2027 Notes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the issuance costs incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the 2027 Notes and were amortized to interest expense over the term of the 2027 Notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022 the Company adopted ASU 2020-06. After adoption, the Company now accounts for the 2027 Notes as a single liability measured at amortized cost. The impact upon adoption on the Consolidated Balance Sheets was an increase of approximately $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="goss:LongTermConvertibleSeniorNotes" format="ixt:num-dot-decimal" scale="6" id="f-393">44.8</ix:nonFraction>&#160;million in convertible senior notes, net, a write-off of $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-394">9.4</ix:nonFraction>&#160;million in deferred income tax liabilities and a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-395">53.5</ix:nonFraction>&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment of $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-396">8.7</ix:nonFraction>&#160;million to increase the beginning balance of accumulated deficit on the Consolidated Balance Sheets for previously recognized interest expense related to amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-381-3" continuedAt="f-381-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-397" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 842), the Company determines if an arrangement is a lease at inception. Operating leases are included in the balance sheet as right-of-use assets and operating lease liabilities at the present value of the lease payments calculated using the Company&#8217;s incremental borrowing rate, unless the implicit rate is readily available. The Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and elected to not separate lease and non-lease components for its long-term leases. The Company records rent expense on a straight-line basis over the term of the lease.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-398" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-399" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In process research and development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In process research and development costs relate to a milestone payment to Pulmokine for the initiation of the Phase 3 clinical trial for seralutinib.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LegalCostsPolicyTextBlock" id="f-400" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-401" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC&#160;740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company's policy is to include interest and penalties related to income taxes within its provision (benefit) for income taxes.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the United States, California, Florida, Ireland and Luxembourg. As of December&#160;31, 2024, the Company&#8217;s tax years since inception are subject to examination by taxing authorities due to the Company&#8217;s unutilized net operating losses ("NOLs") and tax credits.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-402" continuedAt="f-402-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its licensing and other agreements are collaborative arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. For arrangements that the Company determines are collaborations, it identifies each unit of account, and then determines whether a customer relationship exists for that unit of account. If the Company determines </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-381-4" continuedAt="f-381-5"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-402-1">a performance obligation within the collaborative arrangement to be with a customer, it applies its revenue recognition accounting policy. If a portion of a distinct bundle of goods or services within the collaborative arrangement is not with a customer, the Company applies recognition and measurement based on an analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational and consistently applied accounting policy election. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and the collaboration partner are within the scope of other accounting literature. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC Topic 606, Revenue from Contracts with Customers (ASC 606).</ix:continuation> See Note 12, "Significant Agreements and Contracts," for more information.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-403" continuedAt="f-403-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when a customer obtains control of promised goods or services in a contract for an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. For contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for contracts with customers, the Company develops assumptions that require judgment to determine the standalone selling price of each distinct performance obligation identified in the contract. In addition, variable consideration such as milestone payments are evaluated to determine if they are constrained and, therefore, excluded from the transaction price. The Company then allocates the total transaction price proportionally to each distinct performance obligation based on their estimated standalone selling prices, unless an allocation exception applies. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective distinct performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying standalone selling price for each distinct performance obligation, which determines how the transaction price is allocated among the distinct performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each distinct performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a distinct performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-381-5" continuedAt="f-381-6"><ix:continuation id="f-403-1"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include cost-share reimbursements, we will recognize such payments when control of the related goods or services are transferred to the customer. Cost-sharing reimbursements are presented as revenue from contracts with collaborators.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-404" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants and shares purchasable under the Company's 2019 Employee Stock Purchase Plan ("ESPP") using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. The Company estimates the fair value of restricted stock units based on the closing price of the Company's common stock on the date of grant. The Company accounts for forfeitures as they occur. All share-based compensation costs are recorded in the statements of operations based upon the underlying employees or non-employee&#8217;s roles within the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-405" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities of non-U.S.&#160;subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated to U.S.&#160;dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates during the year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss) in the Company's consolidated balance sheets. Foreign exchange transaction gains and losses are included in other income, net in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-406" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements - Adopted</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures (&#8220;Topic 280&#8221;), which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Lastly, the amendment requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We have adopted this standard for our fiscal year ended December 31, 2024. We have applied this standard retrospectively for all prior periods presented in the financial statements. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13, Segment Reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on our consolidated financial statement disclosures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-407" continuedAt="f-407-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The Company uses the if-converted method for assumed conversion of the 2027 Notes to compute the weighted average shares of common stock outstanding for diluted net loss per share. Diluted net loss per share excludes the potential impact of the Company&#8217;s common stock options, warrants for the purchase of common stock, unvested shares of restricted stock and the potential shares issuable upon conversion of the 2027 Notes because their effect would be anti-dilutive due to the Company&#8217;s net loss. Since the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-381-6"><ix:continuation id="f-407-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-408" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-409">12,321,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-410">12,321,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-411">12,321,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-412">34,416,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-413">23,626,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-414">17,487,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of Chiesi Equity Option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-415">22,433,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-418">32,467,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-419">32,467,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested shares under restricted stock grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-422">427,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-423">1,350,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-424">101,639,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-425">68,843,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-426">31,159,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i23ab80a59eff4535a15f3b4d8b987e4a_136"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3&#8212;<ix:nonNumeric contextRef="c-1" name="goss:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-427" continuedAt="f-427-1" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-428" escape="true"><ix:continuation id="f-427-1"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-429">11,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-430">10,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-431"><span style="-sec-ix-hidden:f-432">Operating lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-433">961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-434">3,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:AccruedConsultingFeesCurrent" scale="3" id="f-435">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:AccruedConsultingFeesCurrent" scale="3" id="f-436">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-437">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-438">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:AccruedLegalFeesCurrent" scale="3" id="f-439">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:AccruedLegalFeesCurrent" scale="3" id="f-440">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued in process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:AccruedInProcessResearchAndDevelopmentCurrent" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:AccruedInProcessResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-442">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued accounting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:AccruedAccountingFeesCurrent" scale="3" id="f-443">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:AccruedAccountingFeesCurrent" scale="3" id="f-444">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-445">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-446">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-447">15,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-448">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i23ab80a59eff4535a15f3b4d8b987e4a_139"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-449" continuedAt="f-449-1" escape="true">Fair Value Measurements and Available for Sale Investments</ix:nonNumeric></span></div><ix:continuation id="f-449-1" continuedAt="f-449-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Observable inputs such as quoted prices in active markets;</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash equivalents and available-for-sale investments within Level&#160;1 or Level&#160;2. The fair value of the Company&#8217;s investment grade corporate debt securities and commercial paper classified as Level 2 is determined using proprietary valuation models and analytical tools, which utilize market pricing or prices for similar instruments that are both objective and publicly available, such as matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and offers.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-2" continuedAt="f-449-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-450" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the hierarchy for assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market<br/>Prices for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other&#160;Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-451">25,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-452">25,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-455">56,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-456">56,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-459">188,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-461">188,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-463">19,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-465">19,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-467">25,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-468">25,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-471">92,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-472">92,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-475">168,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-477">168,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-479">3,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-481">3,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying amounts of the Company&#8217;s financial instruments, which include cash, prepaid and other current assets, interest receivable, accrued research and development expenses, accounts payable and accrued expenses and other current liabilities, approximate fair values because of their short-term maturities.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InterestReceivableCurrent" scale="6" id="f-483">0.2</ix:nonFraction> million interest receivable as of December&#160;31, 2024. There was <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt-sec:numwordsen" scale="6" id="f-484">no</ix:nonFraction> significant interest receivable as of December 31, 2023. Interest receivable is recorded as a component of prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023 the fair value of the Company's 2027 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-485">110.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-486">74.9</ix:nonFraction> million, respectively. The fair value was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy (see Note 5).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available for Sale Investments</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in U.S. Treasury and agency securities, corporate debt securities, and commercial paper, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below.&#160;The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operations and comprehensive loss. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recover of their amortized cost basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-3" continuedAt="f-449-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-487" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in marketable securities&#160;as of&#160;December&#160;31, 2024 and 2023 are as follows&#160;(in thousands except securities amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-488">56,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-489">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-491">56,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-492">19,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-493">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-495">19,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-496">188,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-497">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-498">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-499">188,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-500">265,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-501">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-502">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-503">265,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="c-5" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-504">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Treasury and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-505">92,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-506">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-507">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-508">92,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-509">3,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-510">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-512">3,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-513">168,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-514">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-515">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-516">168,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-517">264,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-518">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-519">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-520">264,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="c-6" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-521">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and December&#160;31, 2023, the Company classified $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-522">25.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-523">25.2</ix:nonFraction> million, respectively, of assets with original maturities of 90 days or less as cash and cash equivalents.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Factors considered when evaluating available-for-sale investments for impairment include the severity of the impairment, changes in underlying credit ratings, the financial condition of the issuer, the probability that the scheduled cash payments will continue to be made and the Company&#8217;s intent and ability to hold the investment until recovery of the amortized cost basis. The Company intends and has the ability to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. As of December&#160;31, 2024 and 2023, there were no material declines in the market value of the Company's available-for-sale investments due to credit-related factors.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-524" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of available-for-sale debt securities, as of December&#160;31, 2024, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-525">265,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" format="ixt:fixed-zero" scale="3" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-527">265,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;padding-left:4.5pt;text-indent:67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-449-4">The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months.</ix:continuation> </span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_142"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-528" continuedAt="f-528-1" escape="true">Indebtedness</ix:nonNumeric></span></div><ix:continuation id="f-528-1" continuedAt="f-528-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2019, the Company entered into a credit, guaranty and security agreement, as amended on September 18, 2019, July 2, 2020, December 7, 2022 and February 14, 2023 (the &#8220;Credit Facility&#8221;), with MidCap Financial Trust (&#8220;MidCap&#8221;), as agent and lender, and the additional lenders party thereto from time to time (together with MidCap, the &#8220;Lenders&#8221;), pursuant to which the Lenders, agreed to make term loans available to the Company for working capital and general business purposes, in a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-529">150.0</ix:nonFraction>&#160;million in term loan commitments, including a $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-530">30.0</ix:nonFraction>&#160;million term loan that was funded at the closing date, with the ability to access the remaining $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-531">120.0</ix:nonFraction>&#160;million in <ix:nonFraction unitRef="tranche" contextRef="c-109" decimals="0" name="goss:NumberOfAdditionalTranches" format="ixt-sec:numwordsen" scale="0" id="f-532">two</ix:nonFraction> additional tranches (each $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-533"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-534">60.0</ix:nonFraction></ix:nonFraction>&#160;million), subject to specified availability periods, the achievement of certain clinical development milestones, minimum cash requirements and other customary conditions. On May 3, 2024, the Credit Facility was terminated and the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-535">7.7</ix:nonFraction>&#160;million payment of the outstanding debt balance in full and discharged, which released the Company </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-528-2" continuedAt="f-528-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the obligations under the Credit Facility, and Lenders&#8217; security interests in the Company&#8217;s assets and property were released. Unamortized debt discount and issuance costs were written off and recorded in interest expense on the consolidated statements of operations and comprehensive loss. Since the Credit Facility was terminated, there was <ix:nonFraction unitRef="usd" contextRef="c-114" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-536">no</ix:nonFraction> debt outstanding as of December&#160;31, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-115" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-537">5.00</ix:nonFraction>% Convertible Senior Notes due 2027</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="goss:DebtInstrumentAggregatePrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="f-538">200.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-115" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-539">5.00</ix:nonFraction>% convertible senior notes due 2027 in a public offering (the "2027 Notes"). The 2027 Notes were registered pursuant to the Company&#8217;s shelf registration statement on Form S-3 filed with the SEC on April 10, 2020. The interest rate on the 2027 Notes is fixed at <ix:nonFraction unitRef="number" contextRef="c-115" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-540">5.00</ix:nonFraction>% per annum. Interest is payable semi-annually in arrears on June 1 and December 1 of each year, commencing on December 1, 2020. The 2027 Notes will mature on June 1, 2027. The net proceeds from the offering, after deducting the underwriting discounts and commissions and other offering costs, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="f-541">193.6</ix:nonFraction> million. The 2027 Notes may be settled in cash, shares of the Company&#8217;s common stock, or a combination thereof, solely at the Company&#8217;s election. The initial conversion rate of the 2027 Notes is&#160;61.6095&#160;shares per&#160;$1,000&#160;principal amount, which is equivalent to a conversion price of approximately&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-542">16.23</ix:nonFraction>&#160;per share, subject to adjustments.&#160;In addition, following certain corporate events that occur prior to the maturity date or if the Company issues a notice of redemption, the Company will increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event during the related redemption period in certain circumstances.&#160;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Notes are senior unsecured obligations of the Company, ranking senior in right of payment to any of the Company&#8217;s indebtedness that is expressly subordinated in right of payment to the 2027 Notes, and are effectively subordinated to the Company&#8217;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their notes at their option only in the following circumstances: (1) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2020, if the last reported sale price per share of the Company&#8217;s common stock exceeds <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="goss:DebtInstrumentConvertibleConversionPricePercentage" scale="-2" id="f-543">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="tradingday" contextRef="c-117" decimals="0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-544">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="tradingday" contextRef="c-118" decimals="0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-545">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="tradingday" contextRef="c-119" decimals="0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-546">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="tradingday" contextRef="c-120" decimals="0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-547">10</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="tradingday" contextRef="c-120" decimals="0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-548">10</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="goss:DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" scale="-2" id="f-549">98</ix:nonFraction>% of the product of the last reported sale price per share of the Company&#8217;s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company&#8217;s common stock; (4) if the Company calls such notes for redemption; and (5) at any time from, and including, March 1, 2027 until the close of business on the scheduled trading day immediately before the maturity date. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have the right to redeem the 2027 Notes prior to June 6, 2024. As of December&#160;31, 2024, the Company has not redeemed the 2027 Notes. On or after June 6, 2024 and on or before the <ix:nonNumeric contextRef="c-116" name="goss:DebtInstrumentRedemptionTermThresholdTradingDays" format="ixt-sec:durday" id="f-550">50</ix:nonNumeric>th scheduled trading day immediately before the maturity date, the Company may redeem the 2027 Notes, in whole or in part, if the last reported sale price of the Company&#8217;s common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="goss:DebtInstrumentConvertibleConversionPricePercentage" scale="-2" id="f-551">130</ix:nonFraction>% of the conversion price then in effect on (1) each of at least <ix:nonFraction unitRef="tradingday" contextRef="c-117" decimals="0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-552">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="tradingday" contextRef="c-118" decimals="0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-553">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. In the case of any optional redemption, the Company will redeem the 2027 Notes at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-554">100</ix:nonFraction>% of the principal amount of such Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change prior to the maturity date of the 2027 Notes, holders of the 2027 Notes may require the Company to repurchase for cash all or part of their 2027 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="goss:PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" scale="-2" id="f-555">100</ix:nonFraction>% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture governing the 2027 Notes provides for customary terms and covenants, including that upon certain events of default, either the trustee or the holders of not less than <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="goss:LongTermDebtPercentageInAggregatePrincipalAmount" scale="-2" id="f-556">25</ix:nonFraction>% in aggregate principal amount of the 2027 Notes then outstanding may declare the unpaid principal amount of the 2027 Notes and accrued and unpaid interest, if any, thereon immediately due and payable. As of December&#160;31, 2024, the Company was in compliance with these covenants. In the case of certain events of bankruptcy, insolvency or reorganization, the principal amount of the 2027 Notes together with accrued and unpaid interest, if any, thereon will automatically become and be immediately due and payable. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-528-3" continuedAt="f-528-4"><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, there were no events or market conditions that would allow holders to convert the 2027 Notes.&#160;When the 2027 Notes become convertible within 12 months of the balance sheet date, the carrying value of the 2027 Notes will be reclassified to short-term.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the 2027 Notes as a single liability measured at amortized cost. As the equity component is no longer required to be split into a separate component, the Company recorded an adjustment to reflect this update.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded&#160;$<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-557">0.4</ix:nonFraction>&#160;million of the debt issuance costs related to the 2027 Notes as a reduction to the liability and amortizes these costs to interest expense over the term of the 2027 Notes.</span></div><ix:nonNumeric contextRef="c-1" name="goss:ScheduleOfNotesTableTableTextBlock" id="f-558" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the 2027 Notes was as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-559">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-560">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-561">2,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-562">3,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="f-563">156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="f-564">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-565">197,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-566">196,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="goss:ScheduleOfInterestExpenseRecognizedTableTableTextBlock" id="f-567" continuedAt="f-567-1" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the interest expense recognized related to the 2027 Notes (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><ix:continuation id="f-567-1"><ix:continuation id="f-528-4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="goss:ContractualInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-568">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="goss:ContractualInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-569">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="goss:ContractualInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-570">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-571">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-572">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-573">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-574">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-575">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-576">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense related to the 2027 Notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-577">10,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-578">10,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-579">10,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_148"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-581" continuedAt="f-581-1" escape="true">Licenses, Asset Acquisitions and Contingent Consideration</ix:nonNumeric></span></div><ix:continuation id="f-581-1" continuedAt="f-581-2"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following purchased assets were accounted for as asset acquisitions as substantially all of the fair value of the assets acquired were concentrated in a group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of employees and early stage of development. Because the assets had not yet received regulatory approval, the fair value attributable to these assets was recorded as in process research and development (&#8220;IPR&amp;D&#8221;) expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2024, 2023, and 2022.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is met.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License from Pulmokine, Inc. (Seralutinib)</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;2, 2017, the Company entered into a license agreement with Pulmokine, Inc. under which it was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine to develop and commercialize seralutinib and certain backup compounds for the treatment, prevention and diagnosis of any and all disease or conditions. On November 26, 2024, Pulmokine became a wholly-owned subsidiary of XOMA Royalty Corporation. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The assets acquired are in the early stages of the FDA approval process, and the Company intends to further develop the assets acquired through potential FDA approval as evidenced by the milestone arrangement in the contract. The development activities cannot be performed without significant cost and effort by the Company. The agreement will remain in effect from the effective date, unless terminated earlier, until, on a licensed product-by-licensed product and country-by-country basis, the later of <ix:nonNumeric contextRef="c-127" name="goss:ProductLicenseTerm" format="ixt-sec:durwordsen" id="f-582">ten years</ix:nonNumeric> from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product or specified regulatory exclusivity for the licensed product in such country. The Company is obligated to make future development and regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="goss:BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" scale="6" id="f-583">48.0</ix:nonFraction> million, which includes a payment of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="goss:BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" scale="6" id="f-584">5.0</ix:nonFraction> million due upon initiation of a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-581-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 clinical trial in a second indication, commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="goss:BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" scale="6" id="f-585">45.0</ix:nonFraction> million, and sales milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="goss:BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" scale="6" id="f-586">190.0</ix:nonFraction> million. The Company is also obligated to pay tiered royalties on sales for each licensed product, at percentages ranging from the mid-single digits to the high single-digits. In addition, if the Company chooses to sublicense or assign to any third parties its rights under the agreement with respect to a licensed product, or the Company&#8217;s seralutinib operating subsidiary undergoes a change of control, the Company must pay to Pulmokine a specified percentage of all revenue to be received in connection with such transaction. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="goss:UpfrontPayment" scale="6" id="f-587">5.5</ix:nonFraction> million in October 2017. The Company made a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="f-588">5.0</ix:nonFraction>&#160;million in connection with the initiation of the first Phase 2 clinical trial of seralutinib in January 2021 and made a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="f-589">10.0</ix:nonFraction>&#160;million, which was accrued in 2023, in connection with the initiation of the Phase 3 clinical trial of seralutinib in January 2024. The Company recognized these milestone payments as research and development expense on its consolidated statements of operations and comprehensive loss. As of December&#160;31, 2024, <ix:nonFraction unitRef="usd" contextRef="c-132" decimals="0" name="us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" format="ixt:fixed-zero" scale="6" id="f-590">no</ix:nonFraction> other milestones had been accrued as the underlying contingencies had not yet been met.</span></div><ix:nonNumeric contextRef="c-1" name="goss:InProcessResearchAndDevelopmentExpensesTableTextBlock" id="f-591" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following IPR&amp;D expense on the consolidated statements of operations and comprehensive loss (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:num-dot-decimal" scale="3" id="f-593">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terminated programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" scale="3" id="f-597">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total in process research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" format="ixt:num-dot-decimal" scale="3" id="f-599">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="goss:ResearchAndDevelopmentInProcessExpenses" scale="3" id="f-600">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_151"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-601" continuedAt="f-601-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-601-1" continuedAt="f-601-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-602" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net loss before taxes for the years ended December&#160;31, 2024, 2023, and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. loss before taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-603">32,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-604">134,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-605">175,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign loss before taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-606">23,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-607">45,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-608">53,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" format="ixt:num-dot-decimal" scale="3" id="f-609">55,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" format="ixt:num-dot-decimal" scale="3" id="f-610">179,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" format="ixt:num-dot-decimal" scale="3" id="f-611">229,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-612" escape="true"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense for the years ended December 31, 2024, 2023 and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-613">886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-616">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-617">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-618">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="f-619">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="f-620">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="f-621">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December&#160;31, 2024, 2023 and 2022 are shown below. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced. The change in the valuation allowance for the year ended December&#160;31, 2024 was an increase of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-622">7.4</ix:nonFraction> million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-601-2" continuedAt="f-601-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-623" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-624">97,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-625">122,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-626">128,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-627">10,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" format="ixt:fixed-zero" scale="3" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-630">20,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:fixed-zero" scale="3" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:fixed-zero" scale="3" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-633">44,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-634">45,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-635">34,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-636">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-637">6,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-638">8,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-639">10,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-640">9,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-641">8,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-642">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:DeferredTaxAssetsLeaseLiability" scale="3" id="f-643">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="goss:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-644">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="f-645">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-646">1,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-647">2,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 174 capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-648">35,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-649">34,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-650">21,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-651">5,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-652">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-653">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-654">229,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-655">222,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-656">205,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-657">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="goss:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-660">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="goss:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="f-661">660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="goss:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-662">1,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-664">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-665">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-666">1,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-667">768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-668">1,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-669">228,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-670">221,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-671">204,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-675">398.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-676">3.3</ix:nonFraction> million, respectively. The federal NOL carryforwards can be carried forward indefinitely and be available to offset up to <ix:nonFraction unitRef="number" contextRef="c-141" decimals="2" name="goss:NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" scale="-2" id="f-677">80</ix:nonFraction>% of future taxable income each year. The California NOL carryforwards begin to expire in 2036. As of December&#160;31, 2024, the Company also has Irish NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-678">113.0</ix:nonFraction> million, which can be carried forward indefinitely. In the current year, the Company removed federal and foreign NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="goss:OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" scale="6" id="f-679">141.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="goss:OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" scale="6" id="f-680">0.4</ix:nonFraction> million, respectively, as a result of mergers and liquidations.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company also had orphan drug credit and federal research tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="f-681">48.2</ix:nonFraction> million and California research tax credits of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="f-682">13.2</ix:nonFraction> million. The federal research tax credit carryforwards begin to expire in 2038, and the California research tax credit carryforward does not expire and can be carried forward indefinitely until utilized. In the current year, the Company removed federal and California credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="goss:TaxCreditCarryforwardsReductionDueToMerger" scale="6" id="f-683">9.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="goss:TaxCreditCarryforwardsReductionDueToMerger" scale="6" id="f-684">0.4</ix:nonFraction> million, respectively, as a result of mergers.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-685" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-686">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-687">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-688">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-689">12.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-690">8.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-691">20.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and experimentation credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-692">3.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-693">5.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-694">3.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-695">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-696">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-697">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GILTI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-698">4.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" format="ixt:fixed-zero" scale="-2" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" format="ixt:fixed-zero" scale="-2" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-701">4.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-702">1.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-703">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nondeductible interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" scale="-2" id="f-704">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" sign="-" name="goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" scale="-2" id="f-705">1.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" sign="-" name="goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" scale="-2" id="f-706">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic/Foreign Restructuring Impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="f-707">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="f-708">12.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" format="ixt:fixed-zero" scale="-2" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-710">1.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-711">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-712">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-713">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-601-3"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax respectively. In general, an ownership change as defined by Sections 382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over a three-year period. The Company had an ownership change with the IPO in February of 2019 which resulted in no forfeiture of NOLs or credits.  The Company had an additional ownership change in July of 2023, which resulted in a significant limitation on the Company's utilization of its NOLs and is expected to result in forfeiture of some or all of the federal credits. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company's effective tax rate.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, California, Florida, Ireland, and Luxembourg. Due to the Company&#8217;s losses incurred, the Company is subject to the income tax examination by authorities since inception. The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as tax expense. For the years ended December&#160;31, 2024, 2023 and 2022 and as of December 31, 2024 and 2023, there were no accruals for interest related to unrecognized tax benefits or tax penalties.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-716" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2024, 2023, and 2022, excluding interest and penalties, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-717">13,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-718">10,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-719">7,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease related to prior year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-720">2,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase related to current year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-723">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-724">3,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-725">3,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-726">13,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-727">13,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-728">10,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2024 is $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="goss:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" scale="6" id="f-729">13.9</ix:nonFraction> million that, if recognized, would not impact the Company&#8217;s income tax benefit or effective tax rate as long as the Company's deferred tax asset remains subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company's unrecognized tax benefits within the next 12 months.</span></div></ix:continuation><div id="i23ab80a59eff4535a15f3b4d8b987e4a_157"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-730" continuedAt="f-730-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-730-1" continuedAt="f-730-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="c-1" decimals="INF" name="goss:CommonStockVotingRightsNumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-731">one</ix:nonFraction> vote. Common stock owners are entitled to dividends when funds are legally available and declared by the Company's board of directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement and Stock Offering</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2020, the Company filed a universal shelf registration statement on Form S-3, covering the offering from time to time of common stock, preferred stock, debt securities, warrants and units, which registration statement became automatically effective on April 10, 2020 (the &#8220;Shelf Registration Statement&#8221;).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-732">9,433,963</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-733">13.25</ix:nonFraction> per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering costs, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-734">117.1</ix:nonFraction>&#160;million. The shares sold in the offering were registered pursuant to the Company&#8217;s Shelf Registration Statement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Financing</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company completed a private placement of <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-735">16,649,365</ix:nonFraction> shares of the Company's common stock at purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-736">7.21</ix:nonFraction> per share. The gross proceeds for the private placement were $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-737">120.1</ix:nonFraction>&#160;million, before deducting offering expenses, which equaled $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-738">0.2</ix:nonFraction>&#160;million. On August 9, 2022, the Company filed a registration statement on Form S-3 registering the shares of common stock issued in the private placement, which registration statement became automatically effective on August 9, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2023, the Company completed a private placement of <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-739">129,869,440</ix:nonFraction> shares of the Company&#8217;s common stock and accompanying warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-740">32,467,360</ix:nonFraction> shares of the Company's common stock at a combined </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-730-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="5" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-741">1.63125</ix:nonFraction> per share and accompanying warrant, or with respect to any purchaser that was an officer, director, employee or consultant of the Company $<ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-742">1.85125</ix:nonFraction>, per share and accompanying warrant. Each warrant has an exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-743">2.04</ix:nonFraction>, was immediately exercisable on the date of issuance and will expire <ix:nonNumeric contextRef="c-153" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-744">five years</ix:nonNumeric> from the closing of the private placement. The aggregate gross proceeds for the private placement were $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-745">212.1</ix:nonFraction>&#160;million, before deducting offering expenses, which equaled $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-746">10.8</ix:nonFraction>&#160;million. On August 18, 2023, the Company filed a registration statement on Form S-3 registering the shares of common stock and shares of common stock issuable upon the exercise of warrants issued in the private placement, which registration statement was declared effective on August 28, 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares of Common Stock Subject to Repurchase</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;3, 2015, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-747">9,160,888</ix:nonFraction> shares of common stock as founder shares for services rendered to the Company, valued at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-748">0.0001</ix:nonFraction> par value per share, for a total of approximately $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-749">4,100</ix:nonFraction> (the &#8220;founder shares&#8221;). On January&#160;4, 2018, incremental vesting conditions were placed on the previously issued founder shares. <ix:nonFraction unitRef="number" contextRef="c-158" decimals="2" name="goss:CommonStockVestingPercentage" format="ixt-sec:numwordsen" scale="-2" id="f-750">Fifty</ix:nonFraction> percent of the previously issued founder shares vested on January&#160;4, 2018, and the remaining founder shares are subject to vesting restrictions over a period of <ix:nonNumeric contextRef="c-159" name="goss:CommonStockVestingPeriod" format="ixt-sec:durwordsen" id="f-751">five years</ix:nonNumeric>. These shares are subject to repurchase by the Company upon a founder's termination of employment or service to the Company.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the employment agreements with the Company&#8217;s founders executed January 4, 2018, the Company provided for certain potential additional issuances of common stock (the &#8220;anti-dilution shares&#8221;) to each of the founders to ensure the total number of shares of common stock held by them and their affiliates (inclusive of any shares subject to equity awards granted by the Company) would represent <ix:nonFraction unitRef="number" contextRef="c-160" decimals="2" name="goss:PercentageOfFullyDilutedShareCapital" scale="-2" id="f-752">15</ix:nonFraction>% of the Company&#8217;s fully-diluted capitalization until such time as the Company raised $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="goss:IncreasedInEquityCapitalAmount" scale="6" id="f-753">300.0</ix:nonFraction> million in equity capital, including the capital raised in the Series&#160;A financing.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In furtherance of this obligation, on May 21, 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-754">251,547</ix:nonFraction> shares of common stock to the founders for services rendered to the Company, valued at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-755">2.61</ix:nonFraction> per share with an additional <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="goss:IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" format="ixt:num-dot-decimal" scale="0" id="f-756">251,547</ix:nonFraction>&#160;shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. In addition, on September 6, 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-757">1,795,023</ix:nonFraction> shares of common stock to the founders for services rendered to the Company, valued at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-758">9.63</ix:nonFraction> per share, with an additional <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="goss:IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" format="ixt:num-dot-decimal" scale="0" id="f-759">1,795,023</ix:nonFraction> shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest. As such, the Company recognizes the measurement date fair value of the restricted stock over the vesting period as compensation expense. As of December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-760">no</ix:nonFraction> shares of common stock subject to repurchase by the Company. The unvested stock liability related to these awards is immaterial to all periods presented.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chiesi Equity Option</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, pursuant to the Chiesi Collaboration Agreement (as defined in Note 12 below) the Company granted to Chiesi (as defined in Note 12 below) an option to purchase directly from the Company, on one or more occasions, up to an aggregate number of shares of the Company&#8217;s common stock (the "Equity Option") such that immediately following such issuance, Chiesi&#8217;s beneficial ownership of the Company&#8217;s common stock shall not exceed <ix:nonFraction unitRef="number" contextRef="c-165" decimals="INF" name="goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" scale="-2" id="f-761">9.9</ix:nonFraction>% of the total number of issued and outstanding shares of the Company&#8217;s common stock. The Equity Option shall be exercisable by Chiesi, in whole or in part, at any time prior to the earliest to occur of the date on which (a) the last patient is last dosed in either (i) the PROSERA Phase 3 study for PAH or (ii) a Phase 3 clinical trial for the PH-ILD Indication, (b) any third party commences a tender offer or exchange offer for more than <ix:nonFraction unitRef="number" contextRef="c-166" decimals="INF" name="goss:CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" scale="-2" id="f-762">50</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock, and (c) the Company publicly announces its intent to consummate a GB002, Inc. change of control. The purchase price of each share the Company&#8217;s common stock subject to the Equity Option shall be equal to <ix:nonFraction unitRef="number" contextRef="c-166" decimals="INF" name="goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" scale="-2" id="f-763">107.5</ix:nonFraction>% of the daily volume-weighted average per share price of the Company&#8217;s common stock on The Nasdaq Stock Market over the <ix:nonFraction unitRef="day" contextRef="c-166" decimals="INF" name="goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" scale="0" id="f-764">30</ix:nonFraction>-trading day period ending on and including the last trading day prior to the date on which Chiesi delivers an exercise notice to the Company; provided that such purchase price shall be no less than $<ix:nonFraction unitRef="number" contextRef="c-166" decimals="2" name="goss:CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" scale="0" id="f-765">1.63</ix:nonFraction> per share. The shares of the Company&#8217;s common stock to be issued will be issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering, pursuant to the terms of a stock issuance agreement to be entered into between the Company and Chiesi in connection with each such exercise of the Equity Option. The Company evaluated the Equity Option granted to Chiesi as consideration payable to a customer and determined it qualified under ASC 718. Due to the market condition included in the Equity Option, the Company used the Geometric Brownian Motion/Monte Carlo model to determine fair market value. The value of the Equity Option is $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="goss:ContractWithCustomerLiabilityFairValueOfEquityOption" format="ixt:num-dot-decimal" scale="6" id="f-766">0.5</ix:nonFraction>&#160;million, which is included in additional paid-in capital on the Company's consolidated balance sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-767" continuedAt="f-767-1" escape="true">Equity Incentive Plans</ix:nonNumeric></span></div><ix:continuation id="f-767-1" continuedAt="f-767-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Equity Inducement Incentive Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company approved the 2023 Employment Inducement Incentive Plan (the "2023 Inducement Plan"). The terms of the 2023 Inducement Plan are substantially similar to the terms of the Company&#8217;s 2019 Incentive Award Plan (as described below) with the exception that incentive stock options may not be issued under the 2023 Inducement Plan and awards under the 2023 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq rules. The 2023 Inducement Plan was adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under the 2023 Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors of the Company or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The Company has initially reserved <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-768">6,762,279</ix:nonFraction> shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2023 Inducement Plan. As of December&#160;31, 2024, an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-769">4,152,779</ix:nonFraction> shares of common stock were available for issuance under the 2023 Inducement Plan, and <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="goss:SharesReservedForIssuanceOnGrantingOfOutstandingAwards" format="ixt:num-dot-decimal" scale="0" id="f-770">2,609,500</ix:nonFraction> shares of common stock were subject to outstanding awards under the 2023 Inducement Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Incentive Award Plan (the &#8220;2019 Plan&#8221;). The 2019 Plan became effective on February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock or cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries. A total of <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-771">5,750,000</ix:nonFraction> shares of common stock were approved to be initially reserved for issuance under the 2019 Plan. The number of shares that remained available for issuance under the 2017 Plan (as defined below) as of the effective date of the 2019 Plan were, and shares subject to outstanding awards under the 2017 Plan as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the <ix:nonNumeric contextRef="c-170" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-772">ten-year</ix:nonNumeric> term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to <ix:nonFraction unitRef="number" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-773">5</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. As of December&#160;31, 2024, an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-774">2,308,197</ix:nonFraction> shares of common stock were available for issuance under the 2019 Plan and <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-775">29,747,623</ix:nonFraction> shares of common stock were subject to outstanding awards under the 2019 Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the "ESPP"). The ESPP became effective as of February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-172" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-776">20</ix:nonFraction>% of their eligible compensation. A total of <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-777">700,000</ix:nonFraction> shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first <ix:nonNumeric contextRef="c-174" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-778">ten-years</ix:nonNumeric> of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to <ix:nonFraction unitRef="number" contextRef="c-174" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-779">1</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. During the years ended December&#160;31, 2024 and 2023, <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="0" name="goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-780">767,125</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-781">336,795</ix:nonFraction> shares were issued pursuant to the ESPP, respectively. As of December&#160;31, 2024, an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-782">4,545,812</ix:nonFraction> shares of common stock were available for issuance under the ESPP.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) permitted the granting of incentive stock options, non-statutory stock options, restricted stock, restricted stock units and other stock-based awards. Subsequent to the adoption of the 2019 Plan, no additional equity awards can be made under the 2017 Plan. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-783">2,059,214</ix:nonFraction> shares of common stock were subject to outstanding options under the 2017 Plan, and <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-784">no</ix:nonFraction> shares of restricted stock awards granted under the 2017 Plan were unvested.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-767-2" continuedAt="f-767-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each employee and non-employee time-vested stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company uses its own volatility to the extent it has sufficient trading history, and for awards in which sufficient trading history is not available, a peer group is used to calculate the expected volatility. Due to the lack of historical exercise history, the expected term of the Company&#8217;s stock options for employees has been determined utilizing the &#8220;simplified&#8221; method for awards. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S.&#160;Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is <ix:nonFraction unitRef="number" contextRef="c-180" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-785">zero</ix:nonFraction> based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2023, the Company granted to its Chairman and Chief Executive Officer <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-786">750,000</ix:nonFraction> options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-787">1.36</ix:nonFraction> per share. This grant contains both service and market based vesting conditions. The awards vest on the later of the date of achievement and the <ix:nonNumeric contextRef="c-182" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-788">one-year</ix:nonNumeric> anniversary of the grant date. The market condition becomes satisfied in <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-789">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-184" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-790">25</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-185" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-791">25</ix:nonFraction>% tranches upon achieving the average per-share closing price of the Company's common stock over any <ix:nonNumeric contextRef="c-182" name="goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" format="ixt-sec:durday" id="f-792">30</ix:nonNumeric> consecutive calendar days following the grant date equal to or exceeding $<ix:nonFraction unitRef="usdPerShare" contextRef="c-183" decimals="2" name="goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" scale="0" id="f-793">5.00</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" scale="0" id="f-794">7.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" scale="0" id="f-795">10.00</ix:nonFraction>, respectively. In the event a stock price tranche has not vested prior to the fourth anniversary of the grant date, any portion of the option attributable to such tranche will be forfeited. Due to the market condition included in this grant, the Company used the Geometric Brownian Motion/Monte Carlo model to value this award. The total stock-based compensation expense related to this award is $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-796">0.4</ix:nonFraction>&#160;million, which is included in general and administrative expense on the consolidated statements of operations and comprehensive loss. The Company expects to recognize this expense over a weighted average period of approximately <ix:nonNumeric contextRef="c-182" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-797">2.2</ix:nonNumeric> years. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 5, 2023, and in accordance with the terms of the 2019 Plan, the Company's board of directors approved a stock option repricing (the &#8220;Option Repricing&#8221;) whereby the exercise price of each Eligible Option (as defined below) was immediately reduced to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-186" decimals="INF" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-798">1.36</ix:nonFraction> per share, the closing stock price on May 5, 2023. For purposes of the Option Repricing, &#8220;Eligible Options&#8221; are <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-799">6,817,057</ix:nonFraction> outstanding stock options as of May 5, 2023 (vested or unvested) granted under the 2019 Plan prior to November 30, 2022 and held by those eligible employees of the Company identified by the Company's board of directors, including the Company&#8217;s executive officers, except for the Company&#8217;s Chairman and Chief Executive Officer.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The participation of the executive officers of the Company in the Option Repricing was subject to their agreement to cancel a portion of their Eligible Options effective immediately (the &#8220;Cancelled Options&#8221;). Each executive was required to agree to cancel one-third of his or her Eligible Options, on a grant-by-grant basis. The Cancelled Options were deducted proportionately from the vested and unvested portions of each Repriced Option grant.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent an Eligible Option is exercised prior to the Premium End Date (as defined below), or the eligible employee&#8217;s employment terminates prior to the Premium End Date, the eligible employee will be required to pay the original exercise price per share of the Eligible Options in connection with any exercise of the Eligible Option. The &#8220;Premium End Date&#8221; means the earliest of (i) May 5, 2024, (ii) the date of a change in control, (iii) the eligible employee&#8217;s death or disability, or (iv) if an eligible employee is an executive subject to the cancellation of a portion of Eligible Options and is terminated under circumstances giving rise to severance under his or her employment agreement, the date of such termination. Except for the reduction in the exercise prices of the Eligible Options as described above, the Eligible Options will retain their existing terms and conditions as set forth in the 2019 Plan and the applicable award agreements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repricing resulted in $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-800">3.4</ix:nonFraction>&#160;million of incremental cost, which was calculated using the Black-Scholes option-pricing model, of which $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-801">2.0</ix:nonFraction>&#160;million of the incremental cost was recognized immediately, and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-802">1.4</ix:nonFraction>&#160;million of the incremental cost will be recognized on the straight-line basis over the remaining vesting period of the repriced options. The incremental cost is included in general and administrative expense and research and development expense on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-767-3" continuedAt="f-767-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="f-803" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of stock option awards granted to employees under the Company&#8217;s equity incentive plans and the shares purchasable under the ESPP during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:42.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.195%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-804">4.6</ix:nonNumeric> - <ix:nonNumeric contextRef="c-188" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-805">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-189" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-806">1.0</ix:nonNumeric> - <ix:nonNumeric contextRef="c-190" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-807">7.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-191" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-808">4.4</ix:nonNumeric> - <ix:nonNumeric contextRef="c-192" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-809">6.1</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-180" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-810">3.59</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-180" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-811">4.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-193" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-812">3.36</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-193" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-813">4.73</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-814">1.31</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-815">4.35</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-180" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-816">100.72</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-180" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-817">104.51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-193" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-818">70.01</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-193" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-819">170.69</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-820">71.10</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-821">89.87</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-822">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-823">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-824">&#8212;</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-195" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-825">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-196" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-826">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-197" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-827">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-198" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-828">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-199" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-829">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-200" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-830">2.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-831">3.88</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-832">5.27</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-833">4.87</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-202" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-834">5.47</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-203" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-835">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-203" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-836">3.51</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-837">83.96</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-838">151.54</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-839">115.19</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-202" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-840">216.45</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-203" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-841">64.98</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-203" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-842">121.43</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-843">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-844">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-845">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-846" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares&#160;Subject&#160;to<br/>Options&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-847">9,434,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-848">12.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-20" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-849">7.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-850">15,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-851">9,271,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-852">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-853">270,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-854">6.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-855">948,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-856">15.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-857">17,487,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-858">9.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-14" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-859">8.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-860">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-861">17,159,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-862">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-865">11,020,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-866">11.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-867">23,626,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-868">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-869">7.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-870">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-871">13,006,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-872">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-875">2,216,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-876">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-877">34,416,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-878">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-879">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-880">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options vested and expected to vest as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-881">34,416,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-882">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-883">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-884">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-885">14,126,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-886">3.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-887">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="f-888">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share for the stock options granted during the year ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-889">0.78</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-890">3.88</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-891">4.77</ix:nonFraction>, respectively.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of stock options that vested during the years ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-892">15.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-893">22.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-894">20.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the above table is calculated as the difference between fair value of the Company&#8217;s common stock price and the exercise price of the stock options. There were <ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-895"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-896">no</ix:nonFraction></ix:nonFraction> options exercised during the years ended December&#160;31, 2024 and 2023. The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-897">1.5</ix:nonFraction> million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-767-4"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2023, the Company completed a private placement of <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-898">129,869,440</ix:nonFraction> shares of the Company&#8217;s common stock and accompanying warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-899">32,467,360</ix:nonFraction> shares of the Company's common stock at a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-900">1.63125</ix:nonFraction> per share and accompanying warrant, or with respect to any purchaser that was an officer, director, employee or consultant of the Company, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-901">1.85125</ix:nonFraction> per share and accompanying warrant. Each warrant has an exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-902">2.04</ix:nonFraction>, was immediately exercisable on the date of issuance and will expire <ix:nonNumeric contextRef="c-204" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-903">five years</ix:nonNumeric> from the closing of the private placement. Given that the warrants are indexed to the Company's shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company's consolidated balance sheets. As of December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-904">32,467,360</ix:nonFraction> warrants outstanding.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-905" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of the Company&#8217;s restricted stock activity during the years ended December&#160;31, 2024, 2023 and 2022 is as follows:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Restricted<br/>Stock Units<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-906">2,561,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-205" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-907">8.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-908">572,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-909">11.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-206" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-910">1,592,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-911">7.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-206" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-912">191,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-913">10.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-207" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-914">1,350,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-207" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-915">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-208" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-208" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-208" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-918">779,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-208" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-919">10.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-208" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-920">142,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-208" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-921">11.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-209" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-922">427,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-209" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-923">10.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-210" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-210" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-210" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-926">427,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-210" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-927">10.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-210" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-210" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-211" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was <ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="6" id="f-932">no</ix:nonFraction> unrecognized stock-based compensation expense related to the unvested restricted stock awards.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-933" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense has been reported in the Company&#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-934">10,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-935">15,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-936">24,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-937">10,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-938">12,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-939">18,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-940">20,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">28,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">42,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the total unrecognized compensation related to unvested stock option awards granted was $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-943">14.0</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="c-180" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-944">2.6</ix:nonNumeric> years.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, total unrecognized compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-945">0.8</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="c-175" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-946">0.8</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-948" continuedAt="f-948-1" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-948-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-949" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-219" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-950">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-220" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-951">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-953">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-223" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-954">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-956">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-225" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-957">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-959">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-227" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-960">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-228" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-961">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-962">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-963">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-964">6</ix:nonNumeric>-<ix:nonNumeric contextRef="c-232" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-965">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-967">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-968">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-969">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-970">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-971">5,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-972">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-973">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-974">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-975">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-976">1.8</ix:nonFraction> million, respectively, and was recorded in general and administrative expense and research and development expense, respectively, on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div id="i23ab80a59eff4535a15f3b4d8b987e4a_169"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-977" continuedAt="f-977-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-977-1" continuedAt="f-977-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously leased certain office and laboratory space under a non-cancelable operating lease which expired in January 2025.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 9, 2024, the Company entered into a lease agreement for office space located at 3115 Merryfield Row, Suite 120, San Diego, CA 92121, consisting of approximately <ix:nonFraction unitRef="sqft" contextRef="c-235" decimals="INF" name="goss:LeaseeOperatingLeaseLeasedArea" format="ixt:num-dot-decimal" scale="0" id="f-978">18,421</ix:nonFraction> square feet. The term of the lease is <ix:nonNumeric contextRef="c-235" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-979">63</ix:nonNumeric> months commencing on August 1, 2024. The base rent is $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="goss:LesseeOperatingLeaseBaseRent" format="ixt:num-dot-decimal" scale="3" id="f-980">109,605</ix:nonFraction> per month effective October 1, 2024, and it is subject to a <ix:nonFraction unitRef="number" contextRef="c-236" decimals="INF" name="goss:LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" scale="-2" id="f-981">3</ix:nonFraction>% annual increase every October. The lease expires on October 31, 2029 with an option for a <span style="-sec-ix-hidden:f-982">one</span>-year extension and an option to terminate on December 1, 2027 with the payment of a termination fee equal to <ix:nonFraction unitRef="month" contextRef="c-237" decimals="INF" name="goss:LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" format="ixt-sec:numwordsen" scale="0" id="f-983">four</ix:nonFraction> months of the then-current base rent upon the termination date. As of December 31, 2024, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monthly rent expense is recognized on a straight-line basis over the term of the leases. The operating leases are included in the consolidated balance sheets at the present value of the lease payments at an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-238" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-984">7</ix:nonFraction>% for each of the initial leased space and expansion space expiring in January 2025 and <ix:nonFraction unitRef="number" contextRef="c-239" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-985">12.4</ix:nonFraction>% for the office lease commenced on August 1, 2024 using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the leases do not provide an implicit rate. As of December&#160;31, 2024, the weighted average remaining lease term was <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-986">4.7</ix:nonNumeric> years, and weighted-average discount rate was <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-987">12.4</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-988" escape="true"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-989">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-990">3,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-991">3,097</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-992">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-993">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-994">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-995">3,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-996">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-997">3,142</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities as of December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-998">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-999">3.3</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1000" escape="true"><ix:continuation id="f-977-2"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross future minimum annual rental commitments as of December&#160;31, 2024, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted&#160;Rent<br/>Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1001">1,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1002">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1003">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1004">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1005">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted rent payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1006">7,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1007">1,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1008">5,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1009">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1010">4,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1011">5,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:5pt"><span><br/></span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_1388"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12 - <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-1012" continuedAt="f-1012-1" escape="true">Significant Agreements and Contracts</ix:nonNumeric></span></div><ix:continuation id="f-1012-1" continuedAt="f-1012-2"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, the Company, GB002, Inc., a Delaware corporation and wholly-owned subsidiary of the Company and Gossamer Bio 002 Ltd., a corporation organized and existing under the laws of Ireland and indirect wholly-owned subsidiary of the Company, entered into a global collaboration and license agreement (the &#8220;Chiesi Collaboration Agreement&#8221;) with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, &#8220;Chiesi&#8221;). The Company concluded that there were <ix:nonFraction unitRef="performanceobligation" contextRef="c-166" decimals="INF" name="goss:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-1013">four</ix:nonFraction> distinct performance obligations under the Chiesi Collaboration Agreement: the U.S. Territory license (as defined below), the ROW Territory license (as defined below), and the research and development services of both PAH and PH-ILD clinical development. Revenue associated with the licenses was recognized upon delivery in May 2024. In addition, the Company granted to Chiesi an option to purchase the Equity Option, as described in Note 8, "Stockholders Equity."</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds (&#8220;Licensed Products&#8221;) in the U.S. (&#8220;U.S. Territory&#8221;) and the rest of the world (&#8220;ROW Territory&#8221;), for therapeutic, prophylactic and diagnostic uses in humans and animals, for the treatment of PAH and PH-ILD and other indications, as may be permitted under the Chiesi Collaboration Agreement.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Chiesi Collaboration Agreement, the Company granted <ix:nonFraction unitRef="license" contextRef="c-166" decimals="INF" name="goss:NumberOfLicensesGranted" format="ixt-sec:numwordsen" scale="0" id="f-1014">two</ix:nonFraction> exclusive, sublicensable (with the Company&#8217;s consent required in the U.S. Territory for third party sublicenses) licenses to Chiesi under intellectual property rights controlled by the Company relating to seralutinib and Licensed Products, for the worldwide development, manufacture and commercialization of seralutinib and Licensed Products. The licenses granted to Chiesi are subject to retained rights of the Company for the worldwide development and manufacture of seralutinib and Licensed Products, commercialization of Licensed Products in the U.S. Territory, and performance of its obligations and exercise of its rights that may be set forth in the global development plan and US commercialization plan, in each case in accordance with the Chiesi Collaboration Agreement.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties agreed to use commercially reasonable efforts to conduct development and commercialization activities in relation to seralutinib and Licensed Products, under the global development plan and US commercialization plan in accordance with the timelines therein. The Company will continue to lead global development of seralutinib in PAH and PH-ILD, and the parties will equally share the costs for the activities included in the global development plan for all Licensed Products, with the exception of the PROSERA Phase 3 study, which the Company will be solely responsible for conducting at the Company&#8217;s own cost and expense. With respect to each country in the ROW Territory, such obligation to equally share such development costs shall end when regulatory approval is received for a Licensed Product in such country. With respect to U.S. Territory, the development costs incurred following regulatory approval shall continue to be shared equally. The Company will lead potential commercialization for PAH and PH-ILD in the US, with both parties contributing <ix:nonFraction unitRef="number" contextRef="c-166" decimals="INF" name="goss:RevenuePerformanceObligationCommercialEffortsContributionPercentage" format="ixt:num-dot-decimal" scale="-2" id="f-1015">50</ix:nonFraction> percent of commercial efforts, including performing <ix:nonFraction unitRef="number" contextRef="c-166" decimals="INF" name="goss:RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" format="ixt:num-dot-decimal" scale="-2" id="f-1016">50</ix:nonFraction> percent of the commercialization activities. Chiesi will lead potential commercialization in the US Territory in any additional indications, and Chiesi will have the exclusive right to commercialize Licensed Products in the ROW Territory. Chiesi further agreed to use commercially reasonable efforts to commercialize Licensed Products in certain specified countries in the ROW Territory following receipt of regulatory approvals. Generally, the Company will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products for the U.S. Territory for PAH and PH-ILD, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1012-2" continuedAt="f-1012-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, subject to any existing obligations of the Company to third party manufacturers, Chiesi will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products in the ROW Territory, in each case in accordance with the Chiesi Collaboration Agreement.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Chiesi Collaboration Agreement, neither party nor its affiliates is permitted to develop or commercialize any compound or product throughout the term whose primary mechanism of action is inhibition of a tyrosine kinase for the treatment of PAH or PH-ILD in the U.S. Territory or ROW Territory, subject to certain restrictions for the EU and UK.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration and as reimbursement for the Company&#8217;s development costs, Chiesi agreed to pay the Company an up-front, nonrefundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="goss:RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" format="ixt:num-dot-decimal" scale="6" id="f-1017">160</ix:nonFraction>&#160;million. Additionally, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="goss:RevenuePerformanceObligationRegulatoryMilestonesAmount" format="ixt:num-dot-decimal" scale="6" id="f-1018">146</ix:nonFraction>&#160;million in regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="goss:RevenuePerformanceObligationSalesMilestonesAmount" format="ixt:num-dot-decimal" scale="6" id="f-1019">180</ix:nonFraction>&#160;million in sales milestones. In the U.S. Territory, the parties agreed to share commercial profits and losses equally. In the ROW Territory, Chiesi will pay the Company an escalating mid-to-high teens percentage royalty on net sales of Licensed Product for PAH and additional indications on a Licensed Product-by-Licensed Product and country-by-country basis with such payment obligations beginning on the first commercial sale of Licensed Product in such country and expiring on a country-by-country basis on the latest of (a) the expiration of a valid claim to a the Company patent right in such country, (b) the expiration of regulatory exclusivity, and (c) the date that is <ix:nonNumeric contextRef="c-240" name="goss:RevenueLoyaltyReceivableExpirationPeriod" format="ixt-sec:duryear" id="f-1020">10</ix:nonNumeric> years after the first commercial sale of such Licensed Product in such country.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as regulatory and commercial milestones, development costs, and profit sharing U.S. Territory will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Chiesi Collaboration Agreement will remain in force until no Licensed Products are being developed or commercialized in the US Territory and in the ROW Territory, on a country-by-country basis, until no royalty terms are in effect for all countries. Either party may terminate the Chiesi Collaboration Agreement for the other party&#8217;s material breach, subject to a specified notice and cure periods, or due to an insolvency event of the other party. In lieu of termination upon a party&#8217;s material breach due to non-payment of development costs within a specified time the non-breaching party may elect an alternative remedy which may involve modifications to their performance and payment obligations. The Company has the right to terminate by providing written notice in the event Chiesi or its affiliates or sublicensee brings a patent challenge and Chiesi does not take certain steps to withdraw from or cease supporting such challenge. Chiesi may terminate the Chiesi Collaboration Agreement without cause upon prior written notice to the Company, subject to a notice period in which all rights to Licensed Products and Licensed Compounds will revert back to the Company.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development services performance obligation related to the Chiesi Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. The transaction price to be recognized as revenue from sale of licenses and revenue from contracts with collaborators under the Chiesi Collaboration Agreement consists of the one-time non-refundable and non-creditable development cost reimbursement payment and research and development costs. The transaction price was reduced by the fair value of the Equity Option. </span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price pursuant to the Chiesi Collaboration Agreement is equal to the one-time development cost reimbursement payment of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="goss:ContractWithCustomerLiabilityDevelopmentCost" format="ixt:num-dot-decimal" scale="6" id="f-1021">160.0</ix:nonFraction>&#160;million less the fair market value of the Equity Option of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="goss:ContractWithCustomerLiabilityFairValueOfEquityOption" format="ixt:num-dot-decimal" scale="6" id="f-1022">0.5</ix:nonFraction>&#160;million. The price allocated for the Equity Option was determined to be at fair market value utilizing the Geometric Brownian Motion/Monte Carlo model and was considered a reduction in the transaction price. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each distinct performance obligation. In estimating the stand-alone selling price for each distinct performance obligation, the Company developed assumptions that require judgment and included forecasted revenues or costs, expected development timelines, discount rates and probabilities of technical and regulatory success. A description of the distinct performance obligations identified under the Chiesi Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:</span></div><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The licenses to the Company&#8217;s intellectual properties, bundled with the associated know-how, represents <ix:nonFraction unitRef="performanceobligation" contextRef="c-241" decimals="INF" name="goss:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-1023">two</ix:nonFraction> distinct performance obligations. The licenses and associated know-how were transferred to Chiesi in June 2024, therefore the Company recognized the full revenue related to these distinct performance obligations in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1024">90.7</ix:nonFraction>&#160;million during the year ended December 31, 2024 as revenue from sale of licenses on its consolidated statements of operations and comprehensive loss. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1012-3" continuedAt="f-1012-4"><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The progress towards completion of the <ix:nonFraction unitRef="performanceobligation" contextRef="c-243" decimals="INF" name="goss:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-1025">two</ix:nonFraction> distinct performance obligations related to PAH and PH-ILD research and development services for the Licensed Products is measured in an amount proportional to the research and development expenses incurred and the total estimated PAH and PH-ILD research and development expenses. In addition, the Company and Chiesi share equally in the costs of ongoing global seralutinib clinical development, with the exception of the PROSERA Phase 3 study, and the costs of commercialization in the US. The Company records the revenue from performing research and development services and the cost-sharing payments due from Chiesi as revenue from contracts with collaborators on its consolidated statements of operations and comprehensive loss. For the year ended December&#160;31, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1026">24.1</ix:nonFraction> million for the PAH and PH-ILD research and development performance obligations and commercialization activities.</span></div><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined that as of December&#160;31, 2024, it is not probable that a significant revenue reversal will not occur related to the potential milestone payments as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the sales and usage based royalty exception. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. No milestone payments were recognized during the year ended December&#160;31, 2024.</span></div><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the licenses are deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the year ended December&#160;31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-1027" escape="true"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities related to the Chiesi Collaboration Agreement (recorded as contract liabilities on the balance sheet) during the year ended December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:85.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="goss:ContractWithCustomerLiabilityUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="3" id="f-1029">159,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from sale of US license</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1030">78,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from sale of ROW license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1031">11,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development service performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1032">9,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development service performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1033">1,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="goss:ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" format="ixt:num-dot-decimal" scale="3" id="f-1034">2,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1035">55,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the contract liability amount of $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1036">55.9</ix:nonFraction> million represents the aggregate transaction price allocated to performance obligations that are unsatisfied under the Chiesi Collaboration Agreement. This amount is expected to be recognized over <ix:nonNumeric contextRef="c-251" name="goss:ContractWithCustomerRevenueRecognitionPeriod" format="ixt-sec:duryear" id="f-1037">4.0</ix:nonNumeric> years, which represents the remaining research period under the Chiesi Collaboration Agreement. As of December&#160;31, 2024, the current contract liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-1038">17.1</ix:nonFraction> million is classified as a current liability since the rights to the research and development service are expected to be satisfied within one year, and the remaining contract liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-1039">38.9</ix:nonFraction> million is classified as a long-term liability.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1040">5.3</ix:nonFraction> million in accounts receivable associated with the Chiesi Collaboration Agreement. The payments are typically due <ix:nonNumeric contextRef="c-246" name="goss:AccountReceivablePaymentTerm" format="ixt-sec:durday" id="f-1041">30</ix:nonNumeric> days after quarterly invoices are issued.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-1042" continuedAt="f-1042-1" escape="true"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our contract revenues from Chiesi Collaboration Agreement disaggregated by timing of revenue recognition and excluding royalty revenue (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1042-1"><ix:continuation id="f-1012-4"><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"/><td style="width:76.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from Chiesi Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US License</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1043">78,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW License</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1044">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development service performance obligation satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1045">9,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development service performance obligation satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1046">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development costs subject to reimbursement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1047">10,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development costs subject to reimbursement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1048">2,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH commercial costs subject to reimbursement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1049">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD commercial costs subject to reimbursement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1050">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1051">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue from Chiesi Collaboration Agreement</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1052">114,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-indent:72pt"><span><br/></span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_1394"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13 - <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1053" continuedAt="f-1053-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-1053-1"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the CODM in making decisions regarding the allocation of resources and assessing performance. The Company's CODM is its chief executive officer. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1054">one</ix:nonFraction> operating segment. The Company's operating segment derives its revenues from its collaboration agreement with Chiesi and is wholly attributable to the United States. The CODM assesses performance for the Company's single operating segment and decides how to allocate resources based on research and development expenses incurred, which is a component of the Company's consolidated net loss as reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Further, segment depreciation expense and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. The CODM uses research and development expenses and results of clinical trial activities completed to date to evaluate how to allocate the Company's resources to advance seralutinib.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1055" escape="true"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1056">114,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1059">129,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1060">103,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1061">63,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1062">45,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1063">80,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1064">155,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-1065">1,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-1066">1,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-1067">1,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1068">11,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1069">13,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1070">13,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1071">14,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1072">15,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1073">1,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1074">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1076">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1077">56,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1078">179,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1079">229,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other segment items include R&amp;D expenses for other terminated programs. These costs include employee expenses, as well as allocations of consolidated overhead and stock compensation. Further, general and administrative expenses are also provided to the CODM regularly, but are included within other segment items as they are not utilized as part of the decision making process as it relates to the allocation of resources.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i23ab80a59eff4535a15f3b4d8b987e4a_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span><br/></span></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_1400"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1080" escape="true"><div style="margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent events</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all subsequent events and transactions through the filing date. There were no material events that impacted the audited consolidated financial statements or disclosures.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.697%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811723000108/goss-20230630xex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811723000151/goss-xex31xamendedandresta.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11/27/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312519014857/d690055dex41.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/23/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811721000019/exhibit43.htm">Description of Securities Registered under Section 12 of the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/26/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000156459020026546/goss-ex41_10.htm">Indenture, dated as of May 21, 2020, by and between the Registrant and Wilmington Trust, National Association.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/21/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000156459020026546/goss-ex42_11.htm">First Supplemental Indenture, dated May 21, 2020, by and between the Registrant and Wilmington Trust, National Association.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/21/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000156459020026546/goss-ex42_11.htm">Form of Global Note representing 5.00% Convertible Senior Notes due 2027 (included as part of Exhibit 4.5).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/21/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/goss-2023x07x19exx41.htm">Form of Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/20/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex101.htm">Gossamer Bio, Inc. 2017 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex102.htm">Form of stock option grant notice and stock option agreement under Gossamer Bio, Inc. 2017 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex103.htm">Form of restricted stock grant notice and restricted stock agreement under Gossamer Bio, Inc. 2017 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex104.htm">Form of Founder restricted stock grant notice and restricted stock agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312519014857/d690055dex105.htm">Gossamer Bio, Inc. 2019 Incentive Award Plan and form of stock option grant notice and stock option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/23/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312519014857/d690055dex106.htm">Gossamer Bio, Inc. 2019 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/23/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231xexx107xdirec.htm">Gossamer Bio, Inc. Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000156459020024690/goss-ex101_13.htm">Gossamer Bio, Inc. Restricted Stock Unit Agreement under the 2019 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/12/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811723000151/goss-xex101xemploymentindu.htm">Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan and Form of Stock Option Agreement thereunder.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11/27/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811721000019/exhibit1011.htm">Letter Agreement, dated November 16, 2020, by and between Faheem Hasnain and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/26/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex1010.htm">Employment Letter, dated December 4, 2018, by and between Bryan Giraudo and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex1011.htm">Employment Letter, dated December 4, 2018, by and between Christian Waage and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811721000087/exhibit101.htm">Employment Letter, dated April 16, 2021, by and between Caryn Peterson and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811721000087/exhibit103.htm">Employment Letter, dated June 21, 2021, by and between Richard Aranda and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811724000019/goss-20231231xexx1015xempl.htm">Employment Letter, dated November 25, 2023, by and between Robert Smith and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/5/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex1014.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000119312518356444/d626950dex1017.htm">Exclusive License Agreement, dated October 2, 2017, by and between GB002, Inc., the Registrant and Pulmokine, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/21/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811722000057/goss-202207x13xexx101.htm">Stock Purchase Agreement, dated July 12, 2022, by and among the Registrant and the Purchasers named therein.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/13/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811723000094/goss-2023x0719xexx101.htm">Securities Purchase Agreement, dated July 19, 2023, by and among the Registrant and the Purchasers named therein.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/20/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811723000108/goss-20230630xexx101.htm">Form of Option Repricing and Cancellation Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/8/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811724000085/goss-20240630x10xqxexx101.htm">Collaboration and License Agreement dated May 3, 2024 by and among GB002, Inc., Gossamer Bio 002 Ltd. and Gossamer Bio, Inc. on the one hand and CHIESI Farmaceutici S.p.A and CHIESI USA, Inc. on the other hand.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231xexx191xinsid.htm">Gossamer Bio, Inc. Insider Trading Compliance Policy and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231xexx211xlisto.htm">List of Subsidiaries of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231xexx231xeycon.htm">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.697%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231x10kexx311.htm">Certification of Chief Executive Officer of Gossamer Bio,&#160;Inc., as required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a) under the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231x10kexx312.htm">Certification of Chief Financial Officer of Gossamer Bio,&#160;Inc., as required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a) under the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231x10kexx321.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="goss-20241231x10kexx322.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1728117/000172811724000019/goss-20231231xexx97xclawba.htm">Policy for Recovery of Erroneously Awarded Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/5/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Report Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.024%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.776%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Portions of this exhibit (indicated by asterisks) have been omitted for confidentiality purposes pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section&#160;1350, and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i23ab80a59eff4535a15f3b4d8b987e4a_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOSSAMER BIO, INC.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Faheem Hasnain</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Faheem Hasnain</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES AND POWER OF ATTORNEY</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Faheem Hasnain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Chairman of the Board of Directors<br/>(principal executive officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Faheem Hasnain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bryan Giraudo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Operating Officer and Chief Financial Officer<br/>(principal financial and<br/>accounting officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryan Giraudo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Russell Cox</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell Cox</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Daniel, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Daniel, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sky Drynan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sky Drynan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sandra Milligan, M.D., J.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Milligan, M.D., J.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Steven Nathan, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven Nathan, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Quisel, J.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Quisel, J.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>goss-20241231xexx107xdirec.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i74ba3ad9d411466bb2bcf549c4c1badb_55"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 10.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:130%">GOSSAMER BIO, INC.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:130%">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:130%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) of Gossamer Bio, Inc. (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:130%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) shall receive cash and equity compensation as set forth in this Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:130%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">This Program has been adopted under the Company&#8217;s 2019</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Incentive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:130%">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">effective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Effective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">described</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">paid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">made,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">applicable,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">automatically</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">without</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">further action of the Board, to each member of the Board who is not an employee of the Company or any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:130%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) who is entitled to receive such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> cash or equity compensation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">unless</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">declines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">receipt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">compensation by written notice to the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">This Program shall remain in effect until it is revised or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">rescinded by further action of the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">This Program may be amended, modified or terminated by the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">at</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">its</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">sole</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">supersede</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">prior</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and&#47;or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">for</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">between</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and any of its Non-Employee Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">No Non-Employee Director shall have any rights hereunder,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">except with respect to stock options granted pursuant to the Program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Capitalized terms not otherwise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">defined</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">herein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">have</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">meanings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">ascribed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">All</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">numbers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">give</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">reverse</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">split</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">effected</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">connection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">its</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">initial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">offering.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;padding-left:8.84pt;text-decoration:underline">Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font></div><div><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Each Non-Employee Director shall receive an annual retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">$40,000 for service on the Board.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">In addition, each Non-Employee Director shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">receive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the following additional annual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">retainers, as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">applicable&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Chairperson of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">serving</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall receive an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">additional annual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">retainer of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">$30,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">for such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">service.</font></div><div style="text-align:justify;text-indent:81pt"><font><br></font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;text-decoration:underline">Independent Lead Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">. A Non-Employee Director serving as Independent Lead Director of the Board shall receive an additional annual retainer of $25,000 for such service.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A Non-Employee Director serving as Chairperson of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Audit Committee shall receive an additional annual retainer of $20,000 for such service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A Non-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">serving</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Chairperson)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">receive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">additional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">annual retainer of $10,000 for such service.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">serving</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">receive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">additional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">annual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">$15,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">for</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A Non-Employee Director serving as a member of the Compensation Committee (other than the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Chairperson)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall receive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">additional annual retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of $7,500 for such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">service.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(v) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">additional annual retainer of $10,000 for such service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A Non-Employee Director serving as a member of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">additional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">annual retainer of $5,000 for</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such service.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The annual retainers described in Sections 1(a) and 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">earned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">quarterly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">based</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">calendar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">paid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">arrears</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">fifteenth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">end</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">each</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">calendar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">quarter.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">applicable.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">     2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Equity Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">granted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">described below.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The awards described below shall be granted under and shall be subject to the terms and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">provisions of the Equity Plan, or any other applicable Company equity incentive plan then-maintained by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Company, and shall be granted subject to the execution and delivery of award agreements, including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">attached exhibits, in substantially the forms previously approved by the Board. All applicable terms of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">subject</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">respects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">For</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">avoidance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of doubt, the share numbers in this Section 2 shall be subject to adjustment as provided in the Equity Plan,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">including with respect to any reverse stock split of the Company&#8217;s common stock effected on or prior to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Effective Date.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Each</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">who</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">initially</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">elected</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">appointed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to the Board after the Effective Date shall receive an option under the Equity Plan, or any other applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Company equity incentive plan then-maintained by the Company, to purchase 230,000 shares of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">common</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">initial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">appointment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">described</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Section 2(a) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:130%">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">No Non-Employee Director shall be granted more</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">one Initial Award.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">A Non-Employee Director who (i) is serving on the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as of the date of any annual meeting of the Company&#8217;s stockholders after the Effective Date and has been</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">serving as a Non-Employee Director for at least six months as of the date of such meeting, and (ii) will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">continue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">serve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">meeting,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">automatically</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">granted an option under the Equity Plan, or any other applicable Company equity incentive plan then-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">maintained by the Company, to purchase 115,000 of the Company&#8217;s common stock on the date of such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">annual meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The awards described in this Section 2(b) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:130%">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">For the avoidance of doubt, a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee Director elected for the first time to the Board at an annual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">meeting of the Company&#8217;s stockholders shall only receive an Initial Award in connection with such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">election,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">not receive any Subsequent Award on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the date of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as well.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Termination of Employment of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Members of the Board who</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">are employees of the Company or any parent or subsidiary of the Company who subsequently terminate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">their</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">remain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are otherwise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">entitled, will receive, after termination from employment with the Company and any parent or subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Company, Subsequent Awards as described in Section 2(b) above.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The per share exercise price of each option granted to a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee Director shall equal the Fair Market Value of a share of common stock on the date the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">is granted.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Each Initial Award shall vest and become exercisable in thirty-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">six</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(36)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">substantially</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">equal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">monthly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">installments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">over</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">three</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">years</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">grant,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">subject</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to the Non-Employee Director continuing in service on the Board through each such vesting date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Each</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Subsequent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">vest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and&#47;or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">become</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">exercisable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">on</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">occur</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">anniversary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of the date of grant or (B) the next occurring annual meeting of the Company's stockholders, subject to the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee Director continuing in service on the Board through such vesting date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Unless the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">otherwise determines, no portion of an Initial Award or Subsequent Award which is unvested and&#47;or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">exercisable at the time of a Non-Employee Director&#8217;s termination of service on the Board shall become</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">vested and&#47;or exercisable thereafter.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Upon a Change in Control, all outstanding equity awards granted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">under the Equity Plan, and any other equity incentive plan maintained by the Company, that are held by a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee Director shall become fully vested and&#47;or exercisable, irrespective of any other provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Plan or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">any award agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">each</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">granted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">be ten (10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">years from</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the date the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">is granted.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Compensation Limits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Notwithstanding anything to the contrary in this Program, all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">compensation payable under this Program will be subject to any limits on the maximum amount of Non-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">set</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">forth in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Plan, as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">in effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">from</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">to time.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;text-decoration:underline">Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">. The Company shall reimburse each Non-Employee Director for all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">reasonable,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">documented,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">out-of-pocket</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">travel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">incurred</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Non-Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Director in the performance of his or her duties to the Company in accordance with the Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">expense reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">policies and procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">as in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">from</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">time to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">time.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:85.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">* * * * *</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>goss-20241231xexx191xinsid.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i710ced6b719d479f936c7b886194efa9_62"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gossamer Bio, Inc.<br>Insider Trading Compliance Policy and Procedures</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence.  These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade.  Violating such laws can undermine investor trust, harm the reputation and integrity of Gossamer Bio, Inc. (together with any of its subsidiaries, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and result in dismissal from the Company or even serious criminal and civil charges against the individual and the Company.  The Company reserves the right to take whatever disciplinary or other measure(s) it determines in its sole discretion to be appropriate in any particular situation, including disclosure of wrongdoing to governmental authorities. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Persons Covered and Administration of Policy</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Insider Trading Compliance Policy and Procedures (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) applies to all officers, directors and employees of the Company.  For purposes of this Policy, &#8220;officers&#8221; refer to those individuals who meet the definition of &#8220;officer&#8221; under Section 16 of the Securities Exchange Act of 1934 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Individuals subject to this Policy are responsible for ensuring that members of their household comply with this Policy.  This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, limited liability companies, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy as if they were for the individual&#8217;s own account.  Notwithstanding the foregoing, this insider trading policy, including without limitation, the preclearance policy, blackout periods and prohibited transactions, does not apply to venture capital entities or other institutional investors, and the related transactions in the Company&#8217;s equity securities by such entities, that may be affiliated with a director of the Company or for Company equity securities that a director may be deemed to have beneficial ownership of by virtue of such affiliation&#59; provided, however, it is the responsibility of each such entity, in consultation with its own counsel (as appropriate), to determine compliance with applicable securities laws in considering whether to adhere to this Policy.  The Company may determine that this Policy applies to additional persons with access to material nonpublic information, such as contractors or consultants.  Officers, directors and employees, together with any other person designated as being subject to this Policy by the Company&#8217;s General Counsel or his or her designee or such other officer designated by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), are referred to collectively as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Questions regarding the Policy should be directed to the Compliance Officer, who is responsible for the administration of this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Policy Statement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Covered Person shall purchase or sell any type of security while in possession of material nonpublic information relating to the security or the issuer of such security in breach of a duty of trust or confidence, whether the issuer of such security is the Company or any other company.  In addition, if a Covered Person is in possession of material nonpublic information </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">about other publicly-traded companies, such as suppliers, customers, competitors or potential acquisition targets, the Covered Person may not trade in such other companies&#8217; securities until the information becomes public or is no longer material.  Further, no Covered Person shall purchase or sell any security of any other company, including another company in the Company&#8217;s industry, while in possession of material nonpublic information if such information is obtained in the course of the Covered Person&#8217;s employment or service with the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, Covered Persons shall not directly or indirectly communicate material nonpublic information to anyone outside the Company (except in accordance with the Company&#8217;s policies regarding confidential information) or to anyone within the Company other than on a &#8220;need-to-know&#8221; basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; includes stocks, bonds, notes, debentures, options, warrants, equity and other convertible securities, as well as derivative instruments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; are defined broadly under the federal securities law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes not only the actual purchase of a security, but also any contract to purchase or otherwise acquire a security.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes not only the actual sale of a security, but also any contract to sell or otherwise dispose of a security.  These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, transfers, gifts, and acquisitions and exercises of warrants or puts, calls, pledging and margin loans, or other derivative securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The laws and regulations concerning insider trading are complex, and Covered Persons are encouraged to seek guidance from the Compliance Officer prior to considering a transaction in Company securities. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Blackout Periods</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No officer, director, employee or any other Covered Person(s) listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (as amended from time to time) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Preclearance Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall purchase or sell any security of the Company during the period beginning on the fifteenth day after any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company, except for purchases and sales made pursuant to the permitted transactions described below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">From time to time, the Compliance Officer may recommend that directors, officers, employees or others suspend trading in Company securities because of developments that have not yet been disclosed to the public, such period, a &#8220;blackout period.&#8221;  Subject to the exceptions noted below, all of those individuals affected should not trade in the Company&#8217;s securities while the suspension is in effect, and should not disclose to others that the Company has suspended trading.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These prohibitions do not apply to&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">purchases of the Company&#8217;s securities from the Company (e.g., Employee Stock Purchase Plan), or sales of the Company&#8217;s securities to the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement, or vesting of equity-based awards, in each case, that do not involve a market sale of the Company&#8217;s securities (the &#8220;cashless exercise&#8221; of a Company stock option or other equity award through a broker does involve a market sale of the Company&#8217;s securities, and therefore would not qualify under this exception)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">purchases or sales of the Company&#8217;s securities (i) mandated under an employee benefit plan maintained by the Company which authorizes the sale of only such securities as are necessary to satisfy tax withholding obligations arising exclusively from the vesting of a compensatory award or (ii) made pursuant to a plan adopted to comply with the Exchange Act Rule 10b5-1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rule 10b5-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exceptions to the blackout period policy may be approved by the Compliance Officer (or, in the case of an exception for the Compliance Officer, the Chief Executive Officer, EVP, Technical Operations or Chief Financial Officer), including any exceptions for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> gifts of the Company&#8217;s securities.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Preclearance of Transactions by Directors, Officers and Employees</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All transactions (including gifts) in the Company&#8217;s securities by a Preclearance Person must be precleared by the Compliance Officer or the Chief Executive Officer, EVP, Technical Operations or Chief Financial Officer for transactions by the Compliance Officer.  Preclearance should not be understood to represent legal advice by the company that a proposed transaction complies with the law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A request for preclearance must be in writing, should be made at least two business days in advance of the proposed transaction, and should include the identity of the Preclearance Person, a description of the proposed transaction, the proposed date of the transaction, and the number of shares or other securities involved. In addition, the Preclearance Person must not be aware of material nonpublic information about the Company. The Compliance Officer, or the Chief Executive Officer, EVP, Technical Operations or Chief Financial Officer for transactions by the Compliance Officer, shall have sole discretion to decide whether to clear any contemplated transaction.  All transactions that are precleared must be effected within five business days of receipt of the preclearance.  A precleared transaction (or any portion of a precleared transaction) that has not been effected during the five business day period must be submitted for preclearance determination again prior to execution.  Notwithstanding receipt of preclearance, if the Preclearance Person becomes aware of material nonpublic information, or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed.  Transactions under a previously established Rule 10b5-1 Trading Plan that has been preapproved in accordance with this Policy are not subject to further preclearance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">None of the Company, the Compliance Officer, or the Company&#8217;s other employees will have any liability for any delay in reviewing, or refusal of, a request for preclearance.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Material Nonpublic Information</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information is considered &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell, or hold a security, or if the information is likely to have a significant effect on the market price of the security.  Material information can be positive or negative, and can relate to virtually any aspect of a company&#8217;s business or to any type of security, debt, or equity.  Also, information that something is likely to happen in the future&#8212;or even just that it may happen&#8212;could be deemed material.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Examples of material information may include (but are not limited to) information about&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">corporate earnings or earnings forecasts&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">possible mergers, acquisitions, tender offers, or dispositions&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">major new products or product developments&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">results of clinical trials or preclinical studies&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">communications sent to or received from the U.S. Food and Drug Administration or foreign regulatory authorities&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">important business developments, such as trial results, developments regarding strategic collaborations or the status of regulatory submissions&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">management or control changes&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant financing developments including pending public sales or offerings of debt or equity securities&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">defaults on borrowings&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">bankruptcies&#59; </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">cybersecurity or data security incidents&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant litigation or regulatory actions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information is &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">nonpublic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; if it is not available to the general public.  In order for information to be considered &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; it must be widely disseminated in a manner that makes it generally available to investors in a Regulation FD-compliant method, such as through a press release, a filing with the U.S. Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or a Regulation FD-compliant conference call.  The Compliance Officer shall have sole discretion to decide whether information is public for purposes of this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The circulation of rumors, even if accurate and reported in the media, does not constitute public dissemination.  In addition, even after a public announcement, a reasonable period of time may need to lapse in order for the market to react to the information.  Generally, the passage of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">one to two full trading days following release of the information to the public, is a reasonable waiting period before such information is deemed to be public. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Termination Transactions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If an individual is in possession of material nonpublic information when the individual&#8217;s service terminates, the individual may not trade in the Company&#8217;s securities until that information has become public or is no longer material.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Prohibited Transactions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company has determined that there is a heightened legal risk and the appearance of improper or inappropriate conduct if persons subject to this Policy engage in certain types of transactions.  Therefore, Covered Persons shall comply with the following policies with respect to certain transactions in the Company&#8217;s securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Short Sales</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Short sales of the Company&#8217;s securities are prohibited by this Policy.  Short sales of the Company&#8217;s securities, or sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale, evidence an expectation on the part of the seller that the securities will decline in value, and, therefore, signal to the market that the seller has no confidence in the Company or its short-term prospects.  In addition, Section&#160;16(c) of the Exchange Act prohibits Section&#160;16 reporting persons (i.e., directors, officers, and the Company&#8217;s 10% stockholders) from making short sales of the Company&#8217;s equity securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Options</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transactions in puts, calls, or other derivative securities involving the Company&#8217;s equity securities, on an exchange, on an over-the-counter market, or in any other organized market, are prohibited by this Policy.  A transaction in options is, in effect, a bet on the short-term movement of the Company&#8217;s stock and, therefore, creates the appearance that a Covered Person is trading based on material nonpublic information.  Transactions in options, whether traded on an exchange, on an over-the-counter market, or any other organized market, also may focus a Covered Person&#8217;s attention on short-term performance at the expense of the Company&#8217;s long-term objectives.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Hedging Transactions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Hedging transactions involving the Company&#8217;s securities, such as prepaid variable forward contracts, equity swaps, collars and exchange funds, or other transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company&#8217;s equity securities, are prohibited by this Policy.  Such transactions allow the Covered Person to continue to own the covered securities, but without the full risks and rewards of ownership.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">When that occurs, the Covered Person may no longer have the same objectives as the Company&#8217;s other stockholders.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Margin Accounts and Pledging</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Individuals are prohibited from pledging&#160;Company securities as collateral for a loan,&#160;purchasing Company securities on margin (i.e.,&#160;borrowing money to purchase the securities), or&#160;placing Company securities in a margin account.  This prohibition does not apply to cashless exercises of stock options under the Company&#8217;s equity plans, nor to situations approved in advance by&#160;the Compliance Officer.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Partnership Distributions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nothing in this Policy is intended to limit the ability of an investment fund, venture capital partnership or other similar entity with which a director is affiliated to distribute Company securities to its partners, members, or other similar persons&#59; provided, however, it is the responsibility of each such entity, in consultation with its own counsel (as appropriate), to determine the timing of any distributions, based on relevant facts and circumstances, and applicable securities laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Rule 10b5-1 Trading Plans</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The trading restrictions set forth in this Policy, other than those transactions described under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibited Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; do not apply to transactions under a previously established contract, plan or instruction to trade in the Company&#8217;s securities entered into in accordance with Rule 10b5-1 (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">has been submitted to and preapproved by the Compliance Officer</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">includes a &#8220;Cooling Off Period&#8221; for </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">Section&#160;16 reporting persons that extends to the later of 90 days after adoption or modification of a Trading Plan or two business days after filing the Form 10-K or Form 10-Q covering the fiscal quarter in which the Trading Plan was adopted, up to a maximum of 120 days&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">employees and any other persons, other than the Company, that extends 30 days after adoption or modification of a Trading Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">for Section 16 reporting persons, includes a representation in the Trading Plan that the Section&#160;16 reporting person is (1) not aware of any material nonpublic information about the Company or its securities&#59; and (2) adopting the Trading Plan in good faith and not as part of a plan or scheme to evade Rule 10b-5&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">has been entered into in good faith at a time when the individual was not in possession of material nonpublic information about the Company and not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">otherwise in a blackout period, and the person who entered into the Trading Plan has acted in good faith with respect to the Trading Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">either (1) specifies the amounts, prices, and dates of all transactions under the Trading Plan&#59; or (2) provides a written formula, algorithm, or computer program for determining the amount, price, and date of the transactions, and (3) prohibits the individual from exercising any subsequent influence over the transactions&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">complies with all other applicable requirements of Rule 10b5-1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer may impose such other conditions on the implementation and operation of the Trading Plan as the Compliance Officer deems necessary or advisable.  Individuals may not adopt more than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 (including Trading Plans which authorize an agent to sell only such securities as are necessary to satisfy tax withholding obligations arising exclusively from the vesting of a compensatory award) and subject to preapproval by the Compliance Officer.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An individual may only modify a Trading Plan outside of a blackout period and, in any event, when the individual does not possess material nonpublic information.  Modifications to and terminations of a Trading Plan are subject to preapproval by the Compliance Officer and modifications of a Trading Plan that change the amount, price, or timing of the purchase or sale of the securities underlying a Trading Plan will trigger a new Cooling-Off Period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company reserves the right to publicly disclose, announce, or respond to inquiries from the media regarding the adoption, modification, or termination of a Trading Plan and non-Rule 10b5-1 trading arrangements, or the execution of transactions made under a Trading Plan. The Company also reserves the right from time to time to suspend, discontinue, or otherwise prohibit transactions under a Trading Plan if the Compliance Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation, or other prohibition is in the best interests of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compliance of a Trading Plan with the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, and none of the Company, the Compliance Officer, or the Company&#8217;s other employees assumes any liability for any delay in reviewing and&#47;or refusing to approve a Trading Plan submitted for approval, nor the legality or consequences relating to a person entering into, informing the Company of, or trading under, a Trading Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Interpretation, Amendment, and Implementation of this Policy </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer shall have the authority to interpret and update this Policy and all related policies and procedures.  In particular, such interpretations and updates of this Policy, as authorized by the Compliance Officer, may include amendments to or departures from the terms of this Policy (including amendments to Schedule I), to the extent consistent with the general purpose of this Policy and applicable securities laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Actions taken by the Company, the Compliance Officer, or any other Company personnel do not constitute legal advice, nor do they insulate you from the consequences of noncompliance with this Policy or with securities laws. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Certification of Compliance</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All directors, officers, employees and others subject to this Policy may be asked periodically to certify their compliance with the terms and provisions of this Policy. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i710ced6b719d479f936c7b886194efa9_65"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Individuals Subject to Quarterly Trading Black-Outs and Preclearance Requirement</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All officers of the Company </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All members of the Company&#8217;s Board of Directors</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Treasurer and Controller and any other finance employee of the Company designated by the Treasurer or CFO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>goss-20241231xexx211xlisto.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i07d59a91eb5549fda2f0d7dba4257bbe_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">List of Subsidiaries of</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Gossamer Bio, Inc.</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Name</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Jurisdiction of Incorporation or Organization</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">GB002, LTD.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Gossamer Bio Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Delaware</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>goss-20241231xexx231xeycon.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6170c65e110f44b7a84468ad944bf533_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Exhibit 23.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:0.1pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1)&#160;&#160;&#160;&#160;Registration Statement (Form S-3 No. 333-274056) of Gossamer Bio, Inc., </font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-indent:-36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2)&#160;&#160;&#160;&#160;Registration Statement (Form S-8 Nos. 333-229586 and 333-277653) pertaining to the Gossamer Bio, Inc. 2017 Equity Incentive Plan, Gossamer Bio, Inc. 2019 Incentive Award Plan, and Gossamer Bio, Inc. 2019 Employee Stock Purchase Plan, and</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-indent:-36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3)&#160;&#160;&#160;&#160;Registration Statement (Form S-8 No. 333-263260) pertaining to the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">of our report dated March&#160;13, 2025, with respect to the consolidated financial statements of Gossamer Bio, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2024.</font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">San Diego, California </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">March&#160;13, 2025</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>goss-20241231x10kexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic7cfb4efdcc848e2b98a4a175f7819e0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Faheem Hasnain, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Gossamer Bio, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 13, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Faheem Hasnain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Faheem Hasnain<br>President and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>goss-20241231x10kexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9951c5edcab643d0b2d74dd09e5961f7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Bryan Giraudo, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Gossamer Bio, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:117pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:180pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 13, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bryan Giraudo</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryan Giraudo<br>Chief Operating Officer and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>goss-20241231x10kexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i777adc4ac67d487ab8e7efc35f76efd4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Gossamer Bio, Inc. (the &#8220;Company&#8221;) hereby certifies, to his knowledge, that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:65.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.136%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Faheem Hasnain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Faheem Hasnain<br>President and Chief Executive Officer</font></td></tr></table></div><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;13, 2025 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>goss-20241231x10kexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia30bb5d435b6474f83ce651fc4c6e3f8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Gossamer Bio, Inc. (the &#8220;Company&#8221;) hereby certifies, to his knowledge, that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bryan Giraudo</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryan Giraudo<br>Chief Operating Officer and Chief Financial Officer</font></td></tr></table></div><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;13, 2025 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>goss-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:27c0f11b-cb15-486e-948f-a34ff077e64b,g:c382099f-c004-46d4-b3a3-9983a179ddc5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:goss="http://www.gossamerbio.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gossamerbio.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="goss-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.gossamerbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.gossamerbio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.gossamerbio.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.gossamerbio.com/role/DescriptionofBusiness">
        <link:definition>9952157 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>9952159 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestments" roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments">
        <link:definition>9952160 - Disclosure - Fair Value Measurements and Available for Sale Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.gossamerbio.com/role/Indebtedness">
        <link:definition>9952161 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensesAssetAcquisitionsandContingentConsideration" roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsideration">
        <link:definition>9952162 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.gossamerbio.com/role/IncomeTaxes">
        <link:definition>9952163 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.gossamerbio.com/role/StockholdersEquity">
        <link:definition>9952164 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.gossamerbio.com/role/EquityIncentivePlans">
        <link:definition>9952165 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNet">
        <link:definition>9952166 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.gossamerbio.com/role/CommitmentsandContingencies">
        <link:definition>9952167 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsandContracts" roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContracts">
        <link:definition>9952168 - Disclosure - Significant Agreements and Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.gossamerbio.com/role/SegmentInformation">
        <link:definition>9952169 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Subsequentevents" roleURI="http://www.gossamerbio.com/role/Subsequentevents">
        <link:definition>9952170 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9955513 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsTables" roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables">
        <link:definition>9955514 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTables" roleURI="http://www.gossamerbio.com/role/IndebtednessTables">
        <link:definition>9955515 - Disclosure - Indebtedness (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensesAssetAcquisitionsandContingentConsiderationTables" roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationTables">
        <link:definition>9955516 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.gossamerbio.com/role/IncomeTaxesTables">
        <link:definition>9955517 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansTables">
        <link:definition>9955518 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetTables">
        <link:definition>9955519 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955520 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsandContractsTables" roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsTables">
        <link:definition>9955521 - Disclosure - Significant Agreements and Contracts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.gossamerbio.com/role/SegmentInformationTables">
        <link:definition>9955522 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.gossamerbio.com/role/DescriptionofBusinessDetails">
        <link:definition>9955523 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails" roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9955526 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9955527 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails">
        <link:definition>9955528 - Disclosure - Fair Value Measurements and Available for Sale Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails" roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails">
        <link:definition>9955529 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Available for sale Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails">
        <link:definition>9955530 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Contractual Maturities of Available-for-sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails">
        <link:definition>9955531 - Disclosure - Indebtedness - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessScheduleofNetCarryingAmountof2027NotesDetails" roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails">
        <link:definition>9955532 - Disclosure - Indebtedness - Schedule of Net Carrying Amount of 2027 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessScheduleofInterestExpenseRecognizedDetails" roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails">
        <link:definition>9955533 - Disclosure - Indebtedness - Schedule of Interest Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails">
        <link:definition>9955534 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails" roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails">
        <link:definition>9955535 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&amp;D Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails" roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails">
        <link:definition>9955536 - Disclosure - Income Taxes - Schedule of Amount of Net Loss Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9955537 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955538 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955539 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails">
        <link:definition>9955540 - Disclosure - Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails" roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails">
        <link:definition>9955541 - Disclosure - Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.gossamerbio.com/role/StockholdersEquityDetails">
        <link:definition>9955542 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails">
        <link:definition>9955543 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails" roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails">
        <link:definition>9955544 - Disclosure - Equity Incentive Plans - Schedule of Fair Value Assumptions Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansScheduleofStockOptionActivityDetails" roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails">
        <link:definition>9955545 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansScheduleofRestrictedStockActivityDetails" roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails">
        <link:definition>9955546 - Disclosure - Equity Incentive Plans - Schedule of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails" roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails">
        <link:definition>9955547 - Disclosure - Equity Incentive Plans - Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails">
        <link:definition>9955548 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails">
        <link:definition>9955549 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9955550 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofLeaseCostsDetails" roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails">
        <link:definition>9955551 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails" roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails">
        <link:definition>9955552 - Disclosure - Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1" roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1">
        <link:definition>9955552 - Disclosure - Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsandContractsAdditionalInformationDetails" roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails">
        <link:definition>9955553 - Disclosure - Significant Agreements and Contracts - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails" roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails">
        <link:definition>9955554 - Disclosure - Significant Agreements and Contracts - Schedule of Contract Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
        <link:definition>9955555 - Disclosure - Significant Agreements and Contracts - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentReportingInformationDetails" roleURI="http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails">
        <link:definition>9955556 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="goss_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="goss_AccruedResearchAndDevelopmentExpenses" abstract="false" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_LongTermConvertibleSeniorNotes" abstract="false" name="LongTermConvertibleSeniorNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_RevenueFromContractsWithCollaboratorsMember" abstract="true" name="RevenueFromContractsWithCollaboratorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_ResearchAndDevelopmentInProcessExpenses" abstract="false" name="ResearchAndDevelopmentInProcessExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" abstract="false" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" abstract="false" name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" abstract="false" name="PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_ProceedsFromMaturityOfMarketableSecurities" abstract="false" name="ProceedsFromMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" abstract="false" name="NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="goss_ScheduleOfNotesTableTableTextBlock" abstract="false" name="ScheduleOfNotesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseRecognizedTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="goss_InProcessResearchAndDevelopmentExpensesTableTextBlock" abstract="false" name="InProcessResearchAndDevelopmentExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="goss_TwoThousandTwentySevenNotesMember" abstract="true" name="TwoThousandTwentySevenNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_AccruedConsultingFeesCurrent" abstract="false" name="AccruedConsultingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_AccruedLegalFeesCurrent" abstract="false" name="AccruedLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_AccruedInProcessResearchAndDevelopmentCurrent" abstract="false" name="AccruedInProcessResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_AccruedAccountingFeesCurrent" abstract="false" name="AccruedAccountingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_OneHundredThirtyPercentApplicableConversionPriceMember" abstract="true" name="OneHundredThirtyPercentApplicableConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_NinetyEightPercentApplicableConversionPriceMember" abstract="true" name="NinetyEightPercentApplicableConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_NumberOfAdditionalTranches" abstract="false" name="NumberOfAdditionalTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="goss_DebtInstrumentAggregatePrincipalAmount" abstract="false" name="DebtInstrumentAggregatePrincipalAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_DebtInstrumentConvertibleConversionPricePercentage" abstract="false" name="DebtInstrumentConvertibleConversionPricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" abstract="false" name="DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_DebtInstrumentRedemptionTermThresholdTradingDays" abstract="false" name="DebtInstrumentRedemptionTermThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" abstract="false" name="PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_LongTermDebtPercentageInAggregatePrincipalAmount" abstract="false" name="LongTermDebtPercentageInAggregatePrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="goss_ContractualInterestExpense" abstract="false" name="ContractualInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_PulmokineIncMember" abstract="true" name="PulmokineIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_InProcessResearchAndDevelopmentSeralutinibMember" abstract="true" name="InProcessResearchAndDevelopmentSeralutinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_ProductLicenseTerm" abstract="false" name="ProductLicenseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" abstract="false" name="BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" abstract="false" name="BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" abstract="false" name="BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" abstract="false" name="BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_InProcessResearchAndDevelopmentTerminatedProgramsMember" abstract="true" name="InProcessResearchAndDevelopmentTerminatedProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" abstract="false" name="NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" abstract="false" name="OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_TaxCreditCarryforwardsReductionDueToMerger" abstract="false" name="TaxCreditCarryforwardsReductionDueToMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" abstract="false" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_StockholdersEquityDeficitTable" abstract="true" name="StockholdersEquityDeficitTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="goss_OfficerDirectorEmployeeOrConsultantMember" abstract="true" name="OfficerDirectorEmployeeOrConsultantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" abstract="true" name="ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_FounderSharesMember" abstract="true" name="FounderSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_FounderMember" abstract="true" name="FounderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_StockholdersEquityDeficitLineItems" abstract="true" name="StockholdersEquityDeficitLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="goss_CommonStockVotingRightsNumberOfVotesPerShare" abstract="false" name="CommonStockVotingRightsNumberOfVotesPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="goss_CommonStockVestingPercentage" abstract="false" name="CommonStockVestingPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_CommonStockVestingPeriod" abstract="false" name="CommonStockVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_PercentageOfFullyDilutedShareCapital" abstract="false" name="PercentageOfFullyDilutedShareCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_IncreasedInEquityCapitalAmount" abstract="false" name="IncreasedInEquityCapitalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" abstract="false" name="IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" abstract="false" name="CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" abstract="false" name="CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" abstract="false" name="CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" abstract="false" name="CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" abstract="false" name="CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="goss_ContractWithCustomerLiabilityFairValueOfEquityOption" abstract="false" name="ContractWithCustomerLiabilityFairValueOfEquityOption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember" abstract="true" name="TwoThousandTwentyThreeEquityInducementIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_TwoThousandNineteenEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_TwoThousandNineteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards" abstract="false" name="SharesReservedForIssuanceOnGrantingOfOutstandingAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" abstract="false" name="ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="goss_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_LeaseAgreementEnteredInJuly2024Member" abstract="true" name="LeaseAgreementEnteredInJuly2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_NonCancelableLeaseAgreementEnteredInAugust2018Member" abstract="true" name="NonCancelableLeaseAgreementEnteredInAugust2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="goss_LeaseeOperatingLeaseLeasedArea" abstract="false" name="LeaseeOperatingLeaseLeasedArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="goss_LesseeOperatingLeaseBaseRent" abstract="false" name="LesseeOperatingLeaseBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" abstract="false" name="LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="goss_LesseeOperatingLeaseExtensionTerm" abstract="false" name="LesseeOperatingLeaseExtensionTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" abstract="false" name="LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="goss_LicensesOfIntellectualPropertyMember" abstract="true" name="LicensesOfIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" abstract="true" name="ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="goss_NumberOfLicensesGranted" abstract="false" name="NumberOfLicensesGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage" abstract="false" name="RevenuePerformanceObligationCommercialEffortsContributionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" abstract="false" name="RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" abstract="false" name="RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_RevenuePerformanceObligationRegulatoryMilestonesAmount" abstract="false" name="RevenuePerformanceObligationRegulatoryMilestonesAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_RevenuePerformanceObligationSalesMilestonesAmount" abstract="false" name="RevenuePerformanceObligationSalesMilestonesAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_RevenueLoyaltyReceivableExpirationPeriod" abstract="false" name="RevenueLoyaltyReceivableExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_ContractWithCustomerLiabilityDevelopmentCost" abstract="false" name="ContractWithCustomerLiabilityDevelopmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_ContractWithCustomerRevenueRecognitionPeriod" abstract="false" name="ContractWithCustomerRevenueRecognitionPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_AccountReceivablePaymentTerm" abstract="false" name="AccountReceivablePaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="goss_USLicenseMember" abstract="true" name="USLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_ROWLicenseMember" abstract="true" name="ROWLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" abstract="true" name="PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" abstract="true" name="PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_ContractWithCustomerLiabilityRollforwardAbstract" abstract="true" name="ContractWithCustomerLiabilityRollforwardAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="goss_ContractWithCustomerLiabilityUpfrontPaymentReceived" abstract="false" name="ContractWithCustomerLiabilityUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" abstract="false" name="ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" abstract="true" name="PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" abstract="true" name="PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_PAHCommercialExpensesSubjectToReimbursementMember" abstract="true" name="PAHCommercialExpensesSubjectToReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_PHILDCommercialExpensesSubjectToReimbursementMember" abstract="true" name="PHILDCommercialExpensesSubjectToReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_EffectsOfExchangeRateMember" abstract="true" name="EffectsOfExchangeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="goss_ReportingSegmentMember" abstract="true" name="ReportingSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>goss-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:27c0f11b-cb15-486e-948f-a34ff077e64b,g:c382099f-c004-46d4-b3a3-9983a179ddc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_85adab5d-dc0b-4bb6-9643-710ca579756a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_342b322e-d227-4075-8a2f-3a2cf3f6ca75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_85adab5d-dc0b-4bb6-9643-710ca579756a" xlink:to="loc_us-gaap_AssetsCurrent_342b322e-d227-4075-8a2f-3a2cf3f6ca75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b536bb03-976e-489a-8810-54a41b7ac52d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_85adab5d-dc0b-4bb6-9643-710ca579756a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b536bb03-976e-489a-8810-54a41b7ac52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_59831463-80b3-4d8b-a464-ba0eabbb04cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_85adab5d-dc0b-4bb6-9643-710ca579756a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_59831463-80b3-4d8b-a464-ba0eabbb04cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6e4dbb81-bd1a-470b-af25-26f084811e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_85adab5d-dc0b-4bb6-9643-710ca579756a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6e4dbb81-bd1a-470b-af25-26f084811e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_093392da-f364-4e9c-bd74-d8ba79a72525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_908305a2-9d30-4b74-829b-31d01b24739e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_093392da-f364-4e9c-bd74-d8ba79a72525" xlink:to="loc_us-gaap_Liabilities_908305a2-9d30-4b74-829b-31d01b24739e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49fd588f-af46-4456-9f3d-d57cc75dd931" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_093392da-f364-4e9c-bd74-d8ba79a72525" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49fd588f-af46-4456-9f3d-d57cc75dd931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_46734fbe-e390-47a2-8af6-f5e16001b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_093392da-f364-4e9c-bd74-d8ba79a72525" xlink:to="loc_us-gaap_StockholdersEquity_46734fbe-e390-47a2-8af6-f5e16001b1c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a164c457-9866-4bd5-b3dc-edd1d0c56d64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_95c38777-55b7-4356-922c-56f3e5662698" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a164c457-9866-4bd5-b3dc-edd1d0c56d64" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_95c38777-55b7-4356-922c-56f3e5662698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a2759e1a-ecc1-4b41-9820-e78f1d6fc0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a164c457-9866-4bd5-b3dc-edd1d0c56d64" xlink:to="loc_us-gaap_LiabilitiesCurrent_a2759e1a-ecc1-4b41-9820-e78f1d6fc0a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermConvertibleSeniorNotes_59b3c8fc-5c2f-4111-bc68-095f9de773e6" xlink:href="goss-20241231.xsd#goss_LongTermConvertibleSeniorNotes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a164c457-9866-4bd5-b3dc-edd1d0c56d64" xlink:to="loc_goss_LongTermConvertibleSeniorNotes_59b3c8fc-5c2f-4111-bc68-095f9de773e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9699ac52-a4ac-47c5-be1a-fcd918a7e96e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a164c457-9866-4bd5-b3dc-edd1d0c56d64" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9699ac52-a4ac-47c5-be1a-fcd918a7e96e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6f283915-3558-4be5-b540-597a4112d271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a164c457-9866-4bd5-b3dc-edd1d0c56d64" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6f283915-3558-4be5-b540-597a4112d271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9109b07c-7ecb-40b5-b730-aa53473add9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7853d036-f3b2-4390-aae9-238a38f25366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9109b07c-7ecb-40b5-b730-aa53473add9c" xlink:to="loc_us-gaap_CommonStockValue_7853d036-f3b2-4390-aae9-238a38f25366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_607297fe-9f93-4d10-9a69-08a7eb42a2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9109b07c-7ecb-40b5-b730-aa53473add9c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_607297fe-9f93-4d10-9a69-08a7eb42a2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8c236e62-0555-42bd-9397-cf4937be5868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9109b07c-7ecb-40b5-b730-aa53473add9c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8c236e62-0555-42bd-9397-cf4937be5868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b90ee7f6-cc63-47f6-b0c7-d8c252085040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9109b07c-7ecb-40b5-b730-aa53473add9c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b90ee7f6-cc63-47f6-b0c7-d8c252085040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f822d216-9151-40b2-ba10-7dc0bab45cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c0a15e2-d487-4dc5-ae3d-e6dd4f966ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f822d216-9151-40b2-ba10-7dc0bab45cdf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c0a15e2-d487-4dc5-ae3d-e6dd4f966ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15996002-10d2-41fe-b8f1-7203abbe2135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f822d216-9151-40b2-ba10-7dc0bab45cdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15996002-10d2-41fe-b8f1-7203abbe2135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ebd6ebc5-66bc-49aa-975d-04b4075708dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f822d216-9151-40b2-ba10-7dc0bab45cdf" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ebd6ebc5-66bc-49aa-975d-04b4075708dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3a92210a-be63-4205-85cb-b8670379c135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f822d216-9151-40b2-ba10-7dc0bab45cdf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3a92210a-be63-4205-85cb-b8670379c135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b2d46516-e9c5-4de7-b984-e97b14c37a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_afe73384-9c32-42d9-81aa-794a70b96bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b2d46516-e9c5-4de7-b984-e97b14c37a90" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_afe73384-9c32-42d9-81aa-794a70b96bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedResearchAndDevelopmentExpenses_f724dfb7-3a30-4935-a4b4-13b053305863" xlink:href="goss-20241231.xsd#goss_AccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b2d46516-e9c5-4de7-b984-e97b14c37a90" xlink:to="loc_goss_AccruedResearchAndDevelopmentExpenses_f724dfb7-3a30-4935-a4b4-13b053305863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d35c549a-0aa8-4b52-a8be-79566a1c9c25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b2d46516-e9c5-4de7-b984-e97b14c37a90" xlink:to="loc_us-gaap_LongTermDebtCurrent_d35c549a-0aa8-4b52-a8be-79566a1c9c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_76aae779-0c64-46e8-a7dd-a5a11676a9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b2d46516-e9c5-4de7-b984-e97b14c37a90" xlink:to="loc_us-gaap_AccountsPayableCurrent_76aae779-0c64-46e8-a7dd-a5a11676a9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a655b069-2638-4313-a042-5d177a82b087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b2d46516-e9c5-4de7-b984-e97b14c37a90" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a655b069-2638-4313-a042-5d177a82b087" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_64cd9ccb-bde5-4515-9296-79a50d866cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f9e084e0-9aaa-4c58-906b-c3a61b1e4b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_64cd9ccb-bde5-4515-9296-79a50d866cee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f9e084e0-9aaa-4c58-906b-c3a61b1e4b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses_6b0c508f-4cff-44e4-a1ea-5d64491d6744" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_64cd9ccb-bde5-4515-9296-79a50d866cee" xlink:to="loc_goss_ResearchAndDevelopmentInProcessExpenses_6b0c508f-4cff-44e4-a1ea-5d64491d6744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fa58cdc5-2bfd-445b-9183-ac474291adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_64cd9ccb-bde5-4515-9296-79a50d866cee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fa58cdc5-2bfd-445b-9183-ac474291adbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6a464b4a-1313-465a-bc3d-b34c56e3ad0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_acc8f34f-a170-459f-9921-d08f9a5dcbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6a464b4a-1313-465a-bc3d-b34c56e3ad0f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_acc8f34f-a170-459f-9921-d08f9a5dcbd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_699e2ec2-86e6-443b-8140-852e5fd678cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6a464b4a-1313-465a-bc3d-b34c56e3ad0f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_699e2ec2-86e6-443b-8140-852e5fd678cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b3a6d092-c4ca-4c4c-9a97-81ff1321bb50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6a464b4a-1313-465a-bc3d-b34c56e3ad0f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b3a6d092-c4ca-4c4c-9a97-81ff1321bb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c54a89f5-6280-463d-966b-d8abea0bd0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_51e1af65-92c8-4dc9-961e-816226d7247c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c54a89f5-6280-463d-966b-d8abea0bd0a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_51e1af65-92c8-4dc9-961e-816226d7247c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_697b93b5-5c85-4fdb-909d-f0d0461be859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c54a89f5-6280-463d-966b-d8abea0bd0a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_697b93b5-5c85-4fdb-909d-f0d0461be859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f59be195-dd90-41fe-9add-8c77caf3f26a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f00e360b-f95f-4ebc-9319-9cfa77c1f16a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f59be195-dd90-41fe-9add-8c77caf3f26a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f00e360b-f95f-4ebc-9319-9cfa77c1f16a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bbda2d0c-4c1e-44d2-88d4-fccba72ad1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f59be195-dd90-41fe-9add-8c77caf3f26a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bbda2d0c-4c1e-44d2-88d4-fccba72ad1ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_074b165e-8406-43a6-bd82-2aca4da7c49b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_49cc83b4-dc8e-46b3-a99a-fec9d20aa512" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_074b165e-8406-43a6-bd82-2aca4da7c49b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_49cc83b4-dc8e-46b3-a99a-fec9d20aa512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5630893e-77ff-456c-8516-63e3e99bdd36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_074b165e-8406-43a6-bd82-2aca4da7c49b" xlink:to="loc_us-gaap_OperatingExpenses_5630893e-77ff-456c-8516-63e3e99bdd36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_18b1d541-92e2-4d87-bbed-3c119b4e7d12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a50fe2a-c77a-43ad-9974-f258df21dbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_18b1d541-92e2-4d87-bbed-3c119b4e7d12" xlink:to="loc_us-gaap_NetIncomeLoss_3a50fe2a-c77a-43ad-9974-f258df21dbdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68cdaf41-5df3-4411-8340-a50d70b4b687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_18b1d541-92e2-4d87-bbed-3c119b4e7d12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68cdaf41-5df3-4411-8340-a50d70b4b687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_106b1c7e-b749-49da-9a8d-c6417b204e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6deae7d1-9da1-46b6-b11e-ba01adb1e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_106b1c7e-b749-49da-9a8d-c6417b204e53" xlink:to="loc_us-gaap_OperatingIncomeLoss_6deae7d1-9da1-46b6-b11e-ba01adb1e34a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6ad3d22b-3ffa-409b-a2b7-bf02d25b9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_106b1c7e-b749-49da-9a8d-c6417b204e53" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6ad3d22b-3ffa-409b-a2b7-bf02d25b9ec1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b508aeb-ecd3-48f7-b4fb-a406ef781f83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_47fd11f8-c317-4888-9353-3bcd30d1e808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b508aeb-ecd3-48f7-b4fb-a406ef781f83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_47fd11f8-c317-4888-9353-3bcd30d1e808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5db0fe4-86fb-4ee9-a88d-c542018575d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b508aeb-ecd3-48f7-b4fb-a406ef781f83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5db0fe4-86fb-4ee9-a88d-c542018575d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99fae092-f757-494a-b969-6634a01c6749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b508aeb-ecd3-48f7-b4fb-a406ef781f83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99fae092-f757-494a-b969-6634a01c6749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5a37afbd-1fcd-4ab1-a4a2-3a5844929ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b508aeb-ecd3-48f7-b4fb-a406ef781f83" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5a37afbd-1fcd-4ab1-a4a2-3a5844929ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bdb280b-49c4-480e-a1b8-54499ba7b4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7884fed4-a123-4ae3-9ea2-232b2cecfec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bdb280b-49c4-480e-a1b8-54499ba7b4a0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7884fed4-a123-4ae3-9ea2-232b2cecfec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_dfba9e38-ecfb-4c38-a072-3f053a23ef7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bdb280b-49c4-480e-a1b8-54499ba7b4a0" xlink:to="loc_us-gaap_ProceedsFromStockPlans_dfba9e38-ecfb-4c38-a072-3f053a23ef7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fc100d7b-bcef-4989-9730-6f07a1226d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bdb280b-49c4-480e-a1b8-54499ba7b4a0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fc100d7b-bcef-4989-9730-6f07a1226d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4974890c-d551-4592-913e-34387998cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bdb280b-49c4-480e-a1b8-54499ba7b4a0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4974890c-d551-4592-913e-34387998cadd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_fed47dbe-f2d9-4585-bd7a-4422cdfe6b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bdb280b-49c4-480e-a1b8-54499ba7b4a0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_fed47dbe-f2d9-4585-bd7a-4422cdfe6b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd150ef5-8915-46fb-b5e3-25f7e38bf394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions_273348bc-6b0d-4ec3-832c-7846aa73c3e1" xlink:href="goss-20241231.xsd#goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd150ef5-8915-46fb-b5e3-25f7e38bf394" xlink:to="loc_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions_273348bc-6b0d-4ec3-832c-7846aa73c3e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d2fd8f2d-9073-43c6-857f-aee2d236cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd150ef5-8915-46fb-b5e3-25f7e38bf394" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d2fd8f2d-9073-43c6-857f-aee2d236cdf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ProceedsFromMaturityOfMarketableSecurities_356f0ee7-8fbb-4875-a0ea-b459e6fd3858" xlink:href="goss-20241231.xsd#goss_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd150ef5-8915-46fb-b5e3-25f7e38bf394" xlink:to="loc_goss_ProceedsFromMaturityOfMarketableSecurities_356f0ee7-8fbb-4875-a0ea-b459e6fd3858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf412908-6078-4045-9a1b-b68b06b115df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd150ef5-8915-46fb-b5e3-25f7e38bf394" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf412908-6078-4045-9a1b-b68b06b115df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3940c34a-311b-4781-b7d0-b98cb5e1fe54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3940c34a-311b-4781-b7d0-b98cb5e1fe54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses_8450c83a-ec6d-48ec-beef-3b6a0631d62e" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_goss_ResearchAndDevelopmentInProcessExpenses_8450c83a-ec6d-48ec-beef-3b6a0631d62e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d973497b-2298-44fa-8a12-bb05ba777bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d973497b-2298-44fa-8a12-bb05ba777bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4163fc4b-8da7-4f8e-a045-330ea1ba5833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4163fc4b-8da7-4f8e-a045-330ea1ba5833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a83daceb-c522-437b-b7b0-3831dc781deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a83daceb-c522-437b-b7b0-3831dc781deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_4be2683b-4931-4d78-b4a4-c71cd6109d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_4be2683b-4931-4d78-b4a4-c71cd6109d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreaseDecreaseInOperatingLeaseLiabilities_1cbba42d-3605-4140-87fa-4c27a4334f42" xlink:href="goss-20241231.xsd#goss_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_goss_IncreaseDecreaseInOperatingLeaseLiabilities_1cbba42d-3605-4140-87fa-4c27a4334f42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87a1e6f9-a1e0-4606-815c-31bcfebc1a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87a1e6f9-a1e0-4606-815c-31bcfebc1a82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_aa283237-3298-436a-a37a-ed6085a34ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_aa283237-3298-436a-a37a-ed6085a34ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_57a51521-6c75-4bfc-9e1e-95ea745d13d3" xlink:href="goss-20241231.xsd#goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_57a51521-6c75-4bfc-9e1e-95ea745d13d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6522b004-052c-42e5-ad72-dd00f03993e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6522b004-052c-42e5-ad72-dd00f03993e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_366cf50a-1b8d-489e-ad18-907d24de29cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_366cf50a-1b8d-489e-ad18-907d24de29cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7ccddc36-0d4c-48ee-b5c4-d03a69797b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7ccddc36-0d4c-48ee-b5c4-d03a69797b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_86560d2c-1e8b-424d-8c5c-9028ea9df188" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_86560d2c-1e8b-424d-8c5c-9028ea9df188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1068bcc5-bf6b-4a1f-b66b-146ac274ff24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_ProfitLoss_1068bcc5-bf6b-4a1f-b66b-146ac274ff24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_136d79d3-51d6-45e7-a3d9-4027391d2342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_ShareBasedCompensation_136d79d3-51d6-45e7-a3d9-4027391d2342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_f0a0550b-9ca2-4dfe-8f70-b704367cd698" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_f0a0550b-9ca2-4dfe-8f70-b704367cd698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_98345544-8631-4a82-ab77-5ffdded6e543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c6fce51-ab1c-4497-8d2f-0dfa30040f80" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_98345544-8631-4a82-ab77-5ffdded6e543" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedLegalFeesCurrent_96508a17-db9b-4412-913d-dbf24d192734" xlink:href="goss-20241231.xsd#goss_AccruedLegalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_goss_AccruedLegalFeesCurrent_96508a17-db9b-4412-913d-dbf24d192734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_887de78f-7a8d-4609-96df-50afe3108362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_us-gaap_InterestPayableCurrent_887de78f-7a8d-4609-96df-50afe3108362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b06da039-d71b-46cd-8a96-83525ce983a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b06da039-d71b-46cd-8a96-83525ce983a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedConsultingFeesCurrent_537a33a4-2f6d-4150-ac2b-37c935a760cc" xlink:href="goss-20241231.xsd#goss_AccruedConsultingFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_goss_AccruedConsultingFeesCurrent_537a33a4-2f6d-4150-ac2b-37c935a760cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8cabfa9-f08b-4b10-be07-954d4a8d4d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8cabfa9-f08b-4b10-be07-954d4a8d4d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedAccountingFeesCurrent_76e44629-b205-4d5c-a998-fa12d9e2e7d2" xlink:href="goss-20241231.xsd#goss_AccruedAccountingFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_goss_AccruedAccountingFeesCurrent_76e44629-b205-4d5c-a998-fa12d9e2e7d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_43a48c64-1f1d-403b-bd5e-5cd563a2f2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_43a48c64-1f1d-403b-bd5e-5cd563a2f2ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedInProcessResearchAndDevelopmentCurrent_fede55bb-8276-4bf1-b2c3-4e88153be6a1" xlink:href="goss-20241231.xsd#goss_AccruedInProcessResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_aa43aaab-fa6f-48a4-a503-4c7412de315d" xlink:to="loc_goss_AccruedInProcessResearchAndDevelopmentCurrent_fede55bb-8276-4bf1-b2c3-4e88153be6a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be4eb5bf-b1f5-447a-8910-6dbe307b8f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6bdcdecd-1f94-40e8-bc01-9884923c3521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be4eb5bf-b1f5-447a-8910-6dbe307b8f4d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6bdcdecd-1f94-40e8-bc01-9884923c3521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_164f05e6-fd4c-4c05-aa4b-d6340f5fa9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be4eb5bf-b1f5-447a-8910-6dbe307b8f4d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_164f05e6-fd4c-4c05-aa4b-d6340f5fa9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7182cd53-0a98-43d9-a84c-f9d66d818e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be4eb5bf-b1f5-447a-8910-6dbe307b8f4d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7182cd53-0a98-43d9-a84c-f9d66d818e8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad297e41-c3e1-411e-acf8-122c5079a3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue_99c8a148-cde5-412c-ba06-92b74b492dfe" xlink:href="goss-20241231.xsd#goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad297e41-c3e1-411e-acf8-122c5079a3ff" xlink:to="loc_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue_99c8a148-cde5-412c-ba06-92b74b492dfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_11f7ebba-a296-4424-95cd-5d07c9809065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad297e41-c3e1-411e-acf8-122c5079a3ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_11f7ebba-a296-4424-95cd-5d07c9809065" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3b8fd0a2-36d0-4cab-9234-7d574830fc65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c93a786d-34c1-49e9-b98f-a22afdd6ff0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b8fd0a2-36d0-4cab-9234-7d574830fc65" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c93a786d-34c1-49e9-b98f-a22afdd6ff0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_b595b26b-4a4c-4fe7-b6bb-20ebce1e8a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b8fd0a2-36d0-4cab-9234-7d574830fc65" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_b595b26b-4a4c-4fe7-b6bb-20ebce1e8a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e071ad62-124e-43da-b6da-d9232bb8b687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b8fd0a2-36d0-4cab-9234-7d574830fc65" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e071ad62-124e-43da-b6da-d9232bb8b687" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessScheduleofInterestExpenseRecognizedDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9d07be35-d6a1-4a69-bb3a-2587ad6b3f69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractualInterestExpense_09eb383d-1b46-4284-bc62-248a7819164e" xlink:href="goss-20241231.xsd#goss_ContractualInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_9d07be35-d6a1-4a69-bb3a-2587ad6b3f69" xlink:to="loc_goss_ContractualInterestExpense_09eb383d-1b46-4284-bc62-248a7819164e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_52a78087-03ac-4afd-ace6-69b588223070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_9d07be35-d6a1-4a69-bb3a-2587ad6b3f69" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_52a78087-03ac-4afd-ace6-69b588223070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c2e834e6-9856-4181-8d97-1b0be798e51e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_9d07be35-d6a1-4a69-bb3a-2587ad6b3f69" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c2e834e6-9856-4181-8d97-1b0be798e51e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_c07a79c0-3b3b-4ea3-a045-b2d75e7aa4ae" xlink:href="goss-20241231.xsd#goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_acced594-15cb-4fea-836d-d348ddac88a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_c07a79c0-3b3b-4ea3-a045-b2d75e7aa4ae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_acced594-15cb-4fea-836d-d348ddac88a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_37de58df-1f99-415f-834b-02407eee286b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_c07a79c0-3b3b-4ea3-a045-b2d75e7aa4ae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_37de58df-1f99-415f-834b-02407eee286b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_e7c81b76-1413-4d41-9c7a-7d1db388d290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d36405ce-a811-4e18-b206-ce784d2f3bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_e7c81b76-1413-4d41-9c7a-7d1db388d290" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d36405ce-a811-4e18-b206-ce784d2f3bbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cd5c5b8b-0d81-42db-82fa-ae421c3662aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_e7c81b76-1413-4d41-9c7a-7d1db388d290" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cd5c5b8b-0d81-42db-82fa-ae421c3662aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4a06253d-ee36-47bd-a065-6d1ec067a0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fde9ed29-4478-4709-bdf8-4d93e06a42ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4a06253d-ee36-47bd-a065-6d1ec067a0ac" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fde9ed29-4478-4709-bdf8-4d93e06a42ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7b9d08ff-5c69-474c-8339-a1c7b3fc1d33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4a06253d-ee36-47bd-a065-6d1ec067a0ac" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7b9d08ff-5c69-474c-8339-a1c7b3fc1d33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_01db7f98-ef43-4005-a36a-16d7ae6c49ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4a06253d-ee36-47bd-a065-6d1ec067a0ac" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_01db7f98-ef43-4005-a36a-16d7ae6c49ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7747e3ec-8c26-483c-8544-4634100e99a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_6c7c3b64-dfbe-496d-976f-21ea88ae48a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7747e3ec-8c26-483c-8544-4634100e99a0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_6c7c3b64-dfbe-496d-976f-21ea88ae48a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DeferredTaxLiabilitiesRightOfUseAsset_4d11138b-1da3-4293-95c8-c6fdb41d1b43" xlink:href="goss-20241231.xsd#goss_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7747e3ec-8c26-483c-8544-4634100e99a0" xlink:to="loc_goss_DeferredTaxLiabilitiesRightOfUseAsset_4d11138b-1da3-4293-95c8-c6fdb41d1b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_165902f6-223e-4b50-8608-2a278e77a07b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7747e3ec-8c26-483c-8544-4634100e99a0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_165902f6-223e-4b50-8608-2a278e77a07b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fb1db60f-3177-414b-a69d-bbb4ec85b962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fb1db60f-3177-414b-a69d-bbb4ec85b962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_af4fc578-5dd4-484c-9a2d-729b7a28b1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_af4fc578-5dd4-484c-9a2d-729b7a28b1e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DeferredTaxAssetsLeaseLiability_9de6dbaf-b07a-41a7-949f-8dc0c5015d32" xlink:href="goss-20241231.xsd#goss_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_goss_DeferredTaxAssetsLeaseLiability_9de6dbaf-b07a-41a7-949f-8dc0c5015d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_6f1d81c8-929c-456c-b094-ad4822ee0aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_6f1d81c8-929c-456c-b094-ad4822ee0aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_80b6d1e1-a26f-42eb-8454-64a9163e2b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_80b6d1e1-a26f-42eb-8454-64a9163e2b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_37ee065e-0a97-4b48-9a79-4419b7cf0da2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_37ee065e-0a97-4b48-9a79-4419b7cf0da2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f7c0c9c5-add5-4b08-9e24-8b0c884f908d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f7c0c9c5-add5-4b08-9e24-8b0c884f908d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ba1b146-1608-48c3-b071-d1abfd047448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ba1b146-1608-48c3-b071-d1abfd047448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_46a1d5cc-ed5d-4dbe-8cbd-0fa49b312cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_46a1d5cc-ed5d-4dbe-8cbd-0fa49b312cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_037b7131-313f-4eb2-854f-08bd21256041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6fe2f2d2-00f2-4576-be40-665645d32fea" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_037b7131-313f-4eb2-854f-08bd21256041" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1efa16de-df22-4aa2-9649-8b0511425059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1efa16de-df22-4aa2-9649-8b0511425059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_0e7b4559-3158-48c9-b6d1-10b128d6a0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_0e7b4559-3158-48c9-b6d1-10b128d6a0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bf00bbca-4a9b-4bc4-a120-8931eb53d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bf00bbca-4a9b-4bc4-a120-8931eb53d7bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2054ba40-1084-479f-a86a-176ced1007e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2054ba40-1084-479f-a86a-176ced1007e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9f1ff450-4b56-4f0d-96bb-4f5d7dbdf17e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9f1ff450-4b56-4f0d-96bb-4f5d7dbdf17e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_957f562d-0316-477f-91ca-2bf460b01076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_957f562d-0316-477f-91ca-2bf460b01076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent_7e3239a2-e5d8-41c0-a6d5-30670ac87dfc" xlink:href="goss-20241231.xsd#goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent_7e3239a2-e5d8-41c0-a6d5-30670ac87dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fbf368a9-5e93-4659-aec3-b13600c5cee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fbf368a9-5e93-4659-aec3-b13600c5cee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_c0a1fb38-c684-4170-9144-34431341a69d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_55ed13a0-3009-4aff-8ebf-81deecbfe6db" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_c0a1fb38-c684-4170-9144-34431341a69d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_973fa723-3ecb-40d8-82b5-e23b61e1589b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1858cc5a-2601-4e78-a144-74bbd8f4570c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_973fa723-3ecb-40d8-82b5-e23b61e1589b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1858cc5a-2601-4e78-a144-74bbd8f4570c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3605b7ba-c365-4643-96ef-48f1cbad1cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_973fa723-3ecb-40d8-82b5-e23b61e1589b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3605b7ba-c365-4643-96ef-48f1cbad1cdd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesScheduleofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7a2eb5f1-6828-4f4d-a29e-ac18195d3654" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1657e76a-fd03-457d-9074-04f9af5edfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7a2eb5f1-6828-4f4d-a29e-ac18195d3654" xlink:to="loc_us-gaap_OperatingLeaseCost_1657e76a-fd03-457d-9074-04f9af5edfa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_06cbf17c-6bd9-4139-b356-d43bd0db2cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7a2eb5f1-6828-4f4d-a29e-ac18195d3654" xlink:to="loc_us-gaap_ShortTermLeaseCost_06cbf17c-6bd9-4139-b356-d43bd0db2cbe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7ddbf8ef-9f0e-41e0-8924-f24124ffcf16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7c5fb975-bbfc-4b0e-aed6-b8daa1eb9dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7ddbf8ef-9f0e-41e0-8924-f24124ffcf16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7c5fb975-bbfc-4b0e-aed6-b8daa1eb9dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6336a218-6b72-49e9-9106-778303217c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7ddbf8ef-9f0e-41e0-8924-f24124ffcf16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6336a218-6b72-49e9-9106-778303217c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36365d85-ee03-4161-9932-71392edce391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_610193fe-e791-4914-9f27-b64ca6e168c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36365d85-ee03-4161-9932-71392edce391" xlink:to="loc_us-gaap_OperatingLeaseLiability_610193fe-e791-4914-9f27-b64ca6e168c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f460375c-6236-4220-8e69-eb5975038c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36365d85-ee03-4161-9932-71392edce391" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f460375c-6236-4220-8e69-eb5975038c9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_880b43fb-ee30-4bd0-a831-cfb83357ffbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25f25503-2d30-4e86-8334-e8cd493982f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_880b43fb-ee30-4bd0-a831-cfb83357ffbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25f25503-2d30-4e86-8334-e8cd493982f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3e627be7-2a38-4525-909e-e4d20f82b68f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_880b43fb-ee30-4bd0-a831-cfb83357ffbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3e627be7-2a38-4525-909e-e4d20f82b68f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e5b88493-0f8b-4a5f-8148-d1c16e9f5c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_880b43fb-ee30-4bd0-a831-cfb83357ffbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e5b88493-0f8b-4a5f-8148-d1c16e9f5c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_02d85001-9044-4230-bf4c-98325b2da073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_880b43fb-ee30-4bd0-a831-cfb83357ffbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_02d85001-9044-4230-bf4c-98325b2da073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ca073233-fba6-4ce6-b9e4-989112735298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_880b43fb-ee30-4bd0-a831-cfb83357ffbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ca073233-fba6-4ce6-b9e4-989112735298" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>goss-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:27c0f11b-cb15-486e-948f-a34ff077e64b,g:c382099f-c004-46d4-b3a3-9983a179ddc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddd5427b-d001-4091-bfcb-5e9ae9366008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_StatementTable_ddd5427b-d001-4091-bfcb-5e9ae9366008" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abde655f-b31e-457f-86ef-e1e1fadaafd8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ddd5427b-d001-4091-bfcb-5e9ae9366008" xlink:to="loc_srt_ProductOrServiceAxis_abde655f-b31e-457f-86ef-e1e1fadaafd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abde655f-b31e-457f-86ef-e1e1fadaafd8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_abde655f-b31e-457f-86ef-e1e1fadaafd8" xlink:to="loc_srt_ProductsAndServicesDomain_abde655f-b31e-457f-86ef-e1e1fadaafd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_abde655f-b31e-457f-86ef-e1e1fadaafd8" xlink:to="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_34a36d8b-cc1c-495d-a5b8-5cdd61acb4af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:to="loc_us-gaap_LicenseAndServiceMember_34a36d8b-cc1c-495d-a5b8-5cdd61acb4af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenueFromContractsWithCollaboratorsMember_d8e40f77-bca9-417c-bd61-bdb863690c89" xlink:href="goss-20241231.xsd#goss_RevenueFromContractsWithCollaboratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:to="loc_goss_RevenueFromContractsWithCollaboratorsMember_d8e40f77-bca9-417c-bd61-bdb863690c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_470c9770-bf7a-4a4a-af45-5d01038a92ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_RevenuesAbstract_470c9770-bf7a-4a4a-af45-5d01038a92ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_974e046b-4283-4d81-a802-94e11d1d65f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_470c9770-bf7a-4a4a-af45-5d01038a92ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_974e046b-4283-4d81-a802-94e11d1d65f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_46334cab-c0c2-4cd6-863d-7950d23e04e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_46334cab-c0c2-4cd6-863d-7950d23e04e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses_132a0d00-4ea1-4f0e-82f2-c85fb3911cc2" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_goss_ResearchAndDevelopmentInProcessExpenses_132a0d00-4ea1-4f0e-82f2-c85fb3911cc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5829b571-aa5a-451b-8534-68995c249586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5829b571-aa5a-451b-8534-68995c249586" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fb87d5ba-0896-41c8-8349-d85c56cbd7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_us-gaap_OperatingExpenses_fb87d5ba-0896-41c8-8349-d85c56cbd7bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_06fafdff-0f72-44ce-9225-bad1627e1788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OperatingIncomeLoss_06fafdff-0f72-44ce-9225-bad1627e1788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7656af5b-d8b2-4e75-b7f3-95fc87c35658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7656af5b-d8b2-4e75-b7f3-95fc87c35658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_5eb3c702-776b-41e2-a06d-1561077ec906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_InterestExpenseNonoperating_5eb3c702-776b-41e2-a06d-1561077ec906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bb5a6d1d-e023-465d-a42e-2e28fe5577e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bb5a6d1d-e023-465d-a42e-2e28fe5577e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_88b0dc8b-97bc-425f-b6dd-2ece65c16f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_88b0dc8b-97bc-425f-b6dd-2ece65c16f98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8f8e471-b0f0-42a4-bf26-4812538bf7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8f8e471-b0f0-42a4-bf26-4812538bf7b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3b5562aa-e45b-4be2-937f-364c8a384a31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3b5562aa-e45b-4be2-937f-364c8a384a31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62b50a9b-955e-441d-9382-e8cabf9f013b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_NetIncomeLoss_62b50a9b-955e-441d-9382-e8cabf9f013b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139345eb-78b3-477a-9afb-d35db6bc0950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139345eb-78b3-477a-9afb-d35db6bc0950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_de0a979f-7fd0-4383-944f-c11e0dc3f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_de0a979f-7fd0-4383-944f-c11e0dc3f6ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0a5927d-dada-4619-b41d-28271ab6f85e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0a5927d-dada-4619-b41d-28271ab6f85e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cc2d81e-256f-4abf-b7c2-97d5f991d9da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cc2d81e-256f-4abf-b7c2-97d5f991d9da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_66676c0f-a762-4440-a2bc-bf6d36f74d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_EarningsPerShareBasic_66676c0f-a762-4440-a2bc-bf6d36f74d5c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_44a8d307-2369-469f-ab98-aa2615651111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_EarningsPerShareDiluted_44a8d307-2369-469f-ab98-aa2615651111" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ec186c-65aa-4e46-bdf9-b28510dfe104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ec186c-65aa-4e46-bdf9-b28510dfe104" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3abd12aa-8fcd-4c98-afa3-b6cbf73772c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3abd12aa-8fcd-4c98-afa3-b6cbf73772c3" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_86557d1c-66d0-4597-82b1-c52275f0b0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_86557d1c-66d0-4597-82b1-c52275f0b0c1" xlink:to="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ed9bca74-7919-4529-a250-f2b47ffbab26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ed9bca74-7919-4529-a250-f2b47ffbab26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed9bca74-7919-4529-a250-f2b47ffbab26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed9bca74-7919-4529-a250-f2b47ffbab26" xlink:to="loc_us-gaap_EquityComponentDomain_ed9bca74-7919-4529-a250-f2b47ffbab26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed9bca74-7919-4529-a250-f2b47ffbab26" xlink:to="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_71c9a270-2d0b-4cdd-98b8-3390091ca2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_CommonStockMember_71c9a270-2d0b-4cdd-98b8-3390091ca2f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a76e6afc-9fd1-4729-b0c0-0d49a81efb68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a76e6afc-9fd1-4729-b0c0-0d49a81efb68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d44ba96-9b1c-4881-bfc4-c20a2ab7a592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_RetainedEarningsMember_9d44ba96-9b1c-4881-bfc4-c20a2ab7a592" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_807e18a0-5c91-410e-b58f-fce9d4bb04e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_807e18a0-5c91-410e-b58f-fce9d4bb04e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_914aa900-64e4-4e40-891e-03dd37871462" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_914aa900-64e4-4e40-891e-03dd37871462" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_914aa900-64e4-4e40-891e-03dd37871462_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_914aa900-64e4-4e40-891e-03dd37871462" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_914aa900-64e4-4e40-891e-03dd37871462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b5a3e9e7-ef94-4318-9e8a-c7df19aad9d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_914aa900-64e4-4e40-891e-03dd37871462" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b5a3e9e7-ef94-4318-9e8a-c7df19aad9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_550c63e5-3a13-4356-8665-ea59b84ada41" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b5a3e9e7-ef94-4318-9e8a-c7df19aad9d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_550c63e5-3a13-4356-8665-ea59b84ada41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86557d1c-66d0-4597-82b1-c52275f0b0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_095675bd-c51f-4637-a7f6-c04ecbfea3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_095675bd-c51f-4637-a7f6-c04ecbfea3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4b81f9b-95f2-46d7-b2fc-a4ca9c7074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockholdersEquity_d4b81f9b-95f2-46d7-b2fc-a4ca9c7074a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df9629ac-240b-4e42-bda2-4c8e797158c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df9629ac-240b-4e42-bda2-4c8e797158c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_640a1907-0352-40ee-9b0e-31b30364e367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_640a1907-0352-40ee-9b0e-31b30364e367" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_be02f6f6-6fef-459c-9d3b-93ce8bbb88bb" xlink:href="goss-20241231.xsd#goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_be02f6f6-6fef-459c-9d3b-93ce8bbb88bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_69e3fa47-1cb9-4b76-bcff-89597a708954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_69e3fa47-1cb9-4b76-bcff-89597a708954" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82cedaac-f03e-4db5-aab0-edfab1c2009b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82cedaac-f03e-4db5-aab0-edfab1c2009b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d278b81-4434-4688-8f14-fa4fa1d3e192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d278b81-4434-4688-8f14-fa4fa1d3e192" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ebe3a50-209d-4d54-ba1a-527b8cac27ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ebe3a50-209d-4d54-ba1a-527b8cac27ce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e437c0e-70c2-4427-bd59-96947d5e9589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e437c0e-70c2-4427-bd59-96947d5e9589" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e46ba266-7e27-409c-bf56-2393137660be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e46ba266-7e27-409c-bf56-2393137660be" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued_42a70866-7d24-4a1e-a462-8a0e09b61a7f" xlink:href="goss-20241231.xsd#goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued_42a70866-7d24-4a1e-a462-8a0e09b61a7f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7fa4f81e-bdb0-44e6-8126-ba5c16a4257c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_NetIncomeLoss_7fa4f81e-bdb0-44e6-8126-ba5c16a4257c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_96db242b-d958-48be-a40f-8da3b167bd92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_96db242b-d958-48be-a40f-8da3b167bd92" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13eaa3dd-b6e8-4e92-8269-8c1671997f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e7e493c3-0d0f-4ad4-818c-0dc819dd4569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:to="loc_srt_RangeAxis_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801" xlink:to="loc_srt_RangeMember_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801" xlink:to="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b7b0ca8-8933-445d-8377-afa57d12214c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:to="loc_srt_MinimumMember_9b7b0ca8-8933-445d-8377-afa57d12214c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_527ea056-0f02-4ba8-90c1-a0caf49c3834" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:to="loc_srt_MaximumMember_527ea056-0f02-4ba8-90c1-a0caf49c3834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ae9cd89b-aac8-41bb-8738-62de8138c0de" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ae9cd89b-aac8-41bb-8738-62de8138c0de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ae9cd89b-aac8-41bb-8738-62de8138c0de_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ae9cd89b-aac8-41bb-8738-62de8138c0de" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ae9cd89b-aac8-41bb-8738-62de8138c0de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_346e833c-3e39-4877-af42-0f2d24f5cee4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ae9cd89b-aac8-41bb-8738-62de8138c0de" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_346e833c-3e39-4877-af42-0f2d24f5cee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9eff51d9-2e87-46af-a56e-3c9d392c42d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_346e833c-3e39-4877-af42-0f2d24f5cee4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9eff51d9-2e87-46af-a56e-3c9d392c42d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88" xlink:to="loc_us-gaap_EquityComponentDomain_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88" xlink:to="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5a5073c4-5f57-45ae-bad7-2141af7383cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5a5073c4-5f57-45ae-bad7-2141af7383cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_15d329ee-153c-458f-80cb-c7354d529fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:to="loc_us-gaap_RetainedEarningsMember_15d329ee-153c-458f-80cb-c7354d529fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_37f82483-32bf-47ff-9e44-1c5f69aebfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_NumberOfOperatingSegments_37f82483-32bf-47ff-9e44-1c5f69aebfa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f9b6a99-b8de-4d72-b312-b23134554b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f9b6a99-b8de-4d72-b312-b23134554b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermConvertibleSeniorNotes_0c4c9282-a4e2-46a9-bea8-2fbd5f23fcd1" xlink:href="goss-20241231.xsd#goss_LongTermConvertibleSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_goss_LongTermConvertibleSeniorNotes_0c4c9282-a4e2-46a9-bea8-2fbd5f23fcd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_25afcdfb-92b6-44e5-bc2b-17574e8d643e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_25afcdfb-92b6-44e5-bc2b-17574e8d643e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5769d47f-2056-4b32-bbef-536019dbf670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_StockholdersEquity_5769d47f-2056-4b32-bbef-536019dbf670" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_861a92e7-7a3e-4733-83f5-2d7578f4e8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c787c5b6-5243-4c65-b98c-f56079501dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_861a92e7-7a3e-4733-83f5-2d7578f4e8d5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c787c5b6-5243-4c65-b98c-f56079501dbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c787c5b6-5243-4c65-b98c-f56079501dbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_b825d98b-0383-4f1d-bc41-b51966a9abb9" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_b825d98b-0383-4f1d-bc41-b51966a9abb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f186c2e4-bf15-4393-94fe-1c3b2012ca77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f186c2e4-bf15-4393-94fe-1c3b2012ca77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_3f5be157-0755-4c22-a77f-ae2dfaaac7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_StockOptionMember_3f5be157-0755-4c22-a77f-ae2dfaaac7cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ff172b84-9fe2-4e99-a482-c0c2d0aacafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_WarrantMember_ff172b84-9fe2-4e99-a482-c0c2d0aacafa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fa886b3d-324c-43e4-82a2-8a0cc78f8765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_RestrictedStockMember_fa886b3d-324c-43e4-82a2-8a0cc78f8765" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7258a3ce-6660-4448-9765-ad229718edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_861a92e7-7a3e-4733-83f5-2d7578f4e8d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7258a3ce-6660-4448-9765-ad229718edfc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a318f8bf-fe8b-488d-8616-b402af15c2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a318f8bf-fe8b-488d-8616-b402af15c2f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a318f8bf-fe8b-488d-8616-b402af15c2f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a318f8bf-fe8b-488d-8616-b402af15c2f3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a318f8bf-fe8b-488d-8616-b402af15c2f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16b8da70-351e-48ce-8a6c-34ca32b4f1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a318f8bf-fe8b-488d-8616-b402af15c2f3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16b8da70-351e-48ce-8a6c-34ca32b4f1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8e49ab69-3b95-4d33-b898-6f438353e387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_16b8da70-351e-48ce-8a6c-34ca32b4f1d4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8e49ab69-3b95-4d33-b898-6f438353e387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_651ca565-254b-4d8a-bb39-0b454c97e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_651ca565-254b-4d8a-bb39-0b454c97e3d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_651ca565-254b-4d8a-bb39-0b454c97e3d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_651ca565-254b-4d8a-bb39-0b454c97e3d3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_651ca565-254b-4d8a-bb39-0b454c97e3d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_651ca565-254b-4d8a-bb39-0b454c97e3d3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_89b52b00-fc1a-4792-8d20-be3472b48179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_89b52b00-fc1a-4792-8d20-be3472b48179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_61986bca-3d0a-4e5e-b3fb-6c8114cac00e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_61986bca-3d0a-4e5e-b3fb-6c8114cac00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b064444e-4aa0-49dc-9371-aabf6422b9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b064444e-4aa0-49dc-9371-aabf6422b9f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_de5e470a-a62c-4295-aa6f-6e69914d0ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_de5e470a-a62c-4295-aa6f-6e69914d0ffb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de5e470a-a62c-4295-aa6f-6e69914d0ffb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_de5e470a-a62c-4295-aa6f-6e69914d0ffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_de5e470a-a62c-4295-aa6f-6e69914d0ffb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_de5e470a-a62c-4295-aa6f-6e69914d0ffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2a87ab8a-f583-48cd-8fda-05dc52e39e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2a87ab8a-f583-48cd-8fda-05dc52e39e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_73e47dbf-9c8b-4da5-a37f-6d14953350e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_73e47dbf-9c8b-4da5-a37f-6d14953350e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2ac910ba-216f-4636-a5c6-08c824b24d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_CommercialPaperMember_2ac910ba-216f-4636-a5c6-08c824b24d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9c8209d3-0247-41f7-923e-9b74b4a97071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9c8209d3-0247-41f7-923e-9b74b4a97071" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c831f9e-a6eb-45c1-8f6a-dd0fe10f24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c831f9e-a6eb-45c1-8f6a-dd0fe10f24fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c4481000-6047-4bd5-a010-3db2628e7493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c4481000-6047-4bd5-a010-3db2628e7493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities_a6c9cd9f-4a58-47dd-9d3b-6e7bb73610d8" xlink:href="goss-20241231.xsd#goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:to="loc_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities_a6c9cd9f-4a58-47dd-9d3b-6e7bb73610d8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0094b449-f2e5-4524-a9dc-3281e0d8c179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0094b449-f2e5-4524-a9dc-3281e0d8c179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0094b449-f2e5-4524-a9dc-3281e0d8c179_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0094b449-f2e5-4524-a9dc-3281e0d8c179" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0094b449-f2e5-4524-a9dc-3281e0d8c179_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23f6852d-51e0-4860-af50-11abfbe8e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0094b449-f2e5-4524-a9dc-3281e0d8c179" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23f6852d-51e0-4860-af50-11abfbe8e11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_47a72a02-64db-46ec-b72e-e554e4de5a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23f6852d-51e0-4860-af50-11abfbe8e11f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_47a72a02-64db-46ec-b72e-e554e4de5a4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6815a940-552d-4cc5-9df0-c60d83c98b74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6815a940-552d-4cc5-9df0-c60d83c98b74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6815a940-552d-4cc5-9df0-c60d83c98b74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6815a940-552d-4cc5-9df0-c60d83c98b74" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6815a940-552d-4cc5-9df0-c60d83c98b74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e24ce8c5-7a1b-4035-945f-5368e53c598e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6815a940-552d-4cc5-9df0-c60d83c98b74" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e24ce8c5-7a1b-4035-945f-5368e53c598e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_47fd755b-1f1c-420f-935d-8b11cbcc8aa7" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e24ce8c5-7a1b-4035-945f-5368e53c598e" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_47fd755b-1f1c-420f-935d-8b11cbcc8aa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_35ec5a5a-acde-4d78-b2ed-b7ababf92a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:to="loc_us-gaap_InterestReceivableCurrent_35ec5a5a-acde-4d78-b2ed-b7ababf92a16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ac555157-2441-46ac-945e-a57545715787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ac555157-2441-46ac-945e-a57545715787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_16e88153-e835-4dfd-a2ba-096aa55e00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_16e88153-e835-4dfd-a2ba-096aa55e00e6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a6b9c3-b80b-41dd-bb76-48351476167c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a6b9c3-b80b-41dd-bb76-48351476167c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d540c9b4-1c5c-4d7e-9179-d761f63c4a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a6b9c3-b80b-41dd-bb76-48351476167c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d540c9b4-1c5c-4d7e-9179-d761f63c4a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d540c9b4-1c5c-4d7e-9179-d761f63c4a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d540c9b4-1c5c-4d7e-9179-d761f63c4a33" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d540c9b4-1c5c-4d7e-9179-d761f63c4a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d540c9b4-1c5c-4d7e-9179-d761f63c4a33" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8cf2075c-f1c7-426d-b55d-e3f03a743a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8cf2075c-f1c7-426d-b55d-e3f03a743a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_35f0dce7-77c2-4972-96f5-c9f22fcf0f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_35f0dce7-77c2-4972-96f5-c9f22fcf0f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_addf9044-b744-44a2-b6d8-6b47701a006b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_addf9044-b744-44a2-b6d8-6b47701a006b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_212c6f74-1716-42ff-aa73-0239b20d60fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_212c6f74-1716-42ff-aa73-0239b20d60fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3fd4d25f-950c-430e-97bc-168f30c7aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3fd4d25f-950c-430e-97bc-168f30c7aad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e9ca2fa-beaa-4b29-b2aa-4c2b4ab348da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e9ca2fa-beaa-4b29-b2aa-4c2b4ab348da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96b1743e-ef38-40ea-8b5e-2817669c3f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96b1743e-ef38-40ea-8b5e-2817669c3f5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d3913461-c017-4398-83a6-bf997017e3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d3913461-c017-4398-83a6-bf997017e3ed" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7226a704-e032-4661-a8e2-2301076dcfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_CreditFacilityAxis_7226a704-e032-4661-a8e2-2301076dcfc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7226a704-e032-4661-a8e2-2301076dcfc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7226a704-e032-4661-a8e2-2301076dcfc1" xlink:to="loc_us-gaap_CreditFacilityDomain_7226a704-e032-4661-a8e2-2301076dcfc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0a43e699-6981-46f0-b7b4-650a095062f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7226a704-e032-4661-a8e2-2301076dcfc1" xlink:to="loc_us-gaap_CreditFacilityDomain_0a43e699-6981-46f0-b7b4-650a095062f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0a8e5375-7901-4d09-980a-13634060eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0a43e699-6981-46f0-b7b4-650a095062f4" xlink:to="loc_us-gaap_LineOfCreditMember_0a8e5375-7901-4d09-980a-13634060eceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a9103245-b3b5-49b4-91d5-c657b90182d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a9103245-b3b5-49b4-91d5-c657b90182d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9103245-b3b5-49b4-91d5-c657b90182d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a9103245-b3b5-49b4-91d5-c657b90182d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9103245-b3b5-49b4-91d5-c657b90182d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a9103245-b3b5-49b4-91d5-c657b90182d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TermLoanMember_f78c1bdd-6568-44e7-b809-093937b5b122" xlink:href="goss-20241231.xsd#goss_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:to="loc_goss_TermLoanMember_f78c1bdd-6568-44e7-b809-093937b5b122" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_1917f96f-4fbb-413c-b28b-2c78750dce11" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_1917f96f-4fbb-413c-b28b-2c78750dce11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9fb7098e-5727-4a4e-8737-029f28abee08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_VestingAxis_9fb7098e-5727-4a4e-8737-029f28abee08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9fb7098e-5727-4a4e-8737-029f28abee08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9fb7098e-5727-4a4e-8737-029f28abee08" xlink:to="loc_us-gaap_VestingDomain_9fb7098e-5727-4a4e-8737-029f28abee08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9fb7098e-5727-4a4e-8737-029f28abee08" xlink:to="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TrancheTwoMember_5bd982d0-2898-47dd-83b2-67d964be12c8" xlink:href="goss-20241231.xsd#goss_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:to="loc_goss_TrancheTwoMember_5bd982d0-2898-47dd-83b2-67d964be12c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TrancheOneMember_e6a19b01-210a-4bcf-abcd-27b88bd4f1ec" xlink:href="goss-20241231.xsd#goss_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:to="loc_goss_TrancheOneMember_e6a19b01-210a-4bcf-abcd-27b88bd4f1ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d56305d2-87f0-45d9-af63-30e707692c5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_srt_RangeAxis_d56305d2-87f0-45d9-af63-30e707692c5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d56305d2-87f0-45d9-af63-30e707692c5c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d56305d2-87f0-45d9-af63-30e707692c5c" xlink:to="loc_srt_RangeMember_d56305d2-87f0-45d9-af63-30e707692c5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d56305d2-87f0-45d9-af63-30e707692c5c" xlink:to="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_496d8b88-0647-4083-97ca-a09b2d90901b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:to="loc_srt_MinimumMember_496d8b88-0647-4083-97ca-a09b2d90901b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3128d6aa-5035-497c-80cc-7dd6046f2eeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:to="loc_srt_MaximumMember_3128d6aa-5035-497c-80cc-7dd6046f2eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_46553fd6-0ccf-4c29-ad87-9299c7add8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_46553fd6-0ccf-4c29-ad87-9299c7add8c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46553fd6-0ccf-4c29-ad87-9299c7add8c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_46553fd6-0ccf-4c29-ad87-9299c7add8c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46553fd6-0ccf-4c29-ad87-9299c7add8c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_46553fd6-0ccf-4c29-ad87-9299c7add8c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OneHundredThirtyPercentApplicableConversionPriceMember_6480e4aa-75e9-40ca-b961-ededa1d25b15" xlink:href="goss-20241231.xsd#goss_OneHundredThirtyPercentApplicableConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:to="loc_goss_OneHundredThirtyPercentApplicableConversionPriceMember_6480e4aa-75e9-40ca-b961-ededa1d25b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NinetyEightPercentApplicableConversionPriceMember_4f2c0132-b080-4d36-bbfb-c3176de6e368" xlink:href="goss-20241231.xsd#goss_NinetyEightPercentApplicableConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:to="loc_goss_NinetyEightPercentApplicableConversionPriceMember_4f2c0132-b080-4d36-bbfb-c3176de6e368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_de945b7c-ea65-4e49-b7f6-723dd72df635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_de945b7c-ea65-4e49-b7f6-723dd72df635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_dc595cd0-6d8f-4450-9a47-770aa5806173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_dc595cd0-6d8f-4450-9a47-770aa5806173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_90c360d1-ae5a-49e9-9916-521c5604a05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_90c360d1-ae5a-49e9-9916-521c5604a05f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfAdditionalTranches_25d3eb00-193a-4c5a-a3d5-1b0c519730cb" xlink:href="goss-20241231.xsd#goss_NumberOfAdditionalTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_NumberOfAdditionalTranches_25d3eb00-193a-4c5a-a3d5-1b0c519730cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_57600822-07a2-40fd-b660-3d37a749261e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_57600822-07a2-40fd-b660-3d37a749261e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_cac08c0d-5896-4a3c-a7bf-c0a269788549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_LineOfCredit_cac08c0d-5896-4a3c-a7bf-c0a269788549" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_861350d2-9efc-49e6-93c9-81072f756d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_861350d2-9efc-49e6-93c9-81072f756d86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentAggregatePrincipalAmount_34c6a6e8-be6b-434f-bf37-e29abe5c13d6" xlink:href="goss-20241231.xsd#goss_DebtInstrumentAggregatePrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentAggregatePrincipalAmount_34c6a6e8-be6b-434f-bf37-e29abe5c13d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_52a9fcaa-0dba-4783-a74d-7538bf368c58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_52a9fcaa-0dba-4783-a74d-7538bf368c58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5db4492c-c0a6-4d3d-9054-6871abd5a2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5db4492c-c0a6-4d3d-9054-6871abd5a2b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27df90ee-8100-43ee-89a2-6cf99b80ae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27df90ee-8100-43ee-89a2-6cf99b80ae6a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentConvertibleConversionPricePercentage_13e326a8-4510-4479-a265-ee0137143e51" xlink:href="goss-20241231.xsd#goss_DebtInstrumentConvertibleConversionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentConvertibleConversionPricePercentage_13e326a8-4510-4479-a265-ee0137143e51" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_05163d5f-53eb-4fb2-b171-d31164b648d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_05163d5f-53eb-4fb2-b171-d31164b648d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage_34757c3a-e79a-49a9-a104-ccb2682a9c87" xlink:href="goss-20241231.xsd#goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage_34757c3a-e79a-49a9-a104-ccb2682a9c87" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentRedemptionTermThresholdTradingDays_1f1c9ef5-66d4-4e66-840f-5f59760edd4d" xlink:href="goss-20241231.xsd#goss_DebtInstrumentRedemptionTermThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentRedemptionTermThresholdTradingDays_1f1c9ef5-66d4-4e66-840f-5f59760edd4d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2a25074a-5ab2-4659-8275-d61d5af06664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2a25074a-5ab2-4659-8275-d61d5af06664" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes_ab3175ce-f705-4763-a6fa-ab02602dd19c" xlink:href="goss-20241231.xsd#goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes_ab3175ce-f705-4763-a6fa-ab02602dd19c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermDebtPercentageInAggregatePrincipalAmount_bc147d90-e85d-4f58-87cd-0fdee9f8f87f" xlink:href="goss-20241231.xsd#goss_LongTermDebtPercentageInAggregatePrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_LongTermDebtPercentageInAggregatePrincipalAmount_bc147d90-e85d-4f58-87cd-0fdee9f8f87f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cbbb0786-ae71-43ae-a73c-858e4a52d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cbbb0786-ae71-43ae-a73c-858e4a52d5b1" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_72fdc781-836a-4a71-9cf1-7fc1148e5ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_DebtInstrumentTable_72fdc781-836a-4a71-9cf1-7fc1148e5ab2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_12fb143e-053a-47ec-b4f5-d2a7d645d182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72fdc781-836a-4a71-9cf1-7fc1148e5ab2" xlink:to="loc_us-gaap_DebtInstrumentAxis_12fb143e-053a-47ec-b4f5-d2a7d645d182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_12fb143e-053a-47ec-b4f5-d2a7d645d182_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_12fb143e-053a-47ec-b4f5-d2a7d645d182" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_12fb143e-053a-47ec-b4f5-d2a7d645d182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80f97819-d080-4aac-a83f-82a52884624b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_12fb143e-053a-47ec-b4f5-d2a7d645d182" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80f97819-d080-4aac-a83f-82a52884624b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_fe283aeb-5f71-419d-8f41-b89673e4b12f" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80f97819-d080-4aac-a83f-82a52884624b" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_fe283aeb-5f71-419d-8f41-b89673e4b12f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_630cc117-faa9-47be-a782-98da6b2fad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_630cc117-faa9-47be-a782-98da6b2fad9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_136a3e3a-04ee-4d84-a70b-1d2d140cbea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_136a3e3a-04ee-4d84-a70b-1d2d140cbea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_8892d470-8238-4fff-8331-d04577450929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_8892d470-8238-4fff-8331-d04577450929" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b3685811-e030-4fbf-bdf8-e6e31d361053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_LongTermDebt_b3685811-e030-4fbf-bdf8-e6e31d361053" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessScheduleofInterestExpenseRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0ba6550e-81af-466f-92c0-a7878bb56bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_us-gaap_DebtInstrumentTable_0ba6550e-81af-466f-92c0-a7878bb56bae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ba6550e-81af-466f-92c0-a7878bb56bae" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8e55897b-72c8-4478-9464-9a4b8d07e694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8e55897b-72c8-4478-9464-9a4b8d07e694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_870ad489-3e0d-4069-bccf-834c640a6a4c" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8e55897b-72c8-4478-9464-9a4b8d07e694" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_870ad489-3e0d-4069-bccf-834c640a6a4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractualInterestExpense_89dd75ad-26cf-4a0d-8af9-2ac251ea541c" xlink:href="goss-20241231.xsd#goss_ContractualInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_goss_ContractualInterestExpense_89dd75ad-26cf-4a0d-8af9-2ac251ea541c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6ae74107-95dd-493f-a888-acb76cd0ed14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6ae74107-95dd-493f-a888-acb76cd0ed14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b9e091ec-01d1-4340-82bf-e17d1964bd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b9e091ec-01d1-4340-82bf-e17d1964bd2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_42641332-fcf6-4be9-bf06-8fe7588af9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_us-gaap_InterestExpenseDebt_42641332-fcf6-4be9-bf06-8fe7588af9b1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca22613e-23bd-4df1-b8e2-0f64d98974e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca22613e-23bd-4df1-b8e2-0f64d98974e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PulmokineIncMember_b2f7ed95-eaa8-4585-b70e-dabd85a9dd49" xlink:href="goss-20241231.xsd#goss_PulmokineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca22613e-23bd-4df1-b8e2-0f64d98974e5" xlink:to="loc_goss_PulmokineIncMember_b2f7ed95-eaa8-4585-b70e-dabd85a9dd49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_438f2ace-99de-423c-b420-ea31728c7acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_438f2ace-99de-423c-b420-ea31728c7acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LicenseAgreementMember_20908a39-b6d8-4205-be73-c7eefb911fe1" xlink:href="goss-20241231.xsd#goss_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_438f2ace-99de-423c-b420-ea31728c7acc" xlink:to="loc_goss_LicenseAgreementMember_20908a39-b6d8-4205-be73-c7eefb911fe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2e8da18e-ddd0-4dd4-bb88-379fb5528547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2e8da18e-ddd0-4dd4-bb88-379fb5528547" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e8da18e-ddd0-4dd4-bb88-379fb5528547_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2e8da18e-ddd0-4dd4-bb88-379fb5528547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e8da18e-ddd0-4dd4-bb88-379fb5528547_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18788e76-f3e9-4df6-8422-02ef91669ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2e8da18e-ddd0-4dd4-bb88-379fb5528547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18788e76-f3e9-4df6-8422-02ef91669ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9b4ac02d-6b43-48f6-98be-5e4b94e71a29" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentSeralutinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18788e76-f3e9-4df6-8422-02ef91669ac7" xlink:to="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9b4ac02d-6b43-48f6-98be-5e4b94e71a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe2e50b0-2201-4836-a320-ec782143b7a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_srt_RangeAxis_fe2e50b0-2201-4836-a320-ec782143b7a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe2e50b0-2201-4836-a320-ec782143b7a7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fe2e50b0-2201-4836-a320-ec782143b7a7" xlink:to="loc_srt_RangeMember_fe2e50b0-2201-4836-a320-ec782143b7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8548e10-08a9-4f85-9ba1-5cea472c2842" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fe2e50b0-2201-4836-a320-ec782143b7a7" xlink:to="loc_srt_RangeMember_a8548e10-08a9-4f85-9ba1-5cea472c2842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c1d902f-d10c-42d9-9055-368f8e442a54" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a8548e10-08a9-4f85-9ba1-5cea472c2842" xlink:to="loc_srt_MaximumMember_0c1d902f-d10c-42d9-9055-368f8e442a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ProductLicenseTerm_6fd6f540-f57a-4394-8bb0-62046b32ce35" xlink:href="goss-20241231.xsd#goss_ProductLicenseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_ProductLicenseTerm_6fd6f540-f57a-4394-8bb0-62046b32ce35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable_94d5ca53-6425-40bd-86b5-2ec44e461e87" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable_94d5ca53-6425-40bd-86b5-2ec44e461e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable_06fa3511-71fe-4d47-8d76-0846af0a2797" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable_06fa3511-71fe-4d47-8d76-0846af0a2797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable_e65de729-66cd-4c6a-a84c-1c5fa28f72c8" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable_e65de729-66cd-4c6a-a84c-1c5fa28f72c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable_881399dd-cb75-45d7-a6e2-d37509665b43" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable_881399dd-cb75-45d7-a6e2-d37509665b43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_UpfrontPayment_40123105-8765-4fd0-9a3c-17c682ec61f9" xlink:href="goss-20241231.xsd#goss_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_UpfrontPayment_40123105-8765-4fd0-9a3c-17c682ec61f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_bddc9fe9-0533-4ed4-8c8e-0093cf0941b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_bddc9fe9-0533-4ed4-8c8e-0093cf0941b2" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_af750692-dc8f-450a-8aae-ce096bde3d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_f4b26e55-b6e4-42c5-9a47-183a3bb0b752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_af750692-dc8f-450a-8aae-ce096bde3d0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_f4b26e55-b6e4-42c5-9a47-183a3bb0b752" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bacaa006-6566-457d-9136-9219da145c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_f4b26e55-b6e4-42c5-9a47-183a3bb0b752" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bacaa006-6566-457d-9136-9219da145c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bacaa006-6566-457d-9136-9219da145c49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bacaa006-6566-457d-9136-9219da145c49" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bacaa006-6566-457d-9136-9219da145c49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bacaa006-6566-457d-9136-9219da145c49" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9e56a921-cda3-4d4d-9b60-75bfc7ff7290" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentSeralutinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:to="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9e56a921-cda3-4d4d-9b60-75bfc7ff7290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember_d9aadfed-cf02-42ca-8579-f9a10f514eb4" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentTerminatedProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:to="loc_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember_d9aadfed-cf02-42ca-8579-f9a10f514eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses_711de1a2-8bc0-4a90-9128-e2f2febd456f" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_af750692-dc8f-450a-8aae-ce096bde3d0c" xlink:to="loc_goss_ResearchAndDevelopmentInProcessExpenses_711de1a2-8bc0-4a90-9128-e2f2febd456f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0add2d89-918b-43a8-81b5-ab4a7452da43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0add2d89-918b-43a8-81b5-ab4a7452da43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0add2d89-918b-43a8-81b5-ab4a7452da43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0add2d89-918b-43a8-81b5-ab4a7452da43" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0add2d89-918b-43a8-81b5-ab4a7452da43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0add2d89-918b-43a8-81b5-ab4a7452da43" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_d9fc2389-7770-4fb9-bf33-b1d8b72caffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:to="loc_us-gaap_DomesticCountryMember_d9fc2389-7770-4fb9-bf33-b1d8b72caffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_37caeefa-59f5-4bc4-bd20-a86e50ba6bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_37caeefa-59f5-4bc4-bd20-a86e50ba6bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_b71b9b1f-4add-4d49-94d1-134a4f4b9b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:to="loc_us-gaap_ForeignCountryMember_b71b9b1f-4add-4d49-94d1-134a4f4b9b96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d49d228-21b7-4f17-8f9c-5035c8e83c03" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:to="loc_srt_RangeAxis_5d49d228-21b7-4f17-8f9c-5035c8e83c03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d49d228-21b7-4f17-8f9c-5035c8e83c03_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d49d228-21b7-4f17-8f9c-5035c8e83c03" xlink:to="loc_srt_RangeMember_5d49d228-21b7-4f17-8f9c-5035c8e83c03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_365ab6de-065e-4e17-b0b3-bb75a5079078" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d49d228-21b7-4f17-8f9c-5035c8e83c03" xlink:to="loc_srt_RangeMember_365ab6de-065e-4e17-b0b3-bb75a5079078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69e6d8dd-d3c2-49cf-ac4d-3dc24c0dedc8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_365ab6de-065e-4e17-b0b3-bb75a5079078" xlink:to="loc_srt_MaximumMember_69e6d8dd-d3c2-49cf-ac4d-3dc24c0dedc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_58c833dc-a935-4c53-a13f-a26ea07ade47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_58c833dc-a935-4c53-a13f-a26ea07ade47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_202c0937-d0ce-4b81-885f-cb4f3c984a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_us-gaap_OperatingLossCarryforwards_202c0937-d0ce-4b81-885f-cb4f3c984a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage_6b565b5f-c536-4e00-ac82-3aa9fe84742a" xlink:href="goss-20241231.xsd#goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage_6b565b5f-c536-4e00-ac82-3aa9fe84742a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation_ec82a0e4-d30b-41e0-af74-d1d531f46f84" xlink:href="goss-20241231.xsd#goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation_ec82a0e4-d30b-41e0-af74-d1d531f46f84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_cefb9530-76f5-422d-b435-4e6e75f94dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_cefb9530-76f5-422d-b435-4e6e75f94dfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TaxCreditCarryforwardsReductionDueToMerger_3f0877b1-fdf1-4687-a5c8-f0e93e6ed885" xlink:href="goss-20241231.xsd#goss_TaxCreditCarryforwardsReductionDueToMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_TaxCreditCarryforwardsReductionDueToMerger_3f0877b1-fdf1-4687-a5c8-f0e93e6ed885" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_c1d3ddfe-9bc4-48f4-a531-af33f513abe3" xlink:href="goss-20241231.xsd#goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_c1d3ddfe-9bc4-48f4-a531-af33f513abe3" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:href="goss-20241231.xsd#goss_StockholdersEquityDeficitLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:href="goss-20241231.xsd#goss_StockholdersEquityDeficitTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ade756cc-0f82-44ff-a305-549e16b370ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ade756cc-0f82-44ff-a305-549e16b370ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ade756cc-0f82-44ff-a305-549e16b370ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ade756cc-0f82-44ff-a305-549e16b370ef" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ade756cc-0f82-44ff-a305-549e16b370ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46594aad-4f07-414b-9a6a-4b693ca1ae36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ade756cc-0f82-44ff-a305-549e16b370ef" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46594aad-4f07-414b-9a6a-4b693ca1ae36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f8cc7e3e-236a-4a3c-a919-22180998fe89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46594aad-4f07-414b-9a6a-4b693ca1ae36" xlink:to="loc_us-gaap_PrivatePlacementMember_f8cc7e3e-236a-4a3c-a919-22180998fe89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a3a107c-26cd-435d-903e-1ed632cee416" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_srt_RangeAxis_2a3a107c-26cd-435d-903e-1ed632cee416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a3a107c-26cd-435d-903e-1ed632cee416_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a3a107c-26cd-435d-903e-1ed632cee416" xlink:to="loc_srt_RangeMember_2a3a107c-26cd-435d-903e-1ed632cee416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b590c4ba-ef6f-427d-a9f4-418dc5eed26a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a3a107c-26cd-435d-903e-1ed632cee416" xlink:to="loc_srt_RangeMember_b590c4ba-ef6f-427d-a9f4-418dc5eed26a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_55e471b9-25ec-4606-944b-3fe6e6d3f528" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b590c4ba-ef6f-427d-a9f4-418dc5eed26a" xlink:to="loc_srt_MaximumMember_55e471b9-25ec-4606-944b-3fe6e6d3f528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aafc354b-2a7d-43cf-a2d9-685a6d3c920f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_srt_CounterpartyNameAxis_aafc354b-2a7d-43cf-a2d9-685a6d3c920f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aafc354b-2a7d-43cf-a2d9-685a6d3c920f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aafc354b-2a7d-43cf-a2d9-685a6d3c920f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aafc354b-2a7d-43cf-a2d9-685a6d3c920f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aafc354b-2a7d-43cf-a2d9-685a6d3c920f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OfficerDirectorEmployeeOrConsultantMember_069d71f7-d61a-40a9-a3ba-11d0e3760eb0" xlink:href="goss-20241231.xsd#goss_OfficerDirectorEmployeeOrConsultantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:to="loc_goss_OfficerDirectorEmployeeOrConsultantMember_069d71f7-d61a-40a9-a3ba-11d0e3760eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_8e3df0ee-2f77-4385-8dcb-4e4ae550ec13" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_8e3df0ee-2f77-4385-8dcb-4e4ae550ec13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12e40312-cae4-44ef-85d0-e26954364e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12e40312-cae4-44ef-85d0-e26954364e6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_12e40312-cae4-44ef-85d0-e26954364e6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12e40312-cae4-44ef-85d0-e26954364e6c" xlink:to="loc_us-gaap_EquityComponentDomain_12e40312-cae4-44ef-85d0-e26954364e6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cf34026a-fc7b-481b-9433-972b2849b173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12e40312-cae4-44ef-85d0-e26954364e6c" xlink:to="loc_us-gaap_EquityComponentDomain_cf34026a-fc7b-481b-9433-972b2849b173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_FounderSharesMember_56d84858-7c93-4e4e-b7b5-7bf8a7505cd2" xlink:href="goss-20241231.xsd#goss_FounderSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cf34026a-fc7b-481b-9433-972b2849b173" xlink:to="loc_goss_FounderSharesMember_56d84858-7c93-4e4e-b7b5-7bf8a7505cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4823656-90c0-4077-8264-c983bb467f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4823656-90c0-4077-8264-c983bb467f25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c4823656-90c0-4077-8264-c983bb467f25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4823656-90c0-4077-8264-c983bb467f25" xlink:to="loc_us-gaap_RelatedPartyDomain_c4823656-90c0-4077-8264-c983bb467f25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_173f6716-cd68-4968-937e-4def0220d89c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4823656-90c0-4077-8264-c983bb467f25" xlink:to="loc_us-gaap_RelatedPartyDomain_173f6716-cd68-4968-937e-4def0220d89c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_FounderMember_8286c1d5-292a-4882-987a-7218a53bf5e4" xlink:href="goss-20241231.xsd#goss_FounderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_173f6716-cd68-4968-937e-4def0220d89c" xlink:to="loc_goss_FounderMember_8286c1d5-292a-4882-987a-7218a53bf5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVotingRightsNumberOfVotesPerShare_007e3add-a47d-4b4e-a09a-9c9abdd689a9" xlink:href="goss-20241231.xsd#goss_CommonStockVotingRightsNumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CommonStockVotingRightsNumberOfVotesPerShare_007e3add-a47d-4b4e-a09a-9c9abdd689a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0d0c64-ccbc-4aa4-b324-f88e982531d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0d0c64-ccbc-4aa4-b324-f88e982531d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_887504a4-fc00-4f2b-9717-e18420fae25b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_887504a4-fc00-4f2b-9717-e18420fae25b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a30b1d77-8e49-4d1f-b978-a0da96216e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a30b1d77-8e49-4d1f-b978-a0da96216e04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f82d3244-7c03-43c3-ad63-49da26711ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f82d3244-7c03-43c3-ad63-49da26711ee1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1f4e1adf-bdc5-4682-b35a-23f3b779f510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1f4e1adf-bdc5-4682-b35a-23f3b779f510" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f075e3e4-7321-4990-91f2-c9d2ac957343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f075e3e4-7321-4990-91f2-c9d2ac957343" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_527a1ef3-823b-4215-b4ba-fb928508cc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_527a1ef3-823b-4215-b4ba-fb928508cc0f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5d85358-0caa-499e-ab12-9bc658a9e395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5d85358-0caa-499e-ab12-9bc658a9e395" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_66152db6-26af-42f3-a44c-c3f981ea62a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_66152db6-26af-42f3-a44c-c3f981ea62a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_894dffa8-0852-4b35-8d10-2741129307cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_894dffa8-0852-4b35-8d10-2741129307cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_864aa2ff-1eb4-4c91-b425-e25defe9a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_864aa2ff-1eb4-4c91-b425-e25defe9a34b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_625a0eed-4d9a-4b72-afec-18acc41f6c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_625a0eed-4d9a-4b72-afec-18acc41f6c2e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVestingPercentage_3144e72b-7a2e-41e5-a323-3ee16931cc4d" xlink:href="goss-20241231.xsd#goss_CommonStockVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CommonStockVestingPercentage_3144e72b-7a2e-41e5-a323-3ee16931cc4d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVestingPeriod_e488a4b9-d059-4370-9c81-ddfb526f50a1" xlink:href="goss-20241231.xsd#goss_CommonStockVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CommonStockVestingPeriod_e488a4b9-d059-4370-9c81-ddfb526f50a1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PercentageOfFullyDilutedShareCapital_d309ed55-951e-468a-9b0b-9374aa7539cc" xlink:href="goss-20241231.xsd#goss_PercentageOfFullyDilutedShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_PercentageOfFullyDilutedShareCapital_d309ed55-951e-468a-9b0b-9374aa7539cc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreasedInEquityCapitalAmount_9fef3642-303a-4ffa-b8e8-5ca7eb8e1aea" xlink:href="goss-20241231.xsd#goss_IncreasedInEquityCapitalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_IncreasedInEquityCapitalAmount_9fef3642-303a-4ffa-b8e8-5ca7eb8e1aea" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting_5b692b29-d815-40f3-9233-1007d313ea26" xlink:href="goss-20241231.xsd#goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting_5b692b29-d815-40f3-9233-1007d313ea26" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_9f637a32-4e15-4ed1-9acd-34fc92015c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_9f637a32-4e15-4ed1-9acd-34fc92015c87" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage_c0b72de0-0a6e-4a32-b696-da37d2ebb1a3" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage_c0b72de0-0a6e-4a32-b696-da37d2ebb1a3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding_f8065adc-9a6c-4646-a8ea-094090bba934" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding_f8065adc-9a6c-4646-a8ea-094090bba934" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice_0fb4d4e4-db20-4b37-b338-468819060018" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice_0fb4d4e4-db20-4b37-b338-468819060018" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays_b0323739-fe17-4eb2-bf36-774a05f13772" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays_b0323739-fe17-4eb2-bf36-774a05f13772" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice_4b85224b-7679-4d7a-ab44-fb08b98930c2" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice_4b85224b-7679-4d7a-ab44-fb08b98930c2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_a2e7005c-aee9-4893-80d3-a28c09a6e807" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityFairValueOfEquityOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_a2e7005c-aee9-4893-80d3-a28c09a6e807" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c8fda2be-1f73-474a-8701-965d22cca51b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_PlanNameAxis_c8fda2be-1f73-474a-8701-965d22cca51b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c8fda2be-1f73-474a-8701-965d22cca51b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c8fda2be-1f73-474a-8701-965d22cca51b" xlink:to="loc_us-gaap_PlanNameDomain_c8fda2be-1f73-474a-8701-965d22cca51b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c8fda2be-1f73-474a-8701-965d22cca51b" xlink:to="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember_8fbe75bd-dd56-4ee4-acc9-47a0769901e1" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember_8fbe75bd-dd56-4ee4-acc9-47a0769901e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandNineteenEquityIncentivePlanMember_939127de-a1a0-459e-8a9d-b6ee330bf4bf" xlink:href="goss-20241231.xsd#goss_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandNineteenEquityIncentivePlanMember_939127de-a1a0-459e-8a9d-b6ee330bf4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember_578baa97-44ae-42a3-85d7-c0395f83ac79" xlink:href="goss-20241231.xsd#goss_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember_578baa97-44ae-42a3-85d7-c0395f83ac79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandSeventeenEquityIncentivePlanMember_90db5c12-8da8-444c-aba7-25d64ff50864" xlink:href="goss-20241231.xsd#goss_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandSeventeenEquityIncentivePlanMember_90db5c12-8da8-444c-aba7-25d64ff50864" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_srt_RangeAxis_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6" xlink:to="loc_srt_RangeMember_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ceaf1d7-e095-4466-bed1-10bb1e5c7f85" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6" xlink:to="loc_srt_RangeMember_3ceaf1d7-e095-4466-bed1-10bb1e5c7f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4eaf2203-e2ff-4f07-bca9-7af4f18f4b9a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ceaf1d7-e095-4466-bed1-10bb1e5c7f85" xlink:to="loc_srt_MaximumMember_4eaf2203-e2ff-4f07-bca9-7af4f18f4b9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd812493-89ad-4ff0-8e1f-c3f105b4186f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_AwardTypeAxis_bd812493-89ad-4ff0-8e1f-c3f105b4186f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd812493-89ad-4ff0-8e1f-c3f105b4186f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bd812493-89ad-4ff0-8e1f-c3f105b4186f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd812493-89ad-4ff0-8e1f-c3f105b4186f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bd812493-89ad-4ff0-8e1f-c3f105b4186f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_417c6a3d-4e59-4e4b-a4d4-c1eb233ca823" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:to="loc_us-gaap_RestrictedStockMember_417c6a3d-4e59-4e4b-a4d4-c1eb233ca823" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5af07ce0-daed-44b5-bf18-c2612fc937d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5af07ce0-daed-44b5-bf18-c2612fc937d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b1b1523e-b84c-4826-8aff-656771eb187a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_VestingAxis_b1b1523e-b84c-4826-8aff-656771eb187a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b1b1523e-b84c-4826-8aff-656771eb187a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_b1b1523e-b84c-4826-8aff-656771eb187a" xlink:to="loc_us-gaap_VestingDomain_b1b1523e-b84c-4826-8aff-656771eb187a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_b1b1523e-b84c-4826-8aff-656771eb187a" xlink:to="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9c4fb2a5-c06f-402d-9a87-67ea35a27a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9c4fb2a5-c06f-402d-9a87-67ea35a27a64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_036430be-cd22-4669-8c93-3eb43766aa55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_036430be-cd22-4669-8c93-3eb43766aa55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_859ad0cc-2256-4989-a089-24331552bd65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_859ad0cc-2256-4989-a089-24331552bd65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b47009b9-6f7d-4567-b5e9-c08086c06e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b47009b9-6f7d-4567-b5e9-c08086c06e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_29f0a080-15bc-4141-b8f8-140f86ccce68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b47009b9-6f7d-4567-b5e9-c08086c06e5d" xlink:to="loc_us-gaap_PrivatePlacementMember_29f0a080-15bc-4141-b8f8-140f86ccce68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a18ce4d0-36a3-4dae-965f-20797f1a21a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_srt_CounterpartyNameAxis_a18ce4d0-36a3-4dae-965f-20797f1a21a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a18ce4d0-36a3-4dae-965f-20797f1a21a0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a18ce4d0-36a3-4dae-965f-20797f1a21a0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a18ce4d0-36a3-4dae-965f-20797f1a21a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_407f36f0-84a6-4daf-aa1a-c35b1ec291af" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a18ce4d0-36a3-4dae-965f-20797f1a21a0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_407f36f0-84a6-4daf-aa1a-c35b1ec291af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OfficerDirectorEmployeeOrConsultantMember_f0f0cb7b-bafc-4e51-8d80-b4c61e0428b9" xlink:href="goss-20241231.xsd#goss_OfficerDirectorEmployeeOrConsultantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_407f36f0-84a6-4daf-aa1a-c35b1ec291af" xlink:to="loc_goss_OfficerDirectorEmployeeOrConsultantMember_f0f0cb7b-bafc-4e51-8d80-b4c61e0428b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5afde2a5-a4c1-466b-901c-eead85ce3426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5afde2a5-a4c1-466b-901c-eead85ce3426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1dbaa75f-6a7d-4686-95f2-7e2b7bc70aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1dbaa75f-6a7d-4686-95f2-7e2b7bc70aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards_244de6ba-c738-45ab-811a-a24813ffd277" xlink:href="goss-20241231.xsd#goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards_244de6ba-c738-45ab-811a-a24813ffd277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2018a2b5-f343-43ad-87b6-b0359211c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2018a2b5-f343-43ad-87b6-b0359211c8a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b1c7f7a-1075-43b7-a0dd-72dc0a37c70c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b1c7f7a-1075-43b7-a0dd-72dc0a37c70c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_187f5a17-cfe9-4fbe-8764-0e92e95fc58f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_187f5a17-cfe9-4fbe-8764-0e92e95fc58f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_843bf012-72c2-4f10-8f4d-119ce37b4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_843bf012-72c2-4f10-8f4d-119ce37b4fe0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_6ced3ede-a096-4aed-a7e2-ffadd7ce7379" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_6ced3ede-a096-4aed-a7e2-ffadd7ce7379" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_21491e5d-7b0f-470f-87c2-288ab57e35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_21491e5d-7b0f-470f-87c2-288ab57e35c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a76ab6eb-1772-4cd5-8b48-d2525540fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a76ab6eb-1772-4cd5-8b48-d2525540fed7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab70586b-3c75-402b-b848-8060745d8b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab70586b-3c75-402b-b848-8060745d8b28" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee62d56c-059e-43f7-8b9c-55a962769e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee62d56c-059e-43f7-8b9c-55a962769e25" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f306157a-9edf-49cc-b7b5-e9596af7e24d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f306157a-9edf-49cc-b7b5-e9596af7e24d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_32efe7a0-acb9-447a-9058-6f5182d5f822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_32efe7a0-acb9-447a-9058-6f5182d5f822" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays_a9a14379-d8df-4946-a6f6-aafc96389700" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays_a9a14379-d8df-4946-a6f6-aafc96389700" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice_9fec38d8-933f-4f6f-8fc9-1f38a98e81a9" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice_9fec38d8-933f-4f6f-8fc9-1f38a98e81a9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_65b61170-f562-48f7-85b1-2cbc6bd7e3db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_65b61170-f562-48f7-85b1-2cbc6bd7e3db" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_541d8d38-0b66-45df-b823-5212b26a7669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_541d8d38-0b66-45df-b823-5212b26a7669" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_192d7754-8d91-4726-8b36-6fecac1863c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_192d7754-8d91-4726-8b36-6fecac1863c1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_86becc6e-5807-4327-a32b-c5e627ba7092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_86becc6e-5807-4327-a32b-c5e627ba7092" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage_481be0ab-d18b-40f3-8a13-d087a84fda15" xlink:href="goss-20241231.xsd#goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage_481be0ab-d18b-40f3-8a13-d087a84fda15" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_17f30084-84db-48a5-904a-17b761174c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_17f30084-84db-48a5-904a-17b761174c77" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8fb87926-a990-4195-82db-07a111bdc162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8fb87926-a990-4195-82db-07a111bdc162" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f57480c3-6f8f-4203-ac96-e35d6e0c0f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f57480c3-6f8f-4203-ac96-e35d6e0c0f25" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_407afc75-34f5-48e2-bbe1-e4f152d53dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_407afc75-34f5-48e2-bbe1-e4f152d53dbc" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e639f-7c84-4ade-b9b2-d85197d061d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e639f-7c84-4ade-b9b2-d85197d061d5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_74697527-bd30-435b-9e23-b4824443277d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_74697527-bd30-435b-9e23-b4824443277d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efaaacc7-e389-4877-bb19-e7d83b8bd07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efaaacc7-e389-4877-bb19-e7d83b8bd07a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50b3e705-c8f2-46e6-9be0-7f45a3c6871d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50b3e705-c8f2-46e6-9be0-7f45a3c6871d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e33634c-6b12-4324-9de5-7786b3222332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e33634c-6b12-4324-9de5-7786b3222332" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_aa1d63f4-f88d-43cd-bf6b-405cdf72e4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_aa1d63f4-f88d-43cd-bf6b-405cdf72e4db" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_326ca768-eda4-4eab-a3ec-7f785afd1125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_326ca768-eda4-4eab-a3ec-7f785afd1125" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b3912cd3-6201-4b7c-ba10-2e7ee33125ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b3912cd3-6201-4b7c-ba10-2e7ee33125ab" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c78a0ab6-53f6-469e-8624-4feca78ac29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c78a0ab6-53f6-469e-8624-4feca78ac29e" xlink:type="arc" order="33"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e20c971-c6b8-4947-ad51-87fae8106944" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:to="loc_srt_RangeAxis_5e20c971-c6b8-4947-ad51-87fae8106944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e20c971-c6b8-4947-ad51-87fae8106944_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5e20c971-c6b8-4947-ad51-87fae8106944" xlink:to="loc_srt_RangeMember_5e20c971-c6b8-4947-ad51-87fae8106944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5e20c971-c6b8-4947-ad51-87fae8106944" xlink:to="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7d72d4a-2b41-4ce0-b6ac-47f08b58ea9e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:to="loc_srt_MinimumMember_e7d72d4a-2b41-4ce0-b6ac-47f08b58ea9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2798c7b9-707c-448b-89de-13469266e27d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:to="loc_srt_MaximumMember_2798c7b9-707c-448b-89de-13469266e27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85bf371c-8dd5-4b7b-ae1a-db650b188cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:to="loc_us-gaap_AwardTypeAxis_85bf371c-8dd5-4b7b-ae1a-db650b188cd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85bf371c-8dd5-4b7b-ae1a-db650b188cd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_85bf371c-8dd5-4b7b-ae1a-db650b188cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85bf371c-8dd5-4b7b-ae1a-db650b188cd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_85bf371c-8dd5-4b7b-ae1a-db650b188cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_885592b3-38a7-487e-946b-98ab939830d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_885592b3-38a7-487e-946b-98ab939830d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EmployeeStockPurchasePlanMember_75f070f2-b1e3-41d9-a12c-5c0edd26a700" xlink:href="goss-20241231.xsd#goss_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:to="loc_goss_EmployeeStockPurchasePlanMember_75f070f2-b1e3-41d9-a12c-5c0edd26a700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_45595051-1129-406b-b53c-fec398a594aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_45595051-1129-406b-b53c-fec398a594aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eabf2fb7-8ea8-4028-bced-e9595521ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eabf2fb7-8ea8-4028-bced-e9595521ac35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_37ee14f0-9d8f-44e9-9ee9-3228b1fe3765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_37ee14f0-9d8f-44e9-9ee9-3228b1fe3765" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1809b677-f9b3-45a9-b6be-f504984330b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1809b677-f9b3-45a9-b6be-f504984330b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59f0e77a-e255-40ab-944d-9cf006950c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59f0e77a-e255-40ab-944d-9cf006950c87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b1e8ce2-9615-4cab-97e1-f7609a1b29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b1e8ce2-9615-4cab-97e1-f7609a1b29c4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansScheduleofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85fdfe27-fa7c-41e6-97fc-249d1bb0ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85fdfe27-fa7c-41e6-97fc-249d1bb0ba33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3afb87b1-2d49-49a9-88fe-436a4ccad2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85fdfe27-fa7c-41e6-97fc-249d1bb0ba33" xlink:to="loc_us-gaap_AwardTypeAxis_3afb87b1-2d49-49a9-88fe-436a4ccad2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3afb87b1-2d49-49a9-88fe-436a4ccad2f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3afb87b1-2d49-49a9-88fe-436a4ccad2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3afb87b1-2d49-49a9-88fe-436a4ccad2f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7700d7ca-d284-407d-83fc-2b977694cf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3afb87b1-2d49-49a9-88fe-436a4ccad2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7700d7ca-d284-407d-83fc-2b977694cf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2435b12d-d326-4a6d-9e37-697f9fb6a1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7700d7ca-d284-407d-83fc-2b977694cf33" xlink:to="loc_us-gaap_RestrictedStockMember_2435b12d-d326-4a6d-9e37-697f9fb6a1cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d2683ff-d50a-403e-96dc-3199806c6ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d2683ff-d50a-403e-96dc-3199806c6ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f256edad-1942-49d5-ba98-ddeefcba690d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f256edad-1942-49d5-ba98-ddeefcba690d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84f0775c-afe4-4d9a-8873-f5ece531624f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84f0775c-afe4-4d9a-8873-f5ece531624f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64da9bbd-0e28-4fdc-93e8-15ae4cab29fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64da9bbd-0e28-4fdc-93e8-15ae4cab29fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9bddd36e-107c-4657-8f95-fee3fc6a8fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49ed55e-d1fb-437b-9b80-3002a75a4a71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49ed55e-d1fb-437b-9b80-3002a75a4a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9905c078-744a-474d-82c2-8393823df917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9905c078-744a-474d-82c2-8393823df917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5c3225f7-3223-4a67-a747-2a0985d8779a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5c3225f7-3223-4a67-a747-2a0985d8779a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab580328-6fe5-4835-8142-67a9b6162e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab580328-6fe5-4835-8142-67a9b6162e5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bfd9a478-0cef-447a-9771-40067f94fecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7f40a68d-3215-471f-9724-6aa80df2c484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_12ce3ff8-e80b-482a-a0f5-6fe9c35b1286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7f40a68d-3215-471f-9724-6aa80df2c484" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_12ce3ff8-e80b-482a-a0f5-6fe9c35b1286" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1f2834b-c36d-48fe-ab84-51ce30b6fd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_12ce3ff8-e80b-482a-a0f5-6fe9c35b1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1f2834b-c36d-48fe-ab84-51ce30b6fd34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f1f2834b-c36d-48fe-ab84-51ce30b6fd34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1f2834b-c36d-48fe-ab84-51ce30b6fd34" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f1f2834b-c36d-48fe-ab84-51ce30b6fd34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1f2834b-c36d-48fe-ab84-51ce30b6fd34" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9c22173e-d657-43a5-a78f-4c2877a40bab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9c22173e-d657-43a5-a78f-4c2877a40bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f32405c0-b0aa-4474-8b04-1da1b6740168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f32405c0-b0aa-4474-8b04-1da1b6740168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a00e84df-4a76-4853-b3c8-cff6bc66064a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7f40a68d-3215-471f-9724-6aa80df2c484" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a00e84df-4a76-4853-b3c8-cff6bc66064a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6f26f8bc-9817-4fa6-a756-52f0f65c1506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6f26f8bc-9817-4fa6-a756-52f0f65c1506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f26f8bc-9817-4fa6-a756-52f0f65c1506_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6f26f8bc-9817-4fa6-a756-52f0f65c1506" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f26f8bc-9817-4fa6-a756-52f0f65c1506_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6f26f8bc-9817-4fa6-a756-52f0f65c1506" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_3e464323-4845-4359-9419-77ec8dee92ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_OfficeEquipmentMember_3e464323-4845-4359-9419-77ec8dee92ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7f9d6a21-8241-4370-9777-6754f159b664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_ComputerEquipmentMember_7f9d6a21-8241-4370-9777-6754f159b664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_23ab50f8-c661-4586-af09-fe8e5f18920b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_23ab50f8-c661-4586-af09-fe8e5f18920b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_4ed4dc40-154a-44fb-8f99-3f9afa65b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_EquipmentMember_4ed4dc40-154a-44fb-8f99-3f9afa65b6d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f9e9d9ea-3b90-4073-b3ea-d708c6371220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f9e9d9ea-3b90-4073-b3ea-d708c6371220" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_724c7011-a638-46a5-a621-3d0680e8f59a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:to="loc_srt_RangeAxis_724c7011-a638-46a5-a621-3d0680e8f59a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_724c7011-a638-46a5-a621-3d0680e8f59a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_724c7011-a638-46a5-a621-3d0680e8f59a" xlink:to="loc_srt_RangeMember_724c7011-a638-46a5-a621-3d0680e8f59a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_724c7011-a638-46a5-a621-3d0680e8f59a" xlink:to="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a45b1aa6-0a3e-40c2-b82a-52aecb886d31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:to="loc_srt_MinimumMember_a45b1aa6-0a3e-40c2-b82a-52aecb886d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c1e20d7-468b-44cb-9602-1cc91813095f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:to="loc_srt_MaximumMember_3c1e20d7-468b-44cb-9602-1cc91813095f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_841b4f79-ea3a-4ebc-990c-0b6406051143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_841b4f79-ea3a-4ebc-990c-0b6406051143" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f6fca2cd-854e-4775-b760-ed0bad51e60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f6fca2cd-854e-4775-b760-ed0bad51e60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45f6076e-a62a-47dc-bc56-1ffedf558955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45f6076e-a62a-47dc-bc56-1ffedf558955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cb2f31d3-6166-46f6-8031-f62774a2a34e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cb2f31d3-6166-46f6-8031-f62774a2a34e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aaeb67cc-8929-47c9-8c17-6c4ad7894a09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aaeb67cc-8929-47c9-8c17-6c4ad7894a09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9144814b-2e05-46bb-b281-e6016a76c899" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aaeb67cc-8929-47c9-8c17-6c4ad7894a09" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9144814b-2e05-46bb-b281-e6016a76c899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9144814b-2e05-46bb-b281-e6016a76c899_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9144814b-2e05-46bb-b281-e6016a76c899" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9144814b-2e05-46bb-b281-e6016a76c899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9144814b-2e05-46bb-b281-e6016a76c899" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LeaseAgreementEnteredInJuly2024Member_603ce1cb-0450-46e1-9182-f722caf2a8ab" xlink:href="goss-20241231.xsd#goss_LeaseAgreementEnteredInJuly2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:to="loc_goss_LeaseAgreementEnteredInJuly2024Member_603ce1cb-0450-46e1-9182-f722caf2a8ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member_758b1523-7dd8-4b5b-915d-65a49c6a43c8" xlink:href="goss-20241231.xsd#goss_NonCancelableLeaseAgreementEnteredInAugust2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:to="loc_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member_758b1523-7dd8-4b5b-915d-65a49c6a43c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LeaseeOperatingLeaseLeasedArea_8f95a55f-ef2f-478a-8a11-5795ac571af9" xlink:href="goss-20241231.xsd#goss_LeaseeOperatingLeaseLeasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LeaseeOperatingLeaseLeasedArea_8f95a55f-ef2f-478a-8a11-5795ac571af9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_94241cf3-c0b7-4f40-a834-20cc754ab8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_94241cf3-c0b7-4f40-a834-20cc754ab8e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseBaseRent_be7b1f80-5c65-4f30-a609-29ded964bf85" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseBaseRent_be7b1f80-5c65-4f30-a609-29ded964bf85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage_b6602001-90f8-45b3-88aa-cfaa43992660" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage_b6602001-90f8-45b3-88aa-cfaa43992660" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseExtensionTerm_58e3d4f5-9086-4f96-b67c-895a210a1696" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseExtensionTerm_58e3d4f5-9086-4f96-b67c-895a210a1696" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent_0bef7ec5-3d6b-4bd3-94ae-7607868a1aba" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent_0bef7ec5-3d6b-4bd3-94ae-7607868a1aba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8af2dd9-29b1-4f06-ac9a-a551d339ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8af2dd9-29b1-4f06-ac9a-a551d339ea58" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c5ac5b9-3606-4a7c-8f35-72e5518f0d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c5ac5b9-3606-4a7c-8f35-72e5518f0d62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ee198143-5751-4df5-b992-cfa0a588a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_OperatingLeasePayments_ee198143-5751-4df5-b992-cfa0a588a1fc" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContractsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f85983e8-95e5-4b9e-931b-59a8b92f94b7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:to="loc_srt_CounterpartyNameAxis_f85983e8-95e5-4b9e-931b-59a8b92f94b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f85983e8-95e5-4b9e-931b-59a8b92f94b7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f85983e8-95e5-4b9e-931b-59a8b92f94b7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f85983e8-95e5-4b9e-931b-59a8b92f94b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed0470f1-bc62-4958-a313-13ccffc5edeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f85983e8-95e5-4b9e-931b-59a8b92f94b7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed0470f1-bc62-4958-a313-13ccffc5edeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_fdc43622-7b6c-4f00-bebf-daad485cea10" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed0470f1-bc62-4958-a313-13ccffc5edeb" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_fdc43622-7b6c-4f00-bebf-daad485cea10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2022b640-7b1a-42b2-b7b3-cde169575b40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:to="loc_srt_RangeAxis_2022b640-7b1a-42b2-b7b3-cde169575b40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2022b640-7b1a-42b2-b7b3-cde169575b40_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2022b640-7b1a-42b2-b7b3-cde169575b40" xlink:to="loc_srt_RangeMember_2022b640-7b1a-42b2-b7b3-cde169575b40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3d4b754-9b9f-46e9-a0d9-1c5daef02a8b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2022b640-7b1a-42b2-b7b3-cde169575b40" xlink:to="loc_srt_RangeMember_b3d4b754-9b9f-46e9-a0d9-1c5daef02a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6282c95a-dd52-44b3-b234-ef89b5b5b31c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b3d4b754-9b9f-46e9-a0d9-1c5daef02a8b" xlink:to="loc_srt_MaximumMember_6282c95a-dd52-44b3-b234-ef89b5b5b31c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e1b351fb-9f65-4710-8555-632ff16c4ec4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:to="loc_srt_ProductOrServiceAxis_e1b351fb-9f65-4710-8555-632ff16c4ec4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1b351fb-9f65-4710-8555-632ff16c4ec4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e1b351fb-9f65-4710-8555-632ff16c4ec4" xlink:to="loc_srt_ProductsAndServicesDomain_e1b351fb-9f65-4710-8555-632ff16c4ec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e1b351fb-9f65-4710-8555-632ff16c4ec4" xlink:to="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LicensesOfIntellectualPropertyMember_5d693d46-d9bb-402c-a07c-2a3a71558391" xlink:href="goss-20241231.xsd#goss_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:to="loc_goss_LicensesOfIntellectualPropertyMember_5d693d46-d9bb-402c-a07c-2a3a71558391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_11fc9594-be31-40a4-a08c-dd3333e08cce" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:to="loc_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_11fc9594-be31-40a4-a08c-dd3333e08cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfDistinctPerformanceObligations_d7307162-7b8d-42c7-8cbc-9ba423e6b76e" xlink:href="goss-20241231.xsd#goss_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_NumberOfDistinctPerformanceObligations_d7307162-7b8d-42c7-8cbc-9ba423e6b76e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfLicensesGranted_17b4bdc2-7f83-4694-b241-5ddc40ec2dfb" xlink:href="goss-20241231.xsd#goss_NumberOfLicensesGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_NumberOfLicensesGranted_17b4bdc2-7f83-4694-b241-5ddc40ec2dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage_8b8d7d37-8499-45d3-8e3c-f02229972bd3" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage_8b8d7d37-8499-45d3-8e3c-f02229972bd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage_4ef0b6d7-430e-4b6e-b829-d10c66cae40d" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage_4ef0b6d7-430e-4b6e-b829-d10c66cae40d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived_a5abc461-dd7c-4a85-b898-d55fb1acaf03" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived_a5abc461-dd7c-4a85-b898-d55fb1acaf03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount_0b2f718a-10cf-496d-b9dc-4f4160bf9ddb" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationRegulatoryMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount_0b2f718a-10cf-496d-b9dc-4f4160bf9ddb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationSalesMilestonesAmount_5b48a941-cd6d-4ab9-a5ea-3247ec1b234e" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationSalesMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationSalesMilestonesAmount_5b48a941-cd6d-4ab9-a5ea-3247ec1b234e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenueLoyaltyReceivableExpirationPeriod_a9a5baf7-b9e4-4af7-8fbf-ccf6c99c4ac0" xlink:href="goss-20241231.xsd#goss_RevenueLoyaltyReceivableExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenueLoyaltyReceivableExpirationPeriod_a9a5baf7-b9e4-4af7-8fbf-ccf6c99c4ac0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityDevelopmentCost_158314a4-6ce9-4c87-8f7a-24ce5117b3a7" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityDevelopmentCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_ContractWithCustomerLiabilityDevelopmentCost_158314a4-6ce9-4c87-8f7a-24ce5117b3a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_3df8d81c-8828-470f-b741-0b79e5a89cf1" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityFairValueOfEquityOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_3df8d81c-8828-470f-b741-0b79e5a89cf1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07a1b1da-eab8-4ef5-99b5-bd3b6c2d7610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07a1b1da-eab8-4ef5-99b5-bd3b6c2d7610" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d0bf44d9-7063-4ab2-85d0-7ff80508f2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d0bf44d9-7063-4ab2-85d0-7ff80508f2b0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerRevenueRecognitionPeriod_6bae4cf2-1212-457e-9f42-916606bf401c" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerRevenueRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_ContractWithCustomerRevenueRecognitionPeriod_6bae4cf2-1212-457e-9f42-916606bf401c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_13e9a90b-7ecf-46b0-b984-60d138a587c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_13e9a90b-7ecf-46b0-b984-60d138a587c9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e3cdd0da-327c-49c4-9c00-7f253a8cac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e3cdd0da-327c-49c4-9c00-7f253a8cac1f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5606c4eb-2583-4302-bd2a-c693e8261699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5606c4eb-2583-4302-bd2a-c693e8261699" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccountReceivablePaymentTerm_be004920-9db1-4ee4-9062-024774bd3ce2" xlink:href="goss-20241231.xsd#goss_AccountReceivablePaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_AccountReceivablePaymentTerm_be004920-9db1-4ee4-9062-024774bd3ce2" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd03d154-f3be-429c-8ed2-1e52e35452b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd03d154-f3be-429c-8ed2-1e52e35452b7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_564d2a01-1cbf-44f8-adf6-a62a1504e6bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:to="loc_srt_CounterpartyNameAxis_564d2a01-1cbf-44f8-adf6-a62a1504e6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_564d2a01-1cbf-44f8-adf6-a62a1504e6bd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_564d2a01-1cbf-44f8-adf6-a62a1504e6bd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_564d2a01-1cbf-44f8-adf6-a62a1504e6bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4619b73-6f3f-4de7-b159-bffe1c798bc9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_564d2a01-1cbf-44f8-adf6-a62a1504e6bd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4619b73-6f3f-4de7-b159-bffe1c798bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_031aad14-435e-47ef-b2df-b47e23154b08" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4619b73-6f3f-4de7-b159-bffe1c798bc9" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_031aad14-435e-47ef-b2df-b47e23154b08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd4c592b-b12a-4a59-b883-0ba18de76f1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:to="loc_srt_ProductOrServiceAxis_dd4c592b-b12a-4a59-b883-0ba18de76f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd4c592b-b12a-4a59-b883-0ba18de76f1d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dd4c592b-b12a-4a59-b883-0ba18de76f1d" xlink:to="loc_srt_ProductsAndServicesDomain_dd4c592b-b12a-4a59-b883-0ba18de76f1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dd4c592b-b12a-4a59-b883-0ba18de76f1d" xlink:to="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_USLicenseMember_dfb0c784-d83e-4570-89a5-1f1cf2373d23" xlink:href="goss-20241231.xsd#goss_USLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_USLicenseMember_dfb0c784-d83e-4570-89a5-1f1cf2373d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ROWLicenseMember_e9ee3a5d-e026-4926-b0ed-859caf5386e7" xlink:href="goss-20241231.xsd#goss_ROWLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_ROWLicenseMember_e9ee3a5d-e026-4926-b0ed-859caf5386e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_98d4c8d8-9054-4f44-ac2d-a9853c2cdd4d" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_98d4c8d8-9054-4f44-ac2d-a9853c2cdd4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_97eb4084-e95c-4056-b186-8dc6885a5827" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_97eb4084-e95c-4056-b186-8dc6885a5827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityRollforwardAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd03d154-f3be-429c-8ed2-1e52e35452b7" xlink:to="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_25c208f0-3705-4bd8-aa87-08d35c0590d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_25c208f0-3705-4bd8-aa87-08d35c0590d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived_cbce7ff7-42ea-4d67-b28b-c083c56a7aa0" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived_cbce7ff7-42ea-4d67-b28b-c083c56a7aa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1127447d-6b2a-4067-ae3d-ca33aa83e2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1127447d-6b2a-4067-ae3d-ca33aa83e2fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate_2969ed78-b843-419c-a141-2f5c1835f72b" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate_2969ed78-b843-419c-a141-2f5c1835f72b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b5860a47-9578-4b57-a9cd-ff6bd8957fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e485803-0952-47b1-bfbf-cb1c086420d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e485803-0952-47b1-bfbf-cb1c086420d8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_44493ebd-659b-4f44-a66a-039f2b8e9a58" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:to="loc_srt_ProductOrServiceAxis_44493ebd-659b-4f44-a66a-039f2b8e9a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_44493ebd-659b-4f44-a66a-039f2b8e9a58_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_44493ebd-659b-4f44-a66a-039f2b8e9a58" xlink:to="loc_srt_ProductsAndServicesDomain_44493ebd-659b-4f44-a66a-039f2b8e9a58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_44493ebd-659b-4f44-a66a-039f2b8e9a58" xlink:to="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_USLicenseMember_7d8ba01e-56b4-432e-9843-dec73b8a6d23" xlink:href="goss-20241231.xsd#goss_USLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_USLicenseMember_7d8ba01e-56b4-432e-9843-dec73b8a6d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ROWLicenseMember_355cd255-5f28-4b73-ac6a-249ed2299fe6" xlink:href="goss-20241231.xsd#goss_ROWLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_ROWLicenseMember_355cd255-5f28-4b73-ac6a-249ed2299fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_e208aa52-6726-44a0-aa07-5304b9ce9d59" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_e208aa52-6726-44a0-aa07-5304b9ce9d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_58c106f6-68d4-455a-923f-915aae39868d" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_58c106f6-68d4-455a-923f-915aae39868d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_32dc228d-d00e-4647-a7b7-46a82c89232a" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_32dc228d-d00e-4647-a7b7-46a82c89232a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_a64c68fb-62d6-4437-99cf-8d68f59ddf6a" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_a64c68fb-62d6-4437-99cf-8d68f59ddf6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHCommercialExpensesSubjectToReimbursementMember_b117cf63-3630-45da-ba14-50aef46b0805" xlink:href="goss-20241231.xsd#goss_PAHCommercialExpensesSubjectToReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PAHCommercialExpensesSubjectToReimbursementMember_b117cf63-3630-45da-ba14-50aef46b0805" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDCommercialExpensesSubjectToReimbursementMember_59fac4a4-0ce0-4f02-a459-7f0d5aa33c23" xlink:href="goss-20241231.xsd#goss_PHILDCommercialExpensesSubjectToReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PHILDCommercialExpensesSubjectToReimbursementMember_59fac4a4-0ce0-4f02-a459-7f0d5aa33c23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EffectsOfExchangeRateMember_f07075b4-9dfe-48ac-9aef-5c1b8b372e3c" xlink:href="goss-20241231.xsd#goss_EffectsOfExchangeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_EffectsOfExchangeRateMember_f07075b4-9dfe-48ac-9aef-5c1b8b372e3c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3ee3760f-66ec-482b-b237-23d8fa860a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3ee3760f-66ec-482b-b237-23d8fa860a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3ee3760f-66ec-482b-b237-23d8fa860a9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3ee3760f-66ec-482b-b237-23d8fa860a9d" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3ee3760f-66ec-482b-b237-23d8fa860a9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3ee3760f-66ec-482b-b237-23d8fa860a9d" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_99615cf5-3b70-4edc-b359-3c981b261ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_99615cf5-3b70-4edc-b359-3c981b261ab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_98001664-912d-4662-80e6-af5c744744ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:to="loc_us-gaap_TransferredOverTimeMember_98001664-912d-4662-80e6-af5c744744ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5f3a696f-cc40-453f-82b3-207dec36d96a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:to="loc_srt_CounterpartyNameAxis_5f3a696f-cc40-453f-82b3-207dec36d96a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f3a696f-cc40-453f-82b3-207dec36d96a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5f3a696f-cc40-453f-82b3-207dec36d96a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f3a696f-cc40-453f-82b3-207dec36d96a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2833fc21-f526-4b8f-af36-f81249af5f02" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5f3a696f-cc40-453f-82b3-207dec36d96a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2833fc21-f526-4b8f-af36-f81249af5f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_28f1f31b-cc6f-44d2-b29f-2e252d57c924" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2833fc21-f526-4b8f-af36-f81249af5f02" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_28f1f31b-cc6f-44d2-b29f-2e252d57c924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c18c6333-7d6b-46ff-a34f-18f970d7ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e485803-0952-47b1-bfbf-cb1c086420d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c18c6333-7d6b-46ff-a34f-18f970d7ecc1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SegmentInformationScheduleofSegmentReportingInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_af94051a-428c-4ddd-bd61-b8b6bdbf68f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_af94051a-428c-4ddd-bd61-b8b6bdbf68f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0753a507-900c-416c-a9b9-34e5826b28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_af94051a-428c-4ddd-bd61-b8b6bdbf68f6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0753a507-900c-416c-a9b9-34e5826b28c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0753a507-900c-416c-a9b9-34e5826b28c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0753a507-900c-416c-a9b9-34e5826b28c3" xlink:to="loc_us-gaap_SegmentDomain_0753a507-900c-416c-a9b9-34e5826b28c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_977c2c67-7dc0-4447-a7c5-6b0971bc9e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0753a507-900c-416c-a9b9-34e5826b28c3" xlink:to="loc_us-gaap_SegmentDomain_977c2c67-7dc0-4447-a7c5-6b0971bc9e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ReportingSegmentMember_10ec031a-3dcf-4faf-8edc-b6ccb6ec6d09" xlink:href="goss-20241231.xsd#goss_ReportingSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_977c2c67-7dc0-4447-a7c5-6b0971bc9e0e" xlink:to="loc_goss_ReportingSegmentMember_10ec031a-3dcf-4faf-8edc-b6ccb6ec6d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e13ecad1-5cb0-49b0-81d1-8477f0a441d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e13ecad1-5cb0-49b0-81d1-8477f0a441d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2d7aff9d-1762-455d-8487-7643c67e77de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2d7aff9d-1762-455d-8487-7643c67e77de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_e3d45b3d-6220-446c-87b1-654a2d3ebeff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_e3d45b3d-6220-446c-87b1-654a2d3ebeff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d4d7a416-0fa2-4e7b-b171-56f3ef6abe4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d4d7a416-0fa2-4e7b-b171-56f3ef6abe4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_d38752a0-1084-4f1d-a7c2-189f1c42fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_InterestExpenseNonoperating_d38752a0-1084-4f1d-a7c2-189f1c42fef1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_58805d4d-47bb-4681-a785-b3c49e94f61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_58805d4d-47bb-4681-a785-b3c49e94f61d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4c8273a2-09b4-4f56-ad8b-e8ebd8a7707e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4c8273a2-09b4-4f56-ad8b-e8ebd8a7707e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0bb3ba8-4af4-4e0d-a52a-23d5c349de96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_NetIncomeLoss_e0bb3ba8-4af4-4e0d-a52a-23d5c349de96" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="41"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>goss-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:27c0f11b-cb15-486e-948f-a34ff077e64b,g:c382099f-c004-46d4-b3a3-9983a179ddc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_bf3261c8-696c-4e60-801b-34bb936d9207_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount funded</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9dbc904b-4471-4d22-b256-11d9d0ce4228_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life (in years), Options vested and expected to vest as of end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcf82a3c-de59-47cf-8391-b5268c184dac_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c4864a08-5917-4247-ad37-f2d9e09390aa_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_04d0171c-e781-4047-b406-830d2984c1a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c1ade0d2-65c7-4082-b37d-e215a07a4613_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions_1351e50c-594e-43f6-b08b-083ff2cdf99a_negatedLabel_en-US" xlink:label="lab_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development asset acquisitions, net of cash acquired</link:label>
    <link:label id="lab_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions_label_en-US" xlink:label="lab_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Proceeds From Research And Development Asset Acquisitions</link:label>
    <link:label id="lab_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions_documentation_en-US" xlink:label="lab_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) research and development asset acquisitions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" xlink:href="goss-20241231.xsd#goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" xlink:to="lab_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c07f1bc1-c2bc-46d5-b976-1d8d38d24549_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8f209b15-505f-4264-9aa4-76bb5bc923b0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_03000f34-f9af-40d6-a1ea-ddcb8b09c0a2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentSeralutinibMember_097cef7b-144a-48e2-bbe5-c8ddc65758b6_terseLabel_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentSeralutinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seralutinib</link:label>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentSeralutinibMember_label_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentSeralutinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development Seralutinib [Member]</link:label>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentSeralutinibMember_documentation_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentSeralutinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In Process Research And Development Seralutinib</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentSeralutinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember" xlink:to="lab_goss_InProcessResearchAndDevelopmentSeralutinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4b435973-c4b9-4b88-aa98-3c759663bb93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Future Minimum Annual Rental Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_cc1e1811-b8ba-478b-a786-c0fa0b47071f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_5bc78459-6f60-48c1-9cd5-1ce708753ef1_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_94c82cde-b0d8-4762-b4cd-7dcf48a353a7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_NumberOfDistinctPerformanceObligations_e985f136-a86a-4f46-8bc7-081786d34c55_terseLabel_en-US" xlink:label="lab_goss_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of significant distinct performance obligations</link:label>
    <link:label id="lab_goss_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_goss_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_goss_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_goss_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfDistinctPerformanceObligations" xlink:href="goss-20241231.xsd#goss_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_NumberOfDistinctPerformanceObligations" xlink:to="lab_goss_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c4c4dbc4-18aa-49c8-a204-fd89dc9745b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_NinetyEightPercentApplicableConversionPriceMember_73dd08f8-92d2-48b1-a4c5-ee6132c61419_terseLabel_en-US" xlink:label="lab_goss_NinetyEightPercentApplicableConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">98% Applicable Conversion Price</link:label>
    <link:label id="lab_goss_NinetyEightPercentApplicableConversionPriceMember_label_en-US" xlink:label="lab_goss_NinetyEightPercentApplicableConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ninety Eight Percent Applicable Conversion Price [Member]</link:label>
    <link:label id="lab_goss_NinetyEightPercentApplicableConversionPriceMember_documentation_en-US" xlink:label="lab_goss_NinetyEightPercentApplicableConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ninety Eight Percent Applicable Conversion Price [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NinetyEightPercentApplicableConversionPriceMember" xlink:href="goss-20241231.xsd#goss_NinetyEightPercentApplicableConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_NinetyEightPercentApplicableConversionPriceMember" xlink:to="lab_goss_NinetyEightPercentApplicableConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_4fd310ee-153b-4ff3-82d1-da0d743f985d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_eafb406e-927f-49ec-93ca-2a1eac8bd744_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ContractWithCustomerLiabilityRollforwardAbstract_c4021691-9326-4244-bcc8-b319afa9b1c6_terseLabel_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityRollforwardAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability [Rollforward]</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityRollforwardAbstract_label_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityRollforwardAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability Rollforward [Abstract]</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityRollforwardAbstract_documentation_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityRollforwardAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityRollforwardAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract" xlink:to="lab_goss_ContractWithCustomerLiabilityRollforwardAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LicenseAgreementMember_0c6ded28-258d-431e-b3c6-d495c0694ec0_terseLabel_en-US" xlink:label="lab_goss_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_goss_LicenseAgreementMember_label_en-US" xlink:label="lab_goss_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_goss_LicenseAgreementMember_documentation_en-US" xlink:label="lab_goss_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LicenseAgreementMember" xlink:href="goss-20241231.xsd#goss_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LicenseAgreementMember" xlink:to="lab_goss_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_98818d06-78ba-4b82-900b-3390a4e66e05_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_RevenueFromContractsWithCollaboratorsMember_427a6682-6647-45c7-bce4-d298d1a20488_terseLabel_en-US" xlink:label="lab_goss_RevenueFromContractsWithCollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contracts with collaborators</link:label>
    <link:label id="lab_goss_RevenueFromContractsWithCollaboratorsMember_label_en-US" xlink:label="lab_goss_RevenueFromContractsWithCollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contracts with Collaborators [Member]</link:label>
    <link:label id="lab_goss_RevenueFromContractsWithCollaboratorsMember_documentation_en-US" xlink:label="lab_goss_RevenueFromContractsWithCollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Contracts with Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenueFromContractsWithCollaboratorsMember" xlink:href="goss-20241231.xsd#goss_RevenueFromContractsWithCollaboratorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_RevenueFromContractsWithCollaboratorsMember" xlink:to="lab_goss_RevenueFromContractsWithCollaboratorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_72ebddaf-a554-4b46-a76a-5846fa490bae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0511f400-38ee-4cf5-8782-3c54111c80f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements and Available for Sale Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_03e8fe78-7d89-4378-ab6d-9b9dd4b0236a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_RevenueLoyaltyReceivableExpirationPeriod_73d7fe24-46da-475e-b14c-5d89f5163a0e_terseLabel_en-US" xlink:label="lab_goss_RevenueLoyaltyReceivableExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loyalty term, expiration period</link:label>
    <link:label id="lab_goss_RevenueLoyaltyReceivableExpirationPeriod_label_en-US" xlink:label="lab_goss_RevenueLoyaltyReceivableExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Loyalty Receivable, Expiration Period</link:label>
    <link:label id="lab_goss_RevenueLoyaltyReceivableExpirationPeriod_documentation_en-US" xlink:label="lab_goss_RevenueLoyaltyReceivableExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Loyalty Receivable, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenueLoyaltyReceivableExpirationPeriod" xlink:href="goss-20241231.xsd#goss_RevenueLoyaltyReceivableExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_RevenueLoyaltyReceivableExpirationPeriod" xlink:to="lab_goss_RevenueLoyaltyReceivableExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_98240f76-57dd-4913-9d76-f6b54a5c5a23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized income (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_114eb65a-d4c0-4cd8-b84a-c23f32a5337e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6964ce34-b8e2-4a7b-8f7c-97f188ce7545_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5fdddfd4-3208-4abc-b2b9-6a8e7938fc5d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_4bc31f34-4090-4e7a-b62d-a5987185ee8f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_32b592e3-92f3-4d48-ac31-2e49e5ba77f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_48f77dc5-34d0-4cf2-987d-4244dfd1129f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest expense</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member_c03d9ba4-b02f-4787-bd39-8f39fcee3b68_terseLabel_en-US" xlink:label="lab_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cancelable Lease Agreement Entered in August 2018</link:label>
    <link:label id="lab_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member_label_en-US" xlink:label="lab_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cancelable Lease Agreement Entered in August 2018 [Member]</link:label>
    <link:label id="lab_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member_documentation_en-US" xlink:label="lab_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cancelable Lease Agreement Entered in August 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member" xlink:href="goss-20241231.xsd#goss_NonCancelableLeaseAgreementEnteredInAugust2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member" xlink:to="lab_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable_edc6bdb4-8061-40e4-8ecd-1b7ea77f074a_terseLabel_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and regulatory milestone payments</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable_label_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Contingent Consideration Development And Regulatory Milestone Payments Payable</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable_documentation_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination, contingent consideration, development and regulatory milestone payments, payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" xlink:to="lab_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8f4a15cd-0fec-4eeb-8f30-fe21666f2b56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_24c33bde-3cc3-4e02-8595-8200271698a2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_05517434-86c2-4722-b8ce-863a3b00f1e2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on revenue</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_e160b740-8db1-4738-bf20-5d5e04cd8444_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_9ee46e1e-f687-47c1-b49a-16285df0d1ec_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_63e5e3f0-c6bd-4c93-83c4-6e159f296cf2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1392dca3-0cd7-4d0a-a35d-b51c231b75d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_8a2f601a-d772-4022-a964-2a60d6e89b98_terseLabel_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityFairValueOfEquityOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, fair value of equity option</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_label_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityFairValueOfEquityOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Fair Value Of Equity Option</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_documentation_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityFairValueOfEquityOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Fair Value Of Equity Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityFairValueOfEquityOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption" xlink:to="lab_goss_ContractWithCustomerLiabilityFairValueOfEquityOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_146910c4-cc4e-435b-910e-eaa7246e5f7b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_cba1bcf3-1562-4230-9bee-3f0cb8c5b37e_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_357ad534-3ce0-4e08-9c73-9fd8a1f808d7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ef39b371-073a-42e2-8f1a-b1701b96d39f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b5c269d1-5e2c-4782-a947-d19904feb257_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_47908b74-6d4f-4c47-908c-e811807f70cc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_8731700e-5dae-4e36-be9f-afa2a014e702_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_01c1e20b-5f80-47d2-804e-32df4619be45_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_843bba03-35ff-4f84-91db-4fdedbf36f8e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_fe84bf7e-df19-4d75-a021-915f94a20511_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_124218f5-d8d8-4081-82ab-9ef40f78f8e1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from convertible debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_11c0ab3b-5ca0-4320-99aa-9553e855214c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_50f2331b-b08b-459e-b63a-90f0256fd6f3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds, after deducting underwriting discounts, commissions, and offering expenses</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b2d374d6-b05b-4544-93ef-bb4315fa7b6c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ea99f78b-e4e2-4e37-b051-8ee656e6a005_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LeaseeOperatingLeaseLeasedArea_ff479d28-0acb-43fc-9606-58eee698c659_terseLabel_en-US" xlink:label="lab_goss_LeaseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leased area</link:label>
    <link:label id="lab_goss_LeaseeOperatingLeaseLeasedArea_label_en-US" xlink:label="lab_goss_LeaseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasee, Operating Lease, Leased Area</link:label>
    <link:label id="lab_goss_LeaseeOperatingLeaseLeasedArea_documentation_en-US" xlink:label="lab_goss_LeaseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasee, Operating Lease, Leased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LeaseeOperatingLeaseLeasedArea" xlink:href="goss-20241231.xsd#goss_LeaseeOperatingLeaseLeasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LeaseeOperatingLeaseLeasedArea" xlink:to="lab_goss_LeaseeOperatingLeaseLeasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c7c30aa2-ad2b-4a3b-ac24-489002c40efb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8ee90713-384c-4ac9-9f56-50797f9ba012_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock_ba6310a1-2fdd-44ea-ae9a-4c0866596009_terseLabel_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of IPR&amp;D Expense</link:label>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock_label_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development Expenses [Table Text Block]</link:label>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock_documentation_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In process research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock" xlink:to="lab_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_390452ba-96ac-4793-bbd8-4a08728853b4_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e8052b9a-885d-4784-9f0f-c6bf3d3bcd74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_13090453-5ece-48a3-9e1a-f3a69c1003c3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options exercisable as of ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aafa18f3-20e0-45fd-ad45-a4205eafe6bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and agency securities and corporate debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc7a4634-8720-49ad-b941-ba0e84a613cc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e8555456-0242-4f52-8e54-6d60852d6a2d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a52b9e8d-2737-4d42-86d2-cc930f69fecb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_0fa0874e-e8b9-4241-8b5b-b6593605446b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_02e8a6ec-47d0-483b-bb67-caeee39cdf50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_b544a2c6-d191-40a6-ad31-03fcd3687369_terseLabel_en-US" xlink:label="lab_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PH-ILD research and development costs subject to reimbursement</link:label>
    <link:label id="lab_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_label_en-US" xlink:label="lab_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PH-ILD Research And Development Services, Expenses Subject To Reimbursement [Member]</link:label>
    <link:label id="lab_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_documentation_en-US" xlink:label="lab_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PH-ILD Research And Development Services, Expenses Subject To Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:to="lab_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_780f0e32-613b-42e6-8943-13e4e37d435d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_83cb35a9-5e5b-4989-a9bb-999eae941e50_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_39005c83-ee36-4df4-ac92-ea952e83f3ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TrancheTwoMember_5267710d-bbbf-430d-9bdb-160000661f52_terseLabel_en-US" xlink:label="lab_goss_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_goss_TrancheTwoMember_label_en-US" xlink:label="lab_goss_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_goss_TrancheTwoMember_documentation_en-US" xlink:label="lab_goss_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TrancheTwoMember" xlink:href="goss-20241231.xsd#goss_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TrancheTwoMember" xlink:to="lab_goss_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LongTermConvertibleSeniorNotes_e0659ae1-c1b6-4fdd-b447-4cb76ca09116_terseLabel_en-US" xlink:label="lab_goss_LongTermConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term convertible senior notes</link:label>
    <link:label id="lab_goss_LongTermConvertibleSeniorNotes_label_en-US" xlink:label="lab_goss_LongTermConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Convertible Senior Notes</link:label>
    <link:label id="lab_goss_LongTermConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_goss_LongTermConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term convertible senior notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermConvertibleSeniorNotes" xlink:href="goss-20241231.xsd#goss_LongTermConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LongTermConvertibleSeniorNotes" xlink:to="lab_goss_LongTermConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8f77ad12-ac4a-4c71-ad03-0c427e04f467_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_a45d0210-6b4b-487e-9391-51383067fd9f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0a72c24d-774b-46ad-a3b1-ad84a9493788_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e29b3b9f-1dad-432b-9d46-ece35df3577b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_58f27ef0-d48a-440b-8098-a3edd07f01a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_a0499fa3-ca70-42f4-ba49-dd3ae1cf4b64_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3f032ef4-2ab6-42f1-80cc-2ae3b2cb72b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_33720c49-4f64-4929-a0f5-f53c7ce06356_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_07cac855-d8d2-49e7-9b63-b60105a72a3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec041ebf-4f4d-4dd3-a9de-887f4117120a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_eac17537-c2e2-4cb9-957c-a4cc98f4bf10_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_628cd1aa-8d6f-48a8-acda-8113846d2301_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_aa827bcc-d372-47c5-9628-5c7df1665f06_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0c4dfd31-5468-45ec-af25-8d91fe9be698_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_429d5120-86d3-4cd4-aa9c-8836a207c035_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161b206b-4109-421d-a9c3-a6173ea7b571_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_040f4c02-2136-42bf-ba81-d4204d758ccd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 1</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ebb1678a-28a3-4bce-8e4d-ff484aad624b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a866bceb-4e70-47da-96e5-af91a022894b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2fb8800f-b650-439b-89c7-2564ffa15497_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PHILDCommercialExpensesSubjectToReimbursementMember_c26771a9-8e71-49f4-a673-29433f763121_terseLabel_en-US" xlink:label="lab_goss_PHILDCommercialExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PH-ILD commercial costs subject to reimbursement</link:label>
    <link:label id="lab_goss_PHILDCommercialExpensesSubjectToReimbursementMember_label_en-US" xlink:label="lab_goss_PHILDCommercialExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PH-ILD Commercial, Expenses Subject To Reimbursement [Member]</link:label>
    <link:label id="lab_goss_PHILDCommercialExpensesSubjectToReimbursementMember_documentation_en-US" xlink:label="lab_goss_PHILDCommercialExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PH-ILD Commercial, Expenses Subject To Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDCommercialExpensesSubjectToReimbursementMember" xlink:href="goss-20241231.xsd#goss_PHILDCommercialExpensesSubjectToReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PHILDCommercialExpensesSubjectToReimbursementMember" xlink:to="lab_goss_PHILDCommercialExpensesSubjectToReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b10e72ee-296b-46dc-b8a9-12f0cf330a95_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of premium on investments, net of accretion of discounts</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage_f9c3ce3e-da51-4ae3-91f5-84f3e8eeb980_terseLabel_en-US" xlink:label="lab_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, option, required cancellation percentage</link:label>
    <link:label id="lab_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage_label_en-US" xlink:label="lab_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Required Cancellation Percentage</link:label>
    <link:label id="lab_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage_documentation_en-US" xlink:label="lab_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Required Cancellation Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" xlink:href="goss-20241231.xsd#goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" xlink:to="lab_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_76c6bdef-5a8e-4d15-9e0b-c3d971334a4c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99df7ea3-0926-4448-8fe0-7b15292d3a65_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, nonvested award, cost not yet recognized, amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_174f678d-055d-4749-a569-eb528d80d9cd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage_21cc3cb0-3b94-4520-960c-f0e04d83a881_terseLabel_en-US" xlink:label="lab_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial efforts contribution, percentage</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage_label_en-US" xlink:label="lab_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Commercial Efforts Contribution, Percentage</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage_documentation_en-US" xlink:label="lab_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Commercial Efforts Contribution, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage" xlink:to="lab_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_496d35fa-d562-4505-98e1-d37ceeb0d0c6_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_889a5858-4624-423e-bc30-b32b813022d2_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_5f877a78-06ac-4ecf-8c8d-9827ae97b36b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e0b80880-b6cd-4a38-9199-2b9c1c09f263_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5258093f-2fa5-40f0-80e7-022b254fb845_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ded84dc2-bf4e-4eba-8c19-3b8b23dd4062_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bd65d718-a379-4dca-88eb-5ad985539efd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9bafcb91-6cb6-460a-b95f-de5da0665bcb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9b550c8c-f89b-4ac0-9b45-2c597fcd8029_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5a6c576a-8756-4189-b476-d00e234e53c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CommonStockVestingPercentage_e1a9d5d2-e576-4450-a87a-4034bc42bc61_terseLabel_en-US" xlink:label="lab_goss_CommonStockVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock vesting percentage</link:label>
    <link:label id="lab_goss_CommonStockVestingPercentage_label_en-US" xlink:label="lab_goss_CommonStockVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Vesting Percentage</link:label>
    <link:label id="lab_goss_CommonStockVestingPercentage_documentation_en-US" xlink:label="lab_goss_CommonStockVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock vesting percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVestingPercentage" xlink:href="goss-20241231.xsd#goss_CommonStockVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CommonStockVestingPercentage" xlink:to="lab_goss_CommonStockVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bd61b821-6b6c-40d8-bda0-b69821ff6d3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_06bd20a9-c213-4385-97c7-e6e0cbd288ac_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_6afc76af-d054-4367-b61a-66e4e4964ac0_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_19f909f6-fe0a-41aa-a8ce-e8cbf02f4b9c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_d237c3d7-9bda-45ce-bcd8-b1b337bd70a1_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0aef0b55-754b-4a98-ba4b-cd036a7b447b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_afd89188-1060-4708-9688-b5ec887730a4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contractual Maturities of Available-for-sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_76b334be-b689-43b8-b888-3431f78d0207_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_af111830-b44f-428d-9745-0b03f9d1a1ea_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b7cb00c5-a828-42cb-80f1-c91cbe1c9538_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0c62ca3e-7e9f-4f57-bc25-f55d56fec621_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ed351ad9-7dd1-4076-87a4-2feba1d7587a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_63ac0be0-3689-49b7-ba4b-ed5009f5737f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7f6831a2-089b-4f68-b477-ef75670c2448_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3c692d8c-aa40-4bcc-b65d-beb773a1c76c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d77463fa-564b-42b9-b0ef-edaef467f20c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1af32a4a-e313-49eb-9afc-aa3d59aa4ab4_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_287ff2e5-ac86-45f4-abb2-d3cc60353aad_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8e791d29-d54c-4d3c-948b-e6c755d57081_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_OfficerDirectorEmployeeOrConsultantMember_fb2c5315-2466-4809-aaf8-f7ba3514bc9d_terseLabel_en-US" xlink:label="lab_goss_OfficerDirectorEmployeeOrConsultantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officer, Director, Employee Or Consultant</link:label>
    <link:label id="lab_goss_OfficerDirectorEmployeeOrConsultantMember_label_en-US" xlink:label="lab_goss_OfficerDirectorEmployeeOrConsultantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer, Director, Employee Or Consultant [Member]</link:label>
    <link:label id="lab_goss_OfficerDirectorEmployeeOrConsultantMember_documentation_en-US" xlink:label="lab_goss_OfficerDirectorEmployeeOrConsultantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Officer, Director, Employee Or Consultant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OfficerDirectorEmployeeOrConsultantMember" xlink:href="goss-20241231.xsd#goss_OfficerDirectorEmployeeOrConsultantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_OfficerDirectorEmployeeOrConsultantMember" xlink:to="lab_goss_OfficerDirectorEmployeeOrConsultantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_159caa75-706a-452b-a2d7-a8801cf643a3_verboseLabel_en-US" xlink:label="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PAH research and development service performance obligations satisfied during reporting period</link:label>
    <link:label id="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_a6e7d5ed-82a1-4035-96e1-0ce1a9f65794_terseLabel_en-US" xlink:label="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PAH research and development service performance obligation satisfied during reporting period</link:label>
    <link:label id="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_label_en-US" xlink:label="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PAH Research And Development Services, Performance Obligations Satisfied [Member]</link:label>
    <link:label id="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_documentation_en-US" xlink:label="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PAH Research And Development Services, Performance Obligations Satisfied</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:to="lab_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_52250b07-a9ad-4c1a-839c-3629d375fbfc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50119a46-3f75-4f34-ae04-8ec216df6a24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8bfbd6c2-0d4a-4926-a477-b64d9adca322_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e18dcd-f7a1-4d9b-a230-9d23d4a71696_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_ff5711a2-8e7c-4fbe-9244-e536d0be3921_verboseLabel_en-US" xlink:label="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PH-ILD research and development service performance obligations satisfied during reporting period</link:label>
    <link:label id="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_d75bfd85-8fd9-4c13-9376-61f679d0804b_terseLabel_en-US" xlink:label="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PH-ILD research and development service performance obligation satisfied during reporting period</link:label>
    <link:label id="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_label_en-US" xlink:label="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PH-ILD Research And Development Services, Performance Obligations Satisfied [Member]</link:label>
    <link:label id="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_documentation_en-US" xlink:label="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PH-ILD Research And Development Services, Performance Obligations Satisfied</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:to="lab_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e7472464-977f-473f-a844-4f881e7c304c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d763f40f-8a91-46c2-9fd5-548bea675d8b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c7a23b50-9af3-4161-9f33-93bde677b3d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5c03c5cc-65d6-4438-8c79-6a826e4769a3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0ed73e03-714e-4ce0-aa8a-fa2cafa2f082_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_c6c3d02d-6628-458f-ac9b-d1c300f13a21_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_352e2188-60dd-4fcf-94a3-710292acf7d5_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ProceedsFromMaturityOfMarketableSecurities_63dc53a0-9c11-4bcf-94c2-06c9ca0f37e9_terseLabel_en-US" xlink:label="lab_goss_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_goss_ProceedsFromMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_goss_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Maturity Of Marketable Securities</link:label>
    <link:label id="lab_goss_ProceedsFromMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_goss_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ProceedsFromMaturityOfMarketableSecurities" xlink:href="goss-20241231.xsd#goss_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ProceedsFromMaturityOfMarketableSecurities" xlink:to="lab_goss_ProceedsFromMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_554f9863-16f6-4529-a6bb-ac440ca3dfb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8ac74631-3f0b-47e5-90d6-458564860c47_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c97bb534-794b-40b7-bc2b-e861c4ac6105_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9c302785-c1c2-4202-8d67-fb0fabb6384b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Option exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9d49991c-84d9-4b63-a136-3df8b7eff2e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_13ab8897-42fe-492e-8187-15562fc71e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_820b4040-f7c9-488c-97f5-34adc70797c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Subject to Options Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5bd6c726-d6e7-4605-b04b-427df698d3c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5e0b394c-a44f-4a91-868b-3de3e4be17f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e7abc980-c77c-4823-92d9-b093ecbe323e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bc3d02bd-45c5-4ba5-a9ca-d16460413bdb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b30a21db-0977-4611-a298-713560e457c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ab818b07-aa81-4ae1-a574-ebcf1be30598_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2a9011f5-3a7f-47b9-8057-c0e4926fc954_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_eb101d06-6fa8-49f3-a842-1d78555a318b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8e179b82-4565-4be9-90e4-6a4287b0a64f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_50023ddf-1fad-4e64-8e8f-9f5136ff59ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e43fd0e3-a91d-403c-a9f2-ba26ac3a6896_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity attributable to parent (decrease) increase</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_e7adc200-876e-4d46-b17c-81c49b9b9929_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AccruedInProcessResearchAndDevelopmentCurrent_2020f819-f42c-4e43-872f-bd232c4eda5d_terseLabel_en-US" xlink:label="lab_goss_AccruedInProcessResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued in process research and development</link:label>
    <link:label id="lab_goss_AccruedInProcessResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_goss_AccruedInProcessResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued In Process Research And Development Current</link:label>
    <link:label id="lab_goss_AccruedInProcessResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_goss_AccruedInProcessResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued in process research and development current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedInProcessResearchAndDevelopmentCurrent" xlink:href="goss-20241231.xsd#goss_AccruedInProcessResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AccruedInProcessResearchAndDevelopmentCurrent" xlink:to="lab_goss_AccruedInProcessResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_837cbd94-2580-42c1-80e8-e45e63fbc455_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f130fb65-4430-48fc-a1b3-5218b3a59ccb_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b587f3b2-4caa-4279-8744-c8e38664e72f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Agreements and Contracts</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9af58ee2-68bd-4e84-843d-d45499b32ca7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_8edaa238-4efb-40fd-a6cb-e8d24dc5ec10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_2bbf0e79-3c44-4d1a-a2b5-bf46f5b4a292_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_StockholdersEquityDeficitTable_98300e5d-df65-4020-85d1-de2a1240e8f9_terseLabel_en-US" xlink:label="lab_goss_StockholdersEquityDeficitTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity Deficit [Table]</link:label>
    <link:label id="lab_goss_StockholdersEquityDeficitTable_label_en-US" xlink:label="lab_goss_StockholdersEquityDeficitTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Deficit [Table]</link:label>
    <link:label id="lab_goss_StockholdersEquityDeficitTable_documentation_en-US" xlink:label="lab_goss_StockholdersEquityDeficitTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders equity deficit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockholdersEquityDeficitTable" xlink:href="goss-20241231.xsd#goss_StockholdersEquityDeficitTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_StockholdersEquityDeficitTable" xlink:to="lab_goss_StockholdersEquityDeficitTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5375d420-d900-4248-bafa-f1591a266add_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a7be68d6-3ae2-4801-83f1-df4ceffcb4d8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1a6d0f0c-a3d2-4521-85a1-054f585e1597_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_018d380b-b53c-43a4-81df-8e1baceaa034_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_27da531a-6816-4000-8180-f0d7ad1e8a08_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable from contracts with collaborators</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_40522ce0-eb84-45f0-8973-2e0522bad44b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_22407ce2-a995-44b7-9ba4-0f6504be61e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_NumberOfLicensesGranted_9dbee1e2-85c7-451d-9877-92a2b44977cc_terseLabel_en-US" xlink:label="lab_goss_NumberOfLicensesGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of licenses granted</link:label>
    <link:label id="lab_goss_NumberOfLicensesGranted_label_en-US" xlink:label="lab_goss_NumberOfLicensesGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Licenses Granted</link:label>
    <link:label id="lab_goss_NumberOfLicensesGranted_documentation_en-US" xlink:label="lab_goss_NumberOfLicensesGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Licenses Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfLicensesGranted" xlink:href="goss-20241231.xsd#goss_NumberOfLicensesGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_NumberOfLicensesGranted" xlink:to="lab_goss_NumberOfLicensesGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6367c7f-ef6f-4446-b980-bc5c442f586f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7c3a3ae4-eb0a-4bb7-a020-6cc8d3b349ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e537b7e3-c70c-4599-a86e-e8c33eecd284_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5edd4d89-c5e6-4f8d-b0d1-ae68255ee366_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_136046c1-20c5-43a6-b964-fb542ba8a67b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4cdd4fa5-fc6b-4824-afa6-dc06dfd299ef_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_b7fb87fe-e3ff-49d9-9f21-e0fc5ba2a093_terseLabel_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3c02c0b5-be2c-4e98-b293-46ddcf8165de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ddcdfe12-cb50-4506-b686-544e993cc47e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0fb51fa7-0f15-4991-b087-aba6b49326d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6139d06d-4cc1-4a29-ad39-c0c100869cdc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e0b47aa1-8ac2-4598-b618-11db7a5589bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a132f627-e3d6-4723-a3ad-e72340013ead_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_001afaf0-dacc-4f58-8563-2121f92a6a0b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_255c56f4-a38a-46ce-84e7-318d3ebb8010_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding_75bd87de-e1f0-4eb5-968e-538fe4b4c6e9_terseLabel_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tender offer or exchange offer, percentage of shares outstanding</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Tender Offer Or Exchange Offer, Percentage of Shares Outstanding</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Tender Offer Or Exchange Offer, Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" xlink:to="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived_d3e8a671-b0a1-4436-855d-6372f77a1918_terseLabel_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments received in advance</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived_label_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Upfront Payment Received</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived" xlink:to="lab_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9339e504-780d-4fd1-a4d8-fa9eb2896474_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbc784b1-35cc-41ed-8dcf-db24dfd91da6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b1265734-3506-43c4-80ff-85645edfc6cd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Liability Activity</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_595e75c9-6e1a-4a40-84cc-7e86457fa188_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5e6c743f-fb3d-4b42-984f-22e70b7fe77e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_850918f9-96b2-446b-bf09-209079bb31af_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Opening balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_acc2a0da-e7d6-46f7-9f39-bb414a2b9012_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_a8155ec5-237e-46bc-8a86-79527bfb02aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, option, exercise price range, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0725cee1-be3e-49f6-bce9-3ed595616c48_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_58f79613-1c02-4630-a71f-8cfe74b4728f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e26f2a69-0492-4a1d-a5c1-76411830a379_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d69c8a0f-ac05-4949-a8b3-2f40d2719979_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_11c0a098-591a-45cf-98c8-d3a4b0940c66_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AccountReceivablePaymentTerm_40b4931b-1ce9-46f7-a986-c5b94686a3c3_terseLabel_en-US" xlink:label="lab_goss_AccountReceivablePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Account receivable, payment term</link:label>
    <link:label id="lab_goss_AccountReceivablePaymentTerm_label_en-US" xlink:label="lab_goss_AccountReceivablePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Account Receivable, Payment Term</link:label>
    <link:label id="lab_goss_AccountReceivablePaymentTerm_documentation_en-US" xlink:label="lab_goss_AccountReceivablePaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Account Receivable, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccountReceivablePaymentTerm" xlink:href="goss-20241231.xsd#goss_AccountReceivablePaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AccountReceivablePaymentTerm" xlink:to="lab_goss_AccountReceivablePaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_fbb2f43e-e279-4059-aa29-022ea6a045b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_42cc9ebf-9290-4c72-9b9c-71b83cb0a7a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_2e53b322-d52c-4784-ade2-85d586dfa7c6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses, Asset Acquisitions and Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1664845e-b289-402a-abc3-8811762a094b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_949c6859-413a-4079-9859-4d62734e772e_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Present value discount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_ba357053-db95-49dc-a03a-8ff5039604a4_terseLabel_en-US" xlink:label="lab_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accrued Research And Development Expenses</link:label>
    <link:label id="lab_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in accrued research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:href="goss-20241231.xsd#goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:to="lab_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_c3668ae8-39f7-4331-a716-ca384c64a912_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b4f34738-1109-489f-9023-a94c989fb0cc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f515d1d2-62a7-4d4c-b3a6-e5d45bc0d984_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_02ce429d-0c7a-43ff-97e6-201bfcfbd408_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d7c89a9-daa9-4b1f-9bcf-55e43254c7aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_dc258d2f-645a-4857-9297-b20879bcd55e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f4a36ff8-ddb4-4973-a8c4-145aeb51a8c4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2dd5d60d-3e23-4b2d-918d-4655c4abfb19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33d9ef4d-3913-4458-83ff-a1aaea4c3556_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_e1fd06d9-37da-497d-b394-39a4105dfa0b_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over Time:</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f3358208-bf2f-477b-bb6f-1162f7bb4ba2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ContractualInterestExpense_2b6f6d66-c8d9-45b5-b0a0-1fe53544b11e_terseLabel_en-US" xlink:label="lab_goss_ContractualInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_goss_ContractualInterestExpense_label_en-US" xlink:label="lab_goss_ContractualInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Interest Expense</link:label>
    <link:label id="lab_goss_ContractualInterestExpense_documentation_en-US" xlink:label="lab_goss_ContractualInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractualInterestExpense" xlink:href="goss-20241231.xsd#goss_ContractualInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ContractualInterestExpense" xlink:to="lab_goss_ContractualInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_d069ce7f-a668-4bf5-aaa1-970636ab7ef1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, redemption percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays_bdfb36c2-fde3-42ce-9eb7-06004255928b_terseLabel_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, threshold consecutive days</link:label>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays_label_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Threshold Consecutive Days</link:label>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays_documentation_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Threshold Consecutive Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" xlink:to="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2d6edc62-3c5e-44cf-91a6-b23566f60db0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements - Adopted and Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c5c3cea5-d055-49fc-8fac-ed9cb5be3973_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_0f5ff2df-9ad5-4ea7-af41-7f7186f5ea39_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from sale of licenses</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b4e2a5f-176f-4a5e-b51e-397058e1aa8a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_036d962b-0053-4298-8adb-51eb76634e5d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b2b105a7-954d-4a9f-bec1-f40912146332_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_c714bbe5-91b0-4277-88ec-c10a3bd96ae3_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_cc9dbf7f-213b-4446-b2b2-eafa886c952f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">U.S. loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7d698ad7-0c6f-4aca-9cf4-4339e26b4fc6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a7501905-f140-4a3f-8c55-8dd1801f46b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6b302982-47ab-43af-a7f4-08c2dd6887d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life (in years), Options exercisable as of end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_51b471ca-956d-48ba-a073-e92e862cca28_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_95c7cdb4-b308-46a1-b1a4-b47039f51eec_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_da18364f-d3c3-48b4-ace5-0e32c2b25f44_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable_350ac23c-b402-49c9-afba-3f3714877a9a_terseLabel_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and regulatory milestone payments, due upon the initiation of a phase 3 clinical trial</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable_label_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Contingent Consideration Initial Phase Three Clinical Payments Payable</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable_documentation_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Contingent Consideration Initial Phase Three Clinical Payments Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" xlink:to="lab_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_3d5e5254-10de-420d-954c-a71285524b0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivable from contracts with collaborators</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_080c90e4-ab1c-452d-b1be-b510a337c8a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c2e90217-3856-4e53-b79c-cb45e53dc3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting_4cbf6a16-bf9a-454a-a64e-f8ecf7bc1cf9_terseLabel_en-US" xlink:label="lab_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares of restricted stock subject to vesting restrictions (in shares)</link:label>
    <link:label id="lab_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting_label_en-US" xlink:label="lab_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Restricted Stock Subject To Vesting</link:label>
    <link:label id="lab_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting_documentation_en-US" xlink:label="lab_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental common shares attributable to restricted stock subject to vesting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" xlink:href="goss-20241231.xsd#goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" xlink:to="lab_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_d47b2240-5745-4c0d-b80a-de7319617db3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6c79c2ce-9fcd-45d9-a3d2-8f747b78db58_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_24cd5952-8fd4-461e-a6f5-2bcdf0c2e4e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 2</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue_bdf7eef5-e65f-4834-9c18-05f3f7b5761b_terseLabel_en-US" xlink:label="lab_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue_label_en-US" xlink:label="lab_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After One Year Fair Value</link:label>
    <link:label id="lab_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue_documentation_en-US" xlink:label="lab_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After One Year Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" xlink:href="goss-20241231.xsd#goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" xlink:to="lab_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_48b987b0-c27e-497d-ba65-622f44942e10_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e8b23dcd-4990-4d70-ad41-86172249703c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PulmokineIncMember_48786815-87b7-49e3-9bd3-fcce84f5460a_terseLabel_en-US" xlink:label="lab_goss_PulmokineIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pulmokine, Inc.</link:label>
    <link:label id="lab_goss_PulmokineIncMember_label_en-US" xlink:label="lab_goss_PulmokineIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pulmokine Inc [Member]</link:label>
    <link:label id="lab_goss_PulmokineIncMember_documentation_en-US" xlink:label="lab_goss_PulmokineIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pulmokine, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PulmokineIncMember" xlink:href="goss-20241231.xsd#goss_PulmokineIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PulmokineIncMember" xlink:to="lab_goss_PulmokineIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3d6ff837-8759-43d0-a521-1ffdfc7d669f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_197c9200-c085-4f2b-8488-dd8dbef19e02_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options forfeited/cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6ed2584a-4a9c-4b9e-b8e5-d0972ad992d4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period of cost expects to recognize (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b4cdf08e-427e-434f-acae-81c446c8a6e0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d32fa812-e4b5-414b-89d3-7076543dd572_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue from Chiesi Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1ad7475b-9c0a-4ef6-95e8-f7ce00ee0148_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_251ac272-0f13-457a-b29b-795ead652e0c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_956f1abb-213a-40d9-a2b4-796918c34af8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_6224071b-e029-4d0d-a5f9-65d08b6db078_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, at carrying value</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_7a996331-6c9b-419c-a8b7-3c6cb36d903d_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7aaf9574-14e2-4ac8-924e-77b1fb969351_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0332c232-263e-4ad1-bde0-e4ae330f7231_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4e8ca2e9-812d-45e8-a4af-5a1629496983_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage_ed9f4038-d516-4a4f-b87b-b41763270276_terseLabel_en-US" xlink:label="lab_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, percentage of last reported sale price of common stock</link:label>
    <link:label id="lab_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage_label_en-US" xlink:label="lab_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Conversion Last Reported Sale Price Percentage</link:label>
    <link:label id="lab_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage_documentation_en-US" xlink:label="lab_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument convertible conversion last reported sale price percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" xlink:href="goss-20241231.xsd#goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" xlink:to="lab_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_a03a15dd-2be5-4b3d-989b-c14358b3ebd6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants in a private offering, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c9953aa1-7176-4d2e-b75a-48ba682e25b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AuditorInformationAbstract_label_en-US" xlink:label="lab_goss_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_goss_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_goss_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AuditorInformationAbstract" xlink:href="goss-20241231.xsd#goss_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AuditorInformationAbstract" xlink:to="lab_goss_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_1c6839c0-6d44-40fb-88aa-56e765be927d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b5e8f801-bf61-4e56-9813-8b024ab47721_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_18dcddf0-b289-420b-92cd-35e64eaa0aaa_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ce7f9757-dd85-46d0-8315-d47b8edb6c7e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cb91102e-78aa-4b81-aa36-dd7f4c412353_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ReportingSegmentMember_c0874c08-2485-44f2-88b2-210ccdd350cd_terseLabel_en-US" xlink:label="lab_goss_ReportingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Segment</link:label>
    <link:label id="lab_goss_ReportingSegmentMember_label_en-US" xlink:label="lab_goss_ReportingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Segment [Member]</link:label>
    <link:label id="lab_goss_ReportingSegmentMember_documentation_en-US" xlink:label="lab_goss_ReportingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reporting Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ReportingSegmentMember" xlink:href="goss-20241231.xsd#goss_ReportingSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ReportingSegmentMember" xlink:to="lab_goss_ReportingSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_a01a8c04-32e2-4e04-a479-77e1335bbdae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_32cdbefc-614a-466e-a5af-279ff2f3a9ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_06e7e28c-b523-43d2-88d1-7b06d99c1c70_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_fa91f361-37a7-43fb-ac31-d145a5e87bc1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_04075799-882b-4c27-b632-91f5cfba15c4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0a52265-297b-44db-a4c5-51442ddf2c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f9d1349-bd7e-4bec-8c8e-e8b3c4113bd4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4fd542f9-a7e3-4174-84f2-1ae743261674_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_26ed8fa0-3ef4-4437-9428-c1c5ef358912_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PAHCommercialExpensesSubjectToReimbursementMember_4bee5d4e-8ea2-4e4b-aa10-59cbe16b039c_terseLabel_en-US" xlink:label="lab_goss_PAHCommercialExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PAH commercial costs subject to reimbursement</link:label>
    <link:label id="lab_goss_PAHCommercialExpensesSubjectToReimbursementMember_label_en-US" xlink:label="lab_goss_PAHCommercialExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PAH Commercial, Expenses Subject To Reimbursement [Member]</link:label>
    <link:label id="lab_goss_PAHCommercialExpensesSubjectToReimbursementMember_documentation_en-US" xlink:label="lab_goss_PAHCommercialExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PAH Commercial, Expenses Subject To Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHCommercialExpensesSubjectToReimbursementMember" xlink:href="goss-20241231.xsd#goss_PAHCommercialExpensesSubjectToReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PAHCommercialExpensesSubjectToReimbursementMember" xlink:to="lab_goss_PAHCommercialExpensesSubjectToReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d92dcc36-e996-4abf-b045-a764b4acedf7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable_9dc3dbdc-284e-4b06-8e56-05588b9e0aeb_terseLabel_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial milestone payments, payable</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable_label_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Contingent Consideration Commercial Milestone Payments Payable</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable_documentation_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination, contingent consideration, commercial milestone payments, payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" xlink:to="lab_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_09e8bc35-df3f-49af-a9a8-d89749a70d6a_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LesseeOperatingLeaseBaseRent_3d1840dc-f7ae-43e3-8c43-6d509470dd9a_terseLabel_en-US" xlink:label="lab_goss_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base rent</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseBaseRent_label_en-US" xlink:label="lab_goss_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_goss_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseBaseRent" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LesseeOperatingLeaseBaseRent" xlink:to="lab_goss_LesseeOperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2368b440-8508-4907-b50d-0381866a8229_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_RevenuePerformanceObligationSalesMilestonesAmount_d2df4727-e7eb-45e0-907c-aa9f3787ce60_terseLabel_en-US" xlink:label="lab_goss_RevenuePerformanceObligationSalesMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, sales milestones receivable</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationSalesMilestonesAmount_label_en-US" xlink:label="lab_goss_RevenuePerformanceObligationSalesMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Sales Milestones, Amount</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationSalesMilestonesAmount_documentation_en-US" xlink:label="lab_goss_RevenuePerformanceObligationSalesMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Sales Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationSalesMilestonesAmount" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationSalesMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_RevenuePerformanceObligationSalesMilestonesAmount" xlink:to="lab_goss_RevenuePerformanceObligationSalesMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage_2c406c27-fd92-4420-bf7b-6a8e28ec501b_terseLabel_en-US" xlink:label="lab_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating sublease, annual increase percentage for base rent</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage_label_en-US" xlink:label="lab_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent Annual Increase Percentage</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rent Annual Increase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" xlink:to="lab_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7de38573-f6bf-4654-a9e4-b3ffb79be98f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate_5a09068d-1cf6-4a00-8b38-532cbd1de904_negatedTerseLabel_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on contract liabilities</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate_label_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Effect Of Change In Exchange Rate</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate_documentation_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Effect Of Change In Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" xlink:to="lab_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2ea84ea9-74f9-4636-8038-07652eba16dc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AccruedAccountingFeesCurrent_60808b8e-28ab-4e69-9f2e-36af078feb66_terseLabel_en-US" xlink:label="lab_goss_AccruedAccountingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued accounting fees</link:label>
    <link:label id="lab_goss_AccruedAccountingFeesCurrent_label_en-US" xlink:label="lab_goss_AccruedAccountingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Accounting Fees Current</link:label>
    <link:label id="lab_goss_AccruedAccountingFeesCurrent_documentation_en-US" xlink:label="lab_goss_AccruedAccountingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued accounting fees current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedAccountingFeesCurrent" xlink:href="goss-20241231.xsd#goss_AccruedAccountingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AccruedAccountingFeesCurrent" xlink:to="lab_goss_AccruedAccountingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_651a419b-ceee-49d2-9860-64da7e38562f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_416401fb-3280-407a-beed-3e7fdd4e7f8d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5efc1fe2-ff08-42b1-9643-be4297c716ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_b63311a5-3591-4a41-a7f9-50d4b7a13508_terseLabel_en-US" xlink:label="lab_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PAH research and development costs subject to reimbursement</link:label>
    <link:label id="lab_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_label_en-US" xlink:label="lab_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PAH Research And Development Services, Expenses Subject To Reimbursement [Member]</link:label>
    <link:label id="lab_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_documentation_en-US" xlink:label="lab_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PAH Research And Development Services, Expenses Subject To Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:to="lab_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7b6759f5-f7aa-4ad6-89b8-33757d0dd5e8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_28257416-5432-4f02-9bfa-595f8a60364e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax_d0f40d90-a204-41f9-8dc1-96dd65126dd2_terseLabel_en-US" xlink:label="lab_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized gain (loss) on marketable securities, net</link:label>
    <link:label id="lab_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax_label_en-US" xlink:label="lab_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax</link:label>
    <link:label id="lab_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax_documentation_en-US" xlink:label="lab_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash investing and financing activities change in unrealized gain on marketable securities net of tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" xlink:href="goss-20241231.xsd#goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" xlink:to="lab_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_62b69642-f9b4-4a36-a63d-73af023a4dc5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e62f0008-b82f-447d-b4ad-b8a8fdce5985_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8c110cc-3f2d-4cd0-86c1-31564fed6970_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_f464829a-5a51-4917-91cf-90b5dc7c66ba_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_USLicenseMember_0a425e40-6b9d-43c0-8e66-00da34d2db05_verboseLabel_en-US" xlink:label="lab_goss_USLicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from sale of US license</link:label>
    <link:label id="lab_goss_USLicenseMember_b6922ada-01a9-42b3-8e86-055245e9c975_terseLabel_en-US" xlink:label="lab_goss_USLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US License</link:label>
    <link:label id="lab_goss_USLicenseMember_label_en-US" xlink:label="lab_goss_USLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US License [Member]</link:label>
    <link:label id="lab_goss_USLicenseMember_documentation_en-US" xlink:label="lab_goss_USLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_USLicenseMember" xlink:href="goss-20241231.xsd#goss_USLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_USLicenseMember" xlink:to="lab_goss_USLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08a6dbaa-e437-4ba0-8843-b49652b3055e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d70ea7db-be1c-4f35-8008-ff666a877475_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b6f516c-cc04-41cc-a147-cc05330a931c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_0eeca15b-9083-4a02-8783-ee44d177555b_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AccruedLegalFeesCurrent_be013bcc-78a6-41bb-a8d5-38aab99a3e23_terseLabel_en-US" xlink:label="lab_goss_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal fees</link:label>
    <link:label id="lab_goss_AccruedLegalFeesCurrent_label_en-US" xlink:label="lab_goss_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:label id="lab_goss_AccruedLegalFeesCurrent_documentation_en-US" xlink:label="lab_goss_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued legal fees current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedLegalFeesCurrent" xlink:href="goss-20241231.xsd#goss_AccruedLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AccruedLegalFeesCurrent" xlink:to="lab_goss_AccruedLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_03882815-ca92-4706-8242-112a3415f6d4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage_a97e2875-986d-4094-8246-3e13931af21c_terseLabel_en-US" xlink:label="lab_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization activities performance, percentage</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage_label_en-US" xlink:label="lab_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Commercialization Activities Performance, Percentage</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage_documentation_en-US" xlink:label="lab_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Commercialization Activities Performance, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" xlink:to="lab_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1ebc650b-06c8-495d-9061-19fcff006fc5_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_66f80e71-db3b-4e1e-b87e-f643f4220b0f_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_55c0400f-aaa6-402b-a55c-c949e968f2e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest as of ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_305aaa93-b590-4065-9328-21a24d7fd660_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_FounderMember_4367c985-7a40-4949-a591-57a7be9034c2_terseLabel_en-US" xlink:label="lab_goss_FounderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Founder</link:label>
    <link:label id="lab_goss_FounderMember_label_en-US" xlink:label="lab_goss_FounderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Founder [Member]</link:label>
    <link:label id="lab_goss_FounderMember_documentation_en-US" xlink:label="lab_goss_FounderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Founder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_FounderMember" xlink:href="goss-20241231.xsd#goss_FounderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_FounderMember" xlink:to="lab_goss_FounderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f310415a-b51f-48b5-80c6-4dfd0029d27b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available for Sale Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LicensesOfIntellectualPropertyMember_e61190fe-0e42-4e57-8bc0-b7b888f4159d_terseLabel_en-US" xlink:label="lab_goss_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US License</link:label>
    <link:label id="lab_goss_LicensesOfIntellectualPropertyMember_label_en-US" xlink:label="lab_goss_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Of Intellectual Property [Member]</link:label>
    <link:label id="lab_goss_LicensesOfIntellectualPropertyMember_documentation_en-US" xlink:label="lab_goss_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licenses Of Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LicensesOfIntellectualPropertyMember" xlink:href="goss-20241231.xsd#goss_LicensesOfIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LicensesOfIntellectualPropertyMember" xlink:to="lab_goss_LicensesOfIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_349ce6fa-5f91-45ee-8660-991b6dd2cded_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards_77288d78-70aa-4e00-aa9a-83946ea023c3_terseLabel_en-US" xlink:label="lab_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for issuance on granting of outstanding awards (in shares)</link:label>
    <link:label id="lab_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards_label_en-US" xlink:label="lab_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Reserved For Issuance On Granting Of Outstanding Awards</link:label>
    <link:label id="lab_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards_documentation_en-US" xlink:label="lab_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Reserved For Issuance On Granting Of Outstanding Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards" xlink:href="goss-20241231.xsd#goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards" xlink:to="lab_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent_2328140b-4a56-4f2f-8906-147620dadf0c_terseLabel_en-US" xlink:label="lab_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination tee, number of monthly base rent</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent_label_en-US" xlink:label="lab_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Number Of Months Of Base Rent</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent_documentation_en-US" xlink:label="lab_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Number Of Months Of Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" xlink:to="lab_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_54d51572-ac2d-4470-8bd6-100b9832c172_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89a95fcb-d8d2-4611-8c2b-e5022cf69f99_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_964764b2-f099-4864-a49c-a17c9ce7ab83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_95057e8d-79fd-4a24-a636-8d6302fa277c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock were subject to outstanding options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_274787c4-417c-4545-87c7-c511460ce6fb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e74637d1-6458-459a-be0d-c3ff4c8d3f84_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation_57520037-abcf-4a6e-82ba-dcc37fa991d3_terseLabel_en-US" xlink:label="lab_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards, amount removed</link:label>
    <link:label id="lab_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation_label_en-US" xlink:label="lab_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Reduction Due To Merger And Liquidation</link:label>
    <link:label id="lab_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation_documentation_en-US" xlink:label="lab_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Reduction Due To Merger And Liquidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" xlink:href="goss-20241231.xsd#goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" xlink:to="lab_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_356f503a-149a-4ca6-96f9-dd1fc06f1ac8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f51def43-568e-4566-a392-4fd36c18fdc1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_f1128619-f88f-48e4-a731-2a5617a20b4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestones accrued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Assets and Liabilities Arising from Contingencies, Amount Recognized, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="lab_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_NumberOfAdditionalTranches_81e68ff5-d1c0-4de8-9426-c612a742df81_terseLabel_en-US" xlink:label="lab_goss_NumberOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional tranches</link:label>
    <link:label id="lab_goss_NumberOfAdditionalTranches_label_en-US" xlink:label="lab_goss_NumberOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Additional Tranches</link:label>
    <link:label id="lab_goss_NumberOfAdditionalTranches_documentation_en-US" xlink:label="lab_goss_NumberOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of additional tranches.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfAdditionalTranches" xlink:href="goss-20241231.xsd#goss_NumberOfAdditionalTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_NumberOfAdditionalTranches" xlink:to="lab_goss_NumberOfAdditionalTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5e610f92-f045-463b-bba1-3b96cc51a27b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_67dd4457-c374-416e-9f9a-699adc2e54a9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_16123a15-3cdc-4a18-a6c1-8b4e1414ddf8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4895d379-d0e7-4f18-b834-1779e5efa930_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_55ada7fb-1fc6-4685-8e8c-158a2d7af48e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_adcf14ce-0692-4338-9d4d-911594f0f330_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_ebc173d2-c3fe-438c-a84c-952dc810ca0d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic/Foreign Restructuring Impact</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_9f56da86-6da2-429e-b922-acae70583b05_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses (&#8220;NOL&#8221;) carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_DebtInstrumentAggregatePrincipalAmount_5b385554-d3c1-4bfd-9326-5b7f73c32b13_terseLabel_en-US" xlink:label="lab_goss_DebtInstrumentAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument aggregate principal amount</link:label>
    <link:label id="lab_goss_DebtInstrumentAggregatePrincipalAmount_label_en-US" xlink:label="lab_goss_DebtInstrumentAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Aggregate Principal Amount</link:label>
    <link:label id="lab_goss_DebtInstrumentAggregatePrincipalAmount_documentation_en-US" xlink:label="lab_goss_DebtInstrumentAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument aggregate principal amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentAggregatePrincipalAmount" xlink:href="goss-20241231.xsd#goss_DebtInstrumentAggregatePrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_DebtInstrumentAggregatePrincipalAmount" xlink:to="lab_goss_DebtInstrumentAggregatePrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_3837688f-9c9b-410e-ae95-c9b2093e51de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Stock Option Award Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_af9cffa1-b8da-4a4e-9288-8b5cb19eef33_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_14aebfbc-c4d9-4dfc-85d3-f52466f10f3d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and experimentation credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5e5d362d-bb76-418f-82c5-c9d48a3f3740_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_847b4d1a-e647-4607-ab44-364e488c0cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8133e4ee-d094-438c-8cfd-6f9d00eeeb8c_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_EffectsOfExchangeRateMember_4c416652-3b94-4e2a-a28c-500c6c10bfd9_terseLabel_en-US" xlink:label="lab_goss_EffectsOfExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on revenue</link:label>
    <link:label id="lab_goss_EffectsOfExchangeRateMember_label_en-US" xlink:label="lab_goss_EffectsOfExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effects Of Exchange Rate [Member]</link:label>
    <link:label id="lab_goss_EffectsOfExchangeRateMember_documentation_en-US" xlink:label="lab_goss_EffectsOfExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effects Of Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EffectsOfExchangeRateMember" xlink:href="goss-20241231.xsd#goss_EffectsOfExchangeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_EffectsOfExchangeRateMember" xlink:to="lab_goss_EffectsOfExchangeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3091a899-1222-4636-b644-686273c02a98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_0d92a1f1-02bb-4cb0-9b21-a1706c01a623_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f938a423-fda8-4803-8d8c-bef593fd0c8c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_fda3668c-cf2e-49a9-8a41-74be70e4e224_terseLabel_en-US" xlink:label="lab_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from PAH research and development service performance obligation satisfied during reporting period</link:label>
    <link:label id="lab_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_label_en-US" xlink:label="lab_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Services, Performance Obligations Satisfied [Member]</link:label>
    <link:label id="lab_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_documentation_en-US" xlink:label="lab_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Services, Performance Obligations Satisfied</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:to="lab_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CommonStockVotingRightsNumberOfVotesPerShare_8da85a41-8897-4a84-a44a-b0ca5a408650_terseLabel_en-US" xlink:label="lab_goss_CommonStockVotingRightsNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, voting right per share</link:label>
    <link:label id="lab_goss_CommonStockVotingRightsNumberOfVotesPerShare_label_en-US" xlink:label="lab_goss_CommonStockVotingRightsNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share</link:label>
    <link:label id="lab_goss_CommonStockVotingRightsNumberOfVotesPerShare_documentation_en-US" xlink:label="lab_goss_CommonStockVotingRightsNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVotingRightsNumberOfVotesPerShare" xlink:href="goss-20241231.xsd#goss_CommonStockVotingRightsNumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CommonStockVotingRightsNumberOfVotesPerShare" xlink:to="lab_goss_CommonStockVotingRightsNumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PercentageOfFullyDilutedShareCapital_534a1f75-5ee9-4794-b6b5-a1d8e5e2b51a_terseLabel_en-US" xlink:label="lab_goss_PercentageOfFullyDilutedShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of fully diluted share capital</link:label>
    <link:label id="lab_goss_PercentageOfFullyDilutedShareCapital_label_en-US" xlink:label="lab_goss_PercentageOfFullyDilutedShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Fully Diluted Share Capital</link:label>
    <link:label id="lab_goss_PercentageOfFullyDilutedShareCapital_documentation_en-US" xlink:label="lab_goss_PercentageOfFullyDilutedShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of fully diluted share capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PercentageOfFullyDilutedShareCapital" xlink:href="goss-20241231.xsd#goss_PercentageOfFullyDilutedShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PercentageOfFullyDilutedShareCapital" xlink:to="lab_goss_PercentageOfFullyDilutedShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_ca7066b1-7c95-4666-802b-ec49021101dc_terseLabel_en-US" xlink:label="lab_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would not impact effective tax rate</link:label>
    <link:label id="lab_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_label_en-US" xlink:label="lab_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</link:label>
    <link:label id="lab_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_documentation_en-US" xlink:label="lab_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would not impact effective tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:href="goss-20241231.xsd#goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="lab_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c5052f5c-5616-46ee-b46c-ea0d56a59932_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f6ce35d0-0f76-4e08-8da4-5cfeb2a22463_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e0b7742f-1b6d-4938-8aa5-d7f7997d59cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f4e107a4-716a-4b88-a3dc-49d0e3d5d7f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f35cc48f-6129-4e45-8543-8f9596908d94_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_70e0e70e-1655-4334-bc62-6d1bb5ac5ade_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f6b662c-812e-44a5-88d7-f0a8c138deed_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_877c3cf8-813b-4ca7-bcd4-048e53982156_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation related to unvested restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ab9eddbc-bfb2-4c10-884c-d021f815b58e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options exercisable as of ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_ace6c339-2d6e-442f-b2d5-3f90deef2aa4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 3</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_f90ecea0-5a8d-45b4-b158-9009556e5175_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TwoThousandNineteenEquityIncentivePlanMember_0821cd31-5be1-4fc8-beeb-d318fe84c341_terseLabel_en-US" xlink:label="lab_goss_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_goss_TwoThousandNineteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_goss_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_goss_TwoThousandNineteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_goss_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand nineteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="goss-20241231.xsd#goss_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="lab_goss_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CommonStockVestingPeriod_f266dc4a-7c10-402d-b452-9270ac0500f6_terseLabel_en-US" xlink:label="lab_goss_CommonStockVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock vesting period</link:label>
    <link:label id="lab_goss_CommonStockVestingPeriod_label_en-US" xlink:label="lab_goss_CommonStockVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Vesting Period</link:label>
    <link:label id="lab_goss_CommonStockVestingPeriod_documentation_en-US" xlink:label="lab_goss_CommonStockVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock vesting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVestingPeriod" xlink:href="goss-20241231.xsd#goss_CommonStockVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CommonStockVestingPeriod" xlink:to="lab_goss_CommonStockVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2ab2c811-8afe-4622-82ba-2c634f919524_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_28567ca9-d7e9-4fd6-b822-e71f959e88e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LesseeOperatingLeaseExtensionTerm_6c0a9be5-5a8e-414d-8df2-b8024a2cfc82_terseLabel_en-US" xlink:label="lab_goss_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseExtensionTerm_label_en-US" xlink:label="lab_goss_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Extension Term</link:label>
    <link:label id="lab_goss_LesseeOperatingLeaseExtensionTerm_documentation_en-US" xlink:label="lab_goss_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseExtensionTerm" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LesseeOperatingLeaseExtensionTerm" xlink:to="lab_goss_LesseeOperatingLeaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_11ecd267-b38f-434a-bcb0-b652d98cfb5f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_792f266a-1140-4b8c-8948-01c2401ad760_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LeaseAgreementEnteredInJuly2024Member_7aec974b-df83-43b9-b483-0a9806d3c839_terseLabel_en-US" xlink:label="lab_goss_LeaseAgreementEnteredInJuly2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Agreement Entered in August 2024</link:label>
    <link:label id="lab_goss_LeaseAgreementEnteredInJuly2024Member_label_en-US" xlink:label="lab_goss_LeaseAgreementEnteredInJuly2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Agreement Entered in July 2024 [Member]</link:label>
    <link:label id="lab_goss_LeaseAgreementEnteredInJuly2024Member_documentation_en-US" xlink:label="lab_goss_LeaseAgreementEnteredInJuly2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Agreement Entered in July 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LeaseAgreementEnteredInJuly2024Member" xlink:href="goss-20241231.xsd#goss_LeaseAgreementEnteredInJuly2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LeaseAgreementEnteredInJuly2024Member" xlink:to="lab_goss_LeaseAgreementEnteredInJuly2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_8e05f1c0-dc9b-44de-ab4b-31ce9ca8180a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ContractWithCustomerRevenueRecognitionPeriod_49cad820-80a4-4032-a200-b83ac71747ae_terseLabel_en-US" xlink:label="lab_goss_ContractWithCustomerRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition period</link:label>
    <link:label id="lab_goss_ContractWithCustomerRevenueRecognitionPeriod_label_en-US" xlink:label="lab_goss_ContractWithCustomerRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Revenue Recognition Period</link:label>
    <link:label id="lab_goss_ContractWithCustomerRevenueRecognitionPeriod_documentation_en-US" xlink:label="lab_goss_ContractWithCustomerRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Revenue Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerRevenueRecognitionPeriod" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerRevenueRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ContractWithCustomerRevenueRecognitionPeriod" xlink:to="lab_goss_ContractWithCustomerRevenueRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_LongTermDebtPercentageInAggregatePrincipalAmount_97f9bea5-122e-4825-be5c-4bcbb0c762e5_terseLabel_en-US" xlink:label="lab_goss_LongTermDebtPercentageInAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage in aggregate principal amount (not less than)</link:label>
    <link:label id="lab_goss_LongTermDebtPercentageInAggregatePrincipalAmount_label_en-US" xlink:label="lab_goss_LongTermDebtPercentageInAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Percentage In Aggregate Principal Amount</link:label>
    <link:label id="lab_goss_LongTermDebtPercentageInAggregatePrincipalAmount_documentation_en-US" xlink:label="lab_goss_LongTermDebtPercentageInAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Percentage In Aggregate Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermDebtPercentageInAggregatePrincipalAmount" xlink:href="goss-20241231.xsd#goss_LongTermDebtPercentageInAggregatePrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_LongTermDebtPercentageInAggregatePrincipalAmount" xlink:to="lab_goss_LongTermDebtPercentageInAggregatePrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0b834085-6d23-4aef-94d3-82d795259675_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_UpfrontPayment_9e0bd21b-2cb7-4194-8cd2-b1c070f29807_terseLabel_en-US" xlink:label="lab_goss_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_goss_UpfrontPayment_label_en-US" xlink:label="lab_goss_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_goss_UpfrontPayment_documentation_en-US" xlink:label="lab_goss_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_UpfrontPayment" xlink:href="goss-20241231.xsd#goss_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_UpfrontPayment" xlink:to="lab_goss_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a1833706-dc06-4b53-82e6-a6b0430e9c20_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_4f5d3256-998d-4c33-8d6c-068e86b52c7d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a213b99c-b5b0-4bd8-a88b-0f79a7703705_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_IncreasedInEquityCapitalAmount_d6adaa7b-5f1c-4471-873a-28f7bee7cd43_terseLabel_en-US" xlink:label="lab_goss_IncreasedInEquityCapitalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased in equity capital amount</link:label>
    <link:label id="lab_goss_IncreasedInEquityCapitalAmount_label_en-US" xlink:label="lab_goss_IncreasedInEquityCapitalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased In Equity Capital Amount</link:label>
    <link:label id="lab_goss_IncreasedInEquityCapitalAmount_documentation_en-US" xlink:label="lab_goss_IncreasedInEquityCapitalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increased in equity capital amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreasedInEquityCapitalAmount" xlink:href="goss-20241231.xsd#goss_IncreasedInEquityCapitalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_IncreasedInEquityCapitalAmount" xlink:to="lab_goss_IncreasedInEquityCapitalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5edc0120-a359-4c07-9c24-d49e165e1909_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_247deda8-6e28-44a0-b467-c44da52149a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities with unrealized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c3110939-700b-4c88-bb22-b443397ebfc0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9a3ccb5c-0441-47ae-b963-8e7537abfbd3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a8edea9a-c5bd-4d51-9073-98e71d370456_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_959e9430-2e40-4c12-be88-0065da44e8ed_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6bc17e64-cc00-40c3-b55d-0e253b4ad64f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock through payroll deductions, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities_be5aa273-1c43-462d-8cf7-7309d4bf633a_terseLabel_en-US" xlink:label="lab_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents And Available-For-Sale Debt Securities</link:label>
    <link:label id="lab_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents And Available-For-Sale Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="goss-20241231.xsd#goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_691afda3-9f9c-4a06-bf80-448a42126f46_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9e593ca5-bf29-46b3-9bca-2c310852daf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c8b1c9c4-1b71-434f-94e7-dcc15757bd67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_f60d5ca6-c18b-4c1d-a104-7b70c6c32cc2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b64813e6-81e0-4843-8745-869876d07b26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest as of ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_2c9ec320-f958-491f-af7b-58fa0979e50f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d145b371-4e22-4557-be62-829128798c67_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_e0b9a030-5025-4d4f-ba75-1089e49d5f86_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage_7334a428-2555-45d7-83f0-beedc9614992_terseLabel_en-US" xlink:label="lab_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses carryforward available to offset future federal taxable income , percentage</link:label>
    <link:label id="lab_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage_label_en-US" xlink:label="lab_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Losses Carryforward Available To Offset Future Federal Taxable Income Percentage</link:label>
    <link:label id="lab_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage_documentation_en-US" xlink:label="lab_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net operating losses carryforward available to offset future federal taxable income , percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" xlink:href="goss-20241231.xsd#goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" xlink:to="lab_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a887ff35-570c-4c96-8e77-af4bcc9a7caf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f28c9492-bea0-4ae4-8cac-c5a843465442_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase related to current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_1e5cda3c-784a-4c75-ba80-e1665b9b8579_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7dc51883-7549-4c38-9ff4-cd5a1ececd3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_917dc767-23fb-43f3-a94d-251856233f8e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with a private offering, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_87f89692-b377-4f1b-afbe-a1f61ab53920_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TrancheOneMember_da6bdbfe-e89b-4ba7-914b-95bc3dc791b1_terseLabel_en-US" xlink:label="lab_goss_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_goss_TrancheOneMember_label_en-US" xlink:label="lab_goss_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_goss_TrancheOneMember_documentation_en-US" xlink:label="lab_goss_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TrancheOneMember" xlink:href="goss-20241231.xsd#goss_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TrancheOneMember" xlink:to="lab_goss_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage_afd09e28-0f45-447e-839f-ef75871b5b45_terseLabel_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity option owned by chiesi</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage_label_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Percentage</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage_documentation_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" xlink:to="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_e2fcc64e-cf7e-4791-845b-a87e01fda481_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_887d24d7-fae2-433e-9935-b48c340881a3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c1a9844f-e99a-410e-bb10-f43ce0fee21d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b7bcd604-6d7f-4b94-9597-0eec5a54be6d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_ca27886b-0a8e-4a0f-9d2f-95c0daccb4fa_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ae2a7404-4b08-4055-9d2c-0b68d5963990_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_73cd8a46-e214-4f5c-8f95-855812ea4502_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c5325a9a-051d-4469-892d-75e75f025af8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_475d6e30-3236-4e6a-bc1c-1c6cc7f48821_terseLabel_en-US" xlink:label="lab_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</link:label>
    <link:label id="lab_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_label_en-US" xlink:label="lab_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc. [Member]</link:label>
    <link:label id="lab_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_documentation_en-US" xlink:label="lab_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" xlink:to="lab_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_DebtInstrumentConvertibleConversionPricePercentage_8100fea7-bcc7-404c-9e30-b3dfbd5dc88d_terseLabel_en-US" xlink:label="lab_goss_DebtInstrumentConvertibleConversionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, percentage of conversion price</link:label>
    <link:label id="lab_goss_DebtInstrumentConvertibleConversionPricePercentage_label_en-US" xlink:label="lab_goss_DebtInstrumentConvertibleConversionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Conversion Price Percentage</link:label>
    <link:label id="lab_goss_DebtInstrumentConvertibleConversionPricePercentage_documentation_en-US" xlink:label="lab_goss_DebtInstrumentConvertibleConversionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument convertible conversion price percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentConvertibleConversionPricePercentage" xlink:href="goss-20241231.xsd#goss_DebtInstrumentConvertibleConversionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_DebtInstrumentConvertibleConversionPricePercentage" xlink:to="lab_goss_DebtInstrumentConvertibleConversionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_74c7ba24-b65d-4322-8083-1b92c99d4594_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e1da8ce6-f406-44ee-8f90-e485fd9858b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_6e08329a-ced4-4c89-8201-d2d0f978481c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_37434c18-2bfe-487a-a343-340ffae65b9a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_d6e15c63-5a5f-4c81-b542-95d4b8fec953_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_c57d516e-0f38-40b7-8af5-1c8a6eba16cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9d66fbd1-09f6-4a13-8469-fc5a95f0e693_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_743eb693-3c5e-4e08-b298-9f9eb867072b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember_ca8b25a6-0a91-4d37-82e1-a4bd90b42db7_terseLabel_en-US" xlink:label="lab_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:href="goss-20241231.xsd#goss_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="lab_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b0796b73-e360-4059-91c3-8bbcd09e25cb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_d53008ad-e784-4472-b136-5f03d7982883_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested shares under restricted stock grants</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_fc44c9f9-8e27-4027-8266-ad8a986a215b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_950d73eb-cf2f-41c9-bb76-1338bb58bf00_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_813ffa14-eb2e-4491-998c-a320736f7fb6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cef3f53b-c66d-4ae8-ae27-7b4f29ee0b5c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_13de0ff4-202f-4ccc-a997-f4e218fe4612_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_43a26dac-a9d2-49cd-b307-5b6886a84913_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense related to the 2027 Notes</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c20c5f68-6756-487c-8677-a09284523f0c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b13b7075-2dfe-4731-aeda-4550bbda1707_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_57a65c20-f91f-4839-9bd0-38424b34124a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8f10a99d-be77-4405-ae06-98a7f41863ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amount of Net Loss Before Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_55db384c-7e3a-4963-8fbf-30274bf2d83c_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2792ccb2-20e3-4aed-849d-7edaf710b66a_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d40e87da-32dc-430d-875b-6e98f011bede_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_28ce79b7-ae83-454f-beef-bb77da618401_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_8d444da9-2a19-49b1-9730-e4295aa0a998_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_OneHundredThirtyPercentApplicableConversionPriceMember_be1ffd20-25bf-4c4d-a7dc-4e2346e6852f_terseLabel_en-US" xlink:label="lab_goss_OneHundredThirtyPercentApplicableConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">130% Applicable Conversion Price</link:label>
    <link:label id="lab_goss_OneHundredThirtyPercentApplicableConversionPriceMember_label_en-US" xlink:label="lab_goss_OneHundredThirtyPercentApplicableConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Hundred Thirty Percent Applicable Conversion Price [Member]</link:label>
    <link:label id="lab_goss_OneHundredThirtyPercentApplicableConversionPriceMember_documentation_en-US" xlink:label="lab_goss_OneHundredThirtyPercentApplicableConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">130% Applicable Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OneHundredThirtyPercentApplicableConversionPriceMember" xlink:href="goss-20241231.xsd#goss_OneHundredThirtyPercentApplicableConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_OneHundredThirtyPercentApplicableConversionPriceMember" xlink:to="lab_goss_OneHundredThirtyPercentApplicableConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_09f4d34a-61ff-47c8-bf23-eb4a4cfe0231_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_a30fdfc2-57fa-4884-bae5-e0e615744d2f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2756e413-ffa6-4571-9b8f-53fafd1807a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted&#160;Market Prices for Identical&#160;Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8fbae534-4237-4d8c-be84-85137a73e8b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AccruedResearchAndDevelopmentExpenses_fe636e96-b364-4e70-8397-52b33c3acecd_terseLabel_en-US" xlink:label="lab_goss_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_goss_AccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_goss_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expenses</link:label>
    <link:label id="lab_goss_AccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_goss_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedResearchAndDevelopmentExpenses" xlink:href="goss-20241231.xsd#goss_AccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_goss_AccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e521e86f-4783-4304-b810-a05a50fab216_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9f97297c-03ac-4da9-be13-0f8758f984b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_be43438d-b937-44db-afd4-8d1d281ba989_negatedTotalLabel_en-US" xlink:label="lab_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Pre-tax Loss</link:label>
    <link:label id="lab_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_label_en-US" xlink:label="lab_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, For Tax Purposes</link:label>
    <link:label id="lab_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_documentation_en-US" xlink:label="lab_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, For Tax Purposes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" xlink:href="goss-20241231.xsd#goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" xlink:to="lab_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount_36b70747-4003-4baf-a033-29a5c7fd726c_terseLabel_en-US" xlink:label="lab_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, regulatory milestones receivable</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount_label_en-US" xlink:label="lab_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Regulatory Milestones, Amount</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount_documentation_en-US" xlink:label="lab_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Regulatory Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationRegulatoryMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount" xlink:to="lab_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TwoThousandTwentySevenNotesMember_ab12f026-5ce1-4835-8dab-3dcef7ac8b2d_terseLabel_en-US" xlink:label="lab_goss_TwoThousandTwentySevenNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027 Notes</link:label>
    <link:label id="lab_goss_TwoThousandTwentySevenNotesMember_label_en-US" xlink:label="lab_goss_TwoThousandTwentySevenNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Seven Notes [Member]</link:label>
    <link:label id="lab_goss_TwoThousandTwentySevenNotesMember_documentation_en-US" xlink:label="lab_goss_TwoThousandTwentySevenNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Seven Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TwoThousandTwentySevenNotesMember" xlink:to="lab_goss_TwoThousandTwentySevenNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fc35fccd-fa43-4a04-91fb-ffeb5c00d610_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_3f1d71b6-10d3-4361-946d-5b9a9e841cce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a2694e6d-ad63-491c-94f7-9cfacae41dec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember_2d4c791f-2123-4fa6-99d9-55c3704f141a_terseLabel_en-US" xlink:label="lab_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Equity Incentive Plan</link:label>
    <link:label id="lab_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember_label_en-US" xlink:label="lab_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Three Equity Inducement Incentive Plan [Member]</link:label>
    <link:label id="lab_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember_documentation_en-US" xlink:label="lab_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Three Equity Inducement Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember" xlink:to="lab_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e2b98d13-ce7a-4812-88b0-63c1e26db4e5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_66d67f06-4449-4751-aeb8-b2c335b47cd2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0d7c75f9-f649-483f-b676-01598031013e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ProductLicenseTerm_1b2df55f-cfe2-4bb8-8b55-8ed3bfb64a7b_terseLabel_en-US" xlink:label="lab_goss_ProductLicenseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product license term</link:label>
    <link:label id="lab_goss_ProductLicenseTerm_label_en-US" xlink:label="lab_goss_ProductLicenseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product License Term</link:label>
    <link:label id="lab_goss_ProductLicenseTerm_documentation_en-US" xlink:label="lab_goss_ProductLicenseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product license term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ProductLicenseTerm" xlink:href="goss-20241231.xsd#goss_ProductLicenseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ProductLicenseTerm" xlink:to="lab_goss_ProductLicenseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_363a1877-bed3-42f9-8584-144da6fbb9d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3917024f-fd22-4726-bafd-e5d8f15f3b2f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7ffe3150-dd72-42da-9161-408c16ea2ebe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_54c56e70-64ca-4c9f-ac21-374a9f1bb21f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ccc41cfd-92dc-4da4-8636-6ab7e065218d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition and Excludes Royalty Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_887c6814-09a8-4a76-b2eb-c0ef884bc924_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0bd5b80f-0d3a-4b0a-ae6a-282fbc0de750_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_04789c17-5f9f-46b6-825e-1b1a4b14c929_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_070797ec-908b-4761-8cde-df83dcd26ca7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options forfeited/cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_cf4a2021-0b23-47d8-979e-5b82bdcaae8f_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_a6b8161c-444d-45f5-b9c0-364a15ea2c18_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_80b907b2-d0aa-4be8-a89f-b7f9de9d7051_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_9eb14223-aa6e-4e14-b73e-50adbb8a5639_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d736cc92-bd77-4ff3-b79c-b17d36718351_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_83d6e936-fcb4-4ecf-8f9a-642eef319c82_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f3dc0e9d-c654-45e5-8fc8-925fe204e8de_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2aafa59-2eb5-45e0-886b-abe674ce352b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_462830db-68c5-44ac-b750-7198ed78fd41_terseLabel_en-US" xlink:label="lab_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock (in shares)</link:label>
    <link:label id="lab_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_label_en-US" xlink:label="lab_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Vesting Of Restricted Stock</link:label>
    <link:label id="lab_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_documentation_en-US" xlink:label="lab_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period shares vesting of restricted stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:href="goss-20241231.xsd#goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:to="lab_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_e2b62759-11a8-4571-8209-bb2ab346444f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_2aeacd88-7537-4c54-bfc5-fb6ff1d0505e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_333d054d-46fb-4852-a6ae-d1fe8b20515d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a8485832-c757-4d7e-b31c-82d6af974a67_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_68125099-21e8-4c1e-9f78-9ab97bb96855_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_b21cd88b-5888-4c65-ba34-97f27a8e6cef_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Point in Time:</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1e00e59d-51e8-4748-aa3e-041ef63034f3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_0b0ba540-4a1b-45ce-8fba-ff910129042d_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_7cc77ba4-fcc0-4bf4-8c7f-071d9d914b75_terseLabel_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share issued under ESPP (in shares)</link:label>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_label_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</link:label>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_documentation_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:to="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TaxCreditCarryforwardsReductionDueToMerger_b65e344d-45cc-4c48-9d30-46df7b1dc0d1_terseLabel_en-US" xlink:label="lab_goss_TaxCreditCarryforwardsReductionDueToMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards, amount removed</link:label>
    <link:label id="lab_goss_TaxCreditCarryforwardsReductionDueToMerger_label_en-US" xlink:label="lab_goss_TaxCreditCarryforwardsReductionDueToMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforwards, Reduction Due To Merger</link:label>
    <link:label id="lab_goss_TaxCreditCarryforwardsReductionDueToMerger_documentation_en-US" xlink:label="lab_goss_TaxCreditCarryforwardsReductionDueToMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforwards, Reduction Due To Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TaxCreditCarryforwardsReductionDueToMerger" xlink:href="goss-20241231.xsd#goss_TaxCreditCarryforwardsReductionDueToMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TaxCreditCarryforwardsReductionDueToMerger" xlink:to="lab_goss_TaxCreditCarryforwardsReductionDueToMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ContractWithCustomerLiabilityDevelopmentCost_4eac14f4-0160-4956-8581-cc00e1bfc410_terseLabel_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development cost reimbursement payment</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityDevelopmentCost_label_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Development Cost</link:label>
    <link:label id="lab_goss_ContractWithCustomerLiabilityDevelopmentCost_documentation_en-US" xlink:label="lab_goss_ContractWithCustomerLiabilityDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Development Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityDevelopmentCost" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityDevelopmentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ContractWithCustomerLiabilityDevelopmentCost" xlink:to="lab_goss_ContractWithCustomerLiabilityDevelopmentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9211a50d-7e46-4699-945c-e65a2026c72f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest as of end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17443fd3-ce33-4a12-a3b7-97b777f67e0a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in transition (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_54cd7495-fcb7-4763-a843-d779df3a7129_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ffbca77b-baf9-4c05-9951-daff87eec128_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d2a158ad-bfa0-4218-9ff4-a62a88d16705_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other&#160;Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ea62e4f2-2734-4e1e-9293-c027cca9333f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TwoThousandSeventeenEquityIncentivePlanMember_3dbbdb5a-1522-4112-9ee2-122a476bcac2_terseLabel_en-US" xlink:label="lab_goss_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_goss_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_goss_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_goss_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_goss_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand seventeen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="goss-20241231.xsd#goss_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_goss_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb978412-2247-46a3-a39d-08d58da368d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1edfad08-f039-451f-843f-11bfabc8d232_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_67ee8406-ef32-4173-8156-bae2b09b656d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with a private offering, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_70e3bf0f-8660-4894-b1be-e5c3a03eef89_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_662dc41d-b167-4fb0-98e3-e01691f2aa9e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3aafff57-2a92-4d7b-93ee-f176dc59ebb8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_02e72a10-7314-4dbb-a9fb-c95ed144380d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936d9a3-645a-4f21-9f81-4a6ffd4a96a4_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent_97c41bff-5683-488d-88ed-98489345a28f_verboseLabel_en-US" xlink:label="lab_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible interest</link:label>
    <link:label id="lab_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent_label_en-US" xlink:label="lab_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent</link:label>
    <link:label id="lab_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent_documentation_en-US" xlink:label="lab_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" xlink:href="goss-20241231.xsd#goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" xlink:to="lab_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b3018d2b-33ee-4b94-854d-17ff741d2185_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e57f843c-ebfa-4844-b014-066c3ce92e50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 700,000,000 shares authorized as of December&#160;31, 2024 and December&#160;31, 2023; 226,604,138 shares issued and outstanding as of December&#160;31, 2024, and 225,409,315 shares issued and outstanding as of December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_ed640677-77f0-4d87-b796-9f928a43145c_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea0bc20e-3f92-4b7e-bf25-1fd431a2bb55_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc5eba44-73c2-4dd8-9192-f543ac7ea81b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2871e602-2eb8-45ae-a51d-7b2ef4123711_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable as of end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_6ccaad80-5b99-43b3-be0c-8b4060c7aa2c_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice_8cc77d85-3036-40ee-b40a-e31d1640368e_terseLabel_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of each share subject to equity option, percentage of daily volume-weighted average per share price</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice_label_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Percentage Of Common Stock's Average Per Share Price</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice_documentation_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Percentage Of Common Stock's Average Per Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" xlink:to="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_ef9c86f4-202c-4b97-b527-c8cd6b5afc6a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5bc02d6e-65b8-4b2b-96be-5b5714ed34be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f35ed24b-9f42-4a5f-8458-a67bda06c480_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes_49993802-e365-445d-bb8e-ed12b132e78d_terseLabel_en-US" xlink:label="lab_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of repurchase price is equal to principal amount of convertible notes</link:label>
    <link:label id="lab_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Repurchase Price Is Equal To Principal Amount Of Convertible Notes</link:label>
    <link:label id="lab_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of repurchase price is equal to principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" xlink:href="goss-20241231.xsd#goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" xlink:to="lab_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0d1f6183-f32b-4edd-b276-4c6bc7593307_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2b6e79db-7b23-4115-b9a7-7d28384e6e11_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7c136f1-d1f6-4b07-9127-5cd325bf5bc4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a0014e12-611e-42d4-8d7c-74a22c78218c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3b933ba8-2b16-4fec-81eb-8dc11b5f651c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9cae3ea4-9dc0-453e-8b90-f72564fd42d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Subject to Options Outstanding, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_cfb4b911-56f0-48f8-8b1e-014ac6dda081_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities written off</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_5d967dd0-2ca7-4953-9d79-1539ad018647_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e2fdff84-60be-4a1b-9586-44f72410a52f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_f367511a-d537-4a99-9fa1-18881cf81e07_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_174d1b15-8e2a-4ccb-91e9-67211451fa19_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_4942b1c2-962c-48bf-a569-88fe15b65763_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_cecb2e37-a9e9-4fd6-aa8f-dc410fcc9311_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_FounderSharesMember_6a2d9772-2a27-4cfc-98f7-4cbccc42f39f_terseLabel_en-US" xlink:label="lab_goss_FounderSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Founder Shares</link:label>
    <link:label id="lab_goss_FounderSharesMember_label_en-US" xlink:label="lab_goss_FounderSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Founder Shares [Member]</link:label>
    <link:label id="lab_goss_FounderSharesMember_documentation_en-US" xlink:label="lab_goss_FounderSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Founder shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_FounderSharesMember" xlink:href="goss-20241231.xsd#goss_FounderSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_FounderSharesMember" xlink:to="lab_goss_FounderSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_TermLoanMember_11c3a533-43e7-4cc9-b7ed-b76c445bcdbe_terseLabel_en-US" xlink:label="lab_goss_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_goss_TermLoanMember_label_en-US" xlink:label="lab_goss_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_goss_TermLoanMember_documentation_en-US" xlink:label="lab_goss_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TermLoanMember" xlink:href="goss-20241231.xsd#goss_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_TermLoanMember" xlink:to="lab_goss_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_47eb02f6-4078-4db4-9a87-507ba19ede1f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of awards</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_acdc482b-2dfc-46c8-b567-a6a078fd0fc7_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon exercise of Chiesi Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_IncreaseDecreaseInOperatingLeaseLiabilities_303a8720-4fc2-4725-87cf-499ad31b2bdb_negatedLabel_en-US" xlink:label="lab_goss_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_goss_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_goss_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label id="lab_goss_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_goss_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="goss-20241231.xsd#goss_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_goss_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_27269dcb-b781-4da2-b225-4f42431097ce_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_84b90efd-19ad-4d1e-95d9-071d4506ee92_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ed412663-fade-4580-bcc8-9da4bf66b376_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c39ddcc6-b104-4412-970e-e163a450e5dd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation related to unvested stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ed4324a7-a26d-4e1b-abc3-967c9f0527a3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6add10cf-c8d2-47ff-b39d-3b21bb1ceb94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, plan modification, incremental cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_fd7d3583-450c-42e7-b9ce-dcaa80acc75c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seralutinib</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_DebtInstrumentRedemptionTermThresholdTradingDays_fdeb3366-a257-479b-99dc-5fe27d30c99e_terseLabel_en-US" xlink:label="lab_goss_DebtInstrumentRedemptionTermThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption term, threshold trading days</link:label>
    <link:label id="lab_goss_DebtInstrumentRedemptionTermThresholdTradingDays_label_en-US" xlink:label="lab_goss_DebtInstrumentRedemptionTermThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Term, Threshold Trading Days</link:label>
    <link:label id="lab_goss_DebtInstrumentRedemptionTermThresholdTradingDays_documentation_en-US" xlink:label="lab_goss_DebtInstrumentRedemptionTermThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Term, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentRedemptionTermThresholdTradingDays" xlink:href="goss-20241231.xsd#goss_DebtInstrumentRedemptionTermThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_DebtInstrumentRedemptionTermThresholdTradingDays" xlink:to="lab_goss_DebtInstrumentRedemptionTermThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_82a441b5-27cf-4cf2-9715-aa85ecfa1bac_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6eca0fa8-3eee-4a40-a39d-d88d38e0dce6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable_5600ce80-502d-45ca-b3a4-3242128722ad_terseLabel_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales milestone payments, payable</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable_label_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Contingent Consideration Sales Milestone Payments Payable</link:label>
    <link:label id="lab_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable_documentation_en-US" xlink:label="lab_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination, contingent consideration, sales milestone payments, payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" xlink:to="lab_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_c79bf3ac-ff5d-4436-9bd4-00a0ea1552cb_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_7ada0ffa-cfa5-4ede-92cf-8b0ca531496f_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S Treasury and agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6796bc07-ba4f-4d44-b9e8-ec1a8d61c488_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed2c37dc-45d2-42eb-a155-298f651f68a0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_bde636cf-d93f-4a93-b247-445c6895c73d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of amount increase in outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_3c21b7b5-007a-4959-bc0d-7237b91f0ad0_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_08d3cd44-6b2e-4641-bcd8-aca05dc09d50_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a6b20f5a-f5a4-4f02-8ba3-1d5bcf0a50f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3c4edf1d-1a1c-43f3-8047-3829656d3fc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_03e9526d-febe-4d74-9923-d1ee7b43346c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b5a0b13a-9260-4955-bbcf-1f0f1e2ed31d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8cb3c7a4-f419-4e86-84ca-2ba4c959717d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d50754cc-316d-4e76-a00b-dd1e3a36fc24_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_78addb8e-d85b-4946-a085-919b951e66c5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8ddbcb42-7cef-4dc3-aa1c-408fb52e90fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e7c3f55e-db8a-4b82-b1fd-ad68a8d3c60b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ec5ebaf6-81f0-4529-859c-8f975f52c3e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_56cf1e36-aa07-48ea-af10-3a032170b82f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_efd6c859-4915-4a96-b60b-49fc1d8a7435_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_84b9d460-d701-49ea-a2d1-02d39ead0030_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0835002e-4f5c-4b23-9d9e-ea1a5b71172c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_42576260-1235-469a-a65a-9b7640c57aea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, options vested in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_edfae080-316c-4c1a-b405-ce4f84b26c00_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d8f1c3e3-b5b8-4ddf-80fa-70e702f22b1d_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_2d5437ad-15bb-4852-ae1b-728731fde289_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ce1a0672-6056-4a91-a1f1-1dc8780224b9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_51bc295d-d3ee-40ce-bc2b-14edc9c4e531_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_48bdc359-ecf1-4515-9ead-9b4aef285b09_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_c5f19c6b-ec92-4535-8680-70a0c0f0c4ad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AccruedConsultingFeesCurrent_02000c03-ea8e-4c40-aca5-a2c74c5f14b9_terseLabel_en-US" xlink:label="lab_goss_AccruedConsultingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued consulting fees</link:label>
    <link:label id="lab_goss_AccruedConsultingFeesCurrent_label_en-US" xlink:label="lab_goss_AccruedConsultingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Consulting Fees Current</link:label>
    <link:label id="lab_goss_AccruedConsultingFeesCurrent_documentation_en-US" xlink:label="lab_goss_AccruedConsultingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued consulting fees current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedConsultingFeesCurrent" xlink:href="goss-20241231.xsd#goss_AccruedConsultingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AccruedConsultingFeesCurrent" xlink:to="lab_goss_AccruedConsultingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70b0f6a9-5a33-4be9-9136-bc9758cad7cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_9713c1c2-6328-48d9-85a2-06919d5c695e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b56710f2-23ef-4e08-9270-3592ac5d9f31_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock_09b48ab8-4ace-4e36-ba0f-7dd1ce3607eb_terseLabel_en-US" xlink:label="lab_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Carrying Amount of 2027 Notes</link:label>
    <link:label id="lab_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock_label_en-US" xlink:label="lab_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Interest Expense Recognized Table [Table Text Block]</link:label>
    <link:label id="lab_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock_documentation_en-US" xlink:label="lab_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of interest expense recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock" xlink:href="goss-20241231.xsd#goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock" xlink:to="lab_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_DeferredTaxLiabilitiesRightOfUseAsset_4cff7826-6797-490d-9d3b-812fdf929d22_negatedLabel_en-US" xlink:label="lab_goss_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_goss_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_goss_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</link:label>
    <link:label id="lab_goss_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_goss_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities right of use asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="goss-20241231.xsd#goss_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_goss_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_3638d443-9014-485a-8f94-a5b8df356aec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_9393e43e-19d9-41d3-bc4e-32227826577e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of equity option pursuant to stock purchase agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived_f743d957-a130-41fb-bbb6-e6303e48d1a0_terseLabel_en-US" xlink:label="lab_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Up-front, nonrefundable payment received</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived_label_en-US" xlink:label="lab_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Upfront Nonrefundable Amount Received</link:label>
    <link:label id="lab_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived_documentation_en-US" xlink:label="lab_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Upfront Nonrefundable Amount Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" xlink:to="lab_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_73e29c68-a438-4e22-9cbc-7b22e0e8242f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_51b11f95-94ae-458f-8ba0-62314c8348ad_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_45562fcc-03a3-4694-bc9e-03db2007b15b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e4093a1b-8870-47a5-8b11-e7263f2ec40f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b48f649b-30e0-4646-82db-718ac0c22d18_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3185647a-1d13-4965-80d1-8db1281720a4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a3731b9f-4976-4971-a7b0-a5f807469bd4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ScheduleOfNotesTableTableTextBlock_74cae707-99cf-40ca-8a72-f923e1c67f7c_terseLabel_en-US" xlink:label="lab_goss_ScheduleOfNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense Recognized</link:label>
    <link:label id="lab_goss_ScheduleOfNotesTableTableTextBlock_label_en-US" xlink:label="lab_goss_ScheduleOfNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Notes Table [Table Text Block]</link:label>
    <link:label id="lab_goss_ScheduleOfNotesTableTableTextBlock_documentation_en-US" xlink:label="lab_goss_ScheduleOfNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of liability components of notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ScheduleOfNotesTableTableTextBlock" xlink:href="goss-20241231.xsd#goss_ScheduleOfNotesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ScheduleOfNotesTableTableTextBlock" xlink:to="lab_goss_ScheduleOfNotesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ee321165-1c53-471b-8d15-8e974108d62b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b5d4248b-0d65-4eb1-a980-7bb84242b812_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_713f4bb8-4ba7-4fc4-a0e7-96aa66394496_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4b55a37d-b760-4229-b324-fca14e254400_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6b9dcbf6-f87c-43fe-b0c8-efa2af331206_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7dace29e-a2b6-4d5b-ac34-218e98b161b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_93952098-f4a9-4f81-8614-e89d947781e5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued_85bcd6d2-cda1-4e40-888b-af320bc3ad25_terseLabel_en-US" xlink:label="lab_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant of equity option pursuant to Chiesi Collaboration Agreement</link:label>
    <link:label id="lab_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued_label_en-US" xlink:label="lab_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Equity Option Issued</link:label>
    <link:label id="lab_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued_documentation_en-US" xlink:label="lab_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Equity Option Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" xlink:href="goss-20241231.xsd#goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" xlink:to="lab_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays_14b90f54-4aaa-46a8-9624-411dea0dcb76_terseLabel_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of each share subject to equity option, number of trading days</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays_label_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Number Of Trading Days</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays_documentation_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Number Of Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" xlink:to="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice_13c55011-1b77-4458-b6bb-2369789e5a67_terseLabel_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, threshold share price (in dollars per share)</link:label>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice_label_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Threshold Share Price</link:label>
    <link:label id="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice_documentation_en-US" xlink:label="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Threshold Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" xlink:to="lab_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice_b5b7c135-b65d-4abf-86df-759e7accc3c2_terseLabel_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of each share subject to equity option, minimum price threshold (in dollars per share)</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice_label_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Minimum Purchase Price</link:label>
    <link:label id="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice_documentation_en-US" xlink:label="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Equity Option Owned By Counterparty, Minimum Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" xlink:to="lab_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ceddde1-d96c-4fd0-8454-ff32146497c3_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted rent payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_7338db0e-0607-4425-8cae-aa3e66550a6e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock, repurchase (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_703164a3-209b-4d16-8b7c-0692b6d64bc5_terseLabel_en-US" xlink:label="lab_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:label id="lab_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_documentation_en-US" xlink:label="lab_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="goss-20241231.xsd#goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_EmployeeStockPurchasePlanMember_6e72de98-388a-43f6-adcd-9061dcf06159_terseLabel_en-US" xlink:label="lab_goss_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_goss_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_goss_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_goss_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_goss_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EmployeeStockPurchasePlanMember" xlink:href="goss-20241231.xsd#goss_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_EmployeeStockPurchasePlanMember" xlink:to="lab_goss_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_de65bc2a-edab-4ac2-92ed-67232ac8876e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1305d5dc-f90a-445d-b825-905b94e07338_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0411653f-06a1-4d0d-9187-ccabd1d50424_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease related to prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a853d742-ac67-4aed-8ddb-12e2b03e2b39_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_DeferredTaxAssetsLeaseLiability_3eaca90a-c4eb-4b4d-af7a-6fa6ad47e21e_terseLabel_en-US" xlink:label="lab_goss_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_goss_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_goss_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Lease Liability</link:label>
    <link:label id="lab_goss_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_goss_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DeferredTaxAssetsLeaseLiability" xlink:href="goss-20241231.xsd#goss_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_DeferredTaxAssetsLeaseLiability" xlink:to="lab_goss_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_64db76aa-2e99-4cdf-a25d-8fa86954b7ae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cfa0cbe0-dc0f-4f13-a68c-f403b912887f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6be7829d-952b-4717-8979-0b3c986093d0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_eb93a1b3-e9e8-46c4-af20-08d5ce618a55_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_824ba8de-7a16-45c6-ae8b-7e638d5af2e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_StockholdersEquityDeficitLineItems_027e9606-06e4-41ab-ae76-139941469285_terseLabel_en-US" xlink:label="lab_goss_StockholdersEquityDeficitLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity Deficit [Line Items]</link:label>
    <link:label id="lab_goss_StockholdersEquityDeficitLineItems_label_en-US" xlink:label="lab_goss_StockholdersEquityDeficitLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Deficit [Line Items]</link:label>
    <link:label id="lab_goss_StockholdersEquityDeficitLineItems_documentation_en-US" xlink:label="lab_goss_StockholdersEquityDeficitLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders equity deficit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockholdersEquityDeficitLineItems" xlink:href="goss-20241231.xsd#goss_StockholdersEquityDeficitLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_StockholdersEquityDeficitLineItems" xlink:to="lab_goss_StockholdersEquityDeficitLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ab2ed9fb-5061-4be7-a7b4-61c9d56a8d4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0248eacd-7eda-45ec-a339-c357e979aca5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f0783af7-eed1-4c33-93ec-cfffe146c4ea_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_edb37992-3180-4d7b-aa24-d305bedbd652_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_4cfeb16a-d99d-48da-ba35-5bb77a21119c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d46fe860-4ba0-42ae-a622-9ead3936f9da_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6742a82-be2d-4e1e-800d-c2ca2547f209_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember_3cd9493e-9f12-4b1a-a3a4-17d598a8f569_terseLabel_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terminated programs</link:label>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember_label_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development Terminated Programs [Member]</link:label>
    <link:label id="lab_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember_documentation_en-US" xlink:label="lab_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In process research and development other programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentTerminatedProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember" xlink:to="lab_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bbf83c26-f76f-4170-8143-bf2092c8689c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of long-term debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dc4b08c-1f9d-4600-b212-6c7a7980fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ResearchAndDevelopmentInProcessExpenses_4dbc5416-36e9-46c8-ba90-6b46b647c5bc_netLabel_en-US" xlink:label="lab_goss_ResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">In process research and development</link:label>
    <link:label id="lab_goss_ResearchAndDevelopmentInProcessExpenses_a29d8d4d-243c-4cd5-b08b-9627e605ea63_terseLabel_en-US" xlink:label="lab_goss_ResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In process research and development expenses</link:label>
    <link:label id="lab_goss_ResearchAndDevelopmentInProcessExpenses_c2cc5e43-b983-44a2-94f8-1f71bd329c5f_verboseLabel_en-US" xlink:label="lab_goss_ResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total in process research and development</link:label>
    <link:label id="lab_goss_ResearchAndDevelopmentInProcessExpenses_label_en-US" xlink:label="lab_goss_ResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development In Process Expenses</link:label>
    <link:label id="lab_goss_ResearchAndDevelopmentInProcessExpenses_documentation_en-US" xlink:label="lab_goss_ResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development In Process Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ResearchAndDevelopmentInProcessExpenses" xlink:to="lab_goss_ResearchAndDevelopmentInProcessExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_67d16930-00b9-42d7-9ce1-12aa8d6848ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a215373c-026b-4e05-8a9f-d3053d9393ff_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2b6138e2-2c0a-4eac-b61c-7cad8f7196c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate fair value of stock options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_97f47973-54c4-4c5a-8183-dfca2c3af0aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_goss_ROWLicenseMember_8016d1f0-92d1-4505-ac0c-a84fcde892cf_verboseLabel_en-US" xlink:label="lab_goss_ROWLicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from sale of ROW license</link:label>
    <link:label id="lab_goss_ROWLicenseMember_e28cb7f3-c5d3-4b34-90dc-8434f1bd3877_terseLabel_en-US" xlink:label="lab_goss_ROWLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROW License</link:label>
    <link:label id="lab_goss_ROWLicenseMember_label_en-US" xlink:label="lab_goss_ROWLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ROW License [Member]</link:label>
    <link:label id="lab_goss_ROWLicenseMember_documentation_en-US" xlink:label="lab_goss_ROWLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ROW License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ROWLicenseMember" xlink:href="goss-20241231.xsd#goss_ROWLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_goss_ROWLicenseMember" xlink:to="lab_goss_ROWLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_b9f3494f-4655-41a6-8724-3e7b6c0ef720_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>goss-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:27c0f11b-cb15-486e-948f-a34ff077e64b,g:c382099f-c004-46d4-b3a3-9983a179ddc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gossamerbio.com/role/Cover" xlink:type="simple" xlink:href="goss-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_883a9a48-ee5f-4e9c-bab0-fc67e5b9ef12" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentType_883a9a48-ee5f-4e9c-bab0-fc67e5b9ef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7ae6825f-4d2b-4a43-842c-cd4178ccb96b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentAnnualReport_7ae6825f-4d2b-4a43-842c-cd4178ccb96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8df8e492-ecc9-4573-9c27-a0b45c2083b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentPeriodEndDate_8df8e492-ecc9-4573-9c27-a0b45c2083b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_605c5b91-ce85-41fd-91c5-81119d6628ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_CurrentFiscalYearEndDate_605c5b91-ce85-41fd-91c5-81119d6628ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f8f1cc35-c707-41bc-b35a-f949012d65d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentTransitionReport_f8f1cc35-c707-41bc-b35a-f949012d65d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a1ba7802-847e-4c03-9402-7283146b86d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityFileNumber_a1ba7802-847e-4c03-9402-7283146b86d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_521ed5da-d62d-4f3f-9291-62df718795eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityRegistrantName_521ed5da-d62d-4f3f-9291-62df718795eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f89c1ef7-c3cc-4cab-99b8-4dc794ed3251" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f89c1ef7-c3cc-4cab-99b8-4dc794ed3251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_eb481552-751a-40e6-bfe3-28cf6d18e5fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityTaxIdentificationNumber_eb481552-751a-40e6-bfe3-28cf6d18e5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0c0a1672-12cd-4571-9510-af16119cce15" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityAddressAddressLine1_0c0a1672-12cd-4571-9510-af16119cce15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0bd48066-4d20-45b2-8ee0-cebf9120ed5f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityAddressCityOrTown_0bd48066-4d20-45b2-8ee0-cebf9120ed5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a60630ac-8f55-4ef2-a278-1029de4ce03a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityAddressStateOrProvince_a60630ac-8f55-4ef2-a278-1029de4ce03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b75f17fc-f3ec-49c0-960c-920b20ca5765" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityAddressPostalZipCode_b75f17fc-f3ec-49c0-960c-920b20ca5765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_09002855-90dd-4088-8eba-80ca8a1b4936" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_CityAreaCode_09002855-90dd-4088-8eba-80ca8a1b4936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bd4eb76c-466a-4873-aee1-e7b6ca09b81f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_LocalPhoneNumber_bd4eb76c-466a-4873-aee1-e7b6ca09b81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5c207061-aaeb-49eb-990a-1293b79a1252" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_Security12bTitle_5c207061-aaeb-49eb-990a-1293b79a1252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_52ea0bbe-7b28-4920-917e-affd03b8fbe9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_TradingSymbol_52ea0bbe-7b28-4920-917e-affd03b8fbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_80562bb6-0312-4fbe-86ff-a85584afa577" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_SecurityExchangeName_80562bb6-0312-4fbe-86ff-a85584afa577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_984241fd-9244-4121-b2e8-22b2fa42b932" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_984241fd-9244-4121-b2e8-22b2fa42b932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_6b82adf1-74ef-42f3-a023-fef9639951a2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityVoluntaryFilers_6b82adf1-74ef-42f3-a023-fef9639951a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_62119d05-0d18-4dad-a882-852bb657f04f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityCurrentReportingStatus_62119d05-0d18-4dad-a882-852bb657f04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_22847ec1-2a4c-4c4c-bf39-7ba187d93bb9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityInteractiveDataCurrent_22847ec1-2a4c-4c4c-bf39-7ba187d93bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7446fc32-079e-420c-a941-90f61d015d4e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityFilerCategory_7446fc32-079e-420c-a941-90f61d015d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dd23d7ea-dd12-4d31-8b8f-f16c44e8d820" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntitySmallBusiness_dd23d7ea-dd12-4d31-8b8f-f16c44e8d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f5bd9e6c-eb59-4d1d-9ec3-95f3d0cf93c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityEmergingGrowthCompany_f5bd9e6c-eb59-4d1d-9ec3-95f3d0cf93c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_be0eca1f-37e8-4928-b8b5-69750c2d396c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_IcfrAuditorAttestationFlag_be0eca1f-37e8-4928-b8b5-69750c2d396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_6a00d89f-00a8-4aa9-aef3-c5ccc1e502ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_6a00d89f-00a8-4aa9-aef3-c5ccc1e502ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a039d9b8-bb73-4e9f-8fa4-79ea0af161bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityShellCompany_a039d9b8-bb73-4e9f-8fa4-79ea0af161bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_3197a931-a297-43a4-ba80-8301e0d5dae7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityPublicFloat_3197a931-a297-43a4-ba80-8301e0d5dae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9f8a951e-d987-43b5-9fdb-2af7a78fd11e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9f8a951e-d987-43b5-9fdb-2af7a78fd11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b40cafa8-ea54-466c-b159-99ee3771fc7c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b40cafa8-ea54-466c-b159-99ee3771fc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d357eeee-351e-4d48-881a-83d51221cf62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_AmendmentFlag_d357eeee-351e-4d48-881a-83d51221cf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_aeb9554e-04c9-4868-ab1f-d433bfd1bf8e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentFiscalYearFocus_aeb9554e-04c9-4868-ab1f-d433bfd1bf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a4cc35c0-66bd-4ca0-874c-90013fe0a6da" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a4cc35c0-66bd-4ca0-874c-90013fe0a6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a95a0312-b12b-43a8-acc6-5b634ecabcaf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d99edaf-c2f0-49a5-8221-526d4e401f62" xlink:to="loc_dei_EntityCentralIndexKey_a95a0312-b12b-43a8-acc6-5b634ecabcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/AuditInformation" xlink:type="simple" xlink:href="goss-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_goss_AuditorInformationAbstract_5f45158c-c8fe-47e4-b196-bdd28a41e4d4" xlink:href="goss-20241231.xsd#goss_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_4603b7ee-ecaf-439f-8a47-782831907c11" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_AuditorInformationAbstract_5f45158c-c8fe-47e4-b196-bdd28a41e4d4" xlink:to="loc_dei_AuditorFirmId_4603b7ee-ecaf-439f-8a47-782831907c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_14d54e14-5b12-4f73-ba6a-c1816c866e0d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_AuditorInformationAbstract_5f45158c-c8fe-47e4-b196-bdd28a41e4d4" xlink:to="loc_dei_AuditorName_14d54e14-5b12-4f73-ba6a-c1816c866e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_4e9fd9ef-090f-4fd2-88ad-125cc0c753f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_AuditorInformationAbstract_5f45158c-c8fe-47e4-b196-bdd28a41e4d4" xlink:to="loc_dei_AuditorLocation_4e9fd9ef-090f-4fd2-88ad-125cc0c753f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c69abb84-e52f-4873-9694-d40d30601557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_42518e3f-bd9d-46e3-bbc6-c9909377d92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c69abb84-e52f-4873-9694-d40d30601557" xlink:to="loc_us-gaap_AssetsAbstract_42518e3f-bd9d-46e3-bbc6-c9909377d92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_878ace68-ae2a-42db-8fc7-70e7f1abeb47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42518e3f-bd9d-46e3-bbc6-c9909377d92d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_878ace68-ae2a-42db-8fc7-70e7f1abeb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_abc21343-7888-43c5-8473-5f46cc2e1249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_878ace68-ae2a-42db-8fc7-70e7f1abeb47" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_abc21343-7888-43c5-8473-5f46cc2e1249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_656e1dde-42b5-4bb9-9fd7-6ba4d4d0acb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_878ace68-ae2a-42db-8fc7-70e7f1abeb47" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_656e1dde-42b5-4bb9-9fd7-6ba4d4d0acb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c19445b5-b913-4a39-8ebe-c166df29bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_878ace68-ae2a-42db-8fc7-70e7f1abeb47" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c19445b5-b913-4a39-8ebe-c166df29bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d05e5dad-08db-4a56-a20a-e606c27062c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_878ace68-ae2a-42db-8fc7-70e7f1abeb47" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d05e5dad-08db-4a56-a20a-e606c27062c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73002040-72d9-47ea-8cfc-27617722f3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_878ace68-ae2a-42db-8fc7-70e7f1abeb47" xlink:to="loc_us-gaap_AssetsCurrent_73002040-72d9-47ea-8cfc-27617722f3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c6a742c2-3bfc-44cf-9467-c84db0a6d5af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42518e3f-bd9d-46e3-bbc6-c9909377d92d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c6a742c2-3bfc-44cf-9467-c84db0a6d5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_60f11b1c-e0d2-4196-9d1a-c46776899f30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42518e3f-bd9d-46e3-bbc6-c9909377d92d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_60f11b1c-e0d2-4196-9d1a-c46776899f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c3261c2a-f97d-4568-9a9e-17f7c54c5238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42518e3f-bd9d-46e3-bbc6-c9909377d92d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c3261c2a-f97d-4568-9a9e-17f7c54c5238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3887d5e8-5d9a-47da-ba41-a6274fb78948" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42518e3f-bd9d-46e3-bbc6-c9909377d92d" xlink:to="loc_us-gaap_Assets_3887d5e8-5d9a-47da-ba41-a6274fb78948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c69abb84-e52f-4873-9694-d40d30601557" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_48fdc356-db53-4a39-a081-2ab5b32853f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:to="loc_us-gaap_AccountsPayableCurrent_48fdc356-db53-4a39-a081-2ab5b32853f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedResearchAndDevelopmentExpenses_b161a0dd-aedd-422b-94aa-978db832c345" xlink:href="goss-20241231.xsd#goss_AccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:to="loc_goss_AccruedResearchAndDevelopmentExpenses_b161a0dd-aedd-422b-94aa-978db832c345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_70e1afb4-b4c5-496a-bc9c-0e141b8f5706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:to="loc_us-gaap_LongTermDebtCurrent_70e1afb4-b4c5-496a-bc9c-0e141b8f5706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9889d68f-bf08-47c2-88fb-69c345149b08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9889d68f-bf08-47c2-88fb-69c345149b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_98856929-ff2b-4647-b59a-90fef0f662f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_98856929-ff2b-4647-b59a-90fef0f662f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_32cdd46b-8067-410a-8584-201a376f14ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4263fe99-46fb-47c2-b4a5-a0a799eb7027" xlink:to="loc_us-gaap_LiabilitiesCurrent_32cdd46b-8067-410a-8584-201a376f14ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermConvertibleSeniorNotes_f22344a3-48bd-4fb5-91ae-c61a0edb94a1" xlink:href="goss-20241231.xsd#goss_LongTermConvertibleSeniorNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_goss_LongTermConvertibleSeniorNotes_f22344a3-48bd-4fb5-91ae-c61a0edb94a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_df165a7c-9220-4587-8d9d-22acc4aeca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_df165a7c-9220-4587-8d9d-22acc4aeca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1d34604-42bb-445b-bd21-b31945497dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1d34604-42bb-445b-bd21-b31945497dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bdaeff66-1c55-402a-9532-58d685c3e2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bdaeff66-1c55-402a-9532-58d685c3e2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c68fdec8-e709-43d5-aae4-07a6679a4c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_Liabilities_c68fdec8-e709-43d5-aae4-07a6679a4c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8439cf84-359a-4c5f-a995-f295c4835529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8439cf84-359a-4c5f-a995-f295c4835529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0219f1a8-a296-49f8-94df-0bb75f4f2af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0219f1a8-a296-49f8-94df-0bb75f4f2af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_013d2178-2052-4beb-87af-8e29ff91a222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0219f1a8-a296-49f8-94df-0bb75f4f2af2" xlink:to="loc_us-gaap_CommonStockValue_013d2178-2052-4beb-87af-8e29ff91a222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f0d5e1d6-3421-4ec9-b9ef-12eea3de0b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0219f1a8-a296-49f8-94df-0bb75f4f2af2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f0d5e1d6-3421-4ec9-b9ef-12eea3de0b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a5a4d4c-9efa-4b05-ae75-6a03e4ef6099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0219f1a8-a296-49f8-94df-0bb75f4f2af2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a5a4d4c-9efa-4b05-ae75-6a03e4ef6099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_89f56710-f0cb-4406-8b59-7fa0d41fb62b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0219f1a8-a296-49f8-94df-0bb75f4f2af2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_89f56710-f0cb-4406-8b59-7fa0d41fb62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_580c9597-98cf-4647-882c-02c6f63ed1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0219f1a8-a296-49f8-94df-0bb75f4f2af2" xlink:to="loc_us-gaap_StockholdersEquity_580c9597-98cf-4647-882c-02c6f63ed1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bea8b478-77e9-43e2-819f-66954a8224ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de13ca15-1a2b-4ceb-abce-5ce093be279c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bea8b478-77e9-43e2-819f-66954a8224ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3782e8ea-c452-4a1e-92e7-cff028bb02d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1ab35f68-d389-492f-8738-e9f0647f67fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3782e8ea-c452-4a1e-92e7-cff028bb02d8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1ab35f68-d389-492f-8738-e9f0647f67fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_417ceef2-2ac5-4f6c-902a-eae5db084837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3782e8ea-c452-4a1e-92e7-cff028bb02d8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_417ceef2-2ac5-4f6c-902a-eae5db084837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_728d6c80-16f1-44f0-b0d2-ee5e210e47ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3782e8ea-c452-4a1e-92e7-cff028bb02d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_728d6c80-16f1-44f0-b0d2-ee5e210e47ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_37f05cf6-6ec8-44b2-b31c-fee812a9edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3782e8ea-c452-4a1e-92e7-cff028bb02d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_37f05cf6-6ec8-44b2-b31c-fee812a9edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b6fcd8b0-d6bd-41dc-b739-5495f9cf43b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddd5427b-d001-4091-bfcb-5e9ae9366008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b6fcd8b0-d6bd-41dc-b739-5495f9cf43b6" xlink:to="loc_us-gaap_StatementTable_ddd5427b-d001-4091-bfcb-5e9ae9366008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abde655f-b31e-457f-86ef-e1e1fadaafd8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddd5427b-d001-4091-bfcb-5e9ae9366008" xlink:to="loc_srt_ProductOrServiceAxis_abde655f-b31e-457f-86ef-e1e1fadaafd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_abde655f-b31e-457f-86ef-e1e1fadaafd8" xlink:to="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_34a36d8b-cc1c-495d-a5b8-5cdd61acb4af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:to="loc_us-gaap_LicenseAndServiceMember_34a36d8b-cc1c-495d-a5b8-5cdd61acb4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenueFromContractsWithCollaboratorsMember_d8e40f77-bca9-417c-bd61-bdb863690c89" xlink:href="goss-20241231.xsd#goss_RevenueFromContractsWithCollaboratorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ece4a879-f2e8-4939-b3eb-58b2dbb61c0b" xlink:to="loc_goss_RevenueFromContractsWithCollaboratorsMember_d8e40f77-bca9-417c-bd61-bdb863690c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddd5427b-d001-4091-bfcb-5e9ae9366008" xlink:to="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_470c9770-bf7a-4a4a-af45-5d01038a92ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_RevenuesAbstract_470c9770-bf7a-4a4a-af45-5d01038a92ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_974e046b-4283-4d81-a802-94e11d1d65f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_470c9770-bf7a-4a4a-af45-5d01038a92ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_974e046b-4283-4d81-a802-94e11d1d65f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_46334cab-c0c2-4cd6-863d-7950d23e04e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_46334cab-c0c2-4cd6-863d-7950d23e04e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses_132a0d00-4ea1-4f0e-82f2-c85fb3911cc2" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_goss_ResearchAndDevelopmentInProcessExpenses_132a0d00-4ea1-4f0e-82f2-c85fb3911cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5829b571-aa5a-451b-8534-68995c249586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5829b571-aa5a-451b-8534-68995c249586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fb87d5ba-0896-41c8-8349-d85c56cbd7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_855d018c-58e2-4216-afa4-3520e1e4ee3e" xlink:to="loc_us-gaap_OperatingExpenses_fb87d5ba-0896-41c8-8349-d85c56cbd7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_06fafdff-0f72-44ce-9225-bad1627e1788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OperatingIncomeLoss_06fafdff-0f72-44ce-9225-bad1627e1788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7656af5b-d8b2-4e75-b7f3-95fc87c35658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7656af5b-d8b2-4e75-b7f3-95fc87c35658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_5eb3c702-776b-41e2-a06d-1561077ec906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_InterestExpenseNonoperating_5eb3c702-776b-41e2-a06d-1561077ec906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bb5a6d1d-e023-465d-a42e-2e28fe5577e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bb5a6d1d-e023-465d-a42e-2e28fe5577e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_88b0dc8b-97bc-425f-b6dd-2ece65c16f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4ea45d71-acd1-4dfd-b43a-ab057260891d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_88b0dc8b-97bc-425f-b6dd-2ece65c16f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8f8e471-b0f0-42a4-bf26-4812538bf7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8f8e471-b0f0-42a4-bf26-4812538bf7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3b5562aa-e45b-4be2-937f-364c8a384a31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3b5562aa-e45b-4be2-937f-364c8a384a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62b50a9b-955e-441d-9382-e8cabf9f013b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_NetIncomeLoss_62b50a9b-955e-441d-9382-e8cabf9f013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139345eb-78b3-477a-9afb-d35db6bc0950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139345eb-78b3-477a-9afb-d35db6bc0950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_de0a979f-7fd0-4383-944f-c11e0dc3f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_de0a979f-7fd0-4383-944f-c11e0dc3f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0a5927d-dada-4619-b41d-28271ab6f85e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6f6b2799-4506-44ec-9e03-fb95f4331656" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0a5927d-dada-4619-b41d-28271ab6f85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cc2d81e-256f-4abf-b7c2-97d5f991d9da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cc2d81e-256f-4abf-b7c2-97d5f991d9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_66676c0f-a762-4440-a2bc-bf6d36f74d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_EarningsPerShareBasic_66676c0f-a762-4440-a2bc-bf6d36f74d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_44a8d307-2369-469f-ab98-aa2615651111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_EarningsPerShareDiluted_44a8d307-2369-469f-ab98-aa2615651111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ec186c-65aa-4e46-bdf9-b28510dfe104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ec186c-65aa-4e46-bdf9-b28510dfe104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3abd12aa-8fcd-4c98-afa3-b6cbf73772c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24dae62-e9ab-4afa-aea9-9a8d2d3e0272" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3abd12aa-8fcd-4c98-afa3-b6cbf73772c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ff8a1fea-fb5b-4913-94dd-3f30ddfade0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ff8a1fea-fb5b-4913-94dd-3f30ddfade0b" xlink:to="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ed9bca74-7919-4529-a250-f2b47ffbab26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ed9bca74-7919-4529-a250-f2b47ffbab26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed9bca74-7919-4529-a250-f2b47ffbab26" xlink:to="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_71c9a270-2d0b-4cdd-98b8-3390091ca2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_CommonStockMember_71c9a270-2d0b-4cdd-98b8-3390091ca2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a76e6afc-9fd1-4729-b0c0-0d49a81efb68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a76e6afc-9fd1-4729-b0c0-0d49a81efb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d44ba96-9b1c-4881-bfc4-c20a2ab7a592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_RetainedEarningsMember_9d44ba96-9b1c-4881-bfc4-c20a2ab7a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_807e18a0-5c91-410e-b58f-fce9d4bb04e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_061fd441-e5eb-443b-bc55-93b877590605" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_807e18a0-5c91-410e-b58f-fce9d4bb04e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_914aa900-64e4-4e40-891e-03dd37871462" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_914aa900-64e4-4e40-891e-03dd37871462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b5a3e9e7-ef94-4318-9e8a-c7df19aad9d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_914aa900-64e4-4e40-891e-03dd37871462" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b5a3e9e7-ef94-4318-9e8a-c7df19aad9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_550c63e5-3a13-4356-8665-ea59b84ada41" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b5a3e9e7-ef94-4318-9e8a-c7df19aad9d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_550c63e5-3a13-4356-8665-ea59b84ada41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_86557d1c-66d0-4597-82b1-c52275f0b0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b8be234-cf40-49e1-aa67-e9b7c2a712e8" xlink:to="loc_us-gaap_StatementLineItems_86557d1c-66d0-4597-82b1-c52275f0b0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86557d1c-66d0-4597-82b1-c52275f0b0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_095675bd-c51f-4637-a7f6-c04ecbfea3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_095675bd-c51f-4637-a7f6-c04ecbfea3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4b81f9b-95f2-46d7-b2fc-a4ca9c7074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockholdersEquity_d4b81f9b-95f2-46d7-b2fc-a4ca9c7074a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df9629ac-240b-4e42-bda2-4c8e797158c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df9629ac-240b-4e42-bda2-4c8e797158c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_640a1907-0352-40ee-9b0e-31b30364e367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_640a1907-0352-40ee-9b0e-31b30364e367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_be02f6f6-6fef-459c-9d3b-93ce8bbb88bb" xlink:href="goss-20241231.xsd#goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock_be02f6f6-6fef-459c-9d3b-93ce8bbb88bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_69e3fa47-1cb9-4b76-bcff-89597a708954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_69e3fa47-1cb9-4b76-bcff-89597a708954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82cedaac-f03e-4db5-aab0-edfab1c2009b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82cedaac-f03e-4db5-aab0-edfab1c2009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d278b81-4434-4688-8f14-fa4fa1d3e192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d278b81-4434-4688-8f14-fa4fa1d3e192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ebe3a50-209d-4d54-ba1a-527b8cac27ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ebe3a50-209d-4d54-ba1a-527b8cac27ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e437c0e-70c2-4427-bd59-96947d5e9589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e437c0e-70c2-4427-bd59-96947d5e9589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e46ba266-7e27-409c-bf56-2393137660be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e46ba266-7e27-409c-bf56-2393137660be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued_42a70866-7d24-4a1e-a462-8a0e09b61a7f" xlink:href="goss-20241231.xsd#goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued_42a70866-7d24-4a1e-a462-8a0e09b61a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7fa4f81e-bdb0-44e6-8126-ba5c16a4257c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_NetIncomeLoss_7fa4f81e-bdb0-44e6-8126-ba5c16a4257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_96db242b-d958-48be-a40f-8da3b167bd92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_96db242b-d958-48be-a40f-8da3b167bd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13eaa3dd-b6e8-4e92-8269-8c1671997f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13eaa3dd-b6e8-4e92-8269-8c1671997f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e7e493c3-0d0f-4ad4-818c-0dc819dd4569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_092686c3-a24d-43d6-af5a-2ec136ae5c16" xlink:to="loc_us-gaap_StockholdersEquity_e7e493c3-0d0f-4ad4-818c-0dc819dd4569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ddccd1eb-594a-4354-9cac-89619cef260d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1e495880-eaef-4785-8aae-0fd8a961d421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ddccd1eb-594a-4354-9cac-89619cef260d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1e495880-eaef-4785-8aae-0fd8a961d421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_a0f2c0b7-f83d-4687-88dd-a87ed846c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ddccd1eb-594a-4354-9cac-89619cef260d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_a0f2c0b7-f83d-4687-88dd-a87ed846c13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="goss-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a610cdc1-1977-4e34-9ff9-fb998990d941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a610cdc1-1977-4e34-9ff9-fb998990d941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7cba1b4e-fcab-4f36-af9d-0dea24e1ac17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a610cdc1-1977-4e34-9ff9-fb998990d941" xlink:to="loc_us-gaap_ProfitLoss_7cba1b4e-fcab-4f36-af9d-0dea24e1ac17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a610cdc1-1977-4e34-9ff9-fb998990d941" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6c0a3728-3c80-4734-9589-2ed0c3b63fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6c0a3728-3c80-4734-9589-2ed0c3b63fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1557b10d-18f4-423d-8687-ce5e92a95ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_us-gaap_ShareBasedCompensation_1557b10d-18f4-423d-8687-ce5e92a95ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses_3dc276c1-cceb-46d5-973a-be73d0ac707b" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_goss_ResearchAndDevelopmentInProcessExpenses_3dc276c1-cceb-46d5-973a-be73d0ac707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d3bd61f4-3398-4f10-9196-d7d5bb73108c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d3bd61f4-3398-4f10-9196-d7d5bb73108c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2dc3b6f1-63eb-4b63-bffb-c03e20552fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2dc3b6f1-63eb-4b63-bffb-c03e20552fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_75c198f5-6666-4d5d-9766-8283a255761a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_75c198f5-6666-4d5d-9766-8283a255761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2605ddd2-d20a-41ef-8774-f80d4e7405d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2605ddd2-d20a-41ef-8774-f80d4e7405d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ec0814b-bc4e-435a-8e5a-5e08b192faa0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_06018962-291f-4b4c-99d0-623ccaa6e6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_06018962-291f-4b4c-99d0-623ccaa6e6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dc3c7551-b45c-4e09-9143-9d6d0c510754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dc3c7551-b45c-4e09-9143-9d6d0c510754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_622968c0-ef47-4208-8588-fdc5804890d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_622968c0-ef47-4208-8588-fdc5804890d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreaseDecreaseInOperatingLeaseLiabilities_5b4caee3-798e-4a15-b97c-8458af8e5832" xlink:href="goss-20241231.xsd#goss_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_goss_IncreaseDecreaseInOperatingLeaseLiabilities_5b4caee3-798e-4a15-b97c-8458af8e5832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_48f8c427-ade2-40bf-a969-e9b18cdc9167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_48f8c427-ade2-40bf-a969-e9b18cdc9167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c30c0c32-098e-4e96-bad5-d9741df68e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c30c0c32-098e-4e96-bad5-d9741df68e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_19939406-44cb-4f3c-b80a-23fefb86240a" xlink:href="goss-20241231.xsd#goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_19939406-44cb-4f3c-b80a-23fefb86240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2ef62b65-0a5a-4b3f-961c-9a28325769c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2ef62b65-0a5a-4b3f-961c-9a28325769c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_25371f09-08ec-4968-a7da-06db28ad35c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_25371f09-08ec-4968-a7da-06db28ad35c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_e69d1870-4b5c-4e4f-a7d4-d034d446e992" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07d8ab9e-16c5-4f25-9d54-24b44d1ceb69" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_e69d1870-4b5c-4e4f-a7d4-d034d446e992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29f3c1a7-8820-4a13-86c5-6fd6786ae3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a610cdc1-1977-4e34-9ff9-fb998990d941" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29f3c1a7-8820-4a13-86c5-6fd6786ae3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11aeedb2-a0fc-4a79-8b54-e1056c4d7b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11aeedb2-a0fc-4a79-8b54-e1056c4d7b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions_b57c1451-6084-4397-9d2c-c7ab3c6a8b01" xlink:href="goss-20241231.xsd#goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11aeedb2-a0fc-4a79-8b54-e1056c4d7b50" xlink:to="loc_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions_b57c1451-6084-4397-9d2c-c7ab3c6a8b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_befc1c81-ba0a-4c24-a16a-29d451e23f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11aeedb2-a0fc-4a79-8b54-e1056c4d7b50" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_befc1c81-ba0a-4c24-a16a-29d451e23f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ProceedsFromMaturityOfMarketableSecurities_0778ff60-295a-44ab-b1ff-12f63010a4b3" xlink:href="goss-20241231.xsd#goss_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11aeedb2-a0fc-4a79-8b54-e1056c4d7b50" xlink:to="loc_goss_ProceedsFromMaturityOfMarketableSecurities_0778ff60-295a-44ab-b1ff-12f63010a4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30d49cb5-cff0-49b2-812d-b1397cdb603e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11aeedb2-a0fc-4a79-8b54-e1056c4d7b50" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30d49cb5-cff0-49b2-812d-b1397cdb603e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4c33da99-723e-4408-b5fe-29271b7c490e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11aeedb2-a0fc-4a79-8b54-e1056c4d7b50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4c33da99-723e-4408-b5fe-29271b7c490e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_bf7ba3d5-0cc0-4c14-b49f-26a2d8b79113" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_bf7ba3d5-0cc0-4c14-b49f-26a2d8b79113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_463ed0b3-c700-4740-bb01-7f90f91ad1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:to="loc_us-gaap_ProceedsFromStockPlans_463ed0b3-c700-4740-bb01-7f90f91ad1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f007a79f-73a0-4aee-88b0-67763bfe4b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f007a79f-73a0-4aee-88b0-67763bfe4b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_71443c94-f0b3-4284-bfde-e0d988a61f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_71443c94-f0b3-4284-bfde-e0d988a61f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e6a59198-c8ad-450c-a519-e8a17183ef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e6a59198-c8ad-450c-a519-e8a17183ef4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b43c99bc-58da-4f2d-a56a-853aa587b6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd67c073-b06d-4d2d-a134-5a89b7d57327" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b43c99bc-58da-4f2d-a56a-853aa587b6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_65832fb2-3374-43fc-a7e7-e760965297be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_65832fb2-3374-43fc-a7e7-e760965297be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44025e36-2559-4667-800d-ddebe831b493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44025e36-2559-4667-800d-ddebe831b493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f228f2df-2fa9-4cb3-a5a1-9eafc493cd99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f228f2df-2fa9-4cb3-a5a1-9eafc493cd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3dc5ff69-3587-448f-91e2-bfb19af51466" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3dc5ff69-3587-448f-91e2-bfb19af51466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_660c8e6f-4128-4eb9-b3a6-0c7b24d8f27e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_660c8e6f-4128-4eb9-b3a6-0c7b24d8f27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_95c52cc5-b012-4025-bf80-36844bd65f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_660c8e6f-4128-4eb9-b3a6-0c7b24d8f27e" xlink:to="loc_us-gaap_InterestPaidNet_95c52cc5-b012-4025-bf80-36844bd65f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1157b511-50e0-41b3-a53d-9b1a3df305fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1c99abf-ce8a-4bf3-aae4-5b2791259bd2" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1157b511-50e0-41b3-a53d-9b1a3df305fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0aaccbff-da25-4ff1-8299-c5f589722ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1157b511-50e0-41b3-a53d-9b1a3df305fc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0aaccbff-da25-4ff1-8299-c5f589722ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax_be226a91-c276-468c-8bbb-60b11be1b1f2" xlink:href="goss-20241231.xsd#goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1157b511-50e0-41b3-a53d-9b1a3df305fc" xlink:to="loc_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax_be226a91-c276-468c-8bbb-60b11be1b1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_137ff696-c19c-4463-a9f5-2f211a63da9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1157b511-50e0-41b3-a53d-9b1a3df305fc" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_137ff696-c19c-4463-a9f5-2f211a63da9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="goss-20241231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6b90b64-97c2-474f-8934-77217b23b5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9a771699-d4e7-403e-bd3e-49c3284d4f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6b90b64-97c2-474f-8934-77217b23b5bc" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9a771699-d4e7-403e-bd3e-49c3284d4f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="goss-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4015395a-1fc6-4057-af0a-47543b4b2bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f6d8d0f-a4ac-4e0c-afa0-3bef13086035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4015395a-1fc6-4057-af0a-47543b4b2bc9" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f6d8d0f-a4ac-4e0c-afa0-3bef13086035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="goss-20241231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f0a16241-4dc5-4dcf-9191-82cecd558f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_51c79755-0392-457f-91fe-16d1888c5369" xlink:href="goss-20241231.xsd#goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f0a16241-4dc5-4dcf-9191-82cecd558f7d" xlink:to="loc_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_51c79755-0392-457f-91fe-16d1888c5369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestments"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_071e3b52-0388-4502-b363-3ac3cd22098f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f7d3bf57-e64b-478e-a6bd-ffcdcfdf3f99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_071e3b52-0388-4502-b363-3ac3cd22098f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f7d3bf57-e64b-478e-a6bd-ffcdcfdf3f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/Indebtedness" xlink:type="simple" xlink:href="goss-20241231.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_082e9e0d-178b-43be-b2b5-9cac83f7b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6c54eee5-e592-4d87-8c92-e431ecd28f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_082e9e0d-178b-43be-b2b5-9cac83f7b3d8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6c54eee5-e592-4d87-8c92-e431ecd28f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsideration" xlink:type="simple" xlink:href="goss-20241231.xsd#LicensesAssetAcquisitionsandContingentConsideration"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsideration" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3ebefe64-7d20-4c46-8508-434b701acd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c5cc1335-e56f-499e-9cd9-d4abb51ca7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3ebefe64-7d20-4c46-8508-434b701acd0a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c5cc1335-e56f-499e-9cd9-d4abb51ca7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9fbafdcf-5b7c-4f70-ad2c-d7daaa3a79c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_bd2e13f1-c56f-4231-bba9-65db9a62c621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9fbafdcf-5b7c-4f70-ad2c-d7daaa3a79c7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_bd2e13f1-c56f-4231-bba9-65db9a62c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="goss-20241231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6c8a8bae-1bdf-4fa7-b988-6ed2b90e1dee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_348c4a16-873c-43f4-b899-d05fbf6c0f88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6c8a8bae-1bdf-4fa7-b988-6ed2b90e1dee" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_348c4a16-873c-43f4-b899-d05fbf6c0f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a19c4af-acfe-45a0-970f-1547004d5d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_eac9b095-c1f6-4921-9738-8ff1363093e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a19c4af-acfe-45a0-970f-1547004d5d63" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_eac9b095-c1f6-4921-9738-8ff1363093e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="goss-20241231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6ea6eb32-b84e-49ff-9174-8ddcc00343ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2f6b2f3d-5e11-401e-893e-6f64cfea23e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6ea6eb32-b84e-49ff-9174-8ddcc00343ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2f6b2f3d-5e11-401e-893e-6f64cfea23e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_21119dc6-9d68-4cc7-aa60-81924936e02a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4f9de597-67e1-47be-9320-3fa08a7c4279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_21119dc6-9d68-4cc7-aa60-81924936e02a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4f9de597-67e1-47be-9320-3fa08a7c4279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContracts" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContracts"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContracts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ff5f97e-e31a-40ce-89b5-0a2de80e2ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_91bf8f90-8f20-440d-be2e-ad9555f40038" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ff5f97e-e31a-40ce-89b5-0a2de80e2ba3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_91bf8f90-8f20-440d-be2e-ad9555f40038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SegmentInformation" xlink:type="simple" xlink:href="goss-20241231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_846b1e14-d81e-4511-97ee-bb5204ceed74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_0e15d4af-0fea-4806-8529-478cd14a528f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_846b1e14-d81e-4511-97ee-bb5204ceed74" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_0e15d4af-0fea-4806-8529-478cd14a528f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/Subsequentevents" xlink:type="simple" xlink:href="goss-20241231.xsd#Subsequentevents"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/Subsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_99a2a1df-a907-4580-9d66-788d6ed1e0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_166637a2-a8ea-49be-8909-e2ce36cd5d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_99a2a1df-a907-4580-9d66-788d6ed1e0c3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_166637a2-a8ea-49be-8909-e2ce36cd5d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="goss-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b1e610fc-888e-4f48-b98d-8eb0a2fe50b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b1e610fc-888e-4f48-b98d-8eb0a2fe50b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7e0fd3bb-dc07-47e6-a909-e158c5267e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_UseOfEstimates_7e0fd3bb-dc07-47e6-a909-e158c5267e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2ce5a18e-6b76-4353-bdf1-1d9b0a571840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2ce5a18e-6b76-4353-bdf1-1d9b0a571840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_630847db-fc6c-44cd-8f59-cde205b2bc22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_630847db-fc6c-44cd-8f59-cde205b2bc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_4cd6f342-fbe1-483e-a02d-048c218174e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_4cd6f342-fbe1-483e-a02d-048c218174e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_bd6e7cc1-fe0c-45ee-83eb-ad473b5b0159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_bd6e7cc1-fe0c-45ee-83eb-ad473b5b0159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3832b22e-aa49-463d-b985-733b8597e71b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3832b22e-aa49-463d-b985-733b8597e71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_5d782e0a-8bcd-4223-977e-b6d9764031d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_DebtPolicyTextBlock_5d782e0a-8bcd-4223-977e-b6d9764031d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9e19acac-22b7-4e80-a770-3ea8df4e9029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9e19acac-22b7-4e80-a770-3ea8df4e9029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2788f197-3e66-416a-b10a-aa1c97b70f05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2788f197-3e66-416a-b10a-aa1c97b70f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_696f1f4e-989c-442f-9c61-24fcd8df8456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_696f1f4e-989c-442f-9c61-24fcd8df8456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_d366c3b5-7c26-4516-aa0e-4b643df314d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_d366c3b5-7c26-4516-aa0e-4b643df314d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_249150ca-8d88-45c1-ab3d-f2b998e87b07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_249150ca-8d88-45c1-ab3d-f2b998e87b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8b83cb6a-4654-438a-96d8-1dc8407e50c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8b83cb6a-4654-438a-96d8-1dc8407e50c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a99e0ac3-5ef4-45bf-a9e9-6897d4535305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a99e0ac3-5ef4-45bf-a9e9-6897d4535305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c4cbb8aa-e4e0-4d76-ae37-b683ffd644d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c4cbb8aa-e4e0-4d76-ae37-b683ffd644d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_407b5b04-a0d7-48de-80da-43e7ddbf5e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_407b5b04-a0d7-48de-80da-43e7ddbf5e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c6aa2c3d-50f4-4726-a3ed-c6e02ce1630e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c6aa2c3d-50f4-4726-a3ed-c6e02ce1630e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a8f93df1-b587-453d-8f08-5c8e334db066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bbf1cf0-04c1-41de-be9f-2c834ae218aa" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a8f93df1-b587-453d-8f08-5c8e334db066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="goss-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18ad7bbc-38c4-4e3f-a2f2-9e8447806477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b06846a3-aab7-4c1c-bd42-4a1aa73c40ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18ad7bbc-38c4-4e3f-a2f2-9e8447806477" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b06846a3-aab7-4c1c-bd42-4a1aa73c40ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="goss-20241231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9cc803d8-dba4-4d68-825b-271ee4392414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d9856b5d-9783-40f9-b6f4-5dfd7ae33eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9cc803d8-dba4-4d68-825b-271ee4392414" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d9856b5d-9783-40f9-b6f4-5dfd7ae33eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dea17926-548b-4e97-a151-9758cd788748" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f125573b-a44c-4d8a-98b1-28a2c2d57b40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dea17926-548b-4e97-a151-9758cd788748" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f125573b-a44c-4d8a-98b1-28a2c2d57b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dfa15190-a858-401d-81dc-35df1971542f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dea17926-548b-4e97-a151-9758cd788748" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dfa15190-a858-401d-81dc-35df1971542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ed241544-8fa0-4565-bcd7-3c1b9156d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dea17926-548b-4e97-a151-9758cd788748" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ed241544-8fa0-4565-bcd7-3c1b9156d9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessTables" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IndebtednessTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_631f7784-58dd-4784-8308-f31cf736d2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ScheduleOfNotesTableTableTextBlock_24379c4e-7992-40dd-8282-ae43b7d08fa0" xlink:href="goss-20241231.xsd#goss_ScheduleOfNotesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_631f7784-58dd-4784-8308-f31cf736d2e2" xlink:to="loc_goss_ScheduleOfNotesTableTableTextBlock_24379c4e-7992-40dd-8282-ae43b7d08fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock_7b1ab648-0a11-4dba-8904-fc4616161dc6" xlink:href="goss-20241231.xsd#goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_631f7784-58dd-4784-8308-f31cf736d2e2" xlink:to="loc_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock_7b1ab648-0a11-4dba-8904-fc4616161dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationTables" xlink:type="simple" xlink:href="goss-20241231.xsd#LicensesAssetAcquisitionsandContingentConsiderationTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_84112106-bd52-44de-8170-e91ecdef2626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock_2254327e-ca06-4e2a-b56f-ddb803373693" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentExpensesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_84112106-bd52-44de-8170-e91ecdef2626" xlink:to="loc_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock_2254327e-ca06-4e2a-b56f-ddb803373693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_15d7f979-f926-4a0c-be20-7aa8545d00de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3b034675-fe00-41a1-a980-28f2c1f5293a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15d7f979-f926-4a0c-be20-7aa8545d00de" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3b034675-fe00-41a1-a980-28f2c1f5293a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8e23d832-d1f8-431d-a6e3-701da0d4802a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15d7f979-f926-4a0c-be20-7aa8545d00de" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8e23d832-d1f8-431d-a6e3-701da0d4802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5e5edd37-fba6-4451-98bb-acbaa688ddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15d7f979-f926-4a0c-be20-7aa8545d00de" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5e5edd37-fba6-4451-98bb-acbaa688ddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9926206e-087b-422c-a9e4-0f610c6841ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15d7f979-f926-4a0c-be20-7aa8545d00de" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9926206e-087b-422c-a9e4-0f610c6841ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_66f00a5d-5396-4ddc-9bad-8491e805bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15d7f979-f926-4a0c-be20-7aa8545d00de" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_66f00a5d-5396-4ddc-9bad-8491e805bafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a1f06d-45fd-40ad-8167-f5d17691a502" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_3c616616-4c37-490a-bc74-55399934bf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a1f06d-45fd-40ad-8167-f5d17691a502" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_3c616616-4c37-490a-bc74-55399934bf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_dc6a03e5-feed-4c73-bd42-d4d0a92a2310" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a1f06d-45fd-40ad-8167-f5d17691a502" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_dc6a03e5-feed-4c73-bd42-d4d0a92a2310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0e359542-00bd-4329-9d0a-888204de0e22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a1f06d-45fd-40ad-8167-f5d17691a502" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0e359542-00bd-4329-9d0a-888204de0e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_d49acf98-ece5-47e1-bbda-51eef2e50102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a1f06d-45fd-40ad-8167-f5d17691a502" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_d49acf98-ece5-47e1-bbda-51eef2e50102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="goss-20241231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f3037ab2-bca4-4cbc-89bf-e79230eb7b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e20d2dd-c9bc-483c-b9c1-fb087705a24a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f3037ab2-bca4-4cbc-89bf-e79230eb7b3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e20d2dd-c9bc-483c-b9c1-fb087705a24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d2e61440-7444-4ba5-b3ca-86a69a8bc3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_fdfc6f2a-4ba0-4485-a656-052de54ed9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d2e61440-7444-4ba5-b3ca-86a69a8bc3f3" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_fdfc6f2a-4ba0-4485-a656-052de54ed9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_88070ce7-cd20-4337-bf32-34e7c07db390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d2e61440-7444-4ba5-b3ca-86a69a8bc3f3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_88070ce7-cd20-4337-bf32-34e7c07db390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsTables" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContractsTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContractsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27a8e059-fa5f-4570-95f4-08cadbefc9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08e4550c-b4c0-4087-9ae5-885775496889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27a8e059-fa5f-4570-95f4-08cadbefc9aa" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_08e4550c-b4c0-4087-9ae5-885775496889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4c2ba19b-75e6-4e20-be79-18321a641524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27a8e059-fa5f-4570-95f4-08cadbefc9aa" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4c2ba19b-75e6-4e20-be79-18321a641524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="goss-20241231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ea97e0d7-c96b-4f90-bfae-84af749c3971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4c72b15b-154d-4870-9414-d9e1c981a182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ea97e0d7-c96b-4f90-bfae-84af749c3971" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4c72b15b-154d-4870-9414-d9e1c981a182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_be9d415b-c091-4829-b7d9-f16b14062259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c8f5fbcd-bb15-4b32-980c-8a04342c38be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be9d415b-c091-4829-b7d9-f16b14062259" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c8f5fbcd-bb15-4b32-980c-8a04342c38be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca6512db-5c66-45d3-8eff-d48812309a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca6512db-5c66-45d3-8eff-d48812309a5c" xlink:to="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:to="loc_srt_RangeAxis_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7ceccf3d-5d4d-42e2-9ce9-550a8af3d801" xlink:to="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b7b0ca8-8933-445d-8377-afa57d12214c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:to="loc_srt_MinimumMember_9b7b0ca8-8933-445d-8377-afa57d12214c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_527ea056-0f02-4ba8-90c1-a0caf49c3834" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ec086cb0-2cdd-4a8e-9b9e-5b8c0beac6e4" xlink:to="loc_srt_MaximumMember_527ea056-0f02-4ba8-90c1-a0caf49c3834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ae9cd89b-aac8-41bb-8738-62de8138c0de" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ae9cd89b-aac8-41bb-8738-62de8138c0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_346e833c-3e39-4877-af42-0f2d24f5cee4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ae9cd89b-aac8-41bb-8738-62de8138c0de" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_346e833c-3e39-4877-af42-0f2d24f5cee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9eff51d9-2e87-46af-a56e-3c9d392c42d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_346e833c-3e39-4877-af42-0f2d24f5cee4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9eff51d9-2e87-46af-a56e-3c9d392c42d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbc5ad68-7ae7-4d85-bcf9-7409e52e4b88" xlink:to="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5a5073c4-5f57-45ae-bad7-2141af7383cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5a5073c4-5f57-45ae-bad7-2141af7383cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_15d329ee-153c-458f-80cb-c7354d529fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b07e01d-0ac1-49da-a9bd-29c8a448987d" xlink:to="loc_us-gaap_RetainedEarningsMember_15d329ee-153c-458f-80cb-c7354d529fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_62bda098-469a-4b91-8b3a-eda0bfd0c3c9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_37f82483-32bf-47ff-9e44-1c5f69aebfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_NumberOfOperatingSegments_37f82483-32bf-47ff-9e44-1c5f69aebfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f9b6a99-b8de-4d72-b312-b23134554b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f9b6a99-b8de-4d72-b312-b23134554b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermConvertibleSeniorNotes_0c4c9282-a4e2-46a9-bea8-2fbd5f23fcd1" xlink:href="goss-20241231.xsd#goss_LongTermConvertibleSeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_goss_LongTermConvertibleSeniorNotes_0c4c9282-a4e2-46a9-bea8-2fbd5f23fcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_25afcdfb-92b6-44e5-bc2b-17574e8d643e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_25afcdfb-92b6-44e5-bc2b-17574e8d643e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5769d47f-2056-4b32-bbef-536019dbf670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a158e26f-1adc-44ae-a75c-c925e0bb58a6" xlink:to="loc_us-gaap_StockholdersEquity_5769d47f-2056-4b32-bbef-536019dbf670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_488f22b7-48f8-4cb4-b177-04d8ede367ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c787c5b6-5243-4c65-b98c-f56079501dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_488f22b7-48f8-4cb4-b177-04d8ede367ee" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c787c5b6-5243-4c65-b98c-f56079501dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c787c5b6-5243-4c65-b98c-f56079501dbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffb79a12-17f7-4c96-a91f-4a594cb0bc4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_b825d98b-0383-4f1d-bc41-b51966a9abb9" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_b825d98b-0383-4f1d-bc41-b51966a9abb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f186c2e4-bf15-4393-94fe-1c3b2012ca77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f186c2e4-bf15-4393-94fe-1c3b2012ca77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_3f5be157-0755-4c22-a77f-ae2dfaaac7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_StockOptionMember_3f5be157-0755-4c22-a77f-ae2dfaaac7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ff172b84-9fe2-4e99-a482-c0c2d0aacafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_WarrantMember_ff172b84-9fe2-4e99-a482-c0c2d0aacafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fa886b3d-324c-43e4-82a2-8a0cc78f8765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_66afc9b6-9760-4562-8015-3767211d71a3" xlink:to="loc_us-gaap_RestrictedStockMember_fa886b3d-324c-43e4-82a2-8a0cc78f8765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_861a92e7-7a3e-4733-83f5-2d7578f4e8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c787c5b6-5243-4c65-b98c-f56079501dbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_861a92e7-7a3e-4733-83f5-2d7578f4e8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7258a3ce-6660-4448-9765-ad229718edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_861a92e7-7a3e-4733-83f5-2d7578f4e8d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7258a3ce-6660-4448-9765-ad229718edfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_05f4f2eb-b3a5-4089-b29d-e3be4fd9bdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_05f4f2eb-b3a5-4089-b29d-e3be4fd9bdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e397d004-5763-4f45-a60f-d7bb29092dce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e397d004-5763-4f45-a60f-d7bb29092dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedConsultingFeesCurrent_7bd3d374-1235-4852-b9d1-8dded4a944c1" xlink:href="goss-20241231.xsd#goss_AccruedConsultingFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_goss_AccruedConsultingFeesCurrent_7bd3d374-1235-4852-b9d1-8dded4a944c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_6354512f-2587-4400-b5b2-ad02f176b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_us-gaap_InterestPayableCurrent_6354512f-2587-4400-b5b2-ad02f176b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedLegalFeesCurrent_e90ca370-7a0c-410b-8aaf-3e156b323b34" xlink:href="goss-20241231.xsd#goss_AccruedLegalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_goss_AccruedLegalFeesCurrent_e90ca370-7a0c-410b-8aaf-3e156b323b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedInProcessResearchAndDevelopmentCurrent_baaa9295-1556-4d14-887e-e6dbc102f6ff" xlink:href="goss-20241231.xsd#goss_AccruedInProcessResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_goss_AccruedInProcessResearchAndDevelopmentCurrent_baaa9295-1556-4d14-887e-e6dbc102f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccruedAccountingFeesCurrent_75366277-66c3-4a5f-92ee-9ab057001afa" xlink:href="goss-20241231.xsd#goss_AccruedAccountingFeesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_goss_AccruedAccountingFeesCurrent_75366277-66c3-4a5f-92ee-9ab057001afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3331fb97-c4a5-4125-b05d-98408b997af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3331fb97-c4a5-4125-b05d-98408b997af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7f1462f2-f659-4735-badf-1c1e540dffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7f1462f2-f659-4735-badf-1c1e540dffb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6567abda-400c-4222-bdc6-4f0df41f8e29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba0ab0c6-75aa-461a-b304-c38c51e19d70" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6567abda-400c-4222-bdc6-4f0df41f8e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7e24bcc3-031c-4191-99b5-0e12db52d740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7e24bcc3-031c-4191-99b5-0e12db52d740" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a318f8bf-fe8b-488d-8616-b402af15c2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a318f8bf-fe8b-488d-8616-b402af15c2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16b8da70-351e-48ce-8a6c-34ca32b4f1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a318f8bf-fe8b-488d-8616-b402af15c2f3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16b8da70-351e-48ce-8a6c-34ca32b4f1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8e49ab69-3b95-4d33-b898-6f438353e387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_16b8da70-351e-48ce-8a6c-34ca32b4f1d4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8e49ab69-3b95-4d33-b898-6f438353e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_651ca565-254b-4d8a-bb39-0b454c97e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_651ca565-254b-4d8a-bb39-0b454c97e3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_651ca565-254b-4d8a-bb39-0b454c97e3d3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_89b52b00-fc1a-4792-8d20-be3472b48179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_89b52b00-fc1a-4792-8d20-be3472b48179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_61986bca-3d0a-4e5e-b3fb-6c8114cac00e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_61986bca-3d0a-4e5e-b3fb-6c8114cac00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b064444e-4aa0-49dc-9371-aabf6422b9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da74f0f9-c5ca-4b4d-891a-d4569ebc2542" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b064444e-4aa0-49dc-9371-aabf6422b9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_de5e470a-a62c-4295-aa6f-6e69914d0ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_de5e470a-a62c-4295-aa6f-6e69914d0ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_de5e470a-a62c-4295-aa6f-6e69914d0ffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2a87ab8a-f583-48cd-8fda-05dc52e39e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2a87ab8a-f583-48cd-8fda-05dc52e39e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_73e47dbf-9c8b-4da5-a37f-6d14953350e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_73e47dbf-9c8b-4da5-a37f-6d14953350e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2ac910ba-216f-4636-a5c6-08c824b24d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_CommercialPaperMember_2ac910ba-216f-4636-a5c6-08c824b24d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9c8209d3-0247-41f7-923e-9b74b4a97071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f54d89d1-55ef-40db-b92f-d91047fa52e1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9c8209d3-0247-41f7-923e-9b74b4a97071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d5a4862-5362-4405-8d30-298baeb2a8c8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c831f9e-a6eb-45c1-8f6a-dd0fe10f24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c831f9e-a6eb-45c1-8f6a-dd0fe10f24fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c4481000-6047-4bd5-a010-3db2628e7493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c4481000-6047-4bd5-a010-3db2628e7493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities_a6c9cd9f-4a58-47dd-9d3b-6e7bb73610d8" xlink:href="goss-20241231.xsd#goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3311f45c-e47a-49c6-bc36-7dade4fab086" xlink:to="loc_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities_a6c9cd9f-4a58-47dd-9d3b-6e7bb73610d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fcd72d9a-3a55-4015-bae7-3ea418da2ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fcd72d9a-3a55-4015-bae7-3ea418da2ce5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0094b449-f2e5-4524-a9dc-3281e0d8c179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0094b449-f2e5-4524-a9dc-3281e0d8c179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23f6852d-51e0-4860-af50-11abfbe8e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0094b449-f2e5-4524-a9dc-3281e0d8c179" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23f6852d-51e0-4860-af50-11abfbe8e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_47a72a02-64db-46ec-b72e-e554e4de5a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23f6852d-51e0-4860-af50-11abfbe8e11f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_47a72a02-64db-46ec-b72e-e554e4de5a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6815a940-552d-4cc5-9df0-c60d83c98b74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6815a940-552d-4cc5-9df0-c60d83c98b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e24ce8c5-7a1b-4035-945f-5368e53c598e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6815a940-552d-4cc5-9df0-c60d83c98b74" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e24ce8c5-7a1b-4035-945f-5368e53c598e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_47fd755b-1f1c-420f-935d-8b11cbcc8aa7" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e24ce8c5-7a1b-4035-945f-5368e53c598e" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_47fd755b-1f1c-420f-935d-8b11cbcc8aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_da450245-4d54-4267-b67d-6e80216bd75c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_35ec5a5a-acde-4d78-b2ed-b7ababf92a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:to="loc_us-gaap_InterestReceivableCurrent_35ec5a5a-acde-4d78-b2ed-b7ababf92a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ac555157-2441-46ac-945e-a57545715787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ac555157-2441-46ac-945e-a57545715787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_16e88153-e835-4dfd-a2ba-096aa55e00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72df5ef8-6440-4638-b5eb-1561ebf3916c" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_16e88153-e835-4dfd-a2ba-096aa55e00e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8e6859a1-0bbb-4fa2-ad91-69a9c5d741f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a6b9c3-b80b-41dd-bb76-48351476167c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8e6859a1-0bbb-4fa2-ad91-69a9c5d741f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a6b9c3-b80b-41dd-bb76-48351476167c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d540c9b4-1c5c-4d7e-9179-d761f63c4a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a6b9c3-b80b-41dd-bb76-48351476167c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d540c9b4-1c5c-4d7e-9179-d761f63c4a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d540c9b4-1c5c-4d7e-9179-d761f63c4a33" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8cf2075c-f1c7-426d-b55d-e3f03a743a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8cf2075c-f1c7-426d-b55d-e3f03a743a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_35f0dce7-77c2-4972-96f5-c9f22fcf0f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_35f0dce7-77c2-4972-96f5-c9f22fcf0f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_addf9044-b744-44a2-b6d8-6b47701a006b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8303e52a-831f-451c-96ec-01fa6126324c" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_addf9044-b744-44a2-b6d8-6b47701a006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a6b9c3-b80b-41dd-bb76-48351476167c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_212c6f74-1716-42ff-aa73-0239b20d60fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_212c6f74-1716-42ff-aa73-0239b20d60fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3fd4d25f-950c-430e-97bc-168f30c7aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3fd4d25f-950c-430e-97bc-168f30c7aad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e9ca2fa-beaa-4b29-b2aa-4c2b4ab348da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e9ca2fa-beaa-4b29-b2aa-4c2b4ab348da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96b1743e-ef38-40ea-8b5e-2817669c3f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96b1743e-ef38-40ea-8b5e-2817669c3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d3913461-c017-4398-83a6-bf997017e3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c2223ef-3064-4068-a050-c7d3ae2dfe53" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d3913461-c017-4398-83a6-bf997017e3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9c812a96-d916-46b2-a8a2-1453bc2be255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_93bc5899-5dbc-4531-ad55-22cfb53913f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9c812a96-d916-46b2-a8a2-1453bc2be255" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_93bc5899-5dbc-4531-ad55-22cfb53913f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue_208379f8-6279-46f1-8510-8e4cc1606235" xlink:href="goss-20241231.xsd#goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9c812a96-d916-46b2-a8a2-1453bc2be255" xlink:to="loc_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue_208379f8-6279-46f1-8510-8e4cc1606235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a000419c-c496-453a-89ad-42036081ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9c812a96-d916-46b2-a8a2-1453bc2be255" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a000419c-c496-453a-89ad-42036081ad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f75ea79-72aa-44ed-8a47-398edcf1382b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f75ea79-72aa-44ed-8a47-398edcf1382b" xlink:to="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7226a704-e032-4661-a8e2-2301076dcfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_CreditFacilityAxis_7226a704-e032-4661-a8e2-2301076dcfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0a43e699-6981-46f0-b7b4-650a095062f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7226a704-e032-4661-a8e2-2301076dcfc1" xlink:to="loc_us-gaap_CreditFacilityDomain_0a43e699-6981-46f0-b7b4-650a095062f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0a8e5375-7901-4d09-980a-13634060eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0a43e699-6981-46f0-b7b4-650a095062f4" xlink:to="loc_us-gaap_LineOfCreditMember_0a8e5375-7901-4d09-980a-13634060eceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a9103245-b3b5-49b4-91d5-c657b90182d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a9103245-b3b5-49b4-91d5-c657b90182d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a9103245-b3b5-49b4-91d5-c657b90182d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TermLoanMember_f78c1bdd-6568-44e7-b809-093937b5b122" xlink:href="goss-20241231.xsd#goss_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:to="loc_goss_TermLoanMember_f78c1bdd-6568-44e7-b809-093937b5b122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_1917f96f-4fbb-413c-b28b-2c78750dce11" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e1323f9-cf61-4977-997f-957bdda7d71d" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_1917f96f-4fbb-413c-b28b-2c78750dce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9fb7098e-5727-4a4e-8737-029f28abee08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_VestingAxis_9fb7098e-5727-4a4e-8737-029f28abee08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9fb7098e-5727-4a4e-8737-029f28abee08" xlink:to="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TrancheTwoMember_5bd982d0-2898-47dd-83b2-67d964be12c8" xlink:href="goss-20241231.xsd#goss_TrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:to="loc_goss_TrancheTwoMember_5bd982d0-2898-47dd-83b2-67d964be12c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TrancheOneMember_e6a19b01-210a-4bcf-abcd-27b88bd4f1ec" xlink:href="goss-20241231.xsd#goss_TrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f8787159-7a1c-4a04-bf4b-9412ac9716bd" xlink:to="loc_goss_TrancheOneMember_e6a19b01-210a-4bcf-abcd-27b88bd4f1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d56305d2-87f0-45d9-af63-30e707692c5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_srt_RangeAxis_d56305d2-87f0-45d9-af63-30e707692c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d56305d2-87f0-45d9-af63-30e707692c5c" xlink:to="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_496d8b88-0647-4083-97ca-a09b2d90901b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:to="loc_srt_MinimumMember_496d8b88-0647-4083-97ca-a09b2d90901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3128d6aa-5035-497c-80cc-7dd6046f2eeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e651de05-c376-4a35-9601-ae6506fde12e" xlink:to="loc_srt_MaximumMember_3128d6aa-5035-497c-80cc-7dd6046f2eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_46553fd6-0ccf-4c29-ad87-9299c7add8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_46553fd6-0ccf-4c29-ad87-9299c7add8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_46553fd6-0ccf-4c29-ad87-9299c7add8c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OneHundredThirtyPercentApplicableConversionPriceMember_6480e4aa-75e9-40ca-b961-ededa1d25b15" xlink:href="goss-20241231.xsd#goss_OneHundredThirtyPercentApplicableConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:to="loc_goss_OneHundredThirtyPercentApplicableConversionPriceMember_6480e4aa-75e9-40ca-b961-ededa1d25b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NinetyEightPercentApplicableConversionPriceMember_4f2c0132-b080-4d36-bbfb-c3176de6e368" xlink:href="goss-20241231.xsd#goss_NinetyEightPercentApplicableConversionPriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d0ad6035-5eb2-4394-9f51-7c988d919bbc" xlink:to="loc_goss_NinetyEightPercentApplicableConversionPriceMember_4f2c0132-b080-4d36-bbfb-c3176de6e368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_713bc8d0-d94a-48b2-b481-40274acd66e2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_de945b7c-ea65-4e49-b7f6-723dd72df635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_de945b7c-ea65-4e49-b7f6-723dd72df635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_dc595cd0-6d8f-4450-9a47-770aa5806173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_dc595cd0-6d8f-4450-9a47-770aa5806173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_90c360d1-ae5a-49e9-9916-521c5604a05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_90c360d1-ae5a-49e9-9916-521c5604a05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfAdditionalTranches_25d3eb00-193a-4c5a-a3d5-1b0c519730cb" xlink:href="goss-20241231.xsd#goss_NumberOfAdditionalTranches"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_NumberOfAdditionalTranches_25d3eb00-193a-4c5a-a3d5-1b0c519730cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_57600822-07a2-40fd-b660-3d37a749261e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_57600822-07a2-40fd-b660-3d37a749261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_cac08c0d-5896-4a3c-a7bf-c0a269788549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_LineOfCredit_cac08c0d-5896-4a3c-a7bf-c0a269788549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_861350d2-9efc-49e6-93c9-81072f756d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_861350d2-9efc-49e6-93c9-81072f756d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentAggregatePrincipalAmount_34c6a6e8-be6b-434f-bf37-e29abe5c13d6" xlink:href="goss-20241231.xsd#goss_DebtInstrumentAggregatePrincipalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentAggregatePrincipalAmount_34c6a6e8-be6b-434f-bf37-e29abe5c13d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_52a9fcaa-0dba-4783-a74d-7538bf368c58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_52a9fcaa-0dba-4783-a74d-7538bf368c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5db4492c-c0a6-4d3d-9054-6871abd5a2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5db4492c-c0a6-4d3d-9054-6871abd5a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27df90ee-8100-43ee-89a2-6cf99b80ae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27df90ee-8100-43ee-89a2-6cf99b80ae6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentConvertibleConversionPricePercentage_13e326a8-4510-4479-a265-ee0137143e51" xlink:href="goss-20241231.xsd#goss_DebtInstrumentConvertibleConversionPricePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentConvertibleConversionPricePercentage_13e326a8-4510-4479-a265-ee0137143e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_05163d5f-53eb-4fb2-b171-d31164b648d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_05163d5f-53eb-4fb2-b171-d31164b648d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage_34757c3a-e79a-49a9-a104-ccb2682a9c87" xlink:href="goss-20241231.xsd#goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage_34757c3a-e79a-49a9-a104-ccb2682a9c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DebtInstrumentRedemptionTermThresholdTradingDays_1f1c9ef5-66d4-4e66-840f-5f59760edd4d" xlink:href="goss-20241231.xsd#goss_DebtInstrumentRedemptionTermThresholdTradingDays"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_DebtInstrumentRedemptionTermThresholdTradingDays_1f1c9ef5-66d4-4e66-840f-5f59760edd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2a25074a-5ab2-4659-8275-d61d5af06664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2a25074a-5ab2-4659-8275-d61d5af06664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes_ab3175ce-f705-4763-a6fa-ab02602dd19c" xlink:href="goss-20241231.xsd#goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes_ab3175ce-f705-4763-a6fa-ab02602dd19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LongTermDebtPercentageInAggregatePrincipalAmount_bc147d90-e85d-4f58-87cd-0fdee9f8f87f" xlink:href="goss-20241231.xsd#goss_LongTermDebtPercentageInAggregatePrincipalAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_goss_LongTermDebtPercentageInAggregatePrincipalAmount_bc147d90-e85d-4f58-87cd-0fdee9f8f87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cbbb0786-ae71-43ae-a73c-858e4a52d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ae8f4b6d-03b9-4642-87e2-324cb3e55bd9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cbbb0786-ae71-43ae-a73c-858e4a52d5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fc172494-faad-4c21-a71e-94471a9ecfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_72fdc781-836a-4a71-9cf1-7fc1148e5ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc172494-faad-4c21-a71e-94471a9ecfc4" xlink:to="loc_us-gaap_DebtInstrumentTable_72fdc781-836a-4a71-9cf1-7fc1148e5ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_12fb143e-053a-47ec-b4f5-d2a7d645d182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72fdc781-836a-4a71-9cf1-7fc1148e5ab2" xlink:to="loc_us-gaap_DebtInstrumentAxis_12fb143e-053a-47ec-b4f5-d2a7d645d182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80f97819-d080-4aac-a83f-82a52884624b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_12fb143e-053a-47ec-b4f5-d2a7d645d182" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80f97819-d080-4aac-a83f-82a52884624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_fe283aeb-5f71-419d-8f41-b89673e4b12f" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80f97819-d080-4aac-a83f-82a52884624b" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_fe283aeb-5f71-419d-8f41-b89673e4b12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72fdc781-836a-4a71-9cf1-7fc1148e5ab2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_630cc117-faa9-47be-a782-98da6b2fad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_630cc117-faa9-47be-a782-98da6b2fad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_136a3e3a-04ee-4d84-a70b-1d2d140cbea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_136a3e3a-04ee-4d84-a70b-1d2d140cbea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_8892d470-8238-4fff-8331-d04577450929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_8892d470-8238-4fff-8331-d04577450929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b3685811-e030-4fbf-bdf8-e6e31d361053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1b3e8499-b84b-4a22-94bc-e1fa19e678ae" xlink:to="loc_us-gaap_LongTermDebt_b3685811-e030-4fbf-bdf8-e6e31d361053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IndebtednessScheduleofInterestExpenseRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f77312d3-0956-4f72-bcdb-56d9fff36d88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0ba6550e-81af-466f-92c0-a7878bb56bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f77312d3-0956-4f72-bcdb-56d9fff36d88" xlink:to="loc_us-gaap_DebtInstrumentTable_0ba6550e-81af-466f-92c0-a7878bb56bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ba6550e-81af-466f-92c0-a7878bb56bae" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8e55897b-72c8-4478-9464-9a4b8d07e694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ee5b9b9-f5a6-4b19-8b6d-904c20b150f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8e55897b-72c8-4478-9464-9a4b8d07e694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentySevenNotesMember_870ad489-3e0d-4069-bccf-834c640a6a4c" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentySevenNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8e55897b-72c8-4478-9464-9a4b8d07e694" xlink:to="loc_goss_TwoThousandTwentySevenNotesMember_870ad489-3e0d-4069-bccf-834c640a6a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ba6550e-81af-466f-92c0-a7878bb56bae" xlink:to="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractualInterestExpense_89dd75ad-26cf-4a0d-8af9-2ac251ea541c" xlink:href="goss-20241231.xsd#goss_ContractualInterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_goss_ContractualInterestExpense_89dd75ad-26cf-4a0d-8af9-2ac251ea541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6ae74107-95dd-493f-a888-acb76cd0ed14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6ae74107-95dd-493f-a888-acb76cd0ed14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b9e091ec-01d1-4340-82bf-e17d1964bd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b9e091ec-01d1-4340-82bf-e17d1964bd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_42641332-fcf6-4be9-bf06-8fe7588af9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08862a6e-fdb4-42eb-a1af-ed9a390a2f8f" xlink:to="loc_us-gaap_InterestExpenseDebt_42641332-fcf6-4be9-bf06-8fe7588af9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d69b3347-3840-409b-b0e4-063bf265e2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d69b3347-3840-409b-b0e4-063bf265e2c5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca22613e-23bd-4df1-b8e2-0f64d98974e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3a3ff214-47b0-4ea4-9446-d6bbba5b26e9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca22613e-23bd-4df1-b8e2-0f64d98974e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PulmokineIncMember_b2f7ed95-eaa8-4585-b70e-dabd85a9dd49" xlink:href="goss-20241231.xsd#goss_PulmokineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca22613e-23bd-4df1-b8e2-0f64d98974e5" xlink:to="loc_goss_PulmokineIncMember_b2f7ed95-eaa8-4585-b70e-dabd85a9dd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_438f2ace-99de-423c-b420-ea31728c7acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c5f20703-f6cc-4c28-bb9b-b3048a8ec0ba" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_438f2ace-99de-423c-b420-ea31728c7acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LicenseAgreementMember_20908a39-b6d8-4205-be73-c7eefb911fe1" xlink:href="goss-20241231.xsd#goss_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_438f2ace-99de-423c-b420-ea31728c7acc" xlink:to="loc_goss_LicenseAgreementMember_20908a39-b6d8-4205-be73-c7eefb911fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2e8da18e-ddd0-4dd4-bb88-379fb5528547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2e8da18e-ddd0-4dd4-bb88-379fb5528547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18788e76-f3e9-4df6-8422-02ef91669ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2e8da18e-ddd0-4dd4-bb88-379fb5528547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18788e76-f3e9-4df6-8422-02ef91669ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9b4ac02d-6b43-48f6-98be-5e4b94e71a29" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentSeralutinibMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18788e76-f3e9-4df6-8422-02ef91669ac7" xlink:to="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9b4ac02d-6b43-48f6-98be-5e4b94e71a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe2e50b0-2201-4836-a320-ec782143b7a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_srt_RangeAxis_fe2e50b0-2201-4836-a320-ec782143b7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8548e10-08a9-4f85-9ba1-5cea472c2842" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fe2e50b0-2201-4836-a320-ec782143b7a7" xlink:to="loc_srt_RangeMember_a8548e10-08a9-4f85-9ba1-5cea472c2842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c1d902f-d10c-42d9-9055-368f8e442a54" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a8548e10-08a9-4f85-9ba1-5cea472c2842" xlink:to="loc_srt_MaximumMember_0c1d902f-d10c-42d9-9055-368f8e442a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2022293b-b8f5-437d-bdc1-50e71ab7e9a5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ProductLicenseTerm_6fd6f540-f57a-4394-8bb0-62046b32ce35" xlink:href="goss-20241231.xsd#goss_ProductLicenseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_ProductLicenseTerm_6fd6f540-f57a-4394-8bb0-62046b32ce35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable_94d5ca53-6425-40bd-86b5-2ec44e461e87" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable_94d5ca53-6425-40bd-86b5-2ec44e461e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable_06fa3511-71fe-4d47-8d76-0846af0a2797" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable_06fa3511-71fe-4d47-8d76-0846af0a2797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable_e65de729-66cd-4c6a-a84c-1c5fa28f72c8" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable_e65de729-66cd-4c6a-a84c-1c5fa28f72c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable_881399dd-cb75-45d7-a6e2-d37509665b43" xlink:href="goss-20241231.xsd#goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable_881399dd-cb75-45d7-a6e2-d37509665b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_UpfrontPayment_40123105-8765-4fd0-9a3c-17c682ec61f9" xlink:href="goss-20241231.xsd#goss_UpfrontPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_goss_UpfrontPayment_40123105-8765-4fd0-9a3c-17c682ec61f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_bddc9fe9-0533-4ed4-8c8e-0093cf0941b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a3b97b3d-adf5-4f3a-9c26-e4d2941bfe49" xlink:to="loc_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_bddc9fe9-0533-4ed4-8c8e-0093cf0941b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b19779c2-6bb0-4959-97b7-76a800104bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_f4b26e55-b6e4-42c5-9a47-183a3bb0b752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b19779c2-6bb0-4959-97b7-76a800104bdd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_f4b26e55-b6e4-42c5-9a47-183a3bb0b752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bacaa006-6566-457d-9136-9219da145c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_f4b26e55-b6e4-42c5-9a47-183a3bb0b752" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bacaa006-6566-457d-9136-9219da145c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bacaa006-6566-457d-9136-9219da145c49" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9e56a921-cda3-4d4d-9b60-75bfc7ff7290" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentSeralutinibMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:to="loc_goss_InProcessResearchAndDevelopmentSeralutinibMember_9e56a921-cda3-4d4d-9b60-75bfc7ff7290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember_d9aadfed-cf02-42ca-8579-f9a10f514eb4" xlink:href="goss-20241231.xsd#goss_InProcessResearchAndDevelopmentTerminatedProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_259bdad2-277e-4205-a13b-0131b0231b7f" xlink:to="loc_goss_InProcessResearchAndDevelopmentTerminatedProgramsMember_d9aadfed-cf02-42ca-8579-f9a10f514eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_af750692-dc8f-450a-8aae-ce096bde3d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_f4b26e55-b6e4-42c5-9a47-183a3bb0b752" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_af750692-dc8f-450a-8aae-ce096bde3d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentInProcessExpenses_711de1a2-8bc0-4a90-9128-e2f2febd456f" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentInProcessExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_af750692-dc8f-450a-8aae-ce096bde3d0c" xlink:to="loc_goss_ResearchAndDevelopmentInProcessExpenses_711de1a2-8bc0-4a90-9128-e2f2febd456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_88822693-37fa-4a78-955d-424a0841311f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_be87cbc2-c421-45ab-8d5f-14e2dd2bd84a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88822693-37fa-4a78-955d-424a0841311f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_be87cbc2-c421-45ab-8d5f-14e2dd2bd84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e67d3aef-6f66-4936-885f-96ab4bd1b73a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88822693-37fa-4a78-955d-424a0841311f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e67d3aef-6f66-4936-885f-96ab4bd1b73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_6fd93493-bec0-4a79-b340-4a746b793bd8" xlink:href="goss-20241231.xsd#goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88822693-37fa-4a78-955d-424a0841311f" xlink:to="loc_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes_6fd93493-bec0-4a79-b340-4a746b793bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5d58a89d-0b0d-4c3a-a56a-edefd07e0ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2831fe9-b859-47a5-a87f-646fe4335e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d58a89d-0b0d-4c3a-a56a-edefd07e0ae8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2831fe9-b859-47a5-a87f-646fe4335e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9d417c40-1c81-45d1-a21b-7bec9c75fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2831fe9-b859-47a5-a87f-646fe4335e50" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9d417c40-1c81-45d1-a21b-7bec9c75fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e89eefea-99ca-4975-85f7-391ee34e49ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a2831fe9-b859-47a5-a87f-646fe4335e50" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e89eefea-99ca-4975-85f7-391ee34e49ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_fb823bb6-1e09-4e0b-af76-57af7bb929f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d58a89d-0b0d-4c3a-a56a-edefd07e0ae8" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_fb823bb6-1e09-4e0b-af76-57af7bb929f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_77bfbcac-b1eb-4eae-b226-e610dcfcd4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77bfbcac-b1eb-4eae-b226-e610dcfcd4ac" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0add2d89-918b-43a8-81b5-ab4a7452da43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0add2d89-918b-43a8-81b5-ab4a7452da43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0add2d89-918b-43a8-81b5-ab4a7452da43" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_d9fc2389-7770-4fb9-bf33-b1d8b72caffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:to="loc_us-gaap_DomesticCountryMember_d9fc2389-7770-4fb9-bf33-b1d8b72caffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_37caeefa-59f5-4bc4-bd20-a86e50ba6bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_37caeefa-59f5-4bc4-bd20-a86e50ba6bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_b71b9b1f-4add-4d49-94d1-134a4f4b9b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7981430-b548-4bb6-aae8-0b594006e2de" xlink:to="loc_us-gaap_ForeignCountryMember_b71b9b1f-4add-4d49-94d1-134a4f4b9b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d49d228-21b7-4f17-8f9c-5035c8e83c03" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:to="loc_srt_RangeAxis_5d49d228-21b7-4f17-8f9c-5035c8e83c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_365ab6de-065e-4e17-b0b3-bb75a5079078" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d49d228-21b7-4f17-8f9c-5035c8e83c03" xlink:to="loc_srt_RangeMember_365ab6de-065e-4e17-b0b3-bb75a5079078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69e6d8dd-d3c2-49cf-ac4d-3dc24c0dedc8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_365ab6de-065e-4e17-b0b3-bb75a5079078" xlink:to="loc_srt_MaximumMember_69e6d8dd-d3c2-49cf-ac4d-3dc24c0dedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dc81e52b-aab2-43b5-8843-02b6d6550115" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_58c833dc-a935-4c53-a13f-a26ea07ade47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_58c833dc-a935-4c53-a13f-a26ea07ade47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_202c0937-d0ce-4b81-885f-cb4f3c984a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_us-gaap_OperatingLossCarryforwards_202c0937-d0ce-4b81-885f-cb4f3c984a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage_6b565b5f-c536-4e00-ac82-3aa9fe84742a" xlink:href="goss-20241231.xsd#goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage_6b565b5f-c536-4e00-ac82-3aa9fe84742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation_ec82a0e4-d30b-41e0-af74-d1d531f46f84" xlink:href="goss-20241231.xsd#goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation_ec82a0e4-d30b-41e0-af74-d1d531f46f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_cefb9530-76f5-422d-b435-4e6e75f94dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_cefb9530-76f5-422d-b435-4e6e75f94dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TaxCreditCarryforwardsReductionDueToMerger_3f0877b1-fdf1-4687-a5c8-f0e93e6ed885" xlink:href="goss-20241231.xsd#goss_TaxCreditCarryforwardsReductionDueToMerger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_TaxCreditCarryforwardsReductionDueToMerger_3f0877b1-fdf1-4687-a5c8-f0e93e6ed885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_c1d3ddfe-9bc4-48f4-a531-af33f513abe3" xlink:href="goss-20241231.xsd#goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c6aba9ed-0c01-45e7-9c58-90a0a39bf764" xlink:to="loc_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_c1d3ddfe-9bc4-48f4-a531-af33f513abe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_72f30605-ac79-48d4-add1-00c50489c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72f30605-ac79-48d4-add1-00c50489c4a3" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_658d3f5e-304a-4fe2-836a-844b24bbce27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_658d3f5e-304a-4fe2-836a-844b24bbce27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_9d311653-8186-449d-9b5b-eef964998d65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_9d311653-8186-449d-9b5b-eef964998d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_7c94f9fb-4aae-4995-af80-6be599244781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_7c94f9fb-4aae-4995-af80-6be599244781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_448850d5-3e5e-492c-b490-0a4b3eafe4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_448850d5-3e5e-492c-b490-0a4b3eafe4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6e4e64b6-a12b-40e0-bc7e-a262ad607a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6e4e64b6-a12b-40e0-bc7e-a262ad607a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_36644e86-d182-4229-a0d7-bfddb285bfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_36644e86-d182-4229-a0d7-bfddb285bfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DeferredTaxAssetsLeaseLiability_af215486-3173-49a0-9fcc-e8d4a07cdd4e" xlink:href="goss-20241231.xsd#goss_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_goss_DeferredTaxAssetsLeaseLiability_af215486-3173-49a0-9fcc-e8d4a07cdd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_78c0c115-cdc0-4dfb-bb6d-075876f289ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_78c0c115-cdc0-4dfb-bb6d-075876f289ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_24a1f1dc-6465-4699-9093-f3e9ff7faaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_24a1f1dc-6465-4699-9093-f3e9ff7faaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_34b896ce-601c-443e-a6d6-17b4e279d680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_34b896ce-601c-443e-a6d6-17b4e279d680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fbc9dac0-56cd-4685-b08e-8ed45c5aee25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_dcf1b916-e347-4c44-8315-7f32ab201f15" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fbc9dac0-56cd-4685-b08e-8ed45c5aee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_9edfc367-e19b-4d31-bc32-06faa37adf60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72f30605-ac79-48d4-add1-00c50489c4a3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_9edfc367-e19b-4d31-bc32-06faa37adf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_87564850-0457-49f6-96d5-a4257048b158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_9edfc367-e19b-4d31-bc32-06faa37adf60" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_87564850-0457-49f6-96d5-a4257048b158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_DeferredTaxLiabilitiesRightOfUseAsset_572d8dc4-6191-4111-b49b-d1ee542b3eef" xlink:href="goss-20241231.xsd#goss_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_9edfc367-e19b-4d31-bc32-06faa37adf60" xlink:to="loc_goss_DeferredTaxLiabilitiesRightOfUseAsset_572d8dc4-6191-4111-b49b-d1ee542b3eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5bab8ea0-2375-4c3a-bea0-220504626d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_9edfc367-e19b-4d31-bc32-06faa37adf60" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5bab8ea0-2375-4c3a-bea0-220504626d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_52ea403e-b623-4ef8-9edb-0656711ee2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_9edfc367-e19b-4d31-bc32-06faa37adf60" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_52ea403e-b623-4ef8-9edb-0656711ee2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5037691a-f1ec-4005-b147-66f1e6e15673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72f30605-ac79-48d4-add1-00c50489c4a3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5037691a-f1ec-4005-b147-66f1e6e15673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_67f0ac51-bd70-485f-b222-e2639d76535c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72f30605-ac79-48d4-add1-00c50489c4a3" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_67f0ac51-bd70-485f-b222-e2639d76535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_210dc611-21c0-45d6-bbf8-8bba51d9a11b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_210dc611-21c0-45d6-bbf8-8bba51d9a11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7235a6a1-73d9-45bc-8ce4-cf1cf4a070ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7235a6a1-73d9-45bc-8ce4-cf1cf4a070ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_53d3d058-638a-4878-b6d3-402d432a3865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_53d3d058-638a-4878-b6d3-402d432a3865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_98d3cb75-c3ea-4c83-a523-04a7be3b799e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_98d3cb75-c3ea-4c83-a523-04a7be3b799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_160559f6-0f3f-4a22-94ac-52e578f0313a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_160559f6-0f3f-4a22-94ac-52e578f0313a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_77e96752-2026-4cc7-9f2f-a65343949d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_77e96752-2026-4cc7-9f2f-a65343949d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent_9d03280f-5eb4-44b4-9251-d7dbc59d6174" xlink:href="goss-20241231.xsd#goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent_9d03280f-5eb4-44b4-9251-d7dbc59d6174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_633b1c60-d41d-4a5f-a403-6214cf9cc040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_633b1c60-d41d-4a5f-a403-6214cf9cc040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c9e96232-561f-4da1-acbf-28b69d488fba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c9e96232-561f-4da1-acbf-28b69d488fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_272e3dc6-0d8d-449c-86e4-8b34f26aa09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca7f5126-d4a3-43aa-9d03-da794af0915e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_272e3dc6-0d8d-449c-86e4-8b34f26aa09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b95eef6-7bab-457c-9b12-10ea8c6f3760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ec56f60b-d167-4a4a-bc73-712fcbf71299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b95eef6-7bab-457c-9b12-10ea8c6f3760" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ec56f60b-d167-4a4a-bc73-712fcbf71299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_46897c85-eba1-4e7c-a13b-1758c64b1a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ec56f60b-d167-4a4a-bc73-712fcbf71299" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_46897c85-eba1-4e7c-a13b-1758c64b1a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d8eab54d-5612-4a95-8d54-4ebd32f5efaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ec56f60b-d167-4a4a-bc73-712fcbf71299" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d8eab54d-5612-4a95-8d54-4ebd32f5efaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b85173b7-0b92-4b91-b7d6-48e777344af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ec56f60b-d167-4a4a-bc73-712fcbf71299" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b85173b7-0b92-4b91-b7d6-48e777344af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4b19201b-7f0f-4d66-b601-57db8b115162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ec56f60b-d167-4a4a-bc73-712fcbf71299" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4b19201b-7f0f-4d66-b601-57db8b115162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b2e2ec42-ccb3-4ff0-ad31-7577e03a465e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:href="goss-20241231.xsd#goss_StockholdersEquityDeficitTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b2e2ec42-ccb3-4ff0-ad31-7577e03a465e" xlink:to="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ade756cc-0f82-44ff-a305-549e16b370ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ade756cc-0f82-44ff-a305-549e16b370ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46594aad-4f07-414b-9a6a-4b693ca1ae36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ade756cc-0f82-44ff-a305-549e16b370ef" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46594aad-4f07-414b-9a6a-4b693ca1ae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f8cc7e3e-236a-4a3c-a919-22180998fe89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46594aad-4f07-414b-9a6a-4b693ca1ae36" xlink:to="loc_us-gaap_PrivatePlacementMember_f8cc7e3e-236a-4a3c-a919-22180998fe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a3a107c-26cd-435d-903e-1ed632cee416" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_srt_RangeAxis_2a3a107c-26cd-435d-903e-1ed632cee416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b590c4ba-ef6f-427d-a9f4-418dc5eed26a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a3a107c-26cd-435d-903e-1ed632cee416" xlink:to="loc_srt_RangeMember_b590c4ba-ef6f-427d-a9f4-418dc5eed26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_55e471b9-25ec-4606-944b-3fe6e6d3f528" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b590c4ba-ef6f-427d-a9f4-418dc5eed26a" xlink:to="loc_srt_MaximumMember_55e471b9-25ec-4606-944b-3fe6e6d3f528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aafc354b-2a7d-43cf-a2d9-685a6d3c920f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_srt_CounterpartyNameAxis_aafc354b-2a7d-43cf-a2d9-685a6d3c920f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_aafc354b-2a7d-43cf-a2d9-685a6d3c920f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OfficerDirectorEmployeeOrConsultantMember_069d71f7-d61a-40a9-a3ba-11d0e3760eb0" xlink:href="goss-20241231.xsd#goss_OfficerDirectorEmployeeOrConsultantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:to="loc_goss_OfficerDirectorEmployeeOrConsultantMember_069d71f7-d61a-40a9-a3ba-11d0e3760eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_8e3df0ee-2f77-4385-8dcb-4e4ae550ec13" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_776126ff-db77-4bd0-9b3d-035b0cdba5a2" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_8e3df0ee-2f77-4385-8dcb-4e4ae550ec13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12e40312-cae4-44ef-85d0-e26954364e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12e40312-cae4-44ef-85d0-e26954364e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cf34026a-fc7b-481b-9433-972b2849b173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12e40312-cae4-44ef-85d0-e26954364e6c" xlink:to="loc_us-gaap_EquityComponentDomain_cf34026a-fc7b-481b-9433-972b2849b173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_FounderSharesMember_56d84858-7c93-4e4e-b7b5-7bf8a7505cd2" xlink:href="goss-20241231.xsd#goss_FounderSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cf34026a-fc7b-481b-9433-972b2849b173" xlink:to="loc_goss_FounderSharesMember_56d84858-7c93-4e4e-b7b5-7bf8a7505cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4823656-90c0-4077-8264-c983bb467f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4823656-90c0-4077-8264-c983bb467f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_173f6716-cd68-4968-937e-4def0220d89c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4823656-90c0-4077-8264-c983bb467f25" xlink:to="loc_us-gaap_RelatedPartyDomain_173f6716-cd68-4968-937e-4def0220d89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_FounderMember_8286c1d5-292a-4882-987a-7218a53bf5e4" xlink:href="goss-20241231.xsd#goss_FounderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_173f6716-cd68-4968-937e-4def0220d89c" xlink:to="loc_goss_FounderMember_8286c1d5-292a-4882-987a-7218a53bf5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:href="goss-20241231.xsd#goss_StockholdersEquityDeficitLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitTable_73f7cd2a-e603-47ab-a281-7a4495be1bdd" xlink:to="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVotingRightsNumberOfVotesPerShare_007e3add-a47d-4b4e-a09a-9c9abdd689a9" xlink:href="goss-20241231.xsd#goss_CommonStockVotingRightsNumberOfVotesPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CommonStockVotingRightsNumberOfVotesPerShare_007e3add-a47d-4b4e-a09a-9c9abdd689a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0d0c64-ccbc-4aa4-b324-f88e982531d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0d0c64-ccbc-4aa4-b324-f88e982531d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_887504a4-fc00-4f2b-9717-e18420fae25b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_887504a4-fc00-4f2b-9717-e18420fae25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a30b1d77-8e49-4d1f-b978-a0da96216e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a30b1d77-8e49-4d1f-b978-a0da96216e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f82d3244-7c03-43c3-ad63-49da26711ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f82d3244-7c03-43c3-ad63-49da26711ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1f4e1adf-bdc5-4682-b35a-23f3b779f510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1f4e1adf-bdc5-4682-b35a-23f3b779f510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f075e3e4-7321-4990-91f2-c9d2ac957343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f075e3e4-7321-4990-91f2-c9d2ac957343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_527a1ef3-823b-4215-b4ba-fb928508cc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_527a1ef3-823b-4215-b4ba-fb928508cc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5d85358-0caa-499e-ab12-9bc658a9e395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5d85358-0caa-499e-ab12-9bc658a9e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_66152db6-26af-42f3-a44c-c3f981ea62a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_66152db6-26af-42f3-a44c-c3f981ea62a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_894dffa8-0852-4b35-8d10-2741129307cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_894dffa8-0852-4b35-8d10-2741129307cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_864aa2ff-1eb4-4c91-b425-e25defe9a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_864aa2ff-1eb4-4c91-b425-e25defe9a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_625a0eed-4d9a-4b72-afec-18acc41f6c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_625a0eed-4d9a-4b72-afec-18acc41f6c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVestingPercentage_3144e72b-7a2e-41e5-a323-3ee16931cc4d" xlink:href="goss-20241231.xsd#goss_CommonStockVestingPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CommonStockVestingPercentage_3144e72b-7a2e-41e5-a323-3ee16931cc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CommonStockVestingPeriod_e488a4b9-d059-4370-9c81-ddfb526f50a1" xlink:href="goss-20241231.xsd#goss_CommonStockVestingPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CommonStockVestingPeriod_e488a4b9-d059-4370-9c81-ddfb526f50a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PercentageOfFullyDilutedShareCapital_d309ed55-951e-468a-9b0b-9374aa7539cc" xlink:href="goss-20241231.xsd#goss_PercentageOfFullyDilutedShareCapital"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_PercentageOfFullyDilutedShareCapital_d309ed55-951e-468a-9b0b-9374aa7539cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncreasedInEquityCapitalAmount_9fef3642-303a-4ffa-b8e8-5ca7eb8e1aea" xlink:href="goss-20241231.xsd#goss_IncreasedInEquityCapitalAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_IncreasedInEquityCapitalAmount_9fef3642-303a-4ffa-b8e8-5ca7eb8e1aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting_5b692b29-d815-40f3-9233-1007d313ea26" xlink:href="goss-20241231.xsd#goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting_5b692b29-d815-40f3-9233-1007d313ea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_9f637a32-4e15-4ed1-9acd-34fc92015c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_9f637a32-4e15-4ed1-9acd-34fc92015c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage_c0b72de0-0a6e-4a32-b696-da37d2ebb1a3" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage_c0b72de0-0a6e-4a32-b696-da37d2ebb1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding_f8065adc-9a6c-4646-a8ea-094090bba934" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding_f8065adc-9a6c-4646-a8ea-094090bba934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice_0fb4d4e4-db20-4b37-b338-468819060018" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice_0fb4d4e4-db20-4b37-b338-468819060018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays_b0323739-fe17-4eb2-bf36-774a05f13772" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays_b0323739-fe17-4eb2-bf36-774a05f13772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice_4b85224b-7679-4d7a-ab44-fb08b98930c2" xlink:href="goss-20241231.xsd#goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice_4b85224b-7679-4d7a-ab44-fb08b98930c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_a2e7005c-aee9-4893-80d3-a28c09a6e807" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityFairValueOfEquityOption"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_StockholdersEquityDeficitLineItems_36bda9c6-bc3b-4688-a899-2bed3dde2c02" xlink:to="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_a2e7005c-aee9-4893-80d3-a28c09a6e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4e2267f1-da35-43d5-a8b2-d6b6298ecd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4e2267f1-da35-43d5-a8b2-d6b6298ecd7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c8fda2be-1f73-474a-8701-965d22cca51b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_PlanNameAxis_c8fda2be-1f73-474a-8701-965d22cca51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c8fda2be-1f73-474a-8701-965d22cca51b" xlink:to="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember_8fbe75bd-dd56-4ee4-acc9-47a0769901e1" xlink:href="goss-20241231.xsd#goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember_8fbe75bd-dd56-4ee4-acc9-47a0769901e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandNineteenEquityIncentivePlanMember_939127de-a1a0-459e-8a9d-b6ee330bf4bf" xlink:href="goss-20241231.xsd#goss_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandNineteenEquityIncentivePlanMember_939127de-a1a0-459e-8a9d-b6ee330bf4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember_578baa97-44ae-42a3-85d7-c0395f83ac79" xlink:href="goss-20241231.xsd#goss_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandNineteenEmployeeStockPurchasePlanMember_578baa97-44ae-42a3-85d7-c0395f83ac79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_TwoThousandSeventeenEquityIncentivePlanMember_90db5c12-8da8-444c-aba7-25d64ff50864" xlink:href="goss-20241231.xsd#goss_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d6f5c35c-23ab-4de0-9f3f-eef7b1dbc126" xlink:to="loc_goss_TwoThousandSeventeenEquityIncentivePlanMember_90db5c12-8da8-444c-aba7-25d64ff50864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_srt_RangeAxis_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ceaf1d7-e095-4466-bed1-10bb1e5c7f85" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c78bfb9-5293-43b6-9d8b-bcb7e75735c6" xlink:to="loc_srt_RangeMember_3ceaf1d7-e095-4466-bed1-10bb1e5c7f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4eaf2203-e2ff-4f07-bca9-7af4f18f4b9a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ceaf1d7-e095-4466-bed1-10bb1e5c7f85" xlink:to="loc_srt_MaximumMember_4eaf2203-e2ff-4f07-bca9-7af4f18f4b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd812493-89ad-4ff0-8e1f-c3f105b4186f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_AwardTypeAxis_bd812493-89ad-4ff0-8e1f-c3f105b4186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bd812493-89ad-4ff0-8e1f-c3f105b4186f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_417c6a3d-4e59-4e4b-a4d4-c1eb233ca823" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:to="loc_us-gaap_RestrictedStockMember_417c6a3d-4e59-4e4b-a4d4-c1eb233ca823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5af07ce0-daed-44b5-bf18-c2612fc937d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a50a27b8-d553-4f22-ac9d-3a9c8e69678e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5af07ce0-daed-44b5-bf18-c2612fc937d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b1b1523e-b84c-4826-8aff-656771eb187a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_VestingAxis_b1b1523e-b84c-4826-8aff-656771eb187a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_b1b1523e-b84c-4826-8aff-656771eb187a" xlink:to="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9c4fb2a5-c06f-402d-9a87-67ea35a27a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9c4fb2a5-c06f-402d-9a87-67ea35a27a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_036430be-cd22-4669-8c93-3eb43766aa55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_036430be-cd22-4669-8c93-3eb43766aa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_859ad0cc-2256-4989-a089-24331552bd65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_689aab91-3002-46a7-8310-37256341c8ae" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_859ad0cc-2256-4989-a089-24331552bd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b47009b9-6f7d-4567-b5e9-c08086c06e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c29fdeb-6220-4db6-82d5-5a844c7ce0f4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b47009b9-6f7d-4567-b5e9-c08086c06e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_29f0a080-15bc-4141-b8f8-140f86ccce68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b47009b9-6f7d-4567-b5e9-c08086c06e5d" xlink:to="loc_us-gaap_PrivatePlacementMember_29f0a080-15bc-4141-b8f8-140f86ccce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a18ce4d0-36a3-4dae-965f-20797f1a21a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_srt_CounterpartyNameAxis_a18ce4d0-36a3-4dae-965f-20797f1a21a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_407f36f0-84a6-4daf-aa1a-c35b1ec291af" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a18ce4d0-36a3-4dae-965f-20797f1a21a0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_407f36f0-84a6-4daf-aa1a-c35b1ec291af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_OfficerDirectorEmployeeOrConsultantMember_f0f0cb7b-bafc-4e51-8d80-b4c61e0428b9" xlink:href="goss-20241231.xsd#goss_OfficerDirectorEmployeeOrConsultantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_407f36f0-84a6-4daf-aa1a-c35b1ec291af" xlink:to="loc_goss_OfficerDirectorEmployeeOrConsultantMember_f0f0cb7b-bafc-4e51-8d80-b4c61e0428b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66ca37bb-2a24-476e-bf22-95b22156ba4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5afde2a5-a4c1-466b-901c-eead85ce3426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5afde2a5-a4c1-466b-901c-eead85ce3426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1dbaa75f-6a7d-4686-95f2-7e2b7bc70aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1dbaa75f-6a7d-4686-95f2-7e2b7bc70aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards_244de6ba-c738-45ab-811a-a24813ffd277" xlink:href="goss-20241231.xsd#goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards_244de6ba-c738-45ab-811a-a24813ffd277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2018a2b5-f343-43ad-87b6-b0359211c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2018a2b5-f343-43ad-87b6-b0359211c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b1c7f7a-1075-43b7-a0dd-72dc0a37c70c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_4b1c7f7a-1075-43b7-a0dd-72dc0a37c70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_187f5a17-cfe9-4fbe-8764-0e92e95fc58f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_187f5a17-cfe9-4fbe-8764-0e92e95fc58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_843bf012-72c2-4f10-8f4d-119ce37b4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_843bf012-72c2-4f10-8f4d-119ce37b4fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_6ced3ede-a096-4aed-a7e2-ffadd7ce7379" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued_6ced3ede-a096-4aed-a7e2-ffadd7ce7379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_21491e5d-7b0f-470f-87c2-288ab57e35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_21491e5d-7b0f-470f-87c2-288ab57e35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a76ab6eb-1772-4cd5-8b48-d2525540fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a76ab6eb-1772-4cd5-8b48-d2525540fed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab70586b-3c75-402b-b848-8060745d8b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab70586b-3c75-402b-b848-8060745d8b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee62d56c-059e-43f7-8b9c-55a962769e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee62d56c-059e-43f7-8b9c-55a962769e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f306157a-9edf-49cc-b7b5-e9596af7e24d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f306157a-9edf-49cc-b7b5-e9596af7e24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_32efe7a0-acb9-447a-9058-6f5182d5f822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_32efe7a0-acb9-447a-9058-6f5182d5f822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays_a9a14379-d8df-4946-a6f6-aafc96389700" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays_a9a14379-d8df-4946-a6f6-aafc96389700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice_9fec38d8-933f-4f6f-8fc9-1f38a98e81a9" xlink:href="goss-20241231.xsd#goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice_9fec38d8-933f-4f6f-8fc9-1f38a98e81a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_65b61170-f562-48f7-85b1-2cbc6bd7e3db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_65b61170-f562-48f7-85b1-2cbc6bd7e3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_541d8d38-0b66-45df-b823-5212b26a7669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_541d8d38-0b66-45df-b823-5212b26a7669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_192d7754-8d91-4726-8b36-6fecac1863c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_192d7754-8d91-4726-8b36-6fecac1863c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_86becc6e-5807-4327-a32b-c5e627ba7092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_86becc6e-5807-4327-a32b-c5e627ba7092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage_481be0ab-d18b-40f3-8a13-d087a84fda15" xlink:href="goss-20241231.xsd#goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage_481be0ab-d18b-40f3-8a13-d087a84fda15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_17f30084-84db-48a5-904a-17b761174c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_17f30084-84db-48a5-904a-17b761174c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8fb87926-a990-4195-82db-07a111bdc162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8fb87926-a990-4195-82db-07a111bdc162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f57480c3-6f8f-4203-ac96-e35d6e0c0f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f57480c3-6f8f-4203-ac96-e35d6e0c0f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_407afc75-34f5-48e2-bbe1-e4f152d53dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_407afc75-34f5-48e2-bbe1-e4f152d53dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e639f-7c84-4ade-b9b2-d85197d061d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_481e639f-7c84-4ade-b9b2-d85197d061d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_74697527-bd30-435b-9e23-b4824443277d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_74697527-bd30-435b-9e23-b4824443277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efaaacc7-e389-4877-bb19-e7d83b8bd07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efaaacc7-e389-4877-bb19-e7d83b8bd07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50b3e705-c8f2-46e6-9be0-7f45a3c6871d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50b3e705-c8f2-46e6-9be0-7f45a3c6871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e33634c-6b12-4324-9de5-7786b3222332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e33634c-6b12-4324-9de5-7786b3222332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_aa1d63f4-f88d-43cd-bf6b-405cdf72e4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_aa1d63f4-f88d-43cd-bf6b-405cdf72e4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_326ca768-eda4-4eab-a3ec-7f785afd1125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_326ca768-eda4-4eab-a3ec-7f785afd1125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b3912cd3-6201-4b7c-ba10-2e7ee33125ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b3912cd3-6201-4b7c-ba10-2e7ee33125ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c78a0ab6-53f6-469e-8624-4feca78ac29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0580493b-262e-439a-868f-38373fe5b991" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c78a0ab6-53f6-469e-8624-4feca78ac29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14657506-549c-4a6e-92f3-c66fa778ad56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14657506-549c-4a6e-92f3-c66fa778ad56" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e20c971-c6b8-4947-ad51-87fae8106944" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:to="loc_srt_RangeAxis_5e20c971-c6b8-4947-ad51-87fae8106944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5e20c971-c6b8-4947-ad51-87fae8106944" xlink:to="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7d72d4a-2b41-4ce0-b6ac-47f08b58ea9e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:to="loc_srt_MinimumMember_e7d72d4a-2b41-4ce0-b6ac-47f08b58ea9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2798c7b9-707c-448b-89de-13469266e27d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7753995-1031-4baa-8623-8879e987277f" xlink:to="loc_srt_MaximumMember_2798c7b9-707c-448b-89de-13469266e27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85bf371c-8dd5-4b7b-ae1a-db650b188cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:to="loc_us-gaap_AwardTypeAxis_85bf371c-8dd5-4b7b-ae1a-db650b188cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_85bf371c-8dd5-4b7b-ae1a-db650b188cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_885592b3-38a7-487e-946b-98ab939830d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_885592b3-38a7-487e-946b-98ab939830d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EmployeeStockPurchasePlanMember_75f070f2-b1e3-41d9-a12c-5c0edd26a700" xlink:href="goss-20241231.xsd#goss_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdfc1f9e-eb1d-4af0-8bc1-2fbb6f151cdb" xlink:to="loc_goss_EmployeeStockPurchasePlanMember_75f070f2-b1e3-41d9-a12c-5c0edd26a700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d63fde3-19bc-4e87-ae26-2821fb1f16fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_45595051-1129-406b-b53c-fec398a594aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_45595051-1129-406b-b53c-fec398a594aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eabf2fb7-8ea8-4028-bced-e9595521ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eabf2fb7-8ea8-4028-bced-e9595521ac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_37ee14f0-9d8f-44e9-9ee9-3228b1fe3765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_37ee14f0-9d8f-44e9-9ee9-3228b1fe3765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1809b677-f9b3-45a9-b6be-f504984330b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1809b677-f9b3-45a9-b6be-f504984330b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59f0e77a-e255-40ab-944d-9cf006950c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59f0e77a-e255-40ab-944d-9cf006950c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b1e8ce2-9615-4cab-97e1-f7609a1b29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b7314a7-b644-4d10-903b-741d05591ce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b1e8ce2-9615-4cab-97e1-f7609a1b29c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a270e94-6582-49a3-9607-135a375335e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a270e94-6582-49a3-9607-135a375335e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30629052-fbfc-4173-8945-7b120c0b5200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a270e94-6582-49a3-9607-135a375335e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30629052-fbfc-4173-8945-7b120c0b5200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3f35b01e-e46a-471a-adae-f7aa9d7e034a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a270e94-6582-49a3-9607-135a375335e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3f35b01e-e46a-471a-adae-f7aa9d7e034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f421e30c-ec10-4df0-9e07-dab2c9c1a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a270e94-6582-49a3-9607-135a375335e1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f421e30c-ec10-4df0-9e07-dab2c9c1a84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4d4173f6-2153-4b26-bbd6-75920cc60671" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a270e94-6582-49a3-9607-135a375335e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4d4173f6-2153-4b26-bbd6-75920cc60671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8863eb41-8fb0-4e6a-9552-8d754b713321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a270e94-6582-49a3-9607-135a375335e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8863eb41-8fb0-4e6a-9552-8d754b713321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_68a7bb9a-19cf-458f-a19b-bfc208ad78de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_68a7bb9a-19cf-458f-a19b-bfc208ad78de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_878d8cc6-c657-448a-b762-53046c6a5579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_878d8cc6-c657-448a-b762-53046c6a5579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2326d28f-fd50-4ced-b6d1-4674c3aaa8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2326d28f-fd50-4ced-b6d1-4674c3aaa8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d334834c-97d4-4ea7-9dd6-99ed93377b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2326d28f-fd50-4ced-b6d1-4674c3aaa8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d334834c-97d4-4ea7-9dd6-99ed93377b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_87333804-83a1-4fb4-b9b7-7d9a51523b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2326d28f-fd50-4ced-b6d1-4674c3aaa8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_87333804-83a1-4fb4-b9b7-7d9a51523b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b89787f3-d6fa-4bd8-a548-b0bd39fc3dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2326d28f-fd50-4ced-b6d1-4674c3aaa8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b89787f3-d6fa-4bd8-a548-b0bd39fc3dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60c97e2f-ae67-4f8e-9302-608b60b94729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2326d28f-fd50-4ced-b6d1-4674c3aaa8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60c97e2f-ae67-4f8e-9302-608b60b94729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e829a3e-f4e2-46ad-a7bb-6f3bb94ce3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2326d28f-fd50-4ced-b6d1-4674c3aaa8cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e829a3e-f4e2-46ad-a7bb-6f3bb94ce3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_33043a0b-491d-4f2c-9942-8de4426251bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_33043a0b-491d-4f2c-9942-8de4426251bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b0fc7497-7e4b-476d-8deb-db934222c78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b0fc7497-7e4b-476d-8deb-db934222c78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d5d5d2a0-a8fb-4c84-9c0e-9ddcd83551e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d5d5d2a0-a8fb-4c84-9c0e-9ddcd83551e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0ce4806d-5d8f-4b66-bf20-b8f477987458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0ce4806d-5d8f-4b66-bf20-b8f477987458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d1a1cfff-27d7-4810-944c-7182f688406d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d1a1cfff-27d7-4810-944c-7182f688406d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4a7d95-3c86-412d-9366-9ce137341084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4a7d95-3c86-412d-9366-9ce137341084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8d29e298-fb6e-42ef-9981-f8622fdab507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8d29e298-fb6e-42ef-9981-f8622fdab507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f5212149-c45b-4606-a243-c9c19f9c49b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4decae84-e5e4-4130-b3a6-16f1fa8eff8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f5212149-c45b-4606-a243-c9c19f9c49b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansScheduleofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23fd8ba1-7671-4256-83cb-a5c15a169768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85fdfe27-fa7c-41e6-97fc-249d1bb0ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23fd8ba1-7671-4256-83cb-a5c15a169768" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85fdfe27-fa7c-41e6-97fc-249d1bb0ba33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3afb87b1-2d49-49a9-88fe-436a4ccad2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85fdfe27-fa7c-41e6-97fc-249d1bb0ba33" xlink:to="loc_us-gaap_AwardTypeAxis_3afb87b1-2d49-49a9-88fe-436a4ccad2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7700d7ca-d284-407d-83fc-2b977694cf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3afb87b1-2d49-49a9-88fe-436a4ccad2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7700d7ca-d284-407d-83fc-2b977694cf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2435b12d-d326-4a6d-9e37-697f9fb6a1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7700d7ca-d284-407d-83fc-2b977694cf33" xlink:to="loc_us-gaap_RestrictedStockMember_2435b12d-d326-4a6d-9e37-697f9fb6a1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85fdfe27-fa7c-41e6-97fc-249d1bb0ba33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d2683ff-d50a-403e-96dc-3199806c6ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d2683ff-d50a-403e-96dc-3199806c6ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f256edad-1942-49d5-ba98-ddeefcba690d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f256edad-1942-49d5-ba98-ddeefcba690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84f0775c-afe4-4d9a-8873-f5ece531624f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84f0775c-afe4-4d9a-8873-f5ece531624f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64da9bbd-0e28-4fdc-93e8-15ae4cab29fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64da9bbd-0e28-4fdc-93e8-15ae4cab29fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9bddd36e-107c-4657-8f95-fee3fc6a8fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d17455bb-e59a-4b7c-8a94-196905397ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9bddd36e-107c-4657-8f95-fee3fc6a8fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e031e313-d328-49c4-8ac1-a30a6b4a7a4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49ed55e-d1fb-437b-9b80-3002a75a4a71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49ed55e-d1fb-437b-9b80-3002a75a4a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9905c078-744a-474d-82c2-8393823df917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9905c078-744a-474d-82c2-8393823df917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5c3225f7-3223-4a67-a747-2a0985d8779a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5c3225f7-3223-4a67-a747-2a0985d8779a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab580328-6fe5-4835-8142-67a9b6162e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab580328-6fe5-4835-8142-67a9b6162e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bfd9a478-0cef-447a-9771-40067f94fecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a67d59e4-65ae-495f-866e-55ff87802e35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bfd9a478-0cef-447a-9771-40067f94fecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28a98e89-df7b-4e14-bc8c-491b5c4b9a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_12ce3ff8-e80b-482a-a0f5-6fe9c35b1286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28a98e89-df7b-4e14-bc8c-491b5c4b9a7f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_12ce3ff8-e80b-482a-a0f5-6fe9c35b1286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1f2834b-c36d-48fe-ab84-51ce30b6fd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_12ce3ff8-e80b-482a-a0f5-6fe9c35b1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1f2834b-c36d-48fe-ab84-51ce30b6fd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1f2834b-c36d-48fe-ab84-51ce30b6fd34" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9c22173e-d657-43a5-a78f-4c2877a40bab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9c22173e-d657-43a5-a78f-4c2877a40bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f32405c0-b0aa-4474-8b04-1da1b6740168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f70397a-4c30-4e54-96ac-612a3ee0249a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f32405c0-b0aa-4474-8b04-1da1b6740168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7f40a68d-3215-471f-9724-6aa80df2c484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_12ce3ff8-e80b-482a-a0f5-6fe9c35b1286" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7f40a68d-3215-471f-9724-6aa80df2c484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a00e84df-4a76-4853-b3c8-cff6bc66064a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7f40a68d-3215-471f-9724-6aa80df2c484" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a00e84df-4a76-4853-b3c8-cff6bc66064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9def3c64-8400-4310-9f60-2f840d218ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9def3c64-8400-4310-9f60-2f840d218ca0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6f26f8bc-9817-4fa6-a756-52f0f65c1506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6f26f8bc-9817-4fa6-a756-52f0f65c1506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6f26f8bc-9817-4fa6-a756-52f0f65c1506" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_3e464323-4845-4359-9419-77ec8dee92ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_OfficeEquipmentMember_3e464323-4845-4359-9419-77ec8dee92ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7f9d6a21-8241-4370-9777-6754f159b664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_ComputerEquipmentMember_7f9d6a21-8241-4370-9777-6754f159b664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_23ab50f8-c661-4586-af09-fe8e5f18920b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_23ab50f8-c661-4586-af09-fe8e5f18920b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_4ed4dc40-154a-44fb-8f99-3f9afa65b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_EquipmentMember_4ed4dc40-154a-44fb-8f99-3f9afa65b6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f9e9d9ea-3b90-4073-b3ea-d708c6371220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1898b68f-f966-4a1f-a78b-41287209829e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f9e9d9ea-3b90-4073-b3ea-d708c6371220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_724c7011-a638-46a5-a621-3d0680e8f59a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:to="loc_srt_RangeAxis_724c7011-a638-46a5-a621-3d0680e8f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_724c7011-a638-46a5-a621-3d0680e8f59a" xlink:to="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a45b1aa6-0a3e-40c2-b82a-52aecb886d31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:to="loc_srt_MinimumMember_a45b1aa6-0a3e-40c2-b82a-52aecb886d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c1e20d7-468b-44cb-9602-1cc91813095f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09e4dee4-0f98-48be-ab58-b862268c46a4" xlink:to="loc_srt_MaximumMember_3c1e20d7-468b-44cb-9602-1cc91813095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4cb3e788-e25f-4e5b-af5e-c59cc68e5c82" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_841b4f79-ea3a-4ebc-990c-0b6406051143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_841b4f79-ea3a-4ebc-990c-0b6406051143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f6fca2cd-854e-4775-b760-ed0bad51e60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f6fca2cd-854e-4775-b760-ed0bad51e60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45f6076e-a62a-47dc-bc56-1ffedf558955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45f6076e-a62a-47dc-bc56-1ffedf558955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cb2f31d3-6166-46f6-8031-f62774a2a34e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6800ed4e-7871-473b-b934-8fcdcf238bed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cb2f31d3-6166-46f6-8031-f62774a2a34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#PropertyandEquipmentNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c019e0ff-b7a7-4fef-b478-f17e030698fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b382240e-8bf1-41a9-a6eb-76df08b190b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c019e0ff-b7a7-4fef-b478-f17e030698fe" xlink:to="loc_us-gaap_Depreciation_b382240e-8bf1-41a9-a6eb-76df08b190b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_87c2ebe2-cdf7-490c-8070-6e4a7a9687b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aaeb67cc-8929-47c9-8c17-6c4ad7894a09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_87c2ebe2-cdf7-490c-8070-6e4a7a9687b3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aaeb67cc-8929-47c9-8c17-6c4ad7894a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9144814b-2e05-46bb-b281-e6016a76c899" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aaeb67cc-8929-47c9-8c17-6c4ad7894a09" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9144814b-2e05-46bb-b281-e6016a76c899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9144814b-2e05-46bb-b281-e6016a76c899" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LeaseAgreementEnteredInJuly2024Member_603ce1cb-0450-46e1-9182-f722caf2a8ab" xlink:href="goss-20241231.xsd#goss_LeaseAgreementEnteredInJuly2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:to="loc_goss_LeaseAgreementEnteredInJuly2024Member_603ce1cb-0450-46e1-9182-f722caf2a8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member_758b1523-7dd8-4b5b-915d-65a49c6a43c8" xlink:href="goss-20241231.xsd#goss_NonCancelableLeaseAgreementEnteredInAugust2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5b852b37-579c-4de5-8963-6858d858daff" xlink:to="loc_goss_NonCancelableLeaseAgreementEnteredInAugust2018Member_758b1523-7dd8-4b5b-915d-65a49c6a43c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aaeb67cc-8929-47c9-8c17-6c4ad7894a09" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LeaseeOperatingLeaseLeasedArea_8f95a55f-ef2f-478a-8a11-5795ac571af9" xlink:href="goss-20241231.xsd#goss_LeaseeOperatingLeaseLeasedArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LeaseeOperatingLeaseLeasedArea_8f95a55f-ef2f-478a-8a11-5795ac571af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_94241cf3-c0b7-4f40-a834-20cc754ab8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_94241cf3-c0b7-4f40-a834-20cc754ab8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseBaseRent_be7b1f80-5c65-4f30-a609-29ded964bf85" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseBaseRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseBaseRent_be7b1f80-5c65-4f30-a609-29ded964bf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage_b6602001-90f8-45b3-88aa-cfaa43992660" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage_b6602001-90f8-45b3-88aa-cfaa43992660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseExtensionTerm_58e3d4f5-9086-4f96-b67c-895a210a1696" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseExtensionTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseExtensionTerm_58e3d4f5-9086-4f96-b67c-895a210a1696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent_0bef7ec5-3d6b-4bd3-94ae-7607868a1aba" xlink:href="goss-20241231.xsd#goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent_0bef7ec5-3d6b-4bd3-94ae-7607868a1aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8af2dd9-29b1-4f06-ac9a-a551d339ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8af2dd9-29b1-4f06-ac9a-a551d339ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c5ac5b9-3606-4a7c-8f35-72e5518f0d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c5ac5b9-3606-4a7c-8f35-72e5518f0d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ee198143-5751-4df5-b992-cfa0a588a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_794bb129-b086-4032-a815-df21988128a5" xlink:to="loc_us-gaap_OperatingLeasePayments_ee198143-5751-4df5-b992-cfa0a588a1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesScheduleofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef729fbe-bf0b-46c7-b74b-885c67d74502" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_598a85eb-c038-4030-aac8-f230c24b6264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef729fbe-bf0b-46c7-b74b-885c67d74502" xlink:to="loc_us-gaap_OperatingLeaseCost_598a85eb-c038-4030-aac8-f230c24b6264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_1a96633c-ef21-4bc7-bddc-6950b41c65b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef729fbe-bf0b-46c7-b74b-885c67d74502" xlink:to="loc_us-gaap_ShortTermLeaseCost_1a96633c-ef21-4bc7-bddc-6950b41c65b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_59cd2b94-c432-4866-a7f9-05ee17199bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef729fbe-bf0b-46c7-b74b-885c67d74502" xlink:to="loc_us-gaap_LeaseCost_59cd2b94-c432-4866-a7f9-05ee17199bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c1eeb377-47de-4e6d-a56f-3f422247e27a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c1eeb377-47de-4e6d-a56f-3f422247e27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_666a19cc-b5bd-48ef-b44c-72797e1ca495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_666a19cc-b5bd-48ef-b44c-72797e1ca495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5770b3ff-de7a-441b-bdfc-ac8cfbacc400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5770b3ff-de7a-441b-bdfc-ac8cfbacc400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_24b24fa7-d7e4-4c25-9d3f-2e43a0f97278" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_24b24fa7-d7e4-4c25-9d3f-2e43a0f97278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5c5f8045-5cc2-4f77-8dd0-7381880e2966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5c5f8045-5cc2-4f77-8dd0-7381880e2966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f397c101-22ba-4ac1-a21f-a21818829a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f397c101-22ba-4ac1-a21f-a21818829a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5e692e3c-aece-4713-8cb2-276199ac1f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5e692e3c-aece-4713-8cb2-276199ac1f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_056fd5d2-6b92-4c91-85a6-0e67e02df41a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_OperatingLeaseLiability_056fd5d2-6b92-4c91-85a6-0e67e02df41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7727fd74-81aa-40e9-bd1e-d5b336b089d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7727fd74-81aa-40e9-bd1e-d5b336b089d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3acff68d-a5c3-40a2-b8a8-d4a11de68541" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3acff68d-a5c3-40a2-b8a8-d4a11de68541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_242ebc7f-9087-40ca-aa96-54f4307ebe46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7bf2f75-7f74-49c5-be6f-b23e15f9e37d" xlink:to="loc_us-gaap_OperatingLeaseLiability_242ebc7f-9087-40ca-aa96-54f4307ebe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContractsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ebc304-cb30-403b-83f5-39cb403b5800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ebc304-cb30-403b-83f5-39cb403b5800" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f85983e8-95e5-4b9e-931b-59a8b92f94b7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:to="loc_srt_CounterpartyNameAxis_f85983e8-95e5-4b9e-931b-59a8b92f94b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed0470f1-bc62-4958-a313-13ccffc5edeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f85983e8-95e5-4b9e-931b-59a8b92f94b7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed0470f1-bc62-4958-a313-13ccffc5edeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_fdc43622-7b6c-4f00-bebf-daad485cea10" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed0470f1-bc62-4958-a313-13ccffc5edeb" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_fdc43622-7b6c-4f00-bebf-daad485cea10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2022b640-7b1a-42b2-b7b3-cde169575b40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:to="loc_srt_RangeAxis_2022b640-7b1a-42b2-b7b3-cde169575b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3d4b754-9b9f-46e9-a0d9-1c5daef02a8b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2022b640-7b1a-42b2-b7b3-cde169575b40" xlink:to="loc_srt_RangeMember_b3d4b754-9b9f-46e9-a0d9-1c5daef02a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6282c95a-dd52-44b3-b234-ef89b5b5b31c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b3d4b754-9b9f-46e9-a0d9-1c5daef02a8b" xlink:to="loc_srt_MaximumMember_6282c95a-dd52-44b3-b234-ef89b5b5b31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e1b351fb-9f65-4710-8555-632ff16c4ec4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:to="loc_srt_ProductOrServiceAxis_e1b351fb-9f65-4710-8555-632ff16c4ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e1b351fb-9f65-4710-8555-632ff16c4ec4" xlink:to="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_LicensesOfIntellectualPropertyMember_5d693d46-d9bb-402c-a07c-2a3a71558391" xlink:href="goss-20241231.xsd#goss_LicensesOfIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:to="loc_goss_LicensesOfIntellectualPropertyMember_5d693d46-d9bb-402c-a07c-2a3a71558391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_11fc9594-be31-40a4-a08c-dd3333e08cce" xlink:href="goss-20241231.xsd#goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bbef1086-a066-4920-b71f-8db634c9d522" xlink:to="loc_goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_11fc9594-be31-40a4-a08c-dd3333e08cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73d51235-1f66-4948-9499-cf0155c43533" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfDistinctPerformanceObligations_d7307162-7b8d-42c7-8cbc-9ba423e6b76e" xlink:href="goss-20241231.xsd#goss_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_NumberOfDistinctPerformanceObligations_d7307162-7b8d-42c7-8cbc-9ba423e6b76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_NumberOfLicensesGranted_17b4bdc2-7f83-4694-b241-5ddc40ec2dfb" xlink:href="goss-20241231.xsd#goss_NumberOfLicensesGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_NumberOfLicensesGranted_17b4bdc2-7f83-4694-b241-5ddc40ec2dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage_8b8d7d37-8499-45d3-8e3c-f02229972bd3" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage_8b8d7d37-8499-45d3-8e3c-f02229972bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage_4ef0b6d7-430e-4b6e-b829-d10c66cae40d" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage_4ef0b6d7-430e-4b6e-b829-d10c66cae40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived_a5abc461-dd7c-4a85-b898-d55fb1acaf03" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived_a5abc461-dd7c-4a85-b898-d55fb1acaf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount_0b2f718a-10cf-496d-b9dc-4f4160bf9ddb" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationRegulatoryMilestonesAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount_0b2f718a-10cf-496d-b9dc-4f4160bf9ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenuePerformanceObligationSalesMilestonesAmount_5b48a941-cd6d-4ab9-a5ea-3247ec1b234e" xlink:href="goss-20241231.xsd#goss_RevenuePerformanceObligationSalesMilestonesAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenuePerformanceObligationSalesMilestonesAmount_5b48a941-cd6d-4ab9-a5ea-3247ec1b234e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_RevenueLoyaltyReceivableExpirationPeriod_a9a5baf7-b9e4-4af7-8fbf-ccf6c99c4ac0" xlink:href="goss-20241231.xsd#goss_RevenueLoyaltyReceivableExpirationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_RevenueLoyaltyReceivableExpirationPeriod_a9a5baf7-b9e4-4af7-8fbf-ccf6c99c4ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityDevelopmentCost_158314a4-6ce9-4c87-8f7a-24ce5117b3a7" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityDevelopmentCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_ContractWithCustomerLiabilityDevelopmentCost_158314a4-6ce9-4c87-8f7a-24ce5117b3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_3df8d81c-8828-470f-b741-0b79e5a89cf1" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityFairValueOfEquityOption"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_ContractWithCustomerLiabilityFairValueOfEquityOption_3df8d81c-8828-470f-b741-0b79e5a89cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07a1b1da-eab8-4ef5-99b5-bd3b6c2d7610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07a1b1da-eab8-4ef5-99b5-bd3b6c2d7610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d0bf44d9-7063-4ab2-85d0-7ff80508f2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d0bf44d9-7063-4ab2-85d0-7ff80508f2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerRevenueRecognitionPeriod_6bae4cf2-1212-457e-9f42-916606bf401c" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerRevenueRecognitionPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_ContractWithCustomerRevenueRecognitionPeriod_6bae4cf2-1212-457e-9f42-916606bf401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_13e9a90b-7ecf-46b0-b984-60d138a587c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_13e9a90b-7ecf-46b0-b984-60d138a587c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e3cdd0da-327c-49c4-9c00-7f253a8cac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e3cdd0da-327c-49c4-9c00-7f253a8cac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5606c4eb-2583-4302-bd2a-c693e8261699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5606c4eb-2583-4302-bd2a-c693e8261699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_AccountReceivablePaymentTerm_be004920-9db1-4ee4-9062-024774bd3ce2" xlink:href="goss-20241231.xsd#goss_AccountReceivablePaymentTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2954211d-cc99-4ed2-9ebc-2c664790dfb0" xlink:to="loc_goss_AccountReceivablePaymentTerm_be004920-9db1-4ee4-9062-024774bd3ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf5cfd1e-2db7-4472-8c1d-e6c12cd27d28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf5cfd1e-2db7-4472-8c1d-e6c12cd27d28" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_564d2a01-1cbf-44f8-adf6-a62a1504e6bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:to="loc_srt_CounterpartyNameAxis_564d2a01-1cbf-44f8-adf6-a62a1504e6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4619b73-6f3f-4de7-b159-bffe1c798bc9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_564d2a01-1cbf-44f8-adf6-a62a1504e6bd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4619b73-6f3f-4de7-b159-bffe1c798bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_031aad14-435e-47ef-b2df-b47e23154b08" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4619b73-6f3f-4de7-b159-bffe1c798bc9" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_031aad14-435e-47ef-b2df-b47e23154b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd4c592b-b12a-4a59-b883-0ba18de76f1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:to="loc_srt_ProductOrServiceAxis_dd4c592b-b12a-4a59-b883-0ba18de76f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dd4c592b-b12a-4a59-b883-0ba18de76f1d" xlink:to="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_USLicenseMember_dfb0c784-d83e-4570-89a5-1f1cf2373d23" xlink:href="goss-20241231.xsd#goss_USLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_USLicenseMember_dfb0c784-d83e-4570-89a5-1f1cf2373d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ROWLicenseMember_e9ee3a5d-e026-4926-b0ed-859caf5386e7" xlink:href="goss-20241231.xsd#goss_ROWLicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_ROWLicenseMember_e9ee3a5d-e026-4926-b0ed-859caf5386e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_98d4c8d8-9054-4f44-ac2d-a9853c2cdd4d" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_98d4c8d8-9054-4f44-ac2d-a9853c2cdd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_97eb4084-e95c-4056-b186-8dc6885a5827" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8bdb6d36-5fef-4b0b-bc72-deb2df1d322c" xlink:to="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_97eb4084-e95c-4056-b186-8dc6885a5827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd03d154-f3be-429c-8ed2-1e52e35452b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec8e8a30-0fac-411e-bd0d-34c749f03c6f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd03d154-f3be-429c-8ed2-1e52e35452b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityRollforwardAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd03d154-f3be-429c-8ed2-1e52e35452b7" xlink:to="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_25c208f0-3705-4bd8-aa87-08d35c0590d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_25c208f0-3705-4bd8-aa87-08d35c0590d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived_cbce7ff7-42ea-4d67-b28b-c083c56a7aa0" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityUpfrontPaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived_cbce7ff7-42ea-4d67-b28b-c083c56a7aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1127447d-6b2a-4067-ae3d-ca33aa83e2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1127447d-6b2a-4067-ae3d-ca33aa83e2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate_2969ed78-b843-419c-a141-2f5c1835f72b" xlink:href="goss-20241231.xsd#goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate_2969ed78-b843-419c-a141-2f5c1835f72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b5860a47-9578-4b57-a9cd-ff6bd8957fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_goss_ContractWithCustomerLiabilityRollforwardAbstract_55eef115-b349-4f37-8dcd-207cfde1afe8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b5860a47-9578-4b57-a9cd-ff6bd8957fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf0cfd85-0d90-411d-ba7e-0d4988826c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf0cfd85-0d90-411d-ba7e-0d4988826c44" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_44493ebd-659b-4f44-a66a-039f2b8e9a58" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:to="loc_srt_ProductOrServiceAxis_44493ebd-659b-4f44-a66a-039f2b8e9a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_44493ebd-659b-4f44-a66a-039f2b8e9a58" xlink:to="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_USLicenseMember_7d8ba01e-56b4-432e-9843-dec73b8a6d23" xlink:href="goss-20241231.xsd#goss_USLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_USLicenseMember_7d8ba01e-56b4-432e-9843-dec73b8a6d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ROWLicenseMember_355cd255-5f28-4b73-ac6a-249ed2299fe6" xlink:href="goss-20241231.xsd#goss_ROWLicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_ROWLicenseMember_355cd255-5f28-4b73-ac6a-249ed2299fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_e208aa52-6726-44a0-aa07-5304b9ce9d59" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_e208aa52-6726-44a0-aa07-5304b9ce9d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_58c106f6-68d4-455a-923f-915aae39868d" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember_58c106f6-68d4-455a-923f-915aae39868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_32dc228d-d00e-4647-a7b7-46a82c89232a" xlink:href="goss-20241231.xsd#goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_32dc228d-d00e-4647-a7b7-46a82c89232a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_a64c68fb-62d6-4437-99cf-8d68f59ddf6a" xlink:href="goss-20241231.xsd#goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember_a64c68fb-62d6-4437-99cf-8d68f59ddf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PAHCommercialExpensesSubjectToReimbursementMember_b117cf63-3630-45da-ba14-50aef46b0805" xlink:href="goss-20241231.xsd#goss_PAHCommercialExpensesSubjectToReimbursementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PAHCommercialExpensesSubjectToReimbursementMember_b117cf63-3630-45da-ba14-50aef46b0805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_PHILDCommercialExpensesSubjectToReimbursementMember_59fac4a4-0ce0-4f02-a459-7f0d5aa33c23" xlink:href="goss-20241231.xsd#goss_PHILDCommercialExpensesSubjectToReimbursementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_PHILDCommercialExpensesSubjectToReimbursementMember_59fac4a4-0ce0-4f02-a459-7f0d5aa33c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_EffectsOfExchangeRateMember_f07075b4-9dfe-48ac-9aef-5c1b8b372e3c" xlink:href="goss-20241231.xsd#goss_EffectsOfExchangeRateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ac76b79-b0dd-4499-9271-fd3c5e6ec1c7" xlink:to="loc_goss_EffectsOfExchangeRateMember_f07075b4-9dfe-48ac-9aef-5c1b8b372e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3ee3760f-66ec-482b-b237-23d8fa860a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3ee3760f-66ec-482b-b237-23d8fa860a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3ee3760f-66ec-482b-b237-23d8fa860a9d" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_99615cf5-3b70-4edc-b359-3c981b261ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_99615cf5-3b70-4edc-b359-3c981b261ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_98001664-912d-4662-80e6-af5c744744ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_3c91ec5a-2cde-46de-b6f3-c1679ab70e2d" xlink:to="loc_us-gaap_TransferredOverTimeMember_98001664-912d-4662-80e6-af5c744744ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5f3a696f-cc40-453f-82b3-207dec36d96a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:to="loc_srt_CounterpartyNameAxis_5f3a696f-cc40-453f-82b3-207dec36d96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2833fc21-f526-4b8f-af36-f81249af5f02" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5f3a696f-cc40-453f-82b3-207dec36d96a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2833fc21-f526-4b8f-af36-f81249af5f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_28f1f31b-cc6f-44d2-b29f-2e252d57c924" xlink:href="goss-20241231.xsd#goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2833fc21-f526-4b8f-af36-f81249af5f02" xlink:to="loc_goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member_28f1f31b-cc6f-44d2-b29f-2e252d57c924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e485803-0952-47b1-bfbf-cb1c086420d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_41c234db-e895-42a1-815d-00a98069597f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e485803-0952-47b1-bfbf-cb1c086420d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c18c6333-7d6b-46ff-a34f-18f970d7ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e485803-0952-47b1-bfbf-cb1c086420d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c18c6333-7d6b-46ff-a34f-18f970d7ecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="goss-20241231.xsd#SegmentInformationScheduleofSegmentReportingInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e55fe6e5-aad2-4308-b464-55c2b2ce9b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_af94051a-428c-4ddd-bd61-b8b6bdbf68f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e55fe6e5-aad2-4308-b464-55c2b2ce9b1a" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_af94051a-428c-4ddd-bd61-b8b6bdbf68f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0753a507-900c-416c-a9b9-34e5826b28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_af94051a-428c-4ddd-bd61-b8b6bdbf68f6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0753a507-900c-416c-a9b9-34e5826b28c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_977c2c67-7dc0-4447-a7c5-6b0971bc9e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0753a507-900c-416c-a9b9-34e5826b28c3" xlink:to="loc_us-gaap_SegmentDomain_977c2c67-7dc0-4447-a7c5-6b0971bc9e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_goss_ReportingSegmentMember_10ec031a-3dcf-4faf-8edc-b6ccb6ec6d09" xlink:href="goss-20241231.xsd#goss_ReportingSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_977c2c67-7dc0-4447-a7c5-6b0971bc9e0e" xlink:to="loc_goss_ReportingSegmentMember_10ec031a-3dcf-4faf-8edc-b6ccb6ec6d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_af94051a-428c-4ddd-bd61-b8b6bdbf68f6" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e13ecad1-5cb0-49b0-81d1-8477f0a441d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e13ecad1-5cb0-49b0-81d1-8477f0a441d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2d7aff9d-1762-455d-8487-7643c67e77de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2d7aff9d-1762-455d-8487-7643c67e77de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_e3d45b3d-6220-446c-87b1-654a2d3ebeff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_e3d45b3d-6220-446c-87b1-654a2d3ebeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d4d7a416-0fa2-4e7b-b171-56f3ef6abe4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d4d7a416-0fa2-4e7b-b171-56f3ef6abe4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_d38752a0-1084-4f1d-a7c2-189f1c42fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_InterestExpenseNonoperating_d38752a0-1084-4f1d-a7c2-189f1c42fef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_58805d4d-47bb-4681-a785-b3c49e94f61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_58805d4d-47bb-4681-a785-b3c49e94f61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4c8273a2-09b4-4f56-ad8b-e8ebd8a7707e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4c8273a2-09b4-4f56-ad8b-e8ebd8a7707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0bb3ba8-4af4-4e0d-a52a-23d5c349de96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_d93c8d4c-84b3-4376-9c54-7f62605f5680" xlink:to="loc_us-gaap_NetIncomeLoss_e0bb3ba8-4af4-4e0d-a52a-23d5c349de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>goss-20241231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 goss-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #1 JP# 2(  A$! Q$!_\0
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MK=2-,SB)$C&2S-Y;G Z 9.*.=]PY(=CH_P"Q4_Y_=0_\#'_QH_L5/^?W4/\
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MQ4_Y_=0_\#'_ ,:/[%3_ )_=0_\  Q_\:T:*.9]P]G'L9W]BI_S^ZA_X&/\
MXT?V*G_/[J'_ (&/_C6C11S/N'LX]C._L5/^?W4/_ Q_\:/[%3_G]U#_ ,#'
M_P :T:*.9]P]G'L9W]BI_P _NH?^!C_XT?V*G_/[J'_@8_\ C6C11S/N'LX]
MC._L5/\ G]U#_P #'_QH_L5/^?W4/_ Q_P#&M&BCF?</9Q[&=_8J?\_NH?\
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M?^!C_P"-']BI_P _NH?^!C_XUHT4<S[A[./8SO[%3_G]U#_P,?\ QH_L5/\
MG]U#_P #'_QK1HHYGW#V<>QG?V*G_/[J'_@8_P#C1_8J?\_NH?\ @8_^-:-%
M',^X>SCV,[^Q4_Y_=0_\#'_QH_L5/^?W4/\ P,?_ !K1HHYGW#V<>QG?V*G_
M #^ZA_X&/_C1_8J?\_NH?^!C_P"-:-%',^X>SCV,[^Q4_P"?W4/_  ,?_&C^
MQ4_Y_=0_\#'_ ,:T:*.9]P]G'L9W]BI_S^ZA_P"!C_XT?V*G_/[J'_@8_P#C
M6C11S/N'LX]C._L5/^?W4/\ P,?_ !H_L5/^?W4/_ Q_\:T:*.9]P]G'L9W]
MBI_S^ZA_X&/_ (T?V*G_ #^ZA_X&/_C6C11S/N'LX]C._L5/^?W4/_ Q_P#&
MC^Q4_P"?W4/_  ,?_&M&BCF?</9Q[&=_8J?\_NH?^!C_ .-']BI_S^ZA_P"!
MC_XUHT4<S[A[./8SO[%3_G]U#_P,?_&C^Q4_Y_=0_P# Q_\ &M&BCF?</9Q[
M&=_8J?\ /[J'_@8_^-']BI_S^ZA_X&/_ (UHT4<S[A[./8SO[%3_ )_=0_\
M Q_\:/[%3_G]U#_P,?\ QK1J&[NX+"UFNKJ:.WMH4,DLTK!410,EB3T %',^
MX>SCV*G]BI_S^ZA_X&/_ (T?V*G_ #^ZA_X&/_C6+;_%3PG=:?=WJ:Y +>U,
M8E\R.1''F<1X1E#-NP=NT'=@XS4VG_$CPOJE]I5E;:W;27FJO-'96YW+)*\*
MAI4VL 590P)5@#R*7,^XN2'8U/[%3_G]U#_P,?\ QH_L5/\ G]U#_P #'_QK
M*TCXF>%=>UR+1M.UZSO-5E-R([6)B78V[JDX'&#L9E!Y[UG1?&OP1=-"MKKR
M7YF5F3[#:SW'RK(T1)\N-L#>CKSCE31SON')#L=-_8J?\_NH?^!C_P"-']BI
M_P _NH?^!C_XUCVWQ0\+7FK'3(M8C-W]HDM,/#*D9F3.^,2LH0L-K<!NQ]*;
M9?%7PCJ'F?9]>MG"&,9974.))!&C(64;U+LJAER,D<T<S[AR0[&U_8J?\_NH
M?^!C_P"-']BI_P _NH?^!C_XU2E\>>'89=8CDUBU631Y8H-07<2;627'EJ_'
M5LC%;Q!4D'@T^9]Q^SCV,[^Q4_Y_=0_\#'_QJWX1:3[+?QO-+.(KR2-&F<NP
M48P,GZU-4/A/_5ZI_P!?\O\ [+2;;B[CC%1J*WF5-%Z:E_V$+C_T*N*\1?!>
M#Q5XRN=8U">.YTRZEA>>P>(G>B6D]N5W9ZGSMP/;;7:Z+TU+_L(7'_H5>.ZQ
M\)M5\:?%SQ;J!:UTJS6?3'M=5FMI&O$$<:LXM9 X5 2"K94\LV:)[DP^%&G9
M_L^7,&CZ197?B&6]>WU"YDO[J:#Y]0L9IEE-M)S][,<8+=\,<?-5NS^#.H:?
MXEUZ_BET>/\ M:[NKD7YM)&OH!,FW"Y;RVV\<%<$<&O++'X;^,M'TG2[RQLI
M+74;VPU*-)=.@,%VMR\C,([N0L=P:(-Y;\8?;GJ*Z76/#MQ=7$K>"M UK2_"
M@@MAK>G^7);RWN+A&D2)&;<THB$@=@?F! R34#^1U>E_ Z_M?#GBO2Y=2L[1
M=:L5LTM=+M9(K.%AG,_E,[;7;."$PH '7K6MX@^%-SJGBW_A([34UL]3M19O
M9^9 9(T>%9482#(RKK,PX((QFO+I/!>I^)_$5MI^E^'[73_#*:M]HMI+G3;A
M;-LVDP;S+:23C:PB!9=H9FSC(JE;^'_'TNBZ%#I6C7$5QX+\W498;VZ>W6>^
M-PQ:&V54830B 2(BD@ 3ISE> #O8_P!G=]4OI3KFNW?]F327%S_9FDW%Q"L<
MLL*PMMD=V;9Y?F9' W2L0!6K:_"&^_L'5[&]UQ;NYO\ PQ#X<^U&$@_NS.%F
M;GDE9ER/52>]>.ZAX9\:7V@Z]I5OINM)IFL:V_B99&WK)%LN@!;=<KOQ#(%Z
M823UKZREQYKXZ;C0-69YA<_"._ET_4] CUF!/"^K7@OKV%K8FZ#%E>6.-]VT
M*[)G)&5#$#/&.?NOV<[B./2WTKQ'_9EU%9W5I?M'!\ERTJO&LZC/RRI'*Z[N
MXVY^Z*]MHICLCQZW^!>H>%?$5IJ/A77L6MM-'<I9:\9;K$JVSVQ(<$$*8C&,
M>L8]:];LQ.MK"+IHVNMB^:T((0OCDJ#SC/3-344#M8KR_P#'];?[DG_LM6 "
MW &35>7_ (_K;_<D_P#9:X_XM6-U?:-I(6UNK_2(]3ADU>SL@3+-:!7R-H.6
M4.8V91R5!Z]" =R59>H(_"C:>.#STKQ#P_J%GX3^(-K?6WA[Q!I7A>33[J"V
MC-I-,N\SQMN6(9,*'#%5(' )P,USC:7XZDO/$FLWNCZDNG>-+6YB:+2KIGOK
M/RSFT/DNBK$?)#J0&.YF )!H)YCZ3\M\XVMGTQ3>G6OF)?#=U-H3V[Z'>0:#
M#J:S130Z-.;*X)MRI\[3FD\Q5#'&Z,XWX;'4U[M\,EO4^'^@IJ-A+IEZML%D
MM)I6D>/!(4%G);[N#AB2,X)XH&G<Z>BBB@84444 %%%% %>W_P"/B[_WQ_Z"
M*LA2>0"?PJM;_P#'Q=_[X_\ 017C?QF\':QXL\:6MO9-J5I9S0:=&;^P9E-N
MZW^]G!'&54!B#U P>* 9[:(V;HI/X4;6_NG\J^7AI>HZEX_AO?B+X4O[^QBN
M=0AN([:TDN8)91!:I'-$J9PLA1V4]B2."*NZ'X7\46L=N?$FFZM>Z*ATTZE9
M@M++):JE[L1P#F3RR]MYBC)..<XH)YCZ4VMR-IR.O%+Y;_W&_*OG3Q1H/B;Q
M!;6-GX%\.WFC:7HCSZU:IJUY);"6X#@0+&H5SLPLI\EMH =>F<5)??#NUFM_
M&^MZ1X3DTR\O8M*GL52 I-&7*M<HN.A!SOQZ4!<^AMC8SM./7%&TC.01CK7@
M&I>']2:.=(-&U4?$3^U9YI]9V/Y+V9D<_P"MSM:(P%46(<AL< C-3?!KP[XK
M\+ZYX(T?5;>_N=%LO#LLL&H7+%FA:06^;2<DY,D;J^TGJIQU4T!<]XHHHH*"
MBBB@ HHHH **** "BBB@ HHHH *R]'_Y"&M?]?*_^BUK4K+T?_D(:U_U\K_Z
M+6@#4H&3P.317)?%RSO-2^%?B^TT^*6>_GTJYC@C@SO=S&0H7'.2?2@#KFC9
M>JD?44;6]#TSTKY^L?A#XD\*ZIX9O=*N[#3I[B_M_-M-+L)5L+54M;@--+$T
MI+.Q=5+9 X7C-<[)X9^)5])J$-G9F>[T'6+_ %Q+FXGDLXKN=I1Y"Q(%?S%\
MM)1L) _>KS03S>1]1[&P#M./I0RLOWE(^HKYD\0:7J^H:]K>I:=X?UF;4=42
M[D9;RTEBN+6&2T<+LN4?8\0)4"!EW!C@8(S7H/P#TNSTG3+B&&RAL[IK:W\X
MPZ%+IQ+!<'<SD^802>GOZT!S:GK.".HQ17#?"W0;KP[)XPM[A[Z:*3799K>?
M4)6EDEC:&'Y@Q_AW;@ , 8P!7<T%!1110 4*I8X R?:BO/?CUHM_XB^&=[IV
MF6WVN[GN[("$HSHR"ZB+[U4@E-H.X CC- 'H;*R]5(^HHVD9R#QUXKPS2/A9
MXH\&^-M-.CZI8VD-Q%?S2I;6$ATVSR+95BCB:4E2Y1FR6Z[L 5QWA'2?B'8Z
M?X1UL:/</'X1@A@GM[BXDBN+KS96-X4@V$2_NVC"[F&"AQF@FY]2^6W'RMST
MXI"K*<%2#]*^3]=\*ZRFF^([:QT+5;J6Z@F-]=7=C,ERF;J-U65E<I>@@-MV
M@,%!Z<BO5O#4&E:3\+_$Z1Z7<2VBAWFL]#T>;39[C*CY(T8[BQQC<#T- <QZ
MRRE>",'WHKS_ ."-C]C\'SOY$EC]JO9+@::8)(H[$,% @C$@!*C&2V "S,0
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M_P# F'_XJCE?]-![1>?W/_(U=Q'0D4F3ZUE_VIJ'_0#N/_ F'_XJC^U-0_Z
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M'_XJCE?]-#]HO/[G_D:E%9?]J:A_T [C_P "8?\ XJC^U-0_Z =Q_P"!,/\
M\51RO^F@]HO/[G_D:F31FLO^U-0_Z =Q_P"!,/\ \51_:FH?] .X_P# F'_X
MJCE?]-![1>?W/_(U*,G^M9?]J:A_T [C_P "8?\ XJC^U-0_Z =Q_P"!,/\
M\51RO^F@]HO/[G_D:E%9?]J:A_T [C_P)A_^*H_M34/^@'<?^!,/_P 51RO^
MF@]HO/[G_D:E0^$_]7JG_7_+_P"RU1_M34/^@'<?^!,/_P 55KP5(\UKJ3R0
MM;N;^7,;,&*].XXH::BQPDI5(V\^C(-%Z:E_V$+C_P!"K1K.T7IJ7_80N/\
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M+-9VTDZ1MT9E&0#7F6H?'B\\&PP)XFT-A/<$R0^0XA=X=A*N8F+%<NKKRPZ
M^U=O'\3/#]U(L*2SS-(=@46S$,2<8]ZZ)8;+4ECG$=O=CD))M63V(!Y[Y'%
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M_H5:-5+<FG\*"BBBH+"BBB@ HHHH **** "BBB@"O+_Q_6W^Y)_[+5BJ\O\
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M?4;?3IS6C\/+.X@\9>+'$;16*PZ?;./X6NXX,3%?HIB4^ZUZ#3'9=CS;PG\
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MXRKDY_V<@8KR78O]T?E2[1Z#\JJ>/H3DY/#K7^NW]??=0R^O3BHK$/3^N_\
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M+1I);N\O([,1^>B1[V>,, 6((PDJ-N(VDY&:N:/\>-*\1^(-)TK3;65I+Z1
M7F=<(A4%N%)PP+*,'U-0^)O$VAZ3<:E:R>&](N)(4TV)(YA&AFCN'8D<KPJ%
M<YZ#DG&*U/A?JUCXNAO;^;0M,T[5;2:-)/LL8+INC5ERV.N,8*D@@ ^U ]3T
M"H?"?^KU3_K_ )?_ &6IJA\)_P"KU3_K_E_]EI_98U_$C\RIHO34O^PA<?\
MH5:-9VB]-2_["%Q_Z%6C52W)I_"@HHHJ"PHHHH **** "BBB@ HHHH KR_\
M'];?[DG_ ++5BJ\O_'];?[DG_LM>0_&?XB?$+P3XT\+:;X9M/#E]8^())K>"
M/4([@W*RPV[SN,HP4AA'M7W(S0#=CV:BO$/^&K-$N-.L+G3/#^K:XUX^FVJ1
MV9B4F[O(W=+?YV&'01_-DX&X59_X:DT".XOOM&@ZY#80I?+:WZP))'?SV8)N
MH(55BVY"K $@!MK8/% N9'LU%>(-^U!I4VAZ)K<-A)_9]X^H"6.*:&Y8K:VK
M7!VR1R;5) QAAG/! ZU4;]L+P[!H,MY=>'-;LM2^TVUO;Z/<&!9K@3VYN8Y
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M3YGT_#>,H8',Z=;$2Y8VEK\GV/FRBO</^&5=6_Z&"Q_[\O1_PRKJW_0P6/\
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M[S'_ #TK>HHK]II4X481ITU:*T2/PFK5G7J2JU'>4G=L*RO$G_(/A_Z^H/\
MT8*U:RO$G_(/A_Z^H/\ T8*WA\2.:I\#-5OO&L'QIJ=CI>CQG4-.358KBYBM
MH[218RKR.<+G?\H YY-;S?>-5[ZPM=4M7MKRVAN[:3[\,Z!T;Z@\5!H>4?\
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M_DE$C)(WB+(/ /<\\US^J?!?QKK?C"\\?G0]+LM07Q#9:K%X1>^5HKB*"V>
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MC"'Y/E!&>?:B.\\7MI<\S^&[-+Y9%6*V&I JZ'.YB^S@CCC'.:GZW3>MI?\
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MF5-%Z:E_V$+C_P!"K1K.T7IJ7_80N/\ T*M&JEN33^%!1114%A1110 4444
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MZ5RXC:-_YD=F%;YY6_E9Z31116H@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L+Q7X;@UZWMK@PF34-.D^U6;))Y9\P X4MC[K="/2MVBLZD(U
M(N,MC2G4E3DI1W./\)^)(_%6BQ7RPM;3AFBN;5_O03*<.A^A_3%;%8GB6#4-
M%\26FL17$8T%HFBU&&9UC2#&66=2>^?E([Y%;2L&4,I!4C((Z$4L/4E).%3X
MHZ/I?S7D_P [HG%4XQDIT_AEJNMO)^:_*S%HHHKJ.(**** "LKQ)_P @^'_K
MZ@_]&"M6LKQ)_P @^'_KZ@_]&"KA\2,ZGP,U6^\:S[OP_I=_>&[N=/MKBZ:(
MPF:2,%C&0P*Y],,P^C&M!OO&BH-#BO&-SX6^'?AF]GN]%@.FWLF+FUMXD F.
MTLQ*D@' 4G Y]*XFY\>^!/L\36G@]I+FWMG>R7[/''FV#LCRJV[A0Q;K\V3D
M#O7KNK:'IVO6ZP:G8V]_ K;ECN(PZ@X(S@^Q(_&JEQX,T"ZCBCFT6PECBQL5
M[=2%P21CCU)/XT"L<+XM\6^$M(UA[#4?#$NH2:9"+=;QX4>-%$<;[=S-N("R
MQYX/WCC/-8%E\4O 4MQ/+)X/9M1MX)%E^QV F548L=A; 'S@L?0 D5['=:#I
ME])(]QI]M.\GWVDB!+9"CGUX51_P$>E5'\%>'Y#EM$L"=I3/V=>A.<=*!69Y
MMI/Q6\&V5G<VT7AMK32["07"M#'$\85T51+@-G+&7R\<GKG JDWC?X?PZG!;
MMX8U!9K>TFB;2X[%9(K<2XD;<$R-T@C7YLD  #BO5?\ A"?#H='&AZ>&084_
M9EX& OIZ ?E4D_A'0[F;S9='LI)<$;V@4G!&#V].* LS%\*:+X0\2>'].U73
M] L8[693+$C6Z;D).&!QD9^7GZ5LZ?X.T+2;F"XLM'L[2X@0QQ2Q1 ,BGJ ?
M?)J[INDV.CP^386D-G%Q\D"!1QTX%6Z"@J'PG_J]4_Z_Y?\ V6IJA\)_ZO5/
M^O\ E_\ 9:?V6)?Q(_,J:+TU+_L(7'_H5:-9VB]-2_["%Q_Z%6C52W)I_"@H
MHHJ"PHHHH **** "BBB@ HHHH KR_P#'];?[DG_LM6*KR_\ '];?[DG_ ++5
MB@84444""BBB@ HHHH **** "BBB@"O;_P#'Q=_[X_\ 017SW^U+\=]8^&>O
M:'IGAS44M+JTM)->U2$V;7)N;6-U1;8;5/EM)^](8X'[OK7T);_\?%W_ +X_
M]!%<#X\^)G@'X<^(YT\0*8=6OM-\VZF@TN:Y8V*,5S,\:-MC4LWWC@9- I;'
M*7?[24L?Q&30X-'MWTB\MQ-I-Y),X.J,UH;A%BE"F)6."NR0J< MG%86D?M4
M:GK.BV\$6C:7;>*;O58=,2RU&XFM(+,R6[3[KEG3(&$95*%@_48KT_3;+X:V
M\YOK:P\/V8M;>"-+YX(HHO)EB_=!)& 5@8^!@]..E7_^$)\ FQ?PY_8OATVM
MZ%NFTKR82)PH^63R^K #HV.!TH%KW/,O"/[35_XZU3P_%INB:38VL]G:WFIM
MK&K"W<":XD@ M/EVS8:)CDXW;E Y-<_H/[6%XL?AVWDL;;4IKS4OL=ZKSN9X
M%EU":UA<E4"*O[O(SR<$=LGVVZTSX?WD>G:K<0>&9H]%806=])]G*6+#HB/T
M0CC"@C%(W@GP!+J5A&VB^'6U +]HLT\J'SMN\R>9&/O$;R6W#N2>](5I=SP'
M1OVL?&5A:Z=::CX=TS7M9N+J^FE&GW#QJ+6&\^S"- 5QYP.3\Q V@$\M74:+
M\?\ Q#XP^.'A?18(;'3/#5UJ>L:?)!]H$E].;2'AIHRO[H;_ )A@\CK7H/BS
M3?AKX=DD;5_#NERSPSIJ1CBTD7$HGFE$2R!50DR2/@>IVD]J7P[J7P[UCQQ'
M>:?I-I;>,;J:>-I9]*:VOQ(D2-)YA9 RGRY$.6^\&XS0&NUSR_XC_M@7/PV\
M=:QX;NO#4<TVF331R3+.P&UXD;3VZ?\ +>1FC]BIQ65K7[0GCV'Q%+I]N=-L
M8$N/$%O>?:'+RI+964<J+#\N"%9\@'.<<G%>Z:G+X&U'0;_Q=?V%A=6"D&ZO
MY[+>[?9I61=P*[CY<@;;Z'D56U1OA[<>']7\0WNEZ?<Z?I-]=27=PUAYCQW0
M/DW#!=NYG/W20/F'K0&O<Y3X"?&#Q!\0-!U:R\1V-I:ZWI6C:=J/VNSG,B7*
MW5H9D=@5&U\J20/EYXK@O"/[4WBE=/\ "L=]H^GZQ;R6&AS:IJ3W)AG:349G
MA4QQJNWY64$\CC->U^'?%G@F!KXV-JNC7""TLKN&YTZ2SF6-@8[8.CJ#Y?5%
M;[HZ9K>C\ ^&H$6-/#^FQHBP(JK;( %A8M"!QT1B2OH3Q3#7N?-FC_M9>,M.
ML;.VU+P]IFOZQ<:AJ;.NGSO&!:VUV+?RD!7_ %V3QN(& ">6KIM2_:7\56NE
M:_K$/A*QET>P\07.A1RI+--.@@5F>::%%+8^ZN$W$9)(P*]EN?ACX/O&W3^%
M=&F;[6U_F2QC/^D-C=+T^^<#)[X%6+SP%X:U*SDM;OP_IMS;27+7KQ2VR,K3
MM]Z7&/OGN>IH"TNYX')^T1XFOO%6IBU?1YO#QD\.#3S9SL)6^WGYR69/FC/(
M)P",#'4U1\%_M.>)/[%TV_\ $S:0;JZT_4IT6WE=;=I(]22UA1E"%]_SD +U
MX[G(^BY? ?AF>^BO)/#^F-=PQQ11S_94WHD3!HE!QP$(!4=L<5 ?AKX1*7*?
M\(QI&RY\SSU^QQXDWL'?<,<[F56/N : L^YY-\+?CMK/Q,^(7@Z!X4TK3[[3
M=;^VZ>HW;KBSNXX%D!(W*,%OE[9YSBM;PS\7M0A^'?Q1U[4+BWU*_P##>L:S
M':6C,L9,%L28XR%YQ@8W=:].TGP7X?T":WETS1+#3Y+=9$A:UMUC,:R,&D"X
M' 8@$XZD51C^%_@Z'7)]:3PMI"ZO.9&FOA9IYLA<$.6;'.X$@YZYH'9GCUQ^
MT]J^H7GV#0-#TG4+V74-(TZ!IKYEAWWMBURQ=E!QY;+MP!DCWK'O/VP]4;0[
M34K'PUI:I'IEC?7\5]J1CD+W5RUNJ6RA?WH4HQ.<'D"O?=)^&_A+041-,\,Z
M3IZ1S)<JMK9I&%E52JR# ^\ S 'K@FN0\:?LX^$?'&L:)>7:W%E::2$6'3+%
M8H[9E63S0IRA907Y(1ESWH$U+N>I,,$BN.\*W-I_PN#Q%;BT_P!.^PQN;OS#
MS'N V;?KSFNQ)R2:Y#PK>S?\+<\0VGV:/[.+..7[1Y7S[L@;-_ICG;^-<N(V
MCZKI?_AO4[\+\<O1];?\/Z&9X9\4^(-+T>VUG5YGN+2\OUMB]Q*"D41D<%]J
MQJ4QA1R3UJMHWQ:UF34EN-06UBT^X2W80E&7R5=)27#=\LBKS_>%>Q8&,8XH
MVCT'Y5Y2P->*@HUW:/E>[\]=O(]MX_#R<W/#J\NSM9>6F_F>1P_%S7I=#;4C
MIEFD>ZVB((?Y&EA\PNQ)'R@_+]2/I5OQMXNNHF\+27&K3>&K>^LIYYV@57Q*
M$C*)\RG/+'C S7J.T=,<4%0W49JOJ>(<'"5=N]NG9WZ-/5:;D_7L.JBG&@E:
M_7NK=4UH]=CR32?BEXGF5;:?18?ML-B)Y8Y-R2,PB61FQZ')4#'![]JG?XK:
MS<3:<L>E1Q0:A$9X2Q82&)F<(0#_ !!5#$8/WATKU3'.<<T8''%"P>)2M]8?
MW('C<*W?ZLOO9XYIGQ:UJU\/V\D]K#=W$=D)'60,LSD6_FF=L#:(RWR\=_RJ
M:X^+FNK'-]GL=/N5A223[0HE\J8+Y/"=\@RD'W6O5[RQM]0M9K:YB6:"9#')
M&PX93U!]JDCC2*-410J*,!0. *A8+%I<OUAV]-31X[!M\WU=7]=/R_K\O+H_
MBMK:Z]%ILFDV[%;AX))5+*LVV0J3'D]@ 2#GKVJ'3_B3K^JZEH44L=I8PW%Q
M:M.Z1N5,<T4C!"6/!W(!GOD5ZS@=<4;1Z5?U/$W5Z[M?M^!G]=PUG;#J]N_X
M["T445[!XH4444 %%%% !1110 4444 5]0L[?4+&XM;N-)K69&26.095E(P0
M?PKA/AO=P3:"]M8R75UI=E,]K:7UT1FX121E<=57[H)ZXS6QXTU#5FN--TO1
MXU!NILWEXZATMX%Y8%3_ !./E'XGM5ZUM8+&WCM[:%+>WB7;'%&N%5?0"N2,
M?:8CGCIRJSTWO9V]%U\^NZ.JI)4\-[.6KDTUKM:ZOZO9>6ZV9+1117H'E!11
M10 5E>)/^0?#_P!?4'_HP5JUE>)/^0?#_P!?4'_HP5</B1G4^!FL?O?C7G>H
M?%:XL5%RFC1W5E)J,FFPQQWR"ZDDCF\ICY3 #&0Q'S< #.,UZ&WWC7)>,;.P
M\.Z7?:[9>'+75-9+Q^7&(U5YI&=0/FQQV.>IVBH+9S-M^T1X?N)9HUL=3F>,
M-(5MK5I2J ,4W8Z%MCC'0$=>:TX?C%IUUX=EUJ&TGELX[R.T\N/YY263<<*,
MY8<C&:XE?B#H]Y:"ZL_ MCJ5N/.C#6Z<CRRHN69"F0H+X!]<YP#FNOL/%7A*
M;PA;30:)%/;75VT0TRUMU9O-5&?+!MJY$8W$Y^A- KEK4/C-HNG>'=*UE[6]
MEM=0BDE18D5FC",%(8 ]=S*H SUJG%\=]&N)TMXM+U9KN3RQ';R0+"\C,<$
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MZ%6C6=HO34O^PA<?^A5HU4MR:?PH****@L**** "BBB@ HHHH **** *\O\
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M/_/\G_?+?X4<DNP>TI_S+[S5HK*_X2C2?^?Y/^^6_P */^$HTG_G^3_OEO\
M"CDEV#VE/^9?>:M%97_"4:3_ ,_R?]\M_A1_PE&D_P#/\G_?+?X4<DNP>TI_
MS+[S5HK*_P"$HTG_ )_D_P"^6_PH_P"$HTG_ )_D_P"^6_PHY)=@]I3_ )E]
MYJT5E?\ "4:3_P _R?\ ?+?X4?\ "4:3_P _R?\ ?+?X4<DNP>TI_P R^\U:
M*RO^$HTG_G^3_OEO\*/^$HTG_G^3_OEO\*.278/:4_YE]YJUEZ3_ ,A'6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>goss-20241231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 goss-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9J"J # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10!Y'^TI\>K;X#^"$OHX4O=>U!S!IMG(2%9@,M(^.=B C(')+*.,Y'AWAO\
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M-_VY/&&NW4WB2Z\*> -,F58K&U))).=B[00'? +,[9VEL 8.!]6_!^PCU7X
M^"+*;/DW/ABQA?;UVM:H#^AKX]^&_C7Q+^PWXNUSP_XN\.W>J>%M1G5XM1LQ
MA7*@@20LWR,2I^:,D$$#D8Y /37_ .">>C::IFT#QUKVDWP&4G94;##H<)L/
M'UKZ$^$/A77_  7X!T[1O$VN-XDUBU:42:G([LTRF1BF2_S9"E1R3TZFN/\
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M6'P3QQ_IEC_Z7+3?CMX=U/\ 9B^,5G\7O"ULTGAO59O(U[3H>%W.<OGT#XW
M]!(O/# 4 ?95?(?_  3XUK4-8LO'YO[^YOC'>6P3[3,TFT$2Y R3CI7U/X7\
M3:;XS\.Z?KFCW*WFF7\*SP3+_$I]1V(.00>0017R7_P3G_X\?B)_U^VW\IJ
M/LFN%^-7Q9TWX+?#^_\ $NHI]H:,B&UM VUKF=L[(P>W0DGL%)YZ5W5?&_[;
MS-XN^+'PD\#S,5T^_O5,RJ2-QFGCA!_ !L?[QH S_"'P3^)'[55HGBWXA^+;
MS0/#E\/,L=%L00'A/1EC)VHI'1F#,PY/&"=C5/V"[OPC:MJ/PY\?:MI6NPC?
M&+I_+64CHOF1;2GU(8>U?7EO;QVMO'!"BQ0QJ$1%& J@8  ],5)0!\W?LO\
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M.,M<2?+'QWP3N(]%-9_[,OQ._P"%K_!O0=7FE\W4H(_L-_Z^?$ I8^[+M?\
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MY_B#K6DKX?G2%9(W>4S;GE7)!D&W_5>_6OT?KXV_8/\ ^2B?&'_K\A_]'7-
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M#NJ_$K]M*#P5!XFU'0+._LT/FVDKD1E+1Y<A R@Y*8_&NU_X81U+_HKFO_\
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M>&[/6KW1X-86&RDEM)679YMUY>_:&&X@-^E;K_L*ZS&I>V^,&O17"\QNT+D
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MB;![Y&UQV8=MP% 'G?[0FM:A9_MD_">SM[^Y@LYH[/S;>.9EC?-W*#N4'!X
MZU]>5\;?M&_\GK?"'_KG9?\ I7-7V30 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG]GOX%:;\!?!/]DVT_V_4[IQ/J%^4V^=)C 51V11P ?4GO0!Y]^W[_R0%O\
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MA(S.WTV?)]9!7BGPS^$7[37P[\)V^F^%M1TS1=+F/VO[+(+1W#N 27+Q,V[
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M0-(^%S:A;7-\]\TM[&V\,T<:$#;(!C$8_,T ?>]%?)?_  OC]HW_ *)!:_\
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MKP[I6GZ#<6Y$.I:9I\*Q+%<!1EMJCD.!N#')QP22#5C]K#_DW?QQ_P!>2_\
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MK\\,N,$XYP#WQ7WS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"^E_\ B:GL?!=EI]W%<1RW#/&=P#,N/_0: -^BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\]^
M./V^;X>7DFF7'EB*5&N2CX)B!(*@CON*\>@-9OP+\8&[^']R^J76$TN5D:XG
M;I%M##)/IDCZ 5YLL=&.+^JR5KJ]^A'-[W*>J45E:#XHTGQ1;M-I5_#>HIPW
MEM\R_53R/Q%:M>A&<:B4H.Z+"BBBJ **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "N0^('C;2O#^D:G92:G%;:L]A-);P[L.6V-MP>Q)'&>O:
MNOKX[^*'B*+Q3XZU34+<,+=G6./?UPBA<_B03^->#G&/>!H)PUE+3Y=695)\
MJ.B^&ZR3?#CXA LS1"WA8*3QNRY)^O H\)WGV?X*>,U!^9KBW4#_ 'G4'] :
MTOA;:[OA/X]DQG="1_WS&Q_K7&Z7JT5K\-==LFDQ-<WUMLC]0 [$_H/S%?&*
M7LJ5&3ZTY_CS'+LEZ,Z#]GJZ:W^(D<88@36TJ$9ZX ;_ -EKZBKY+^"-Q]G^
M)VBGLQE0_C$X_GBOK2OI^&Y<V#:[2?Y(WH_"%%%%?5'0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7G=U\!_"EWJMW?-!<+]H5LVZ2@1(S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\
M94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
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MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_
MZ!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S
M/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\
M94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
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MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_
MZ!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S
M/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\
M94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
MV5=-10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@
M5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H
M%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_
MVMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E
M1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#9
M5TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4
M?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5
M'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:
MWB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5'
M]K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7
M344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_
M]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?
M_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>
M(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?V
MMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-
M10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_W
MU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]
M]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB
M_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:W
MB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU%
M ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7
M_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU
M_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_
M *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_ &5']K>(
MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &54M8\7:QH.EW.H7NG116MNF]WSGC_OKUKLZ\Y^/U]]C^&]W'G!
MN9HH?_'M_P#[)7+BJSP]"=5;Q39,GRILKZ'X\O?B9X=U!+'3QY,BO:R[N&7<
MN/[V#P:P_A=\/O$'P]O+^ZDLXKF:X01+M;A5!R>XY/'Y5M?L[6/V7X?&;'-U
M=R29]@%3_P!E-=SXM\11^$_#E]JTL+7"6J;O*4X+$D #/;DCFO-P\88BC2QV
M)^**O?U\O0A6DE.10_M;Q%_T"H_^^O\ [*C^UO$7_0*C_P"^O_LJY#1/VAM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBOFO^9S_ -N?J8?\O?D>ET445]*;A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/3[: XS%$J''3@ 58HKT\#EE++Y3E2;]ZV_2QI&FH;!1117KF@4444 %%%%
M!1110 4444 %%%% 'G'[0'_)-KO_ *[P_P#H50?L[_\ ).Q_U]R_^RU/^T!_
MR3:[_P"N\/\ Z%4'[.__ "3L?]?<O_LM?-O_ )'*_P 'ZF'_ "]^1Z=1117T
MAN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%0WEU'8VD]S+D10HTCX&3
M@#)_E7!>$_C!8^--+UV:"UEL9M.@:?;*P;<FUB&!'?CD>XY-<U3$4J4XTYRL
MW>WRW)<DM&=1H?C71/$E_=V6FZC%=W5K_K8U!&.<9&1\PSW&16W7SK^S-9F3
MQ-J]W_SSM!%_WTX/_LE?15<F6XJ>-PRK5%9N^WJ3"3E&["BBBO4- HHHH Y#
MXLZ#_P )#\/]7MU7=-'%]HCQUW(=V![D C\:^0MK;=V#MSC..,U]V5P?Q*\+
M:3#\.]=6WTNS@V1-<KY4"+B0#[XP.N,\^]?*YSE7UQ_6(RLXI_.VISU*?-J<
MY^S/-N\'ZG%G[M^6_.-!_2H_VCO%-O::#!H.QVNKMEN-P^ZB*W?ZG/Y57_9C
MEW:/KD?]V>-OS4C^E<O^TE(9O'.GQ+SML$X]S))_]:N*I6E3R*+CU5OQ:);_
M '1Z7^S_ &[0_#>U8J5\V>5QD=1NQG]*](J&SLX=/M8K:WB2&")0B1QJ%50.
MP Z5-7UN%H_5Z$*-[\J2.B*Y4D>6Z]\';G5/BC:>)K>^B@M%FBN)HL'S-\>W
MA>,$-M&23QD]:W/%WQ7TOP?XDL-&NH;B6:Y"LTD0&V(,Q52><GD'IVKM))%C
M1G=@B*,EF. !ZU\U?%B:/5?C-91PNLR%K2,%""#D@]?^!5XV.DLLI.IAM)3D
MK]=]S.7[M7CU/I>BBBOHS8**** "BBB@ HHHH **** "BBB@ HHHH S?$7AZ
MQ\4Z1/INHQ>=:S8W*&*D$'(((Z$$4WPWX;L/">DQ:;IL1AMHR6 9BS$DY))/
M4UJ45E[*'/[7E]ZUK];"LKW"BBBM1A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%17%Q%9V\L\\BQ0Q*7>1SA54#))/IBI:^4/B-\2=<U;Q#K]DFI2KI3S/;+;*
M<(8T? _/;DGODCI7DYCF$,OIJ<E=O8SG-01]'^&?&6B>/+2\_LRY^U11'RID
M9"I (.#@CH0#@^QKY=T'6/\ A#KSQ192.R^?8W&GXQU8L /Y']:^@/@GX';P
M=X5$MRA34=0VS3*>J+CY$^H!)/NQKS3Q5\#_ !#JWQ OGMK=%TN]NFG^V>8N
MV-7;<V5SNR,D8QS7@9C3QF(P^'KJ'[S6Z2VO_6IC/FDD[:G1?LQV/EZ3KEYM
M_P!;/'$&_P!U2?\ V>O:ZS/#GAZR\+:/;:;81".WA7'NQ[LWJ2:TZ^FP&&>$
MPT*+W7_#F\(\L4@HHHKO+"BBB@ K*\5:7)KGAG5M/B($MU:RPH6Z;F0@9]LD
M5JT5,HJ<7%[,#RGX#^!]9\&VNLMJ]L+0W3Q"*/>K-\F_).TGCYACZ5P'QO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY3WFXO+>T:,3SQPF1MJ"1PNX^@SU-35\X_M+7+_\)AI<.6"QV(=>>,F1P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBH[BXCM;>6>9Q'%&I=W;HJ@9)_*C8"2BOGN3XK:UXM^*
MVG0>'[R5-*:>.*.W==JR(.9&<?3=[@ =*^A*\_"8ZGC>=TMHNU^C]"(R4KV"
MBBBO0+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MST^VCM+6/.V*)< 9.2:\IX.3QRQ=].6UOF9\OO\ ,7****]4T"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2)))F+-MVH0"3R>6-<#QD5BUA+:M7N1S>]RGI-%%%=Y84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP<@\8!Z8->R:;\%[#2_B$WB:&[81>8TR6(B "R,""=V>F22!BL;]F_PV=/\
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M@SSZ7)<33+<JK#S$*!,*&'8[\\8Z5U/P-^)M]XPCN=*U0-/>VL?FK=XQYB9
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M?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\
M?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[
M^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:
M+5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_
M:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[
M4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]
MP?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G
M[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q
M?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+
M_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5
M%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:E
MG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L
M_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<
M'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_
M +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\
M: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C
M1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5
M?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_
M ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^
M?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\
M?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[
M^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:
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M\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T
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M2S_Y^X/^_B_XT 6J*J_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"- %JBJO\
M:EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^- %JBJO]J6?_/W!_P!_%_QH_M2S_P"?
MN#_OXO\ C0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]
MP?\ ?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\ S]P?]_%_QH_M2S_Y^X/^
M_B_XT 6J*J_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"- %JBJO\ :EG_ ,_<
M'_?Q?\:/[4L_^?N#_OXO^- %JBJO]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\
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M*4E-GEW[1N@/IGB#3?$%MF,W"^6[KVE3E6^I7'_?%>V>#_$">*?"^FZJF/\
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M\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T
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M8[:&.&&-8HHU")&@ 55 P  .@H ?1110 5CW7A73;VXDGEA9I)#ECO(K8HH
MPO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_
M '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_
M )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:*
M ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-
M_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])
M_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MV
MB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">
M#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O
M2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK
M=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\
MG@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$
M+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\
M:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_
M )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\
MA"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;
M_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])
M_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_
M (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_
M&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O
M2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH
M_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\
M?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$
M+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\
M:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_
M '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\
MA"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;
M_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-
M_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_
M (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_
M&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">
M#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"
M_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\
M?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\
MG@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH
MPO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_
M '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_
M )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:*
M ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-
M_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])
M_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MV
MB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">
M#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O
M2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK
M=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\
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MK70A42D>A;&<5X6!H5,UPE'FE94Y6MW2M^/0RBG4BO(SO^$+TG_G@W_?QO\
M&C_A"])_YX-_W\;_ !K=HK[@ZC"_X0O2?^>#?]_&_P :/^$+TG_G@W_?QO\
M&MVB@#"_X0O2?^>#?]_&_P :/^$+TG_G@W_?QO\ &MVB@#"_X0O2?^>#?]_&
M_P :/^$+TG_G@W_?QO\ &MVB@#"_X0O2?^>#?]_&_P :/^$+TG_G@W_?QO\
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M10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\
MOXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_
M +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D
M_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7
MI/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M%
M &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_
MC?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\
MOXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_
M ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D
M_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4
M>9_%SPS8:9\.]9N;:-XYD2,!O,/>10?T)K$_9STZ&\\,W-U,&>:WOF6([CA1
ML0XQ]2?SKK_C7_R3#7/]V+_T:E<U^S3_ ,B;J7_7^W_HN.OFZK?]L4U_<?YL
MQ?\ $7H>NT445](;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW^_47LHIIH****^C-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG7C'<UQ;1S$^NY0?ZU?KS#X3_$O1+KPSX?T>YU".'5_*^S+;L&YV$JHSC )
M& 3DYK2\%_%[3O&GB6^TBWMI8&@#/%,[ B95;!..W4''I711Q^'J0I^^KR_.
MU[?\.-35EJ=[1117IF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA1D]47"/+%(****[RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ./\ B[8W&I?#G6K>UA>XG:-&
M$<8RQ"R*QP/H#7.?L[:7=Z9X+NS=VTEL9KUGC652I9=B#.#VR"/PKU.BO/E@
MXRQ<<7?5*UB.7WN8****] L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH XGXP^*KGPEX'NKJRD,-Y,Z6\,@'*%
MCDGZ[0U8?PU^(#6/PSCUKQ7J1\O[2\,5Q(I9W7L.!ECD/^ ]JI?M,7&WPCID
M&?\ 67P?_OF-Q_[-7)^*-.,?[.WAHA3F.[\YCCLQFZ_]]#]*^1Q6+K4L=5E!
MZ0IWMTO=;_><\I-2=NB/H'3-3M=9T^"^LIEN+6==\<BYPPJU7R]\+_BAXBT_
M4M!\/VS13:>URL7DO&-VUW^;YNHQDG_&OJ&O9R[,(9A2YXJS6_KY&D)J:N%?
M/W[3CSMJ>AH8V%JL,A63'RERPR/KA5_.OH&O'_VF(\^$M+D_NWP7\XW_ ,*P
MSJ'/@*BOM9_BA5?@9Y-\/-2GL_B5X=D:9]S2009+9^1D50OTP>E?7-?&6D72
M1>)_#ERC@LDENS8/W2L@'/X**^Q[RU2^LY[:0LL<T;1L4." 1@X/8\UY7#DG
M[*K'?6_WHSH[,^9OC%\2I]<\7(FD7TT5EIWR1R0R%0\H/S.,=>P!]L]Z^E]/
MN#=Z?;3GK+$KG\0#7RK\4_AFGPXDTY$OVO\ [9YK;FB$>T*5P,9.3\W7]*^D
M/A_KEIX@\'Z7<V<PF5($ADP""LBJ RD'W_I5934K?7<1#$Z3=G:_Y?)H*;?,
MU+<Z*BO#_BC\1M=T;XF:=I>F7A@M8_)WPA01*SMSNXYX(%>X5]#A\7#$5*E.
M"=X.S-XR4FUV"BBBNXH*\+^.'PMTVQTO4O%%F9TNWG1YH=P\KYFPS 8SDL0>
MOK7NE9/BS14\0^&M3TYX_-^T0,BKG'S8RIS[, ?PKSL?A88S#RIR5W9V\G8B
M<>96.$^!WB>SC^&UHE[>P6WV6>6W#3RJF>=X')]'%>8?\)MKDWQDN+C2KJ2]
M:2_:WBAWEHI(0Y4# XV[1G/;K7GFH:7>Z5=?9;VTGM;@?\L9HRK=<=#[C]*]
M'_9YTN:;X@-.86"6EO(78KPK'"@'WY/Y&O@Z>-K8R6'P=G'E:UZZ?\ Y%)RM
M$^G*IKH]C'J3Z@ME;K?NNQKH1+YI7T+8SBKE%?ICBGNCN"BBBF 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMJUOILUS%?V-NK2PQDQK(&;S 2/N@$D\]J^E*\]^ ]]]L^&NGH3EK>26$_\
M?98?HPKT*OHLKH1C!XE.[J)-_<;4UIS=PHHHKVC4*\N^*'P?N/'GB33]2M;^
M*S5(A!<;U)8*&+!EQU/S8P<=!S7J-8'COQ*OA'PGJ6J$CS(8L1*W>0\(/S(_
M#-<.-HT:U"2Q'PK5_(F236IOT5XU^S_XVUCQ-<:U;:K>R7PC$<L;2X)4DL&
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MIOFES:W$EN9 -N\*Q&<>^,XK[=K@K_X*^&]4\4S:Y=QW$TLS^:]JT@$)?N2
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MC^%0Q!^F #7P^<83EQM*O%_'))^JM;\#EJ1]Y/N?5%%%%?<'4%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M78UT(E\TKZ%L9Q5RBDXI[H HHHI@%%%% !1110 4444 %%%% !1110 4444
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MVTLWLMG]EP-@50RC ]<@'-<&*QD,(Z:FOC=B)24;7/=Z***[RPHHHH ****
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M%/G$D8( .0, GG':O;***]/!X.G@J?LJ6U[ZFD8J*L@HHHKM*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *ISZ/875]#>S6-M->0C$5Q)"K2)_
MNL1D?A5RBDXJ6Z ****8!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 455U+4K;1]
M/N+V\E6"U@0R22-T %4?"_BS2_&.GM>Z5<_:8%<QME2K*PYP01GH16;J04U3
M;7,^G45U>QL4445H,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2M<"'<6F9=I=F))..W7]*W:**^JITXTH*$%9+1&ZTT04445H,**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ./^+W_ "3;7O\ K@/_ $):XK]F7_D6
M]7_Z^Q_Z *[7XO?\DVU[_K@/_0EKBOV9?^1;U?\ Z^Q_Z *^;K?\CBE_A?ZF
M+_B(]EHHHKZ0V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#DOBRH;X<Z^#S_ *,3^HKA?V9&/]@:R.WVE3_XY7=?%C_D
MG.O_ /7L?YBN$_9D_P"0#K7_ %\I_P"@U\U7_P"1Q1_PO]3!_P 1'M%%%%?2
MFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCO7PLD$DD4DBKE(\;CZ9Z5]0>&_B"-/^"UMX@FC^T2V=N(#&3C>ZMY:Y/O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M +*C^UO$7_0*C_[Z_P#LJ .FHKF?[6\1?] J/_OK_P"RH_M;Q%_T"H_^^O\
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M +*C^UO$7_0*C_[Z_P#LJ .FHKF?[6\1?] J/_OK_P"RH_M;Q%_T"H_^^O\
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M_M;Q%_T"H_\ OK_[*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH
MZ:BN9_M;Q%_T"H_^^O\ [*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_
M .RH_M;Q%_T"H_\ OK_[*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_
M^RH Z:BN9_M;Q%_T"H_^^O\ [*C^UO$7_0*C_P"^O_LJ .EZ=*6N9_M;Q%_T
M"H_^^O\ [*C^UO$7_0*C_P"^O_LJ -O5M032=+O+Z12T=K"\S*.I"J21^E>6
M^%?CHNM>'_$5_J-HEDVG1J\2PL6W[R55>>^['/O[5!\9O&'B/2O"?DM:1V4%
M\YM99  Q*,C949)QD9YKP738-2OH9[.P@N+E)&1I8[>,N3@D+G Z9;\R*^-S
M7-:N&Q4:5'HG==VUI]QS5*CC*R.G^&_@G_A,[+Q*BLR3V]COAV_Q2;@P4^QV
M$?CGM53X6^'(_%7CK2[&==UL',THQD%4!;!]B0!^->X?#?PWJO@708X(-%C%
MY.JO=3,V7=N2 ?FZ+G&!_4U'X5\!3>#]>O-6L-(;[1<!E"22@I$I.2$&>G Z
MDUST<BE;#SE:ZUEZ7NE^C)5+8]3FACN(7BEC62)QM9' *D>A%5-*T33]#A:'
M3K&WL8F;<R6\2H"?4X%8_P#:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5?<
M<L6^:VIUG345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &54!TU%<S_:
MWB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5 '345S/]K>(O\ H%1_]]?_ &5'
M]K>(O^@5'_WU_P#94 =-17,_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E0
M!Y5^T]8;;C0+T#[R2PL?H5(_FU>@>&_B5H4.F^&=.O-06/4[ZS@*Q;6/S,H
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MXJU_1?!^JW;V*6H6$H)E;E"Y" CGJ"PKW:M14J<JDMDF_N-6[*YZ$K*P)!!
M.#@U\T_!&/\ X23XL7.I7'SR(D][D_WF8+G_ ,B&M#X(W6L:;X9\17MK$;FS
M8X.]OE1E0LQ'/4AE_(5F_L_-?6_B#4[BPM5N76U$;!CC +@^H_NU\E5Q'UZM
M@IN-KMNWIM^1SN7,XL^FJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RK[
M(Z3IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:N<^(GAN;Q=X,U/
M2K<JMQ.BF,R' W*P8 GMDKC\:9_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
MV59U*<:L)4Y;-6^\35U8QO@OX,U+P1X7N+35!&D\UTTXCC?=M!55Y(XS\O;V
MKOZYG^UO$7_0*C_[Z_\ LJ/[6\1?] J/_OK_ .RK/#T8X:E&C#9!%<JLCIJ*
MYG^UO$7_ $"H_P#OK_[*C^UO$7_0*C_[Z_\ LJZ!G345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 &SK6KV^@Z3=ZC=%A;VL;2OL&3@#H!ZUB^ _B!I_Q!TZ>ZL8Y
MH#!)Y<D4X 8<9!X)&#_0USOQ$U+7)? ^MI<:='%"ULP=P>@]>M<?^S;<7D=O
MJ<<%NLEL\\?FR$\I\I]Z\>KBJD,PIX9?#)-O\?\ (S<GSJ)[S1117L&@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 55U2YGL],N[BUM3>W44+O%:APAF<*2J;CTR<#/;-6J*
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MD88'(^88."2.>O>F> _ACX8^&=K=6WAG28]+BNI!)-MD>1G8# RSL3@9.!G
MR?6N;V+<8TXZ1Z]SV?[0C&O4Q57WZU_==ER/H[KTV+7A3PG8^&[02)8:?!J]
MS&AU&\LK5(3=S ?,[%0"<L6//K6GJVDVFO:7=Z;?P+=6-W$T$\+YPZ,"&!_
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M!.N_]=X__037S>(_Y&]#_"_U,9?Q$>V4445](;!1110 4444 %%%% !1110
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M  . *X/X\:?XWU/X?SV_@";R=<:=-VR5(I&AYW!'<@*V=ISD< X.:P=.U/\
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M*V&SS@<<UC*K"I&T9VUL>E0P.)P=5RK8?FM%R:?;O\NVYZ]11176?/A1110
M4444 %%%% !1110 4444 %%%% !1110!Y!K'[,OA?7?BT/'5[)//*72:339
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6?XBU#^R?#^IWV=OV6UEFSZ;4)_I6A7+_%*;R/ACXOESC9H]XV1
M[0.:TIQYIQCW9$WRQ;/SA\/^"M0\2:#XAU>U:/[-HD$=Q<JY.Y@\@0!<#D\D
MG.. :Q8[6::WFF2-FBAP9& X7)P"?QXKZ%_95\+R>+O!?Q6TN% ]Q=Z;#;P[
MC@>8RS[/_'@/RKK?V2?A#J5A)XKE\6^'9(+"YACLUM=5ML"?#EF^1QR 57GI
MGITK](K9A'#NMS_8:T]4O^"?#4L%*M[/E^U?7T;/,OV/['[5\;M/EQG[+:7$
MOTRA3_V>MN/]S^VF=G&=;/ZH<_SKZR\)_"?PEX%UN_U;0M%@TV^OAMF>$MMV
MY!*HI.U%R <* .!Z"ODW6?\ 1_VU(]_?6X.G^TB8_G7D4L9''5ZTX*R]FUK_
M %YGI5,-+"4:4).[Y[GW!1117Q1]4%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !115?4+K[#87-R%WF&)I-N<9P"<4F[*[ L5P7Q
MNUC4-#\ W%SIMS):3F:-&FB.UPI/.#V/3D5D?!CXH:IX\O-5MM3C@#0JLL30
M(5P"2"IY.>V/QK>^,VG2:G\-=9BAC:25%24*HR<+(K'_ ,=!KQZN)CC,!4K4
M&]5*W?2YFY<T&T9_P2\<#Q1X6BM;S4!=ZQ:[A*LA_>F/=\K'UX(&?IGFO1J^
M-O 'C67P%KW]IQ6RW;>4T1C9RH()'.<>U?7/A_5EU[0]/U)8F@6[@2<1L<E=
MR@XSWZ]:Y<ES!8N@J4G[\?R[DTI\RMU-"BBN!^)'QP\)_"G4M+L?$%Y+!<:A
MR@AB+B- <>8^.BY^IX/'%?0RE&"O)V1V4:-3$3]G2BY/LCOJ*16#J&4AE89!
M'(-+5&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%07U];Z;97%Y=S
M1VUK;QM++-*P5(T499B3T  )S0-)MV1Q'Q=UJ[D\,ZCX=\-:[8Z;XXOK;?IM
MM-=)'/( PW; QSDJ' /8\]B1Y9^SW\#X+R2W\:>,[A-9\:VMVX\R/45N@FU5
M5/.9&8-*N#SN/&W/(K2U;X&^#?CMXZA^(.F^*YKNU&V*6+3Y%9?-C4!</UC(
M&PE<<]>-U=)\!/V?H/@:NM&/7)M9DU)H\[H/)2-4W8&W<V6^<Y.?P%<'+*I5
M4I1NO73R=CZGVU'!X"="E5:J.UURM.[TE'F[):V/6Z***[SY4Y;6/A?X5U_Q
M=I_B?4-$M[K7;  6]X^[*X.5)7.UBIY!8$CMBNIHHI**6R-)5)U$E.3:6B\O
M0****9F%%%% !1110!YS\;OC38_!/P_9ZE=Z?/J<EY<?9XH(7"#(4L2S$' P
M/0]:X+X4_MB:+\2/%EKX?N="N]&O+R0QVL@F6>-CMR Q 4J3@C@$=.17N'B#
MPQI'BRP^Q:UIEIJMGO$@AO(5E0,.C $<'D\^]8NE?"7P7H6N6^L:;X7TO3]2
MMT,<5Q:VJQ% 002 H S@D;L9P<9KFE&MSIQE[O8]JA6RZ.%<*U)NIK:2>GEI
M^>AUM>'?&/\ :FT[X/\ C:U\/W.A76I!K=;B>YBF$9C#$@!%(^<_+SR!S7N-
M<_XJ^'WAKQQY)U_0K#5FA_U;W4"NR<YP&QD#U'0UI44Y1M3=F<>"J8:G5OBX
M.4.R=CQ^X^(7Q/UCXV>'1H.ER3?#C48+:Y6=K,>6UO)$KO))+C*2*6;";AG
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MCO%V84445R'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^BLBX_56JI8JK#,8X=_#*-_F',^?E/7J***]HU"BBB@ HHHH **** "BBB@
MHHHH BN;B*SMY9YG$<,2%W=NBJ!DD_A7BMG\:K[Q5X^.CZ?!%)H=TKPQ[D*R
MD>627SGCD'C'3\ZZ/XX>.['0?"][HZSYU6_AV+"O)6-CAF;T!&X#UK@_V>_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*KC2?V-/AO'_ ,(UI%WK7]I:AB2:^N.%8IG+LJ@?=7   [G/KZ[I/Q TVX\
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M%M-)<N_F,I[2,QX,;N /N_-GWKEO@I\(?C+X%UIIKW5HH=-@TJ6*WT^>]\^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#2&22*V-JY8Y(,3M& ?P4?F*_/SPSH)UYM4'/^AV$UY\I_N &OKG]AO5'N/
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MOQHA&/O6%P/T4_TK[TKISJG"EBN6"LK(Y\KJ2J8>\W=W84445X)[ 445XO\
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M EC<LFDYZ.+UE%_/H^_G]U?X7^!_^%;^ ='\-_;I-2.GQ%#=2+M+DLS' R<
M%L 9X  KJ:**]",5%)+H?*U*DJLY5)N[;N_5GSIXF^'/Q&\=?&C4-/\ $+"\
M^%UVIWVXG58?*"YC"J"'$HD"MN]NI7BL?X-_%&;P+\7[OX52Z'9>'?#D,\\5
MAY[NMP[[B4D9W8B0R]@!W4+P,5]1UXM\6/@OX,O/&EI\2O$NLW&DPZ3Y,EPI
M<"&0QN#'G@L,G PO)XQ@]>&I1<'[2#UOK?MV]#Z3#9A3Q,7AL5&T7&T5%/XE
MM*RWD]KG2^!_CMX1^(/C+5/#>C7,TFIV*L7:2$K',J-M8HW< D=<=<C->B5Y
M[\,_!?P^CNKKQIX,L[1Y-9W&2_MY'8-ELNJJQQ'\PY4 <CD<5Z%753YN6\[?
M(\3&*A&KRT%))6NI;WZA1116IQ!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y+^T
M7#\2)_#6G+\.6877VG_3! T:S;,?+M+G&,]<<\CMFO0_"*ZNGA72%U]HWUL6
MD0O6AQM,VT;\8X^]GIQZ5;UB\FT_2;VZM[5[ZX@@>6.UC.&F95)"#W)&/QKQ
M/X#_ +1MS\0&O[3QE;Z=X:OQ=+!IZM(8/M9.X&-4D8LSH0 2.[J, ]>9N-.K
MJW>7W:'L0IUL5@G[.G'EIO5KXG?\6D;/[2&K?$?2_#NE'X=VLLUP]R?MDMM"
MDTR* -@","-I.<G'&!V)K'_:%\9?$'P7\%=(UK3)(-.U>,V_]M30*C^264!@
M@<$%?-('&3R.V36/\9OVG/$7@OQ_?^#/#?A.34M22V5H+B17D9W9 Y=(D&71
M5W#KU4]E(.;\(OC'XY^*?BY?!OCGP9#)HMW8,;QY-/EBVC87220.2NU_E48
MY((KFG4A*<H1D[O3R3/;P^#KT</2Q%6C!PA[[NUS2B^_Z>?0]<^ ?Q*;XJ_#
M/3=9G);48\VMZ?+V SH!N( XP05/'KVZ5Z+7SSX[_:)\$_!+P[%I?@FPT_5F
MMKLVTVGV,PACMS@EF9@IW$D8R,\@Y.1BO;_"/B >+/"ND:TMM)9C4+2*Z%O-
M]Z/>H;:?7&>M=5*HG[E[M;GA8["U*;>)5-PIS;Y4]_N->BBBN@\D*J+J]BVI
M-IRWMNVH+'YK6@E7S0G]XIG./?%<-\>M2TFW^&NJZ=JGB:+PJ=4C-I!?2$YW
MGDKA>2I (;'0$U\I7W[)_P 1_"L^B:QX,U*/6KB6#S/[0TF^6V,&<@;'=U+(
MT97E?5AC&">2M6E3E:$>;O\ \,?08#+:&*IN=>O[-NZ5UH[+^;1'=_&GXK?$
MOX+_ !D76KTO>^#+AC'96*R*MO/&$&5) )60,<[B,G'&5XKK/&G[-T7Q.U6?
MXAZ'KVI:#KVK:?'<6UO(=HAE:!5 9A\RC9\I Z$GM\M'P4\"_%JU\=7\GQ&N
MUU7P_P#9ODCN[B.YC><%=C1(/N%1NR<+G/?K7T565.E[5-U+V;V>Z.W&8[ZC
M*G#"N//&-G*&JDNS5M^_?\%\3_#K2_ NA?$/3O#'Q*N+C5/&>EW19-4>=OL$
M(4"2."1V8%PI#-N*@9?:<@"OM2WN(KRWCG@E2:"10Z21L&5E/(((ZBO*OC!^
MS?X8^*UG?7 MXM)\1S["NKPQ[F)7@!UR P(XSUX'/&*XG]G'P]\3_ /C#4/"
M.MQ-/X'TV.9+2[FC158^9E&B898[@6)4DA1QP0 2DI4)\CCH^J_4,;*CFE#Z
MS"K:<%K&6WFX=-^A]'T445Z!\D%%%% !1110 4444 %%%% !1110 4452UK6
M;+P[I-WJ>I7*6=A:1M--/)]U% R31L-)R:26IX3\4_VO=(\%ZMKGA_1M)N]5
M\0:>#&K2)BV\Q3\X.#O(1<D\ ':>1UKSCX-_";7OVA/$'_"=_$:6\:RB,9L"
M@2$7(61FV;0N?*!.,\$YP#W'4?$KP_JOQ0UK0O'OP4FTZ:=IFAU#4[8K;W'F
M ( 9?- .T)P5QD@C(8$8[[]H3X0^*OBQX=T&TT/7X=,N;*4R722R2113DJ!O
M^0$Y4@X!'\9Y%>5*,ZDG*7O);+HS[JG5PV#I4Z-"U*=324FVYPMNK6TN]OZM
M[)16=X=T^XTGP_IEC>7;:A=VMK%#-=R?>G=4 9S[L03^-:->H?#223:3N%%%
M%,D**** "BBB@ HHKR#]HKXG^+_AGI>BS^$] 767N[AH[B22"298L;=B[4(.
M7);G/\..I%1.:IQ<F=.&P\\55C1IVN^[LCU^O#_%'[0.K>'_ -H#3/ ">&OM
M.G79AC^V;F$C>8 3*G&"B9(/^XW(I^@?M9>$=3OM6T^^@O\ 3+[2;-[F[66$
M,A>,#SHH\'<2IR.0,X-3_#7]JCP7\3O$5EHMI%?V&K72N(8[R!0I(!8J'5CR
M0N?3CUKGE6A.RA.SO_2/7HY?B,-[2=?#.<5%^5KK26G87XT? >3QAX!_L'P0
M^G^%7:]6[N(88_L\%T,'(D\I<G!((X(^4>Q'-?%#]F_Q;XZ\-^!=,M_&($FB
MP""]ENFD42, ,3(%R6< $?,1D8Y'.?HJBKEAZ<KWZG/1S;%4%!1:]UMJZ3=V
MK/<\R^$?[/OAOX-W.IW.D2WMW<:@JQR/?2*VQ 2=JA5'!)[Y/ KIYOAKX7G\
M70^*)-#M&UZ%!''>E/F4 8''3(' .,@<9KIJ*TC3A%**6B.*IC,16J2JSFW)
MZ-WW7;T/FWXW?#:W\">/9_C5/J=]>PZ9Y$AT:(89Y1MB11+SLB)(+?*>K?WN
M-3P7^V)X*\0RZ);WMG=Z/JVKR^5)&(Q+%"V[8A>7Y2P8\ A>.X YKWBZM(+^
MVEM[F&.XMY5*20RH&1U/4$'@BN \=?#'PXMF/$=AX/L-3\1Z%:2/I-NB>6ID
M4%D38I"M\W(!!P2<8)S7/*G.G)RI.R>K1Z]+&8?$THT<;%RE'2+32LK:)K;?
M5MZG#?%SXY^+?#_Q.@\!^'/#RR7&HVOEVNI3;N)I%(65>-NR-B"V<]#^/@]Q
M\*_B?\.4/Q)U73;G4/%<6I*J(S"[95V,#/((R<C(51SCU'(KZ>_9V\=>-/'?
MA?4+CQKHK:5=V]UY4$CVSVYF7&3\C<_*>,C@_4&O6*S]C]87M')^7D=:S)Y3
M)X6%&.EE-WOS?/HGU1@> M6U77O!>BZAK=A_9FK7-JDMS:8(\MR.1@\KZX/(
MS@]*WZ**[UHK'RLY*4G)*R?3L%9VO>'=+\4Z:^GZQI]MJ=BY#-;W<2R(2#D'
M!'45HT4;Z,49.+4HNS/D_P 5_##4/V7[_P 1?$KPY/\ VPL\C00Z6UN4AM8I
M6W%I=K?.B%54 ;>JG(Q71_LJ^%OB%]MU+QCXMU:X;3];@+QZ;=.YD,GF9$I1
MAB,!0P4#J''0 5]&UX]^T3X%^('C:UT%? NNMI!MYW-W&EV]L7SMV/N49(7#
M97WZ&N&5!4GSQNTNB[GT]/,I8Z'U6NXJ4]'4E_*EHMM->O\ PY[#17+:]XWT
MKX;>%[*\\7:Q;VKA$A>=N//FVC=L7KR03[#KBO.?V>?V@=2^-6J:_!=Z"NG6
MECMDAN8F8C:Q(6-\_P >!G(..#Q74ZL%)0;U9XL,#7J49XF,?<CN_P -.Y[?
M1116IP!5:XU.SM+JWMI[N"&YN"1##)(JO+CKM!.3CVK(\=>(G\,^&;^ZM7M#
MJGD2"PMKN=8EN+C:2D8+$9)..*^7O!/P:\??'3Q59>,_'UY=^'+C2KB**&"2
MQ,$TR1N9,HI(\ODXW;>>O)'//4JN+48QNV>O@\#"O3E7KU%"$?FV^EE^9Z)\
M9OA'X4^/?C[3[+_A-(;+6M'A*7>EVY2:5H2P8X7<-C<\G#=5R.F>6\4_L)Z1
M/;VR>'/$-W8.)V>X.H*)@R'&T+MVX*_-USG=U%>J^'?V>_#OAKXL:AX^MKB^
M;4KQI9?LKR+Y,<DN?,88&3G)P"<#)]L>HUE]7A4O*K'5G<\WQ&#5.G@ZS<(K
M9I;O=>:[7/ /@;X>^,>D-XMB\7ZAYB?9S%I;W<R3+]H (61 O2/&,@XSD<9S
M7A%[KGB_QUK,GPD^)&HWT&L3ZI!):W:B.46\K(V%D5" \3"1""#\G7IQ7T5?
M6WQ;;]H>"6"2/_A7P5=R[T$7E;/F!'WS+OSC\.<9KUB;PMHUQKT.MRZ392:S
M"ACCU!K=#.BGL'QN Y/?N?4UE[%U(\J;5G;7JOZV.W^THX6JZTX0;G%27)O"
M2V]/[R_0^;M2^!?Q&M_%&A>$K;5)=1^%\=G#9WA>X2,>5M_?;H\[MY;<R$!@
MN4&<*:ZW7+[PS^QG\.8$TO3;_68]0U#!\^=0[R%.6=PFT *@  7G\S7MNK6<
MFH:7>6L-R]G-/"\27$?WHF92 X]P3G\*\7^ _P"SW?\ PZT_Q!9^+-0LO$UI
MJ4\<T=F\9FA5D+9E82#[[;AG _A')[6Z+IR_=K5]>QS1S".*I-XN2Y8M7@E;
MVFNK;75;^9Z[X2\1P>+_  OI.N6T4D-OJ-K'=)',,.H=0P!]QFM*XN(K.WDG
MGE2&"-2[R2,%55')))Z"O$O@[\+OB!X-^*'B?5?$'B%;_P /70=+:W$[/ORX
M,;",C$6U,K@=,X&1S74?$R;PO\3K'6?AE)XGM[#7;V%<P1.&FC*E9!\N1NX4
M$ID$J3T'-;QJ2Y+R5G^?_#GEU<+26)Y*<^:&C;2;Y4]_N.SO?%6EV?AV?7!>
M0W.F0PM-Y]O(LBN%!X0@X8G&  >3Q7R[JG[57COXD1P?\*U\)72FSNU6]S"+
MPLKY\D-@#8K;9-Q[8'S#OOZU^QO+>?#30O"UIXLD62QOYKV>::W/E2>:J*=L
M8;@J$&.>=S],\>^>#?!NE>!=#M],TFRM[2..-%D>"!(C.ZJ%,C[0,L<9)K%J
MM5=G[J/1A/+<#!SC^^FV[)II)+JUUNON-/3[J2>UA%R(XK[RD:>"-PWEL1R/
MIG/-6J\2\%_L\7GA7XYZUX]E\1/=VUZT[I9["'_>G.QVS@JG;']U>F*]MKJI
MRE)>\K'BXJG1IS2HSYDTGLU9]5KV"BD9@JDDX Y)->5_'KQ%XXL? MI??#:)
M=1O)+I1+):Q+<N(<-\R*<J?F !X.,_B'.7)%R9GAZ#Q%6-)-*^EWHOFSU6BO
MG;PAX4^-&H?%G0O$FNZJMCH+V437VGQW'[E#Y0#Q>1G&\OEMPSC/WN,5O?'K
MX]:Q\(_$7AK3M-\,MK,6IM\\K%AYAW!?)BVC_6=^<]1P:Q]NE%SFFDCT'ELY
MUH8>A.,Y-7T>BWNKOT/:Z*IZEJUIHNEW&HZA<)965O&9IIIF"K&H&22:R_!'
MC[P_\1M&.J^'-2CU.Q$C1-(J,A5QU5E<!@>0>1T(-;\RO:^IY:IS<'447RK2
M_3[SH***\._:%_X6VVO>&U^'>Y;#)^TM#Y>?-W<>;O\ ^6>W\.N?X:FI/V<>
M:U_0WPN'^M552YU&_63LCW&BO'_V<[7XFVNEZVOQ(D9Y/M""Q$SQO+C#>828
M^-I.S;GT;MBO5M1U2RT>W^T7]W!90;@GFW$JQKN/09)QDT0GS14FK>H8C#^P
MK.C&2G;K'5/T+5%(K!E!!R#R"*6M#D"BBB@ HHHH **** "BBB@ JGK&J0:'
MI-[J-SN^S6<#W$NQ=S;44L<#N< U<JOJ%U;6-C<7%[+%!9PQL\TL[!41 ,L6
M)X  SG-)[%1^)75SX_\ %G[55Y\99H_!'AS0+BRM-< L9KIG+W*;VQN54(&T
M#E@3R-PR.M:W[(.I^)_!_C#Q%\/-0TJ=M,M))KAKR2-U\F52J8Y^7:X&0!SW
MY'3W3P9-X5N/!VL7/PQCT7<XEV?V?&L<3703Y!( !W*]>QKF/V;Y?B?)8:]_
MPLA9 1.GV'[0L0D_B\W[G\/W,9]\<5YL:<O:QE*5WW2TMV/LZV*H?4J]"C14
M(*VDI/GYK_$E;IVO_D>RT445Z9\4%%%% !1110 4444 %%%% !1110 4R:&.
MYADAFC66*12CQNH*LI&""#U!%/HH \I^+'[./AKXK6NB6\SS:)%I+2"*/3$2
M-#&Y!==NW Y4'('<]:]+TJWMK/3;:ULV#6UL@@3#[L!!MP3ZC&*CU_2SKF@Z
MEIJW,EDUY;26XN8?OQ;U*[U]QG(^E>8? 'X)7'P+T/7(9]7?7'O)A,L4,6Q$
M5%(&U23\[9YYQPH[9K#EY*EXQWW9ZGM'7PO+5K:P?NQMO=ZN_3YGIOB+Q!9>
M%=!U#6-1D,5C8P/<3.JEB%49. .I]J\+^"G[3FI_&#XG:CHT'A]8/#R0M-!=
M#/G0JN #-R5.XG "XQ[\FL[X9?M<Z/XZU'5]%\<6-CX;MY#Y,"W#LT<H8E6A
ME## ('4G"]<@=_>_"/@K0O FEG3_  _ID&EV;.96C@'WF/5B3R3@ <]@*RC-
MUVI4Y>ZMSLJ8>.6TZE'&46ZDOA=]%YJV[_KUVZ***[#Y\**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO>,+,K\ ?AW<;/E^WZF-WU>/_P"(/Y5]SD[Y</3\YO\ ])9\EF:YJT_**_\
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MR,X&<   8'-=?3(9/-AC?&-RAL?44^NNE1IX>"ITU9(]1))604445L,****
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M.YZ6#PE6M^^3Y81:O+^6[T?<];^#_P &]&^#&A76FZ1/=7?VJ?SYKB[92['
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M)G<1[XKD?CAJGC#1_AW?W/@:U^U:\K)M58Q+(D>?F9$.0S =L'J>#7E/PK^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9::K:;@XAO(5D4,.A (X/^-34BY1M'<UPE:%&LI5+N/5)V;7:YC26/AOXU>
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MG_<R%OW<A("D,V&P&Q[&I/VK/B/\0_AK)H>J>& L'A^/)O;CR$E#2E@%CDW
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M^Z.6QUP.3C ZU\\_"+]H7XI>*/'&@Z/KGA(?V;=A_/NTTZ:%]@S^]#%MH"D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+XK:'9:_\
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MU*E1=?T/!OB$;CQ)\3/$=Q;V\C/?:C<7,49 W;'=G7/_  $BO==0GBL/@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTD0B50!A0%!/..ISS[5Z91171&,:<5&.QX]>O4Q51UJSO)[L****LP"BBB@
MHHHH **** "BBB@ K"\/^!O#_A2^U"\T?1[/3;K4'\RZEMX@C2MDGG'N2<>Y
MK=HI63U9:G**<4]'OYA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#&\8^(]'\)^&=0U77YH[?2+>/\ TAIDWJ5)"A=N#N))
M QCG-5/A]XN\/>-?"]KJ7A>:&72,F*-88C$(RIY0H0-I'ICN#WJ'XJ>']/\
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MA^&=7\)^8BZ@OAQYQ=:>KG:&_>':X!*YQGDXR!@UZ=\5/C)HWPO^&K^,9?\
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MVI9_\_<'_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D_P#/!O\
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M_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_  A>D_\
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M_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\
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M7I/_ #P;_OXW^- &G_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\
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MQ?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?\
M:EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OX
MW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_  A>D_\ /!O^_C?XT?\
M"%Z3_P \&_[^-_C0!I_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"-9G_"%Z3_
M ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI9_\ /W!_W\7_ !H_M2S_ .?N
M#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_ &I9_P#/W!_W\7_&
MC^U+/_G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_VI9_\_<'
M_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?X
MT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D_P#/!O\ OXW^-'_"
M%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C69_PA>D_
M\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_X
MUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W!_W\7_&C^U+/_G[@
M_P"_B_XUF?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^- &G_:EG_S]P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(SBZKDO<EK&.VK7=I_(^1M.T_P 4_M9?%M[Z^67P?:^&ML>V-)&,)$Q;9DD
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M^S]\&M;MT$.M>-H+\R7^E12[A:Y81@R.H*E5V@':3AG"D@GCZ8^%GC:3XC>
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M=)M[JQN'?[7>743O&I&W;'\I&TMDG)/...AKW2O#?VN/B78>"_AK<Z)+Y_\
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MNP80W)U#4(@77.$G\Q&./]V0D?A7GUW9W%A,(KF&2"4HDFR12IVLH93@]BK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDL;%D'/+;25_\B5]!D:_VIR?1-GC9M_N_*NK1Y/X;\0'1_"?BRS!VMJD%O;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,7QK>6^G^#]:N+N1(;=+.7>TG3E",?B3C'?->+_L
MQ_\ (6UW_KA'_P"A&O9O'.FVVL>#=:M+N(36\EI)N4^RD@_4$ _A7C/[,?\
MR%M=_P"N$?\ Z$:^:QM_[3PO_;WY&4[<T>^I]!4445]*:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !7R[^W!XJU#2;#PIIEC>SVD=S)<7$ZP2%-Q3RPF<=<%F/U%?45?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <_\0-'FU[P3K>GP3R6\UQ:2(CQ?>SC./H>A
M]B:\?_9CC?\ M/7GVG8(8E+8XSN;BO8_'4VMV_@W69/#D:3:\MK(;)),8,NT
M[>O&<],\9QGBN"_9NF\=W'@V]?Q[:?9=0:\8P&2".&:2/:,EU0 ?>S@D9/TQ
M7D5\*JN-HUK_  WZ?KT.E8652@\1SI*+M:^KOU2['K5%%%>N<P4444 %%%%
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M#7I4]9-K^OP.G&5(T<71J3T6I^BE9?B3Q-I7@_1YM4UF^BTZPAQOGF. "3@
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M>-2[,3UY/ Z <"OF_P#:>^!.N77Q,AU/PSH5S?V6KQIO%E 62"=0$(;:,(I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]F619"D?EA!EE)&2=QX/3%?<X_&4:-*<J$USMK9_UT/DL'A:M6I&-6/NJ_\
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M::O FI6*I-+<0W(WJZK"P4$'J VS\JY74O#:R?%&ZT")/+1M9:Q5$&,#SR@
MKUI87#5%'"55?V<4^WE^AYL<17@WB:;MSMK^OO,_2?"^L>*K76=1LK5KN'38
M?M=](&4>6A;&[!.3SZ9[FOLS]C+QJ->^&<VB32[KK1;AD52<GR9"70_]]>8/
MH!7:_#G]G[PM\-=-UVRL1=7\.LIY-U]OD5R8L,/+&U5P,,?<^O2OF3X%QR?#
M/]J*;P]'([6K7-WIC$GEXP&:,GWRB&O,Q&)IYI1K4X?8]Y?):_J=]'#SR^K3
MG+[6C_0^YJ***^)/JPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_&37J>$=;;341]0%E,;=
M9/NF38=H/XXKP[]F7_D9-7_Z]!_Z&*]Q\9:HFB>$=<U&2-Y8[2QGG:.,99@L
M;-@>YQ7AW[+F+W5M9O+=EFM5MTC,L; KN9L@?D#7S>.BWF.%M_>_(F<9/EE;
M2[U^X^B:***^D*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^*OVY;(Q_$+0;O'RRZ6(@?]R:0_P#LXK[5
MKYH_;4\ ZOXFTOP[J^DZ=<:@-/:>*Z6UC,CHCA&5BH&=HV-D]LBO:R>HJ>,@
MY.R=U^!Y>9P<\+*RVM^9V'[)7BZZ\6?"& 7UU)=W6GW4MFTDS%G*C:ZY)Y.
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M>GRZ_P!>AY].M_:6(B[6C#7Y]/Z]3TVBBBOD3Z0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX?_8L_<_&/58TX7^R9U_
M30_X5]P5\/\ ['_^B_'35(A\H^P728;KQ+&<?I7T&7_[IBEY+]3QL;_O.']7
M^A]P4445\^>R%%%% !1110 5X/\ ME>)X='^$K:69=MSJUU'$D8ZLD;"1C]
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MJ&SO(-0M(;JVE2XMID62*6-@RNI&0P(Z@@U-4E!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&ZNE@2>6TSB6)6 ^\#Z$@'&0#Q77UQSIRIRY9JS.F,XS7-%W04445!84444
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MF_/\S@Q\>;#37D6O@Q\5/#?ASX,^!5UW6K739KN!K:!;A\%O+E://L!M'S'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &9XHL7U3PSJUE'</:27%I-"MQ']Z,LA
M 8>XSG\*\&_9G8_\)5JHSQ]BSC_MHM>]>)FNT\-ZJVGHDE^+24VZR?=,FP[0
M?;.*\$_9G_Y&O5/^O+_VHM?-9A_R,<+_ -O?H9U+WA\_T/HVBBBOI30****
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MCR/%'_/Q:_D/_B:Z:B@#F?(\4?\ /Q:_D/\ XFCR/%'_ #\6OY#_ .)KIJ*
M.9\CQ1_S\6OY#_XFCR/%'_/Q:_D/_B:Z:B@#F?(\4?\ /Q:_D/\ XFCR/%'_
M #\6OY#_ .)KIJ* .9\CQ1_S\6OY#_XFCR/%'_/Q:_D/_B:Z:B@#F?(\4?\
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MD*G.Q,]%'#8'L<5ZUXE_:E\5ZOX9M_#UB(+#2AI2:;<*4#RSGR@DC[_X<G.
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M]K_F?+T\+B)U)JD]8:;V/ES4OC7XROO%U[XCBUR\L=0NE*-]GE*HB8QL5>@
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M2FG^!GEL^?$17:-OQ/;J***^'/K HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /C3]J7X VOA==:\>6NINR7]\K-IQ@^Y)(27;S-W(+9.-O\76O8
M/V/V#?!&P .2+NX!_P"^ZB_;&_Y(K<_]?MO_ .A&C]CG_DBMM_U^W'_H0KZ:
MK6J5\J3J.]I6^21X-.G"EF#4%:\;_B>X4445\R>\%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!5U33XM6TR[LIT$D-S"\+JW0JRD$'\#7CGP'\!ZWX7\0:M<ZG9FUA\
MG[.K%@=[;P3MP>1\O7Z5[%JUD^I:7>6D=Q):27$+Q+<1??B+*0&'N,Y_"O(_
MV<?@7JOP5@UY=3UR/5!J$L;1PVX81IMW9<[OXVW#./[HY/;S<1A8UL32JM/W
M+_CW.F-"E4HRJSJ6E&UHVWOOKTL>ST445Z1S!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.?$7PBGCSP-
MK>@.RH;ZU:*-WZ))U1C[!@I_"O@+6/@+\2-'NK?3;CPOJ4P:4B+[,OGP[FP"
MVY"57.T<DC@#/2OT@HKU\#F57 IQBDT^YYN+P-/%M2DVFCYZ^'/['7A_PCXA
M&JZQ>_\ "11HN8-/N;91%&YZE_F(DQVR .^*^@XXTAC6.-%2-0%55&  .@ I
MU%<6(Q-;%2YJTKLZZ-"GAURTU8****Y3<**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#X*\-^)++X2_M2:QJ&K.]MIEKJ.H+*50LWENLICP!UR2GY_C7GEWXZ>Z^
M*TOB]?-B+ZP=250?G5?.WA>O4#BOI;]IK]GCQ'\0/'EAK?ABQ@N%NK=+>]9I
MDB\MU) D;<06&TJ/ER?DZ5Y+^T=\%;?X0P^$ELLSQ3V;PW5V<_OKE7+,Q'8$
M2* /1.^":_1<)B<-6<'?WYQLUZ7N?$XBA7I*:M[D7>_K8L_"W6'^)?[5%GKM
MI9RQP7%_+?&-OF,4:HV"Q' _A'U(%?47C7]G'P=X^\<0^*-6ANGN@JK/:QRA
M8+DJ,*9!C=P,#AAD*/?/D7[!]F%M?&=V1RSVD0/T$I/\Q^5?5U?.YIB9T<7R
M47R\B4=.VY[67T(U,/S55?F;9\'_ !J_9:U;X;VFJ>(--NH;_P -02*41F8W
M42,<?.-NT@$@9![@X'.-?PS^V=K7A_PSI&DOH\%[+9V;6\M[-*V^1P"(FQTX
M&S=G)8YZ5]F:SI-KKVDWNFWL8FL[R%X)HS_$C @C\C7YV_$CX!^+OAA9W.H:
MM9)_9,=V+6*\BF1Q+G<5?:"64$+_ ! <D"O3P.)I9E#V.-LY)Z=+_P#!.'%T
M*F!E[3"W2>_D?0'[(7Q>\0^.-<\0:/XAU275'6!;VW:?&Y/GVN 0/N_.G'0=
MJ^@/'VN#PSX'\0:L6V&SL)YU/^TJ$J/KG%?!G[,_C#_A"_C%HDLK>7:Z@3I\
MQ/'RRX"GZ;PA_"O5/VKOC5=Z]J\GP[\."1XUE6*_>$$O<39&V!0.2 <9]6XZ
M#GGQF7.IF"C3C:+2;[)+?^O,UPN.4,$Y3=Y+3S\CD?V7?@[I/Q8A\6Q:TDRV
ML,,$45Q;L%DCD9RV4)!&<1X.0>&K[-\"^"=,^'?A>RT#2%D6RM00K2L&=V+%
MF9C@9))/:N*_9S^$TWPF\!BUOV5M7OY/M=VJ\B(E0%C![[0.3ZDXXQ7JE>5F
M>,EB:\XQE>%].VBM<]' 854*47*-I6U_,^/_ -LWX3SP:M!XWTRU:2VN$$.I
M>4N?+D4825L=BORD] 5'K7L'[)NG3Z?\#]%\^*2%IY)YE608)4RMM8#T( (]
M<YKV"BLZN83JX2.%DOA>_EV-*>#C3Q$L1%[] HHHKRCT HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /$/VQ@3\%;K Z7MOG_OHTG[')!^"MM@]+
MZXS^8J7]L#_DB.H_]?5O_P"C!57]C/\ Y(RO_81G_DM?0?\ ,I_[?_0\;_F8
M_P#;OZGNM%%%?/GLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M2>ZCTV[:R2.2]6)
MS DIPC2;3M!/IG%>&?LO?$#QQXPF\16_C2[@NFA,4MJ56)74,7#K^[ !487D
M\\]3V]QU:[73]*O;IU=TAA>1EC&6("DX [GBOGG]FD_\5IJ(_P"H>W_HR.O%
MQF)G1Q>'IQVE>_X&ZQ+I4W1Y$^?JUJK=GT\SZ1HHHKVC **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 0WDBQVD[NP1%1B68X &.IKYT_9I_Y'/4?^P>W_HR.OHG4(8[JQN894$D4
MD;(ZMT((((KYV_9I'_%::B>_]GM_Z,CKYK,?]_PGK+]#&?Q1/I&BBBOI38**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I%4*H & . !2T4 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KZA&9M/
MN8UD:)GB91(G5<@\CWKYV_9I'_%::B<_\P]N/^VD=?1=VLC6LPB"M*48(&.
M6QQGVKP?]G3PGK^D^)-5O-6T6[TB*.V-L?MBA=\A=3\F"=R@*?F''(P37@8Z
MC4J8W#3C&Z3E?RV$Z<Y6FMEN>_4445[XPHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/VLO^2$
M>(/]^U_]*(ZYW]B7_DD=]_V%YO\ T5#73?M6*&^ GB<D9(-J1_X%15RO[#[%
MOA/JH)R!K4P'_?B"OH(?\BF?^/\ 1'C2_P"1C'_#^K/H6BBBOGSV0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** &32"&)Y"&(52Q"C)./05X_P# G]HR#XV:MKEC'H4^
MD'3PLL;O,)1)&6*_-\HVMQTY[\\<^Q$A023@"N ^'/C[PQXFUG5++0M.%A/S
M<RR+;I$+GYL&0[>2<L/O<\URU:L85(0<[<U].YU4ZM"%*<*D+S=N5WM;OIUN
M>@4445U'*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y+^U9_R0/Q1_VZ_^E4-<G^P__P DGU;_
M +#<W_HB"NQ_:D4/\!_%((R-EN?RN8C7$_L.L?\ A6&LKGY1K$A ^L$/^%?0
M4_\ D4S_ ,?Z(\:?_(QC_A_5GT71117SY[(4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #719$9&4,K#!4]"*^;/V:O^1ZOO^P;)_P"C8J^E&&Y2,E<CJ.HKYK_9J_Y'
MJ^_[!LG_ *-BKYK,O]^PGK+]#&?Q1/I6BBBOI38**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@U\5_M<?"Z/P'XHT[QAH$3V,&H3$SFW^58+I<,KJ1]TMR?JA/>O6I8JEFO\
MLU>"C)WLUW_K[SS:F'J9=^_I2;BMT^Q]JT5\7WG[<GB1[81VOA_3H9/)V&6:
M1Y#YF,;\#:,9YV_K73_ _P#:[NM>UNTT#QE%%YUY*L-MJEN@0;V.%61.G)P-
MPQC(R.]>;/)\93@ZCCMYZG?#,\-.:@GN?5-%%%>(>J%%%% !1110 4444 %%
M%% !1110 4444 %%%% !167XH\3:=X.T"]UG5K@6NGV:>9+*03@9P  .I)(
M'<D5YEXA_:(TBY^#&M^-/#+^?+:,+6."\CVLD[,JKN7/( <-P>0.M=%+#U:U
MG".C:5^EV8U*U.G?F>MK_)'L-%>.?LQ_%C5OBOX/U"XUSR7U&QN_),L*; Z%
M0RDJ.,YW#CT%>QTJ]&6'J.E/=#HU8UH*I#9A1116!J%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@GP'A\)R>/O$/\
M87BJ#6[JSC>$VT<+QE4,@R^YAAP"H7*Y'/N,^]UYW\.?@3X1^%_B#5=7T"VF
MBO+Y3$_F3;UA0L',:#L,A3SD\#FN*OAXUJM.HU?E;[Z'52CAI4YNM?G5N6VU
M^MST2BBBNTY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)_LG<0S#TXSSCG K'V>5XII4Y.F_/;]?S->?,,.O?BIKR_K]#[5HKX0T^?\
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M@#:HK%_X3#2/^?O_ ,A/_A1_PF&D?\_?_D)_\* -JBL7_A,-(_Y^_P#R$_\
MA1_PF&D?\_?_ )"?_"@#:HK%_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\
M"@#:HK%_X3#2/^?O_P A/_A1_P )AI'_ #]_^0G_ ,* -JBL7_A,-(_Y^_\
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MI'_/W_Y"?_"@#:HK%_X3#2/^?O\ \A/_ (4?\)AI'_/W_P"0G_PH VJ*Q?\
MA,-(_P"?O_R$_P#A1_PF&D?\_?\ Y"?_  H VJ*Q?^$PTC_G[_\ (3_X4?\
M"8:1_P _?_D)_P#"@#:HK%_X3#2/^?O_ ,A/_A1_PF&D?\_?_D)_\* -JBL7
M_A,-(_Y^_P#R$_\ A1_PF&D?\_?_ )"?_"@#:HK%_P"$PTC_ )^__(3_ .%'
M_"8:1_S]_P#D)_\ "@#:HK%_X3#2/^?O_P A/_A1_P )AI'_ #]_^0G_ ,*
M-JBL7_A,-(_Y^_\ R$_^%'_"8:1_S]_^0G_PH VJ*Q?^$PTC_G[_ /(3_P"%
M'_"8:1_S]_\ D)_\* -JBL7_ (3#2/\ G[_\A/\ X4?\)AI'_/W_ .0G_P *
M -JBL7_A,-(_Y^__ "$_^%'_  F&D?\ /W_Y"?\ PH VJ*Q?^$PTC_G[_P#(
M3_X4?\)AI'_/W_Y"?_"@#:HK%_X3#2/^?O\ \A/_ (4?\)AI'_/W_P"0G_PH
M VJ*Q?\ A,-(_P"?O_R$_P#A1_PF&D?\_?\ Y"?_  H VJ*Q?^$PTC_G[_\
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M\)AI'_/W_P"0G_PH VJ*Q?\ A,-(_P"?O_R$_P#A1_PF&D?\_?\ Y"?_  H
MVJ*Q?^$PTC_G[_\ (3_X4?\ "8:1_P _?_D)_P#"@#:HK%_X3#2/^?O_ ,A/
M_A1_PF&D?\_?_D)_\* -JBL7_A,-(_Y^_P#R$_\ A1_PF&D?\_?_ )"?_"@#
M:HK%_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\ "@#:HK%_X3#2/^?O_P A
M/_A1_P )AI'_ #]_^0G_ ,* -JBL7_A,-(_Y^_\ R$_^%'_"8:1_S]_^0G_P
MH VJ*Q?^$PTC_G[_ /(3_P"%'_"8:1_S]_\ D)_\* -JBL7_ (3#2/\ G[_\
MA/\ X4?\)AI'_/W_ .0G_P * -JBL7_A,-(_Y^__ "$_^%'_  F&D?\ /W_Y
M"?\ PH VJ*Q?^$PTC_G[_P#(3_X4?\)AI'_/W_Y"?_"@#:HK%_X3#2/^?O\
M\A/_ (4?\)AI'_/W_P"0G_PH VJ*Q?\ A,-(_P"?O_R$_P#A1_PF&D?\_?\
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MF3N\FZC#@'U&>A]QS7CWBK]CGP#KD;'38[S0)R2P:UG,B=.A63=Q[ BO6_\
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MG_PJ8YUC8[SO\D4\KPKVC;YL^,;?X<_'GX:R30Z5_:QM8WW_ /$OO%GAD/\
M>$9))_%<U))\<OCOIL#_ &JUU)!"I,DEQH04J!U+?NP!BOLK_A,-(_Y^_P#R
M$_\ A1_PF&D?\_?_ )"?_"M?[64]:U",GZ?\.9_V:X:4JLDO7_ACXOTW]L7X
MBZ;<+=WL5A?V<RD1Q36AC0D<$JRD$G/7DCFM;_AN7Q9_T -&_*7_ .+KZUF\
M3:!<(J2RQRHOW5>!B!]/EJ'^V?#/]VW_ / 4_P#Q-#S#!2U>&7W_ / !8/%1
MT5=_=_P3XS\)^$O%_P"U1\1DUK75EAT52%N+R.,I!%$I_P!3#G.6)SW.,EC[
M_9UA\.?"NERVTUKX<TJ*XMXE@BN!9QF544!57>1NX '>K">+M&C142Z"(HP%
M6)P /^^:7_A,-(_Y^_\ R$_^%<6+Q\\2THKEBM$D=>&P<:";D^:3W;-JBL7_
M (3#2/\ G[_\A/\ X4?\)AI'_/W_ .0G_P *\L[S:JIJFDV6N6,MEJ-G!?V<
MHQ);W,8D1Q[J1@U0_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\ "FFT[H6^
MC/+_ !=^R-\/_%5XMU!;76@R8PR:5(J1O[E&5@/^ XK#TG]B7P58WJ37>HZM
MJ,*];>25(U;ZE5!_(BO;/^$PTC_G[_\ (3_X4?\ "8:1_P _?_D)_P#"O0CF
M.+C'E51V.-X+#2ES.".:\*_ ?P'X/M+JWL/#=I(MTNR=KT&Y9U_NYD)P.G P
M.!5O4?@OX%U316TF;PKI:63<[;>V6%E/]X.@# ^X.:VO^$PTC_G[_P#(3_X4
M?\)AI'_/W_Y"?_"N9XBLY<SF[^K-U0I)<JBK>APEY^R[\,KU8 WAB.+RL >3
M=3IN [-A^?J>?>NDF^#O@6>T@MG\(:*88/\ 5K]AC&,]><9.<<^M:_\ PF&D
M?\_?_D)_\*/^$PTC_G[_ /(3_P"%5+%5Y6YJC=O-B6'HQV@ON1CV7P;\"Z==
M17-OX1T>*>)MR.+-,J?4<=:["2-)D9'571A@JPR#6/\ \)AI'_/W_P"0G_PH
M_P"$PTC_ )^__(3_ .%8RJ3J:S;9I&$8?"K&U39(TF1D=5=&&"K#(-8__"8:
M1_S]_P#D)_\ "C_A,-(_Y^__ "$_^%9EER30].FC:.33[5T8896A4@CT(Q7.
MP_!WP+!>"[C\(:*DX;<&%C'@'UQC%:W_  F&D?\ /W_Y"?\ PH_X3#2/^?O_
M ,A/_A6D:M2/PR:(=.$MT8<OP3\ 32-(W@[1=S')VV48'Y 57N_@)\.[VWD@
MD\'Z4J.,$PP"-OP9<$?@:Z3_ (3#2/\ G[_\A/\ X4?\)AI'_/W_ .0G_P *
MT^LUUM-_>R/8TG]A?<>!^-/V(= U283>&M8N-#)/S6]ROVF+'^R<AA^);\*\
MZNOV,?'^F7DT>F:OIDUJ3\LPN9(6<?[2[3@_B?K7V#_PF&D?\_?_ )"?_"C_
M (3#2/\ G[_\A/\ X5Z5/.,937+S77FKG!/+,--WY;>A\>V_[&?Q!U*XCCU#
M5]+BMP<F1[J64CZ+LY/XBM#P]^PSK]Q<7 UOQ#86,*9$1L8WN&D/8G<$VC\S
MQT[U]9?\)AI'_/W_ .0G_P */^$PTC_G[_\ (3_X5I+.\8U9-+Y$+*L,G=IO
MYG@OPC_9!L_#T6M+XX33M>6Z"Q6T=JTG[I022^\A65CP/E[ \G-=#I/[&_P\
MT^.9;F'4=3+N65KB[*F->RCRPN1[G)KUG_A,-(_Y^_\ R$_^%'_"8:1_S]_^
M0G_PKDGF6+G)R]HU?MH=,<#AHQ4>1.W<X+1_V7/AIHUU]H3PXMTXZ+>7$LR#
M_@+-M/X@UYY^SW(G_"R)O+0HC6DVU0N-HW*0/;BOH#_A,-(_Y^__ "$_^%?,
M_P ,O&5AX)\<7.I:@LSVSQRQ?N%#$%F!!()''%?%9YBIRQ6$J8B;:3>[VV+]
MG3HM<D4O0^LJ*@L;V'4K&WN[9_,M[B-98W ^\K $'\C4]?0IIJZ.P****8!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\\_MG65Q:>$_!WBI89+JP\,^([34;^%!G]P
M&P6([X;:O_ Z^AJBN;:&\MY;>XB2>"52DD4BAE=2,$$'@@CM0!YE\4/C)X/T
MSX/ZWKRZ[I][976G2K:+#.K&Y=XR$C5<Y))(!';G.,&H?V5?#-_X0_9_\':;
MJ<3PW@MY+AHI/O()9I)5!'8[7'':KNE_LU_##1=<CU>S\%:7#?QN)(W\LLB,
M.050DJ"#TP.*]+H **** "N1\#Z?:W>DRO/;0S.)R TD88XVKQR*ZZH+.Q@T
M^,QV\2Q(3N*KZ^OZ4 0_V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH
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M\+7_ +\K_A5VB@#E/&FFVEKHX>&UAA?S5&Z.,*<8/H*VX=%T\PH38VQ.T?\
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M*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\
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MU_[\K_A4T-C!;32S11*DDIR[#JU3T 4O[%T__GPM?^_*_P"%']BZ?_SX6O\
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M]^5_PJ[10!2_L73_ /GPM?\ ORO^%']BZ?\ \^%K_P!^5_PJ[10!2_L73_\
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ME7$2RQYSM;IF@"M#HNGF%";&V)VC_EBOI]*?_8NG_P#/A:_]^5_PJXH"@ <
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MB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\
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MNT4 4O[%T_\ Y\+7_ORO^%']BZ?_ ,^%K_WY7_"KM% %+^Q=/_Y\+7_ORO\
MA7/>#-/M;JUNS-;0S%9R 9(PV!@<<BNNJ"TL8+%66WB6)6.XA>Y]: (?[%T_
M_GPM?^_*_P"%']BZ?_SX6O\ WY7_  J[10!2_L73_P#GPM?^_*_X4?V+I_\
MSX6O_?E?\*NT4 4O[%T__GPM?^_*_P"%']BZ?_SX6O\ WY7_  J[10!2_L73
M_P#GPM?^_*_X5SVJ:?:Q^+--A6VA6%T):-8P%/WNHQ775!)8P374=P\2M/&,
M*YZC_.: (?[%T_\ Y\+7_ORO^%']BZ?_ ,^%K_WY7_"KM% %+^Q=/_Y\+7_O
MRO\ A1_8NG_\^%K_ -^5_P *NT4 4O[%T_\ Y\+7_ORO^%']BZ?_ ,^%K_WY
M7_"KM% %+^Q=/_Y\+7_ORO\ A5?4='L(]/NF6QMU98F((B4$'!]JU:;)&LL;
M(XW*PP1Z@T <WX1TRSN=#ADFM()9"S99XU)ZGN16S_8NG_\ /A:_]^5_PJ>U
MM8;*$101B*,<A5Z5-0!2_L73_P#GPM?^_*_X4?V+I_\ SX6O_?E?\*NT4 4O
M[%T__GPM?^_*_P"%']BZ?_SX6O\ WY7_  J[10!2_L73_P#GPM?^_*_X4?V+
MI_\ SX6O_?E?\*NT4 <CH&GVLVO:Q');0O'&^$5HP0O)Z#'%=#_8NG_\^%K_
M -^5_P *FAL8+::6:*)4DE.78=6J>@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+I_\
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M ;#0!]NT5S'PS\;P?$CX?Z#XFMD\J/4[1)VB!SY;XPZ9[[6##/M73T %%%%
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M4/B+XZO;SQQXQD_L'2-2MDBTOPK&H(AC!R)Y&(W;VR<#C(/(X4#V>@ HHHH
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M3^@!^A\U\*_M'>)+?Q]HOAKXB> 9O!(\0DKI%V+U+E)).T4FT?*QRH]<L,J
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M^*_Q2^R>"H+=OAYH;/!JFO7:%QJ$^W BMB",[3@E^G?H5# 'MM%%% !1110
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M?,,@'%;7[1-]K\?PMU73/#.@W&OZOKBG2(XX0-D G4HTTA)X103STR1G R:
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MJQY((H \\L_VAO'G@GQ9HEC\4O EOX<T;7+E;2SU33KP7"03,?E2;#,/QR.
M2 <''T57@?[3'AOQG\3-8\(^#O#&D+'9QWD>M7FOWPS:0>2Q"18!RS$MDKP2
M,8.-Q7#N/%GQ-^ ?Q$\,6_C3Q/!XZ\'>)KU=.-]]@CLYK"Z<_+A4_@/7J>%;
M 4CD ^F**** "BBB@ JMJ.H6VD:?<WU[/':V=K$TTT\K;4C102S$]@ ":35-
M4L]$TZXO]0NH;*QMT,DUQ<.$CC4=2S'@"O(X_BQ\*/VD++5O -GXE^WO?1%)
M+:(36DLJJ0Q,3.J[\;<D#.0#D%: .4U#]ISQSJMA<>)O!_PJO-;\!VNYCJES
M>+!/=1K]Z2*#!?;P<$!L@<XY ]J^&OQ#TKXJ>"=,\3Z,SFQOD)$<H DB=6*N
MC#U# CT/4<$5#X\UR7X;_#J_O="T"XU>;3K98[+2=.BW%CPD:A1T09&<=%!X
MXKYL\'_#?X\_!SX1VMYH^M:' -,22^G\*_8ED:<,S2R!YNOF<XVQE5P, YZ@
M'V!17(?"/XB6WQ8^'.A^*[6!K9-1A+/ QSY<BLR2+GN ZL >XP:Z^@ HHHH
M***\P\=_M+?#?X;>($T37O$L-MJ>0)((89)S!GIYA12$[<'G!SC% %+XE?'*
M]T+Q8O@OP3X;E\:>,_)%Q<6J3K#;6$1Z//*>%)R"%XR".1D9K?"'X]:AXO\
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M%"WC>XM&N7M,YD>T,S HV6&"W(QD_=)%?><,R7$22Q.LD;J&5T.0P/((/<4
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M<9RQQ@';]:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$XR&!XZ4 >?6O[5'P\\2?"F^UCQ3$EK+;.++4_"]Y"LUR+G/^I$+XW@E202
M/E.=I4@>AR:OX%^$'@9]<%MIWA#P\R+.RPV0M,EAE5,2J&+G^[C=G(Q7E7PJ
M^ MYXJ^(U]\6/B/HUG8>(+B4-IV@PJK)8JORI+,PXDFP!@GIUZX"?0]Y9V^H
M6[074$=S Q!,<R!U)!!!P?0@'ZB@#PK]GS3=3\:>//&7Q:U*PFTBS\0K#9Z-
M8W *R_8X@ )G';S"%8#Z]003[W110 444UW6-&=R%51DL>@% #J^?OCW\/\
M5?CA\3O"O@:[M+VS\"VEM+K&I:C"=JSRC,<<*-R-ZELX/9R>U8_AF3XD?M+:
M?=>+M&\<R?#_ ,*O<30Z+9V5DLTUQ'&Y3SIV+#DLI&T' P?J=SX4_%;QAX;^
M(W_"L/B@(+C6YXFN-&U^UC"1:G&N2RE0 %< $\ ="",X+ &+\/?B)KG[/OBJ
MT^&WQ*O#=:%<'R_#GBV;B.1!P()V/W6' R3QP"2I!'I?P[\6> ?BMXBUW5O#
M^CVMY>Z/=BT;7FTY +A]H),,^,N!T.#Z'H5)YKX^_#7Q3\;->T?P;]GMM-\
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MY#]G?]G^_P##ZZ7XO\?,M_XM@L8;+3K'K!HUJB!$BC'3S-H^9AW)QG))^@Z
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M&<@'I6F_#+P]#X\N?'C:8Z^)[VUCMWFNI?,-NJK@J@R50D8#;>#CW.>PHHH
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M^ T@&> 3[*3P/5O@[\7-'^-'@V+7M)$ENRN8+NQG(\VUF7[R-C\"#W!'3D
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MVC6*&WA0*D: 8"J!T % '@?Q-M?$'[17B(^ ;;1-2T'P)8WJOKVM:A"8&O\
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M"M[]NMHM6A\F[U6^3A'\H\I$ASUZ\CN=GT,JK&JJJA548"@8 'I3J "BBB@
MHHKYXGUKQU\?/&_BK3/"OBD^!?"7AF^;2Y+ZVM5FN[Z\3_6@%CA$4XZ=<CKG
MY0#N/C'\+]0^+&K>$]+N;B-?!%O=27>MV0<K)>%%!MXN!S'OR6&?3N 1Y_\
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M_9[UC5]"\+:]\18BMAHD)_X1_P -2J1' 6<R-<S(>LC,Q(!Z<9Z   [#P/\
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M.^\#7+>./#6B^)-=\*IH6MS0B0VEXJ2SVW)P-^ 1D8., C." <UUU !1110
M445X;\:O&FO_  @^)'A?QE/?37'P\NE&CZQ98^2QD=\QW? SUP"3G 7 Y84
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MG^UN/&GQ2\?_ !1ATVZTC0->6VL]-CNXS%)=I$@#7)0_PM@;3[GWKZ I ,#
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M/U&<'('?_#76/$7B#P7INH^*M'AT'6[A#)-I\,ID\H$G8&R.&VXR.<'\AT]
M!1110 445X)\.O%VL_#KXV:]\.O%FI7&I6FM2R:QX:U.\?+2(Q+2VN>F4.<
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M,>I*]3O-=C#\)ENOC1>>/=7NDU+R;&*ST6T=#C3_ +QG<9)!9R1AA@@$CWH
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ML!Z"O9O#WPE^']Y=6'BNW\"Z9INJ7"1W:FXTV.*>!R-PW)C"2#/)ZY'7B@#
M_9*\,:MX1^ /A>PUJ*2VO"DMPMM+]Z&.25Y$4CJ#M8'!Y&<=J]@HHH ****
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M\I=JH[AL D\_*JC[W !ZQXV\;Z)\._#=WKWB"_CT[3+49>:3)))Z*JCEF)Z
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M9Y/FDF1&&R*,?Q,26P.@'H!QZ)H?P&^%7B)[#Q9;^!-/AGO(H[N-+BS,6W<
MPW6Y^56]<K0!F_L=Z+J6@_ +0(-2BFMQ*\]S:03_ 'X[>25GC!^H.[_@5>U4
M@&!@# I: "BBB@ JCKFN:=X:TNXU/5KZWTW3[==\UU=2".-!TY8\=?YUY=??
M%;6/"'[04/A/Q(EO%X8\16B'P_>QH5Q=)_K89&)Y9B>.W^K &6-'C[X3W_Q6
M^+&E'Q+'%<?#O1;1;J#3?,#+?:@S,,S)W5$ P#P=W<%A0!NKXL\)?'KP-XET
M;PWXCL]3BO+&:PG:UD^>'S8V0,R\,!SUQ@X->5_LZ?&O3_!>BQ_##X@W%OX5
M\5^&P;.,W\@AM[R!2?+>.1L*?EP,9^8 ,,Y(#O$'@W3/AS^US\-;KPQ8V^C0
M^(=/U&UU*TL8Q##(D,)D5BB@#.[9]=B]^:[6WU/X9_M':]KFDS:!;^)T\/.D
M#:M<68:W9VR6CAGZG:1\P! .01D<T <9I6HZ7\1OVP+37?!T\=_8Z'H<EIKN
MIV9#6\LCEA##O'#L#@Y']S&?EQ7TE63X9\)Z-X+TF/3-!TNUTC3XR66WLXA&
MF3U.!U)]3S6M0 4444 %%>:_'WQSXD^&O@F+Q-H%A#J=KIUY%-J]NX)E-CG]
MZ8N<!AQR<@#)[4?$C5=>\>?"%;CX;74<MWKBVZ6^HK(%-O;2LHDG7./F5"W&
M00<XY&* -\?%;P8WBK_A&AXITDZ_O\O^SOMB>=OY^3;G[W'W>OM7AOB'Q.?V
M=?VE=;\0^(8W7P1X[AMHSJP4NME=01[%60@9"D;C]&!_@;#?C5^S3X%\&?L[
MZT=)TB&VUG0[3[=!KF +Z2:,AF9Y?O'=@_+G SP!@5WE[\4?"LG@7X?Z)XWB
M76=4\865FITG[+]J:5I(U9I7CP<(&_BQP1QT. #E/VMO%W@_QE\&9M"L=1L/
M$.O:O<6Z:'::;<)<327!E7#IM)P-I8%NF&QGFO?_  _;W=KH.FP7\OGWT=M&
MEQ)G.^0( Q_$YKDO!7P*\ _#O5'U+P[X6L=-U!@1]I56>10>H4L3M!_V<5WE
M !1110 44C9VG;@''&:\F^!/Q8U3QI<>)/#/BV"WL/&_AV]>*]MK<%8Y8&8F
M&:('DH5(&?\ =)^\* .Z\8?$#PW\/[.*Z\2:Y8Z+!*VR)KR=8S(>X4'EL9[=
M*\I_:1T.?XI?"?2O$O@>XM]<OM U&#7K#[)()DNO)W;D7&0QP2<=25QU.*D\
M'_ L>,/&'B3QE\4-*L];U6YNY;32M,O56YM;&P1RL>U#E2SCYBQ&><\$M7-_
M *;3/@_XQ^.&B37J:9X,\/W]K?0>?)^ZM1/$[NH]AMC4#J< <F@#T/X>_M*^
M O'WA--9_P"$@T_1IHH]U[I^I720S6C#[P8,1D9Z,.#]>!QW[(]C%(WQ'UW1
MX'MO!VL>()9]&1DV(Z+E9)$7LA. /9,=JWO#OP[^$_QZT^S\>?\ "$V\SWS/
M(LU_9FWDFPQ7>Z [9 V,ACNR#7L%K:P6-K%;6T,=O;Q*$CAB4*B*!@  < #T
MH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NJ:E;:+IMW
MJ%[,MO9VD+SSS/T2-5+,Q]@ 37SO#\2OC?\ $W1I/%O@/0O#^E^&/F?3['6V
MD:^U.,9 D&W"H&Q\H)7KU(P3U.O>-O\ A8?C'Q]\'-=M/[ N;[26.D7ROO%[
M;21%7D&0/F1R?E'96_NDGR^W^,'Q4_9Y^%)T3Q!\.4OO^$?MDL[;Q!#J*+9R
M1 K% 2N-S-RHVC#''(7F@#WKX-_$JV^-7PVM=;ET[[%),9+2_P!.F&X12H2L
MB'(Y!Z\CH>:\P^$=Q+\ OBU??"G4)&'A?6FDU/PI<RDD)DYFM-Q[@Y('X]9
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MIK?2?B9X*U0M<:5=C9&+I,"6%@>5#[59<G'52<Y(Q/B/KWQ2^.&N:'\)=?\
M#>F^ AJR?VC?SB\34'-O X8.%0[0ID4 *222!D@9R >T?M$?"VX^)G@F"^T*
M3[-XOT&4:GH=XG#"9<,8\^C@ >F0I/ K:^!_Q4MOC!\/;#78T^S7ZYMM1LR"
M&MKI !(A!Y R01GLPKQ+XD:;XX_9GN-'\:VWC_6O&6@27\-IK&D:Y() 4D.-
M\..(^F % P2.HR*Z#7M+O?@1^T%8^(M*M)[GP?X]N4L-5L[6,O\ 9=0.?+N
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M:_IGB3PW:?99K&.Q/ER[,*LOF$A55B02Q[DXW9&:?PNTGX^?#/X7C4]&\/\
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MB@#T+]GGXD>*?$UQXM\)>.([9O%GA.ZBM[F\LUVQ7<<JLT4N   2$8\ <$<
MY%<CX>_XQM^.DGAY_P!Q\/O'4[7&F'I'I^I<!X?]E9.,?\  ^ZQKFOA/^S]K
M7Q8\*W'C_P 0^/O$.A:UXL?^U/LWANY%K!%P5AW\,T@5,8&1M!QG.2='P/X>
MUGXX_#;X@_"_QMJ']I:WX5U+[+8^(B#O,B@F"4GKN!!#'.2KX/.20#V/X_\
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M37B7=O._:)G50%;E1QDY89"YJ3]ICP/J:V^D_$OPG%GQ?X08W C4'-[9\^=
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M.WMH4$<4,2A410,!5 X  [5-110 5%=74-C:S7-Q*D%O"C222R'"HH&2Q/8
M"I:\<\1^.;?XI:Q\2/A$T,WA_7%TIDL[BZ;Y;R*:(J9D"_PJS $9R0?8@ ',
M3?M ?$?QE9W/B'X=?#J/6?!]L[K'>:C=^3<ZBJ$AF@BR"!D$#.XG'3/RCN=!
MUCPW^U-\$Y6FM9(M,UB%[:YM9<&6TG1L'G^\C@,IQV4X[5XQX5_:,UWX%?"B
M+P[XK^&7B*'5O#5HMH+RWMP--E12$CD:XSA<DJ,J&!/0Y. GP]^&_P >_A[\
M,Q?:-JV@6MPS2ZK)X<DLR\L[R'S&1Y#]U\?*%4@< ;LY- 'H_P"S1XWU.&'5
MOAEXLDSXM\(D0"5NM]9<>3.N>3\I4'ZH3R33?VJO!'C+Q_8^!M.\'0A;NWU^
M._?4)"OEV31QOLE<'J 6)Z'D =2!7 ^*/$5Y\1/A[X/_ &A/!]@;?Q-H".NJ
M::IR+JS5F6YA)[A?F=3U"L3U %?3/@WQ;IOCOPMIGB#2)OM&G:A L\+]\'JI
M'9@<@CL010!SWPB^$6C_  ?\-G3]/,EYJ%T_GZCJUS\UQ?3G):1VZ]2<#/&>
MY))[JBB@ HHK@?C-\5%^#WAFSU^XTFXU+2_M\%M?S0,/]"@=L-.1U;!P,#J6
M'(H QOB3\<YO#/BI/!_A'PS=>-_&30BXET^VF6"&TB/W7GF;Y4SQ@'J".1D9
M;\'?CP_Q&U[5_"VO^'+KP?XSTF-9KG2KF02J\1('FQN -RY*]OXEP6ZUY=8^
M/)/@%\:/'&K>(-'U#5O"WC-[?4--\0Z3;FY3 0A86QVPV!@]@0,-D9F@^(?'
MWQN^-&M?$#X;:1IVC6&G:;_PC:7GBQ9(RSK+YT@\J++;]Q"\\*O^UP #KOB7
M&W[//QDL_B3:*R>#?$TD>G>)X4'RV\YXAN\=A_>/^]U+BOHF29FLWFM@MPQC
M+Q ,,.<9'/H>.:\'\ >.-0^,$GC/X3?%+0;6Q\0VEKFX%@6-M>6SX"S1%B2I
M!*$'/4@X!! E_9K\5:GX=O-9^$GBF8R^(/"P!L+I^/MVFD@12+_N@JI] 5'4
M&@#D?V8/V8=3\/P:5XE^(Q-UJ^GF1M(T65E>+3B\A=YF ^4RLQ)'7:,<Y V?
M4]%% !113)I#%"[K&TK*I(C3&YN.@R0,GW- '.?$?XA:1\+?!]]XCUN1TLK4
M ".(!I9I&.%CC7(RS'@?F< $UXCK7[1GQ,\#V=OXH\6_"T:9X(ED03/;WPEO
MK.-SA7E3UY'!"X/!()%5/B)KVH?M+?!73]?\':<T?B3POX@COKGPW>-F3SK<
MN&@<< DAU<>N"O6L+XL?M ZS\6_!D'P\TGX=^(M#\3>*G_L[.O6PM[:(KM:8
MHQ^:3:H.3M7:#DCH" >N_'WX>2?%7P#I^O>%IPOBK1636- OHNKL '\L9_AD
M4#@\9"YXS72_!;XI6GQ@^'NG>(;=!;W3 P7UG_%;728$D9!Y'/(SSM93WKQ;
MQ-XB^,/[.>AZ9K^MWFA>*?!5CY%K?Z=IUJT$EC#E8U:)V^9P,@98GDC(YR+F
ML747[/\ \:;/Q?:-L^'/Q =(]2(XCLM08;H[C_960$Y^KD]%H @^+GP1\7?%
MS]HB1UN+C0?!)T"'3M0U&%E#W4!G:5[>+N&9@ Q[*.<@A6^BO#/AG2_!N@V6
MBZ+91:?IEG&(H+>$851_4DY))Y)))Y-:E% !1110 5X/KGQS\:^+O$&L:;\*
M/"%KXCLM%F:UO=:U.Z$-M)<*,M#"-PWD< MG&?;!/<ZQ\7;/0/B]H_@74;":
MS&L6+W%CJDC 0W$RM\UNO^T%YY(Z@8Y&?!OAGXX\2?LLZ1K'@KQ-X#\0:[I]
MG<W-YI^O:';":&YA)+EIF+ )@ L6)) X(^7) /9?@W\6+;XX^&=<L=8T-M'U
MG396TS6M#NOW@1F4@CD#*, PP1V(YZGB/@??7'P4^).I_!W5YG?29M^I^$[J
M8D^9;L2TEMGNR'<??#GH5KC?A3X8^,7C*S\2_$7PWJVA^$/^$NNO[1M[&\M3
M<RRQ("D*NY&$7;G#!23G.!D :$TVN_M*_"W4));)-!^+OP_U1O):V.%^U1$$
MJF2?ED"XP3C<H/(H ]2_:H\,Z_XT^!^O:%X;L'U'5-0DMH5AC95.S[1&S')(
M&,+SZ D]J=\#?@;'\,X;O6];N_[>\=ZL ^IZQ(,XZ8AAX^6-< 8 &=HX "JN
M[\%/BE:_&#X>Z?K\,?V:\YM[^SY#6UTG$D9!Y'/(SSAA7=T %%%% !7'?%KX
MF67PE\$7GB"\MY+Z1&6"UL8?]9=7#G;'$O!QD]\' !.#TKKY"XC8QJK/@[58
MX!/8$X./RKYAUN\UC]JCX4:GI,4</AGXE^#]<6YDTUVS''<PLXB.3GY'1FPW
M3<I_AH =XJ\<?M ?#O07\=:Y9^&+W0K?;-?>&[(/]HMH">3YA'+*",D,P&,X
M(S7MOB3P_H?QN^%\EC=HTNC:_8)-$[*-\8=0\<@]&4E6'N*^</B=\2OBWX^T
MG1OACJW@2T\&ZIXM=M/DU1]22X62- &N'CB3E5"YSEFX; )/-:GQ \(_$K]G
M3PG;^,](^(=WXHT[15ACO]!U&U2*VDM@5CQ$JY$>,CISCG/&" =U^S-XZU-;
M;5?AIXLD_P"*O\(,+<R,3_IMG_RQG7/)&TJ"?0H3RU2_&O\ 9S_X79\1?"NH
MZIJ?D>%]*MIDN["%F6:Y9G4[-PX",%&X]?EP.N5QOCMH6HK#X6^-7@NSDEU[
M1H8Y;NQ0?/?Z;(-SQ,!U*AB1Z98]0*]^T^\_M#3[:Z\F:V\^)9?)N$V21[@#
MM9>S#."/6@!--TVTT;3[:PL+:*SLK:-8H;>% J1H!@*H'0 59HHH *P/'GC7
M3?AUX/U;Q)J[LFGZ= 9I-@RS= J+_M,Q"CW(K?KYD^*%]K/Q<U;XA_!;Q!]E
MTC4[V*/5/"MXH817<$95_+<G)W!HSN('=R!A!D =JWCS]H&/PR_CZ#1/#5OH
M,</VW_A%Y#*]]]EQN)9^!YFSG (_W<_+7LN@ZEHGQT^%-K=SV9ET3Q%I_P"]
MM9OO*KC#(3_>4Y&1W&17SUXW^-WQ?L/ MMX0UCX=IIGB76I4\/1:V^HQF":>
M92@DCC4$Y(R<Y*J>3_=JWK?PF^*?P+^&$.M>'/B0=2/AFR\Z?09K"-+*2WB7
M=(JXY)"ACD_,W)RI- '6?LX>(]0\!Z_J_P &?$]PTNI:"//T.\EX^W::Q^3'
MJ4Z8'09'\!K;_:'^!6H?'&_\&VL>KC2=%TZYGEU)HF87#HZ*H6+ QDC>IST#
MYP>AYCXKZ7??%3X6^#OB_P"#K=K/QGHEM'K%I"/F:6%D#3VK8Y<8W8'?D#[]
M>Z>"_$G_  F'A'1]<^Q7&G'4+6.Y-I=(5EA+*"58$=O7OUH D\*^%=*\$^'[
M+1-$LH]/TRSC$<-O$. .Y)ZDDY))Y)))K6HHH ***\M^.WQ4U;X0V_AO78].
MBO/"G]H+;Z]<?,9K6%QM21 .,!CR3Z*O\60 <[XN\?>./B)\1=6\#_#:[LM!
MAT%8_P"V?$M] +CRYI%)2""(Y5F Y);I@CC W)\'?'WCS2OBAJWPS^(L]GK&
MIPZ=_;&G:Y91"(75OYHC(=%  8,>P&-K=>"<>Z\%_$3X<_%#7O&'PWL]+\7^
M&O%PCO+K3KJ\6!HI@O$L<AX*MN)&,YW8(X!KC?AC\/\ Q/\ M+>(-?\ B+XA
M\5W_ (24E]!M+?PG/Y+F"%\MB9@6\LR$DC'S$$\# H Z_P"(T;?L[_&:U^(M
MHK)X+\4R)8>)H4'R6UQTAN\#IU.X_P"]W<5[EXWTV[\2>!=?T_29HDOK_3;B
M"TFD8^6)'B948D \9(/%>!?#O3]9NO&WCOX%^/-6G\::&VE+?V6J7A)N1 [*
MNR1CG+AF4J2<@ID<$!>O_9GU'Q%H5GKOPY\3PW$U]X1F2WM-5:-O*O;)P3 0
MW3<JC&,\#:.H- %C]G3]G:P^">@K/>2C5O%MU"D5YJ3DMY:* %@ASRL:X _V
ML G   ]DHHH ***@OOM/V.X^Q^5]K\MO)\_/E[\?+NQSC.,XYQ0!P7QG^*TG
MPSTK3(-,TQM=\4ZW<_8=(TM6VB:7&2SM_"B#!)]QTY(\LUCXG?&'X,ZMHNK?
M$.#P[K'A'4[J.RNFT-9$DTUY&PK?.,LHY]<XQD'&>9N-5\;?&?3O#GB;2;2U
MC^+/PSU2>VU7P_,RQ1W2R *Y0DX =8\#D#_68/"Y3XA>)_B)^T%XOT'X87/A
M>'X=OM37[V>[NX]0D$,+X5O+4!=OFX 5OO$#.!G(![U\>/A3'\7OA_<Z7%)]
MDUJU=;W2;X':UM=)RC!AR ?NGV.>H%5/V>_BO)\5/ P?4XOL?BG293IVM6+#
M:T5RG!;;V#8R.P.X<[:\M\47/Q$_9P\6>&-7U'QM=>.O!^M:E%I>H6NI0(DU
MM)(#MDC*YP/E8X&!Q@@Y!&_\1O#VI_"7XV:-\1O#EA<7VD>(98M'\2Z=9QEV
M+,0L%TJ#J0< GVQ_&30!/XJ_9@@^(GQ\G\:^*+N*^\-PVMLEKHR[L32Q@_Z\
M'@H"2P49W;L' !#>\JJQJJJH55& H& !Z4ZB@ HHHH CN)X[6"2:9UCBC4N[
ML<!5 R2?PKYPTOQ5\7_CU97?B;P)K>F>"/"8E>/2$OK);BXU(1L5,DI96\I&
M((^49&._4]IXF^)EUIOQH7X?^)K*&V\+^)],,6CZC&3NFN ")H7)X#$,-H'^
MSU+X'DMG??&#]E7P#K&DQZ'H_BCP=HJ33V&NW%Z(6@B9BRI)$"'<[F^Z!U;&
M[&, 'L/P$^(^H?%SP3K-IXLTNWM=>TB_N-#U>UC&Z"5T #$ D_*0V",D9![$
M5Q/P9NIO@1\5-1^$>IRL?#NI&34_"=U,21L))EM,G^)3DCZ$_P 8%87P\_9E
M\5ZIX#.N7'Q/\1>'O$VO2OKDD&C3>19I<3@.?-1<&4_=!^8 8P!CJW1]/\0_
MM*? 6X>]E2'XE^"]8F@L=6M\()+RWVL&!P  X95/;<H;'&* /5_VD/A;K?Q@
M\"V&@:'J$.ER_P!JV]S<74Q8&.%-Q+(%ZN&*D#(SCJ*ZKX8_#'0OA+X4M]!T
M&W,<"'?-<2?--<RG[TLC?Q,?R P!@ "JWP:\>7/Q*^&^C:_>Z=/I6H3QF.ZM
M9XFCVS(Q23:#U4LI(]CCJ#7:T %%%% !7CGQ8^)?B>7QUIWPX^'R6:>*;NT.
MHWNJ7ZEX--M VT/M&=SLW !X&5R/FR.F^-_BSQ'X%^'.H>(/#&G0:I>Z<T=S
M<6L^[YK56!FVX_BV _09/) !\I\1:'XF\3^,/#GQM^$4MCK!U/2ULK_1]1E$
M2W$&[=PW\+JPP1D8,8Z\@@%OPSXR^)GPM^+WA[PA\0-9LO&&B^)UF33M9MK-
M+66">--QC=$ &#QV.=P.>"*F_:.\.W_@/7]'^,WAFW:74=!'V?7+.+C[=IK'
MY\CN4SG)Z##'[@KAM+T3QQ^TO\8+_P#X274?^$$MO H^S+'X;N-]RMQ<Q_.%
MN"" P1<%@O'0#DM71>&H/$OP9^.VB?#[4_$NH>-_!?B^SNC;+KTGVBYM)(HR
MSJSD?,A48QP#OZ#:20#Z'\-^(K#Q;H&GZUI5PMUIU]"MQ!,O\2L,CZ'U'8Y%
M>'? ']EQ/AWK^H>+/%=Q#K7BJ:ZGDM?++/;V*/(S%H]P'SODDM@8S@=R7?!#
M3=5^#/Q.UWX72V]U=>$[B-]:\.WNUG2VB+@2V[MVPS<9[\]7%?0- !1110 5
M@>._'.C_  W\*W_B+7KK[)IMDFZ1L99B3A44=V)( 'O6W<3?9[>678\OEJ6V
M1C+-@9P!W-?,WQ:\37'[07P/T+Q=X(TZ;4YM!U^'4KSP],O[^3[.6#P,@SEO
MF5MO.5Z9.!0!?O/VKO$?AD6FM^*_A5K'A_P/>2(B:R]TDDT"L<*\T 7* Y'!
M(([;B0*](^-GPQM/C5\-Y].M[A(M04+?Z1J,;?ZBY4;HW5AT!S@D=F)'.*\+
M^+W[2^G_ !@^';^!_"OAG7)O%'B=ETZ*VU"S$,<#Y5I SL<$J,].!]XD 5MZ
MM\2/BW^SWI>C:CXST7PWJG@.'R+*Y;07G-SIT?"(S&3 ;L.A!/&5R,@'IW[/
M/Q6F^*'@EEU:/[)XMT64Z;K=DPVM'<)D%\=@^"?3.X=JX+]H#X/>,OBQ\8_"
MT6DW4FB>&8-)N(+_ %F)E\Q%E?$L,8Z[W0*,X PS<GD&/XO(WP3^)>E?&/1D
M:3PSJPBT_P 4V\"D@Q-@0W87^\OR@_0#^-C7T;:W4-]:PW%O*LT$R"2.2,Y5
MU(R"#W!% &/X)\$Z-\._#-EH&@626&F6B;4C7JQ[LQZLQ/))Y)K=HHH *9-,
MEO$\LKK'&BEF=S@*!R23V%/KQ7XH>.G\7:SXS^$$-M+I&NZEX>DET>^N) L6
MH,Z.'1".FWH>YPYP H) ,/5/VK=5O(;[5O!OPSUGQ?X0L799M>CG%NDBJ<.\
M$91FE4<\C'3G%>H>']=\,_'WX7+>0(;[P[KMJ\,L$P"NH.4=& )VNI!&0>"
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MV%.<@'=UR!GF;GQ)XT_:.^-6FZQX'TA?"4/@F":$WGBNV(E2>Z3:P\E2?FV
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MA;KM!8G'3)-6:* "BBB@ HJEKFL6GAW1;_5;^3R;&QMY+JXDP3MC12S' ZX
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M=)^,6B>(59M:T;7KC5(K121+J$=P8TA*9ZEF"9.. ZFMS4+O]I.WT<^,TET
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M-8O[2'CSPCJ7Q*^%UYX9/_"4>*],U9;N5?#(6\N39H-S0G8?XS@ $\#>> :
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MLV>H% 'F_P 2M/\ &OPG^.$_Q(\.^'+GQIH&L:?'8:IIEADW<#1_=>-0"6&
M.@[L#C(-2:;I?B[]H+XA>&?$'B+PS=>"_!?ABY^WV>GZF0+Z_O !Y;NF/W:)
MUP><YZY^7N?V??BM+\4O P?5(OL?BK2)6T[6[%AM:*Y3@MM[!L9] =PYVUZ=
M0!2O-%T_4+^QOKJRM[B\L69K6XDC#/ 67:Q0GE21P<=JNT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5#:V<%C&R6\$=NC.TC+$@4%F
M8LS$#N222>Y)-344 ?$]GK'B_P ;?&SXN>$? 2R:=<ZQJ\<.K>)#]S3;2",Q
M$)C_ ):NWF <@\<8Y9/I33/@+X.L?A=8^ +C3CJ?A^U9)?+NY&9Y)5?S#(6!
M!!9LYVX&&(Z'%=II7A_3-#DO7T[3[:Q>^G:ZNFMXE0S3, &D? Y8X&2>:T*
M$50JA5   P .U+110 4444 %<1\:O "?%#X5^)/#156FO+1OLQ;^&=?GB/\
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MNU^%^MZW^T#INM:GXM\,V5K\.]0,)T72=2AWW4ZHV[[1+SMVL0I YZ#''S.
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MY[XSWKM]!\-Z7X7L7L](T^WTVU>:2=H;:,(ID=BSM@=R36E10 4444 %%%%
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M)Y- 'E'P'M?#/QF^#6M?#WQ3<:K<^)8[B1_$%EK$Y-[#<F3<9HMP^5 X&,#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!8$;T)Z$5C?##X8:%\)/"=MH&@6WE6\?SS3R<S7,I^]+(W=C^0& ,  5UM%
M!1110 4444 %%%% !7 6/P7T2#XJZA\0+V:ZU?6YHD@LUOG#Q:=&%PRP+CY=
MW))Z\G'4Y[^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(KH3-:S"V:-+@H?+:52R!L<%@""1GL"/K7E'P<^"$_@_5M0\8>+]0C\2?$'5
M"?M&I 'RK6/M#;@@;4 P,X&>G KURB@ HHHH **** "BBB@ KR3XF?!6^^+?
MCS27\0ZPDOP^TZ-;C_A'H%9&N[L,>9VSAHP,8'U&.23ZW10!'!!':P1PPQK#
M#&H1(XU"JJ@8  '0 5)110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_"S_P!HW_GS\1?^$TG_ ,CT?V-5_P"?L/O_ . ']J4_^?<ON_X)]P45\/\
M_"S_ -HW_GS\1?\ A-)_\CT?\+/_ &C?^?/Q%_X32?\ R/1_8U7_ )^P^_\
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M3K=I[NXBM8%^]),X11]2:^:?C%XBT_QA\8?V<-<TFX6[TR^N[V>"=.A5DMR
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M]*^9O"=Y\#O$G@Q;WXA7.O:_XYU6'S[_ %B2UO6D@E89"Q%1LQ'P!P0<>F
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M-^$?[+_A'X@_#K3/%7C^WNO%?BGQ):IJ-UJ-Y>2JT8E4-&D81@%"J5_'T&
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M_!>P/[1_[+D&B^-Q-<79\VQ>\F4^>KQ-^ZG!;DN%*?,?O$'/4T ?1=%?'_\
MPLCX@>(;+_A0DOF0^/EF-C?^)%.8QI(0-]K!SGS'C8+CKD]0QX^HO O@G2OA
MUX3TWP[HEO\ 9].L(A'&O\3'JSL>[,26)]2: -ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M [#\V1_K#SU!^FJ* /F"*;Q=\2OVE/AGXRE\!ZMX;\-6,.HVXFU.,+<@&VD
M>>,9\D%G555B22&KJM<\)ZS/^V5X?\11Z9=/H4/A5K234%B)A2;SISL+=-V&
M4X]Q7NM% 'B'[37A76/$UY\+VTG3;G45L/%MG=W1MXR_DPJ3ND;'11ZUU/[1
M6BW_ (B^"/C#3=+LYK_4+FQ:.&VMT+R2-N'  ZFO1J* /#?&7PAU+XD?LMZ'
MX3CW:;X@M=(T^6W6X!0QW4,2'8W]TDAE)[9SVJCH_P"TMXETFQAT_P 6?"'Q
MPOB*-?+F.B::+NTF<#!=) X&TGG W8SU/6OH"B@#Q#]I"PUSXD?LOZW#8>'[
MY-;U&&RE71@GF7,9%U"[(0O4JH)./0UZOX/MY;/PCHEO/&T4T5C DD;C!5A&
MH((]0:V** ,+QY:S7_@;Q%;6T33W$VG7$<<48RSL8F  '<DFOF3X(_%+QO\
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M,%4=1S]S.?>NQL?#OC[X_?%#P?XE\4^%O^$$\)^%9VOK:RNK@2WEY<':5+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?C#PCINJZAH]YH&H31_Z3IM]$R202#AEY'*YY#=P1T.17144 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388594720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 06, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GOSSAMER BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5461709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3115 Merryfield Row, Suite 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">684-1300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GOSS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,221,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Certain sections of the registrant&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of this fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001728117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387654016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389697552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 46,074<span></span>
</td>
<td class="nump">$ 32,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">248,444<span></span>
</td>
<td class="nump">264,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivable from contracts with collaborators</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,032<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">309,888<span></span>
</td>
<td class="nump">306,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,111<span></span>
</td>
<td class="nump">3,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">315,292<span></span>
</td>
<td class="nump">311,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,319<span></span>
</td>
<td class="nump">5,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">10,455<span></span>
</td>
<td class="nump">7,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current contract liabilities</a></td>
<td class="nump">17,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">15,186<span></span>
</td>
<td class="nump">26,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,010<span></span>
</td>
<td class="nump">51,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LongTermConvertibleSeniorNotes', window );">Long-term convertible senior notes</a></td>
<td class="nump">197,523<span></span>
</td>
<td class="nump">196,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">4,398<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">38,869<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">285,800<span></span>
</td>
<td class="nump">249,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 700,000,000 shares authorized as of December&#160;31, 2024 and December&#160;31, 2023; 226,604,138 shares issued and outstanding as of December&#160;31, 2024, and 225,409,315 shares issued and outstanding as of December&#160;31, 2023</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,296,848<span></span>
</td>
<td class="nump">1,275,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,268,568)<span></span>
</td>
<td class="num">(1,212,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">1,189<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">29,492<span></span>
</td>
<td class="nump">62,769<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 315,292<span></span>
</td>
<td class="nump">$ 311,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LongTermConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LongTermConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628482591360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">700,000,000<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">226,604,138<span></span>
</td>
<td class="nump">225,409,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">226,604,138<span></span>
</td>
<td class="nump">225,409,315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388924736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 114,701<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">138,487<span></span>
</td>
<td class="nump">135,304<span></span>
</td>
<td class="nump">170,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ResearchAndDevelopmentInProcessExpenses', window );">In process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">36,133<span></span>
</td>
<td class="nump">38,455<span></span>
</td>
<td class="nump">47,609<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">174,620<span></span>
</td>
<td class="nump">183,759<span></span>
</td>
<td class="nump">218,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(59,919)<span></span>
</td>
<td class="num">(183,759)<span></span>
</td>
<td class="num">(218,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(11,517)<span></span>
</td>
<td class="num">(13,511)<span></span>
</td>
<td class="num">(13,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">14,022<span></span>
</td>
<td class="nump">15,456<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">4,284<span></span>
</td>
<td class="nump">3,942<span></span>
</td>
<td class="num">(10,785)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(55,635)<span></span>
</td>
<td class="num">(179,817)<span></span>
</td>
<td class="num">(229,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,528)<span></span>
</td>
<td class="num">(179,817)<span></span>
</td>
<td class="num">(229,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized income (loss) on marketable securities</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="num">(619)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (54,989)<span></span>
</td>
<td class="num">$ (179,593)<span></span>
</td>
<td class="num">$ (229,997)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
<td class="num">$ (2.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
<td class="num">$ (2.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">226,228,016<span></span>
</td>
<td class="nump">152,621,669<span></span>
</td>
<td class="nump">84,574,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">226,228,016<span></span>
</td>
<td class="nump">152,621,669<span></span>
</td>
<td class="nump">84,574,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">Revenue from sale of licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 90,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_RevenueFromContractsWithCollaboratorsMember', window );">Revenue from contracts with collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 24,019<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ResearchAndDevelopmentInProcessExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development In Process Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ResearchAndDevelopmentInProcessExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_RevenueFromContractsWithCollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_RevenueFromContractsWithCollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628391351376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,752,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 121,463<span></span>
</td>
<td class="num">$ (44,838)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 932,944<span></span>
</td>
<td class="num">$ (53,527)<span></span>
</td>
<td class="num">$ (811,534)<span></span>
</td>
<td class="nump">$ 8,689<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with a private offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,649,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with a private offering, net of offering costs</a></td>
<td class="nump">$ 119,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">119,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">270,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">42,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock pursuant to Employee Stock Purchase Plan</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted stock units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(229,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(619)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,423,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">12,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">1,044,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,032,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with a private offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,869,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with a private offering, net of offering costs</a></td>
<td class="nump">$ 201,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">201,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 28,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock pursuant to Employee Stock Purchase Plan</a></td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted stock units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(179,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">225,409,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,409,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 62,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">1,275,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,212,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 20,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock pursuant to Employee Stock Purchase Plan</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted stock units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued', window );">Grant of equity option pursuant to Chiesi Collaboration Agreement</a></td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="nump">$ 1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">226,604,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,604,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 29,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 1,296,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,268,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Equity Option Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares vesting of restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387446208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 10,779<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 80: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388350848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (56,528)<span></span>
</td>
<td class="num">$ (179,817)<span></span>
</td>
<td class="num">$ (229,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">20,619<span></span>
</td>
<td class="nump">28,518<span></span>
</td>
<td class="nump">42,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ResearchAndDevelopmentInProcessExpenses', window );">In process research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">3,318<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of long-term debt discount and issuance costs</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on investments, net of accretion of discounts</a></td>
<td class="num">(13,062)<span></span>
</td>
<td class="num">(9,450)<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivable from contracts with collaborators</a></td>
<td class="num">(5,338)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">62<span></span>
</td>
<td class="num">(3,892)<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(3,386)<span></span>
</td>
<td class="num">(2,982)<span></span>
</td>
<td class="num">(2,721)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,656)<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
<td class="num">(1,813)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(10,718)<span></span>
</td>
<td class="num">(835)<span></span>
</td>
<td class="num">(1,659)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">2,676<span></span>
</td>
<td class="num">(7,847)<span></span>
</td>
<td class="num">(579)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,701<span></span>
</td>
<td class="num">(3,240)<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">55,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest expense</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,468)<span></span>
</td>
<td class="num">(159,158)<span></span>
</td>
<td class="num">(187,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions', window );">Research and development asset acquisitions, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(494,777)<span></span>
</td>
<td class="num">(441,670)<span></span>
</td>
<td class="num">(238,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ProceedsFromMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">523,800<span></span>
</td>
<td class="nump">330,700<span></span>
</td>
<td class="nump">237,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">29,023<span></span>
</td>
<td class="num">(110,970)<span></span>
</td>
<td class="num">(1,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock and warrants in a private offering, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">201,323<span></span>
</td>
<td class="nump">119,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of equity option pursuant to stock purchase agreement</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of long-term debt</a></td>
<td class="num">(12,581)<span></span>
</td>
<td class="num">(11,613)<span></span>
</td>
<td class="num">(5,806)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(11,488)<span></span>
</td>
<td class="nump">190,154<span></span>
</td>
<td class="nump">117,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(102)<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="num">(517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">13,965<span></span>
</td>
<td class="num">(79,864)<span></span>
</td>
<td class="num">(71,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at the beginning of the period</a></td>
<td class="nump">32,109<span></span>
</td>
<td class="nump">111,973<span></span>
</td>
<td class="nump">183,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at the end of the period</a></td>
<td class="nump">46,074<span></span>
</td>
<td class="nump">32,109<span></span>
</td>
<td class="nump">111,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">10,561<span></span>
</td>
<td class="nump">12,288<span></span>
</td>
<td class="nump">12,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">5,298<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax', window );">Change in unrealized gain (loss) on marketable securities, net</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash investing and financing activities change in unrealized gain on marketable securities net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for (Proceeds from) research and development asset acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ProceedsFromMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturity of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ProceedsFromMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ResearchAndDevelopmentInProcessExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development In Process Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ResearchAndDevelopmentInProcessExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387458256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gossamer Bio, Inc. (including its subsidiaries, referred to as "we," "us," "our,", or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension ("PH') including pulmonary arterial hypertension ("PAH") and PH associated with interstitial lung disease ("PH-ILD").  The Company was incorporated in the state of Delaware on October&#160;25, 2015 (originally as FSG Bio, Inc.) and is based in San Diego, California.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Gossamer Bio, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant operating losses since its inception. As of December&#160;31, 2024, the Company had an accumulated deficit of $1,268.6 million. From the Company&#8217;s inception through the year ended December&#160;31, 2024, the Company has funded its operations primarily through equity financings, convertible senior notes and the Chiesi Collaboration Agreement (as defined in Note 12 below).</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the Company will need to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Management believes that it has sufficient working capital on hand to fund operations through at least the next 12 months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387441952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued research and development expenses, stand-alone selling price of performance obligations and estimated collaboration expenses associated with the Company&#8217;s collaboration and license agreement. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers securities with original maturities of greater than 90&#160;days to be marketable securities. The Company has the ability, if necessary, to liquidate any of its marketable securities to meet its liquidity needs in the next 12&#160;months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying consolidated balance sheets which reflects management&#8217;s intention to use the proceeds from sales of these securities to fund our operations, as necessary. The Company&#8217;s marketable securities consist of U.S. Treasury and agency securities, commercial paper and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operation and comprehensive loss. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December&#160;31, 2024.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury and agency securities and commercial paper with maturities less than three months and in money market funds that invest in U.S. Treasury and agency securities.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s available for sale securities are also invested in U.S. Treasury and agency securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, which consists mainly of lab equipment and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:f-390">two</span> to seven years, using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASU 2020-06, the Company accounted for the 2027 Notes as a liability and equity component. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component was not re-measured as long as it continued to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (&#8220;debt discount&#8221;) was amortized to interest expense over the term of the 2027 Notes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the issuance costs incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the 2027 Notes and were amortized to interest expense over the term of the 2027 Notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022 the Company adopted ASU 2020-06. After adoption, the Company now accounts for the 2027 Notes as a single liability measured at amortized cost. The impact upon adoption on the Consolidated Balance Sheets was an increase of approximately $44.8&#160;million in convertible senior notes, net, a write-off of $9.4&#160;million in deferred income tax liabilities and a decrease of $53.5&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment of $8.7&#160;million to increase the beginning balance of accumulated deficit on the Consolidated Balance Sheets for previously recognized interest expense related to amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 842), the Company determines if an arrangement is a lease at inception. Operating leases are included in the balance sheet as right-of-use assets and operating lease liabilities at the present value of the lease payments calculated using the Company&#8217;s incremental borrowing rate, unless the implicit rate is readily available. The Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and elected to not separate lease and non-lease components for its long-term leases. The Company records rent expense on a straight-line basis over the term of the lease.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In process research and development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In process research and development costs relate to a milestone payment to Pulmokine for the initiation of the Phase 3 clinical trial for seralutinib.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC&#160;740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company's policy is to include interest and penalties related to income taxes within its provision (benefit) for income taxes.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the United States, California, Florida, Ireland and Luxembourg. As of December&#160;31, 2024, the Company&#8217;s tax years since inception are subject to examination by taxing authorities due to the Company&#8217;s unutilized net operating losses ("NOLs") and tax credits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its licensing and other agreements are collaborative arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. For arrangements that the Company determines are collaborations, it identifies each unit of account, and then determines whether a customer relationship exists for that unit of account. If the Company determines </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a performance obligation within the collaborative arrangement to be with a customer, it applies its revenue recognition accounting policy. If a portion of a distinct bundle of goods or services within the collaborative arrangement is not with a customer, the Company applies recognition and measurement based on an analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational and consistently applied accounting policy election. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and the collaboration partner are within the scope of other accounting literature. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 12, "Significant Agreements and Contracts," for more information.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when a customer obtains control of promised goods or services in a contract for an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. For contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for contracts with customers, the Company develops assumptions that require judgment to determine the standalone selling price of each distinct performance obligation identified in the contract. In addition, variable consideration such as milestone payments are evaluated to determine if they are constrained and, therefore, excluded from the transaction price. The Company then allocates the total transaction price proportionally to each distinct performance obligation based on their estimated standalone selling prices, unless an allocation exception applies. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective distinct performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying standalone selling price for each distinct performance obligation, which determines how the transaction price is allocated among the distinct performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each distinct performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a distinct performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include cost-share reimbursements, we will recognize such payments when control of the related goods or services are transferred to the customer. Cost-sharing reimbursements are presented as revenue from contracts with collaborators.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants and shares purchasable under the Company's 2019 Employee Stock Purchase Plan ("ESPP") using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. The Company estimates the fair value of restricted stock units based on the closing price of the Company's common stock on the date of grant. The Company accounts for forfeitures as they occur. All share-based compensation costs are recorded in the statements of operations based upon the underlying employees or non-employee&#8217;s roles within the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities of non-U.S.&#160;subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated to U.S.&#160;dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates during the year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss) in the Company's consolidated balance sheets. Foreign exchange transaction gains and losses are included in other income, net in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements - Adopted</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures (&#8220;Topic 280&#8221;), which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Lastly, the amendment requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We have adopted this standard for our fiscal year ended December 31, 2024. We have applied this standard retrospectively for all prior periods presented in the financial statements. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13, Segment Reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on our consolidated financial statement disclosures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The Company uses the if-converted method for assumed conversion of the 2027 Notes to compute the weighted average shares of common stock outstanding for diluted net loss per share. Diluted net loss per share excludes the potential impact of the Company&#8217;s common stock options, warrants for the purchase of common stock, unvested shares of restricted stock and the potential shares issuable upon conversion of the 2027 Notes because their effect would be anti-dilutive due to the Company&#8217;s net loss. Since the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,321,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,321,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,321,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,416,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,626,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,487,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of Chiesi Equity Option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,433,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,467,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,467,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested shares under restricted stock grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,639,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,843,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,159,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386387328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-431"><span style="-sec-ix-hidden:f-432">Operating lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued in process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued accounting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388139008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Available for Sale Investments</a></td>
<td class="text">Fair Value Measurements and Available for Sale Investments<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Observable inputs such as quoted prices in active markets;</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash equivalents and available-for-sale investments within Level&#160;1 or Level&#160;2. The fair value of the Company&#8217;s investment grade corporate debt securities and commercial paper classified as Level 2 is determined using proprietary valuation models and analytical tools, which utilize market pricing or prices for similar instruments that are both objective and publicly available, such as matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and offers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the hierarchy for assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market<br/>Prices for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other&#160;Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying amounts of the Company&#8217;s financial instruments, which include cash, prepaid and other current assets, interest receivable, accrued research and development expenses, accounts payable and accrued expenses and other current liabilities, approximate fair values because of their short-term maturities.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $0.2 million interest receivable as of December&#160;31, 2024. There was no significant interest receivable as of December 31, 2023. Interest receivable is recorded as a component of prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023 the fair value of the Company's 2027 Notes was $110.0 million and $74.9 million, respectively. The fair value was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy (see Note 5).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available for Sale Investments</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in U.S. Treasury and agency securities, corporate debt securities, and commercial paper, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below.&#160;The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operations and comprehensive loss. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recover of their amortized cost basis.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in marketable securities&#160;as of&#160;December&#160;31, 2024 and 2023 are as follows&#160;(in thousands except securities amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Treasury and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and December&#160;31, 2023, the Company classified $25.3 million and $25.2 million, respectively, of assets with original maturities of 90 days or less as cash and cash equivalents.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Factors considered when evaluating available-for-sale investments for impairment include the severity of the impairment, changes in underlying credit ratings, the financial condition of the issuer, the probability that the scheduled cash payments will continue to be made and the Company&#8217;s intent and ability to hold the investment until recovery of the amortized cost basis. The Company intends and has the ability to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. As of December&#160;31, 2024 and 2023, there were no material declines in the market value of the Company's available-for-sale investments due to credit-related factors.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of available-for-sale debt securities, as of December&#160;31, 2024, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628390038160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text">Indebtedness<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2019, the Company entered into a credit, guaranty and security agreement, as amended on September 18, 2019, July 2, 2020, December 7, 2022 and February 14, 2023 (the &#8220;Credit Facility&#8221;), with MidCap Financial Trust (&#8220;MidCap&#8221;), as agent and lender, and the additional lenders party thereto from time to time (together with MidCap, the &#8220;Lenders&#8221;), pursuant to which the Lenders, agreed to make term loans available to the Company for working capital and general business purposes, in a principal amount of up to $150.0&#160;million in term loan commitments, including a $30.0&#160;million term loan that was funded at the closing date, with the ability to access the remaining $120.0&#160;million in two additional tranches (each $60.0&#160;million), subject to specified availability periods, the achievement of certain clinical development milestones, minimum cash requirements and other customary conditions. On May 3, 2024, the Credit Facility was terminated and the Company recorded a $7.7&#160;million payment of the outstanding debt balance in full and discharged, which released the Company </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the obligations under the Credit Facility, and Lenders&#8217; security interests in the Company&#8217;s assets and property were released. Unamortized debt discount and issuance costs were written off and recorded in interest expense on the consolidated statements of operations and comprehensive loss. Since the Credit Facility was terminated, there was no debt outstanding as of December&#160;31, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5.00% Convertible Senior Notes due 2027</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company issued $200.0&#160;million aggregate principal amount of 5.00% convertible senior notes due 2027 in a public offering (the "2027 Notes"). The 2027 Notes were registered pursuant to the Company&#8217;s shelf registration statement on Form S-3 filed with the SEC on April 10, 2020. The interest rate on the 2027 Notes is fixed at 5.00% per annum. Interest is payable semi-annually in arrears on June 1 and December 1 of each year, commencing on December 1, 2020. The 2027 Notes will mature on June 1, 2027. The net proceeds from the offering, after deducting the underwriting discounts and commissions and other offering costs, were approximately $193.6 million. The 2027 Notes may be settled in cash, shares of the Company&#8217;s common stock, or a combination thereof, solely at the Company&#8217;s election. The initial conversion rate of the 2027 Notes is&#160;61.6095&#160;shares per&#160;$1,000&#160;principal amount, which is equivalent to a conversion price of approximately&#160;$16.23&#160;per share, subject to adjustments.&#160;In addition, following certain corporate events that occur prior to the maturity date or if the Company issues a notice of redemption, the Company will increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event during the related redemption period in certain circumstances.&#160;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Notes are senior unsecured obligations of the Company, ranking senior in right of payment to any of the Company&#8217;s indebtedness that is expressly subordinated in right of payment to the 2027 Notes, and are effectively subordinated to the Company&#8217;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their notes at their option only in the following circumstances: (1) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2020, if the last reported sale price per share of the Company&#8217;s common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company&#8217;s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company&#8217;s common stock; (4) if the Company calls such notes for redemption; and (5) at any time from, and including, March 1, 2027 until the close of business on the scheduled trading day immediately before the maturity date. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have the right to redeem the 2027 Notes prior to June 6, 2024. As of December&#160;31, 2024, the Company has not redeemed the 2027 Notes. On or after June 6, 2024 and on or before the 50th scheduled trading day immediately before the maturity date, the Company may redeem the 2027 Notes, in whole or in part, if the last reported sale price of the Company&#8217;s common stock has been at least 130% of the conversion price then in effect on (1) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. In the case of any optional redemption, the Company will redeem the 2027 Notes at a redemption price equal to 100% of the principal amount of such Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change prior to the maturity date of the 2027 Notes, holders of the 2027 Notes may require the Company to repurchase for cash all or part of their 2027 Notes at a repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture governing the 2027 Notes provides for customary terms and covenants, including that upon certain events of default, either the trustee or the holders of not less than 25% in aggregate principal amount of the 2027 Notes then outstanding may declare the unpaid principal amount of the 2027 Notes and accrued and unpaid interest, if any, thereon immediately due and payable. As of December&#160;31, 2024, the Company was in compliance with these covenants. In the case of certain events of bankruptcy, insolvency or reorganization, the principal amount of the 2027 Notes together with accrued and unpaid interest, if any, thereon will automatically become and be immediately due and payable. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, there were no events or market conditions that would allow holders to convert the 2027 Notes.&#160;When the 2027 Notes become convertible within 12 months of the balance sheet date, the carrying value of the 2027 Notes will be reclassified to short-term.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the 2027 Notes as a single liability measured at amortized cost. As the equity component is no longer required to be split into a separate component, the Company recorded an adjustment to reflect this update.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded&#160;$0.4&#160;million of the debt issuance costs related to the 2027 Notes as a reduction to the liability and amortizes these costs to interest expense over the term of the 2027 Notes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the 2027 Notes was as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,591&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the interest expense recognized related to the 2027 Notes (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense related to the 2027 Notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387441952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses, Asset Acquisitions and Contingent Consideration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Licenses, Asset Acquisitions and Contingent Consideration</a></td>
<td class="text">Licenses, Asset Acquisitions and Contingent Consideration<div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following purchased assets were accounted for as asset acquisitions as substantially all of the fair value of the assets acquired were concentrated in a group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of employees and early stage of development. Because the assets had not yet received regulatory approval, the fair value attributable to these assets was recorded as in process research and development (&#8220;IPR&amp;D&#8221;) expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2024, 2023, and 2022.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is met.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License from Pulmokine, Inc. (Seralutinib)</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;2, 2017, the Company entered into a license agreement with Pulmokine, Inc. under which it was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine to develop and commercialize seralutinib and certain backup compounds for the treatment, prevention and diagnosis of any and all disease or conditions. On November 26, 2024, Pulmokine became a wholly-owned subsidiary of XOMA Royalty Corporation. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The assets acquired are in the early stages of the FDA approval process, and the Company intends to further develop the assets acquired through potential FDA approval as evidenced by the milestone arrangement in the contract. The development activities cannot be performed without significant cost and effort by the Company. The agreement will remain in effect from the effective date, unless terminated earlier, until, on a licensed product-by-licensed product and country-by-country basis, the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product or specified regulatory exclusivity for the licensed product in such country. The Company is obligated to make future development and regulatory milestone payments of up to $48.0 million, which includes a payment of $5.0 million due upon initiation of a </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 clinical trial in a second indication, commercial milestone payments of up to $45.0 million, and sales milestone payments of up to $190.0 million. The Company is also obligated to pay tiered royalties on sales for each licensed product, at percentages ranging from the mid-single digits to the high single-digits. In addition, if the Company chooses to sublicense or assign to any third parties its rights under the agreement with respect to a licensed product, or the Company&#8217;s seralutinib operating subsidiary undergoes a change of control, the Company must pay to Pulmokine a specified percentage of all revenue to be received in connection with such transaction. The Company made an upfront payment of $5.5 million in October 2017. The Company made a milestone payment of $5.0&#160;million in connection with the initiation of the first Phase 2 clinical trial of seralutinib in January 2021 and made a milestone payment of $10.0&#160;million, which was accrued in 2023, in connection with the initiation of the Phase 3 clinical trial of seralutinib in January 2024. The Company recognized these milestone payments as research and development expense on its consolidated statements of operations and comprehensive loss. As of December&#160;31, 2024, no other milestones had been accrued as the underlying contingencies had not yet been met.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following IPR&amp;D expense on the consolidated statements of operations and comprehensive loss (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terminated programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total in process research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388784496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net loss before taxes for the years ended December&#160;31, 2024, 2023, and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. loss before taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign loss before taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">229,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense for the years ended December 31, 2024, 2023 and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December&#160;31, 2024, 2023 and 2022 are shown below. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced. The change in the valuation allowance for the year ended December&#160;31, 2024 was an increase of $7.4 million.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 174 capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">229,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,086)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(768)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,809)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(228,683)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(221,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204,050)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal and state NOL carryforwards of approximately $398.1 million and $3.3 million, respectively. The federal NOL carryforwards can be carried forward indefinitely and be available to offset up to 80% of future taxable income each year. The California NOL carryforwards begin to expire in 2036. As of December&#160;31, 2024, the Company also has Irish NOL carryforwards of approximately $113.0 million, which can be carried forward indefinitely. In the current year, the Company removed federal and foreign NOL carryforwards of $141.0 million and $0.4 million, respectively, as a result of mergers and liquidations.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company also had orphan drug credit and federal research tax credit carryforwards of approximately $48.2 million and California research tax credits of $13.2 million. The federal research tax credit carryforwards begin to expire in 2038, and the California research tax credit carryforward does not expire and can be carried forward indefinitely until utilized. In the current year, the Company removed federal and California credit carryforwards of $9.7 million and $0.4 million, respectively, as a result of mergers.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and experimentation credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GILTI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nondeductible interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic/Foreign Restructuring Impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax respectively. In general, an ownership change as defined by Sections 382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over a three-year period. The Company had an ownership change with the IPO in February of 2019 which resulted in no forfeiture of NOLs or credits.  The Company had an additional ownership change in July of 2023, which resulted in a significant limitation on the Company's utilization of its NOLs and is expected to result in forfeiture of some or all of the federal credits. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company's effective tax rate.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, California, Florida, Ireland, and Luxembourg. Due to the Company&#8217;s losses incurred, the Company is subject to the income tax examination by authorities since inception. The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as tax expense. For the years ended December&#160;31, 2024, 2023 and 2022 and as of December 31, 2024 and 2023, there were no accruals for interest related to unrecognized tax benefits or tax penalties.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2024, 2023, and 2022, excluding interest and penalties, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease related to prior year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase related to current year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2024 is $13.9 million that, if recognized, would not impact the Company&#8217;s income tax benefit or effective tax rate as long as the Company's deferred tax asset remains subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company's unrecognized tax benefits within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387435952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock is entitled to one vote. Common stock owners are entitled to dividends when funds are legally available and declared by the Company's board of directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement and Stock Offering</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2020, the Company filed a universal shelf registration statement on Form S-3, covering the offering from time to time of common stock, preferred stock, debt securities, warrants and units, which registration statement became automatically effective on April 10, 2020 (the &#8220;Shelf Registration Statement&#8221;).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company completed a public offering of 9,433,963 shares of its common stock at a public offering price of $13.25 per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering costs, were approximately $117.1&#160;million. The shares sold in the offering were registered pursuant to the Company&#8217;s Shelf Registration Statement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Financing</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company completed a private placement of 16,649,365 shares of the Company's common stock at purchase price of $7.21 per share. The gross proceeds for the private placement were $120.1&#160;million, before deducting offering expenses, which equaled $0.2&#160;million. On August 9, 2022, the Company filed a registration statement on Form S-3 registering the shares of common stock issued in the private placement, which registration statement became automatically effective on August 9, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2023, the Company completed a private placement of 129,869,440 shares of the Company&#8217;s common stock and accompanying warrants to purchase up to 32,467,360 shares of the Company's common stock at a combined </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase price of $1.63125 per share and accompanying warrant, or with respect to any purchaser that was an officer, director, employee or consultant of the Company $1.85125, per share and accompanying warrant. Each warrant has an exercise price per share of $2.04, was immediately exercisable on the date of issuance and will expire five years from the closing of the private placement. The aggregate gross proceeds for the private placement were $212.1&#160;million, before deducting offering expenses, which equaled $10.8&#160;million. On August 18, 2023, the Company filed a registration statement on Form S-3 registering the shares of common stock and shares of common stock issuable upon the exercise of warrants issued in the private placement, which registration statement was declared effective on August 28, 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares of Common Stock Subject to Repurchase</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;3, 2015, the Company issued 9,160,888 shares of common stock as founder shares for services rendered to the Company, valued at $0.0001 par value per share, for a total of approximately $4,100 (the &#8220;founder shares&#8221;). On January&#160;4, 2018, incremental vesting conditions were placed on the previously issued founder shares. Fifty percent of the previously issued founder shares vested on January&#160;4, 2018, and the remaining founder shares are subject to vesting restrictions over a period of five years. These shares are subject to repurchase by the Company upon a founder's termination of employment or service to the Company.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the employment agreements with the Company&#8217;s founders executed January 4, 2018, the Company provided for certain potential additional issuances of common stock (the &#8220;anti-dilution shares&#8221;) to each of the founders to ensure the total number of shares of common stock held by them and their affiliates (inclusive of any shares subject to equity awards granted by the Company) would represent 15% of the Company&#8217;s fully-diluted capitalization until such time as the Company raised $300.0 million in equity capital, including the capital raised in the Series&#160;A financing.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In furtherance of this obligation, on May 21, 2018, the Company issued 251,547 shares of common stock to the founders for services rendered to the Company, valued at $2.61 per share with an additional 251,547&#160;shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. In addition, on September 6, 2018, the Company issued 1,795,023 shares of common stock to the founders for services rendered to the Company, valued at $9.63 per share, with an additional 1,795,023 shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest. As such, the Company recognizes the measurement date fair value of the restricted stock over the vesting period as compensation expense. As of December&#160;31, 2024, there were no shares of common stock subject to repurchase by the Company. The unvested stock liability related to these awards is immaterial to all periods presented.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chiesi Equity Option</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, pursuant to the Chiesi Collaboration Agreement (as defined in Note 12 below) the Company granted to Chiesi (as defined in Note 12 below) an option to purchase directly from the Company, on one or more occasions, up to an aggregate number of shares of the Company&#8217;s common stock (the "Equity Option") such that immediately following such issuance, Chiesi&#8217;s beneficial ownership of the Company&#8217;s common stock shall not exceed 9.9% of the total number of issued and outstanding shares of the Company&#8217;s common stock. The Equity Option shall be exercisable by Chiesi, in whole or in part, at any time prior to the earliest to occur of the date on which (a) the last patient is last dosed in either (i) the PROSERA Phase 3 study for PAH or (ii) a Phase 3 clinical trial for the PH-ILD Indication, (b) any third party commences a tender offer or exchange offer for more than 50% of the outstanding shares of the Company&#8217;s common stock, and (c) the Company publicly announces its intent to consummate a GB002, Inc. change of control. The purchase price of each share the Company&#8217;s common stock subject to the Equity Option shall be equal to 107.5% of the daily volume-weighted average per share price of the Company&#8217;s common stock on The Nasdaq Stock Market over the 30-trading day period ending on and including the last trading day prior to the date on which Chiesi delivers an exercise notice to the Company; provided that such purchase price shall be no less than $1.63 per share. The shares of the Company&#8217;s common stock to be issued will be issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering, pursuant to the terms of a stock issuance agreement to be entered into between the Company and Chiesi in connection with each such exercise of the Equity Option. The Company evaluated the Equity Option granted to Chiesi as consideration payable to a customer and determined it qualified under ASC 718. Due to the market condition included in the Equity Option, the Company used the Geometric Brownian Motion/Monte Carlo model to determine fair market value. The value of the Equity Option is $0.5&#160;million, which is included in additional paid-in capital on the Company's consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389313616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">Equity Incentive Plans<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Equity Inducement Incentive Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company approved the 2023 Employment Inducement Incentive Plan (the "2023 Inducement Plan"). The terms of the 2023 Inducement Plan are substantially similar to the terms of the Company&#8217;s 2019 Incentive Award Plan (as described below) with the exception that incentive stock options may not be issued under the 2023 Inducement Plan and awards under the 2023 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq rules. The 2023 Inducement Plan was adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under the 2023 Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors of the Company or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The Company has initially reserved 6,762,279 shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2023 Inducement Plan. As of December&#160;31, 2024, an aggregate of 4,152,779 shares of common stock were available for issuance under the 2023 Inducement Plan, and 2,609,500 shares of common stock were subject to outstanding awards under the 2023 Inducement Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Incentive Award Plan (the &#8220;2019 Plan&#8221;). The 2019 Plan became effective on February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock or cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries. A total of 5,750,000 shares of common stock were approved to be initially reserved for issuance under the 2019 Plan. The number of shares that remained available for issuance under the 2017 Plan (as defined below) as of the effective date of the 2019 Plan were, and shares subject to outstanding awards under the 2017 Plan as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 5% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. As of December&#160;31, 2024, an aggregate of 2,308,197 shares of common stock were available for issuance under the 2019 Plan and 29,747,623 shares of common stock were subject to outstanding awards under the 2019 Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the "ESPP"). The ESPP became effective as of February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 700,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. During the years ended December&#160;31, 2024 and 2023, 767,125 shares and 336,795 shares were issued pursuant to the ESPP, respectively. As of December&#160;31, 2024, an aggregate of 4,545,812 shares of common stock were available for issuance under the ESPP.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) permitted the granting of incentive stock options, non-statutory stock options, restricted stock, restricted stock units and other stock-based awards. Subsequent to the adoption of the 2019 Plan, no additional equity awards can be made under the 2017 Plan. As of December&#160;31, 2024, 2,059,214 shares of common stock were subject to outstanding options under the 2017 Plan, and no shares of restricted stock awards granted under the 2017 Plan were unvested.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each employee and non-employee time-vested stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company uses its own volatility to the extent it has sufficient trading history, and for awards in which sufficient trading history is not available, a peer group is used to calculate the expected volatility. Due to the lack of historical exercise history, the expected term of the Company&#8217;s stock options for employees has been determined utilizing the &#8220;simplified&#8221; method for awards. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S.&#160;Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2023, the Company granted to its Chairman and Chief Executive Officer 750,000 options with an exercise price of $1.36 per share. This grant contains both service and market based vesting conditions. The awards vest on the later of the date of achievement and the one-year anniversary of the grant date. The market condition becomes satisfied in 50%, 25% and 25% tranches upon achieving the average per-share closing price of the Company's common stock over any 30 consecutive calendar days following the grant date equal to or exceeding $5.00, $7.50 and $10.00, respectively. In the event a stock price tranche has not vested prior to the fourth anniversary of the grant date, any portion of the option attributable to such tranche will be forfeited. Due to the market condition included in this grant, the Company used the Geometric Brownian Motion/Monte Carlo model to value this award. The total stock-based compensation expense related to this award is $0.4&#160;million, which is included in general and administrative expense on the consolidated statements of operations and comprehensive loss. The Company expects to recognize this expense over a weighted average period of approximately 2.2 years. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 5, 2023, and in accordance with the terms of the 2019 Plan, the Company's board of directors approved a stock option repricing (the &#8220;Option Repricing&#8221;) whereby the exercise price of each Eligible Option (as defined below) was immediately reduced to $1.36 per share, the closing stock price on May 5, 2023. For purposes of the Option Repricing, &#8220;Eligible Options&#8221; are 6,817,057 outstanding stock options as of May 5, 2023 (vested or unvested) granted under the 2019 Plan prior to November 30, 2022 and held by those eligible employees of the Company identified by the Company's board of directors, including the Company&#8217;s executive officers, except for the Company&#8217;s Chairman and Chief Executive Officer.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The participation of the executive officers of the Company in the Option Repricing was subject to their agreement to cancel a portion of their Eligible Options effective immediately (the &#8220;Cancelled Options&#8221;). Each executive was required to agree to cancel one-third of his or her Eligible Options, on a grant-by-grant basis. The Cancelled Options were deducted proportionately from the vested and unvested portions of each Repriced Option grant.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent an Eligible Option is exercised prior to the Premium End Date (as defined below), or the eligible employee&#8217;s employment terminates prior to the Premium End Date, the eligible employee will be required to pay the original exercise price per share of the Eligible Options in connection with any exercise of the Eligible Option. The &#8220;Premium End Date&#8221; means the earliest of (i) May 5, 2024, (ii) the date of a change in control, (iii) the eligible employee&#8217;s death or disability, or (iv) if an eligible employee is an executive subject to the cancellation of a portion of Eligible Options and is terminated under circumstances giving rise to severance under his or her employment agreement, the date of such termination. Except for the reduction in the exercise prices of the Eligible Options as described above, the Eligible Options will retain their existing terms and conditions as set forth in the 2019 Plan and the applicable award agreements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repricing resulted in $3.4&#160;million of incremental cost, which was calculated using the Black-Scholes option-pricing model, of which $2.0&#160;million of the incremental cost was recognized immediately, and $1.4&#160;million of the incremental cost will be recognized on the straight-line basis over the remaining vesting period of the repriced options. The incremental cost is included in general and administrative expense and research and development expense on the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of stock option awards granted to employees under the Company&#8217;s equity incentive plans and the shares purchasable under the ESPP during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:42.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6 - 6.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4 - 6.1</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.59% - 4.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.36% - 4.73%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.31% - 4.35%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.72% - 104.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.01% - 170.69%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.10% - 89.87%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.88% -5.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.87% - 5.47%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.60% - 3.51%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83.96% - 151.54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.19% - 216.45%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.98% - 121.43%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares&#160;Subject&#160;to<br/>Options&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,434,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,271,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(948,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,487,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,159,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,020,667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,626,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,006,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,216,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,416,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options vested and expected to vest as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,416,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,126,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share for the stock options granted during the year ended December&#160;31, 2024, 2023 and 2022 was $0.78, $3.88 and $4.77, respectively.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of stock options that vested during the years ended December&#160;31, 2024, 2023 and 2022 was $15.7 million, $22.7 million and $20.7 million, respectively.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the above table is calculated as the difference between fair value of the Company&#8217;s common stock price and the exercise price of the stock options. There were no options exercised during the years ended December&#160;31, 2024 and 2023. The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2022 was $1.5 million.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2023, the Company completed a private placement of 129,869,440 shares of the Company&#8217;s common stock and accompanying warrants to purchase up to 32,467,360 shares of the Company's common stock at a combined purchase price of $1.63125 per share and accompanying warrant, or with respect to any purchaser that was an officer, director, employee or consultant of the Company, $1.85125 per share and accompanying warrant. Each warrant has an exercise price per share of $2.04, was immediately exercisable on the date of issuance and will expire five years from the closing of the private placement. Given that the warrants are indexed to the Company's shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company's consolidated balance sheets. As of December&#160;31, 2024, there were 32,467,360 warrants outstanding.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of the Company&#8217;s restricted stock activity during the years ended December&#160;31, 2024, 2023 and 2022 is as follows:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Restricted<br/>Stock Units<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,561,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">572,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,592,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,350,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(779,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(142,437)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(427,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was no unrecognized stock-based compensation expense related to the unvested restricted stock awards.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense has been reported in the Company&#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,553&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the total unrecognized compensation related to unvested stock option awards granted was $14.0 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, total unrecognized compensation expense related to the ESPP was $0.8 million, which the Company expects to recognize over a weighted-average period of approximately 0.8 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387436448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 was approximately $0.8 million, $1.6 million and $1.8 million, respectively, and was recorded in general and administrative expense and research and development expense, respectively, on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386868016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously leased certain office and laboratory space under a non-cancelable operating lease which expired in January 2025.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 9, 2024, the Company entered into a lease agreement for office space located at 3115 Merryfield Row, Suite 120, San Diego, CA 92121, consisting of approximately 18,421 square feet. The term of the lease is 63 months commencing on August 1, 2024. The base rent is $109,605 per month effective October 1, 2024, and it is subject to a 3% annual increase every October. The lease expires on October 31, 2029 with an option for a <span style="-sec-ix-hidden:f-982">one</span>-year extension and an option to terminate on December 1, 2027 with the payment of a termination fee equal to four months of the then-current base rent upon the termination date. As of December 31, 2024, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monthly rent expense is recognized on a straight-line basis over the term of the leases. The operating leases are included in the consolidated balance sheets at the present value of the lease payments at an incremental borrowing rate of 7% for each of the initial leased space and expansion space expiring in January 2025 and 12.4% for the office lease commenced on August 1, 2024 using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the leases do not provide an implicit rate. As of December&#160;31, 2024, the weighted average remaining lease term was 4.7 years, and weighted-average discount rate was 12.4%.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities as of December&#160;31, 2024 and 2023 was $3.8 million and $3.3 million, respectively.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross future minimum annual rental commitments as of December&#160;31, 2024, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted&#160;Rent<br/>Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted rent payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628484635856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements and Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Agreements and Contracts</a></td>
<td class="text">Significant Agreements and Contracts<div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, the Company, GB002, Inc., a Delaware corporation and wholly-owned subsidiary of the Company and Gossamer Bio 002 Ltd., a corporation organized and existing under the laws of Ireland and indirect wholly-owned subsidiary of the Company, entered into a global collaboration and license agreement (the &#8220;Chiesi Collaboration Agreement&#8221;) with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, &#8220;Chiesi&#8221;). The Company concluded that there were four distinct performance obligations under the Chiesi Collaboration Agreement: the U.S. Territory license (as defined below), the ROW Territory license (as defined below), and the research and development services of both PAH and PH-ILD clinical development. Revenue associated with the licenses was recognized upon delivery in May 2024. In addition, the Company granted to Chiesi an option to purchase the Equity Option, as described in Note 8, "Stockholders Equity."</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds (&#8220;Licensed Products&#8221;) in the U.S. (&#8220;U.S. Territory&#8221;) and the rest of the world (&#8220;ROW Territory&#8221;), for therapeutic, prophylactic and diagnostic uses in humans and animals, for the treatment of PAH and PH-ILD and other indications, as may be permitted under the Chiesi Collaboration Agreement.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Chiesi Collaboration Agreement, the Company granted two exclusive, sublicensable (with the Company&#8217;s consent required in the U.S. Territory for third party sublicenses) licenses to Chiesi under intellectual property rights controlled by the Company relating to seralutinib and Licensed Products, for the worldwide development, manufacture and commercialization of seralutinib and Licensed Products. The licenses granted to Chiesi are subject to retained rights of the Company for the worldwide development and manufacture of seralutinib and Licensed Products, commercialization of Licensed Products in the U.S. Territory, and performance of its obligations and exercise of its rights that may be set forth in the global development plan and US commercialization plan, in each case in accordance with the Chiesi Collaboration Agreement.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties agreed to use commercially reasonable efforts to conduct development and commercialization activities in relation to seralutinib and Licensed Products, under the global development plan and US commercialization plan in accordance with the timelines therein. The Company will continue to lead global development of seralutinib in PAH and PH-ILD, and the parties will equally share the costs for the activities included in the global development plan for all Licensed Products, with the exception of the PROSERA Phase 3 study, which the Company will be solely responsible for conducting at the Company&#8217;s own cost and expense. With respect to each country in the ROW Territory, such obligation to equally share such development costs shall end when regulatory approval is received for a Licensed Product in such country. With respect to U.S. Territory, the development costs incurred following regulatory approval shall continue to be shared equally. The Company will lead potential commercialization for PAH and PH-ILD in the US, with both parties contributing 50 percent of commercial efforts, including performing 50 percent of the commercialization activities. Chiesi will lead potential commercialization in the US Territory in any additional indications, and Chiesi will have the exclusive right to commercialize Licensed Products in the ROW Territory. Chiesi further agreed to use commercially reasonable efforts to commercialize Licensed Products in certain specified countries in the ROW Territory following receipt of regulatory approvals. Generally, the Company will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products for the U.S. Territory for PAH and PH-ILD, </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, subject to any existing obligations of the Company to third party manufacturers, Chiesi will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products in the ROW Territory, in each case in accordance with the Chiesi Collaboration Agreement.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Chiesi Collaboration Agreement, neither party nor its affiliates is permitted to develop or commercialize any compound or product throughout the term whose primary mechanism of action is inhibition of a tyrosine kinase for the treatment of PAH or PH-ILD in the U.S. Territory or ROW Territory, subject to certain restrictions for the EU and UK.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration and as reimbursement for the Company&#8217;s development costs, Chiesi agreed to pay the Company an up-front, nonrefundable payment of $160&#160;million. Additionally, the Company will be eligible to receive up to $146&#160;million in regulatory milestones and $180&#160;million in sales milestones. In the U.S. Territory, the parties agreed to share commercial profits and losses equally. In the ROW Territory, Chiesi will pay the Company an escalating mid-to-high teens percentage royalty on net sales of Licensed Product for PAH and additional indications on a Licensed Product-by-Licensed Product and country-by-country basis with such payment obligations beginning on the first commercial sale of Licensed Product in such country and expiring on a country-by-country basis on the latest of (a) the expiration of a valid claim to a the Company patent right in such country, (b) the expiration of regulatory exclusivity, and (c) the date that is 10 years after the first commercial sale of such Licensed Product in such country.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as regulatory and commercial milestones, development costs, and profit sharing U.S. Territory will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Chiesi Collaboration Agreement will remain in force until no Licensed Products are being developed or commercialized in the US Territory and in the ROW Territory, on a country-by-country basis, until no royalty terms are in effect for all countries. Either party may terminate the Chiesi Collaboration Agreement for the other party&#8217;s material breach, subject to a specified notice and cure periods, or due to an insolvency event of the other party. In lieu of termination upon a party&#8217;s material breach due to non-payment of development costs within a specified time the non-breaching party may elect an alternative remedy which may involve modifications to their performance and payment obligations. The Company has the right to terminate by providing written notice in the event Chiesi or its affiliates or sublicensee brings a patent challenge and Chiesi does not take certain steps to withdraw from or cease supporting such challenge. Chiesi may terminate the Chiesi Collaboration Agreement without cause upon prior written notice to the Company, subject to a notice period in which all rights to Licensed Products and Licensed Compounds will revert back to the Company.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development services performance obligation related to the Chiesi Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. The transaction price to be recognized as revenue from sale of licenses and revenue from contracts with collaborators under the Chiesi Collaboration Agreement consists of the one-time non-refundable and non-creditable development cost reimbursement payment and research and development costs. The transaction price was reduced by the fair value of the Equity Option. </span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price pursuant to the Chiesi Collaboration Agreement is equal to the one-time development cost reimbursement payment of $160.0&#160;million less the fair market value of the Equity Option of $0.5&#160;million. The price allocated for the Equity Option was determined to be at fair market value utilizing the Geometric Brownian Motion/Monte Carlo model and was considered a reduction in the transaction price. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each distinct performance obligation. In estimating the stand-alone selling price for each distinct performance obligation, the Company developed assumptions that require judgment and included forecasted revenues or costs, expected development timelines, discount rates and probabilities of technical and regulatory success. A description of the distinct performance obligations identified under the Chiesi Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:</span></div><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The licenses to the Company&#8217;s intellectual properties, bundled with the associated know-how, represents two distinct performance obligations. The licenses and associated know-how were transferred to Chiesi in June 2024, therefore the Company recognized the full revenue related to these distinct performance obligations in the amount of $90.7&#160;million during the year ended December 31, 2024 as revenue from sale of licenses on its consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The progress towards completion of the two distinct performance obligations related to PAH and PH-ILD research and development services for the Licensed Products is measured in an amount proportional to the research and development expenses incurred and the total estimated PAH and PH-ILD research and development expenses. In addition, the Company and Chiesi share equally in the costs of ongoing global seralutinib clinical development, with the exception of the PROSERA Phase 3 study, and the costs of commercialization in the US. The Company records the revenue from performing research and development services and the cost-sharing payments due from Chiesi as revenue from contracts with collaborators on its consolidated statements of operations and comprehensive loss. For the year ended December&#160;31, 2024, the Company recognized $24.1 million for the PAH and PH-ILD research and development performance obligations and commercialization activities.</span></div><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined that as of December&#160;31, 2024, it is not probable that a significant revenue reversal will not occur related to the potential milestone payments as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the sales and usage based royalty exception. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. No milestone payments were recognized during the year ended December&#160;31, 2024.</span></div><div style="margin-top:5pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the licenses are deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the year ended December&#160;31, 2024.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities related to the Chiesi Collaboration Agreement (recorded as contract liabilities on the balance sheet) during the year ended December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:85.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from sale of US license</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78,947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from sale of ROW license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development service performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development service performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the contract liability amount of $55.9 million represents the aggregate transaction price allocated to performance obligations that are unsatisfied under the Chiesi Collaboration Agreement. This amount is expected to be recognized over 4.0 years, which represents the remaining research period under the Chiesi Collaboration Agreement. As of December&#160;31, 2024, the current contract liability balance of $17.1 million is classified as a current liability since the rights to the research and development service are expected to be satisfied within one year, and the remaining contract liability balance of $38.9 million is classified as a long-term liability.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company recorded $5.3 million in accounts receivable associated with the Chiesi Collaboration Agreement. The payments are typically due 30 days after quarterly invoices are issued.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our contract revenues from Chiesi Collaboration Agreement disaggregated by timing of revenue recognition and excluding royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:76.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from Chiesi Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US License</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW License</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development service performance obligation satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development service performance obligation satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development costs subject to reimbursement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development costs subject to reimbursement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH commercial costs subject to reimbursement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD commercial costs subject to reimbursement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue from Chiesi Collaboration Agreement</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387941568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the CODM in making decisions regarding the allocation of resources and assessing performance. The Company's CODM is its chief executive officer. The Company views its operations and manages its business as one operating segment. The Company's operating segment derives its revenues from its collaboration agreement with Chiesi and is wholly attributable to the United States. The CODM assesses performance for the Company's single operating segment and decides how to allocate resources based on research and development expenses incurred, which is a component of the Company's consolidated net loss as reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Further, segment depreciation expense and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. The CODM uses research and development expenses and results of clinical trial activities completed to date to evaluate how to allocate the Company's resources to advance seralutinib.</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,817)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(229,378)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other segment items include R&amp;D expenses for other terminated programs. These costs include employee expenses, as well as allocations of consolidated overhead and stock compensation. Further, general and administrative expenses are also provided to the CODM regularly, but are included within other segment items as they are not utilized as part of the decision making process as it relates to the allocation of resources.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387436448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent events</span></div><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all subsequent events and transactions through the filing date. There were no material events that impacted the audited consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387681520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,528)<span></span>
</td>
<td class="num">$ (179,817)<span></span>
</td>
<td class="num">$ (229,378)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628482424320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387272880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389473392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity governance program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity governance program includes reporting channels to the executive management team and an internal Cybersecurity Oversight Committee, as well as governance processes which communicate cybersecurity risks to departments across the organization, including legal, strategic, operational, and financial areas. This encourages consideration of cybersecurity oversight, accountability and diligence across the organization.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key elements of our cybersecurity governance program includes but are not limited to the following:</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Processes to assess cybersecurity risk, designed to help identify material risks from cybersecurity threats to critical systems and information;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a security team principally responsible for coordinating and managing (1) cybersecurity risk evaluation processes, (2) implementation of cybersecurity controls, and (3) response to cybersecurity incidents;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of the organization&#8217;s cybersecurity processes;</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cybersecurity awareness training of employees, including incident response personnel including third party providers, and senior management; </span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a cybersecurity incident response plan which includes procedures for responding to cybersecurity incidents; and</span></div><div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, which have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect the organization, including operations, business strategy, results of operations, or financial condition. See &#8220;Risk Factors - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or Chiesi or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our seralutinib development program, which could materially affect our results.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our cybersecurity governance program includes reporting channels to the executive management team and an internal Cybersecurity Oversight Committee, as well as governance processes which communicate cybersecurity risks to departments across the organization, including legal, strategic, operational, and financial areas.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Governance</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated oversight of cybersecurity risks, including oversight of management&#8217;s implementation of the cybersecurity governance program. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. </span></div><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assessment and management of material risks from cybersecurity threats are performed by the Executive Director, Information Security, Risk &amp; Compliance and the Vice President, IT and Facilities, reporting to the Executive Vice President, Technical Operations and Administration. Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions, in addition to holding active technical cybersecurity certifications and maintaining active membership in cybersecurity professional organizations, as well as local groups, to support knowledge share and ongoing cybersecurity professional development. </span></div>Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us and alerts and reports produced by security tools deployed in our IT environment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated oversight of cybersecurity risks, including oversight of management&#8217;s implementation of the cybersecurity governance program.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Assessment and management of material risks from cybersecurity threats are performed by the Executive Director, Information Security, Risk &amp; Compliance and the Vice President, IT and Facilities, reporting to the Executive Vice President, Technical Operations and Administration. Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions, in addition to holding active technical cybersecurity certifications and maintaining active membership in cybersecurity professional organizations, as well as local groups, to support knowledge share and ongoing cybersecurity professional development. Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us and alerts and reports produced by security tools deployed in our IT environment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. </span></div> Assessment and management of material risks from cybersecurity threats are performed by the Executive Director, Information Security, Risk &amp; Compliance and the Vice President, IT and Facilities, reporting to the Executive Vice President, Technical Operations and Administration. Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions, in addition to holding active technical cybersecurity certifications and maintaining active membership in cybersecurity professional organizations, as well as local groups, to support knowledge share and ongoing cybersecurity professional development.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387663088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued research and development expenses, stand-alone selling price of performance obligations and estimated collaboration expenses associated with the Company&#8217;s collaboration and license agreement. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div>The Company considers securities with original maturities of greater than 90&#160;days to be marketable securities. The Company has the ability, if necessary, to liquidate any of its marketable securities to meet its liquidity needs in the next 12&#160;months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying consolidated balance sheets which reflects management&#8217;s intention to use the proceeds from sales of these securities to fund our operations, as necessary. The Company&#8217;s marketable securities consist of U.S. Treasury and agency securities, commercial paper and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operation and comprehensive loss. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury and agency securities and commercial paper with maturities less than three months and in money market funds that invest in U.S. Treasury and agency securities.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s available for sale securities are also invested in U.S. Treasury and agency securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, which consists mainly of lab equipment and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:f-390">two</span> to seven years, using the straight-line method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASU 2020-06, the Company accounted for the 2027 Notes as a liability and equity component. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component was not re-measured as long as it continued to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (&#8220;debt discount&#8221;) was amortized to interest expense over the term of the 2027 Notes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the issuance costs incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the 2027 Notes and were amortized to interest expense over the term of the 2027 Notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022 the Company adopted ASU 2020-06. After adoption, the Company now accounts for the 2027 Notes as a single liability measured at amortized cost. The impact upon adoption on the Consolidated Balance Sheets was an increase of approximately $44.8&#160;million in convertible senior notes, net, a write-off of $9.4&#160;million in deferred income tax liabilities and a decrease of $53.5&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment of $8.7&#160;million to increase the beginning balance of accumulated deficit on the Consolidated Balance Sheets for previously recognized interest expense related to amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 842), the Company determines if an arrangement is a lease at inception. Operating leases are included in the balance sheet as right-of-use assets and operating lease liabilities at the present value of the lease payments calculated using the Company&#8217;s incremental borrowing rate, unless the implicit rate is readily available. The Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and elected to not separate lease and non-lease components for its long-term leases. The Company records rent expense on a straight-line basis over the term of the lease.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In process research and development</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In process research and development</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In process research and development costs relate to a milestone payment to Pulmokine for the initiation of the Phase 3 clinical trial for seralutinib.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC&#160;740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company's policy is to include interest and penalties related to income taxes within its provision (benefit) for income taxes.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the United States, California, Florida, Ireland and Luxembourg. As of December&#160;31, 2024, the Company&#8217;s tax years since inception are subject to examination by taxing authorities due to the Company&#8217;s unutilized net operating losses ("NOLs") and tax credits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its licensing and other agreements are collaborative arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. For arrangements that the Company determines are collaborations, it identifies each unit of account, and then determines whether a customer relationship exists for that unit of account. If the Company determines </span></div>a performance obligation within the collaborative arrangement to be with a customer, it applies its revenue recognition accounting policy. If a portion of a distinct bundle of goods or services within the collaborative arrangement is not with a customer, the Company applies recognition and measurement based on an analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational and consistently applied accounting policy election. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and the collaboration partner are within the scope of other accounting literature. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC Topic 606, Revenue from Contracts with Customers (ASC 606).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when a customer obtains control of promised goods or services in a contract for an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. For contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for contracts with customers, the Company develops assumptions that require judgment to determine the standalone selling price of each distinct performance obligation identified in the contract. In addition, variable consideration such as milestone payments are evaluated to determine if they are constrained and, therefore, excluded from the transaction price. The Company then allocates the total transaction price proportionally to each distinct performance obligation based on their estimated standalone selling prices, unless an allocation exception applies. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective distinct performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying standalone selling price for each distinct performance obligation, which determines how the transaction price is allocated among the distinct performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each distinct performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a distinct performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include cost-share reimbursements, we will recognize such payments when control of the related goods or services are transferred to the customer. Cost-sharing reimbursements are presented as revenue from contracts with collaborators.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants and shares purchasable under the Company's 2019 Employee Stock Purchase Plan ("ESPP") using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. The Company estimates the fair value of restricted stock units based on the closing price of the Company's common stock on the date of grant. The Company accounts for forfeitures as they occur. All share-based compensation costs are recorded in the statements of operations based upon the underlying employees or non-employee&#8217;s roles within the Company.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities of non-U.S.&#160;subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated to U.S.&#160;dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates during the year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss) in the Company's consolidated balance sheets. Foreign exchange transaction gains and losses are included in other income, net in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - Adopted and Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements - Adopted</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures (&#8220;Topic 280&#8221;), which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Lastly, the amendment requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We have adopted this standard for our fiscal year ended December 31, 2024. We have applied this standard retrospectively for all prior periods presented in the financial statements. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13, Segment Reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on our consolidated financial statement disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The Company uses the if-converted method for assumed conversion of the 2027 Notes to compute the weighted average shares of common stock outstanding for diluted net loss per share. Diluted net loss per share excludes the potential impact of the Company&#8217;s common stock options, warrants for the purchase of common stock, unvested shares of restricted stock and the potential shares issuable upon conversion of the 2027 Notes because their effect would be anti-dilutive due to the Company&#8217;s net loss. Since the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387259808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,321,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,321,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,321,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,416,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,626,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,487,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of Chiesi Equity Option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,433,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,467,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,467,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested shares under restricted stock grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,639,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,843,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,159,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387444544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-431"><span style="-sec-ix-hidden:f-432">Operating lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued in process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued accounting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387683120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the hierarchy for assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market<br/>Prices for<br/>Identical&#160;Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other&#160;Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available for Sale Investments by Security Type</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in marketable securities&#160;as of&#160;December&#160;31, 2024 and 2023 are as follows&#160;(in thousands except securities amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Treasury and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Available-for-sale Debt Securities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of available-for-sale debt securities, as of December&#160;31, 2024, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388119888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ScheduleOfNotesTableTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the 2027 Notes was as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,591&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock', window );">Schedule of Net Carrying Amount of 2027 Notes</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the interest expense recognized related to the 2027 Notes (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense related to the 2027 Notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of interest expense recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ScheduleOfNotesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of liability components of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ScheduleOfNotesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628485802144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses, Asset Acquisitions and Contingent Consideration (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock', window );">Schedule of IPR&amp;D Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following IPR&amp;D expense on the consolidated statements of operations and comprehensive loss (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terminated programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total in process research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_InProcessResearchAndDevelopmentExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In process research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_InProcessResearchAndDevelopmentExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389051344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Amount of Net Loss Before Taxes</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of net loss before taxes for the years ended December&#160;31, 2024, 2023, and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. loss before taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign loss before taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">229,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense for the years ended December 31, 2024, 2023 and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 174 capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">229,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,086)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(768)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,809)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(228,683)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(221,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204,050)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and experimentation credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GILTI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nondeductible interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic/Foreign Restructuring Impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2024, 2023, and 2022, excluding interest and penalties, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease related to prior year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase related to current year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387359808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Option Award Granted</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of stock option awards granted to employees under the Company&#8217;s equity incentive plans and the shares purchasable under the ESPP during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:42.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6 - 6.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4 - 6.1</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.59% - 4.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.36% - 4.73%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.31% - 4.35%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.72% - 104.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.01% - 170.69%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.10% - 89.87%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.88% -5.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.87% - 5.47%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.60% - 3.51%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83.96% - 151.54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.19% - 216.45%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.98% - 121.43%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares&#160;Subject&#160;to<br/>Options&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,434,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,271,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(948,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,487,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,159,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,020,667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,626,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,006,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,216,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,416,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options vested and expected to vest as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,416,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,126,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of the Company&#8217;s restricted stock activity during the years ended December&#160;31, 2024, 2023 and 2022 is as follows:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Restricted<br/>Stock Units<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,561,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">572,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,592,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,350,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(779,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(142,437)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(427,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited / cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense has been reported in the Company&#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,553&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387754736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-7</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388589904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs were comprised of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Gross Future Minimum Annual Rental Commitments</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross future minimum annual rental commitments as of December&#160;31, 2024, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted&#160;Rent<br/>Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted rent payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628390760848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements and Contracts (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Liability Activity</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities related to the Chiesi Collaboration Agreement (recorded as contract liabilities on the balance sheet) during the year ended December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:85.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from sale of US license</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78,947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from sale of ROW license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development service performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development service performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition and Excludes Royalty Revenue</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our contract revenues from Chiesi Collaboration Agreement disaggregated by timing of revenue recognition and excluding royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:76.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from Chiesi Collaboration Agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US License</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW License</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development service performance obligation satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development service performance obligation satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH research and development costs subject to reimbursement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD research and development costs subject to reimbursement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PAH commercial costs subject to reimbursement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from PH-ILD commercial costs subject to reimbursement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue from Chiesi Collaboration Agreement</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387437200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seralutinib</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,817)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(229,378)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other segment items include R&amp;D expenses for other terminated programs. These costs include employee expenses, as well as allocations of consolidated overhead and stock compensation. Further, general and administrative expenses are also provided to the CODM regularly, but are included within other segment items as they are not utilized as part of the decision making process as it relates to the allocation of resources.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387442480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 1,268,568<span></span>
</td>
<td class="nump">$ 1,212,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386438032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LongTermConvertibleSeniorNotes', window );">Long-term convertible senior notes</a></td>
<td class="nump">$ 197,523<span></span>
</td>
<td class="nump">$ 196,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities written off</a></td>
<td class="num">(1,086)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
<td class="num">$ (1,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent (decrease) increase</a></td>
<td class="nump">29,492<span></span>
</td>
<td class="nump">62,769<span></span>
</td>
<td class="nump">12,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent (decrease) increase</a></td>
<td class="nump">1,296,848<span></span>
</td>
<td class="nump">1,275,136<span></span>
</td>
<td class="nump">1,044,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent (decrease) increase</a></td>
<td class="num">$ (1,268,568)<span></span>
</td>
<td class="num">$ (1,212,040)<span></span>
</td>
<td class="num">$ (1,032,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(811,534)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LongTermConvertibleSeniorNotes', window );">Long-term convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent (decrease) increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,838)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent (decrease) increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,500)<span></span>
</td>
<td class="num">(53,527)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent (decrease) increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="nump">$ 8,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LongTermConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LongTermConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628390951520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">101,639,406<span></span>
</td>
<td class="nump">68,843,073<span></span>
</td>
<td class="nump">31,159,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=goss_TwoThousandTwentySevenNotesMember', window );">2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">12,321,900<span></span>
</td>
<td class="nump">12,321,900<span></span>
</td>
<td class="nump">12,321,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Shares issuable upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">34,416,337<span></span>
</td>
<td class="nump">23,626,115<span></span>
</td>
<td class="nump">17,487,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Shares issuable upon exercise of Chiesi Equity Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">22,433,809<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Shares issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">32,467,360<span></span>
</td>
<td class="nump">32,467,360<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Non-vested shares under restricted stock grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">427,698<span></span>
</td>
<td class="nump">1,350,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=goss_TwoThousandTwentySevenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=goss_TwoThousandTwentySevenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388471184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">$ 11,995<span></span>
</td>
<td class="nump">$ 10,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">3,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AccruedConsultingFeesCurrent', window );">Accrued consulting fees</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AccruedLegalFeesCurrent', window );">Accrued legal fees</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AccruedInProcessResearchAndDevelopmentCurrent', window );">Accrued in process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AccruedAccountingFeesCurrent', window );">Accrued accounting fees</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 15,186<span></span>
</td>
<td class="nump">$ 26,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Total accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Total accrued expenses and other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AccruedAccountingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued accounting fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AccruedAccountingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AccruedConsultingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued consulting fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AccruedConsultingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AccruedInProcessResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued in process research and development current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AccruedInProcessResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued legal fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388176304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">$ 265,516<span></span>
</td>
<td class="nump">$ 264,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">56,900<span></span>
</td>
<td class="nump">92,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">19,963<span></span>
</td>
<td class="nump">3,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">25,264<span></span>
</td>
<td class="nump">25,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">56,900<span></span>
</td>
<td class="nump">92,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">188,653<span></span>
</td>
<td class="nump">168,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">19,963<span></span>
</td>
<td class="nump">3,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">25,264<span></span>
</td>
<td class="nump">25,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">56,900<span></span>
</td>
<td class="nump">92,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other&#160;Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other&#160;Observable Inputs (Level 2) | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other&#160;Observable Inputs (Level 2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">188,653<span></span>
</td>
<td class="nump">168,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other&#160;Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">19,963<span></span>
</td>
<td class="nump">3,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level 3) | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level 3) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. Treasury and agency securities and corporate debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-For-Sale Debt Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387182288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other&#160;Observable Inputs (Level 2) | 2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible senior notes</a></td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="nump">$ 74.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628384447984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Schedule of Available for sale Investments by Security Type (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 265,362<span></span>
</td>
<td class="nump">$ 264,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 265,516<span></span>
</td>
<td class="nump">$ 264,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities with unrealized losses | security</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 56,875<span></span>
</td>
<td class="nump">$ 92,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">56,900<span></span>
</td>
<td class="nump">92,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19,950<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">19,963<span></span>
</td>
<td class="nump">3,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">188,537<span></span>
</td>
<td class="nump">168,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 188,653<span></span>
</td>
<td class="nump">$ 168,534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628485802144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Schedule of Contractual Maturities of Available-for-sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than one year</a></td>
<td class="nump">$ 265,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 265,516<span></span>
</td>
<td class="nump">$ 264,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Debt Maturities After One Year Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389538832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>May 03, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 21, 2020 </div>
<div>USD ($) </div>
<div>tradingDay </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 02, 2019 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember', window );">2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_DebtInstrumentAggregatePrincipalAmount', window );">Debt instrument aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0616095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible notes, initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_DebtInstrumentConvertibleConversionPricePercentage', window );">Convertible notes, percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_DebtInstrumentRedemptionTermThresholdTradingDays', window );">Debt instrument, redemption term, threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Convertible notes, redemption percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes', window );">Percentage of repurchase price is equal to principal amount of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LongTermDebtPercentageInAggregatePrincipalAmount', window );">Percentage in aggregate principal amount (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember', window );">2027 Notes | Minimum | 130% Applicable Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible notes, consecutive trading days | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember', window );">2027 Notes | Minimum | 98% Applicable Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible notes, consecutive trading days | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember', window );">2027 Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage', window );">Convertible notes, percentage of last reported sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember', window );">2027 Notes | Maximum | 130% Applicable Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible notes, consecutive trading days | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember', window );">2027 Notes | Maximum | 98% Applicable Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible notes, consecutive trading days | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Amount funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_NumberOfAdditionalTranches', window );">Number of additional tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of debt</a></td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility | Term Loan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility | Term Loan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_DebtInstrumentAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument aggregate principal amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_DebtInstrumentAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible conversion last reported sale price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_DebtInstrumentConvertibleConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_DebtInstrumentConvertibleConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_DebtInstrumentRedemptionTermThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Term, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_DebtInstrumentRedemptionTermThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LongTermDebtPercentageInAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Percentage In Aggregate Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LongTermDebtPercentageInAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_NumberOfAdditionalTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional tranches.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_NumberOfAdditionalTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of repurchase price is equal to principal amount of convertible notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=goss_TwoThousandTwentySevenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=goss_OneHundredThirtyPercentApplicableConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=goss_OneHundredThirtyPercentApplicableConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=goss_NinetyEightPercentApplicableConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=goss_NinetyEightPercentApplicableConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=goss_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=goss_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=goss_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=goss_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=goss_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=goss_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387149296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness - Schedule of Net Carrying Amount of 2027 Notes (Details) - 2027 Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(2,321)<span></span>
</td>
<td class="num">(3,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 197,523<span></span>
</td>
<td class="nump">$ 196,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=goss_TwoThousandTwentySevenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=goss_TwoThousandTwentySevenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388585920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness - Schedule of Interest Expense Recognized (Details) - 2027 Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractualInterestExpense', window );">Contractual interest expense</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance cost</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense related to the 2027 Notes</a></td>
<td class="nump">$ 10,932<span></span>
</td>
<td class="nump">$ 10,882<span></span>
</td>
<td class="nump">$ 10,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractualInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractualInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=goss_TwoThousandTwentySevenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=goss_TwoThousandTwentySevenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387697776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details) - Pulmokine, Inc. - License Agreement - Seralutinib - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ProductLicenseTerm', window );">Product license term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized', window );">Milestones accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=goss_PulmokineIncMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable', window );">Development and regulatory milestone payments</a></td>
<td class="nump">$ 48,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable', window );">Development and regulatory milestone payments, due upon the initiation of a phase 3 clinical trial</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable', window );">Commercial milestone payments, payable</a></td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable', window );">Sales milestone payments, payable</a></td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, contingent consideration, commercial milestone payments, payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, contingent consideration, development and regulatory milestone payments, payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Initial Phase Three Clinical Payments Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, contingent consideration, sales milestone payments, payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ProductLicenseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product license term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ProductLicenseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount, measured at acquisition-date fair value, of all the assets acquired and liabilities assumed that arise from contingencies and were recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=goss_PulmokineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=goss_PulmokineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=goss_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=goss_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentSeralutinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentSeralutinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386243616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&amp;D Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ResearchAndDevelopmentInProcessExpenses', window );">Total in process research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentSeralutinibMember', window );">Seralutinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ResearchAndDevelopmentInProcessExpenses', window );">Total in process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentTerminatedProgramsMember', window );">Terminated programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ResearchAndDevelopmentInProcessExpenses', window );">Total in process research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ResearchAndDevelopmentInProcessExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development In Process Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ResearchAndDevelopmentInProcessExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentSeralutinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentSeralutinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentTerminatedProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentTerminatedProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628390791456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Amount of Net Loss Before Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. loss before taxes</a></td>
<td class="nump">$ 32,178<span></span>
</td>
<td class="nump">$ 134,073<span></span>
</td>
<td class="nump">$ 175,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign loss before taxes</a></td>
<td class="nump">23,457<span></span>
</td>
<td class="nump">45,736<span></span>
</td>
<td class="nump">53,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes', window );">Pre-tax Loss</a></td>
<td class="nump">$ 55,635<span></span>
</td>
<td class="nump">$ 179,809<span></span>
</td>
<td class="nump">$ 229,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Continuing Operations before Income Taxes, For Tax Purposes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388213440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386286000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would not impact effective tax rate</a></td>
<td class="nump">$ 13.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage', window );">Net operating losses carryforward available to offset future federal taxable income , percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses (&#8220;NOL&#8221;) carryforwards</a></td>
<td class="nump">$ 398.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation', window );">NOL carryforwards, amount removed</a></td>
<td class="nump">141.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit</a></td>
<td class="nump">48.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_TaxCreditCarryforwardsReductionDueToMerger', window );">Tax credit carryforwards, amount removed</a></td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses (&#8220;NOL&#8221;) carryforwards</a></td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit</a></td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_TaxCreditCarryforwardsReductionDueToMerger', window );">Tax credit carryforwards, amount removed</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses (&#8220;NOL&#8221;) carryforwards</a></td>
<td class="nump">113.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation', window );">NOL carryforwards, amount removed</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating losses carryforward available to offset future federal taxable income , percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Reduction Due To Merger And Liquidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_TaxCreditCarryforwardsReductionDueToMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforwards, Reduction Due To Merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_TaxCreditCarryforwardsReductionDueToMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits that would not impact effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386463664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 97,940<span></span>
</td>
<td class="nump">$ 122,987<span></span>
</td>
<td class="nump">$ 128,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Deferred loss</a></td>
<td class="nump">10,575<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss</a></td>
<td class="nump">20,348<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">44,803<span></span>
</td>
<td class="nump">45,445<span></span>
</td>
<td class="nump">34,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Amortization</a></td>
<td class="nump">2,646<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">10,984<span></span>
</td>
<td class="nump">9,886<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 capitalization</a></td>
<td class="nump">35,715<span></span>
</td>
<td class="nump">34,268<span></span>
</td>
<td class="nump">21,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,076<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">229,769<span></span>
</td>
<td class="nump">222,161<span></span>
</td>
<td class="nump">205,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">(1,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(565)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(1,086)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
<td class="num">(1,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(228,683)<span></span>
</td>
<td class="num">(221,393)<span></span>
</td>
<td class="num">(204,050)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386170176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(12.38%)<span></span>
</td>
<td class="num">(8.73%)<span></span>
</td>
<td class="num">(20.25%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and experimentation credits</a></td>
<td class="nump">3.03%<span></span>
</td>
<td class="nump">5.69%<span></span>
</td>
<td class="nump">3.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(3.75%)<span></span>
</td>
<td class="num">(2.13%)<span></span>
</td>
<td class="num">(1.88%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">GILTI</a></td>
<td class="num">(4.72%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(4.61%)<span></span>
</td>
<td class="num">(1.44%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent', window );">Nondeductible interest</a></td>
<td class="num">(4.13%)<span></span>
</td>
<td class="num">(1.27%)<span></span>
</td>
<td class="num">(0.99%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges', window );">Domestic/Foreign Restructuring Impact</a></td>
<td class="nump">2.52%<span></span>
</td>
<td class="num">(12.49%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.44%<span></span>
</td>
<td class="num">(0.62%)<span></span>
</td>
<td class="num">(0.37%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389308704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 13,654<span></span>
</td>
<td class="nump">$ 10,572<span></span>
</td>
<td class="nump">$ 7,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease related to prior year positions</a></td>
<td class="num">(2,028)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year positions</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
<td class="nump">3,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the year</a></td>
<td class="nump">$ 13,919<span></span>
</td>
<td class="nump">$ 13,654<span></span>
</td>
<td class="nump">$ 10,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628383312256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 24, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 15, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 21, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 06, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 21, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 04, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 03, 2024 </div>
<div>USD ($) </div>
<div>day</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CommonStockVotingRightsNumberOfVotesPerShare', window );">Common stock, voting right per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,433,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash flows from financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 212,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 201,323,000<span></span>
</td>
<td class="nump">$ 119,946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,323,000<span></span>
</td>
<td class="nump">$ 119,946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Shares of common stock, repurchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=goss_FounderMember', window );">Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,795,023<span></span>
</td>
<td class="nump">251,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_PercentageOfFullyDilutedShareCapital', window );">Percentage of fully diluted share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_IncreasedInEquityCapitalAmount', window );">Increased in equity capital amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting', window );">Additional shares of restricted stock subject to vesting restrictions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,795,023<span></span>
</td>
<td class="nump">251,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=goss_FounderSharesMember', window );">Founder Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,160,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CommonStockVestingPercentage', window );">Common stock vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CommonStockVestingPeriod', window );">Common stock vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding', window );">Tender offer or exchange offer, percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice', window );">Purchase price of each share subject to equity option, percentage of daily volume-weighted average per share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays', window );">Purchase price of each share subject to equity option, number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice', window );">Purchase price of each share subject to equity option, minimum price threshold (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityFairValueOfEquityOption', window );">Contract with customer, liability, fair value of equity option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage', window );">Equity option owned by chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.63125<span></span>
</td>
<td class="nump">$ 7.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in transition (in shares) | shares</a></td>
<td class="nump">129,869,440<span></span>
</td>
<td class="nump">16,649,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds, after deducting underwriting discounts, commissions, and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Officer, Director, Employee Or Consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.85125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_StockholdersEquityDeficitLineItems', window );"><strong>Stockholders Equity Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares) | shares</a></td>
<td class="nump">32,467,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Option Owned By Counterparty, Minimum Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Option Owned By Counterparty, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Number Of Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Percentage Of Common Stock's Average Per Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Option Owned By Counterparty, Tender Offer Or Exchange Offer, Percentage of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CommonStockVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock vesting percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CommonStockVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CommonStockVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CommonStockVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_CommonStockVotingRightsNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_CommonStockVotingRightsNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractWithCustomerLiabilityFairValueOfEquityOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Fair Value Of Equity Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractWithCustomerLiabilityFairValueOfEquityOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_IncreasedInEquityCapitalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased in equity capital amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_IncreasedInEquityCapitalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental common shares attributable to restricted stock subject to vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_PercentageOfFullyDilutedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fully diluted share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_PercentageOfFullyDilutedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_StockholdersEquityDeficitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_StockholdersEquityDeficitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=goss_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=goss_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=goss_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=goss_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=goss_OfficerDirectorEmployeeOrConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=goss_OfficerDirectorEmployeeOrConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628380264496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock were subject to outstanding options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,416,337<span></span>
</td>
<td class="nump">23,626,115<span></span>
</td>
<td class="nump">17,487,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,434,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,006,228<span></span>
</td>
<td class="nump">17,159,617<span></span>
</td>
<td class="nump">9,271,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,619<span></span>
</td>
<td class="nump">$ 28,518<span></span>
</td>
<td class="nump">$ 42,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-based payment arrangement, option, exercise price range, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,817,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage', window );">Share-based payment arrangement, option, required cancellation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Share-based payment arrangement, plan modification, incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based payment arrangement, nonvested award, cost not yet recognized, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,467,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in transition (in shares)</a></td>
<td class="nump">129,869,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,649,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 1.63125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Officer, Director, Employee Or Consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 1.85125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Non-vested shares under restricted stock grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation related to unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares issuable upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays', window );">Award vesting rights, threshold consecutive days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of cost expects to recognize (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="nump">$ 22,700<span></span>
</td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, options vested in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation related to unvested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares issuable upon exercise of stock options | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice', window );">Award vesting rights, threshold share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares issuable upon exercise of stock options | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice', window );">Award vesting rights, threshold share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares issuable upon exercise of stock options | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice', window );">Award vesting rights, threshold share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares)</a></td>
<td class="nump">32,467,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember', window );">2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,152,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards', window );">Shares reserved for issuance on granting of outstanding awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,609,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=goss_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of amount increase in outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock were subject to outstanding options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,747,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=goss_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,545,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of amount increase in outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued', window );">Number of share issued under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,125<span></span>
</td>
<td class="nump">336,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of cost expects to recognize (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation related to unvested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=goss_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase of common stock through payroll deductions, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=goss_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock were subject to outstanding options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,059,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=goss_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan | Non-vested shares under restricted stock grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Stock awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Threshold Consecutive Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Threshold Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Required Cancellation Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Reserved For Issuance On Granting Of Outstanding Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=goss_OfficerDirectorEmployeeOrConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=goss_OfficerDirectorEmployeeOrConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=goss_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=goss_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=goss_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=goss_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=goss_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=goss_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389754896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Fair Value Assumptions Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.36%<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">100.72%<span></span>
</td>
<td class="nump">70.01%<span></span>
</td>
<td class="nump">71.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">104.51%<span></span>
</td>
<td class="nump">170.69%<span></span>
</td>
<td class="nump">89.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=goss_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="nump">4.87%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.27%<span></span>
</td>
<td class="nump">5.47%<span></span>
</td>
<td class="nump">3.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">83.96%<span></span>
</td>
<td class="nump">115.19%<span></span>
</td>
<td class="nump">64.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">151.54%<span></span>
</td>
<td class="nump">216.45%<span></span>
</td>
<td class="nump">121.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected life</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=goss_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=goss_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628378199760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options Outstanding, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,626,115<span></span>
</td>
<td class="nump">17,487,165<span></span>
</td>
<td class="nump">9,434,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">13,006,228<span></span>
</td>
<td class="nump">17,159,617<span></span>
</td>
<td class="nump">9,271,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(270,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited/cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,216,006)<span></span>
</td>
<td class="num">(11,020,667)<span></span>
</td>
<td class="num">(948,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,416,337<span></span>
</td>
<td class="nump">23,626,115<span></span>
</td>
<td class="nump">17,487,165<span></span>
</td>
<td class="nump">9,434,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest as of ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,416,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable as of ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,126,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Shares Subject to Options Outstanding, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="nump">$ 12.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">0.96<span></span>
</td>
<td class="nump">1.16<span></span>
</td>
<td class="nump">6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Option exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited/cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
<td class="nump">11.07<span></span>
</td>
<td class="nump">15.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="nump">$ 12.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest as of ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercisable as of ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life (in years), Options vested and expected to vest as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life (in years), Options exercisable as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic&#160;Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 15,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options exercisable as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388465728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning balance (in shares)</a></td>
<td class="nump">427,698<span></span>
</td>
<td class="nump">1,350,035<span></span>
</td>
<td class="nump">2,561,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">572,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(427,698)<span></span>
</td>
<td class="num">(779,900)<span></span>
</td>
<td class="num">(1,592,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(142,437)<span></span>
</td>
<td class="num">(191,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">427,698<span></span>
</td>
<td class="nump">1,350,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested beginning balance (in dollars per share)</a></td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="nump">$ 8.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">10.92<span></span>
</td>
<td class="nump">10.67<span></span>
</td>
<td class="nump">7.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/cancelled (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11.39<span></span>
</td>
<td class="nump">10.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested ending balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628385696720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 20,619<span></span>
</td>
<td class="nump">$ 28,518<span></span>
</td>
<td class="nump">$ 42,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,172<span></span>
</td>
<td class="nump">15,871<span></span>
</td>
<td class="nump">24,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,447<span></span>
</td>
<td class="nump">$ 12,647<span></span>
</td>
<td class="nump">$ 18,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386908096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 7,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(5,432)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389042448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387622112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 09, 2024 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>month</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent', window );">Termination tee, number of monthly base rent | month</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=goss_LeaseAgreementEnteredInJuly2024Member', window );">Lease Agreement Entered in August 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LeaseeOperatingLeaseLeasedArea', window );">Leased area | ft&#178;</a></td>
<td class="nump">18,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LesseeOperatingLeaseBaseRent', window );">Base rent</a></td>
<td class="nump">$ 109,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage', window );">Operating sublease, annual increase percentage for base rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_LesseeOperatingLeaseExtensionTerm', window );">Extension term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=goss_NonCancelableLeaseAgreementEnteredInAugust2018Member', window );">Non-cancelable Lease Agreement Entered in August 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LeaseeOperatingLeaseLeasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasee, Operating Lease, Leased Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LeaseeOperatingLeaseLeasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent Annual Increase Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LesseeOperatingLeaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LesseeOperatingLeaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Fee, Number Of Months Of Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=goss_LeaseAgreementEnteredInJuly2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=goss_LeaseAgreementEnteredInJuly2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=goss_NonCancelableLeaseAgreementEnteredInAugust2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=goss_NonCancelableLeaseAgreementEnteredInAugust2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387011488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,706<span></span>
</td>
<td class="nump">$ 3,114<span></span>
</td>
<td class="nump">$ 3,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,754<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
<td class="nump">$ 3,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628387360912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted rent payments</a></td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value discount</a></td>
<td class="num">(1,699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">5,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">$ 3,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">4,398<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 5,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628384060992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements and Contracts - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 03, 2024 </div>
<div>USD ($) </div>
<div>performanceObligation </div>
<div>license</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,701<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,869<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_NumberOfDistinctPerformanceObligations', window );">Number of significant distinct performance obligations | performanceObligation</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_NumberOfLicensesGranted', window );">Number of licenses granted | license</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage', window );">Commercial efforts contribution, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage', window );">Commercialization activities performance, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived', window );">Up-front, nonrefundable payment received</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_RevenueLoyaltyReceivableExpirationPeriod', window );">Loyalty term, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityDevelopmentCost', window );">Development cost reimbursement payment</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityFairValueOfEquityOption', window );">Contract with customer, liability, fair value of equity option</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,919<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerRevenueRecognitionPeriod', window );">Revenue recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_AccountReceivablePaymentTerm', window );">Account receivable, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc. | US License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_NumberOfDistinctPerformanceObligations', window );">Number of significant distinct performance obligations | performanceObligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc. | Revenue from PAH research and development service performance obligation satisfied during reporting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_NumberOfDistinctPerformanceObligations', window );">Number of significant distinct performance obligations | performanceObligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount', window );">Collaboration agreement, regulatory milestones receivable</a></td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_RevenuePerformanceObligationSalesMilestonesAmount', window );">Collaboration agreement, sales milestones receivable</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_AccountReceivablePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Account Receivable, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_AccountReceivablePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractWithCustomerLiabilityDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Development Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractWithCustomerLiabilityDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractWithCustomerLiabilityFairValueOfEquityOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Fair Value Of Equity Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractWithCustomerLiabilityFairValueOfEquityOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractWithCustomerRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Revenue Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractWithCustomerRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Distinct Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_NumberOfLicensesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Licenses Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_NumberOfLicensesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_RevenueLoyaltyReceivableExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Loyalty Receivable, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_RevenueLoyaltyReceivableExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Commercial Efforts Contribution, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Commercialization Activities Performance, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_RevenuePerformanceObligationRegulatoryMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Regulatory Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_RevenuePerformanceObligationRegulatoryMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_RevenuePerformanceObligationSalesMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_RevenuePerformanceObligationSalesMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Upfront Nonrefundable Amount Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_LicensesOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_LicensesOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628388170320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements and Contracts - Schedule of Contract Liability Activity (Details) - Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityRollforwardAbstract', window );"><strong>Contract With Customer, Liability [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Opening balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived', window );">Payments received in advance</a></td>
<td class="nump">159,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate', window );">Effect of exchange rate changes on contract liabilities</a></td>
<td class="num">(2,103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">55,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Revenue from sale of US license</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityRollforwardAbstract', window );"><strong>Contract With Customer, Liability [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue</a></td>
<td class="num">(78,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Revenue from sale of ROW license</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityRollforwardAbstract', window );"><strong>Contract With Customer, Liability [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue</a></td>
<td class="num">(11,721)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Revenue from PAH research and development service performance obligations satisfied during reporting period</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityRollforwardAbstract', window );"><strong>Contract With Customer, Liability [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue</a></td>
<td class="num">(9,555)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Revenue from PH-ILD research and development service performance obligations satisfied during reporting period</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_goss_ContractWithCustomerLiabilityRollforwardAbstract', window );"><strong>Contract With Customer, Liability [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue</a></td>
<td class="num">$ (1,291)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Effect Of Change In Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractWithCustomerLiabilityRollforwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability Rollforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractWithCustomerLiabilityRollforwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_goss_ContractWithCustomerLiabilityUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">goss_ContractWithCustomerLiabilityUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>goss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_USLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_USLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_ROWLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_ROWLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628386708624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements and Contracts - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">$ 114,701<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member', window );">Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">114,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_USLicenseMember', window );">US License | Point in Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">78,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_ROWLicenseMember', window );">ROW License | Point in Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember', window );">Revenue from PAH research and development service performance obligation satisfied during reporting period | Over Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">9,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember', window );">Revenue from PH-ILD research and development service performance obligation satisfied during reporting period | Over Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember', window );">Revenue from PAH research and development costs subject to reimbursement | Over Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">10,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember', window );">Revenue from PH-ILD research and development costs subject to reimbursement | Over Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">2,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_PAHCommercialExpensesSubjectToReimbursementMember', window );">Revenue from PAH commercial costs subject to reimbursement | Over Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_PHILDCommercialExpensesSubjectToReimbursementMember', window );">Revenue from PH-ILD commercial costs subject to reimbursement | Over Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=goss_EffectsOfExchangeRateMember', window );">Effect of exchange rate changes on revenue | Over Time: | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Effect of exchange rate changes on revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from Chiesi Collaboration Agreement</a></td>
<td class="num">$ (93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_USLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_USLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_ROWLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_ROWLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PAHCommercialExpensesSubjectToReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PAHCommercialExpensesSubjectToReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_PHILDCommercialExpensesSubjectToReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_PHILDCommercialExpensesSubjectToReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=goss_EffectsOfExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=goss_EffectsOfExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45628389369184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 114,701<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(1,779)<span></span>
</td>
<td class="num">(1,997)<span></span>
</td>
<td class="num">(1,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">11,517<span></span>
</td>
<td class="nump">13,511<span></span>
</td>
<td class="nump">13,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(14,022)<span></span>
</td>
<td class="num">(15,456)<span></span>
</td>
<td class="num">(1,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Segment net loss</a></td>
<td class="num">(56,528)<span></span>
</td>
<td class="num">(179,817)<span></span>
</td>
<td class="num">(229,378)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=goss_ReportingSegmentMember', window );">Reporting Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">114,701<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Seralutinib</a></td>
<td class="nump">129,247<span></span>
</td>
<td class="nump">103,158<span></span>
</td>
<td class="nump">63,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">45,373<span></span>
</td>
<td class="nump">80,601<span></span>
</td>
<td class="nump">155,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(1,779)<span></span>
</td>
<td class="num">(1,997)<span></span>
</td>
<td class="num">(1,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">11,517<span></span>
</td>
<td class="nump">13,511<span></span>
</td>
<td class="nump">13,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(14,022)<span></span>
</td>
<td class="num">(15,456)<span></span>
</td>
<td class="num">(1,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Segment net loss</a></td>
<td class="num">$ (56,528)<span></span>
</td>
<td class="num">$ (179,817)<span></span>
</td>
<td class="num">$ (229,378)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=goss_ReportingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=goss_ReportingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MMJ*-XIHZ\/WWG?I=]O#P, LBZ9#'?T6A6E\W^@T4TB5)8S7C+[_0[0-=:+V
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M1>JB<Z569?<NV_6.83=A 1?0%XGNEF=HKF 80UR@(4^9$F_P&9J!VM5'8R-
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M? /DA E22<ZITJ0%U9WZZ5@J.OX+QV][QK8()D$0A+F_W3?Y;-B!_&20G[Q
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M-XPFK*P ZO<5Y_)P43W@^%;'\C]02P,$%     @ ,(!M6F-@8[^."@  Q&X
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M=5%G%J8HD/;.9IOB065+I9H,0-D5+8S3#<Y#':2[ XA(MP%Y]E#L6@V+[&J
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M&."/E(=H>(Y:$1PU4FZ[ O9G23#MSK .5,LN8:L?)W=%K+,=8%D)TD#K]0U
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M*4=-FAM:%E--4<WP8U0SO*GK^8*BF*56N<W):#H;/UAU/-$E4,''@6!0<X@
M40A\1J4)1*C-0:&::4"/=)1"I0T'-49T^^&<5.^S75_Y,-7]LL/4"P@8<W]<
MP4 U20D)-]2?U;3KHA'-(B) R3*P "NL!9&6Q?8"3%\>0[#D6'Q;5.2VA8@
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M@EIC^10;0T$Q8.)ZKC'^1;(VU!G8O01"!)&(YS=JJP!_6'-#"(*/)^-B(OP
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MR@B]Q,<&Y%\QYG!*<$4S>',95&@>4*&!#8ZI#!H/=Y=N6PFHAN@AT<"'5+:
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M(8$]F!%C);4_LRKEI%YB&V"( 7VLA:\DLB!LAH.:X%X:EV%&()SD!24C5:Y
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M.8KBVMT$V_"GKZ4-P=9\62HDHJ,)&%]9-(+IAC;HOX7>_@=02P,$%     @
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M,HM]#X)KPP0=(L,1B/6-T-MC<'_3@/&FHE7"I&&<:&NDM#D[)'#[_=83V4"
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M"4@.1CH;XL*MC[@^E@^2**#T@T6!'X"I/DN/4/OF[NK04#/VW;^4M3![945
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M9ON(:?_:T7^QJG6O^FZ4M6KMEBO!4;-H WY?*F6'+R1@^^[W_+]02P,$%
M  @ ,(!M6K)ON]6R"P  0"$  !D   !X;"]W;W)K<VAE971S+W-H965T,38N
M>&ULO5IID]LV$OTK*,6;C*MHC4AIKOBH&A])G%K'4YX]/FSM!XB$)*PI@@;
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M9(<#T))T9XY:5QQ"63H^GZ9]?CBJ3B* MHWVY&]7PXFD#_FEE4I8Q'X;23Q
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M8!853):$'UWEEKT,V7?*^5#^JT)[;@X8PARGHLTQ='1WVC2N[/PSW&^,HKQ
M_PT#<K6EBB\MX]W#+GM*$@!)!C3%V,V=YW M$87;QK@U!(\\Z"280ATL50'
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MY,/,"T>3='Y=5:!B4HS.,'5%?2*YF\\"F$&@\<\O)Y,L@9'Y6'2ZTBO>FC+
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MQK!X2;UBK9I?KE:U)$2 D; T49.FU6[>J.4*KRE<FC5^]&] @M)TA]U\4+)
M =T!2=#N:Z0E4+!Q[H6%]^9J>-'-0M( O]:]28,9/[.Y PB,I#JX84:6]_8=
MMPJ0JPQ'D.,W65=B.4(3*46-M>%NV-PKY1TL<)NJG%L1CIJ.F7DEM=%J3ACC
MI0_<B=T9K<Q"%:$KJ5-.UW:U],6'4GR'2;%WX,ACL,'DE6_7B",;4Q&\72NY
M@IPRZS@S?- =#V';#M9(&*Q0>]D:/?D_J_\\]"<S4K0.?V0 MH/+%I.JDK
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MX8]KF2+]T@"\7U55:[_0 N[_7/#J?P%02P,$%     @ ,(!M6D: N&%M P
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M/&'P33LN7\E)X)L.DEE"?-;.:>CD;=W*$'6!=#%RP<,T.D]GV06<CP>CC%W
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M-50;XYN'WS 0>/+;@I+VTS^6:G]8T(%A@.GMNO8 !TN8OR45O[?%,L9<O+X
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M]*L[(S0#A5%<3?SE8I@S#J3A>Z@>;O*F.IZCAQ6-")<':T.%AYBFF<_3!+6
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MP/<+ TV<_P,/B#_-?O-O4$L#!!0    ( #" ;5J:/)GGX@4   0.   9
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M8N@)F+>'>0=R'4&R;X"D&7PPVE<.?M(%%OL 0V+4T\HVM*ZS%Q%O,3^!<9I
M-LHF+^"->S/' 6_\'3/OL#'62UW"'V\7SEM*BC\/V1O1)H?1N%#.72-RO!Q0
M)3BT*QQ<O?XA/1V]>8'KI.<Z>0G]WX;D/X/ QP:M",:[N.M 6 19T%(N)18@
M'.2F;HP.FV8)0@,MT396.@2"@G4E\XH &D%8"(5TN45:+*46.I="@=Q1*4G%
M2D@E%BJ*XTJH-NXMGL!7"#<?;S^0#"7U U,K,)=<\8Y*OA2VX/_XF%#*Y%&0
M>)'736MS)'C-M!TZQR?)PJ!<YW@"GQF=S!'ZZ4?7Z7$@R;*\DK@$?,2\Y:9
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MMR><N:&CAP7:-G;1QB+U9)S6] B""PZT7UJ+NT4(,#ZK^4]02P,$%     @
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M@9*1"I@DG"$!>>RL_.5Z8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/ ^G:
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MU\ZW0YPV_OT!$Q+\_D%K=PQ"@>E%*W\!4$L#!!0    ( #" ;5K[IG!^*@L
M /$Q   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;.U;6V\;MQ+^*X0+
M! F@VI9R;9P8R+7'.$UCV#[M0W >J%VNEC!WN26Y5M1??[X9[DVVO++C%.A!
M_9)(N^3<YYL94GZUM.[<YTH%\;4PI7^]DX=0O=S;\TFN"NEW;:5*O,FL*V3
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M8JW%W.]*Y/)"(<\N ""52OFU+BK#B^F[2-;(+7K75,XNG"R$QD**.A$L/0L
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M7E#3HO=_.%X-#8RL4,ML>94N'ZQ((I;8K'!C:QCZAS5-BFZZ+1"SM'[.VF)
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M.@[N X&L3$WH.L;N$F1SZC=?[7<#+O6*;C/AI*> '*1-YY8RM,G+%@>?6!G
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MH.SJ&+V1NSM&&T)Z *%#^J]R9Q]3LDUVT"-A%.H7J1B&P\/]%:2^1- ,;P9
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MX4J"QN4DF,47EYGS]PY?.&[,G@VNDH52/]W@II@$D2.$ G/K$!C]/> 5"N&
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MCN946-;T8T#C'>A[I;4[&#[ \*M9_0M02P,$%     @ ,(!M6E;D1)R+ P
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M0&4-Z/U"2K-YL <T?T3&_P)02P,$%     @ ,(!M6I5YB]H4!   RP@  !D
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MCBI0SL'>EU*:D^&Z81A^V5]02P,$%     @ ,(!M6KQPDP:V!@   #@  !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&ULO9M=;]LV%(;_"N$56PHTL43)
MDMTE!A)+PCHT0["LV\6P"UJB;:Z2Z(I4G +]\:,^8EFRS$;!R6X:V>9Y^/&2
M1]1;\7+'L\]B0ZE$CTF<BJO11LKM^_%8A!N:$''!MS15OZQXEA"I/F;KL=AF
ME$1E4!*/L6$XXX2P=#2_++^[R^:7/)<Q2^E=AD2>)"3[>D-COKL:F:.G+WYG
MZXTLOAC/+[=D3>^I_+2]R]2G\9X2L82F@O$4971U-;HVWP>64024)?YD="<.
MKE'1E27GGXL/'Z*KD5&TB,8TE 6"J#\/=$'CN""I=GRIH:-]G47@X?43/2@[
MKSJS)((N>/P7B^3F:C0=H8BN2![+W_GN%UIW:%+P0AZ+\E^TJ\L:(Q3F0O*D
M#E8M2%A:_26/]4 <!%BG G =@#L!&)\(L.H Z[D!=AU@/S=@4@=,GAO@U %.
M.?;58)4C[1%)YI<9WZ&L**UHQ44I5QFM!IBEQ<RZEYGZE:DX.;^O9A3B*W3/
MUBE;L9"D$EV'(<]3R=(UNN,Q"QD5Z!Q=1Q$KY@.)T8>TFM7%[#CSJ"0L%F_1
M&\12],>&YX*DD;@<2]7"HIYQ6+?FIFH-/M$:$Z-;GLJ-0'X:T:@-&*NN[?N'
MG_IW@[5$CX87R#+?(6Q@&WVZ]]#9F[=(T+5:';*G@8OGXZPG7 _&>SX&:S"^
M'O,K22^0\7U,\/S6F/V8UMA;^[EEE5SK)'<IU401,LN+T49_?U0%T =)$_%/
MW]RH:'8_K4BQ[\66A/1JI'*HH-D#'<U__,%TC)_[=(2$>9 P'Q(6 ,%:^MI[
M?6T=??Y;GBQI5J0.=:/+2)DMZI4ET#?-(KNIN$[)+>Y]#W/S<OQP*)^VYJ'R
M0<)\2%@ !&O)-]G+-]'*]Y&GZW-)LP2%/'V@F63+F"K54L8SE'))>Q-XQ70/
MI9NY$VQU].LKYDQF'9D];0N'*@,)"X!@+66<O3*.5AF/KFB6T0A)\HAB1I8L
M5O===0O>94Q*FJHEM^K3QCE:5N>F,74ZTO24<IUI1QCG2+]S<VK,VJ5\;3>&
MCC@0K#7B[G[$7>V(WTL>?M[P.**9^ G1+SF37Q&1,F/+7))B74B.MB0K;F-G
M$0W5)E[0MVJW4UWUB>$>#3.>V3/<$>.XE(-=IS/.WG$I$QNNVU%#V\6A:KC'
M"QB;MM.L\]8X3_?C/-6.\\$.<DM8=*ZVBR'9,DGBOB'4LH9N""!A'B3,AX0%
M0+"6NK.]NC/0#=\,4E](F <)\R%A 1"LI:]I-$^+QO^=)^L:V\EMYDSMSBUI
MT5O0G9A6YP;G]14T;'OJV)V$J>_L4&5ZJIU9*N?;_2G3/'A$-_5),PSS)(^)
M5#N"B*HG=-:[J=93ABXG4)H'2O-!:0$4K:TN;M3%H$FSQD')#$GS0&D^*"V
MHK5E;KP04_LH_BJ9T^K9I&-G.NGNYA?])=4>TC:ZN;.OI&%AW'W"\_7]':R.
M=?Q4,C7-B74J>S8FA:EW*195[F0/%/FK%0WE.W1',\:CPKBXCOBVV(^^4U?_
MYD*>,BST=0Q>=*#N!BC-!Z4%4+2V]HW#84Y@<RNDA;  I7F@-!^4%D#1VC(W
M=HFI]TM>YF3IH8/%AJ1YH#3?/'9SU';8Z.3^ *K2MHJ-!6/J/9B7NEYZ[& =
M(6D>*,TWCWV@F7TL(U"=;1D;A\?46SROL=$!-8) :1XHS0>E!36MM:E2"]^:
MGMA3-3Z/J;49AN^IT#<TS/K3-V"PY*#F$"C-!Z4%4+3V?[8W_A V0#=<&-*!
M68#2/%":#TH+H&AMF1M'"NL=J5?(\?H:!\\$4/<*E.;7M%96GEB3H_OXB7+8
M[<_>N'&<L-;J>%GV?IX'J:]YL(J@YA0HS0>E!5"T]HQHS"D,^Z8.!GU5!Y3F
M@=)\4%H 16O+W%AA6&^%O4;:!C7&0&D>*,VO:8</T5/W.&GWE'*FLQ,INS&R
ML/Y=G5N6LB1/>A4 ]:Q :1XHS0>E!5"TMJ*-9X4=V)0+ZE:!TCQ0F@]*"Z!H
M;9D;4POK32U?2):4NZ9/@J[R&'UD*XK.U,/O5THRT?>V[LUWD+@*[945U+P"
MI?F@M "*UI:U,;FPWN2Z)8\G\S&H605*\T!I/B@M@**U%6TL+0S[[A(&-:A
M:1XHS0>E!5"T]HF$QJ"R]"\PO20??P?IGL['^LC!IQ! #2E06@!%JV0='QQH
M2FBV+H^>"52>2:K.-NV_W1]ONRX/=8V;XM79N%N2K5DJ4$Q7*M2X<-6V+ZN.
MFU4?)-^6QZ.67$J>E)<;2M0C4E% _;[B7#Y]*"K8'_J;_P=02P,$%     @
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M1(Q=J4+5$W;3.JS;*BS_1%C0!U\8E6L![JB:0!O 51PU1/FO1-WZO8@)3J]
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M4[#KP&!OB_&NLH^.]P%^&,5!=-@%G&V9=%B>4O^N38+]?=(#HQ^?L-!!5M&
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M%<#G6RG-X\).A.T_@,6_4$L#!!0    ( #" ;5JJO#7LU 8  %H^   9
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M(#@H"0Z,!+]NDAGAF> 5@I!]K3LJ5V!3I37.TPK^-8G0S:"3/;\501<!>Q9
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MQT)(,PQR:U=G86BR' MF3M0*)>TLE"Z8I:E>AF:ED<V]J!!A'$7]L&!<!NG
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MK8/.!T!I*91&4317&#L?$(>7X*'C,^A<04\;CL^2?=L)C4A1-%<*.P,0AV<
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M.9=F _W]G1#JZ8WYB8S=CZY<_!]02P,$%     @ ,(!M6E[V^TRL @  *@<
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M9V.=J6@J<]-1O*R+VXHK72KK9J8O,Q0F0+]?<UV2VHZIE]WU&/\!4$L#!!0
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M:.R&=ICC 0>D >#]A<!\-1/S@/;(%/\&4$L#!!0    ( #" ;5H+A'*O0 0
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M"79@Y:BU<F1_$S*R:;)-V,(F++0)BRS!#DR^;DV^-KZO"WC! W-1G2WT"4;
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M36C@.D&=9XS)7: OZ&9^]!]02P,$%     @ ,(!M6HK ,!@W!   YQ   !D
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M9,,A&$-=EP471&DTT:WAL5U#?+YQJXZ>U^K>H+/W_U_[]J;9\K?*-J[CT3Q
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M/NIAB*DYZ"(HW_6^:&=$I%3?PTBH9D U$ZI94,V&:@Y4HU#-;;2+ G>ZZ-G
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MLS4_M1V0QZPLLZ3^<,4"OB>O%N#?7V99^?I)M8)MEG^M-_ON?U!+ P04
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MEWNNU03E]Z_2M'C\1S7 ?9K]42_VY?\#4$L#!!0    ( #" ;5I^1H_V:P4
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MFQ'=9P2'N=,N'B'#<$8['"6#V31_]I3-INF!Q5%"GC) #[L=SEX_D#A]>1C
MP?'!EVBS9>+!:#;=XPU9$O9U_Y3QN]$))8QV)*%1FH",K!\&C_#>1Y9PR"V^
M1>2%GET#,915FOX0-Q_#AX$A>D1B$C !@?G',YF3.!9(O!__EJ"#4YO"\?SZ
MB.[G@^>#66%*YFG\/0K9]F$P'H"0K/$A9E_2ES]).2!;X 5I3//_P4MI:PQ
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M[<U<*VN)5@M^"R*'K]N2KEK;];2B^;K0ZM*>I<%01QKS/:]4\)?Z\9ED>$.
M5VX:P%,6!40I-M0JMDZTA58T3RN:KPNM'A"H"@BD)<T)TSC&&05[DA6OO/J-
M;VWLZB HT";GZ^+0;KSM3:O)4!0L:BNGP@JBAIFO:P!U-:HB VQ-:97I3D_F
MS>;XAJ:TV9N75M \WV4/)_*>4&4&A]"1.568.4-7WHNTC_E63JL\'G8D\JJT
MIR>I6C-XV$RXY1RHV\0K3232+2B3_BNR=EBE[;!?WGXI#>K)OZ9TN>3?;C+'
MIP"Y?J(R@W H9YF>TLX>.A-9B5^1\\,JZ8<=67^?C*BG'%HK B6:-,E,&G(X
M/18!3V'57 1\A55]$:AS7.7\L%_2?U-:U)-[K=6!$JV3>YV->EK1?%UH=<FK
M.@/L*#1<DR/UE%AK\:%$.X]U<]C8.^ELTM.*YNM"JPM<53I@>ZGCF *]/Z9
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MJ("%<NF,(W6"X4WCV-Q(MJY;J1<F56-67ZY4LPU<"]3[!6/R[48/T+7O\_\
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M'DK&):ZF!1H4L9I4IH5@61I3M;*2>,$,DT(Q_E4"UQ2"O ] TC03'W#3SZN
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M[O9$B76QB?5>*"7BXG#%V8*G^0#]_5((]7*2[XLM]T%/_P=02P,$%     @
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M&NN]'>;8PD$: +Z?"Z$W$[-!^Z<@_@M02P,$%     @ ,(!M6NW9KMV= P
M2 T  !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULK9==;]LV%(;_"J$5
M0P(TT9<EV9DM('70K4"+!4F[712]H"7:)DJ1&DG9R;_OH:0HBDPKG=$;6Q\\
M+Y_WB.(YFN^%_*ZVA&CT4#"N%LY6Z_+*=56V)056EZ(D'.ZLA2RPAE.Y<54I
M"<[KH(*Y@>?%;H$I=])Y?>U6IG-1:48YN95(546!Y>,[PL1^X?C.TX4[NMEJ
M<\%-YR7>D'NBOY2W$L[<3B6G!>&*"HXD62^<:_]JZ8<FH![Q#R5[U3M&QLI*
MB._FY$.^<#Q#1!C)M)' \+<C2\*840*._UI1IYO3!/:/G]3?U^;!S HKLA3L
M7YKK[<*9.B@G:UPQ?2?V?Y'64&3T,L%4_8OV[5C/05FEM"C:8" H*&_^\4.;
MB%Z /SD2$+0!P<\&A&U G3FW(:MMW6"-T[D4>R3-:% S!W5NZFAP0[EYC/=:
MPET*<3I=BJ*@&IZ+5@CS'"T%UY1O",\H4>@"W<.ZR2M&D%BC/Z50"KVO="4)
M^D0Y+:H"77->88;N0 '^^G)G-T1CRM0YR'RYOT%G;\[1&T0Y^KP5E8+)U-S5
M8,& N%F+^Z[!#8[@WI#L$H7^6Q1XP<02OOSY\/!EN N)Z[(7=-D+:KWPB-Y'
M BM(H:_7*Z4EK,AO-D>-Q,0N85[3*U7BC"P<> \5D3OBI+__YL?>'S9_OTCL
MA=NP<QN.J:>0M,AFL(E*ZBBS;>Q2/XJ\N;OK@X]*GP@^Z< GKX''-O F*NZ#
M3_QD #XJ?2)XU(%'KX$G-O#( N[% _!1Z1/!XPX\?@U\:@./+>"3Z0!\5/I$
M\*0#3UX#G]G DT/P(!PNE5'I$\&G'?AT%/RS,/MOQ7.J,E%Q37*HLERC$C_6
MV['-U/3 5.)%PZ<Q.NV)IF:=J=FHJ5LC"29VF%4$/5FS69D=6+GPX]ELX&5T
MMA.]^-YSJ?7^AQLHJ,R4C]$GU"KV?45A-+0U/N^IOGHMA#_J:UG)9JD)6;=F
MX S:3(E-(]%Z9!2O**/:-!5GE&>LRF&!8N@Y4":*4G 3#W$XRV0%=\@#]*FF
MM)J>1.@MD= ,-;/TI,ZM*?,/4C:+_6'&_(.:%89>T(UZF8GG=L ?K;_IWR.V
M+Q 3?'.AB2RLV,$!]B2<#5_&=E3R<@,]@OU<U_WQPM[L'<>>V:,5][#HVQ;F
M+ZWZ;J_--=\8G[#<4*X =PWRWF4"%4\V;7MSHD59=[XKH:&/K@^W\*E#I!D
M]]="Z*<3TTQW'T_I#U!+ P04    "  P@&U:EI1_)V<'  #3-0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V.2YX;6R]6VUOVS80_BN$5PPMX,9Z\5NRQ( 3
MJ6B!9@N:9OM,R[1-5!)=BDKBH3]^I"1+HBS3%G!9/S22S'MX>HXB[SE*UR^,
M_T@VA CT&H5Q<M/;"+&]&@R28$,BG%RP+8GE+RO&(RSD*5\/DBTG>)D91>'
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MMTL;?)ZV@6" N %A)]4-[N0-OH"^P6<*'! '*!P8=TKBX$[CX$N(''R.R@%
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M"&!N!6&((7 UX@BF #1@2!A6S\&=YY&_?D[YF_^K1W\!4$L#!!0    ( #"
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M%65<J;(=VO8\[/O8OS.RN5^2?K^<_M6_4$L#!!0    ( #" ;5JL;5!7/ (
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ,(!M6F,R3#OM    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M,(!M6IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  P@&U:PZ\0Z3L(   ;,0  &
M    @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M,(!M6J@DMPD\ @  OP4  !@              ("!?1   'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #" ;5JD^N7.+ 8  ,49   8
M          " @>\2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  P@&U:2V:S(I\"  !N!P  &               @(%1&0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ,(!M6CBL0_*S!@  X2$
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M965T.2YX;6Q02P$"% ,4    "  P@&U:@C>_9_\>  !^8P  &0
M    @('"0   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M #" ;5K/7]42\0(  .4&   9              " @?A?  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ ,(!M6KYI_.'>"@  "1\  !D
M             ("!(&,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  P@&U:?(W7[K(,   E)   &0              @($U;@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #" ;5I(%I*#'0@
M !<5   9              " @1Y[  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ ,(!M6@\],*X,"P  !QX  !D              ("!
M<H,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  P@&U:
MLF^[U;(+  ! (0  &0              @(&UC@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( #" ;5HK:(:JSQ,  ,5    9
M      " @9Z:  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ ,(!M6D: N&%M P  K@<  !D              ("!I*X  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  P@&U:3T3YG>X%  "I#0
M&0              @(%(L@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( #" ;5H;6&D[<A(  *8]   9              " @6VX  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ,(!M6IH\F>?B
M!0  ! X  !D              ("!%LL  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    "  P@&U:X+C#+6$"  !B!0  &0
M@($OT0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( #"
M;5II5O1T7@(  ($&   9              " @<?3  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ ,(!M6BQU:+Y# @  B@8  !D
M         ("!7-8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    "  P@&U:/*4S.!$"  #=!   &0              @('6V   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #" ;5K[IG!^*@L  /$Q
M   9              " @1[;  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ ,(!M6B3%+>EY'   OE\  !D              ("!?^8
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  P@&U::KK.
M?7<#  "E!P  &0              @($O P$ >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( #" ;5K&YU!8  ,  ,L&   9
M  " @=T& 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M,(!M6K9.0%'-!   K T  !D              ("!% H! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    "  P@&U:&%K#IC8#  #=!P  &0
M            @($8#P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( #" ;5J%6S3Q[0(  %0&   9              " @842 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ,(!M6@:[P!^-!@
ME1$  !D              ("!J14! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    "  P@&U:I3CZ"I$&  ")$0  &0              @(%M
M' $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #" ;5IB
M'Q3'[0(  '8&   9              " @34C 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ ,(!M6E;D1)R+ P  @0@  !D
M     ("!628! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M"  P@&U:@>/8^'$$  "4#   &0              @($;*@$ >&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #" ;5J5>8O:% 0  ,L(   9
M              " @<,N 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!
M A0#%     @ ,(!M6N/A:5PL @  " 4  !D              ("!#C,! 'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  P@&U:O'"3!K8&
M    .   &0              @(%Q-0$ >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;%!+ 0(4 Q0    ( #" ;5HL.!95L00  &4;   9              "
M@5X\ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ,(!M
M6B%E+M"7 P  #0P  !D              ("!1D$! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    "  P@&U:JKPU[-0&  !:/@  &0
M        @($410$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( #" ;5H&VH^1' ,  #T)   9              " @1], 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ,(!M6CFIE NS!   FA8
M !D              ("!<D\! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    "  P@&U:- 6T Y8"   $!P  &0              @(%<5 $
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( #" ;5K3![I@
MZ@<  (!%   9              " @2E7 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ ,(!M6E[V^TRL @  *@<  !D
M ("!2E\! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  P
M@&U:V="/CQ$#   ^"0  &0              @($M8@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( #" ;5H+A'*O0 0  'D7   9
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M 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ ,(!M6HK
M,!@W!   YQ   !D              ("!?G,! 'AL+W=O<FMS:&5E=',O<VAE
M970U-"YX;6Q02P$"% ,4    "  P@&U:]O^77+L$  #"$P  &0
M    @('L=P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M #" ;5KW\*A** 0  %L/   9              " @=Y\ 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ ,(!M6H+S'O\^ P  EPD  !D
M             ("!/8$! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    "  P@&U:3^FY>2 .  "LN   &0              @(&RA $ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( #" ;5I8ATNQ(!0
M /T9 0 9              " @0F3 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ ,(!M6GY&C_9K!0  '2(  !D              ("!
M8*<! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  P@&U:
MN(@E,)4&  #A*@  &0              @($"K0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( #" ;5HAPQ[I]@,  ,H/   9
M      " @<ZS 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ ,(!M6N<^BCO0 P  &Q$  !D              ("!^[<! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  P@&U:(I!J)) %   3+0
M&0              @($"O $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( #" ;5J:3A0?@0(  *T&   9              " @<G! 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ ,(!M6B[.[WR_
M!   <A@  !D              ("!@<0! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    "  P@&U:V(Q1GL@"   @"   &0
M@(%WR0$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( #"
M;5KMV:[=G0,  $@-   9              " @7;, 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ ,(!M6I:4?R=G!P  TS4  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( #" ;5HMP;P28@4  -(O   /
M  "  1[K 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  P@&U:K&U05SP"
M  "O*@  &@              @ &M\ $ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  P@&U:0&L7N@ "  #&*0  $P
M@ $A\P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     4 !0 .<5  !2]0$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>263</ContextCount>
  <ElementCount>432</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Fair Value Measurements and Available for Sale Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsideration</Role>
      <ShortName>Licenses, Asset Acquisitions and Contingent Consideration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Significant Agreements and Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SignificantAgreementsandContracts</Role>
      <ShortName>Significant Agreements and Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/Subsequentevents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Indebtedness (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IndebtednessTables</Role>
      <ShortName>Indebtedness (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/Indebtedness</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationTables</Role>
      <ShortName>Licenses, Asset Acquisitions and Contingent Consideration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsideration</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/EquityIncentivePlans</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Significant Agreements and Contracts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SignificantAgreementsandContractsTables</Role>
      <ShortName>Significant Agreements and Contracts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/SignificantAgreementsandContracts</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/SegmentInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/DescriptionofBusiness</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Fair Value Measurements and Available for Sale Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Available for sale Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Schedule of Available for sale Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Contractual Maturities of Available-for-sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Schedule of Contractual Maturities of Available-for-sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Indebtedness - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails</Role>
      <ShortName>Indebtedness - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Indebtedness - Schedule of Net Carrying Amount of 2027 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails</Role>
      <ShortName>Indebtedness - Schedule of Net Carrying Amount of 2027 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Indebtedness - Schedule of Interest Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails</Role>
      <ShortName>Indebtedness - Schedule of Interest Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails</Role>
      <ShortName>Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&amp;D Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails</Role>
      <ShortName>Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&amp;D Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Income Taxes - Schedule of Amount of Net Loss Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Amount of Net Loss Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gossamerbio.com/role/StockholdersEquity</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Equity Incentive Plans - Schedule of Fair Value Assumptions Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Fair Value Assumptions Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Equity Incentive Plans - Schedule of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Equity Incentive Plans - Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Significant Agreements and Contracts - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails</Role>
      <ShortName>Significant Agreements and Contracts - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Significant Agreements and Contracts - Schedule of Contract Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails</Role>
      <ShortName>Significant Agreements and Contracts - Schedule of Contract Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Significant Agreements and Contracts - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails</Role>
      <ShortName>Significant Agreements and Contracts - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="goss-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="goss-20241231.htm">goss-20241231.htm</File>
    <File>goss-20241231.xsd</File>
    <File>goss-20241231_cal.xml</File>
    <File>goss-20241231_def.xml</File>
    <File>goss-20241231_lab.xml</File>
    <File>goss-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>goss-20241231_g1.jpg</File>
    <File>goss-20241231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="885">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "goss-20241231.htm": {
   "nsprefix": "goss",
   "nsuri": "http://www.gossamerbio.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "goss-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "goss-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "goss-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "goss-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "goss-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "goss-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 355,
   "keyCustom": 77,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 34,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2024": 5,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://www.gossamerbio.com/20241231": 2
   },
   "contextCount": 263,
   "entityCount": 1,
   "segmentCount": 76,
   "elementCount": 734,
   "unitCount": 14,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 885,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.gossamerbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.gossamerbio.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.gossamerbio.com/role/DescriptionofBusiness",
     "longName": "9952157 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "9952159 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "goss:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "goss:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments",
     "longName": "9952160 - Disclosure - Fair Value Measurements and Available for Sale Investments",
     "shortName": "Fair Value Measurements and Available for Sale Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.gossamerbio.com/role/Indebtedness",
     "longName": "9952161 - Disclosure - Indebtedness",
     "shortName": "Indebtedness",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsideration",
     "longName": "9952162 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration",
     "shortName": "Licenses, Asset Acquisitions and Contingent Consideration",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxes",
     "longName": "9952163 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.gossamerbio.com/role/StockholdersEquity",
     "longName": "9952164 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.gossamerbio.com/role/EquityIncentivePlans",
     "longName": "9952165 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.gossamerbio.com/role/PropertyandEquipmentNet",
     "longName": "9952166 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.gossamerbio.com/role/CommitmentsandContingencies",
     "longName": "9952167 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.gossamerbio.com/role/SignificantAgreementsandContracts",
     "longName": "9952168 - Disclosure - Significant Agreements and Contracts",
     "shortName": "Significant Agreements and Contracts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.gossamerbio.com/role/SegmentInformation",
     "longName": "9952169 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.gossamerbio.com/role/Subsequentevents",
     "longName": "9952170 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9955513 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables",
     "longName": "9955514 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)",
     "shortName": "Fair Value Measurements and Available for Sale Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.gossamerbio.com/role/IndebtednessTables",
     "longName": "9955515 - Disclosure - Indebtedness (Tables)",
     "shortName": "Indebtedness (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "goss:ScheduleOfNotesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "goss:ScheduleOfNotesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationTables",
     "longName": "9955516 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration (Tables)",
     "shortName": "Licenses, Asset Acquisitions and Contingent Consideration (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "goss:InProcessResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "goss:InProcessResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxesTables",
     "longName": "9955517 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.gossamerbio.com/role/EquityIncentivePlansTables",
     "longName": "9955518 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.gossamerbio.com/role/PropertyandEquipmentNetTables",
     "longName": "9955519 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.gossamerbio.com/role/CommitmentsandContingenciesTables",
     "longName": "9955520 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.gossamerbio.com/role/SignificantAgreementsandContractsTables",
     "longName": "9955521 - Disclosure - Significant Agreements and Contracts (Tables)",
     "shortName": "Significant Agreements and Contracts (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.gossamerbio.com/role/SegmentInformationTables",
     "longName": "9955522 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.gossamerbio.com/role/DescriptionofBusinessDetails",
     "longName": "9955523 - Disclosure - Description of Business (Details)",
     "shortName": "Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9955526 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9955527 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-69",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
     "longName": "9955528 - Disclosure - Fair Value Measurements and Available for Sale Investments - Additional Information (Details)",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails",
     "longName": "9955529 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Available for sale Investments by Security Type (Details)",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Schedule of Available for sale Investments by Security Type (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails",
     "longName": "9955530 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Contractual Maturities of Available-for-sale Debt Securities (Details)",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Schedule of Contractual Maturities of Available-for-sale Debt Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
     "longName": "9955531 - Disclosure - Indebtedness - Additional Information (Details)",
     "shortName": "Indebtedness - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails",
     "longName": "9955532 - Disclosure - Indebtedness - Schedule of Net Carrying Amount of 2027 Notes (Details)",
     "shortName": "Indebtedness - Schedule of Net Carrying Amount of 2027 Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "goss:ScheduleOfNotesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "goss:ScheduleOfNotesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails",
     "longName": "9955533 - Disclosure - Indebtedness - Schedule of Interest Expense Recognized (Details)",
     "shortName": "Indebtedness - Schedule of Interest Expense Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-124",
      "name": "goss:ContractualInterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-124",
      "name": "goss:ContractualInterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails",
     "longName": "9955534 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details)",
     "shortName": "Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-127",
      "name": "goss:ProductLicenseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "goss:ProductLicenseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails",
     "longName": "9955535 - Disclosure - Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&D Expense (Details)",
     "shortName": "Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&D Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "goss:ResearchAndDevelopmentInProcessExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "goss:ResearchAndDevelopmentInProcessExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "goss:InProcessResearchAndDevelopmentExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails",
     "longName": "9955536 - Disclosure - Income Taxes - Schedule of Amount of Net Loss Before Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Amount of Net Loss Before Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9955537 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955538 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955539 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails",
     "longName": "9955540 - Disclosure - Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails",
     "longName": "9955541 - Disclosure - Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.gossamerbio.com/role/StockholdersEquityDetails",
     "longName": "9955542 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "goss:CommonStockVotingRightsNumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "goss:CommonStockVotingRightsNumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
     "longName": "9955543 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-186",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
     "longName": "9955544 - Disclosure - Equity Incentive Plans - Schedule of Fair Value Assumptions Stock Options (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Fair Value Assumptions Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-180",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-180",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails",
     "longName": "9955545 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails",
     "longName": "9955546 - Disclosure - Equity Incentive Plans - Schedule of Restricted Stock Activity (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-209",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-205",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails",
     "longName": "9955547 - Disclosure - Equity Incentive Plans - Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-181",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails",
     "longName": "9955548 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.gossamerbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
     "longName": "9955549 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "longName": "9955550 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-237",
      "name": "goss:LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent",
      "unitRef": "month",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-237",
      "name": "goss:LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent",
      "unitRef": "month",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails",
     "longName": "9955551 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails",
     "longName": "9955552 - Disclosure - Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
     "longName": "9955553 - Disclosure - Significant Agreements and Contracts - Additional Information (Details)",
     "shortName": "Significant Agreements and Contracts - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "goss:NumberOfDistinctPerformanceObligations",
      "unitRef": "performanceobligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
     "longName": "9955554 - Disclosure - Significant Agreements and Contracts - Schedule of Contract Liability Activity (Details)",
     "shortName": "Significant Agreements and Contracts - Schedule of Contract Liability Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-245",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-246",
      "name": "goss:ContractWithCustomerLiabilityUpfrontPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
     "longName": "9955555 - Disclosure - Significant Agreements and Contracts - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "shortName": "Significant Agreements and Contracts - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-252",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails",
     "longName": "9955556 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Details)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-261",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "goss-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "goss_AccountReceivablePaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AccountReceivablePaymentTerm",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account receivable, payment term",
        "label": "Account Receivable, Payment Term",
        "documentation": "Account Receivable, Payment Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r190",
      "r191",
      "r192",
      "r256",
      "r257",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r331",
      "r332",
      "r341",
      "r501",
      "r502",
      "r503",
      "r504",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r538",
      "r539",
      "r540",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r581",
      "r582",
      "r592",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r1014"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r854"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from contracts with collaborators",
        "verboseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premium on investments, net of accretion of discounts",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "goss_AccruedAccountingFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AccruedAccountingFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued accounting fees",
        "label": "Accrued Accounting Fees Current",
        "documentation": "Accrued accounting fees current."
       }
      }
     },
     "auth_ref": []
    },
    "goss_AccruedConsultingFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AccruedConsultingFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued consulting fees",
        "label": "Accrued Consulting Fees Current",
        "documentation": "Accrued consulting fees current."
       }
      }
     },
     "auth_ref": []
    },
    "goss_AccruedInProcessResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AccruedInProcessResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued in process research and development",
        "label": "Accrued In Process Research And Development Current",
        "documentation": "Accrued in process research and development current."
       }
      }
     },
     "auth_ref": []
    },
    "goss_AccruedLegalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AccruedLegalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal fees",
        "label": "Accrued Legal Fees, Current",
        "documentation": "Accrued legal fees current."
       }
      }
     },
     "auth_ref": []
    },
    "goss_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "documentation": "The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "goss_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expenses",
        "documentation": "Accrued research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r150",
      "r677"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r74",
      "r155",
      "r672",
      "r717",
      "r721"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r16",
      "r542",
      "r545",
      "r615",
      "r712",
      "r713",
      "r1000",
      "r1001",
      "r1002",
      "r1011",
      "r1012",
      "r1013",
      "r1015"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r326",
      "r796"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r1011",
      "r1012",
      "r1013",
      "r1015",
      "r1084",
      "r1145"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "goss_AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant of equity option pursuant to Chiesi Collaboration Agreement",
        "label": "Adjustments To Additional Paid In Capital, Equity Option Issued",
        "documentation": "Adjustments To Additional Paid In Capital, Equity Option Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r426"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r101"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r906",
      "r916",
      "r949"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r909",
      "r919",
      "r952"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r944",
      "r953",
      "r957",
      "r965"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, expense",
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r468"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r81",
      "r385",
      "r1097"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance cost",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r385",
      "r1006",
      "r1097"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of long-term debt discount and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r824",
      "r825",
      "r1006",
      "r1097"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities not included from calculation of diluted net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r152",
      "r180",
      "r213",
      "r219",
      "r244",
      "r248",
      "r290",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r532",
      "r536",
      "r583",
      "r668",
      "r754",
      "r812",
      "r813",
      "r854",
      "r873",
      "r1040",
      "r1041",
      "r1103"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r156",
      "r180",
      "r290",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r532",
      "r536",
      "r583",
      "r854",
      "r1040",
      "r1041",
      "r1103"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.gossamerbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r902"
     ]
    },
    "goss_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.gossamerbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r902"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.gossamerbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r902"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r307",
      "r667"
     ]
    },
    "goss_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than one year",
        "label": "Available For Sale Securities Debt Maturities After One Year Fair Value",
        "documentation": "Available For Sale Securities Debt Maturities After One Year Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r664"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Treasury and agency securities and corporate debt securities",
        "terseLabel": "Total Fair Value",
        "totalLabel": "Total Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r307",
      "r562",
      "r659",
      "r842",
      "r845",
      "r1023",
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r520",
      "r832",
      "r833"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r520",
      "r832",
      "r833"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones accrued",
        "label": "Business Combination, Assets and Liabilities Arising from Contingencies, Amount Recognized, Net",
        "documentation": "The net amount, measured at acquisition-date fair value, of all the assets acquired and liabilities assumed that arise from contingencies and were recognized by the entity."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments, payable",
        "label": "Business Combination Contingent Consideration Commercial Milestone Payments Payable",
        "documentation": "Business combination, contingent consideration, commercial milestone payments, payable."
       }
      }
     },
     "auth_ref": []
    },
    "goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestone payments",
        "label": "Business Combination Contingent Consideration Development And Regulatory Milestone Payments Payable",
        "documentation": "Business combination, contingent consideration, development and regulatory milestone payments, payable."
       }
      }
     },
     "auth_ref": []
    },
    "goss_BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestone payments, due upon the initiation of a phase 3 clinical trial",
        "label": "Business Combination Contingent Consideration Initial Phase Three Clinical Payments Payable",
        "documentation": "Business Combination Contingent Consideration Initial Phase Three Clinical Payments Payable"
       }
      }
     },
     "auth_ref": []
    },
    "goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales milestone payments, payable",
        "label": "Business Combination Contingent Consideration Sales Milestone Payments Payable",
        "documentation": "Business combination, contingent consideration, sales milestone payments, payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsideration"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licenses, Asset Acquisitions and Contingent Consideration",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r521"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r88",
      "r89"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r148",
      "r799"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "goss_CashCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities",
        "documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, at the beginning of the period",
        "periodEndLabel": "Cash and cash equivalents, at the end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r85",
      "r176"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r85"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, at carrying value",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1112"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "goss_ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.",
        "label": "Chiesi Farmaceutici S.p.A And Chiesi USA, Inc. [Member]",
        "documentation": "Chiesi Farmaceutici S.p.A And Chiesi USA, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price of warrants (in dollars per share)",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "goss_CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of each share subject to equity option, minimum price threshold (in dollars per share)",
        "label": "Collaboration Agreement, Equity Option Owned By Counterparty, Minimum Purchase Price",
        "documentation": "Collaboration Agreement, Equity Option Owned By Counterparty, Minimum Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity option owned by chiesi",
        "label": "Collaboration Agreement, Equity Option Owned By Counterparty, Percentage",
        "documentation": "Collaboration Agreement, Equity Option Owned By Counterparty, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of each share subject to equity option, number of trading days",
        "label": "Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Number Of Trading Days",
        "documentation": "Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Number Of Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "goss_CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of each share subject to equity option, percentage of daily volume-weighted average per share price",
        "label": "Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Percentage Of Common Stock's Average Per Share Price",
        "documentation": "Collaboration Agreement, Equity Option Owned By Counterparty, Purchase Price, Percentage Of Common Stock's Average Per Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "goss_CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tender offer or exchange offer, percentage of shares outstanding",
        "label": "Collaboration Agreement, Equity Option Owned By Counterparty, Tender Offer Or Exchange Offer, Percentage of Shares Outstanding",
        "documentation": "Collaboration Agreement, Equity Option Owned By Counterparty, Tender Offer Or Exchange Offer, Percentage of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContracts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements and Contracts",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r137"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on revenue",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r353",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r114",
      "r670",
      "r741"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r345",
      "r346",
      "r793",
      "r1030",
      "r1035"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865",
      "r867",
      "r868",
      "r869",
      "r870",
      "r1011",
      "r1012",
      "r1015",
      "r1084",
      "r1144",
      "r1145"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r742"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r742",
      "r760",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 700,000,000 shares authorized as of December\u00a031, 2024 and December\u00a031, 2023; 226,604,138 shares issued and outstanding as of December\u00a031, 2024, and 225,409,315 shares issued and outstanding as of December\u00a031, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r671",
      "r854"
     ]
    },
    "goss_CommonStockVestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CommonStockVestingPercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock vesting percentage",
        "label": "Common Stock Vesting Percentage",
        "documentation": "Common stock vesting percentage."
       }
      }
     },
     "auth_ref": []
    },
    "goss_CommonStockVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CommonStockVestingPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock vesting period",
        "label": "Common Stock Vesting Period",
        "documentation": "Common stock vesting period."
       }
      }
     },
     "auth_ref": []
    },
    "goss_CommonStockVotingRightsNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "CommonStockVotingRightsNumberOfVotesPerShare",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting right per share",
        "label": "Common Stock, Voting Rights, Number Of Votes Per Share",
        "documentation": "Common Stock, Voting Rights, Number Of Votes Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r161",
      "r163",
      "r168",
      "r660",
      "r684",
      "r685"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Liability Activity",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability",
        "periodStartLabel": "Opening balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r413"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contract liabilities",
        "verboseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r413"
     ]
    },
    "goss_ContractWithCustomerLiabilityDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ContractWithCustomerLiabilityDevelopmentCost",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development cost reimbursement payment",
        "label": "Contract With Customer, Liability, Development Cost",
        "documentation": "Contract With Customer, Liability, Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "goss_ContractWithCustomerLiabilityEffectOfChangeInExchangeRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ContractWithCustomerLiabilityEffectOfChangeInExchangeRate",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of exchange rate changes on contract liabilities",
        "label": "Contract With Customer, Liability, Effect Of Change In Exchange Rate",
        "documentation": "Contract With Customer, Liability, Effect Of Change In Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "goss_ContractWithCustomerLiabilityFairValueOfEquityOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ContractWithCustomerLiabilityFairValueOfEquityOption",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, fair value of equity option",
        "label": "Contract With Customer, Liability, Fair Value Of Equity Option",
        "documentation": "Contract With Customer, Liability, Fair Value Of Equity Option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term contract liabilities",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r413"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "goss_ContractWithCustomerLiabilityRollforwardAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ContractWithCustomerLiabilityRollforwardAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract With Customer, Liability [Rollforward]",
        "label": "Contract With Customer, Liability Rollforward [Abstract]",
        "documentation": "Contract With Customer, Liability Rollforward"
       }
      }
     },
     "auth_ref": []
    },
    "goss_ContractWithCustomerLiabilityUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ContractWithCustomerLiabilityUpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments received in advance",
        "label": "Contract With Customer, Liability, Upfront Payment Received",
        "documentation": "Contract With Customer, Liability, Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "goss_ContractWithCustomerRevenueRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ContractWithCustomerRevenueRecognitionPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition period",
        "label": "Contract With Customer, Revenue Recognition Period",
        "documentation": "Contract With Customer, Revenue Recognition Period"
       }
      }
     },
     "auth_ref": []
    },
    "goss_ContractualInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ContractualInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Contractual Interest Expense",
        "documentation": "Contractual interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of convertible senior notes",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities",
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r831",
      "r842",
      "r855",
      "r861",
      "r1141"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seralutinib",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r655"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r367",
      "r395",
      "r618",
      "r637",
      "r666",
      "r800",
      "r802"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r1038"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r1038",
      "r1039"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r189",
      "r195",
      "r202",
      "r294",
      "r300",
      "r332",
      "r500",
      "r501",
      "r514",
      "r516",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r553",
      "r556",
      "r558",
      "r559",
      "r613"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]",
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r189",
      "r195",
      "r202",
      "r294",
      "r300",
      "r332",
      "r500",
      "r501",
      "r514",
      "r516",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r553",
      "r556",
      "r558",
      "r559",
      "r613"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]",
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r189",
      "r195",
      "r202",
      "r294",
      "r300",
      "r332",
      "r500",
      "r501",
      "r514",
      "r516",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r553",
      "r556",
      "r558",
      "r559",
      "r613"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax expense",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r1009",
      "r1083"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r1009",
      "r1083"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r976"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r976"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r978"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r978"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r980"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r978"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r973"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r975"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r975"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r976"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r979"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r977"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r974"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/Indebtedness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indebtedness",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r178",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r352",
      "r353",
      "r363",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r379",
      "r386",
      "r387",
      "r389",
      "r591"
     ]
    },
    "goss_DebtInstrumentAggregatePrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "DebtInstrumentAggregatePrincipalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument aggregate principal amount",
        "label": "Debt Instrument Aggregate Principal Amount",
        "documentation": "Debt instrument aggregate principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r55",
      "r56",
      "r111",
      "r113",
      "r185",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r852",
      "r1007",
      "r1031",
      "r1032",
      "r1033",
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal amount",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r113",
      "r390"
     ]
    },
    "goss_DebtInstrumentConvertibleConversionLastReportedSalePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "DebtInstrumentConvertibleConversionLastReportedSalePricePercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, percentage of last reported sale price of common stock",
        "label": "Debt Instrument Convertible Conversion Last Reported Sale Price Percentage",
        "documentation": "Debt instrument convertible conversion last reported sale price percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, initial conversion price (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r366"
     ]
    },
    "goss_DebtInstrumentConvertibleConversionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "DebtInstrumentConvertibleConversionPricePercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, percentage of conversion price",
        "label": "Debt Instrument Convertible Conversion Price Percentage",
        "documentation": "Debt instrument convertible conversion price percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r59",
      "r99",
      "r100",
      "r366"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r365"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r852",
      "r1007",
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r185",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r852",
      "r1007",
      "r1031",
      "r1032",
      "r1033",
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, redemption percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "goss_DebtInstrumentRedemptionTermThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "DebtInstrumentRedemptionTermThresholdTradingDays",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, redemption term, threshold trading days",
        "label": "Debt Instrument, Redemption Term, Threshold Trading Days",
        "documentation": "Debt Instrument, Redemption Term, Threshold Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r41",
      "r42",
      "r51",
      "r98",
      "r100",
      "r185",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r852",
      "r1007",
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1095",
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities with unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r309"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1095",
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liabilities written off",
        "negatedTotalLabel": "Total gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r112",
      "r492"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 capitalization",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "goss_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred loss",
        "label": "Deferred Tax Assets, Other Loss Carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property, plant and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "goss_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "documentation": "Deferred tax liabilities right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r213",
      "r224",
      "r248",
      "r812",
      "r813"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r428",
      "r459",
      "r460",
      "r463",
      "r835"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r902"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r902",
      "r945"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r203",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r518",
      "r529",
      "r559",
      "r560",
      "r661",
      "r686",
      "r804"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r518",
      "r529",
      "r559",
      "r560",
      "r661",
      "r686",
      "r804"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r211"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r839"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r477",
      "r505",
      "r839"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r839",
      "r1010",
      "r1076"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r480",
      "r839",
      "r1010",
      "r1076"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GILTI",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r1076",
      "r1078"
     ]
    },
    "goss_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nondeductible interest",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic/Foreign Restructuring Impact",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r1010",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r1010",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and experimentation credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r1010",
      "r1076",
      "r1078"
     ]
    },
    "goss_EffectsOfExchangeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "EffectsOfExchangeRateMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on revenue",
        "label": "Effects Of Exchange Rate [Member]",
        "documentation": "Effects Of Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period of cost expects to recognize (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation related to unvested restricted stock awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation related to unvested stock option",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon exercise of stock options",
        "netLabel": "Employee Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "goss_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan member."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r140",
      "r165",
      "r166",
      "r167",
      "r186",
      "r187",
      "r188",
      "r191",
      "r197",
      "r199",
      "r201",
      "r214",
      "r294",
      "r300",
      "r332",
      "r408",
      "r500",
      "r501",
      "r514",
      "r515",
      "r516",
      "r519",
      "r528",
      "r529",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r558",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r615",
      "r682",
      "r712",
      "r713",
      "r714",
      "r730",
      "r780"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r906",
      "r916",
      "r949"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r573",
      "r842"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r573",
      "r842"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r575",
      "r624",
      "r625",
      "r626",
      "r822",
      "r823",
      "r829",
      "r830",
      "r831",
      "r842",
      "r845"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r566",
      "r842",
      "r1089",
      "r1092"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Available for Sale Investments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r570",
      "r571",
      "r572",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r658",
      "r842",
      "r846"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted\u00a0Market Prices for Identical\u00a0Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r416",
      "r421",
      "r563",
      "r573",
      "r624",
      "r829",
      "r830",
      "r831",
      "r842"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other\u00a0Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r416",
      "r421",
      "r563",
      "r564",
      "r573",
      "r625",
      "r822",
      "r823",
      "r829",
      "r830",
      "r831",
      "r842"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r563",
      "r564",
      "r565",
      "r566",
      "r573",
      "r626",
      "r822",
      "r823",
      "r829",
      "r830",
      "r831",
      "r842",
      "r845"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r566",
      "r842",
      "r1089",
      "r1092"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r575",
      "r624",
      "r625",
      "r626",
      "r822",
      "r823",
      "r829",
      "r830",
      "r831",
      "r842",
      "r845"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring Basis",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1092"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r308",
      "r310",
      "r311",
      "r388",
      "r405",
      "r548",
      "r580",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r683",
      "r819",
      "r842",
      "r843",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r855",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1085",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r656",
      "r657",
      "r796"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r796"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Jurisdiction",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r953"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r953"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r953"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r953"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r953"
     ]
    },
    "goss_FounderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "FounderMember",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder",
        "label": "Founder [Member]",
        "documentation": "Founder."
       }
      }
     },
     "auth_ref": []
    },
    "goss_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder Shares",
        "label": "Founder Shares [Member]",
        "documentation": "Founder shares."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r764"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r879",
      "r902"
     ]
    },
    "goss_InProcessResearchAndDevelopmentExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "InProcessResearchAndDevelopmentExpensesTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of IPR&amp;D Expense",
        "label": "In Process Research And Development Expenses [Table Text Block]",
        "documentation": "In process research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In process research and development",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "goss_InProcessResearchAndDevelopmentSeralutinibMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "InProcessResearchAndDevelopmentSeralutinibMember",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seralutinib",
        "label": "In Process Research And Development Seralutinib [Member]",
        "documentation": "In Process Research And Development Seralutinib"
       }
      }
     },
     "auth_ref": []
    },
    "goss_InProcessResearchAndDevelopmentTerminatedProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "InProcessResearchAndDevelopmentTerminatedProgramsMember",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terminated programs",
        "label": "In Process Research And Development Terminated Programs [Member]",
        "documentation": "In process research and development other programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails": {
       "parentTag": "goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "U.S. loss before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r476"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r116",
      "r121",
      "r662",
      "r679",
      "r806",
      "r812",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Pre-tax Loss",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, For Tax Purposes",
        "documentation": "Income (Loss) from Continuing Operations before Income Taxes, For Tax Purposes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails": {
       "parentTag": "goss_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofAmountofNetLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign loss before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r476"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r340",
      "r342",
      "r567",
      "r569",
      "r574",
      "r707",
      "r709",
      "r765",
      "r796",
      "r844",
      "r1114"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r342",
      "r567",
      "r569",
      "r574",
      "r707",
      "r709",
      "r765",
      "r796",
      "r844",
      "r1114"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r477",
      "r478",
      "r485",
      "r497",
      "r839",
      "r1080"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r477",
      "r478",
      "r485",
      "r497",
      "r839",
      "r1080"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r471",
      "r477",
      "r482",
      "r483",
      "r484",
      "r489",
      "r496",
      "r506",
      "r508",
      "r509",
      "r510",
      "r728",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r136",
      "r200",
      "r201",
      "r213",
      "r227",
      "r248",
      "r475",
      "r477",
      "r507",
      "r687",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r473",
      "r474",
      "r489",
      "r490",
      "r495",
      "r499",
      "r724"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "goss_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Increase Decrease In Accrued Research And Development Expenses",
        "documentation": "Amount of increase (decrease) in accrued research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r1005"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest expense",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "goss_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "documentation": "Increase decrease in operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Receivable from contracts with collaborators",
        "label": "Increase (Decrease) in Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "goss_IncreasedInEquityCapitalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "IncreasedInEquityCapitalAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increased in equity capital amount",
        "label": "Increased In Equity Capital Amount",
        "documentation": "Increased in equity capital amount."
       }
      }
     },
     "auth_ref": []
    },
    "goss_IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares of restricted stock subject to vesting restrictions (in shares)",
        "label": "Incremental Common Shares Attributable To Restricted Stock Subject To Vesting",
        "documentation": "Incremental common shares attributable to restricted stock subject to vesting."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r944",
      "r953",
      "r957",
      "r965"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense related to the 2027 Notes",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r383",
      "r392",
      "r824",
      "r825"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "verboseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r1004"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r173",
      "r174"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "negatedLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r222",
      "r248",
      "r812",
      "r1003"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contractual Maturities of Available-for-sale Debt Securities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "goss_LeaseAgreementEnteredInJuly2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LeaseAgreementEnteredInJuly2024Member",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Agreement Entered in August 2024",
        "label": "Lease Agreement Entered in July 2024 [Member]",
        "documentation": "Lease Agreement Entered in July 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r987"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r987"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r853"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "goss_LeaseeOperatingLeaseLeasedArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LeaseeOperatingLeaseLeasedArea",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased area",
        "label": "Leasee, Operating Lease, Leased Area",
        "documentation": "Leasee, Operating Lease, Leased Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r608"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalCostsPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r609"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r609"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "goss_LesseeOperatingLeaseBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LesseeOperatingLeaseBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base rent",
        "label": "Lessee, Operating Lease, Base Rent",
        "documentation": "Lessee, Operating Lease, Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "goss_LesseeOperatingLeaseBaseRentAnnualIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LesseeOperatingLeaseBaseRentAnnualIncreasePercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating sublease, annual increase percentage for base rent",
        "label": "Lessee, Operating Lease, Base Rent Annual Increase Percentage",
        "documentation": "Lessee, Operating Lease, Base Rent Annual Increase Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "goss_LesseeOperatingLeaseExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LesseeOperatingLeaseExtensionTerm",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension term",
        "label": "Lessee, Operating Lease, Extension Term",
        "documentation": "Lessee, Operating Lease, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Future Minimum Annual Rental Commitments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted rent payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Present value discount",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "goss_LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination tee, number of monthly base rent",
        "label": "Lessee, Operating Lease, Termination Fee, Number Of Months Of Base Rent",
        "documentation": "Lessee, Operating Lease, Termination Fee, Number Of Months Of Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r55",
      "r56",
      "r57",
      "r61",
      "r62",
      "r63",
      "r66",
      "r180",
      "r290",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r533",
      "r536",
      "r537",
      "r583",
      "r740",
      "r805",
      "r873",
      "r1040",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r115",
      "r674",
      "r854",
      "r1008",
      "r1029",
      "r1093"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r147",
      "r180",
      "r290",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r533",
      "r536",
      "r537",
      "r583",
      "r854",
      "r1040",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "goss_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "License Agreement [Member]",
        "documentation": "License agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from sale of licenses",
        "label": "License and Service [Member]",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "goss_LicensesOfIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LicensesOfIntellectualPropertyMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US License",
        "label": "Licenses Of Intellectual Property [Member]",
        "documentation": "Licenses Of Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r113",
      "r1111"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r60"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r60",
      "r353"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "goss_LongTermConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LongTermConvertibleSeniorNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term convertible senior notes",
        "label": "Long Term Convertible Senior Notes",
        "documentation": "Long-term convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net carrying amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r113",
      "r376",
      "r391",
      "r822",
      "r823",
      "r852",
      "r1111"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "goss_LongTermDebtPercentageInAggregatePrincipalAmount": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "LongTermDebtPercentageInAggregatePrincipalAmount",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage in aggregate principal amount (not less than)",
        "label": "Long-term Debt, Percentage In Aggregate Principal Amount",
        "documentation": "Long-term Debt, Percentage In Aggregate Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r39",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r423",
      "r469",
      "r566",
      "r653",
      "r706",
      "r708",
      "r722",
      "r732",
      "r733",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r794",
      "r795",
      "r818",
      "r826",
      "r834",
      "r845",
      "r846",
      "r850",
      "r851",
      "r857",
      "r1042",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r423",
      "r469",
      "r566",
      "r653",
      "r706",
      "r708",
      "r722",
      "r732",
      "r733",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r794",
      "r795",
      "r818",
      "r826",
      "r834",
      "r845",
      "r846",
      "r850",
      "r857",
      "r1042",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Segment net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r87",
      "r117",
      "r145",
      "r159",
      "r162",
      "r167",
      "r180",
      "r190",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r206",
      "r290",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r518",
      "r529",
      "r560",
      "r583",
      "r681",
      "r762",
      "r778",
      "r779",
      "r871",
      "r1040"
     ]
    },
    "goss_NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses carryforward available to offset future federal taxable income , percentage",
        "label": "Net Operating Losses Carryforward Available To Offset Future Federal Taxable Income Percentage",
        "documentation": "Net operating losses carryforward available to offset future federal taxable income , percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements - Adopted and Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "goss_NinetyEightPercentApplicableConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "NinetyEightPercentApplicableConversionPriceMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "98% Applicable Conversion Price",
        "label": "Ninety Eight Percent Applicable Conversion Price [Member]",
        "documentation": "Ninety Eight Percent Applicable Conversion Price [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "goss_NonCancelableLeaseAgreementEnteredInAugust2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "NonCancelableLeaseAgreementEnteredInAugust2018Member",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancelable Lease Agreement Entered in August 2018",
        "label": "Non-cancelable Lease Agreement Entered in August 2018 [Member]",
        "documentation": "Non-cancelable Lease Agreement Entered in August 2018"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r910",
      "r920",
      "r944",
      "r953"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "goss_NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrealized gain (loss) on marketable securities, net",
        "label": "Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax",
        "documentation": "Noncash investing and financing activities change in unrealized gain on marketable securities net of tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "goss_NumberOfAdditionalTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "NumberOfAdditionalTranches",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional tranches",
        "label": "Number Of Additional Tranches",
        "documentation": "Number of additional tranches."
       }
      }
     },
     "auth_ref": []
    },
    "goss_NumberOfDistinctPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "NumberOfDistinctPerformanceObligations",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of significant distinct performance obligations",
        "label": "Number Of Distinct Performance Obligations",
        "documentation": "Number Of Distinct Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "goss_NumberOfLicensesGranted": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "NumberOfLicensesGranted",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of licenses granted",
        "label": "Number Of Licenses Granted",
        "documentation": "Number Of Licenses Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r1017"
     ]
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r305"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "goss_OfficerDirectorEmployeeOrConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "OfficerDirectorEmployeeOrConsultantMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer, Director, Employee Or Consultant",
        "label": "Officer, Director, Employee Or Consultant [Member]",
        "documentation": "Officer, Director, Employee Or Consultant"
       }
      }
     },
     "auth_ref": []
    },
    "goss_OneHundredThirtyPercentApplicableConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "OneHundredThirtyPercentApplicableConversionPriceMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "130% Applicable Conversion Price",
        "label": "One Hundred Thirty Percent Applicable Conversion Price [Member]",
        "documentation": "130% Applicable Conversion Price [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r806",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r853"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease payments",
        "totalLabel": "Total operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofGrossFutureMinimumAnnualRentalCommitmentsDetails",
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities - long-term",
        "verboseLabel": "Operating lease liabilities - long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r603"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r853"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r853"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses (\u201cNOL\u201d) carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "goss_OperatingLossCarryforwardsReductionDueToMergerAndLiquidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "OperatingLossCarryforwardsReductionDueToMergerAndLiquidation",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards, amount removed",
        "label": "Operating Loss Carryforwards, Reduction Due To Merger And Liquidation",
        "documentation": "Operating Loss Carryforwards, Reduction Due To Merger And Liquidation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r682"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r109",
      "r160",
      "r163",
      "r197"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized income (loss) on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r289"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "negatedTerseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r908",
      "r918",
      "r951"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r911",
      "r921",
      "r954"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r911",
      "r921",
      "r954"
     ]
    },
    "goss_PAHCommercialExpensesSubjectToReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PAHCommercialExpensesSubjectToReimbursementMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from PAH commercial costs subject to reimbursement",
        "label": "PAH Commercial, Expenses Subject To Reimbursement [Member]",
        "documentation": "PAH Commercial, Expenses Subject To Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "goss_PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from PAH research and development costs subject to reimbursement",
        "label": "PAH Research And Development Services, Expenses Subject To Reimbursement [Member]",
        "documentation": "PAH Research And Development Services, Expenses Subject To Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "goss_PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from PAH research and development service performance obligations satisfied during reporting period",
        "terseLabel": "Revenue from PAH research and development service performance obligation satisfied during reporting period",
        "label": "PAH Research And Development Services, Performance Obligations Satisfied [Member]",
        "documentation": "PAH Research And Development Services, Performance Obligations Satisfied"
       }
      }
     },
     "auth_ref": []
    },
    "goss_PHILDCommercialExpensesSubjectToReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PHILDCommercialExpensesSubjectToReimbursementMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from PH-ILD commercial costs subject to reimbursement",
        "label": "PH-ILD Commercial, Expenses Subject To Reimbursement [Member]",
        "documentation": "PH-ILD Commercial, Expenses Subject To Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "goss_PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from PH-ILD research and development costs subject to reimbursement",
        "label": "PH-ILD Research And Development Services, Expenses Subject To Reimbursement [Member]",
        "documentation": "PH-ILD Research And Development Services, Expenses Subject To Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "goss_PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from PH-ILD research and development service performance obligations satisfied during reporting period",
        "terseLabel": "Revenue from PH-ILD research and development service performance obligation satisfied during reporting period",
        "label": "PH-ILD Research And Development Services, Performance Obligations Satisfied [Member]",
        "documentation": "PH-ILD Research And Development Services, Performance Obligations Satisfied"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "goss_PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development asset acquisitions, net of cash acquired",
        "label": "Payments For Proceeds From Research And Development Asset Acquisitions",
        "documentation": "Payments for (Proceeds from) research and development asset acquisitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "goss_PercentageOfFullyDilutedShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PercentageOfFullyDilutedShareCapital",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fully diluted share capital",
        "label": "Percentage Of Fully Diluted Share Capital",
        "documentation": "Percentage of fully diluted share capital."
       }
      }
     },
     "auth_ref": []
    },
    "goss_PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of repurchase price is equal to principal amount of convertible notes",
        "label": "Percentage Of Repurchase Price Is Equal To Principal Amount Of Convertible Notes",
        "documentation": "Percentage of repurchase price is equal to principal amount of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from convertible debt",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock and warrants in a private offering, net of offering costs",
        "verboseLabel": "Proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of equity option pursuant to stock purchase agreement",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount funded",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "goss_ProceedsFromMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ProceedsFromMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds From Maturity Of Marketable Securities",
        "documentation": "Proceeds from maturity of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under Employee Stock Purchase Plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "goss_ProductLicenseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ProductLicenseTerm",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product license term",
        "label": "Product License Term",
        "documentation": "Product license term."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r655",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r798",
      "r827",
      "r856",
      "r857",
      "r858",
      "r860",
      "r862",
      "r1036",
      "r1037",
      "r1045",
      "r1113",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1142",
      "r1143"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r655",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r798",
      "r827",
      "r856",
      "r857",
      "r858",
      "r860",
      "r862",
      "r1036",
      "r1037",
      "r1045",
      "r1113",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r159",
      "r162",
      "r171",
      "r180",
      "r190",
      "r197",
      "r200",
      "r201",
      "r290",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r518",
      "r529",
      "r531",
      "r534",
      "r535",
      "r560",
      "r583",
      "r662",
      "r680",
      "r729",
      "r762",
      "r778",
      "r779",
      "r840",
      "r841",
      "r872",
      "r1002",
      "r1040"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r608"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r131",
      "r134",
      "r135"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r149",
      "r678"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r608",
      "r665",
      "r678",
      "r854"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r131",
      "r134",
      "r676"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r608"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "goss_PulmokineIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "PulmokineIncMember",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pulmokine, Inc.",
        "label": "Pulmokine Inc [Member]",
        "documentation": "Pulmokine, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "goss_ROWLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ROWLicenseMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from sale of ROW license",
        "terseLabel": "ROW License",
        "label": "ROW License [Member]",
        "documentation": "ROW License"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r415",
      "r423",
      "r454",
      "r455",
      "r456",
      "r469",
      "r566",
      "r627",
      "r636",
      "r653",
      "r706",
      "r708",
      "r722",
      "r732",
      "r733",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r794",
      "r795",
      "r818",
      "r826",
      "r834",
      "r845",
      "r846",
      "r850",
      "r851",
      "r857",
      "r865",
      "r1034",
      "r1042",
      "r1089",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r415",
      "r423",
      "r454",
      "r455",
      "r456",
      "r469",
      "r566",
      "r627",
      "r636",
      "r653",
      "r706",
      "r708",
      "r722",
      "r732",
      "r733",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r794",
      "r795",
      "r818",
      "r826",
      "r834",
      "r845",
      "r846",
      "r850",
      "r851",
      "r857",
      "r865",
      "r1034",
      "r1042",
      "r1089",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r422",
      "r616",
      "r617",
      "r669",
      "r675",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r759",
      "r761",
      "r785"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r422",
      "r616",
      "r617",
      "r669",
      "r675",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r759",
      "r761",
      "r785",
      "r1102"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1007"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r726"
     ]
    },
    "goss_ReportingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ReportingSegmentMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Segment",
        "label": "Reporting Segment [Member]",
        "documentation": "Reporting Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r367",
      "r395",
      "r618",
      "r637",
      "r666",
      "r801",
      "r802"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "goss_ResearchAndDevelopmentInProcessExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ResearchAndDevelopmentInProcessExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationScheduleofIPRDExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "In process research and development",
        "terseLabel": "In process research and development expenses",
        "verboseLabel": "Total in process research and development",
        "label": "Research And Development In Process Expenses",
        "documentation": "Research And Development In Process Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "goss_ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from PAH research and development service performance obligation satisfied during reporting period",
        "label": "Research and Development Services, Performance Obligations Satisfied [Member]",
        "documentation": "Research and Development Services, Performance Obligations Satisfied"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r915",
      "r948"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r912",
      "r922",
      "r955"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested shares under restricted stock grants",
        "verboseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.gossamerbio.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r101",
      "r673",
      "r716",
      "r721",
      "r727",
      "r743",
      "r854"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r186",
      "r187",
      "r188",
      "r191",
      "r197",
      "r199",
      "r201",
      "r294",
      "r300",
      "r332",
      "r500",
      "r501",
      "r514",
      "r515",
      "r516",
      "r519",
      "r528",
      "r529",
      "r541",
      "r543",
      "r544",
      "r547",
      "r558",
      "r592",
      "r593",
      "r712",
      "r714",
      "r730",
      "r1145"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Total revenue from Chiesi Collaboration Agreement",
        "netLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r213",
      "r220",
      "r221",
      "r242",
      "r248",
      "r252",
      "r254",
      "r255",
      "r411",
      "r412",
      "r655"
     ]
    },
    "goss_RevenueFromContractsWithCollaboratorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "RevenueFromContractsWithCollaboratorsMember",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contracts with collaborators",
        "label": "Revenue from Contracts with Collaborators [Member]",
        "documentation": "Revenue from Contracts with Collaborators"
       }
      }
     },
     "auth_ref": []
    },
    "goss_RevenueLoyaltyReceivableExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "RevenueLoyaltyReceivableExpirationPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loyalty term, expiration period",
        "label": "Revenue, Loyalty Receivable, Expiration Period",
        "documentation": "Collaboration Agreement, Loyalty Receivable, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "goss_RevenuePerformanceObligationCommercialEffortsContributionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "RevenuePerformanceObligationCommercialEffortsContributionPercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial efforts contribution, percentage",
        "label": "Revenue, Performance Obligation, Commercial Efforts Contribution, Percentage",
        "documentation": "Revenue, Performance Obligation, Commercial Efforts Contribution, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "goss_RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization activities performance, percentage",
        "label": "Revenue, Performance Obligation, Commercialization Activities Performance, Percentage",
        "documentation": "Revenue, Performance Obligation, Commercialization Activities Performance, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "goss_RevenuePerformanceObligationRegulatoryMilestonesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "RevenuePerformanceObligationRegulatoryMilestonesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, regulatory milestones receivable",
        "label": "Revenue, Performance Obligation, Regulatory Milestones, Amount",
        "documentation": "Revenue, Performance Obligation, Regulatory Milestones, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "goss_RevenuePerformanceObligationSalesMilestonesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "RevenuePerformanceObligationSalesMilestonesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, sales milestones receivable",
        "label": "Revenue, Performance Obligation, Sales Milestones, Amount",
        "documentation": "Revenue, Performance Obligation, Sales Milestones, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "goss_RevenuePerformanceObligationUpfrontNonrefundableAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "RevenuePerformanceObligationUpfrontNonrefundableAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Up-front, nonrefundable payment received",
        "label": "Revenue, Performance Obligation, Upfront Nonrefundable Amount Received",
        "documentation": "Revenue, Performance Obligation, Upfront Nonrefundable Amount Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r797",
      "r803"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r853"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds, after deducting underwriting discounts, commissions, and offering expenses",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in transition (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available for Sale Investments by Security Type",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r520"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Federal Statutory Income Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r839",
      "r1076"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockBasedCompensationExpenseReportedinCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition and Excludes Royalty Revenue",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount of Net Loss Before Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "goss_ScheduleOfInterestExpenseRecognizedTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ScheduleOfInterestExpenseRecognizedTableTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Carrying Amount of 2027 Notes",
        "label": "Schedule Of Interest Expense Recognized Table [Table Text Block]",
        "documentation": "Schedule of interest expense recognized."
       }
      }
     },
     "auth_ref": []
    },
    "goss_ScheduleOfNotesTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ScheduleOfNotesTableTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense Recognized",
        "label": "Schedule Of Notes Table [Table Text Block]",
        "documentation": "Schedule of liability components of notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r608"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r105"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r427",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Stock Option Award Granted",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r838"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r213",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r255",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r330",
      "r343",
      "r344",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r809",
      "r812",
      "r813",
      "r820",
      "r859",
      "r1113",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r231",
      "r233",
      "r234",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r255",
      "r807",
      "r810",
      "r811",
      "r812",
      "r814",
      "r816",
      "r817"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r233",
      "r234",
      "r248",
      "r812"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r251",
      "r254",
      "r808",
      "r809",
      "r815"
     ]
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights, threshold consecutive days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Threshold Consecutive Days",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Threshold Consecutive Days"
       }
      }
     },
     "auth_ref": []
    },
    "goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights, threshold share price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Threshold Share Price",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Threshold Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested beginning balance (in shares)",
        "periodEndLabel": "Nonvested ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Restricted Stock Units Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested beginning balance (in dollars per share)",
        "periodEndLabel": "Nonvested ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r427",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "goss_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share issued under ESPP (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, options vested in period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited/cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited/cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic\u00a0Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock were subject to outstanding options (in shares)",
        "periodStartLabel": "Outstanding as of beginning balance (in shares)",
        "periodEndLabel": "Outstanding as of ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Subject to Options Outstanding, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding as of ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Subject to Options Outstanding, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options exercisable as of ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options exercisable as of ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest as of end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest as of ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest as of ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of amount increase in outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, plan modification, incremental cost",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 1",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 3",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 2",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r432",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, option, exercise price range, shares outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104"
     ]
    },
    "goss_ShareBasedPaymentArrangementOptionRequiredCancellationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "ShareBasedPaymentArrangementOptionRequiredCancellationPercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, option, required cancellation percentage",
        "label": "Share-Based Payment Arrangement, Option, Required Cancellation Percentage",
        "documentation": "Share-Based Payment Arrangement, Option, Required Cancellation Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofFairValueAssumptionsStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Life (in years), Options exercisable as of end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Life (in years), Options vested and expected to vest as of end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fair value of stock options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock through payroll deductions, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance price per share (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "goss_SharesReservedForIssuanceOnGrantingOfOutstandingAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "SharesReservedForIssuanceOnGrantingOfOutstandingAwards",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for issuance on granting of outstanding awards (in shares)",
        "label": "Shares Reserved For Issuance On Granting Of Outstanding Awards",
        "documentation": "Shares Reserved For Issuance On Granting Of Outstanding Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock, repurchase (in shares)",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares",
        "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r853"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r177"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.gossamerbio.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/SegmentInformationScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r144",
      "r213",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r255",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r330",
      "r334",
      "r343",
      "r344",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r809",
      "r812",
      "r813",
      "r820",
      "r859",
      "r1113",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r71",
      "r72",
      "r140",
      "r165",
      "r166",
      "r167",
      "r186",
      "r187",
      "r188",
      "r191",
      "r197",
      "r199",
      "r201",
      "r214",
      "r294",
      "r300",
      "r332",
      "r408",
      "r500",
      "r501",
      "r514",
      "r515",
      "r516",
      "r519",
      "r528",
      "r529",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r558",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r615",
      "r682",
      "r712",
      "r713",
      "r714",
      "r730",
      "r780"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r214",
      "r593",
      "r655",
      "r723",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r742",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r780",
      "r866"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r214",
      "r258",
      "r593",
      "r655",
      "r723",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r742",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r780",
      "r866"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r907",
      "r917",
      "r950"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with a private offering, net of offering costs (in shares)",
        "terseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101",
      "r725",
      "r780",
      "r791"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for restricted stock units vested (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Option exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101",
      "r438"
     ]
    },
    "goss_StockIssuedDuringPeriodSharesVestingOfRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStock",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock (in shares)",
        "label": "Stock Issued During Period Shares Vesting Of Restricted Stock",
        "documentation": "Stock issued during period shares vesting of restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with a private offering, net of offering costs",
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101",
      "r730",
      "r780",
      "r791",
      "r872"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r71",
      "r72",
      "r101"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon exercise of Chiesi Equity Option",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Stockholders' equity attributable to parent (decrease) increase",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r90",
      "r744",
      "r760",
      "r781",
      "r782",
      "r854",
      "r873",
      "r1008",
      "r1029",
      "r1093",
      "r1145"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "goss_StockholdersEquityDeficitLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "StockholdersEquityDeficitLineItems",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders Equity Deficit [Line Items]",
        "label": "Stockholders Equity Deficit [Line Items]",
        "documentation": "Stockholders equity deficit."
       }
      }
     },
     "auth_ref": []
    },
    "goss_StockholdersEquityDeficitTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "StockholdersEquityDeficitTable",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders Equity Deficit [Table]",
        "label": "Stockholders Equity Deficit [Table]",
        "documentation": "Stockholders equity deficit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r179",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r408",
      "r549",
      "r783",
      "r784",
      "r792"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.gossamerbio.com/role/Subsequentevents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r620"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "goss_TaxCreditCarryforwardsReductionDueToMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TaxCreditCarryforwardsReductionDueToMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards, amount removed",
        "label": "Tax Credit Carryforwards, Reduction Due To Merger",
        "documentation": "Tax Credit Carryforwards, Reduction Due To Merger"
       }
      }
     },
     "auth_ref": []
    },
    "goss_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Term Loan [Member]",
        "documentation": "Term loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r1045"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r1045"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.gossamerbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "goss_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Tranche One [Member]",
        "documentation": "Tranche one."
       }
      }
     },
     "auth_ref": []
    },
    "goss_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Tranche Two [Member]",
        "documentation": "Tranche two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Point in Time:",
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Time:",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r388",
      "r405",
      "r548",
      "r580",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r683",
      "r842",
      "r843",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r855",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1085",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "goss_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Employee Stock Purchase Plan",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand nineteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "goss_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Equity Incentive Plan",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand nineteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "goss_TwoThousandSeventeenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Equity Incentive Plan",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "documentation": "Two thousand seventeen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "goss_TwoThousandTwentySevenNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TwoThousandTwentySevenNotesMember",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofInterestExpenseRecognizedDetails",
      "http://www.gossamerbio.com/role/IndebtednessScheduleofNetCarryingAmountof2027NotesDetails",
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 Notes",
        "label": "Two Thousand Twenty Seven Notes [Member]",
        "documentation": "Two Thousand Twenty Seven Notes."
       }
      }
     },
     "auth_ref": []
    },
    "goss_TwoThousandTwentyThreeEquityInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "TwoThousandTwentyThreeEquityInducementIncentivePlanMember",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Equity Incentive Plan",
        "label": "Two Thousand Twenty Three Equity Inducement Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Three Equity Inducement Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "goss_USLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "USLicenseMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofContractLiabilityActivityDetails",
      "http://www.gossamerbio.com/role/SignificantAgreementsandContractsScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from sale of US license",
        "terseLabel": "US License",
        "label": "US License [Member]",
        "documentation": "US License"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.gossamerbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofAvailableforsaleInvestmentsbySecurityTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury and agency securities",
        "verboseLabel": "U.S Treasury and agency securities",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r829",
      "r855",
      "r861",
      "r1141"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Balance at the end of the year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r486",
      "r838"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease related to prior year positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r838"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesScheduleofReconciliationofBeginningandEndingAmountsofUnrecognizedTaxBenefitsExcludingInterestandPenaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to current year positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r838"
     ]
    },
    "goss_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would not impact effective tax rate",
        "label": "Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate",
        "documentation": "Unrecognized tax benefits that would not impact effective tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "goss_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gossamerbio.com/20241231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/LicensesAssetAcquisitionsandContingentConsiderationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Upfront Payment",
        "documentation": "Upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r127",
      "r129",
      "r132",
      "r133"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gossamerbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/IndebtednessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.gossamerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon exercise of warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.gossamerbio.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.gossamerbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant term",
        "terseLabel": "Warrants and rights outstanding, term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r209"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.gossamerbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r209"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-9"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001728117-25-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001728117-25-000021-xbrl.zip
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M1CZQEYZY^.%E!VXWZ\UVO=56BR11?63;T_GMR2\R6TSB<.'VCM_ M^K!>]C
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M Y@B9*;7FRWX/_6[]#N]33=]M-6N=UKI*\0WZF_UDC>9<Q>#H5T", CG,99
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M=VT+Z**J>KG]Y$YA10BB/!AY<O>TRFY9"?SF=M7]YF?3865 5M4=[J=7+&7
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MXQ0MS-&4G?LT!JRP^=<)(IQ?%]8 H8 4F/]N %(;Q,C<YYIDY]_!L'=^_O,
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MTYX[ ;Z@:EW2 4AOLE :=VK8E5FQLEQND,Q7B82,Z9EJ[0E&H4$TP-JB#J9
M8E 8%[.:.54@%:AP(!$OH&QM5&KD\%#*AXP"6#4/BX\R&7<*]@B %&!IAS-
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M[,3==%*#Z!_#X#3^88Z=2[>>3$1U]L+#*+M,& <9IUR+5NF69P;]&H*7QC(
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M_W+LY85D_DT;]P9VQ/#ZUQ'0ESFV,ZU"I MN#)_]%OSZNS&.)1:1*S& &.?
M\/0&SBBR=3D:RLJ8T47(9/FH&;U5,P"^3@-?27E3)2J5J=4[:9\:M:-D04E)
M[X$G*])1A4J;66@.C #P>Q#S/MZ9,47'W!XP'+TF*[,*M7_#>B]N52UZ2\P)
M:U8R34M.10^4C1:J1$G-.FY:$_ Z[K"FUK4!=N1V]+4*TDK)&-B8VU9^'[E
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MM_$@2L!UVX>OZ26=PSI1W'+QIHA+__SPX'4.%D-9S#E'H!=Y(-DI: J/2)R
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M& Z5;4C#-^_5F])>LU,^H):7^Y$1X<L_JQKH]6]T^(U4X"?UL;RX,35%YJ-
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M7CU_2T_6Y-<%K505(Z2"R"K@O%;LHA_;(9.J/4KMMRRT*'/I/F1@4+ !EBX
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M$4R5A_T( ";9@P0]F.7!CLZ46)HRY54XJQMYW9&\6F+$QR]D1@#TOTA0@-'
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MQ @640I#2MM@R8;UZOTRPHBPHAUCS2/^"WTN^?[AZ4]1Y<KUD S3G,)%X=^
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M(CI=U,V"83V$N@BA!T8S;2"7NJ194=I'DH6%HNPV60,I+'$:0-A;,?><%HW
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M+J5H5E[B#_<T_&+"-;'3#(]P3V K+_-R)9!0O<5H]""<E@I4?)%@86+_?YR
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MTZZ[D[@C9L@Z2 (U903Q)NA+F07W]HPT5?0?WL3R_NE\5@X6XX@N1@'RO#3
M9 ++S O!Y:&&?X?X(*HI4]42. #[ M^[ARYXZ,)?[Z$+G\=8_B30!3+C"5$4
MV2AVU>;23K"IP=4]H.)G;;S\7;P@168B#.5X7A02^ :3\:TBJBF<*#:4]1/&
MLGZO#+LIVH2?\)NF:=I>O-FS]W1?]*P>HQ:'EP^LM7Z/BK:<FXB#^)6_>7AW
MO$\*E:AK]RYXUYYI5_N05\XF<.0"O&[J?*9N. KOX=Z.CT>],,JKC=WH?H;3
M;+H.EJXA_53AQM?0N^YP]"49L"3ONXPY7*I3-:.E;1^;^LOP+J>'H1K#U3B%
M!J+.!->20N+KF@0AY)?:@B9(?8QJXWE4Y">E=U$]':=OHBZ WO_#1MK=CD!:
MHR\:5[Q,GX%.%47::[)WS#OH)ZB4=8[^CI,4GBS0<*P[8[S#B^F?OZ/D!"WR
M,\?61V91P/V74@$Y-/-PGFJ,%,7;Q&C['1JI?DQACHL^?%*$%%0FB@Z:4]H8
MU?!5GL-V%U\"GQ)L-9->D*+HR>0%)<W>Y91;Z^/EYJ3$% [:]&URBF7 <O;:
M)"]AXXZ@&J.I=!1RL>U(!_]A@TT98_*1.:5()SBJUAJWXQTX;]$;O"955)%D
M#UEX:KBY1R<Q2X6+NUT_8E=1;Y*VX_"AWQ?HA?49?P'80T;/;'I=4'MY8A/<
MP^CES?.2Z"ST4M+S=&\,?^AFU&]"=D@9A3#Q#7>Z.5OGVI:<:O6F"-M-Y$X]
M*>3D9_H>=W1QHFPXK#3-A@A,46>^.[$MIDD?#- /5.)HZB7:5IA,UXN[&FIE
M!RHR7F$R<0Z@UTYOBEDG>S0%A^H(1D84WP7,F5Q=Y)Z)L?'SMAQ>S_;CD(E3
M;K',[0\9+QI+JFW,5EL3#)-9# ?->8RV2%!FAT@L>SYF6WX+6V&[D#PX;ZD0
ML8:OHY^=TWG;?B;8S"M=*+/>%:K--V-#)U98C2;>^T.DQ>":D"*%]JT(PXW
MO 8_R9UFA33O>OO$/I>#!7(6B:\PQP\A09#GS?,-6>4*?ACW:E$W5O&N-#[.
M\$YPN*I1_"%YA@Z2%1:5*7UC1LG_4.1R5G;\^AI=)S-3IW# +V^>^LF@TD /
ML1R76BQ<K//P>RQ3Z40@\0+8@?#< <&-)A0;P'J_4;9B*HA6QFBDV*>B Z@*
M6$K3P>!<UN-U&XVQ7F,;;><]XRN#975+:MG64!<.!@/60CS<'%ZFEZ 5$?X_
M/&:CC8N^0N?G9M=#I#5\A^?2MQ1)SG>G<9&.+>7\HV&9WSGJOXVO>3P@:\VL
MFM6Q?LKDAWN?BQP6(XZ;=X!_K7WE6ZR,2*E,NN>5W2'5R/1&A)*Z.^K(7N'2
MJ84MP_FK<L[66J_\N!N78,;SL$56ZPT+;C5%BF$C@?FNF4;?SN&P!%#O' Z7
M?1B=;E8XF,\)OT")YM0G[_=KTC[(;XDIW76Q^.R^,LHD/^*V8*M0\K9\IZTF
MYAK CV)/-)U2WY"3$$:,-M@ F,*Q$X3VI$J.WB#]+K7ZM(?7EI*D;&9>4G!C
M5TD/1$T;<=CD/7+ )(N3G$[R_DAI1=I@1?G@61*/#;V>#SB3;;+]VP_^<2%)
MZ_'N#+P,Q*?:YL5^.BA>2,?.KG,+4*VL3,C7MP6K"J\)4443I',G8AM,25EY
M*<WT@2)<MPH/I780W*^E9NW*L!<IJXN7#%?V=3F3=-**A':7*+%]T+B2U_N
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M @6GNL.M>I"1A8-3U7=21'5P%>KYZQJWUS01ZO]FCL_0,:S YS7>95[I!(V
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M3(Z$/B)6O7\)0V(V-L\LY\I@8X6RXF01-F>3S\KZ>- "20F15EG#^3.F>:Q
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M!9M;=I)'<J.\.2WBASPVG8:8N02/^]!W,WQOW'36^'E3+Q4X3XC!C>PM.B9
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M70!ZQ$YM8Q2=N>Z&!Z@"Z_6>SY"238KQYM2::"XZ@DF8,NR>)^%6_^"R[N>
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MO^SA*(?CZH>7S\%3H#]HHF&WJ]53$$YVL8.3MZB^&-C&9UDW@7^?6FS7CE6
M'93%RN5>DA2$7V?5OW8MLWB>M<^SVY>NVC'QG>I/J#0,HJING2#K6_[\\KDA
M.H1MF[9H4L)5;G&>W*-C=&P^-G#QVGYHHX#6]8JOLHVVEND](8"RG?/GV3S>
M;$9]S]C*F&K&6)+JF-  NT+*L5EN$BXO;8F<]&-":@;*X49O;.,PJ"YKILE
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MFK\SQLIBK+X^8ZP>QK,\# ZMHR^XK6$/ME8-S55F]XLE\M'<WIS'M+_53/Z
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M(N\ V5B&3^D.UZIT#.,1A/P<*]>LN[9XRS6K0.A28#4TL$33N22GBN Y)E6
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M7+&:E(!10ZIKI6ZS<@B@*P<%=#QZ]I60\STJO]+RA8@*,^6+GS6B^(;77E/
MLGA*AAB*.G"8:<IH$D]*=+$M5\3&_>CR*QOC%>B8"/Y?'1?(6%[+#/-D89$
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M0P3F=CWXSO! /[YX;?5KOJ/L1U79UPBU9X22^0L2DL5F;E"GD[B<_&CY73?
MA!'B-UIJW*&CLQ"P^FB8S&_HE-0<39@X\ YX//%!2DFQP<-*/U;^.11[AS.]
MZQ!OCH%9$H;B7L6<3;(22:].U[Z_S:N?7R:+RMC=L!9ZI=+C84J;LS/KEA<5
M+G+<_S>EW>F$QFN[%1H)C+9H/FT3C^T"/CARVH)%MXH&,AW'"E*T#M:@SL_%
M8O$3. 9W4CGBZ$A?U#YR,A,X"W)1V0=!3CU"@IC-5K<P:75YTVL4E-7H"O&#
M,34ZQ+?FEXP!A9>_JQ'%93(YFF=-N7@$;,V35[4OA$#TCWPH!2[P@ZFB#4:-
M*28SWO4AAR>NA?42+ETJ[/<X$?8+;?F&'L6<E?!8E-J)-LB:#JX$!%HUAX?H
MU/R2%T%:=\+F.>=#$"X,9/G@G"6TL)DEY@,*D3L!ZQ/ P%DGYHCDBF$R,KO2
M&L0S;=WQ9D%#IP],1[>N_4X;V1LZ#_S1!CZHOY+C$LAK(FG2Y=@/[1:2T)N*
M@E($@)),Z1UWR1>)^7AZQGP\C&<Y*R0]?%OD'<ZQ0\55RF0O"5&2!N2QX"0
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M@ 8BG4M;6?7F>]. =HDD59IUM>+C9J;JFBX%)F/9HB,D<:@]&?+W0[<37K6
M\RHU,.$Q$%RD!TDA/$T1Y,6P36GPFGAOF(ABNJ<B(?BVU$_^20FY=^G/IJ:)
M:+W#\N.VU%R!6@@\S0,$:3UB&R>D'YX967(OIB\UJYU=A?SD7"Q>NGX'P0NS
M?0J)V@+9^NB4Y#=F$A<@;(%W"-B^B-Q$NP-IT4QK['*BY!]HENA"O$YS-=;@
MA*)] PMA0CX&#X 4K^1G2H48S?A FPCJQ=VN%29%3LV8I2W:1939[5RP(@LL
M1%(4?EVUM3U;$P_F1SAW@L6RTR_%1A56-(N;#QA!)3#'9#J@*Y[!Q-NVVRC9
M=]:Z:M.:&-A]#D5QQ[T>]M+8,'X?I-7B%0D&Z4:5,ID^),?<IE[1'W .S\@"
MWI7&YHLL*G][+BH_C&?YSY%0N1];_HN<E_]VVF!X,AZTP<Y+N6JNLST*AR1+
M<QE)8 M3NKE$>UD# UGHW>8NT80S'+*;XHG'JN4VM6@R-%!!;GI4N9;/@(5E
M/H&Q%-5Q\[P^\(.4WU5$R&^:S3&Y(\6[N*%=)=(E3(NKL^8FVB;/XYRC5YXE
MO^CX1Z9@[@\R4P?UK^=WUY8=PWB.D.$.2.4QM@0^/*$@.+5PXP=-/88$TDP.
M+&C3W<XO@Z4G)$*(^>:3-5 AJ (8]P?R'?H8\$&\8^C9Z@9(J%>LI F#/9C!
MWCT.&6U0TWNL[Z5R!/BQL$J,W;7S.X]"WBD[+,19I#YC$X!QHI_<=*XC$-_/
MW<<+V7*%>+I<O/G^I[=1IS_XQX:H49$NB- (60C;,Y9.8*1=S@2NDQ$M600!
MKX;<[7Z@-OO>[XR2Z K&1OY,I%!Q <W5H<40&?5IL&!Z@SBDK 2'<D[^/R^1
M;,+?V@\*L&/X38C 3C]@^/>H]DACX=]I*Z?%T+9U2@-3?23I"F_F?KKXLXQ#
MCC P:._@N9?ORRL2*#(O5L321@L2Z<:O]?[V?E+Y&P,*A:&&];;E]T!%^@),
M%0A[L^I3VZW>.[<3G*2-^S,'2%!KQU&<'B<Y=8EH:<AZ,1J&N+["/F H:MA3
M%*F'D(&>'%X"&\)P8D4V/I!MA8,LQ\/4S[)?P-5360):T,U^NINYVB 9V,A
M7"S^ ?%''"<!%R)(:'H#,S84B!XX(D(B)):T0GW@Z)Q!=55D) *Q=I366.X+
M.11O@7Q-*MMF3;:SG/>S#.:1@^ GQ1N\JY!T:J[Z<_/=,=NSX\,Q^$!\%$Y(
MMV+;'G$"122FL4<%E[KV<6F#X3Y==T6K02K@3!UT;FCY=+,M0Q^=AI1V8I:,
MI'G?&JZP3-BUR3@PY\D\8O\847G!G ;1*#^35VW'WAH>("UAYCJ!.4!>O"0=
MI-H-A*8=&\8.\2?P=20,0ZZH\Y1^NOVY'GN0N[P/K6:0?8?@=)6*WB@!0=C&
M2M\9?6]=U<3H.?)O+/F;7SSMLDQ]_?-B..)B$./,]'K$S,[%!K;.M%JHVB;5
M&W+<4?J#7/<SE<JGG#7#K"ADD)A-T#B9V!;AJ%3>0TDIG5PB!W(-**/0D1P>
M83J4OIU>#+ :O7_92S XE^VU8(0WU64U(>:<I9@A43>68E'('N4@B1O3BF=A
M/C$BC,PI/B'Q)TJOV2OI31IW1;RCU#@">,G9"7I $^)/#2VZV4QH[O#@+V+7
MS%)R0LL-X!*97U,S+"2?N.7T2"1<!N)13<DZ.ZJ:Q#S^1L>:\#:YC'0.^ 1J
MF!"&4Q;D^U\7.]!A*I=NI/Z>&F)YKHI"CZX"%["PP2*?RL;,66F)50NC0 ES
M)VFTU_$]WA(2;(\A_?=CU^Z<:F%?.TC!^,V^"438]!4_[U!:H(0%W.AG/W;8
MS_KLR;,GE*++?%-G#2JC;<^)>GCN7A%(US!*X=6O'0Y3-TX(DS&=)K2JU,;R
MR*8M$;RDR+2QT[/=3 _*'W&=%P\=?AC!C-;5E:!J"-ZX\S?%-'8Y;(C'TPW+
MBZ^\P]G3)NHW1%+[?-=Y(_CLS]B_\#6-"+TUEA*N%3^W1< J"GI1JQ4ORW8W
M9$;]==G55:DH+C/&?IJJ6E'),L"T?%$R!44$*7T%RTY'R3\*W(A%!N&^!)4F
ME!'S))O,"G_3O]:?Z;7"VV"IN;V!.922LS5001T%NUVJ-EGOWKJ,/:%T\1M
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M]9+N12'Y,<O [X>]=)B_=^PGV*GW@<@PY@3E0XC":Q1N!K"IUHC 42!@H*3
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M(-F29E4Z)+?$$3!:7)U*5H@&5[2?O!T:H[;-J"NAA33XZ46MD!P-;V_B=0)
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M\;"$&+I+,2)<CH+<DU4%]4@F6D/@02M,*L:RQJW;K%>L#/69206 ?(5P_*\
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MA.0X D%]I(?3SZF\"^T&*T1-^##RHHMOHS?P1R*=QUEW;>1+R!3,>[:$7W=
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ME8:]NL59WH5K-&@.1>V8]2]1X.=B+&?#5M6E6%'167-X=G"%!0LH!3];T]!
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MDL[1=4YL#,-1B=H1PSVM5W/4>=6<(3L/*)QV78G-6B4=DZW8SZQ15@JV=+8
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MYDK20D7J(?!YC:1>PIA33/>ND 5,876'^S<EYM\1&Q8#)15H2KZ4LG%K,X1
MO-XC"3''G578GQ5@)D,:6\*%*I#C?'6*$AXA^CZH$%*&(&GBFDNP]@,!N5S4
M/ZIBR[WR65-8 AR-8J$4MY@?XCW37%#*8Z:9N[34*>/D#32V)*M4F'9YI-!A
MFH RBM1.\7%X.8"[&!#5#RHEH5H64:)L4"UI2B^I0:\S)HHQ%U&3'U+$MF)J
M'$(5-U?T_VO_LMINKG6DNW8M\01<@Y:B88(H@F,!OBOC*8\(I"+/]0I']*IR
MB3;Q^K7KU'G^3.HB8,>#X+Y/0=0^FOSQC[.KS@VX;Z7/FQ3%)8IZJ6#0\>'%
MJ7FS/]N)'L\F#[*]@^;"559!0S51L;P;V^#I"3Z6$$,8C+8)78.46.CT<%2>
MD=Q%[+ENR:I)<OZ:K,[+.8E18I:0E""$B#UE5) YBZ+P2K0!=Y*I-I*,L'?0
M)QE>%*"L-,88S22CEWAZD\<6.5+X*!!\Q\E19 $)NPX2EK2L^0HFBG5\,@AA
ME:M?1I,V8K!POGP*"Z*UL$NOK8\JRRI</"RENK\N7"VXBUEJSP>1XA(/(7\+
MWP02:VR<C:4!VM3<6\%*DUG57D0D58M'@M6;2E2#4?0S(UD:DMO9BB+AW(@.
MD#9 NCI5\L!I4< 4+<A:!S,=9GNEW!8= [.M.JT+3E=#2_J)":]+\GC31[I[
M!1;I3,BH*O.P0)TSC\HH5J;%"I%;TF,;5RGF4R4O/:I?3C53:YO%%.1)YUKE
M+;,&^=A5PN7^Z(S."WR>G$E_2Y5RD1$!DKX2$/H\[#=O_?ZAW@2W9?%^"=X
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M3F^XE+,'8$H8G^)ETY&,G<K&.+5*3H"Y]O$YO'[A%..K0NE:YKCCTZ9RUW/
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M+3E.2WLM%I^B;,F0.A7(AE 8O2H;36.@V2"X(;$ [F10ZOZHR@.#H%I!RS'
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MW26C*,("$R:1B+7";S:$/HN$(>A3SV7JZ)%I^*=V21@ "2*Y+7^MMR,>@N9
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M 6#LC_S9:V>^XGN:O3]R*'O[,GN>'#*Z&)]#;3HS"DW=L>-C;F1_J=JP4%<
MP)Z<BW2L.T?3?]@3MU2K9$WX:P"2R;M4_73LBX0EH^WLY[)H8]=*?KU1#'*T
MSJKP=O @;?-3W:1GTAZ9CT#^/A8C^+)78'6DA3S,"3#IADF&&MY"U5Q1KA=
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M2#^Q<K3S,*5^RG3&[]E-9(#H\V<O]!BRT^<':8%\Y5S-OY6W3Q<_H1Z>_[Z
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M]A*BVFST)QCE3#&L. L2)ABP/Y\Q8(_C67XG@H2SL2\@$A-"!.>]SNWM.3G
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M*#-U'8&[=='1;E\3>1.&^,Y%@$B15D(X6HBQ8-6-5Q34KFKN9]=QHZ90XAK
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M#@1)JNM:L/7%KR&$+PZ]S5<^O2!1!QK)#&;<X52&R\RD])N.AY068[[NTMT
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M>2J\6;3>C6.4KQ2GDS:#^2FS9(;/$%)?2R01'EHU(*OX$+;D!8E+$^IRUM)
M4A#X5&@JEK'$D[0P5](H&B2'KJMV'+#1B.110KU<^)!*,; 3R3B'PQ9>2O!!
ME=-$_$?S+E/E:?8V 48F;*RHI,H/S72M)\")] :3&Q7BCBIM5 *A2G$R80[U
MAIX28=)V5 7)F^LZ15=24F115442+F7WR^9W:@R;@^E5EZ9>*"7TC1W5&75
MXP/5Y!/\S>L0B[Z(\$=UH0TP C3;>]>O1^2!]+KOK$FB%V$L$?^$L+H_J@CT
MW4 IQULP :^ H+LM(%B/M?PD8 *8ET*S(8M "+&YB%$AFJJ@B@)XM$2+,.)4
M6X6H+/ED4J-6-U5_!-52D%X=LO\#"O>,1%#)I6VN./2,(ZG32Q">CYI>!J#U
M4S1*N?$=%H(CQD'Q@#633[$;UWTSC2,%'I])<H *\CD!1_89@^$X7Y0.];P8
M11E)'VE=XH?1!,H:(Q@<'(7_B15*1"YHF.0H=FP@I:B24GDSCG4 6J<*XV \
MZQ=)3($0JAFP7J_QI<D#!#?"G NVVWN"$V.;IE>![6\)XI*]BNUFV)3KUW!3
M*[*9%NB;1UB13 !ILBR$X*S(XK+@$HPFY+6]3#&_"7=/CB@%F'"98%1A3# M
MI2@SS<'.;*B"!DJ#3CH2J!TN._D79FY-=RM#BWEJ@@D5_AH*BF0)"K"B(*LF
M+5V;6^CV*;YK*K?7A2'81C+BJ^=<>QK5&;A2L5.#7Z&-;.\'VVXSHUG=&:H$
MTF"7ST/NI?;7!+%D$@CWVFE3@F)6YO)M0?V\BV<C55)8@"*JXO8L1OKBOG$,
MA>B>N8\RIIBM'IRWM& SLD8:[&O*@66VB8IEH"G'TSF JQ<EM,AV!L_E=/R=
MNN2T7"[9!^>,3)5.3#-5^+X'23&H)SS[3@Q#&NH27>? .[Q=4[!K9VR@W=$?
MUB6!4F#_'XB"0:!HBNQ@^1SPNMC<_P12EO  V7A^/T0I?:H2)!6SCZ.QF+G$
M$JS$;P@E[HQ$#G-INA"7N5370F^IA3+RMX*KKRNIOM;PIA(( M\ Y @\?5K(
ME'!F("S:F*JH0.$[UHDJ<$+YAQT\=> '<*FQ'50^ S8G4GEJ?N&L3QNJ^NVZ
M \1F[8""XKQIEUL"YM ;!Z/1%37DW F '\<XY.+&1)+[(&+5M9V4/-?YTAS,
MSE)(:\#0)*(H?N-S-?5*4.&]F26>299%X[5P0R'W>J.D)"DO@1S30^C75-OP
M#[=V.,+3K64;!E(F!M)TL7^=5*L%E5H"2=8O-\$!NV!;7J-%">,[Z%QL@0TH
M<&R%JMR8IS0#V_=+5X'^;DO P2EM(YJTT=]F(JFY80+!-H?=DF/2<5^F;&^>
MBE;E4L-2<H<':A\9=U\HG4*F/@58*%?U<*U]2E$)) &;&M1*73=SND<NF?,)
M:./$:U5T@WTVEXX;P^;*N=0JO=C6  %KD<<K.2$GWND^&$TS<S4R]LHMSF #
MSSB?1EW;K4JUVUS;D)*08]8(AEU)!XG3Z.OFV74O."?5Z8"\DD7N'2?BF")&
MYF#FBT<*U.OQIV[Q)\7+3,$I"0JL G,M1S=P8-0EMU,2^"6>YJ!.N<.=8F!(
M+:*HI?O6X<.6^"[G=/6C79'4GPF8GXS0GM<9-'&6;%_9$1FZIKN%[@'?3O.+
M, HYH@I625:,DRD<_N^Y($&97  W*^[64S,9P.G$C>:D'^\&4RPFG R4H4.&
M).ZXS$.R3(Z0)4YRE1;C;-FT)C8NFLB@B=JA^S"NI8O)#GX#H0IW"-J;:\[*
MMK=K2P@_+V_7\[SD<]3Q9J:5FZBD,7DY(C1?'>!V F& 'T-CW <XD+G.RB9E
M0MYIZ,A2]]PL=I%C+EIJB3)/@5A3SE@7S).M4$2$)>L(_'EUII66%9W729Y:
MGEG(9$[E ,D!OVO=O?BV/-C"I-<VTR4FY7M38&L5IIY>K0H!)R*6<3KSI9"V
MT=!GCDI\Y3GUYI87;)SMW2@2:\-0 $NV&H.[](WH,+]!30;V%;J@%"QI1$9*
M$PO!\$GE?WJ8YCG"5X%,PK@)D78UFXYSLHR&"7T+3@:%#[!(I"/"? .Z%H9^
MJP,W.;5G4M^NB>$0G]O$C&-!A@[ZKV2LL)"8ACF0_0+<,]PEF24@#)Y1T%HE
M5]FJ.,<XX *\>=QP8WQ)85VYV%IAVE74)C=?NL=NN%/%B,)(XT>@)D2[(MNE
MD\F+N4"7-2Y;3ZI1?<;DSLB'6.H4Q5*)7F)Z">O[*IEV #3\(5&C/'3!G@@:
MCH8/.^0$A$*2A_D-%O\_>:9*I[]=HU!HC4FH]%AUHA@6C5^ZPK.Y_%('RG ,
M1JS7'1F_<Z30B@<_C HT@=MQAW7V+<MO! R+?!2:2NADQ_DZ^BL)GH; ?6RA
MLS;B^0^GXW:4YGVT9&#+P(4#A]LYM"D6L6/TEP;]4D,2VH/#2%92U<[W+69F
MFH I'.NXXKU5)FMSIX_W^8__CDD\"#BW_'^1PN527 PZ<Q!B,Y+LE)1>*G%H
M-J/G0C.NJ:Z%NX.3(76\5D1;*[?$1G%%8SI!0B?EV+M&!PHHP@9V$;9A($6@
M!L=+Z@U2Z>)"0-M0HXOHDK>R;AK.[@<,>8Z*_*8:AX8GZ:]UQB%F]K@(+Q=?
MZ2+K, 2$>4SI@&"ZYJX]71&"'GO,;.BT%35(@[TY!5\V;FL]#QP=#N_F:@HX
MEF10-6=3Y=DH%S%)?S=S0;[490D"'9?WQ[<"A]S0OR_*(E*,?O#W:!*Y612K
M:$"R8B:<*Q'87^Z@PA#?"9:7EW83/H:]FR"NLZH0H"P4 H@;QC,#R!#F!9?S
M.Z)\N2PZM"=ICU'.IUKA0FQSAB/ :J0[DSR7[9@[LNO7!Z,UA/H> <'T4>5)
M,Q")>?U@E&V&:LY,>B+5HRB6D92FI'N!R)2VQ'Z11Q@JL)\2EQH//09/KV!2
M1&04#I#@<G<I;63YTS'\I*ZP\@>K>3$%"<VA.M_%\S-)&CV$"-O7Q#R8S]&T
M'9C#?]S\"P>,T;"002E[^P*6DO-%84,G+ V^'?P7-K;-@O=1]HW<WJO_>L\O
MOJ)YZ.@MX-\T4<#.IBG<G8"L<,!+(7X(@:69GE)IC0@^*,K0@XFE?6-G] >]
M\-.'BW,[UP)>M6MNCFR8N?MQ;K&IZ*0F",Y"HH:W5;CH$.%BR>_2H33ZT?2Q
M1*-BP^%N:QO<VH;>MK9A/=;RD]0V6"/&,UT<R]J,+2!7AEU5W9-C7!@)A,Y,
MNT"KO4'I( +?TN^)P5$"(0*"K%45Z%Y5^R*G.$ WXW 109U)ER]=!9M4)?\@
MLLCNB1IU*80'[_2-0ZW"K9A2C#8T;%>::-DVPLOMZI+2150S0&%1VB3KKA81
M+ 7OB!:1S9RJVECU:=NR;GD3YOVPB#5.,$!*/<3T,_=FR@\:=VFQ/T1FDT$2
MQ_AJ9HKIY/DI83EX)?Q2$NJOTRZ,W&6T[-.9+ANE]V1! TA)[)KELAQL61NJ
M<WTOV "E!C*#5VS;H%F[<9J 4AT2G>9)KF@!@_J,<R?PXJ7LTBAK=MIQKW9"
MU2UX>5SYF2EW.*);SSB7;0@7DLM\>Z6 >D1%E3ES:Q>;]ICB8=.<BF/\^"\#
MW?F^K!.!PI2XGT&%QXQRRMZ D,)JD%KXC"#8XY%J@:-@F?;K7_K%FU^?W_6]
M'X*5$][\HW/5\>H.=!(-^P,+\1TG]$];HV%Z4#!MWX>]YARXJI)=4#LZ8V#Z
M7N@/"& VH[(;'%"' :R6MICY3E5IH:%T#W;'Q [8K=.MXUPS-<91!0N(X@E6
MMPQ,T5B119[!7#K)5RK%TD5-C?RKI*$YA$7N,E>M23V437OX!&DB72:%N6D!
M\GF"$;K04VT=^FCOW/+=4"*WC_R(LYB"&I78S5_<;]'GSBFG5OK/PQ=H*"&C
M<Z77 6L'C#_M=5O)JP@W4CO8^(JO!?FI,_1)0 AY&(>?"403Q=TGX8DS1@\^
M-XQ@J-LA^]4HOO6 ]/O.^:G!)8%J#!@ZCB'ECX]]0!WS74/S_2+IXQQ)S(_7
M%1<GFJF\W1/Z]'DGP*C7\3O$& W=8P&=E3)0'?WRZBRX//OZY>+S5XM>)TQA
MTN^&MVCW^O5W'(?ILW"B&B8_H=MMJ)=2"@K/6J5,(:4R8#"1MD '40H!02^-
MDWY2.>ZV]5N=Z78,1N TKY@1#5[J//0ZO=RXC%>;G\56JW$N5LIRJ%(*UC2A
M(!U-Y:+C"$6!,H@%CZ@60 KVIND/1L51%[;^*;1 &!8_DB8_5E1,I5)N0T#P
M;,G8#I)IH@05EZ",&<>'^C)P?"A5X<!63,6BC%3VBT.H&+39EZWARUMF,89L
M7J6IE_*)Z+J"G(2^8GQ7QD1N%+9,$4J7B.\-%X-*4LE::7 $DP1O$38CI0$8
M_*-*D)&1->Z]M?606_AQ/F'WM)G.=,$#-Z50$E]C+MAR6S@!IQ0%Z6L@<2_[
M:_!V$0V( AWCO*10#[5*4/@D,?"NO%B/$C4<4%OW/?,42P\3@$Q2UJ.6G>9*
MA!^1#4**>6K,2S-6B0@=6567K3%8 4^OQ<8SS#RE*N9:;#/IRXJ#6:/J@&&F
M6EIN8U4.4"C%&(V^5L'B[ML!/#X5%TKL <%7H!XVJ45@KDM*7===.05IHB6Y
M-!C_A5R5(' SA=[!9I+O1-\-'M6$#]Y6:.@3YCA4$=6Q!V/KE8&0J>&U$1D3
M9>.,#J]FG/11P^@PUVL3"D;M&W%/4LT,V76 "356B]2E2&"7+$=10J'#H*7;
MN5C:&E>P(FAIYLV=QL_L.%EL?<K4DWNC(_V-21%S60EO.J'6C[I-?=Z_,4!E
M#G\CE(Y?&PDR12; 4OY@)"G::VT:$8<YF_("QXT5$\QM<]6WY$K"!9D-Q"3^
M6*,"HY&_J8&<-X!P"/U24S1"FO8D#$HRP7;$9^:239R^=+#/M=I*O,41C(P<
M!$ZJ0J1E"5K\HQX#'7_S,B>$T @:+,+(#0WKCAOTZ2W$HS99E>#UJ])"-CFQ
M?+L?27/[SI?S_F42+PXEX^YDWT8G-*8D-K/"3T=IC*W19MWH["A7K-4T!F@P
MAK/50TRH7;X!O3#OOGK^0!8WHG:.2VN+S4PMBG"L:ZP;A8"F"$C,A"%!+/II
M0^RO09Y\]6#!@DK,IARPX13Z@X?1.K,(/A9'WC3\2M"*QPBHZ[Q2GB+6>70L
MUG102G'664()D\U3;F=M)W33=M12^1D-B+-]P%Q3_!+,>^@LSUIQP45FNR/B
M=<1"/A<B2 "Z'?0:<A_*T'1##*E90N?SKCZ>!XS"&6ID3O&Y=&Q0@^ V([1+
MS5OUPY(^5*PG!GE&&-*-[0"+\ZD3-N25QL'O41E'_Q+D0.G8<B;A8@JT\1KF
M_,:T ?=$LSE(8E=*\&?)!Z/(?5*.3>$^ 0U@0)J##+:OW6G;F#L;UB]TQG:P
ME"U-8VG/0&(Z:.!4)+M31_!</N1QO/NIP%SN/W%XR555*%4%7Q1!8.!;SG5I
MR*5TVL.&#:IO=R\TQXLC;O2I.\JL?8YSHI%&L<!,3S&-T+C)8O;%I-^\I"&8
MZ-7JKG.0$7-DS?7*I!@(Y;@#&S$#Z41)83^K6QSBE&(X^1=M#^A/C8%SN3&U
MX<V1%WCMS,!P_,B"C\^M$'"%&@JSIC)J1YUV^S+UD[RQR$8BVK(XIXI#DA-N
M1*4-9(0^@!TO%F//%#8Y!30;)VF_+APC[@.+ST&*ZT'!TI3+O.HC:7LUB>)5
M-UBUY6XJR8 1H*YC.U%:I0%$RHD=0B*5U%ZI?*J7"2W;8@.WV&!_6VRP'FOY
M28H-J*3+#$/28.;6T+6Q@PQT"$6"&V7GNC:)U--LI9SQW86ZK>TM7'3IH Z0
M@"*3/%:.7,NHVLD9U^G_B6)=6CCZV6<>IA!8<$#:,BG[)G25]VB.V5 \1CYF
MW.?<]+4U@Q(B&ELE/8E;K%+("W<V%H_"<R+(>D8:F]@\/:T-GM4;'M7P7Q:!
M(S8QI<J(#U2W3NK&L#9X=]QG*7T 1&H,EIH3PJ%,%_(L KI)%ZR1^[.F.:N?
M>34BQ&!J8UL4C=.IY9VG*<YPSE,0X.4B:,\,FI\H)XB6TUTJ0\<YCK&&ESMC
M_NSO,0^0 (MQZ!S#+G-S[C;/N;XP_:*2$C !*Y =Z0RO46+D9)Z48S<.;_RJ
MO#!_=L=XM7VT=0A? U-?IU&1L*Y!X4]T;EQJP3?2!%QFP(#(/AHL1T/8BDJF
M(=BS9(KFP^3IPW?<G[X9/OE:T[1W^K(HNZ:IJA*!KM.\:!XX(!EI^DAU'8X.
M(E3.9OD^]5YEDSJ:E:E1Q%![PO?8ZP6O:Q3YD+S1[T;H&'HSPK50C=L(\^VE
M??X\.?$+T^0;M3 (";6_:&Z;I6V(Y=YF#/*);D'QCI$&RQG"#1F=LNE[\$8N
M&T(F3>/7:7#]6G/Y>=%D!@I2K<8)ZR1PG%"I44B2-J9(LP.L)Z/L=<*%[L':
M&":Z%#8CP[H3,,+"2ET8(+5R3C6]G23JAE@CU*1A8">-D-^;EQ:&D4LZJ6EU
M?C'&>?>9P+*)Y7<9EHBGI"_R.<33QLG32R=^U)C^U R<->Q@G$WLV$H<-J3I
MQ!0G)[@P*E_51,BVX5":Z)>DQT[P=STJ_@=&]'"FA@*O16Q+T3!N@Y$NMC0]
M&$H>9\Q+M:BO7') Z0Z),3BQW&&"/1ZZ$+EA2O+4+1VE^[$S\8)^[J6UCQW#
MU<CH,: O"</-G9&# 2D?63"=C,U+/C(.G^E*)UO-Q]@%=4G',!$=[=!.16T:
MM/>5-DXM>@0 \UVT-_LH;C WS@>U@?_$MJW2B)(I^#<)FU,&"T*GG/*"0'ST
MG8D<Y)EI7(YDX;;0P2-($8.ANOP6$H?0GEHR;IQT<L<F</4.5KQ/J.;M'F>/
M0[XME[/GJF=R<:^H#.8Z<,>34$.1"F9YS>_D<FJ7T8U3?Z.B;QDAYK([Z%"E
M8EB0@62K5R2:3 "#L-":2V2&MKK=0;]>]H&Z@UNZ49.,*RR:]=6B\ZU4]\EQ
MF0'!@PCLN6&:WY2:TQZ+E[@!8G61;6BJ=.;US5WIP@N=K7Z=N>U.PP7T88D9
ME4RXPKQ0UXFZ*9>0$636TU4)-(O&R'*U2W,=')W2[LIB\>&YB_-3O%V4%S?Q
M;V$(Z3?]F63J;'K)%"RX]7I<,B9 DY;"25YS:\[\Q:QZ_!IWTB8,23D)#TDV
MUD@)_30-=F64.L+AS.4)G< *.BQ%(J46TH5HL"\Y)25]H+IR?>,\D'.;L,2R
M-RKB0AJ]:U;%BK@]C@C9- 6&C^& *_98I$@BY)AJVM?'%NJB;O@7F5:A%_0D
MM*^83LW/1@OW^P58./H"4T)9'%I&51F%!0+!@4(/3B;4FR+K4#+0,79CQ1S@
M0XMRRG#M]BHI)<M-VG!;2P,V+88'<?JA3/V#S5A:9:&#J!IRD#ODA0I)(QNX
M10O)J/\>"QACN B,Q8>F:P'0\AXGBD*'7CQ0%_>*&I4U&E#-Z>76 6_]Y"8+
M90OJM^X-A'4K0R7Q7U_=G>+IGKZZKZ#J[7>'O<<<RGF!\)W=]QU@"YPZEEXS
M:PPQ&37A$/E#R9%^-/B&R--9O"N[&]+_>_=D @8LT#.3_/[A?=W1!?=3)J /
M%B>@E^>77N_5-FO]HK+6SRG;SCO!N8N-W.#[Y/O;+,]^QRHO;I/'X_F"QS#8
M[;X*LFB"*Y[%;[V'X SCWTR,YE+/?OF4%V<4JP%E=L'PI@@.?9;%]&'XYU<>
M!_(57O(^!9_A%?'$<'?_Z%6@2K!RD9N+6KU:05<\H6!=8-MZV-,TW_DWOPC@
M2AJ[7XPN,2U2W$\NA5+.[!YLX?*.Q2M.Y+E!5 $IX_QDED_;W"5.ZM#0)6FZ
M= "OC".JISPUYFP]^#2F=3AZQM'GL["Q47VL?:KKD)#Z[[I'Z$*:\4EF79GP
M*S[CJQTBX9/R)WB<0BBB8.?WBZNOP?G5I]<8TTW00H8=84PKX;)[C-TJ]A<<
MN&,> C!PV[=#.]M6RAPI3VTK#N 7&3H.4G6L1T;H!;"1/*JQRQ"G0JMT2K,[
M1=R$<B*A%*<@&[9.U@ [1%U+8/Q1NK2?G5 >5K9?$ ^B/S(OO$_FA/<CO?I3
M&HU>!<S48$I]K]X.D^\JWJ6WZM4<,[3K$N*'HHFE&^L<8]5L:L(NMMC$S4@H
MF7D6.6%4GW$^4_\F7 6Y$52_XA6M^ZOA71KG6 /*MM,MI:%UNSJPPJ# 2BQ"
M>7-:-.?@LD.+[1U:'X]:##SWFLJT@ >\"_RU^3/+ )7A0$(:](REJXC_83#H
M_:7G^CQ,1X,+L!##/T<4H5RPF_N&NYZ=!?]3S7!2DNF_F)\@=QM=XG .G95S
M!G0P% JBK\/MOEU:7$VQ5"P;[:9J",O;.VE(,##!GA&F\Z37.WKW?-EX_W#V
M>YU#/ LC@)PDY#Q+AMY8&])'6AG9"#3S+D^E:)N/1^F-.TR8=]NK?K2K=@86
MD'B?%CA"9BI5"H2SF>CV^D'. 5:37)V(<Q/L=%^W$$B@$'I!0 SLF,R=WNN6
M 93^UYW&3WC/SOYK#_1SP<R;+9T\'IU0.)CQ-##:2ZJ_!0/KAO*^!"D!E$28
M:T:$<)V!B>O?)"5-HT_*2B;0\> !783GZD&#3C,WA92):GOSCW?S_I%'.)6*
M$A45=H9+,;:#I.'F760FE&%=VQ+@PO]H:)692TB,4I E7DW,N\5M/]M[_G%-
MT"Y6G>M+(]U49TPU.\^85(04W<LLI$5R&F]W>Y./=I,_X(1^16Z\1&8TGMQ9
M%DM(4R(7-NJYC%-ZBI3U(&ZQ7=M'0F5:RBD^V$/=9:=XD%UB)<J<?R<JA8CY
MFYJU3)4R428J!#(8-J*V$AN1TR- YF<^2$\XNM>T'G@XE@VV>)_;B,QO)LE[
M)JB8GXLOX*KGF/">_8/*[+_FS4]]$=RKK%I$),,H+2V5=&UDEV)[9I:HZ\#0
M-)!%8[X7)K,I,H@(M(O$H:[*I[>[.6V- NKGRGUZ"N>A>Q=DM2G>V(8X,,<#
M_U0,"WFW[S:.*JD(1;@R+(J(:*:2OA[=!D$%>(V-W1JZ>= -!E=*Z8)=2E)\
M$@"OW:!-=#\%MRPL(EH\L<EQB-WIQ^(S<\'6."_=\31(*N=?/C<Q:$,+EV6P
MS!B"&4\U$AP]F<Z*S59Y)5,S-5"\"W?&4Q6HQ0++_VI$]IN?"M@ZW.^N.9LN
M7%[+S$W_F?,$QM/VB%(Z4KK=R%,VQ.W]I=1[[-G[//R@._F,]IR+&1_T7IF>
M^OBLXE_ATU](%O!O)JZWU5Y"%R84_KFXJONFL?.+#:]\RHM;*&:_21PH#MY+
MERB'G]OB<ZB(N*=O2(6S]#L3D 9>YE)4LD@0QR16&#"GJ;'F0W.!&0&@=B2U
M^UEK6!F/?3[20YG..V+!\TKIH;+W8KW"B?,(8-B#-3$_%^:N2N=ZYJ_D:)Z)
MCU9BXI=,]$XF2RJ9RJ4/]O !,VHM5_T@_'C07",V^SS)>2WE\1R_^O4,>W)L
M"FZ.F6123<F/2J4QS;24DLEW\=7-_14@&@IB^!9YT "M<A'/2#77TUBW\C=6
M1L*'+D7'#A-NQ"K](.*BU]MYYP1UK(5AQ=-5G58$UXQ)O5GFG:>YNB]TME]S
MVNQ2]WC"A-4\,=.-+0FQ.DU%&=A#2BA!JI%V?+3MG( .S,1B[SSOS'_>(9;O
M^O;/7B9YN,7I68^U/$[%(U"[6 4R%"NVYOV\S=_;? .A;;=H!_WZ(S+U2YZJ
MST,G[C>G@$_GC_-TWOHZL[$Y6Q*E0W7+)ZAI7##W7EAHQ8^F/D:[?&%PX3CH
M5_*4D*LB_RV:3-^Y4SYT:^I_86SQ$IQ4TF(A*EW\TZ=H8&9]VR(=D?CVW<UO
M?S559Y_]@*,_=.*!--Y'G)94):5W6;<9=X=[;8[,#V^GJ1'-$QC*<9RHH?,2
MGF]12#4?<M T0,A$3&4DDZAPTMY<J*/A1 B !'3M7:Y+&$347,X@^6[3W1*E
M4HWLBF3 &E!:&)=V2Z&DP<DK'*(&=(S32)S9CK;2+AA"#5\G<8T(_BFV?PI"
MO+=^_. 2RS8+!F'+^"A#]XUZJ&/"SB:YC(HF,@N]^V>J/5.!@N;FJP3A2UH_
MW@CIVZ\WS0\: :G-5*I9@7NGB"V?D2W:;!0C()F;NDV+8BKY3_GVA%JD:?9C
MTHP28X ?J\.I(+4Q4<"ICL/IUBG3I R-J*?44FRG 93CJ-#3FF1:Z^(W.3&S
M=LO.E=\+!?IIF_HZ1?45M#QDSA[T__P"%1X=Q6+=WV,QUZRCK*)OR."5FC(R
M6$789:)E&#R)""W/$%T!FVVUC)L6-$8WI*9LA#*>\'@$Z3S6N WM591<6J6=
M)M!Q!!V@1PM-5.3CKPICXU@=-4149)9 1J19NM,BZITH3OI,:NH;#8:S&\9F
M&#H$S<"'6IQ9K,YL&<T"PK31VFE*4=S8-<]L(55=RRBN5!653KVQKA#('H9D
M-RH_1YAA$*U8S!#KIFD0.@Y8;J>-YIN_"5H*%9;L@3I<\Y[!7@=!D4GSJ_*6
MS/<#KN:%P A1;;;!K!ZK*!;X<+8Q4?A73'57L+@/B1KE87".*()YD261#I#<
MN&V_*8&C4:CD.[7JPN^Z)^%!KQN4^'05#+$[ ?,I/-<+-B[]PQK\:\&2V!I*
MTIF4_LF'0@,-%[KJQ4[.,4W9>3%S\TZZ9I!P$5TESX-(>2,\Q ?LLB$;P#.T
M(I*"V^<_@YD- @VQ1TYI!WV5)NK:0<48&K.93A0L$7A;Q?@?= S. $=GL+3T
M+2<R<=0"2T:I#,^[EH,K#82_M.*D!EQ"4F,X \-,<*(:2LF%RG1,#T#GWIW%
MO9,UEQ+[G> ?A ]-,5B%POH%-9C\TX)&.9CA4L1&.%].!33C9$^=<P@^H;K3
M4QX89<""JR;9-;=C V'-?9=3K 9.9)!&R:2TI5KB 7&9+DVGJ0O."-N>_2\4
M)4P%]H0^7E>"OH"]^XVWR2MPXA9W\V<&EM?MYH>5"Y[@$&%?<$R#U/!5E2"(
M$$QKR #>>CH1]IZ35G<LA&$D8*CB)+=/+A< +0O_*;NP+*JMB\Z]E?%^=PDV
M>^=$%_^L2RQ_?T[..^@$O\%?0(<,%5#C!P.Q_^# ((^NX9?MV_\I0\E'#]%Q
MOW^P[;A_0?'GY834;73[Z#+J\NS+U^#BXMX2^7C-#9]#$+\6<MF6(9IZB',&
M#OM(@]]#^ 1GXMS1+;\A$*8,;[L ?8=S:$!)C@D@&,B OZMCS,E:CX-J/RHY
M(B=BOKX[N,V9<S#@$A-%-0WH-'7I;VG>!QON2F$D5M,&"0+& YU-^GFJJQ/_
M]OGJJKU4;9U.I/U._T[$6[*<HH,AFE[?;2R<5 8[^ T]7(:[/"*TR\-08UKB
M?WJ]XQ#N*.P==3DB:YM<79K H<#8_H^^+\VJ[<\:OOK^03"VYU:@JHC;'B7I
MBJS&&#-A=.(XZ6L=.J-B25R'2!!^D Q9,H %.I:G,L6C>X/\)I-7SX/#4Z&
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MSKRW4 :/=39G\"@!H-<+YDCD+%:^7^KO+US4H8<'@ ^&5]%"O8IM]URE \\
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MR 0P-6 @!,TQ]+%1?."!;=7.X]^'&F)\>,#=2F)84"<7)QC<].S&-9!<9(Q
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M2R?S<QL?=!PARD=3";C4-$+=IT4(57VE, 2A<! +%?)$!,YI[5QQ A \98"
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M2:!RK,!OPK?('%2]($'6(&BY1-&05Y")F0,N1ZDF@R=?Q!3AP8KS.J/I4GK
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M;/_?.',W^$@I 0T0^F__JWNT]TY00@_HK! N=-/\D*^>T:BKC#G8(XGRDL(
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MNY\/O&%>459UG @'MKV7QS;3=Z=%/BJBR2T\)/=\T.L<8]7D-"\3FC9?J)1
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M-#>14UMJTL7D6&NWM171MX%!X [A":0:T;-)P1V'>X3C@ ^%TE*U.)HB#^@
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M(6B:[TS\F=N,\.6% F4CX8I)] U^D<^B%'2/:?@#*H459FI@^P^1ALN(VS9
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M\3.0/W[6X%"O"NR+"%!I"@\,RGJ(4T,4<P$/H_ 1G<U@AHH\\HK(*X.3"[I
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M)P:Q<"J@$QWE$.K4%CPEOFN.X< IQ=OB[3T^KG;F.YC1@&4>/NN&J&7<;S3
MJ06H1F6F&;B.,G990KN-Z0T<GDZ*>!?S)31K-B]*_ROR;)ZT@'\I<"!N38.\
M XS3:1(P$VBWM/#(LEH5DUMYFCG8FMX#=^ '.% BB%W+NX0GI5$14!9WQ%'9
M[3T^WCVVVU;(3F:.,TX(48-Q!JL<H?"E#,<-#QRWVA0_%@THE$[C*[9W]FAW
MAK<3JS2:Z7EKI6W3E^OA*#@+5C5-8C4!;R=.RLV<@OL'V.8I#SZG?&)$)M\
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MTV]"YJJ8TS8)HV #TH"9+T%(4^:9&WT!QB[/KN+C:G,G4<&3:YJR>7)5B.
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MD)SM:3!S-2YUGBSH\<*YY'3P"=A#)2FEXU&'>.R%+O6V?4T3EX,0V][P,N"
M(Q(_X*'_GNZX>7AIF!4D,GT(*2"&'] 1DF^6FSQ8&V J(=T D]?,A2S2I=.#
M3-=(H654ONG!_-L\-P(7D#Z"NQFP&/&9%LA"3,.93\6&QT0Q7""PO"_"'PA7
M+4C[0D@KG#%^A^9JIY>@C?<U1.\WFA;(^C=%X@CNS1G?2$BZE?PPF$Q2G"=U
MXDZ4?"+B-9Q$7&! N$JCK"<0W5;XEDM0,$=AD & IY=$2\0&J"UTCK-IZ5%R
MST-VXMSED[Y,Q.I3P><]P3EYW(T94*>T)+2 "M.ZBO<Z+]=;_QZ3U:.H_)9=
MO%Z/,J/DUN<9^=%RVAZ;X-M@2W,<1&ZNC)\3$8<_OL=FGS]1J4M<_AYJK4X^
M/'1/Y176(O1'G+63IJ-UXO(K>W0F-[B#)38[T.48L7COH#=$HYT=&^AN%D7R
MR)OP'#P7:W"B&;\\:8-D&@T3A6B)TJ=S<4>)[TDX";4ZE,0L-Q0 3;&9+VZH
MI)E&ID_F35"1C,0C""Z8N%Y$";W/;$_B4T1-EJ+T*&OU^+8TV-<Q^I>2D-)B
M@9%7]#QE'<A+?5 ? _A/ZH+Z<OWP,?5!73_<<"=+I]74-;G\3V7']Q9'D20Y
M8LZBYPHM*8W]\1/B3AMT0:%K:*Y9S"L/^(*.6G124%@GFGO8LGXSR;7&6W9B
MWA5O3XA?0:N2_35CU+\8V] \9[E.6=>R11]7:>LB? L\,63P<#_"3,OU2^-%
M L6"-,JVIPXVU.MGP.(77,>2=_...O"603+E;\GK.*V9[W '$JXV:=?$>/NJ
MA%94:#F7UY\M)Y/GB1\*&TB%$;O4_COM=9+6G_%/"P2X5-J6LS_PR1Q"M.PT
ME9KAI^';NLC67EYJ%9'9%%+OAK1.H4AYWB UB$5')+*+C]K<G4O42"]'VG(2
MY8O*))ZH3WT6#64H4_%& R%VJ?T/KPLL?Q3[Y44+36=S?$B6#B*0>U_H).:^
MGF3\_"+M(.UEFGR>]Q<M/>7<@?&6683A7PYU#,^UU8'WD229Q>. "N)(9B3<
M)5!)"TE*+A<7_<+M[#5K2+O(IP".V7#,U6+4&;+$KSP%\-4O6/[G1&DI^)R*
MG2LCP+9?W">5[](U)P/_"=8N:1RX'!Y1IQ;O:9B;=#+@] DQ?DYG\_+7HRBY
MQ36GF-#>"7J\YS[CW.>/FF&\*%_K!?N9,]/GFDGF9P+HVA=8J^?"7VZ1C#ZO
M6?TZ^\6>!L$L?*S0USR-1R R*/4\:92>.O]16.:6N8CS>8Q[+,I7;BV^9>:#
M7<9!BX6TA4[4[QK?[KY&8HX#W894^%*K@ISK#/[,KK,HTV*OUTQA+G;7@)\=
M9\N+N<UKN=T?G5(]=_-0AS%>1\ZKM:DC!/8\3*Q![OU.^Q^*\O Y:N0;@6>*
M3TXT8Y'A<S"!C_X[\.8:J3OIP&J>K"J^,PC0O8\^."9:SCH\2;+4+Y>/>!)3
M<YVFK!Z,5Z#Q2O47M NX-W1N!X46W[D0Z\+FJ<83U9JD$1U<KJ#C4O*6R'U"
MUM"31HE^_EG)9AUM.(OB *=W\/0?>.K8F_)K.M%Y84D+#[W4;D?+EJDRDRIF
M)O549I(<:SET9E*K-#/)?J-+:9L&1?Q*[3M+VN,FBB'/P%\BMD4TDO?N3L41
MB3:>&,%+ND5WX;E\B'RK;[K^22XY^:H$!S,PX1.@!PW@I/F1%0-*&RU4E/L6
M5CH7PQ)+GELF-AG@Z>U\1D4:>\/_=R;!XRLYUH4Z)EZ<[0W,;KRSJ+-S2*8O
M3^:E]7#GQC3T>/<E>II.11M)OUY=XT@7[DP1 8>%3++4DP(E>7X(+RE:L+D*
M1,D1+QK"_9I8@]UF=X$XBU>^$_'Q)XGQDGMNWEF1?E^T_)WOE8SWLH\/"UGI
M4H0644;/PCV&O1O0 HJ*7H$5:TW+38#NN<E5:Y R7R(14%K3TE<LHS%/S6IC
M=>!WP2%4FG8CXJ\B/^A&+ &T=?P6?/Y]6:>7!\:2Z3JZUIB;]I!3PK!Q9_)X
MO<$[.@?D0$\;V.[2ED7LXWO&04N]XL7<3OC9<2KYR>GEMGW,VGW.J9-(;NH7
ME5,X@P%OV$&I @&YW4"2/7DH'(L2VJ/O"M@1YE!Z\NI$XM6TO9JH]\KY1O)L
MEYNX)/)5R&_Y:SA&7LLQ8V$)7%T?SC-6LIMHGKG%?<@7,PK0BXF29X2O ]D[
MC:ZT=][[1'=_3=9,3WX7O5^4'!_@TXL?7]:1/FO\2D^CK\)WLU9A/)T@DU+4
MJ P_]OP^+5PL_U#B(=CXU2@JWL%C4S3,@^$=GB+L-D^Y")X59=9,^:OF'?F!
M/\DN7N[<?F872&:02RZ;)".&Q+'AF[D[&. VX(6$I9.5\)I)AC', XI_'0\C
MGB3^L$4,E65)P?>(J".4Q$DEB#AC<@#E1EWG;ZS1QL 3D?NH.%E"=!!+N^[/
M]X^CBX4"5N7S#^@P4E5JB;J7ZXF^ (6%VB2<.$"$GR=KDCM32# 0L0+1',^=
M7SK7AUZ%?>Q3AJE/C6!<4?:$G=%T/!\>?DEKMPL G\<5&<T)1PCG=$ #T J,
M@2H85SHI-0I=;IL0;*&0-TLS6W8449IH[/CYENU8\BT\?YP/2G:2$\E.)I4)
M:7.%X25L3PV,HGQ9<Y)EF+;Q6+?5 L,OPU"4BH#CBZS<SEU2O''4;!+C"*)E
M0G.>?9^ JQ,>7C<J9CU#<].6RLR6\C:E-VZ U20(F_/TC(.7)8"9PTHVOG7-
M*^;[<>:"&DLGL^!5B:W-DKA%1K%LP@$R_]")>/*FF%!#XI32]?*93O!=1AT+
M]5S9GI-F6/+;(@F"XM+2@ UWZCUB 0&V-1/S^):U]MQ(-"R*.&P+P6<"INQ!
MI=)@KWF\3AV73Q,7*9T>_@$W"IHT_%*B%&&42ZF,R9(: W)'4N[JA)58SDN6
MN"A@%TSTORGI,6E?F6\H():$=Z98S6;W W''8-5%P"_F76^!HQ,[(VKWPL<%
M+8GB8$B/U!G,R)TF':7F.]ER3TQZ["F%1!;Z,JUO[M;/Y-_2*&_*ALN/H'C5
M)-NC>R3_ XQ<"ITJ+'R<I3Z#] <HFT3SB)FH=$DBM^EZQ(>YQI^.(4T;/W)/
MDDCI35/TT7)9$.<B<!;-R6CN!:'/^<*KDXS?>AK0.6PB$O+1YW5?S-^IF7@@
MQT91@A## "NEG^-;RKN91--=6';6 BB5)I3"/ LQ!"+&@O&#Y]-F<BX*>FIV
MS*MUL4QZXM>$-TV8C/R]L!42K(M3QM(-Y5J6\_KWXK-RY.,B?>+D[@TD6%;W
MG?/O+9%IQR9&KF.1MYOHDHG>/^>MY<TLA9>LJ*G/,T!V;'F\9@4!J=+N40Y_
M9I'!JP>,0P96@-G]MZ-2J\V9C[&E5Q"F$H&DXQDAZ+8-<$BMP'*6E9]M@%<'
M>E$A3:L$F7\4#92Y@6,Y;]VB' XHZ%;FP,S/MT.'2%9+D%,MB V?TU* K&D>
MOG8E(7F-1JZ,ASR.R>/F"W@T 05L8IV 8)&O%L7[Q3R+9MK2*P\<TMN3EA,Y
M!*2$RV61;$.DM&DWM9Y.M;JY^A.N2--R)TG',:XI\#CI,CF!:TK8.I'6E&T\
M*3$&N=K%EY7VV5C((0VX)XQZ4Z#U!#)P.+Z837E%9*)KD_8D)D+.B4YJ#XH]
M'O,3LN<^L>@M2&F)E4 "FD(^XNFDZ\0"NB2I:XDFL4B(XN6-*CGU=N7#]/!]
M/GOD.SW4/HY-^):G B2&#0U_N.#N@C!XY?E8^2GJN:[%)=Z3N8S0"3*'*'M,
M;!LGKTZYZ.E/M$'.R\P-,($(U828/?'LMR2E,UV/X*J2D?)%_Y_PMTVH/!G6
M@M[05+5+N%.,O.""&^A#3M#T4\NU)#%KKYC2R9?*VP932FZF?Z0_2C4E>B4E
M?? .WZE7 B-B;F&C2UH1)Z]<0/6R'!;5V*5J^H315/D3<JSET/D3=FG^1'M%
MM@+&!H__,D#7U44TY@J%]S28A5'2ROF%+0I<TD/2BX"$9R[@EI>VY66V);9U
M%K&X25;"-?7\6D2^ONBAGO<XK[W72V3@O,RK-EL7"?41+T"4U'#'T4/NR,*Y
M]K%A';HOGAEV@XX6LTB/<](NMF"[H"UK^3T?FTHT9_\G]>#4C5-H0L/<YLBW
M*;HW1&G_DNPG:9,1<IM3;;C >:(_SBE)F9OT$1@ !!XJO,76P(Y(Y%P,?8?N
M7!D[+W%=MG+^D'R^=DZU$5_(V:FX-)QVO79#Q.RY$?0YUSTWNN9MLCG+/&]H
MX\2N]"%S%GTR!VWN.<[*Y><-^'F*)Y5 7-$2!D4VE"'5]=(^R&4^'Y><R7/(
M26,"%!J>[U*-1Y(TAJ:#YM AX1HE$^$6AIYGM1-FT^AIGY.6(<1VVGTR10[E
MB?:N\?GA_K[Q/M=4Z./$ 1@\#,<!*;?3U&["#U"\.DW9G8OY).TZDDY%2_IN
MYT F<)5E)Y4,GAM0,\.Y0%.2+^WYZ#7WXZR69V[N>JXTERSZXK,3I^?FYY%-
M/Q9'@WG'"^;+<!)$<Z'I^3-!0RCPDY,5-7#"6J437NB]E,_"@O^-F*@5YC,/
M7[GU 28]7*J$BC(&SFJ(\T6B(G)5-E>L4/N3B]3E1%8X)\-2NH:$G**/J<Z"
M"]! 0!3[-S3X</CZ([/Q([@TZ9\B77QI<I9]C'>GV+>6;/S8[LSK\I)- !]"
M">?K\,(BN&PBS_6H[1&_#3@X&8_AH%4\$6,O,1G4?_;"P.=C1UXH^92^L_ Q
M3_ T" SAB$M^I6>Z9%I"EBW&1>TOY.(\2:)9+"E-*OWF^L*Y(G1(M674U4S<
MM]F4K/G7XJV'?KM'MO@F-YMD0%6KI:.NEZTJ[P+#-0F-@+N_Z+$9PRQW"FXP
MM5*4T;W#TJOW:V8:S@\AI5@603O=>'[5I9,8\Y[P=1,5\X[9DKF*"^)OR5S%
M&@48\%.N. S &^ U1E1?.=JOU6P?H]SZSM",R;<?F-^S=J%=\T;NQR;1;GWM
M&\XJ&@#\S*9I<:\;-E&@;LA99WKKHMG1M0?& ZW?4Y50M*\TN\WWVFUN\!'*
M(/XI,4V:?_&3%Z&*04I TK(A?4+2MR$=H!FXO/1*I+>(;XI\$=*Z.-.+9)U4
M%0BS%T?\Q4)F (A]EW],,-B,=S!-TGT6WD2S5K( F'A89B^EX14>1 (E(ZVB
M3QW\H+Z/<FTY/[$A+^']P_D)1'_7N+G[](>H[TQ%@E _<NHW<_.QU&0AV+O.
MBU/)4MBDB!/PO<WOBQRW)':2AZ'S.<(*UB+YTF;OT3#TTO ES3+![I7<KPEZ
M7-H^G<^1GEM+^3)(P&.B)S_5I!([T3R!-B*LA$0'D9NJQ$E^%'UD%@F4+!(+
M<YB*],*\ R 7W0F4+T!)7,EG%N+4V$N=H@#TQB#+X@4$!F"/X'WTU8GBPI:3
M'2<P 8MG /*&9[:^:J)_16Y>0PG=!9KHM.:QF1*4^MWEN)33"SY/98;YG>6_
M#%M/^0YA@]U[."M@[FTZNX*G@ON4UB)&]V6]X,G7F]94:X:M"QG"L8R3:I_2
MKPE(CSQL22\*J]<]JG6I?2:F2F=2>-1#[\F+:73@_S!10RJF:,2XC4ATAJ&U
MX]3NW"LQYLK<[#WIH-OL46F[V/RC0A:'09*-">L9B<@'[PI9&&JXJ@<)\:@8
M%N 'R>0-Q/0L+!-<^0P@WC I'5&0 B!_L.4=47C=B54BP3>.Y1W3;0S;U?X7
MM*CCO953B*Z[E7M:(]]*2%S($78+>7]5N)*SC^:OX@9O8S!-O \Y$3UWM2[V
MFM#3R>$4Q%N8PA!R(8E57V I92._Y[I;8+_6R[GM%.0/,L92&30_7 ?$!GF\
MV;S4R(F,O'L"DQG)A,)B/>%Z2\R4=/QP8HRD50Q<3+J9<*"8 +&=X.(Y);VL
M%U".7^O4RD%6(DVB>Q:27WZI$MXIJ>SJ'&=EUS?@\J]XE\.F-=KUL3'[1R>"
MHT6;CW02'(K,PT\XVSKO;\M/ L7!>MXSUTO2KRZ.[\I_6PR-21KQ\!7AE2(,
M=G]&T@9U)>Z>77Q[,(L)\4G%3)8;,L]4J2KFC2[$["12QRBID>Y-=+NRN2DL
MQ0%G?/6XU_+E;KA(UYL0N8K4O03YM^QW21ISM" )DKMZM,0TSR]D*NH/7BC2
MF)O5-4U<V MKQ]H3,:LYVUS!99M(Z&Q1XL,TNX9<Z=/ 7TW; 1LZ,S[8!\MB
MN'CCJ7P#5'EC[X+H1H4GRSO7)'2[U!ZH/PY^1N575,VO,%1^A1QK.71^Q:I,
MBLZ:3(HWZRV;)&.A,R"5FXFC8MF(=YWR+H?<F"X3NHD8)-GK""],!*I-7E1Q
M9\6+%S$ME4Z9%,P_@B0<]UGG15G20"@M5TFK56I.B<",ZMF$W8VNX1G)ZQ_2
M<?.?Q5N_A,'3#=UQ/&=BM*B^E2AN529GR*+?H'+ 59(!FP0O6:/1]/0FK]F1
M1BF=*-]O,5T\C<]F-]OR.SZ#3X!#D:-@V2WWCGKJYZYO-'K 'D!=G4/J_=4F
M:J4]/Y$TO5N$19_<5R'(G M*RIE&["KYRP>P"J83Y_7*\XF(]*4/XNGBDL,7
MT#1*H(-X";V/_UJ(^U[OLM/LH,2/0_B?F[Q87 :7<"B_%7_>-B_-EE7ZJ^:E
M4?KS98\RFI=MJ_Q7RQZU_.>V=>J+6OWRW^@0^4$"5!"$_]FP&IEJX**V>]74
M#.#PW^8_9MB%SYG37_C)(DP7<<4A5;?,Z"Z(C()11ZI*WC^7\EWL[D:,[&."
M TE03K$/#=CJ6K*IHR(4^B[G"+3#AL^):)8B6G6BF558<> ,?SZ& >C7%V*%
MPR$#C7K5KB=L5+S>@NGA]99DQ\)B7@H6L]IVFUK)IFGTWF%.>L.-+QU8S%6A
MPLSB5GYF<7-1'=Y1";ZF[AF;33EN9HIRK]$W3-TR#;W7;"X9=KQXK!612X?9
MW/0HEXN(=:\K%3$*>8@\6S[D&4V%O#- 7EM"Y!D2(J^REC"B_SL>+>&AS/W.
M?F&U:%3(@M].DR@AR8ER54="KC(;?:NEMXRV;EF=7;FJ'-U[D^<+KZLLS\\'
M>5T)D6>!#6+I;;.M&X:MD'>BR.M)B+P6:!(=O=7MZ$9;%N2=O+]AK2:!F<21
MIWW^:X;IH[S&5KDF5C%7NRDA<]D@UDV]95EZM]F31$U7!F+=R#,.C;R1]XNY
M%W^S,"@#7;O1I\0=\X-"W(DBSI0+<1W9$*=<$4DNHO)"K&0D2T*EH=OH6Z T
MM#NZU=[9MZ=L04F1)V$DS>@IY)T!\@X>25NI/)C-VI0'Y7W8###? O]BOOR
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M-WTOY]\E'U!A"BXNL6+,IY_QM=!U93-F1/X@&^ F*:JT@BTOT8>3O08I[R;
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MNDB>_[7;KAYUII0 @02#V0-(J'_[19\6W>1F,U$M-!.UK6;BF="4&P#(&F9
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MC+OOA#P"A?ZPEX0"#Y;$J(,PP[F<(M_06N3\;?45%C-GE)0IUQUA/OL3&ST
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M%[U4TQ'K;%(6J6")#K18XK-T7/\.]85KT9I"@0>"A.>(+83:DA3":$5@12&
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MV7K\A$E.B8;+$QP?#C37;93&,YK7BB81JA@F%EF"U0&6@[D *X+8M.=S<;_
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MH5)?4]&6,%K".%?_BB,01N-::MZ"\;!=!_R.$ZOVRN MF]I_X=11BC@(BCA
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M' 3^<M 1+S1 %'A&-CHT3 :'[K2L);7!?DJ'@NQ@=6<XY/G%A:)XD!9;4]B
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MZ7<'G__E=R08Z3UH4PZH%D#$U'4@W"7W (@MD". PRGE$TB#IVIWG R-9H)
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M+J[)>P6*%X=I(%%.>)6&*Z$&5$^G%>YIH543IBU/*$I&;HIZJ:;;?H8K5&_
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M;M2%Z_DE_SGP+&6B%G[5ZRJ%GV]:2AEU)X-^I:4V?SX8UK2I87>D#9JVJ1$
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MD<?#B=SOYSUCW/'BE5*W4!;J\SE_!$7:LT  3 M>!^Y\"2)$"M;X9V4@J3N
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M+WTU/T11\OX$U #=A#&_*R&* D!785<R#D_3V]Z"D\Z29HGHP<_N_P<L_+!
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MX_9H$VYW<\9\>9\$;0A[V%-#[;SS83R^P"[+OPGB]H!4GH%DN;_*]&ZNC?)
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M*Q37G; BN/$IAJJ)S\7VF'DE5(M'V-Q-8#CQ*&%))G<XLPQN3/Y\+%@W?MK
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M##'%PL4C(@EH!.4ZIB+SPH*]PM51(.&V$ J36%P@JYCG(<+G4VJ"^CJ?@/H
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MZO!LN2=VI&,[\/)(HI.H^-1X<@D[,Q+)<Q*S)&9)S%I'%4O,*D>HML0LB5F
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M%:,!;Y0$RUD*VGJK3;B\,G4:,YK'0H0ES.)"CJN/?5:7[!F.YK/U3Q:+N%C
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MT+GTR:?I(^^/RI5VT27.+Y9N4+2/R+V&G&OO@EHFYT/.X)*U*1191/-.@)<
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M5938R=>^QZ"[,,7^(%JG4X%TJ'=6E[V^Q(+3*6Z_]'7@;.!HBJ_]V&N_-F;
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M7]_*N/0^/B&Y!INU#8M3.HNVT@<8UCU':F1/6\RSU;55ZU$&-@B,NG P3E!
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M,+;[XY\G9PZDC@[*^1\$/?OA^<S;F_ST%<>I/\'<,QYE"<H"3]&#BM9 3*6
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M;VQ=E]1V!8=*^#T*=^\=(L=3_K&3BQOIX<=OJ[]@%O4M)5H?R,?BMM@Z)-)
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MVN9=UMYV(:,J(3+7NG5,TP7L>VBT #,/)[.LR=ZA4U1+4SN>,@TN2P:"/."
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M<)JYE#;+V-R".'M"?E[<.J3^[M//=D*_G[[B./4G.#/YKWYXA9GWHLY.2^V
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M6BV]U\"9K&Y3J#:LD."<]>B=%=8VF9W6M0(?F([65G_;"*RQWGXE25U<7BR
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MN>B0M.6A^.[68>TX^U!^^Z-':X$.$-6_FO9==)7WY^5Z(8R\(MVE(B&Q6'/
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MTAI6P- <"6(M:!*T>0F970DU\<!W*OGL<;W7 =8+ORL92H$#Y-<] W&UNKJ
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M_B#=0\AX_\%#-'0,Q( J7, ])&3D>RC(/Z5&O/5$O >@X*'B4[&)W7^D8/"
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M',;R-7Q&^YY^RS[HL,4V/NF;<PUF?\LW2(]0B!+H W=2>*/BM0VTZZY@2Y[
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M?+C+)F&[A.% 7H+=NX;A'M"<\)QKQK0F]5U,=I3Z+(F7?O>5LS4 $RD426<
M%95 0105/3L<T'N1T7BY-AD"7F7U=ZYWBK>Z:*@[V/_X*9.?'2,OY%#ER9=9
M[.6':YQ(V^\+FY0C\C(M2'L$'5<;.:2O-%8C[E_-R?$+YQM98'6HG;Z.G<2G
MY!ZBGE&E7[604=P@+=<JWD?2=O[DD!KHQ _^Y%B6.2_HA>=#0E=36QO%&%+"
MK<KC]V3Z54N#>=N!@4\ :5IBJN*U5?>/^;/5SP7/6Q5Q1IOEISP8"W,25P5
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M\=-?DJOXJY@22S?L"$N'Z(V%^3<C3,WJ'Q[Z2ZD 0DWB < P"YEO>M#J>3C
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M B-R$HYY^A*<WXA'_,95_4/+-:QY"R8&*]R$ TY7H'MW0[89C2*_$?Z%(=0
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M45B"#^X1!M[<^,(!DN@3OW=K/:0'<[\/J-YV!9,?DAF//6UDEV5$">=BZE\
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M<*.LG6 RKOBB+0O.B4_!XWW+77TUJ ;-/B^(\IH@4TTMVG-*J/$[ASR;[1(
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MN@,B?QP%1OP": **_++QF+O"(GM::G-AOO8594 !4)^/:U_D3SI[(S!\#\J
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M@!;U-P@T.-F]*C#I2NBYJ;Q1/PX6&*R>\_O3!W[!P!3U;RKW# D6ZU?SA7\
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MLBI;4)SP@-5CV9V42P"![.^ ^+U)Z5S9%7-0L8)U0+MVSB5@:#=@CN^"XD^
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M+FIP9^R]!U137;3ONQ$D-(WT3E104 2D"4H)BH"(2+'00:6#@(KT0 2D2(N
M@( 2%*5(B2B]13H(2.\E)""]))002'M\9]S[WCWGOGM>.6.\=^X=K)$?(V/,
M?S9K[KG77&NNG4(?H\\"IV[KZNL"#(?M-L-M *!/ MH X[%C_SP.&]/AXSC+
M\>-,3,?90"!F%@XV#@YV-G;V$R>Y3ITXR7F2G?T4WRE.;AY>7EX.,+\ 'X\
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M+L,DS(@.T0$GN;B'</XZF:<#_EX/,CM&RY;\;?Z\V-\!Q__:X9)3O\S#0'P
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MZS;NYYR/SS7N>'P1% D3R)V-9OESE_VE-[Q1K8S=/^[ *[Z\2\/Z1*?_LC!
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M5I>F=9-$ ]+@+)0UI+>!=\ 'Q>\J9/O5BXBZ,K*RSG5SVD]1]GZ60A&X+P;
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M3?^[P&MSI,*-&%)A(QU@Y)^S6S.9)3QA"KDP$#+M_77*V=6)/WGC=>6C68[
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M@R:[?ZY<^_;JK)GO1'MR9\+EL;VW,0<Q;;]/7/D]\V?D7-C$C'*,U-O')CS
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MZJZ@N<,IC^(JY1WGA*+%H3ING+"!2X9[9OPUG%2.;4D/-P"JEC"+"6EN8""
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M%P=?1[@-4A)+)#T3/3@4C')O'3#8/BWM3Y!;^?&PIOZ LV?S15:!CJ.+IM0
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M*NQ-=43OA>M+EAZEX:=(@+$1Y#M#DYM@'/^NHPVV*=NSQH$M=K6<K1JX""S
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MZ";'ENR-2"GP\8=NRP2'*_ 5Y"H9"9A+RP^"-UU1Q4L2:(PF_>U#?^,W_C-
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M1C619/TJ.Y:;TBP+/.ESK/M_RHZ'4DSSM'<Q#RP=L/LRK8P>^;35I+<N3R7
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MWTZINE=<#,-,66- 3>O:AB\%7$\?HBN,C1KS#GL/<AT>*\#=-IPP1#Q(UI
M-/W(52LB#EQ7T-NQCWHC\VV]X1)A.,NV(,PK-'%H6/&*Q\LY*ZY#>5K'D02Z
M8'#I3(//SF6+G%;JT_?<F)KYA9V=D 8$Y3U9>P79-'-E74C;K;/!$QBU?$-=
M@WS_,,>G$Q94%U373XZ?C'@G-"94\@I50V7V)P;'ZFOO=HN\_[[VKAT*"8YN
M11"W3"P"7^YO\W4G6QN^RAL>!W?!-*#W$$_-7(@=YIX7#S8NJF89Q]("?+G/
M;UGB-!.52TH/;@[T%U^?LIRD%!,NUU.'5S4QK#DM)A1:X/5^L'.^:'M(<F5&
M+BHKN=WR0^1TR'*QD)6*BZ23@=!:?4RI1SDJDG!\=7+2/%QF)!F!QGL*V9]
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MG;2==0&AA>UD&,!,+\QA@GR01\-6*WNW5%;Z^*3TC)-X0;;4"W0,$P'N-4%
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M_"_LR:A<@2JY$5+8GDH9,#_5X[BL*3*3^3@7EA-N!BA O)6R2VQY:H[WU.4
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MG,20@)G"9IBJS85-D!"J$6DU#A+@A;<T6=<4\T*P2E--0PY+*=%X1BZS;J+
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M1L^E^L"66B/8@T9V*,L#32Q_CKQ3:Z(NT?PG1QC16M>J"/=PQB_GLKPK]VM
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MR<+73SH&?E7=H@V^1R_*L?A5'6W<],D7^@XK^:*ZFLK$@"?X'L)>@&6=<">
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M<]_$X5(ACJQ9 M9V*0I5N2$K$NJ"2M8L)>+-#(!G! <B:$B9R/C\0]OQTVN
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MCP4ZB?'CG-:K):NE2TQT!:./HY@21%-XN225YYUA(4O6[ /?8J7A+1 RX6A
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M')+&76ZC%1[G1W6\U10S=2&&2[_Q^+ IGEIX2''R$J'EL][83O-840"3]ED
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MG9,L'?DP:>WS7A>?T.5\W"7^#&WG0Q!]Q01KM5DX-Z;E"RJJ1#+$*/?5.!>
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M 'F2F!1&1J^M]M+;613-S;V\.T![QS7W1H_*$)]!,UA^;=2^.\[8XTK7EK:
M+27E5GUM>K>XTO8O9/PO_]P'0OYQ .!?S?^,9C^/@G\8L#13CS/IT3*\2UGG
M5=WZ*Z^$,#_QMT$JV@"1NV_.@J*ZS;-+52]2K*+H[H,>L^OY'K<P7E_KLM"U
MOH/+\'0'JADKV>">9AA9 P2?_ES02G)-S 9U><R+\NS8UE:'PC?9K.VMH+%-
MXFQ\+I(V'4(\"'?3V4H&*GI=/T[/E?JB97?=8@0/:Q$:O)Z#?GW0JAK]*WEI
M_C@2C%)I%- Y\")';]?KHDU@/S%ZB J^?L\51\:1I_URNKC5 1\!@:)'+"08
ML5(TC5P\OHAAW\9>E:?P<[.E)*RK9C[7D!MU)9@%EOKZC=^I?O4DPR$-UF>V
MI-!$+HG']_U<))--S]RX3,@DC/>-_,QW V-3U*RFMR*DHLRYK(R>N-8G=G(K
M?:?249T0N2&ECM2H@=9\S'!G;U4-SM$),;P#_(4K*_TE+2Z[];6#'#S_(X*M
MBZ>NX"[[[]_GS7^Y/25P:I;!681H''BB1L3R75LVP^";#QBN'TZ: <N2/'UC
M>"ZU+T[85Y_P:PB &]S)MDTGVH.!F%EI(]LR+_U<(GA GUXGG@8/*4EG$B/.
MJKCF@ N%+"06ZECAMP.,B=2TRQ1*A$&/9%71IOK<A68)%=J$N\70P$765&V7
M#+O?9'"+OAFT?X7]+*>F&$C2=TJEPWEZV8!0<-A%$[C:ZL?F]FPB/]JM'!O[
M +19%9?-J?D0I*_!?#]IE>-C+UDCUTHFLZ;T7+-=^F@'1\S;W4+%G5E4BM.*
MXD389=E*E^6V!9UY<@J"P>1<-#8C6>F=2"BMN?R$;@V&9_./P!$K[WCX>#D0
M%,6A<]Q_?)/:=OIG!G"&%;Q2NE[[0V<[X#S^%41PJ@VOFBS)/:F5"26LI4UJ
MB3>-.P(*+K9)*?1?((I[0DM'=X GW#L(U@._JS+X^.T$>@'DL%SUU9Y4$JF:
M<Y/>UO&7=-W9:N/J[X[JQTM?L6J[=OKR(*S?E1G/'*-_=8GD&FB=VY-<>I+3
MJQE)/Q9\KC:,3E*89'9[U!K] I\DB2I8 L>*27"@S;.C-B<2T0Y%D9PJ,)AR
M\[:UCK;V&UEXD3EN^AD4H$-)3'H796:_!N4IL5=T'[HPX+A_DAM[\X)U5U>:
M"K8BW^EG,F_?K.6S\6GHQ%29;B$*.PF?";##0V_$_3T^SB&H9V;A#%R=PJ.Q
M;S58#B3S29_JOGWBGR68NO[L);Y>RJK9CWM]+Y,S^;>71*G;@OQA01^:@R*.
M#_/KV]I;_/.(A_0F<5D90C8HKO9OILQO_@)+H^BR[E-TOYIOO29ICZM,XQ/.
M4\)LWZX>-^'Y.X".:J5BR12(B-]W(,U\9.6@_<6ND7\1T;7@J('^W+LQ,AS-
MA#R!OWW9W>&^"ELG.3_,B09/]J\XL_L+&=$B@G?'M/;-3__RN)E/JFC\RI%;
M&RWT_YV05T-\X15!"LC ,J\++@=JBE ;YS=-^/C;Q<]X5LJTM(NXDQ8X;A'Z
M!Y5^%#^JV1Z\$!<7/=7LHKT#P-C0->XEII"3)YK^R3=;;YON #\CZH#X*R!Z
M< 1$P1]$WE1K%=;6KFOS\I>2C+(-)OS][=A( !A.H@'OGG$V<WKE2(L - +S
MKNM/]%Q9S"M",^(JEZ"%:XFCF[_@8X7_,%5?L^;_1[F\+!/]$=;4:K8^HJD*
MY88^S/WR*Q+;K?HMP6%2(\8^Y]]/!OJ>7/WE[!HFHN!6=3/#?C3_^HA:%S--
M8]T,CKWTG+IXO-A*'97>1KSPR<5%Y>T_6A.5EJ&%E2C&/I>C&BJ/_\=2J#+D
M/\J!+YC^%?"O@'\%_"O@7P'_Y  &R=DJ\+==,;^XB7=@$(/J]7T-P Y>A26:
M#'X_!X6GD;W7+_%-0&5SD'+]/J,U,P&M[/B<%.JA]AP[$MB01N_A^G+V%U/7
MCHS?',OU\V5S)7#) &[SH./IP-9/3:Z3'#_4'KQ47J HPH(X&8RZ ["*<8[F
M^H]0:IEW??NO6"/JF6EO^<L('<%GIU=7%(A:];]WTV5R<6<DO,XDOA@QS@T&
MRJ&_ED,LT#'PA'O[+,A"OKH[ %I15/:0A?/:C2!PZC)0?4EQK&6.9*[ OS+1
MUATU#!O-*X0H(:6S&4.WUA7X$C@*WPOU1TA0:#YG^D""^':[+<UHD#_'A6*5
M0\E&20,_H95Z/\("++EF;9I31_CR4EY6"PJ)O7 CA?U<?(J]G1,O6YL0'DB,
M)GJ#.NYIXH?0P9D(M#U2%V_M6;->1U<P?&3Z@2\C'#8>EGY6]9'Y?NM-;CO6
MCK8<MSWP2?KJL%EUTHN7<MZ;D5C-GP2.VE"9I['ZS"770)]M>/A,14?O&DM?
M"=J!(-5K_$R-',0TS(7[*LG6U31L -C+K-2QM-0'PG&1I^\A=B!GC064?GL+
MP'N!"X#LEOM<([RC6[G$PBW1;YMEHXX?/_>6/%C,5.S&?5=?](* ;3V)DL(@
MH6W\#Z9WRT9ZK1'<,MJ94]5_7N;+N;_ P<IL7=ZW 7YK]B5D_JW!NW^61Y>>
M:( VR4.5MFGGCR8@<6:X=A[;$Z[W ^LD(AE>+]OJ;=,#IZ=\6; P;]Q#AYVS
M7&>W'M^ >F3?&36@:WM107Y#SS'Y [<CQBQ4LG99#/#++@LJHR7CP0+S+E<'
MBM4MO??9P@)2:<P9$HP(UFQ0SDTDYQ**WR3R^K=\QZ:(_-],.*H+(DOD>:HT
M2FL[_E!]R(CJ>-D7[2PQ3_ I<"$WF@>14/2?]_<OYJ]Z,E7NS+?M5-W%H'JX
M4RH4)*=2ES+_<"X>8XEN*D'S]Z9*>J5LP"P?+ON6M 2J8,DTTB&R%=Y"GJ K
MRO<M'M!/Z;79']8_N#7EC:L19_C,_ZV3E>F$NV@ '/F[&Y1>]'$!GJ8&?HK=
M0IK)C;MT?NMYXO-KR*<<NRJLN;;V*&GV#I XQM7T$B7S8Z#?2S(GS*+7*W_0
MKF'2E$J:O)IB**!+FZ<'B&=W@AZ&4VVU02!3=NI3R:OV!$MHLB]W@$X%SQQ\
M"C)R"%OKN/&%%"BCL D:*TRR7,P6/JK,T-3G*4L 9%!''FMVJ)455U8Z;^A;
MX4OIZ3(29VOJZ.<9"):%5[#[L'O?\@1] 8G1C!_RB;3PM!3S%=5"T[?(SG54
M*&H';O?)$]%ZI4^K2E1X_[:S4$% ^KA7]OX!1@ZQ!*80W>\F1R2!M&B!(([G
MF(7UMP ?&6[-.'.B5E31!T2,1I1Z $C\*^LSRN;UB#>:=!LLW6WWHD^W@[\_
MU2W, ]MW5+E)4*4?0;1*?91,)A[YGI-PGXQ2NM(E^1@9N X"* 3\F%/.Q;H9
M:*9N&79<?L8Q7*ESS-+*2M62W1 V7\99:U=^_WRN3T>Y=_H#DTT78*\7>^P)
M[HW2V?!NU%*@.N/HTCVN\R?15F8^Z5\\7'>:$$'Q?!DK31*7)LU.^9OYE.K(
MW_)6Y__:PU0EAKY"Y#R$R"#I9B \>7%6;ZY57^V-MY816S^W?OKAX4^M'3%W
M,_Z>FR M%$V8A[J\236]8HVO0ZVFY8(.@W=W]HL=%U^ZKJW:;=,C)HVBB$R[
M9XJ9%4L!'B>2DG @-[JVY[=&&#"\#)W*0K(*2CU96#25>C?Q5?68.42-[,LG
MF3Y/O_XRI^_V8LTI!]GJ69EDKM)?.!WM"KZL^P% 78=G=X"(G :1B;TE41\^
M#P)JKG>6U2*)3<]*T:N$@OK7^6+F2E14UI,;<4TY\F78<JKFJS^2BI@6#6IW
MVS.R- \VD;8Z:$%8FZ;F]'G4N5AKT\-\+UAK<;"IM?,V[UI\=YLY?)6GV)PN
M3R77-2)>@;A<!E]D!V&(T'U!I?OVZ0ZN9-T'*O'B :LT\JB2Z KN<Y;66P4I
M)N:>U^EPD!0#2,794.1$CC!/M>>[)=ZOP'JW:.[1]\M9\P:C:PU>'V'NZS<,
MYBC<R@)OF8*U!:>\J2)#[ZMHHY2%Q.Y8A2Y"C2#ZWQPE('J^'#@)4(U)NW])
M^T<RP^$1W,C*T4VH'%\TQ=!?6?Q2JEH\IP3^SL*$<V)AJ;(H _(8?;4.9MY=
MU$\KL"C,*L'7IYPX^FADX$"6:!BK$DS&6BEI4&80[1-TH8+4#,<$6,'C1,_Q
MZ4<M@+S2O^AQDS,94U9"LN\?]>R:]Y0ZI*;S97@66RPK@6Q #.HB)XS<3V*3
M-"<+T^JT;@[C7/<)N ?73=,#F'<O3GE S!P3&%GV<K_""JO"0:];LV9STWS%
M]XC-%[W.TO%XQ1625_M]:V08JFOSH/?[OV4_'EFJ<Z5/>D;<HRUY7*W7R>WW
M:?[1=A%5S;4LA@9EV[WBWNL=^ @E>S%3?XJ%P_,L"?RX=AMX!VC>< W)+DH.
MT:%/=O\1!_^]O%A(1J9)NLG=6F_5RFCLW:&T6W)8IZ7@D?U42\'*9ZQG##Y&
ML/>;VWRXL.VF+A5^Q-)!O<GJLF&[FZBRNDA#6<"6?]"2/C["U&NIG&6MN//3
MC0RA694"!*!+>]9S$HX"*=;4?4LM5LR.KMTJE^SR!>_C)^9DX'@&Z4QAN_ZN
M_%&@LZAXXY<U?\#0I;?1!I^!'X**9KL4*/4',JGDS:<L#,?/F8 \)<_RFQN2
M<)MBCKN-5",M7#,3"BRJ^&Z^MS(@^!E\^%:'NXS+[--VO7YH4, J%NT:JA?9
MS+^P,7J(7P!ZUYZ9J&YK4!,6V'7K:*D?72AR=E9]T+D=6Z5 O5I],O>]XT>&
MF%NYW>IK<L58,Z0O>]JQ*P:[PO56 J51?ZUJ1\V/3+9HFI+]48EI4QU54?_\
MQ858^TC;+<P*22:-2C0_7E_!TX(B[V?DH0NW9$!:U[30CI1VF\S$"#S6+5IQ
MMGB_RT(?,EA"!)!N<<7$QU8E02UZ3XYMR=J7;IZ8N+9&G$Z<KG/PO!)LN6RE
M(:E4Y;YP.QX+FN[3N]RW6/$R3<AK/INOAVD2S*.=QY53Z2'T;;_L/!F&>70_
MK/S"^W6@>\^M+P%87U1F_SS](LV[<*T3JB_F*O*P^ZHG[QXM2^=,,T_E( \S
M<:F&SC98Y]<SC,SZVD(,[ A::KA@JE#8.^SJIA<[-=3[00$G<268"3 (K-_J
M()(F*_P#6%ED_4Z<)NT_@E];92AG/][*WWT0EW>*_;9?MV3=P]%U:>=&1ZUN
MMFX_@^C:[OA9Y8,^D8=/K3U9<1XX0",AP@4^2BHQKR<\T")+^!^YP,XANA1N
MFDW PJ9-Q9/H:YZBK_LZOY@D]=B]]C65>*=BC"O\KM(]_H^!]W?^V'0H89AL
M!)![?J$';J*8+45';Y>O\OKU5VR79=D/P<)GS"D+LYQQK?PL<:VLY79"R\.V
MS'F.%R/2LKYBQ+9KR]YT5 ^C/QL[;"LRYY?HQ2+$: )F=^IA%U.R-8Z(B0)H
MFEJ$:,3RXD]F@:CGX=H$M  K9 7]E?=+%#@BR,KI^5IW>FJ9-]Q)2:M%S/OE
M"!7UD!"5/.TP!0& T983!]7O$@1*B/)>94<5A6-(OINN[(Y.RDLM7U50:K?V
MO7H5SE"=F7FQ[/.STLC2"M^LPD!^N2A9M]=2EVOP6L*LI+[9I 5\8WI]K]UR
MIL-9G5\#9=K\&DC9U@R-.%MLZVPB>OQF2:W<GU0S]XCNG&IT_R'_H6O>3CI-
M)$3%$U3F8Z-593/S6% ID#"7(1_?A)B.@'#^#F"TE+Z+D07#V_@OHL)>)7?^
M#AB(A.D*@X[S'Z6Z?=HPJQ^5^#2X)/-S?\1&<BK#?$PAX+(#([@4,5P];R,:
M8SJEY=0')3)Q\COE]'""N*#=$3%K#';IE^$0!3"L@V2^**?X_<:2TL/R\(UL
M!49EPK=,:RL2ZW-U/E9]Z6)Q(C7%.WXI[266I@/;)L!-8LF2,^EXLN)\E&V$
M8ZL]+$OSY;1\!N_+^Z$6O W5.)YXT\Q*DTTY81UX'E5AS$R-DW7#&1EK=<L,
M'ROYHI9'@K\!_OSP]M&>BA3ABHC:992#)1=<(#%.R;Y'.1^JZ;46M%^R.J%
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MNB'^^ !='*3F)"+AT?T7/D.HJ6G;6FA]Q.2LE-WC> :?<<5/_=^U=(EQ 2X
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M[M7R"+I\$QAP#MAOK> Z=:L,P,2_ULXO4YOG^#Z5X?\'Y(T9_^9QC\?[[RT
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MW3'[^_P$&$YD6HAGRXW)RXFW4^"JB(5LBB6O#8KB_$.%GWB$@'4_PBLQHSN
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MS^98=;V6B,[.19]!-U>4#FDC<&UF<@5#\TO0/>+(YP80[#E16)9;8H,\ M*
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MFQ%0#IQH0>"?IJ!HKZMWW66^UOR.XRJC]./T\94D/VT%-[VE+HF&_ R[VJ-
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MG&<[$'KFF>$4F8A<K <Z NYZ-M;#H<J0\'2X#QWS"9&T18E6## !V?#2EVI
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M#L$%_Z'0<L?#K@? 4T ;.+U#UEU<%C*N,H 57IA^+S?15_5WORXI<Z):W.V
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MZ[)B4K@J-TW[\@\OTA74:^+;X+F<?1+P[SB2H_^\Z9E6'33]L44V;W''+WG
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MYJ5#=(^YL Q8_1^UCT]:0TXGL8I%*0\82@*,')W'+1Y >P@R4RZ7FNL<-->
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MYV^A-W':DX5>)WH3,7?5EU68FQ)+S-TSSY9.#[;^\WGKOJE(1+C%G4M3U#6
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MFY/S*5YL^A TS;/,J1W-U)D':Q_*/9D_>XM[^'[-D%J+@7% ?'4EM'X>L7>
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MNZ%UHC* HUM2;Z0,IQ4K=>6=,6,W;G)8AM]1<]W6I<P6W8)5$47A31?A!%<
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M6_:4Q[.HO?25WLJ 7]5APC00HQF\"&IC<@Z28LTVOUTL5OILIR>+8_3E(SV
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MJ:'IW49#H= GGM_;V*:=14@9;$SEYV?)?WDG:#>4J1+*2A!]DNUHO108:WD
M45;%LB:L:@#?U!HNS<4,9!;]6>]W*YAE[,"%80D[SK3:32TZD8PA)=,<:1X)
M"@*?J.L7&/Z$NQ_0<0"(2MU@%91A>TWBY](X^1EM@UB?]RD;[P,*F2MEXB_M
M^Q<P/(!CM;_&-\ZOY[:/'#MD3'>\59Q(IRZ&0X+#N/.5:YQSLJ)_!XCY$AE
MY7RS-#3'W-/E"C#C[1T'>4L>_-B4"M*+RD)([(S6N](_U;09".RH2II>=:Y
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M%G\NOR[U.ROLT-\ -12&J XMJ'<N*_T&CGCUJOCGK:WJ0(>?#/3,D:<FU/I
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M8S39@DGX"1F% N^3FU2;E#_V0&)0Y8NP['&\XJV%X&HF?_97J:2RR2BO?0#
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MCL1AZ,2V&1W6*0YM^MA3EE([[/]@[SV#FG"_==$H/T$%1%2:-!4$I8C2I45
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M=;7@I9A81O_+E7XR)0[+%_ EN,3EPH97W#V[WQG'6KY5"LBB:V.F*BFXF-A
M4U!14+M?9Q'EVMS]V)>\#HW*&SU^=6OG*<8Q1!&2V.C1V@3)N^0ZWK?L09EK
M5%PVVNE&!#]/APAR!:X5A>>HGUE&,"N3R9) \H%0'#F]MEN+Z9(%$V-),?EX
M=) AOU)RN]^W(;!G^F]'XSA:^G?G8,E BUUSRKX^+#@F%37YEJS$Y9OXRR-/
M$."?H*>L(RAH6W/=66AG.+=XPV\U+$(RPU5/NRGRM'W)I\N3WL[2@?<7\XZ:
M=4X1F_VEPO*/D??R'_Z_GSWZGZ%8;*_LL(DSJK\A97Y\7CK%S'))_X;=%R*
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M1&\0<\\X97CRL 1]VR"_I >Z>W>MQ*Y(X9*/SX72WQ1+;<EO_U:$,T=\0KD
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M/1\*Q,DLI<@:@Q1M5R/E+GYS)W'@I?S5_+O%=C=R;.&D'@LD-E[W%/&Y+XF
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MT)X0QE8[".[WN=]]X4;6MCUW^V>,'([">Z,%>F4G@!9]H\RM:#I-#Y)56?*
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MR5/Q02]*F>M^S$^/+4,+M]3=)47,#6[GBE[&4)T;_WZ=_S?"Y!:*!7BK=^6
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M^B3'A\31>R=^_*H$[-MY#3@BY_8IQEY[+""94)\I-BGPU2 NQ]$+#FXY%S/
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MZ$8I2,]4N[!!UWO-K7>%.>#CA2OR]_*3E4EIZ4DD=^]GKNIX")K/MZ<@9#=
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M)XLXOL!-$]9DHT942_II9&FKXIOOG ZK/4UFG VS@RY_)V%5MT0:TAOF%].
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MPO$[E+\3/'-CN&O43A49.%ZSUDA$5>U6RKG[CD)U[XZ^'@IDTK[O;$R:<,:
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MO8C\SVTDTK/)A!7>7=+^.#\(/V4!2H]@?C!J/A#I9F. +8+J*.2X-<@-*_B
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MOF0UJJ5>^N.'JC8,+]2*YI4<(A?\&@"I@"[,1[2J"D9UV;EXTTYD8JR_=LK
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M&>WMZ$;'H[<C\Y2 P6Z3["8T>AK.3#LF,LNT:#ZQP]H<"!+#B\,%.,WA#K<
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M"PQ_!X@A&9XIM*_0T_/I:<6LWB-/Z?W,V^G^-)'^$G1TI:@0Y-2'O[RO8B9
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MMH1VQLSK=C\:>\I#A;V8-.%R(HG;Y',=+!?WYN7O8^6H\$,/N?EIH5::HWN
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M?67[ U[-#+W7/PK$:8<]GZU+NMXJ^E9BVUYHM#XC<%\!>HG)55M?'; ?--<
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MK"QJC"'1%1'AFOC66H4L^XH,T]TS^>>M"RZ?0ZI?R[13@U"#]41^PL(9A]=
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M\Z?UT/HT]W>\U6U\0SN!XUH##TCXC.6".M_[H$UF+R/_9<AOZ$M?L)];;C"
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M8YO?V/\OUMXJKNF_C1L?$J,GW8P25$I!ND5*A"E*ETB#@$@-& Q$.D:( <I
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M4%R$DD94.-U7((C0T*7.B\ETP4QLIU^;8S3_OM7.O\JL><@V-_;?T\J=B$?
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M4+P,KB6DE!#F_OBPPJ-[7V2]/ZHZ???S%:N,;@0S?.!7'5PDK:.F J$*-!/
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M>K?C\,]9:A]R*MX<-0A\><?D&$ EP6C#@1<)&/'XW2A)TCO1#1\^AB3MM#<
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MD(-TV4M)!XSO=:U">(9GE&61@RI\VA&'9]_^\N@UD9%T6]-SJ;TD!29V'"Y
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MXWRT&C?0O2"FSD;6(LY5Y@-W3MC6JS=Y@WG[3'S$:P2OG6].B[+^@CDGO*S
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MGI]_,3['^XEY/]&9;O%/E/<WVJ\,[?8*0G*;;<+$DUA2,QZ>*>\\M#)U'&'
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MS//L;C/!WNC5UB$)_1A5XV!W<\QOZ6[^H5[*+[<-07Y(JE3UL:?$+T9Q-J)
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M67$GDBXG'$ 1OI_&]9;/-'_0U&/Q/3U:SFTEUI,4]6DAT5P_#6DK)!,0L&
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MT=U99R_@UH$M\4=F>LUQIM&%Z7C;!\YJ6Z:&X.P&( [<MO';B$1 38XO/&]
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M3N3.,Y[]W=77/CQ&!V3A(7AT;]:<"!@2(FD1=A:@<7$9(4N=\9URBVL=W.(
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MY-FRGR<-3E(Q5EUM[%RY9*LAP[&-"5Y47?$3Q;MW^U8<N_4VN-!A])^[%*J
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M&>!=:_4GBO<X/VRO #K_NU#(@2':,0U*ML@Y-FJ!&G[GP\BAB8S!-)&M<$E
MD7M$ZY>T*?H!M[OYZ":%0'IM(FLGXTTXG]::$0IE:P)RQ^"6*R#<KMB>KU0R
M%1/*_%$B#8.GF^RT*I?!2'0VND+BFI35\U*,3[,H<-IW0O(FY.%95[JW)?U*
MJRFQQYVN!&*_S"1>#FN^E"7&'U[G$S@_KO5O_71HAUUB=$,[X]B<*::RQ+'(
MSD0[AN/.F _.:L;33WAQM#\TAED!*X6EK@YBZ+5R]$:"05O>;$*MDVE&$S8?
MXK^,9?5R2/?K.^EG1[ZC>:&V%Z%(A_6#!0I.G9LZ%)5;<$Z32/S\GLSXS*64
MS%9WP:Q2@U6W"O"BP?F(S*%$0'1A+4ZQ+WY=Q.HV)DR!9%6XME5)FJT'I&F+
M_]'*+^-OQ^<G&8R&&!HRXK'EQGC2X*B83%B/>#"?'>M5S9IJRCSN)(DR!;V#
MQH!M+*]3DI5&F#,YUOT)/9-0]P[K:MJ) TVF18O=XOW@A'=YSXE9)ZX ^OFS
M!-LG*-X8_6=<GO?Z5SA"ED/E8B)UQRL\8IG]^)AMWVSOC*B2?VW!2[@.30;J
M ,Z,'H'V=/ Y.*#45C;N5+LMO86JQ:XF]=>$Z%N.H&5V"E_KF*5_GQ") ="Z
M<]3*K;K AH74V%.O^N6O#UE-J&3K3"<>YNQ>P!7['08"[]K6!,ZRW8DY0 Z]
M-0EHCW^YX8X:_(S.++&0CZ6=.PF>5Q$A9,ZL9K[\/G'M?ZUU6JK:&Q,VOVW>
M#H7PF ]POR&IJ;IVL8$2NMV7]&/^]+FSZRVL<29.Z;:9' UO_4L5BY,U![A7
MDS5YQ7%6<FJS*PJP:\@5+*\I6M^7+A\ID]?0,;HK0&I*_&Y/\W$F1RSMT@ O
MKPQ'& A20$+/#1#+*![6_9.PX"POU=EL;_'V5*AH8A+#$5/#?;+<24.$B'?B
M]&7,SAH%A'$1+"(KR90,?!^=SW0@" 6)P[*E,(L[;%(DMS@:&Y>*6C]1"@_G
MI(H-8W#&O7U/16.  ^?9+636='=0^&E@[)<A%D1=C::?_\A%;[;A_+?VP>ZU
M=K'%U@!"F*]E^+;%L,;XSN&<488F@MFV^V[23&T#H9NVW7^'6'Q_Z*N5P;W9
M'-1THC7&(KS4$FO=RQ0]67?A_*A1"N=9!)FH[_,72IN2AQPUBE\^!\OC(H<2
M:C&1*^)@ZB,%DBV8!=L8/_?XH9RV&EAP=Z. ]WOV@^'^5DW NY_]".K2-.*Q
M]=5JV" ;ONCX\(<,9T,KI"N9UM^99$%M)U_ZL.SP'R\0O>+(=@7T6%!.U7T5
MTKO\-N',_[,Q].SU'L>L!F5<PL=<2FFL\]D3K-2UVA9PZ)844Z@X^C3$^GZ\
M:O^(1X?ULV*/)'V)'H,W:?_Y(_05$!M(?/ZL'9NS?,'I3&W+-/&X%Z5 ,O':
MT[93ORD*)UEIJVNU ?*F<CH*_'*)8C.'V(.2=.:A1X4?#$,X[J_\1E*7=<I;
M_FW"P]:?4<,LUG@D2$6V<V]LQ4J U1+R9U'*<WFC/,O?BNP8OB2%J,;XX'Y]
MKI/D%^FV7'F=%OY5Q.V<YWKIQU_0T'.^*P ?8F,:H? $ JZ7"+#J5R;()'E8
M(_(#Q?2H2#)L6/KXU/()^L?'"HB7.>GCVH2SAQF4M5J.LKM&CZP)]RL>WKDA
MYP<IWT&%$B43<>HE]3*%Z^L) [C!P,Z3O],D'S <B@##@G"/'&_ GD7\^F7^
M>%#K6(]Y.VUY1TQZ4PT%X*9$''8=QDMN/<*05T346AU/HP<HSDS7&]JM_:FK
MOUX'1<_.PTJ2X>6LK+Y>2WI(GT6V@*=$+%%=JRGS!^6$L0E!GEA"CK J\FS9
MJCT+4,4F8FG[&>I+W0+;77FC9:%;FKS'AB''<8LSBVP/7''3;&=CXH)]#PX"
MT!3%QS\P'H&TF<@W<'C $[\@*O42%6N'RQJ4!OV=V".?FRZ4%I&%GF \11IL
M!.5-"W]U; CDA$UR\L6^=57,?8'#UB<JI)YZ+KJXO-GJ[FD*NC!SW!ZFZ8A#
M<U.4=D***VK+[E=KPYE"TX]/-2Z<AMSG73ICL$K@=]1\ $FPF,<P^8:)8%[)
MTLS&\7%ZRZ<RB6V,&NTNJ_Z]= 4TX:9?BLD_2M,&$@L[]8X5E]L!&=9K+4@>
MWPY%+3Y"CL3=2NH_35!_;"*N1Z!6=YS-BDX]*+<CCX^/>ZM&0,NE,<QP"!C!
MEW \<VC/=;#62-V(18*6%O1E="%\')+8^_@5MUJR3>9V0]\9UC7E0O$$8?(K
MT0$E0*\WYOQN\%6 ,T_Y>KE^G5.A\0T9%NK^4C9BM$X\>@\F:4(0\C*-Z=5G
M1XWI,K;MOC(1^62?V\$B$I1O?=7R,'Q*F*[L359GS=KD@6Q>$B&N%\&W.W^'
M)O?@))C.D.S^'\W+Y%6.OZ*SINK1:=I!#[\YM%.WQ)K7I*I_;W_\/2?X4>,D
MOH\Z?)C*Q%]ENIT%FXAT7\B);9QR-;^?X<ZA4?Y12W9A][<26:_:;H>PO".T
M2DB 8T* M[XY_G7C1R89+M=WWV!X("MRGRN@*R>XG0[+7+1H"@DDYFYJ>]]V
M,OU2?K>9AVL>^*WO ISPIBBQ/4:S3</ C.WD#I:4_D]=2^>Q:7+1H!XZDY[5
M19C;R_G7L2Z_]:09.CMER"C<EAYN'(O8-4A.N1#<-(57J[$.-DP"9-7<*2$3
MGS+RG)&L=-,]TQ8<D5KUL68M(8[%$W3LMY,E9$A,*V4#7-K#F/Z]881SX+WC
M>":W&43%WQ?CS[)#&5-18?%M<^JN?,<.G]H/*]XB9$H<6IFK9N(2_Z*JG6'C
MDKJQ>G(Q",]>5I_/43+$V^:NGUMLHQ7M(^'?+F)AX^Q&HP;I <@ 9OT)SO:O
M8_Q.>U;,ULW9LVP/&'_@WDI28E,XNP/QVA^_5K_11>,_1^OV:!UJ-UN\/HKN
MV#I^.(\SPFIY]CW"[Z/=8+N!M<X[E\BT=*2X6[$RY4DX8?-?.XH,0+?X>BP<
M<@1W 5@=_UU6QDE$00G7LZ7'+!]-'Y9I6W5%63O[W$Q2H8@3&XG+5I<XX(UT
ME@>=R5Q.6-RNFSP\$R)>EX6GVV=0Y*U&[4P^5LYB[%RN^\CSX0JX$>IC<OJC
M1EX;24X*3[LQ:#E:[EFFZCA(?E'SJ'0&OLS PL*6GP'\/NO)9A^[!/L'HFD"
MR>^6SD!D4=KJ!AC\IHONEX*#'BD,;KUJ2BLL"?&)+A@C6  IW((#O=A88BJW
M:0%J=BAC1+W+YQ-=+KLU\,0KZ^NW.,P[ST,0Q88%_7@R3&W<43R31L;4@8&.
MH>L(D4N&,1'_^XNJ>HP+U!4M4&EV4S-I]!IDLMQ0DF;<"U-B6<CII23=9%-H
M1YLQ];9BT[[1-F7 N(4-&3L5B''Q0OK)B*$TV"'WTG-2[*P-QHJ4--ZHVR0U
M=$/VW/";A992.8D.X2.7_&SI%^_,F 9&KX"7 5J&V$")!?7'CLPKW(BWB)FI
MY11%;5C# S(C]KY@61L[Z[BXL-=]QTVMX_Y@=Z0S-59G<PO50UV9>040K8J
M^/2\6!Y!0S^+RBCXQKW242)([Q-*7*)H<T9[FXQZ.%K,]<HV?+5_<[ASN]=$
M*[(IZ.B1-?RI]8OV-P'SGIU0?70QK#YEN2A^&4JCUMAI^VZC<=W4A9]#WZ5B
M6YU\.OA:7X<',F.-8(W$91N+E*.'K%8>2^)I:7H%_=\)#@]N^3 N+R\?[9F_
M JRP0MU>@?CH[!3DCJ)6])NZ.8^&\-T"40T#-8)?EV& !P#@._X=+-Q!-]MY
M(.[(UY%T4)2CJL<<HQ-7O2;CLUB-M> ;H1"@^I!$6[<$:Z.$J;L$30GF1CZ5
M?0/3&W<R..%LY7C,N8R,F.K?% N5N=$VC9+JBEV*S6$4CS[7=7;V1!^HC;^T
M?=,VICVYW:RVF(^'KT?$E8=+F$R8O>$[57O&A$T6H+;(V'J&5?[R72VKM.8C
MS^BJE6XJ.RZ/+YI0OB9NUP38!CN65- OOVF8KN$67K1/TV-\N1XV1#:$O5</
M1B9&M]E@6ONJ(5-\F5"R<XFJ \ZQPXN\5U/1^(\.;D@GMB3,,.S:3X4BC';L
MD)+-&% XE-^?UZZL\%?"-/6V['O7LCM)*[@<Q#;,OC?5Y8WJN_"\JM3)1,J%
MX7E4TA/W2D." 5: !F=PO8/, TR)/3/'A,<]Z2IST%/!1Y6_O7]IX7)&R-S/
M3B>S 1>=W?J/MYG\SR&_ANSH$A!"7@%1]5< E;:?)XJ2>HN>XL#^-&%<]+[I
M:HBP<&GNG66R91? @"W^?YY>P5GKH%(DW0#3RJL@YQ8"]W?7-$87UF3ID,=:
M)0F2\OF,CFUH'0K7<1=G)0/C20/]>U\ZK_7(8?'_(2C_0["I^*$EM^"6#-P8
MYW@)#<^O(*U75\!;/Y4$T2I321R[5T_?[3NM^[#@PF] H8__>]OX+US C&VW
M4$)1V;2)RB/^]]M90G>13Y\V&P_J'+\%B7 ^#S24I_"-VY?;P_Y_EQW^O97_
MGX*0&*.%I$C%^(AK.;KMGISQZK:>Z2->4FV'GN'^U(P059*6!UF:)2 0"&8Y
M2,4.2H,]&L_U7Z*/!J<3\"KY[UV6OR!R%ACZ^>D8]4S@>W6-STC#]*,XIZ<S
M"9^;EMXN$7D(A5V"4G3&\!JEC$09]^KEX$ON?G>YTY/.CJ19"73=-'?O_(_%
M_A-02F)GT<-F6&C1AB]Y3E1059N,^-J9F_3-BZ+-)<9;:A<T5,*="<I[H14(
MK U,UC+,@UF 7K4F]K\&T"@[$W5_N2SXE*S+G:Q[N_Y_KDR">._]9&-:TYK?
MZZ2"FNAVAA@G]P>Y9^]O&N.&JJD%J/H4=UF&\J%7=A#'K0%7 #$H42+LE[WO
M?)B"Z]F7&D5C.  G<)$&[D%+__.FRAAX9_0E!A0I(2 H<'_K8?+^PK+IUFU2
M<?P0YI'LMX92,,H()OIN7>(Y6R;\QE1GT+#XOON_1E!X6__&"18&:*=&_^>B
M+G1@_$,-Q7N;H)M"KULFCYH_:_!/_8;U%JO1DU4)*IK/)_ONNTZL=?SGO0=G
M"[5$>?=LOE9HY*"=?@U!'WXP>U)V9V*%CWK7<"@U%FPX(?\"=7$?3.6O/$E\
MIE: LU]AO4/>Q.ZH)"P6DOV)Y.C;/ZT+_@64&_L1;7B&6DH43\=05"6?*X[G
MFR9BU7,-U5I;R7RR:B/BR)X'J,EPGR[0X+#<5'? <X$QP<CL;W'%WR_]P@#@
MC. \^5]_[S_\X0]_^,,?_O"'/_SA#W_XPQ_^\(<__.$/?_C#'_[PAS_\X0]_
M^,/_CS 2P8@]F:Y+Q-F2RF:H._-J)6.N>#[;5MV/%W[)2>^*VPP8]>]@5([C
M^35J,$1L83#-*P#.-]Z]S!L;^]Z&UFFWCX"+D47^_2NZO5F0\Z@EY170/7R1
M'[0VW&.)U>:] KA&KP!2\''\%9 #OA6$%,\Y3S3OF)D,6MM6O *PA$+'A>#?
M)T*ME\0G^+3H*^"<_PI 2%WZGZM> 6_'@O850.C:*\!VZ?<!AOZ2^OK-^P^#
MK VN%ZLZNP*6"?^\^O_^:E]PIS.;_^NIM@!G:]2%F)XL39*&3=.$>)(M)P?Q
M_7*N1\ES:C++*8B:LE3]0L+'$[&--E< ,)9M39*BIY?<D7Y.O9&Q/YR8PY2)
M9(LOFK,S@4S[FU?,DRIP:9*I9W)T"LZL624WPT6-R1(TCF1_#YKI=URTRLNG
M;]6_:>/EG@+VF53X2X>VO6H3L430FT?J,^<<6"1JQO *Z,FA)XS8+3"':8W4
M34!RAU6%FK6LE\![WM#G6$?D%4 %L8$%/<?H1JO'2G!__&9O^=+4:I3%T5!U
MA2O;+; ^"Z,+;^='.[9_NJ1%\[=+)2,_F:G3?4X+L@'("](,%UIYBQ\9\:)3
MCB.:L/'YD,T]0W0SNG?Z;6$R<ZM:!SUW"U\Z_EM[ K*7KAG ,6GKE@.^87-3
MS,*SAK)'2&7>JF'?[/:G6%JTK@KV"(F+X4*946%S3#%XX_(WA]WOJ5@[U;3P
M/[XGW/DM99L(3J&)P+*G!Q%=*D RD?+>)_3MM(XBGA5T<LV/$E\73EK0\F+=
MAJX ?]R)3\$!U#XE)G9?H-Z>Y*4B)!7B(3C<RS@IT]R!GO)N_-5E^81JC(9/
MWRGO\J&&&:1"C8YC,'G8'6??-]S"?<B/E5/+,Q7M%,M%@I&[[N-R!V'FP[W#
M9+-8[V/322NLV*_A?(L%@>\Y,].Z;O"%#\0]VFG/%?48E9>=E]WNX&[PF1M^
M.[;C:&QKS+:]/'=]6#XX_H4P(?^ 9FOA_K1VH]C"/,R!:(O[QRUUE,,OH=!V
MT,4G>>T*VV2(B%4#1BU[P]69=FBHA[[=BNR=P0Q_9.5R:Z1%=\M?,]HN:>HK
MBPL6_9]"=H62Z1+@@P&PYOM+8D1Y"OWP7PPKP AATYRYB@_)D+.X>\^2E\:,
M:$X>K8"_$3JHUX($O;<C@/P*0DJ6>(/"VU0</3+@T6ZU;T,A+Y(?>%*3=R6,
M_M!ECG!QD4V,7:1*Z0MJT G+E:SP*[0[6;PY^R4@Y+Q9T''JE[>M5(*!<>EJ
M@@O1GA+HB<FF9./0O3DSF,LH:PU1 9G>*0L;.>]Q:O%<8-_QE\#I^"6; \*/
MB>;-/_A6<^)SB.HZ0@*YL'ZE_B)ISOB;)O#2;+;FC$7U)J,8U^#MY%J"5W U
MO^4C8*JX#SJ;TY5-B%6IQ.:K1)Q.]R(>5N:#HK@[,K2:7QL]^;%MBM>@N4S&
M<BL&.*W,/?-L1%P.'D>U3S9ZI[0Y]U4N-D&)L$.86"-TSG9U,;;T1Q"7Y93X
M&<-*$PM#85/\LP4E5B5!-4(]OD[/_D!<]67FPK'*MON7BC$$38T8+I.EBHG&
M3CHJ$2Y;LG./998U^1'"I52\Z8;C Q6RVEZ:6M9JM5U<&;A+?@=;ZOYP+Y3>
MGDWV(L1)XJL1&.$MF:;E]CU<2R,=#?^NO*[YZ%)B'4029+- ,+6F@CG^ZOT%
MDM\GVL4Z.[E7F?7@$6:YP)4/CPCW'4U8#' DQ&*I6X@5ZJ%OJ&%PJC@\B_[\
M#GC8 N_557Q+\CME>2H6TX=RAE7P]D[E,'!5FVMROZIM&75<FZTQ>D3'-U_D
M1NA[JHM2/T_IH F:N;=U!3RH]Z\]DUGP][0,M6!)[*:S( ZB]'&/U?14:SXS
ME/\M18^8<^_PDMZX?FMHR!5 VV94 CGH6:+P#R"/R^8=R4O8D1 0IXW87S@^
MG],1AOEZ &YJ.!9^%[RPR[OUV-3*S>EV=BTHR8*I*FM$'"=.Q2N2O/D&4>^;
M?5",463@#V]Z-A;L "I+#$5;. ^FDRCS;'/88).J:ZE5J3><>\ZL1")*">8]
MXS8\"0E:/6SG"9HAZ;L"E&."%8XW]TD93!P^YC>&^P[PA3\^NEV@2?? 2(TB
M3I111YFM?C^G>PG8"*KGC6Y[L9+(QH^82K4ITRY8SY STTB;&H'3B^(_$?W.
MZ'-$IG'6U('\2AYD8XEXJH1."W%UR2; I!;V1!<,BVFQILX_-*[SBV:_62HC
MOR=SE@^ =$?_;QW2+!C14O <6GG5E3VJ9]@YE0"Y!R&,%3_]5$BX0Y5H.?T#
MCQ[NRM4$KJ]E&\$MQ+'%Q>?^HW4!(!6_1+QO:.)*U3S;.,?+YL4W_G$=DO1<
M<NJ$\@=GGM\*;;XV*'BG31@4JF1+/?[5(9EI,;VWZI=*NPJJ\XYIYX 8W1][
MA29(%\R3GR9K='9^[500K\0,*%'B[0Y:QU%\K$SO.5V+W5&D&"K=0)@YKX@4
M]8F,CWJ_;;K7;E6Z]HLOK?L@.=?=:(?V)[,"A6=89K%.L;BCU*O*LJ*O20N/
M+1S.P-A8>/9M-"7BW+-XH-@>M?D@_G6CY+XF$8F*.(19!P7+[==S_:$KA%:'
MY]"<JV (>QHL)$;F=$:6C23'ON:%4RFSDR0I@GT+O5EGP1[NPV([Z:WY)QT5
M6FDW7#W3Y8.\VUNO@,CF77VC".S@]1*'5T!BAF1B_KJCZ_)'$QR);PCZ*/C2
MEOFOOO[!@Q=N8O40F37=XP2,48\0R;K)HW9@[.<$;P8R;6=G>V@BZ0ON<R*<
MY:S9-ZXAX^*R W?E%$@3S)\8W'VZEKA'.]4B9/']Z)0O'*/8C#K3#:NU;_%*
M9\9^MZO^[G%HCA0D@7XH;?X=\[.J;?4+RU30]A6 $F*"9':"'3!3.;>SRF)+
MJ"0RYN<&N-GODHTN.\K%4H1Q*/?)2.S0B\8W3JR=EG]]6W; QSOHL+69[BPV
M]@5*CN5:T8T)Y,"&H4R%F-8=BVU=^#+M+$:ZH]G?X6OD@+X^:4W8SFF164OY
M'Q;A<&T1(\25AB-M:I)7@,F>I**:929I4E99U[#(3OJ]U.SCF0T?1U43?9D5
M3S:' [OZG<!+]>;'%LIGZI R%'VXA\!M2\#.;9-ZR&70Z_CX]:;&!$X5'H#6
MV6Z0[MS(V/#7K82TCR]O(RJS"N&78DQOW%D5Z"%:H66_[E4&6C6_$9*Y1R@1
M.&KQN':DZ_FOC?&2(6;M68?2#>A+;WVCC,#A14X,-+H-S^G<^]HB-O_+(AK^
MMT7,GYKKOQJFY9E8@ZHB-[^]SW"4LRN5USUNQTQ]1>\M+\"KD4.JAQ7:SHXH
M>J+2'CX1O!<AH$*G<UQLM53/,-D\PD$O'@SW95EZ/BV^#XC\:&:S2MQ5)&98
MX0C^(0H!S\U=:N_O779+=IS>*L N((=TD8E1=</Q;#2-#M';%6-+/8@W0?M7
M@'7(1_!2',[ =JDNB7(M;BYV>N6K'PS$V$Z^CK#X?)SQNM'/AR[/Z4N!V3U^
M9F5N*I&O+;>FOJ;MG\[I--KM[G+6AP0>IDBK@IXX_,J)L^ </W^!B3QVF1;/
M#&\=%ZK<LPGU6#=(G@\.H-137KVI;K]Y+1"1:/NI+?6OV"^885<6-_47KU\V
MO69/:GZK]RE;B?F#=8,M[IR ,WM[^.N&;+DHTX(DZ5?@^W=:VD*[";)_07:0
M%B::9O<22R0PZC!*.@AS=T==^MOM0"I[HW=8OQYB5\>*=2-2V3Z:$F9Q)SR8
M"_?R*G7<K7?$M*.7H\FV58$C)N(=M#O07UBSEL>F=.&O'1ZT"QR(?Q;*]!+K
M7-OU&@("')S=R><YC7DT/SLE,A,\Q<:\FLISL!J-S?S@^#W2GMA,<&5=;&(Z
MU9]CO)T.J][=SHX!P6SJ SB->T[*7GES?V&BL1*M[('/&:\^MPF+V<\)[B#P
M ".HN[U!5.T\RKS1]8Z!J*!:F$1/->R5,TL%0P)[G,BW1F3";V[<6JR?*]_E
M3 YMGIWY9VTA'3Y&ZWIWFF>=.Q8; >7&=LEJZ>D-QXD<W?S[I?2*8;P9O\N6
M06$[\OAG3\YU1\H%A03Y'3U:;^&T?QKBMGW,:+WH<R]WQVR?!B?%X%+H"H!)
MSD).C'4952_*4&7%!T*&"U ;2)3>C5]<]<+ ;[6_Q(@^'X'>-V6\E[<6/U\_
M<#A(\OJ!HWY(?4,:*7Z4N+:6;1O4H$R;+H:T.Y!UJE)B&-?.;6Y^W<V<8(G,
M+5(PS(4,8">[*?/$-4V"'J:+\U=LB3VW6P&S<K=,)19M'M@B;B<X<6LY0%9(
M3+1+U9Z%">KX[J[L+N-NIGHF&;R/,&0DHU!FJ]O\;=K=CC-^R7 YRZ08\GD(
M(JZ+57W=5E_=W&27/.R_6\&B&LU!'"=)+%\-+;7%75EZ*^K_&MN_>&?28SBF
M8\8+X53O6M3GH)B"WX]H-6;3IT@@Y&HTV;L$G3_"G(0IBAK[BV'CW8NWQNRG
MGIAOF.SF4":/;5-\3\[%49YC9@/@A.;S/KS;2YX8+U(0BQ#L#$P\;P=&)R]\
MG+.4NO%"DIK#OP'7:2'+YX?#%[0YO /9@=#2F @4,Y'!*);AI;$Q=8R;,VM%
M6:_%ZY-OKODPOLE9=)^XB7,H^=>0>9IY?^W1(S_=FSP=;W=VN&,.5$5N3%.S
MGKVDC(M[!1E&3UOH$.C>: _ 3)]GI\,LSW L@]9%IYQ['7P"I0)'3;R[Y^;F
M,H,(-WPUISP=M#3C7O\>+"UP@F7EUMFP[8PL!U/F5PA5[*V(FIJINH3$I(7#
M /7'28M-E/%+=#Q8]0*LTSZKA 17F4,#0H[KF_5^3QF'Z V< 699OR,H-78/
MG:)V\<F#%!R=0YZ;"6N)2/2^8?E,Q9W/=)-NF%V%)>:[7^JJ;\HTGL%%U24]
M5LZP$>T=MS+6N'G)@6'+M/;Q.?[8$62/;IJM#9S\;:VCC]MGH0T$^.AI!S@Z
MR^MIN=(\?>C*XK0L=D'HNZ^UAX]5.3;#6J]8WL2*/="6-*B1HF1)?_JH5HNI
MZBU(9 [7_1CN?@C]V,;K@Y;KR28S78HRDCWN6,DR!%VGX<;)4T<%H8:,I+<>
MU]Y"$^*Q^#X'*-LW*Q9+;(K;[#R]\6O[76+%8\(3S<BR?9E^%R_GP!UM'EZ\
M]]=$"3RQJQ=0APEXVSAZ^E>RK=GG*PVWIES6TT^3;FFAK8^MT8V);?B%V#X4
MZ]>^./G'*+Z7$[RM':WOB5;>.S]050. PL!/*[@W@F4IYUZC3"W?T@F10:FO
M *=GY*/53^.'^FAW]^TEJQ;Z''B^WW5GGW]7%RQ'J=<\ ,T$OQ$B0V!UCSU'
MZQ1 GA6%V66OG!U^R;R'YU:9I7$W*%S<O4XF.UZ!\.V"2/R?EIL)'!>O,)M+
M!CS IFWN/_7DF7C\$>_#0MV-P?A<%TJH.,YAKV'+1 5_08Q<[)?GR4\;)-*4
M"H?- %T%<O_1E;U;2Y#&8^(4PXE?#IEG64P3PW*?ZN)XX[6H-UU3=AW48: :
MY[!S9_3I^%.,@P4DO=>D/9.EQL$[_4ED>+:PWH.0AGM%2KB$Q8KO<0X#E%T#
M'!VX'P^YTH@^\H(G2S]9&\&=F!X*PKT4M,\ ;]L(Q0K]DHW(_XPP[R-+YS?N
MM_8R5F$K(/M\@2^%!&UW($%18(JZ85K(Y>)6;^!=#$^IO91)_,_5TM%H?7$[
M!C6<^R66?2/7OV"Q0R?8:C#:J9UQ:T<<RD=)97G'CJ$:]\3?7>_R>TM#,3*1
MR?\^]MF732.F>FCX+D?*PY:V@ /29T9N/7U-RK6@/9;GSRF>'@=A\L_E+CX&
M<F*3N35YQSWC=2!/=%O&7MS W6FZSG:*4*>(*8W\#-2=EQ]VXKE="H=S"4M*
MMGX)O0VJN0+>!K*?RX[+&ZR<^4%IL<4]:25?%NRETI/+U'CT1@M>,."3% :!
ME(,EP:_-39^B^^(5.?SY)SSYXDVFNT]N#A2:6RC^#B\O:[:RGF>?33Q)$!8&
M"#L6+)2MB=-^V>Z@6.A3NZ&_[!\DO53U>+X.XWB_>FO+\MZY-%HP_>PI9 Z^
M*(3IRRQ?S]"!2L9^7E^R31+(U0A->Q_.Q=_U[D++!BQ(27$N-QY('SBSR#PJ
M+N-,_<"9PFQA;N.$GES<Z]6JIT=4-3?''6:\;,U<RK([T.QVAN+S>\X(%7@@
MD?/\>ON]Q$LJ;0Y?]DPY)VM+-^4W7L:]8$U+K&E'O6%>B=2>/QB].[TM.?L3
M].032"*RY<Z] )*[A[F4;S".JXB@<,_,,F\1,^57XM5-C(A!YIM!(A;N9W>Q
M@\\P)YU?<<VF]W*>3#JQK6JY<Y:FS;ER0DD I#Y%5MF(O.<5P*D;%;3-ZGH%
M?,YH][_(!J_"=X.V:<N#UKUI< Z__LIS*%:#>KN3UXCAD__75@.@ZYME+!KQ
MA(B+/>%H/W(;<R:%-4))=8/((6%]-[9ZO=/I @T*C(Q$^\C#6Y)C:33B *2;
M\;YF9=CQTRD;=&+8)8^M5+J[I5T@V32T?!OA/;_A>!-\.T#Q?M"R6K!B5,N$
MP!L3$7=W\N9W.\I\X?,!!+X9Z*#(1JJ.G6B,"5TJ@GOL$%6=)F<DHOJ)8A+N
MCX\5R[L<R:9NPJ9B[A'+:Y<YG%!?9#-6\B0P\T%^VO:XXKU(,.@@\QZ0M03.
M07;+0HAT5&#X"U<?5VN'PIDH\L-?=ESWHP;9#@8,".W7WN6290"G3G^E:(^F
MQ?J<;VYQ5]*JH^Q5_X] 6(]N.5?'NF+D4$*Q1SFQ5)LFA?5I^8(Y>;95RIX\
MA?5M07<S3[CPYQ/<_-@4=^6@LT][F5YU]'8P0E2ZO9GBIV$;_$9/QP6.[A0]
M?HT<Y8F6'\TJ&,SVW6'5T01.NV-^Z_:PW6ZZB&O3*C6=F]$NQ>+V6#E4,'VC
M3JN:"!YH8$O2<(WSV*9@5BQ!4R+-3T(/+]1[LN^D.K?YH33Q%RL\)U0N!FTO
M;A$0$#*RA;C@;/V_-VN-VT7;)L6O -)-*2:!#H2G],IW$<>%E*1D0C<"#=;^
M+Y]2I9O;0V<0G]L=%"6P+9K@UY.1C<>B5P"F5!>KK2@4--Q><06$OKH"5@P.
M.N;J@M8FK@ T[>5KQ4DOF[$ZHR%+=(:_Q160$V!Z!> -7@'P+]=_WW'4R?G9
MYA+VMN6EA/KQ#NCW$?@</^B#G\%LSL-1"S%T1R_HEH003:\CBI2OMK!&)LVA
M%<?Y)U+S"9'!@$!(@F_&L?VQ\(<O*W?/-'HK,\K$C <_FMVIU$5Y%4,W%.F2
M@\CG)'[D_2I-8K%P*&7YF2HS\(-092(#X_R_/_% [/>-Y4T_F?NZH^:!+[]]
MCJU/++2%9G0@Q;%?KP#%T\9+XO0K(/[Q%4!<W+OW^V2R _VHX]R^J:/1]@H8
M+KD"EOG.^X_+:A53/[?;_Z_O91&.#NNQD)X\XIOQU[5Q2;.C6%]KJ3N3\\D,
M)A$N>Z>V.__<=UH-)%4855JB]FD\8"KGX\//*?6)3S_'+"L*.5CPC1ZVWD;7
ME]<.<,?Q)I/^/^U]5U237;=U$"$J"A9ZD% %18IT,"3P*DVJ(B U*DU FK2
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MU#^GIJJZ<,+(D_8/9IS.31^YB+R=U]: 2:"I%3_I>220)5[<4#^R;'%/#Y7
M_)DV"=[DT- Z<(L#[$=<;;(C2U'^I;HL7D4"2Q%>'19R&\H$#V,YC!#(%1"T
MR+>CY6)N_EA?N+1D B)1-G#HA C#WEU/-\F_A;?XDFKZ(#;JRJ^BFVQ^LZ_,
M4#[VF]H 1#11"6_G@)W(8YO6'_'TY_I,]G@[.X1):$D]D]J@@],61(_2AZRE
MCP$QS:>H'4;#6RLMHS)/K54]R@>;4I3QK<R?*G7>AT-4NN"G_&5CP=5ST7C5
M/==F(?2PXK['^ +GC=E;%R\G'@WK.4G4^DX5KQT#OF!B_;)Y_?Y4(Q4FMU/C
ME'96U*]DR1"O>,O9B;&S#@>USB;L:KBOG9%DQL)<V<[Y$G2W6LH['N$/E\9W
M>9]^L..5R/3EXS%M%&8;+8DPUC@7W!))7*XA)<5Z03PXAQZTIN@LLCS0>1>A
MH54>)\G,ADNK@5-!6(OQ(<6]2ZX3%W"<#M>W'C\$7/YVI=F1*DHVZ#H&G(%R
MKH5RUE%5"+/_;!OKWQ\0N"GZ;*<ILB0%V _$PVWO:H)A- 62;B(DB/P::4;N
M3^:)LN@Q40] O2LDN"8_J'*]XM/E_?-&>)# N19E5"1-NLR*(4K0"9<1S\=#
ME8K/]3RV<^6%WXSJUILW7)0+NT8YD&1>/@:<A<7!G%JX$97&7JR;H7(DP9IB
M_=(?]HB &=N9*3W\K4XQ*P'O C7FY>Y^/;NPDT^@DM0V\H@)-97 P6&/,.AH
M!M>D3&B/*&FS!4*J62VS](X!X1Z^;3]Y^-J4?AO]1VVWF/#PVK"7NWG\R L-
M(W[2\IN6H_P'LYWH'!W=:[Q+"P%<Q-?390U^WB;\#8I:@FH\0A%R6L!RJ_?A
M4.4Z*@^A)9H189473Q6?@\IU\5_3RI5+'<2>V/D-J#(IRLRWYR??64U0?F:\
ML14J8;49=@[F:N,5*X_0O4^NC);Q@V_-/*&T;ZP:OX$'[*(^"X&SA4+)^UNA
M&8S1'XQ>(4=WPJ8NX0/C3<*54.Q4+Z.4'5F868)T]SF>^=P;>>+Z0I*/GP5:
M%M-TJ M(8&5?P3P20@Z+N;Y\^_S<6O#C.9O^!\^BK\NUDC$Y$Z6,D*K0^XX!
M[/XZ9$LLBFM#D#NU35"0K!4G!>.X\U[MQ+7/08)RL  ;GYL^8],)#W-04<V2
M9/C6MX*!A<MAK?97R,:I3OX*3PX&7CV-FAHXF\+#)O(3!/*]L;2:X\ L\:=@
M_RH\0MTD?KOEB:P@H@6;RUU/&JM ?YP*25-[H'?BG?E]%X&@[/O<=P=S+*5(
M..N)/PVB+R(6M<=#!:C9V#WU6K1R@5/%&C^BP:9NJ6LTQ3 Q8^I!0@Z/Y\V\
M<LEW'&]A+GD<U&IP8AXG4I\ /VN$_S(^W.6.F'R9?-3U/18PU?\N\<?:)%<T
M7JKR(KT'*D<.?>.S\/5Y9^[I<;3*F-_T]KFI^$\/4PQ9X_1V;@SQB"59)OQ<
M_#/O9=G3U$H+<A'Q;:%;<-&K2LAU<+N\](?<]SV4]'!;_5@Q+7IY/ _HM!@+
M\&N(C;W:)P2S?=U1F6(>G^ZCQ@YOA-V7=5GD6M=T)*2RQIFXNNRD-IT4/%$U
M",2!3R+M%N$1RG29X9]03D2I-?^KK[[%VKXNGN;*<N:7=6&^:GL57;B.9BCU
MB'RKC2Y.-HEJP9\DY46YN&^Z2Y6^D%Y>;INZ_QGPU-3<1,A/-(?68G!74U!X
MD8/-G2</'1WN_T-Q.M//74/P)RA^*2'C<<!%#PO/\!Q4?TVS+,*D4Q!([2F@
M/2#EQJK$X@^97?G'46ZMMHKBF.M59Y%8 4?_?9XJL1 FAO[4D$4?D"V)1BY%
M5*D[)%A,DRC^4Z5HGM4XQ.")].7'B2]NM+^L7>EG]QW3%#J;/$4?H[..T_1)
M [?#SKHFEMA3 ZV_C*4;1V_W"5S;N OT_17YHI^IRX3KIZ(I\/4Z_4H\)9D:
M1MAFMT7 L7/LEZR.DI?)[&\IWH[)MLZR&=L[DTP:ZI7EWBT<H3)4W,)JE-\\
M$#&-3X]#&Y0+<E;5CD%D'66)/_,UN17>]GPA3MU(,59G?@UEY F$\L!FL:A=
MP[[#;,A?]LR5&@^-=^@Q$3;?,Z__T?N6R^X]K4^TUR:M$B820D]1+3K:[)6H
M'H3RQXMZ6DXN)53G;OOIV7^:M/LM7=FBNO3W=335N'X?,?1]@"CL0."(RSOA
MI__ESPVDMUOJ1FWZ/5<.[L,,40MDNOGZBX@0!?M&LD7[JCD5OL@FI2I6WU@_
MM"W\BC?=MYO('&5Z,T4/G.C/6(#>@Z(7-"W9+?E</B/^W:9;1V_.PB<CN'_M
MQ4<];E1?!63MM3!-]3U:\&*?ML4.VMXJLL&)W3LK+Q>K=3) *&Z600;>1V^;
M+VWPM%27ST= C!P"\V?=3E" 22LB*5@Q!S0ES_C4@;EL=!A7DRO)O8T"/4VV
M[.#@=+?.1?%658]"U)[(;&V+W(V)315UZ7DQF".C!Q0*46.((6IKE;2'M7;^
MM @6I+8/^0U<0#1LJ+54CW4<Q4W)W;Y;1:>#@$=C:\^ ,!(8#\TOIK&2<2^1
MN@Z![YMK2MRNM3R)*2U[=NWD&ZT->7D-'[CNG\K[M)O4\D632'N.*I))7#,O
MHL!Z]#>B,S$M']^C%>@2=#'AMF$F"&K+_A+_3%.-N>(HARY(C3<<@S@LSO-:
MRV029'GL=%4HUG5A538ZI^*48?,=#X\!#5_9-2E_6N^AV&P1V10;,BY!<;^)
MIX):T\9/*3RHR'N.;_1"&WE=SSC'F;SD0.410S7<R%FP)&W'H[WXZ9/VH%&T
MR=DYA(4R";OIXOI)_N@3_J+^X;?S8:7BF'.%J5' K\&!<<U22#W2W-<P!Q=2
MW":\6C_S*9I-XS&G0<S^5.\'_01R9-Z&E )>MB./=Q/,N0N.@YWW(/J]M?:
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MK:?JM/2L?DG%6_=6LAW7_WU+[K_XB[_XB[_XB[_XB_\ 3,>3_P502P,$%
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M5+^IEY4^O5\.)OJJ[*3")3V#>?O$+[20ML_3"N[ KT"U%']56'XCS41(MOX
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MRE]0R%/?3[U$)!ZENL5Z!BF-O" ;VO55QRYUT)#7K\XSC-?P0G6*@MEBM0;
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M6(*B**%BRF$5-T-Q755STR4[;54W0S .JKN9OG_!29/L[\[U;ZNK]>I;4:K
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M\CW5#]QG4*[_$.+83T*.$Q(E1L=')UR-K&KOBI6$/Y?G]1?0\0JJK:-G6:Q
MOFPX;EIR4KR@JA: .G-),[-^2?YMR5=UGAAXDAJFMB#M;4DWTZFIBZ:>)$.]
MU6.O[X#K&&SFI,=B?>W0,JDLTL8:=1]0YA0W5VK1"4_3JE"7,!ZH6Z>#.PUA
M43=B;:.!VR7O@M:0)Q#U ACXJBE00 0D./4A0X&'6!*EE&HUB[2@/;*:[7I/
M^$[B28Z"IWF0'@<2P\/SL<B/[67_#'1P25Y&B&JSP&#<B(^CE-]":,<0))HQ
M'(-#6-Z2EISEJX^8UG'_;4LL3H@?)RF&08KEZ8U0#E..&!0"I0AC%@?(J*'8
M,2(C*XF&).AHGN^2I8^.YO7DA3(;WCF:BFM^?S@@CZM+P6,DIKWI&Q#RX/IN
MZ%G+Q8BK;^K_5*C+,UZH#)POO%J5N:K%H?YPM62[O^@].<=I',NE*H]<7.7G
M)@S#+.81Q"+SL1<$:297[5/C55OA<J6Y=B_AR>2#W^=,_]N7-&N/#%4_\"WU
M&< KL));'^$/^5*98\J@5[]H:!GJ@HLF)Q D33U/&F%Q)"<GS A,,YK ((J1
M$-B/4):TD_-AR=[DU'1\.9P8KOQHKS4EFGI\*I -%;XDI$JF2& _]('=L@*:
M1Q3^>[_LO^%P@W !E*N=Y")>IMUR7,!VL#<Y&=2B1]W=7VX^O5?ESWE)<[SX
MT#K,OZ[)WSE=W1=?>/Y(UM*:4V>3]K!%ZT:6.),V9N)#E*GVM7$2PB!#82B2
M./0#+5>A+0,C6Z)?^#-?KGGC7+K["Y3\U??)#8/RQVI5@:KA3UTIEWT.#3J\
MV4 _K *G -1,Z[7P;=F9@8XAT'($[@NPPY--,TX;+ U:Z(V,J5U?/1ML'37:
MNP"/P>Y[-N-.UY+O JEW^O1=,H[]K3FO/1*/1;G*_]7Z/-_G%:W#\N7N<E?R
MQWS]6-TLGWG3:ZZ:$]_C2<"YU.SJ8BAF%))4ZGT_$!X58>CA+)HOZS0 30O8
MCA&MM90U:ZG/COY%0X\;9=\^-3P ^:]\R\:LON>1?\:=%,T=4,N[^36RQ93H
MWS&/!+/U!70#V$]]CGY6^&V8JBW?CBV5X+MAS.T=M3TP#B^P+9B8_';;'JAC
M5]\7C&9AUQYFS&U=[$U'L"^\[O0NC6D)R**YT[V3&EGMPP]\+C(:4AYRR' D
MC5S,0YCY(H(I$B%/.2=9JI5-XH2;D2W>?C;P4WLE@?M7$L53TTVU;+D$M,>F
M\@2T?!I8;!=/D(8I/"7LCB^!;EO$.P9!GT-P]RJ(&QC,4R)O9SV//P-F)K4K
MQ ;MZXN)3&=LN\)CQ_)V-N@%X0#D?*8W.='#\J]R9^3L;URE$W%V]<Q+R5.=
M?ZO2;S>5..9)3&/"N( 13CE$S(]@QCT":<BRQ ]#A!$U#B48G^^1=[F./L0-
M ^"A3O9C*G-9J,SEYSIS605NL4).?=D+YS+-!YAHH@W"'M[6]-GOEI=V(VZ$
MF8%.'-#*<SR/W7'<Q723X#)F8P*NIX_WF&XJCL:*3$C>;J_:9'#P\CFG_'B
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M>AQBZA'NP;!VVV4D:6X..8L\+Y,6=9@(LX354Z1&WBQJPCO>\+I.JED!>@W
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MFJ<\R7P69)!%B$(DUSS,4$H@CVFB(E42+_5-#._>V"/;V??J%;#8TC-TH_=
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M_0(>JX4PUU9+!IXZE&: ;AC8/ GI6_]@H%(D]%4O&#Q)6D ,2$<)6->5[B
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MQ"7*LB@TD=,Q8)ZE=3NG>0 ;_/%%==J2X#5/3RVVZ4FO*V:8R; ]'XS%6(=
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MFWE6IEE2\$1VN\#BI*(IS(LRAW&<)1D-*$V8UDFE#]+_/5 A, ,*!77^;)$
M?T@T@,+#<,Z#!B_U?#=N.61\=[R6.<9.'7UZ'3EX- !.ZNS19\"AX\?@3<O4
M FDX[W^)HSQ*,A2F,$%Q!!$/(EB4',.D2'B.TR!.D=$\\V,0GA7 %N 5PGZ"
M+WK"?1VU9L)L2*AY@/LL+:X"T\< I@THGR7P*!!\_DGSZHJ/M4HTO5GBQ4M3
M-7)<K)H6JUMG<>Y]WWZ>NEXMV6K3'.1G=&CH5V&<I7]<Q%R1;NC=&:<:_.%T
MVJ\.C5;E&V<7G:R0XQ)9PY*.B\]:.';D]#7<_&BG@U3+!W&<?JJ6>$GDSV1=
M/;<SP+OTO=^6-<.+ZK\9_2NNEK?+4[.%O[+U+;_'/^<TX"B@10!Q%""(0E[
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M*,01HAFG:6K4R403KF>QVDUF)1T^8+'+5S6[*.AR4L_.]\ ?,^GL$0!_"@Q
MC\(,;)%0137D0MZ7L5UM2+<CLU@7ZJ16K2$K#HU2T]<M0O:?5INE>+1S6J,X
MS4B1)S##2*B( A40RXEV28:SDA5!C(A^9_.]I3UK@0Z60<1UG_!QB;Z.'#.A
M[<#8E-SODV00!;8FS2Z,VX%SE6AY$OO1T.G^&]/%/D]BNA>\//V$I:.SZT5Z
MRV^><;60EL:G5?T=#_LS[Z<)*6MDURV0QV& P@0+@R'D$.6E+'XF*424TR"(
M"AIE9F475R+D68<,>[=N$03"L 42Q:Z9?EN?*GU;+<HO%J/@K]X833_CA.PV
M]!^>XC04G(:*TX-9 _OX>6T3ZXI=KMQ\UZ(SK?O.$?..W'*NUK4PC;J&)\TM
M_[Q<L\6"J?Z5?4O<[I1E:1@6 6<P8"B"B"49S$L2P#(K\SSG0GT65-MBTH'H
M60E:=3'2XI2&B>6:?C.MU$.7PTV&\'>-O"UL,BW6&)AJKEED9\%=9)4CT\Z$
MVE&+3VNAZ0Q!$[KV[$.C%Z\U&\]W_U8.R!@5A*5R5"270\\3QF">I@$LBK"4
M([ (95JJSQ2P;S^M1J-ZT_&2NBPU->S<,<K0[WL5CZXPS?0(=FZ"70#[2J:6
M'C/.FU2:[UN83BI4VLAYV/4SH\)B^]PT&Y6*NU2-1U0'VT%L5$52FWF617E.
MLQQF@1Q.S8( 8EQ@F,<%2AD.HICHEQ#;X>#[CJF0 G6'E;I=5AU><CC70X>9
MO!FM=K@!K) S3X&Y9C<T##;_/#:\6+;L[1$" B/0HR0'VO5(2;ME@%:;E&)2
M[&W)4@-#SS]K[4P_3RPVLPNO8\ZHI6BY]'2VXW6T[UF35RYE<Z=F3</8=N+4
M%X8;<5G?IG=^8JQ-D[GEOZZ6ZQ_"SI4)-]]DT"V*HSQ$00D13E*(>,1A7@0I
M#%&61@'%E ?Z]8#V>'@^( 9(@#5C,[!4>,CSX%%BLG@!I< $&+9JN(+O.O?V
M2;AI>)M7.,E$PW[(G$)K!H8<_B2?:'&3^JK%3OXD\0/?)N.QB0-@$EY;N@4\
M\]S0>7 UI\9="O;+3^AHN)H'^^Z'ZY=[G:3]P2%VT CQXT]9$-BPN[HB;)X@
MFH1)%D%,Y+0?E 4P+ZDX9(*@+/(X(F$63=@3V@Q[$P&W;OL\M.G:-/TWUO[9
M<,?S A<))R6D.8T@2L,0YB0J(4N"*"(\+7A13-;AV?=^&S=Q/M[MM]3,V7"K
M-;UK;V_S+"[!CJHS]@HPCMHN]P0!1=';J<PPW((W4IBAB_6_55V&X5:X+LLP
M!7_E>')E$'V3<&[Y;PU3/7;F12INJ*B,( ^* J(\11"C0G8]SDA!6(;+7,NK
MJ07-\_5T9]DOF+J&2NAPQ>%&_()52R'+L>4G6:>GL9TQQ$S/'MUROO7,$+#;
M+EX>AIB/T>AZD/E)6*\SS'R,[+,#S4=?,B\L^5C74@O)?!.A0UZ,BDQ.O>M9
M5@7(U9*M-LWBI3W7#^V!'AG]XI.3'!@74A?$F\FE-MUN"U3&B+0J5CFYX&2%
M*V/D#(M81I][]<M^5YA=)$&2L9S"K.#B6H\C<02G<0ISFL9!Q'&4948S!YQC
MZ%D5R+Y'XHO?R-;MX$]6,]!LRG\PLI:EUL,XXZHKSG^U6OOCO8LRE.49D:,B
M,@)1@A(H?LT@2<(0I8%,02E?U25COH/>G2]O9.M8AM(XHR%,49*+K2LP+%E
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M-?Z0W:%Z\XRKA6R$_6E5?\<+)N>B?6=D4U?KBC4WA&P>-PMYQ?UKO6H:&2#
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MV;/;B(*PV+9.[J6W^:4&9?!&2)[W'E[Q,7,@4@LPJ $&/8YC9<,%:@2: 5V
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MKL)8SR5,A9R9VQAII?)=MGH!I9BZ+>M5FX'Q1<7,&]V,"Y@<>:&K5)G44[D
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M=+%4[)4JHEAU*H)RT+&]@1.#E@!OJD\,NUWIHZX7??6"I9GK[%4 MSM8;;0
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MNEC":9UW@@1G/F999OF$:_XS;CC;N9"J:_FRVH##SZ_;C]SC5_6KFS]QS8;
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M?P3A\D^JM*%E&IBVY:[]-T1S(_I7>.\6=Q>.6NW^OOUN?!A]-]2OY:>V1L[
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MGK*,!KDB,X1<OFLC)^[:/JM6[>JZ;3?&/0\Y$Y@%.11!7$"4A +F*!8P#(G
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M/^#O7Z1?5)=!E>JMW2X]4C[K: 7)@JO"[:I1U=E<?G%7][Q6V77S(J,H)$+
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M/FSH[-\</-^7;6_VIB>_>=MT>]J8.B:,V-S+C>R=@<'BS5&YM;FCH=FFA/P
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MXU"]V$U#E4=?GEB1]:CIOO'F(<;CHIZ/(XZ6$J8BN@XK?<O16&A03'!0,*O
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M0:S:3"6(RHN,_&/! IZ1%$<@?_PPN<E#LPUQ;T-^MB/)_P-H,0RC96@0.,,
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MP*PHTBQ,4)+F*<*YSU'.(XJR("QXD8<Y#T.S.X4YT<FO IJ>VA]/<DOH1CT
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MI3R+$,8D1#DN,GD13 /*HS!G<;%X%A5=OQ6F?>+F,8/U1BK3Y9O\2 TB!Q/
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M%HS)GR]^^B^['_]ZZ^?_E)N?YM[[GS??O?S1U?2N'Z2/Y3__SU_?_)X^X5F
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M54L[7%PM?!@J.LYDMA!H3YC8G(UOE^^6BR_3><)),,Q(%A*XHBG>QB(@".N
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M1?9G4T)H)<1@ B3NN$G.&&2Y!0 .+L)L'@0,K/Y'2[$/Y;_9M2Z<U*1I]EB
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MV"8T&V=>XM 'VVG"'C&9M/'M+LYELJ5?<+F>;JI1YM/%\K?%FIRZ(H14% .
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M XCLT+_7J,RRY*UE) 0;B'Y%]!>E06?&F73!B]+Z9+I)0R<^[I$ZO55O=(*
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M]Z'M0*5[A3:)40>3>08RXA*4J;?62B (%*Z@UL17ZTSZPQ2-'+0-#[&&"NG
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MD=W:M8^J8XDVA(39%20)?MR0;$#EVK JIWI=Y6NF(V'*6KMB<^--_  Y)^5
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MN6)&B.93J(=KO/N^RG".^:*U*JUT?G:^N>I\@1253M>3Y(HN=4!J)/2#BE*
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MZ2*_+<_R8CL^L5K!@#YEYR.$D.CDXS&"L]*!$1D=ER2:P]KN? </A] R?C_
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M6(%L(W'%O,BI=37 PQ2-ZP /!:N&6AC[ZF)W.-1NSN>SRM(KO-H<-F:9I55
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MGL*JD+(QV'J,YR-D3.N5-=#[8\'X,:+NX(A[2TO.-S^'5),95X/#K1 F6*8
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M6>+9,U$@<T8!KLB^CGK0((TK#I4200^JO7I!Y?<6G5CIAZALV4)^'3C!CUC
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M:M6ZX2RGDK(*K6]91PPV=J9^\:D&_F_#:O6-!/QG6.7UU95G)J< M:#=$*(
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MI,?HZ.0*LR5ZCA9W#]T^M\>X)C*S$ X$CY9L)[?@BD^@F=3)H9.)#7*4F_:
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M=O%G4M)OM/;JMRT%]+._+=?S*^<N.PQ1JURC"D'2]!I<UHID$+,416,)K>/
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M>0,H=3;($BOCE'V-S]JPC?2O6_O3X>?5;*OK0K@;,?#:URZ46E0J5=%T%J.
M&)$#JL*UR%KF.,H;^1%X&;9Q7MOU?E<(Z66G'%%^?9W)N*D:W1[3[Q:;U7RQ
MGJ<KZT'Q(!KI"]A$;JP*&2'Z*" [S;W-S/!\\J+C!GP-VT&OK1Z@6^3TL)ON
MM/]^Y'GHN\6==N SJXRW6EB(69*K*G4$CT)"5$XH5?-\=LPF_"_1-PS=K[5(
M8#1-=H#2MQ=AO7Y?_B-486[>K[9U.3=<8KI<S3=S7+\-%Q>8?_BV^[GU[@?7
M,RPAA)0L>7_.TQ%GB?'(/:#-3D87,VL^;O!(DH=A^;5>YI]2WQW ^\[6W=ZO
MT.FRE>Y,LRC1,@W)E3JD" WXB QL43K(9)SE(QK<>[0, ^2KO;5NH:$.D/;H
MQKIWMW?SS9O=1!$"2FFD2F B%_4^3X'/J,%:9Z(40DC9.HUY$*'#&FF^UMO=
M\77; 8"O&7BSR%<<W+E^_HBK+[,0>#:R*"C.9>(G98C%U#L]G7*Q E7S$M:7
M:!H&R]=V,3N*QCI X*/;[ Y/,RE,"M8XP!PH L00(4A,="185QN <]X\<_T2
M3<,0^%KO/)MJK ,$CG87=?M)5[_T?O,95Q\_A\5U84^4GHN4)1C!.*AH$\3
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M_9-LKYWAT;XPM#8 "ETG]84(7JD,/A7&#'G1R773%6]O[@9MKYX;K/2^O0X
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M1!WK7+;MJR65P KK+?(4E!^G_FHPB5VY;*> X"&J.3?D$91PIJUE498"&>M
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M)0:CI#A'6E$_ H<JQ*ECB JM_+\Q'OR*/ CCX:8^?ZAG\/O:[]E;>]0T?N3
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M+,9W%%9\2!.7OE=;C<"^X[4UK/GHJAIG=/>->N2_.4UHY?)ZX6/'C>W%%!G
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MSBB3R'XE01F>NT9,BX*@&2X!4XN""BE6W2;?G/+$?$? E%EHI,EHU85+DZA
M6I_JJTW3?PF9CCMM$M=*8R'Q2/>0PX)6"F;M0Y0R515T,V/<,F&-H@8K%EJ+
MTL!%M^80XRYMRKQ-E1,W+?#HJ#\=A:8+:FQ].FT=-PVR;QOD0*>[LLFH/YR$
MSXJ]OO^L[%NP0= /@\F+8 =VR6[92(Q"HH\[8:<UJ&B:XLF>><2WQ+9XWU -
MJGNC_+@S%I#MT.@8_/_WN1U7]O>&DTC9?_)>;B@G'YBD=2H>MMB_RTVS!>W
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M&?M$EKOWFXHLW5,4X/;"<]^.Y"88<=,"@DOW_S!CNIXQ6)X!)R+]<'30<[_
M1EX^JAQ,IN2:\J3WVE-OV4"/C[:W?48[NWTF5>DCMR"[G707EL8[MT'6<]*K
MNCS=L*W"<JD^3F#I]SOE2&69FCHE<BXP;O56ARLL7QJEPO08<F[[O(7DD\?'
MST\W<9@^'VSO,!6[>IB^3KG0OJ362K7U[B3=!N5GL)1W'<7^T744JXK;R#$L
M_< *0.L@@N4!L'MEPXK' ^# JM,1EA&=:;AJ&C+@C>&'9\'O"DM_\#<C-URL
MG>U7_>OW-_MWSWUP-Q;LB8WY#^XR@)O\!^_<GP4%#K'?B"<[T=A]GYU=YX*N
M# S&#;MVY$M^D#6QP-7CB;6V:?;#X?$B3.26+;M6?'=5)._JT=J<3'YS@*AT
M,^3!%KGO4;DA=T+GRKK%E77["ESV/<)RRN\U*R)[_UWGX.9=!XZIE?C!DM^Y
M4CM7:N=*124=EO*N3C@JZ<BY;$%YA*5^PW;> ^# 7JA$"TN^38&#)<C[7LM_
M\!26"1VH%AE4"[SS+3QBN"Q8XPD<W.()O%?\H?ZU$\^+0IG [Z&FC%NWZ$ZG
M(K'I<'#@A]*^*U+6JGQXL+B%1T9EI;UZR[6#:+^F>I&".*9^I(E_Z?.1)3WD
MV93/S/+/YT+VVP._;IBMX$IH%'%CD/"6@3Z0F,UD5T,V[<S8+G+3@9 [$/+6
MF-!YSCO/.2KI'0BY<R*#TK[YVB0/@PG@ON3.G=2YDS!)[]Q)7;9%5]T'E/0?
M!L?H62:PM'?9-1U0^$:<.F<5KJQ)#%GOK&85#(-Y. *#MB2[L/Q*-B\L%SI[
M8DW"!BQ+?'CZI'?<BD[#LN)[S0K<V0#S!Y4+Z3[U)[I,W*FM"W\5L;=J0EIR
M&5,7=]XE30R6#;=G2@8E]%X"?26?$):[M^11WH:>@N/7_<PC6#;=?T6N6(OM
M)?ZT6ZZ=5W[%*[^\3<UK3,!R9>.U-;99>CW>52WZ@L]R7R_%R6!7<WVK\O\Y
MI54%QK"$3*Q%1 D3DOU>]3@S;. [H?@3:; 7@3OD8*E'[G#*M03N;PJ,YL*M
M@_"UY-JZ0QNWOVG$C<#%,3OJNRT/D73<+2_F&<F$XUK$]9X/2[^S<&!I[XP;
M4-(++G"E/L)5;Z'Q92HON,2=>P&LWFI-?%,NYP= OU2X==XRCJS==D7.0&D?
MB9$EDA87*YEPW+-^WC 7E@/(:Y^ 71K 8#+?0AV6^,Z/6_EQ<:$M[SI%%Y%V
MFC@M%Y9ZW,#=>GQYHMPO2&4#QI,JF/G:*WO,72TJ##4OBDS$/,J(-:5'UX/B
M8)GM(8"]D-[ )7/KS3&1-2<NJT^>7N#E'&_L0PS,JBH?XIID@ !7CQS7=4"\
M)]#09,^]0NF0':Y&%=]6><QX;$O'M%DEW\D=!#P\IQ'K'@.NTK=8YAM!?@^>
M;PWYS?R_P_T=17^??RV%G;'-5XKKP-]W/S)AF=#LC[C[8(?Z "5]K+FTP !/
M:#,Y',*PY/,IUPGNEK\P9B/*U!17!0KY;T$6V I/%M9HO4VRH,*&#+CY5Z:,
M_G#:@[=KO;GF+++<,&0$J;/<)\($ATE=8*+6]B\R+H,)RN6,53GK+3=+C<5B
MU:[DS-38.Q4FS@#.JKQVV<^YD,&5X.8'=]]JZL8Y9O661;&1TA61I$N*R^!#
M\%<GE#FNZIF?G"#VC(\UD4_&-3W/]JQ,D*/$W%H>IXZ+=)F*2%1,\2PUUG%7
M!$^+Y^I(^85>:)H(51KWH9-E)_E!-L,%ORC'W'UVYN:F)>;5_E M#%@>MS:$
MP)M9):K"L NMG!3GWHDE1FQ45GXMZ[EM4^:V#!*RDGHO\T'@ S>-5?$7IHK*
M4>NO<[/ -2Z+ZST EGYD:"NP*:_)%$[L<=5ZJW!)!SY1@UH!2STPP@M9Z,^Q
M'5A>?88E'MG#@KSF%Z8T+@N\UP:7^L9;A>NQ_A4;$@5+.Y\HD?CBK[ <4".6
MJ#*R%;#0I%P3DZ4O&6PJY*8P#3"3':Z-T?#$ [5"Z4GNW;=J(I(*T+D:J8!E
M\CP&P*;"IJQVJ03FR9E[.W'<IMKC:MQI;-O=;-PE3QX_/QR<G!H6JSQW$U%=
M2:.1>XICM<<R:L=YX5X[;P4D[>=!%GQP[PVWWU_17;ZK17??2>$C6.QL@]"'
M#G%YB^PCI^1U<-,6W!26 =,4]]@'+B4JJM,'N)0L94$%AJ4?>,_C1:$$-M1:
M+6!1C(]L:%GC3.XE6^!*OYH:TU,C+^^*)H1E\GU1E&P)3>BFJ"AUG')GWQ\^
MJQI8!2<+/&)MQ;4!RX?*I0-+?G!EP5(///'(>U_BSF58XH&A1=!ME6MC%9;^
M8*HBUS?I;%5LD,5GX!._2XVMTD!A.0"</>,Q)+#$S[$S/H8]A\]H&I'6%&IW
M<<.\$^3PX'3#3 I/' K+,Q$OC?QD[<AW*+0=^#/8-']V5X@^J-N*NS6)RKD"
MSM"$KL.O)+&E)?O=@8"B704!_5Y&AKZ6'@&Y YLE[ HXNV:3G*:*[8FG3)BJ
M*;T<>\3D/'(&RR\^+R?B_9&A>H6<-8W+<R(;.+4>B!K<]JG*$H\3OC;TZ*L*
MI.YG(B+<C;F1N>NKB%8U7RW+B!LW/''ICG%I4\.NSE H-%K/356U84\XT9X*
MX SUV%TA9 FL]^""O_SBPIUXY#K#L)1WB-\.\?OHE<AS2H33"H#!GUT#+NB
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M*EO[D$6KLK7[2ZMRG%9!C)#..:G<?<'7CNUW@R5^$:V'94%PM<)2CUWUP.^
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M61#X)B:?\TN1ESGCN2IE:)_G]7-8WG:&R0*BM9 R6&X8PD6(CI2V*0-NN;#
M4,"RH,:.X.(0G.)!HQ%R>0%L UT 8Q2]$NZ>]^?,TOI))Y[.0AD1;#!-&?=P
MI].I2&PZ'!SXGVG?%2EK53X\6-S"(Z.RTEZ]Y=I!M%]3W3RYX&/J1YKXEWX
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MV0&ZH=K9UG'DYTS.R36#!I4J#SKL.G@A^P>"?Y#<'%LCK(LF/B9^Z2?'(=M
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MD=4-8(0!=9DE<0LQ*K45<T*10UU-1 E[R_T;U]&\U]VBM:[<C[)U;UPA.1
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M<W,M,C R-#$R,S$N>'-D4$L! A0#%     @ ,8!M6E,2ZQE1)   <FP! !4
M             ( !=X@# &=O<W,M,C R-#$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( #& ;5JW9FY\Y6L  )K.!  5              "  ?NL P!G;W-S+3(P
M,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  Q@&U:NE/:R =H  !;?   %
M            @ $3&00 9V]S<RTR,#(T,3(S,5]G,2YJ<&=02P$"% ,4
M"  Q@&U:KM31) :O P"7& 4 %               @ %,@00 9V]S<RTR,#(T
M,3(S,5]G,BYJ<&=02P$"% ,4    "  Q@&U:IS,S20E- 0!'\@P %0
M        @ &$, @ 9V]S<RTR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @
M,8!M6K@D4>QOO   %-8( !4              ( !P'T) &=O<W,M,C R-#$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( #& ;5H%,3B-HP<  /P?   ;
M      "  6(Z"@!G;W-S+3(P,C0Q,C,Q>#$P:V5X>#,Q,2YH=&U02P$"% ,4
M    "  Q@&U:QIB8M*,'   '(   &P              @ $^0@H 9V]S<RTR
M,#(T,3(S,7@Q,&ME>'@S,3(N:'1M4$L! A0#%     @ ,8!M6M_PL71=!
MO T  !L              ( !&DH* &=O<W,M,C R-#$R,S%X,3!K97AX,S(Q
M+FAT;5!+ 0(4 Q0    ( #& ;5I?F\1>7@0  ,@-   ;              "
M ;!."@!G;W-S+3(P,C0Q,C,Q>#$P:V5X>#,R,BYH=&U02P$"% ,4    "  Q
M@&U:_G9!LF 5  "B* ( '@              @ %'4PH 9V]S<RTR,#(T,3(S
M,7AE>'@Q,#=X9&ER96,N:'1M4$L! A0#%     @ ,8!M6NTX5B+Z'P  5\L
M !X              ( !XV@* &=O<W,M,C R-#$R,S%X97AX,3DQ>&EN<VED
M+FAT;5!+ 0(4 Q0    ( #& ;5H[;J68K@(  %@,   >              "
M 1F)"@!G;W-S+3(P,C0Q,C,Q>&5X>#(Q,7AL:7-T;RYH=&U02P$"% ,4
M"  Q@&U:@ZGF85T#  "C#   '@              @ $#C H 9V]S<RTR,#(T
K,3(S,7AE>'@R,S%X97EC;VXN:'1M4$L%!@     0 !  8@0  )R/"@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>goss-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:goss="http://www.gossamerbio.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="goss-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2025-03-06</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:RevenueFromContractsWithCollaboratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:RevenueFromContractsWithCollaboratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:RevenueFromContractsWithCollaboratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-02</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-02</startDate>
            <endDate>2019-05-02</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">goss:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-02</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">goss:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-02</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-03</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-21</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:OneHundredThirtyPercentApplicableConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:OneHundredThirtyPercentApplicableConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:NinetyEightPercentApplicableConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:NinetyEightPercentApplicableConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">goss:TwoThousandTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-02</startDate>
            <endDate>2017-10-02</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-02</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">goss:PulmokineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">goss:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentSeralutinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentTerminatedProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentTerminatedProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">goss:InProcessResearchAndDevelopmentTerminatedProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2020-05-21</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-15</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:OfficerDirectorEmployeeOrConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-03</startDate>
            <endDate>2015-12-03</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-03</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-04</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">goss:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-04</startDate>
            <endDate>2018-01-04</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-04</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-21</startDate>
            <endDate>2018-05-21</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-21</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-06</startDate>
            <endDate>2018-09-06</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">goss:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-06</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-03</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-03</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandTwentyThreeEquityInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandTwentyThreeEquityInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-06</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-06</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">goss:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">goss:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:LeaseAgreementEnteredInJuly2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-09</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:LeaseAgreementEnteredInJuly2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-09</startDate>
            <endDate>2024-07-09</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
        </entity>
        <period>
            <instant>2024-07-09</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:NonCancelableLeaseAgreementEnteredInAugust2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">goss:LeaseAgreementEnteredInJuly2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-03</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-03</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-03</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:USLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ROWLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:USLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:ROWLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDResearchAndDevelopmentServicesPerformanceObligationsSatisfiedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDResearchAndDevelopmentServicesExpensesSubjectToReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PAHCommercialExpensesSubjectToReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:PHILDCommercialExpensesSubjectToReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">goss:ChiesiFarmaceuticiS.p.AAndChiesiUSAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">goss:EffectsOfExchangeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">goss:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">goss:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728117</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">goss:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>goss:segment</measure>
    </unit>
    <unit id="security">
        <measure>goss:security</measure>
    </unit>
    <unit id="tranche">
        <measure>goss:tranche</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tradingday">
        <measure>goss:tradingDay</measure>
    </unit>
    <unit id="vote">
        <measure>goss:vote</measure>
    </unit>
    <unit id="day">
        <measure>goss:day</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="month">
        <measure>goss:month</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>goss:performanceObligation</measure>
    </unit>
    <unit id="license">
        <measure>goss:license</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001728117</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="c-20" id="f-196">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-49" id="f-390">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-431">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-432">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-116" decimals="7" id="f-580" unitRef="number">0.0616095</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <goss:ShareBasedPaymentArrangementOptionRequiredCancellationPercentage contextRef="c-186" decimals="2" id="f-947" unitRef="number">0.33</goss:ShareBasedPaymentArrangementOptionRequiredCancellationPercentage>
    <goss:LesseeOperatingLeaseExtensionTerm contextRef="c-235" id="f-982">P1Y</goss:LesseeOperatingLeaseExtensionTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-38796</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">GOSSAMER BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">47-5461709</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">3115 Merryfield Row, Suite 120</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">684-1300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">GOSS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">197400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-30" unitRef="shares">227221261</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Certain sections of the registrant&#x2019;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of this fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-36">&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have developed and implemented a cybersecurity governance program intended to protect the confidentiality, integrity, and availability of our critical systems and information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity governance program includes reporting channels to the executive management team and an internal Cybersecurity Oversight Committee, as well as governance processes which communicate cybersecurity risks to departments across the organization, including legal, strategic, operational, and financial areas. This encourages consideration of cybersecurity oversight, accountability and diligence across the organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key elements of our cybersecurity governance program includes but are not limited to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Processes to assess cybersecurity risk, designed to help identify material risks from cybersecurity threats to critical systems and information;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;a security team principally responsible for coordinating and managing (1) cybersecurity risk evaluation processes, (2) implementation of cybersecurity controls, and (3) response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of the organization&#x2019;s cybersecurity processes;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;cybersecurity awareness training of employees, including incident response personnel including third party providers, and senior management; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;a cybersecurity incident response plan which includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, which have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect the organization, including operations, business strategy, results of operations, or financial condition. See &#x201c;Risk Factors - &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or Chiesi or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our seralutinib development program, which could materially affect our results.&#x201d;&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-38">Our cybersecurity governance program includes reporting channels to the executive management team and an internal Cybersecurity Oversight Committee, as well as governance processes which communicate cybersecurity risks to departments across the organization, including legal, strategic, operational, and financial areas.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-37">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-41">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-42">&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of the cybersecurity governance program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Assessment and management of material risks from cybersecurity threats are performed by the Executive Director, Information Security, Risk &amp;amp; Compliance and the Vice President, IT and Facilities, reporting to the Executive Vice President, Technical Operations and Administration. Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions, in addition to holding active technical cybersecurity certifications and maintaining active membership in cybersecurity professional organizations, as well as local groups, to support knowledge share and ongoing cybersecurity professional development. &lt;/span&gt;&lt;/div&gt;Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us and alerts and reports produced by security tools deployed in our IT environment.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-43">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of the cybersecurity governance program.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. &lt;/span&gt;&lt;/div&gt; Assessment and management of material risks from cybersecurity threats are performed by the Executive Director, Information Security, Risk &amp;amp; Compliance and the Vice President, IT and Facilities, reporting to the Executive Vice President, Technical Operations and Administration. Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions, in addition to holding active technical cybersecurity certifications and maintaining active membership in cybersecurity professional organizations, as well as local groups, to support knowledge share and ongoing cybersecurity professional development.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-45">The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-44">The Audit Committee receives formal annual reports from IT management regarding cybersecurity risks. In addition, management would update the Audit Committee and Board, where it deems appropriate, regarding cybersecurity incidents it considers to be significant or potentially significant. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-47">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-49">Assessment and management of material risks from cybersecurity threats are performed by the Executive Director, Information Security, Risk &amp;amp; Compliance and the Vice President, IT and Facilities, reporting to the Executive Vice President, Technical Operations and Administration. Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions, in addition to holding active technical cybersecurity certifications and maintaining active membership in cybersecurity professional organizations, as well as local groups, to support knowledge share and ongoing cybersecurity professional development. Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us and alerts and reports produced by security tools deployed in our IT environment.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-50">Our Executive Vice President, Technical Operations and Administration reports to the President and Chief Executive Officer. This group holds primary responsibility for our overall cybersecurity governance program, along with our internal Cybersecurity Oversight Committee, which includes senior personnel from key departments in the organization. The collective experience of the individuals listed above, along with the Cybersecurity Oversight Committee, includes decades of experience working in and overseeing IT and cybersecurity functions and enterprise, IT and cybersecurity risk management functions</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-51">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-52">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-53">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-54">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-55">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-56">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-57">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-58">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">46074000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">32109000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">248444000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">264316000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">5338000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">10032000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">10094000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">309888000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">306519000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">1648000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">5111000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">3131000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">283000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">618000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">315292000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">311916000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">2319000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">5526000</us-gaap:AccountsPayableCurrent>
    <goss:AccruedResearchAndDevelopmentExpenses contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">10455000</goss:AccruedResearchAndDevelopmentExpenses>
    <goss:AccruedResearchAndDevelopmentExpenses contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">7779000</goss:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-6" decimals="-3" id="f-82" unitRef="usd">11613000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">17050000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">15186000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-86" unitRef="usd">26680000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">45010000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-88" unitRef="usd">51598000</us-gaap:LiabilitiesCurrent>
    <goss:LongTermConvertibleSeniorNotes contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">197523000</goss:LongTermConvertibleSeniorNotes>
    <goss:LongTermConvertibleSeniorNotes contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">196591000</goss:LongTermConvertibleSeniorNotes>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-3" id="f-92" unitRef="usd">814000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">4398000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-94" unitRef="usd">144000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">38869000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-96" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">285800000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">249147000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-99" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-100" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-101"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-102"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-103" unitRef="shares">700000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-104" unitRef="shares">700000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-105" unitRef="shares">226604138</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-106" unitRef="shares">226604138</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-107" unitRef="shares">225409315</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-108" unitRef="shares">225409315</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">23000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">23000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">1296848000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">1275136000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">-1268568000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">-1212040000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">1189000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">-350000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">29492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">62769000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">315292000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-120" unitRef="usd">311916000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-121" unitRef="usd">90682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-122" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-123" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-124" unitRef="usd">24019000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-125" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-126" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">114701000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-128" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-129" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">138487000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-13" decimals="-3" id="f-131" unitRef="usd">135304000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-14" decimals="-3" id="f-132" unitRef="usd">170919000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">0</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-13" decimals="-3" id="f-134" unitRef="usd">10000000</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-14" decimals="-3" id="f-135" unitRef="usd">65000</goss:ResearchAndDevelopmentInProcessExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">36133000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-137" unitRef="usd">38455000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-138" unitRef="usd">47609000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">174620000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="-3" id="f-140" unitRef="usd">183759000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-141" unitRef="usd">218593000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">-59919000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-143" unitRef="usd">-183759000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-144" unitRef="usd">-218593000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">1779000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">1997000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">1583000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">11517000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-3" id="f-149" unitRef="usd">13511000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-3" id="f-150" unitRef="usd">13880000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">14022000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-152" unitRef="usd">15456000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-153" unitRef="usd">1512000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">4284000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-155" unitRef="usd">3942000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-156" unitRef="usd">-10785000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">-55635000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-158" unitRef="usd">-179817000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-159" unitRef="usd">-229378000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">893000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-161" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">-56528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">-179817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-165" unitRef="usd">-229378000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">1450000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="-3" id="f-167" unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-168" unitRef="usd">-544000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">89000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-3" id="f-170" unitRef="usd">191000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-14" decimals="-3" id="f-171" unitRef="usd">-75000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">1539000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-173" unitRef="usd">224000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-174" unitRef="usd">-619000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">-54989000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-176" unitRef="usd">-179593000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-177" unitRef="usd">-229997000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-178"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-179"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-180"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-181"
      unitRef="usdPerShare">-1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-182"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-183"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-184" unitRef="shares">226228016</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-185" unitRef="shares">226228016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-186" unitRef="shares">152621669</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-187" unitRef="shares">152621669</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="0" id="f-188" unitRef="shares">84574869</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="0" id="f-189" unitRef="shares">84574869</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-15" decimals="0" id="f-190" unitRef="shares">75752664</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-191" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-192" unitRef="usd">932944000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-193" unitRef="usd">-811534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-194" unitRef="usd">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-195" unitRef="usd">121463000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-197" unitRef="usd">-53527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-198" unitRef="usd">8689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-199" unitRef="usd">-44838000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-14" decimals="-3" id="f-200" unitRef="usd">184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-24" decimals="0" id="f-201" unitRef="shares">16649365</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-24" decimals="-3" id="f-202" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-203" unitRef="usd">119944000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-204" unitRef="usd">119946000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <goss:StockIssuedDuringPeriodSharesVestingOfRestrictedStock contextRef="c-24" decimals="0" id="f-205" unitRef="shares">662700</goss:StockIssuedDuringPeriodSharesVestingOfRestrictedStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-24" decimals="0" id="f-206" unitRef="shares">270707</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-207" unitRef="usd">1736000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-208" unitRef="usd">1736000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-209" unitRef="usd">42553000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-210" unitRef="usd">42553000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-24" decimals="0" id="f-211" unitRef="shares">157858</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-25" decimals="-3" id="f-212" unitRef="usd">1214000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-14" decimals="-3" id="f-213" unitRef="usd">1214000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-24" decimals="0" id="f-214" unitRef="shares">929887</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-215" unitRef="usd">-229378000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-216" unitRef="usd">-229378000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-3" id="f-217" unitRef="usd">-619000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-218" unitRef="usd">-619000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-28" decimals="0" id="f-219" unitRef="shares">94423181</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-220" unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-221" unitRef="usd">1044864000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-222" unitRef="usd">-1032223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-223" unitRef="usd">-574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-224" unitRef="usd">12077000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-13" decimals="-3" id="f-225" unitRef="usd">10779000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-33" decimals="0" id="f-226" unitRef="shares">129869440</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="-3" id="f-227" unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="-3" id="f-228" unitRef="usd">201310000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-229" unitRef="usd">201323000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <goss:StockIssuedDuringPeriodSharesVestingOfRestrictedStock contextRef="c-33" decimals="0" id="f-230" unitRef="shares">55225</goss:StockIssuedDuringPeriodSharesVestingOfRestrictedStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-231" unitRef="usd">28518000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-232" unitRef="usd">28518000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-33" decimals="0" id="f-233" unitRef="shares">336795</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-34" decimals="-3" id="f-234" unitRef="usd">444000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="-3" id="f-235" unitRef="usd">444000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-33" decimals="0" id="f-236" unitRef="shares">724674</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-237" unitRef="usd">-179817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-238" unitRef="usd">-179817000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-36" decimals="-3" id="f-239" unitRef="usd">224000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-240" unitRef="usd">224000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-37" decimals="0" id="f-241" unitRef="shares">225409315</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-242" unitRef="usd">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-243" unitRef="usd">1275136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-244" unitRef="usd">-1212040000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-245" unitRef="usd">-350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-246" unitRef="usd">62769000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-247" unitRef="usd">20619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">20619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-42" decimals="0" id="f-249" unitRef="shares">767125</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-41" decimals="-3" id="f-250" unitRef="usd">629000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">629000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-42" decimals="0" id="f-252" unitRef="shares">427698</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <goss:AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued contextRef="c-41" decimals="-3" id="f-253" unitRef="usd">464000</goss:AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued>
    <goss:AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">464000</goss:AdjustmentsToAdditionalPaidInCapitalEquityOptionIssued>
    <us-gaap:NetIncomeLoss contextRef="c-43" decimals="-3" id="f-255" unitRef="usd">-56528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">-56528000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-44" decimals="-3" id="f-257" unitRef="usd">1539000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">1539000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-45" decimals="0" id="f-259" unitRef="shares">226604138</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-260" unitRef="usd">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-261" unitRef="usd">1296848000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-262" unitRef="usd">-1268568000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-263" unitRef="usd">1189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-264" unitRef="usd">29492000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">-56528000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-13" decimals="-3" id="f-266" unitRef="usd">-179817000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-267" unitRef="usd">-229378000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">833000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-269" unitRef="usd">1607000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-14" decimals="-3" id="f-270" unitRef="usd">1832000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">20619000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-272" unitRef="usd">28518000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-14" decimals="-3" id="f-273" unitRef="usd">42553000</us-gaap:ShareBasedCompensation>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">0</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-13" decimals="-3" id="f-275" unitRef="usd">10000000</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-14" decimals="-3" id="f-276" unitRef="usd">65000</goss:ResearchAndDevelopmentInProcessExpenses>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">3318000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="-3" id="f-278" unitRef="usd">2778000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-14" decimals="-3" id="f-279" unitRef="usd">2597000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">1086000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-13" decimals="-3" id="f-281" unitRef="usd">1321000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-14" decimals="-3" id="f-282" unitRef="usd">1163000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">13062000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-13" decimals="-3" id="f-284" unitRef="usd">9450000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-14" decimals="-3" id="f-285" unitRef="usd">1405000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-806000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-13" decimals="-3" id="f-287" unitRef="usd">-726000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-14" decimals="-3" id="f-288" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">5338000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-13" decimals="-3" id="f-290" unitRef="usd">0</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-14" decimals="-3" id="f-291" unitRef="usd">0</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">-62000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-293" unitRef="usd">3892000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-14" decimals="-3" id="f-294" unitRef="usd">-296000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">-335000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-13" decimals="-3" id="f-296" unitRef="usd">-62000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-14" decimals="-3" id="f-297" unitRef="usd">-400000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <goss:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">3386000</goss:IncreaseDecreaseInOperatingLeaseLiabilities>
    <goss:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-13" decimals="-3" id="f-299" unitRef="usd">2982000</goss:IncreaseDecreaseInOperatingLeaseLiabilities>
    <goss:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-14" decimals="-3" id="f-300" unitRef="usd">2721000</goss:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">-1656000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-3" id="f-302" unitRef="usd">3990000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-14" decimals="-3" id="f-303" unitRef="usd">-1813000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">-10718000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-13" decimals="-3" id="f-305" unitRef="usd">-835000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-14" decimals="-3" id="f-306" unitRef="usd">-1659000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">2676000</goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses contextRef="c-13" decimals="-3" id="f-308" unitRef="usd">-7847000</goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses contextRef="c-14" decimals="-3" id="f-309" unitRef="usd">-579000</goss:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">1701000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-13" decimals="-3" id="f-311" unitRef="usd">-3240000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-14" decimals="-3" id="f-312" unitRef="usd">1618000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">55919000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-13" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-14" decimals="-3" id="f-315" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-135000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="c-13" decimals="-3" id="f-317" unitRef="usd">-97000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="c-14" decimals="-3" id="f-318" unitRef="usd">-1000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">-3468000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-320" unitRef="usd">-159158000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-14" decimals="-3" id="f-321" unitRef="usd">-187032000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">0</goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions>
    <goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions contextRef="c-13" decimals="-3" id="f-323" unitRef="usd">0</goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions>
    <goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions contextRef="c-14" decimals="-3" id="f-324" unitRef="usd">65000</goss:PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">494777000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-13" decimals="-3" id="f-326" unitRef="usd">441670000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-14" decimals="-3" id="f-327" unitRef="usd">238060000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <goss:ProceedsFromMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">523800000</goss:ProceedsFromMaturityOfMarketableSecurities>
    <goss:ProceedsFromMaturityOfMarketableSecurities contextRef="c-13" decimals="-3" id="f-329" unitRef="usd">330700000</goss:ProceedsFromMaturityOfMarketableSecurities>
    <goss:ProceedsFromMaturityOfMarketableSecurities contextRef="c-14" decimals="-3" id="f-330" unitRef="usd">237500000</goss:ProceedsFromMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-333" unitRef="usd">410000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">29023000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-335" unitRef="usd">-110970000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-14" decimals="-3" id="f-336" unitRef="usd">-1035000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-13" decimals="-3" id="f-338" unitRef="usd">201323000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-14" decimals="-3" id="f-339" unitRef="usd">119946000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">629000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-13" decimals="-3" id="f-341" unitRef="usd">444000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-14" decimals="-3" id="f-342" unitRef="usd">1214000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-3" id="f-344" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-14" decimals="-3" id="f-345" unitRef="usd">1736000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">464000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-13" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-14" decimals="-3" id="f-348" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">12581000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-13" decimals="-3" id="f-350" unitRef="usd">11613000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-14" decimals="-3" id="f-351" unitRef="usd">5806000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">-11488000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-353" unitRef="usd">190154000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-14" decimals="-3" id="f-354" unitRef="usd">117090000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">-102000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-13" decimals="-3" id="f-356" unitRef="usd">110000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-14" decimals="-3" id="f-357" unitRef="usd">-517000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">13965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-359" unitRef="usd">-79864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-14" decimals="-3" id="f-360" unitRef="usd">-71494000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-361" unitRef="usd">32109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-3" id="f-362" unitRef="usd">111973000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-363" unitRef="usd">183467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-364" unitRef="usd">46074000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-365" unitRef="usd">32109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-3" id="f-366" unitRef="usd">111973000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-367" unitRef="usd">10561000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-3" id="f-368" unitRef="usd">12288000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-14" decimals="-3" id="f-369" unitRef="usd">12712000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">5298000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-14" decimals="-3" id="f-372" unitRef="usd">3029000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax contextRef="c-1" decimals="-3" id="f-373" unitRef="usd">89000</goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax>
    <goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax contextRef="c-13" decimals="-3" id="f-374" unitRef="usd">191000</goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax>
    <goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax contextRef="c-14" decimals="-3" id="f-375" unitRef="usd">-75000</goss:NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-13" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-14" decimals="-3" id="f-378" unitRef="usd">83000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-379">Description of Business&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gossamer Bio, Inc. (including its subsidiaries, referred to as "we," "us," "our,", or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension ("PH') including pulmonary arterial hypertension ("PAH") and PH associated with interstitial lung disease ("PH-ILD").  The Company was incorporated in the state of Delaware on October&#160;25, 2015 (originally as FSG Bio, Inc.) and is based in San Diego, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Gossamer Bio, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred significant operating losses since its inception. As of December&#160;31, 2024, the Company had an accumulated deficit of $1,268.6 million. From the Company&#x2019;s inception through the year ended December&#160;31, 2024, the Company has funded its operations primarily through equity financings, convertible senior notes and the Chiesi Collaboration Agreement (as defined in Note 12 below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the Company will need to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Management believes that it has sufficient working capital on hand to fund operations through at least the next 12 months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-5" id="f-380" unitRef="usd">-1268600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-381">Summary of Significant Accounting Policies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accrued research and development expenses, stand-alone selling price of performance obligations and estimated collaboration expenses associated with the Company&#x2019;s collaboration and license agreement. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers securities with original maturities of greater than 90&#160;days to be marketable securities. The Company has the ability, if necessary, to liquidate any of its marketable securities to meet its liquidity needs in the next 12&#160;months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying consolidated balance sheets which reflects management&#x2019;s intention to use the proceeds from sales of these securities to fund our operations, as necessary. The Company&#x2019;s marketable securities consist of U.S. Treasury and agency securities, commercial paper and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operation and comprehensive loss. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury and agency securities and commercial paper with maturities less than three months and in money market funds that invest in U.S. Treasury and agency securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s available for sale securities are also invested in U.S. Treasury and agency securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, which consists mainly of lab equipment and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally &lt;span style="-sec-ix-hidden:f-390"&gt;two&lt;/span&gt; to seven years, using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of ASU 2020-06, the Company accounted for the 2027 Notes as a liability and equity component. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component was not re-measured as long as it continued to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (&#x201c;debt discount&#x201d;) was amortized to interest expense over the term of the 2027 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the issuance costs incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the 2027 Notes and were amortized to interest expense over the term of the 2027 Notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022 the Company adopted ASU 2020-06. After adoption, the Company now accounts for the 2027 Notes as a single liability measured at amortized cost. The impact upon adoption on the Consolidated Balance Sheets was an increase of approximately $44.8&#160;million in convertible senior notes, net, a write-off of $9.4&#160;million in deferred income tax liabilities and a decrease of $53.5&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment of $8.7&#160;million to increase the beginning balance of accumulated deficit on the Consolidated Balance Sheets for previously recognized interest expense related to amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 842), the Company determines if an arrangement is a lease at inception. Operating leases are included in the balance sheet as right-of-use assets and operating lease liabilities at the present value of the lease payments calculated using the Company&#x2019;s incremental borrowing rate, unless the implicit rate is readily available. The Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and elected to not separate lease and non-lease components for its long-term leases. The Company records rent expense on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In process research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In process research and development costs relate to a milestone payment to Pulmokine for the initiation of the Phase 3 clinical trial for seralutinib.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC&#160;740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company's policy is to include interest and penalties related to income taxes within its provision (benefit) for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in the United States, California, Florida, Ireland and Luxembourg. As of December&#160;31, 2024, the Company&#x2019;s tax years since inception are subject to examination by taxing authorities due to the Company&#x2019;s unutilized net operating losses ("NOLs") and tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its licensing and other agreements are collaborative arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. For arrangements that the Company determines are collaborations, it identifies each unit of account, and then determines whether a customer relationship exists for that unit of account. If the Company determines &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a performance obligation within the collaborative arrangement to be with a customer, it applies its revenue recognition accounting policy. If a portion of a distinct bundle of goods or services within the collaborative arrangement is not with a customer, the Company applies recognition and measurement based on an analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational and consistently applied accounting policy election. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and the collaboration partner are within the scope of other accounting literature. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 12, "Significant Agreements and Contracts," for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when a customer obtains control of promised goods or services in a contract for an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. For contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for contracts with customers, the Company develops assumptions that require judgment to determine the standalone selling price of each distinct performance obligation identified in the contract. In addition, variable consideration such as milestone payments are evaluated to determine if they are constrained and, therefore, excluded from the transaction price. The Company then allocates the total transaction price proportionally to each distinct performance obligation based on their estimated standalone selling prices, unless an allocation exception applies. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective distinct performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying standalone selling price for each distinct performance obligation, which determines how the transaction price is allocated among the distinct performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each distinct performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a distinct performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include cost-share reimbursements, we will recognize such payments when control of the related goods or services are transferred to the customer. Cost-sharing reimbursements are presented as revenue from contracts with collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants and shares purchasable under the Company's 2019 Employee Stock Purchase Plan ("ESPP") using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. The Company estimates the fair value of restricted stock units based on the closing price of the Company's common stock on the date of grant. The Company accounts for forfeitures as they occur. All share-based compensation costs are recorded in the statements of operations based upon the underlying employees or non-employee&#x2019;s roles within the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities of non-U.S.&#160;subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated to U.S.&#160;dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates during the year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss) in the Company's consolidated balance sheets. Foreign exchange transaction gains and losses are included in other income, net in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements - Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures (&#x201c;Topic 280&#x201d;), which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Lastly, the amendment requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We have adopted this standard for our fiscal year ended December 31, 2024. We have applied this standard retrospectively for all prior periods presented in the financial statements. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13, Segment Reporting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on our consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The Company uses the if-converted method for assumed conversion of the 2027 Notes to compute the weighted average shares of common stock outstanding for diluted net loss per share. Diluted net loss per share excludes the potential impact of the Company&#x2019;s common stock options, warrants for the purchase of common stock, unvested shares of restricted stock and the potential shares issuable upon conversion of the 2027 Notes because their effect would be anti-dilutive due to the Company&#x2019;s net loss. Since the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,321,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,321,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,321,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,416,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,626,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,487,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon exercise of Chiesi Equity Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,433,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,467,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,467,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested shares under restricted stock grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,639,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,843,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,159,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-383">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accrued research and development expenses, stand-alone selling price of performance obligations and estimated collaboration expenses associated with the Company&#x2019;s collaboration and license agreement. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-384">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c-1" decimals="0" id="f-385" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-386">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-387">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;The Company considers securities with original maturities of greater than 90&#160;days to be marketable securities. The Company has the ability, if necessary, to liquidate any of its marketable securities to meet its liquidity needs in the next 12&#160;months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying consolidated balance sheets which reflects management&#x2019;s intention to use the proceeds from sales of these securities to fund our operations, as necessary. The Company&#x2019;s marketable securities consist of U.S. Treasury and agency securities, commercial paper and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operation and comprehensive loss. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock contextRef="c-1" id="f-388">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury and agency securities and commercial paper with maturities less than three months and in money market funds that invest in U.S. Treasury and agency securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s available for sale securities are also invested in U.S. Treasury and agency securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, which consists mainly of lab equipment and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally &lt;span style="-sec-ix-hidden:f-390"&gt;two&lt;/span&gt; to seven years, using the straight-line method.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-50" id="f-391">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of ASU 2020-06, the Company accounted for the 2027 Notes as a liability and equity component. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component was not re-measured as long as it continued to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (&#x201c;debt discount&#x201d;) was amortized to interest expense over the term of the 2027 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the issuance costs incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the 2027 Notes and were amortized to interest expense over the term of the 2027 Notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022 the Company adopted ASU 2020-06. After adoption, the Company now accounts for the 2027 Notes as a single liability measured at amortized cost. The impact upon adoption on the Consolidated Balance Sheets was an increase of approximately $44.8&#160;million in convertible senior notes, net, a write-off of $9.4&#160;million in deferred income tax liabilities and a decrease of $53.5&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment of $8.7&#160;million to increase the beginning balance of accumulated deficit on the Consolidated Balance Sheets for previously recognized interest expense related to amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <goss:LongTermConvertibleSeniorNotes contextRef="c-51" decimals="-5" id="f-393" unitRef="usd">44800000</goss:LongTermConvertibleSeniorNotes>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-51" decimals="-5" id="f-394" unitRef="usd">-9400000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-5" id="f-395" unitRef="usd">-53500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-5" id="f-396" unitRef="usd">8700000</us-gaap:StockholdersEquity>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-397">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 842), the Company determines if an arrangement is a lease at inception. Operating leases are included in the balance sheet as right-of-use assets and operating lease liabilities at the present value of the lease payments calculated using the Company&#x2019;s incremental borrowing rate, unless the implicit rate is readily available. The Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and elected to not separate lease and non-lease components for its long-term leases. The Company records rent expense on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-398">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-399">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In process research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In process research and development costs relate to a milestone payment to Pulmokine for the initiation of the Phase 3 clinical trial for seralutinib.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:LegalCostsPolicyTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC&#160;740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company's policy is to include interest and penalties related to income taxes within its provision (benefit) for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in the United States, California, Florida, Ireland and Luxembourg. As of December&#160;31, 2024, the Company&#x2019;s tax years since inception are subject to examination by taxing authorities due to the Company&#x2019;s unutilized net operating losses ("NOLs") and tax credits.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-402">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its licensing and other agreements are collaborative arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. For arrangements that the Company determines are collaborations, it identifies each unit of account, and then determines whether a customer relationship exists for that unit of account. If the Company determines &lt;/span&gt;&lt;/div&gt;a performance obligation within the collaborative arrangement to be with a customer, it applies its revenue recognition accounting policy. If a portion of a distinct bundle of goods or services within the collaborative arrangement is not with a customer, the Company applies recognition and measurement based on an analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational and consistently applied accounting policy election. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and the collaboration partner are within the scope of other accounting literature. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC Topic 606, Revenue from Contracts with Customers (ASC 606).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-403">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when a customer obtains control of promised goods or services in a contract for an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. For contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for contracts with customers, the Company develops assumptions that require judgment to determine the standalone selling price of each distinct performance obligation identified in the contract. In addition, variable consideration such as milestone payments are evaluated to determine if they are constrained and, therefore, excluded from the transaction price. The Company then allocates the total transaction price proportionally to each distinct performance obligation based on their estimated standalone selling prices, unless an allocation exception applies. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective distinct performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying standalone selling price for each distinct performance obligation, which determines how the transaction price is allocated among the distinct performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each distinct performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a distinct performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative revenue from sale of licenses and revenue from contracts with collaborators in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include cost-share reimbursements, we will recognize such payments when control of the related goods or services are transferred to the customer. Cost-sharing reimbursements are presented as revenue from contracts with collaborators.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-404">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants and shares purchasable under the Company's 2019 Employee Stock Purchase Plan ("ESPP") using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. The Company estimates the fair value of restricted stock units based on the closing price of the Company's common stock on the date of grant. The Company accounts for forfeitures as they occur. All share-based compensation costs are recorded in the statements of operations based upon the underlying employees or non-employee&#x2019;s roles within the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities of non-U.S.&#160;subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated to U.S.&#160;dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates during the year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss) in the Company's consolidated balance sheets. Foreign exchange transaction gains and losses are included in other income, net in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-406">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements - Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures (&#x201c;Topic 280&#x201d;), which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Lastly, the amendment requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We have adopted this standard for our fiscal year ended December 31, 2024. We have applied this standard retrospectively for all prior periods presented in the financial statements. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13, Segment Reporting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on our consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-407">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The Company uses the if-converted method for assumed conversion of the 2027 Notes to compute the weighted average shares of common stock outstanding for diluted net loss per share. Diluted net loss per share excludes the potential impact of the Company&#x2019;s common stock options, warrants for the purchase of common stock, unvested shares of restricted stock and the potential shares issuable upon conversion of the 2027 Notes because their effect would be anti-dilutive due to the Company&#x2019;s net loss. Since the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,321,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,321,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,321,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,416,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,626,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,487,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon exercise of Chiesi Equity Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,433,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,467,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,467,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested shares under restricted stock grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,639,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,843,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,159,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-54" decimals="0" id="f-409" unitRef="shares">12321900</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-55" decimals="0" id="f-410" unitRef="shares">12321900</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-56" decimals="0" id="f-411" unitRef="shares">12321900</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-57" decimals="0" id="f-412" unitRef="shares">34416337</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-58" decimals="0" id="f-413" unitRef="shares">23626115</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-59" decimals="0" id="f-414" unitRef="shares">17487165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-415" unitRef="shares">22433809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-416" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-417" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-63" decimals="0" id="f-418" unitRef="shares">32467360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="0" id="f-419" unitRef="shares">32467360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="0" id="f-420" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="0" id="f-421" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-67" decimals="0" id="f-422" unitRef="shares">427698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-68" decimals="0" id="f-423" unitRef="shares">1350035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-424" unitRef="shares">101639406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="0" id="f-425" unitRef="shares">68843073</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-14" decimals="0" id="f-426" unitRef="shares">31159100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <goss:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-427">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-431"&gt;&lt;span style="-sec-ix-hidden:f-432"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued in process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued accounting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</goss:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-431"&gt;&lt;span style="-sec-ix-hidden:f-432"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued in process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued accounting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-429" unitRef="usd">11995000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-430" unitRef="usd">10294000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-433" unitRef="usd">961000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-434" unitRef="usd">3302000</us-gaap:OperatingLeaseLiabilityCurrent>
    <goss:AccruedConsultingFeesCurrent contextRef="c-5" decimals="-3" id="f-435" unitRef="usd">841000</goss:AccruedConsultingFeesCurrent>
    <goss:AccruedConsultingFeesCurrent contextRef="c-6" decimals="-3" id="f-436" unitRef="usd">643000</goss:AccruedConsultingFeesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-5" decimals="-3" id="f-437" unitRef="usd">833000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-6" decimals="-3" id="f-438" unitRef="usd">968000</us-gaap:InterestPayableCurrent>
    <goss:AccruedLegalFeesCurrent contextRef="c-5" decimals="-3" id="f-439" unitRef="usd">65000</goss:AccruedLegalFeesCurrent>
    <goss:AccruedLegalFeesCurrent contextRef="c-6" decimals="-3" id="f-440" unitRef="usd">385000</goss:AccruedLegalFeesCurrent>
    <goss:AccruedInProcessResearchAndDevelopmentCurrent contextRef="c-5" decimals="-3" id="f-441" unitRef="usd">0</goss:AccruedInProcessResearchAndDevelopmentCurrent>
    <goss:AccruedInProcessResearchAndDevelopmentCurrent contextRef="c-6" decimals="-3" id="f-442" unitRef="usd">10000000</goss:AccruedInProcessResearchAndDevelopmentCurrent>
    <goss:AccruedAccountingFeesCurrent contextRef="c-5" decimals="-3" id="f-443" unitRef="usd">180000</goss:AccruedAccountingFeesCurrent>
    <goss:AccruedAccountingFeesCurrent contextRef="c-6" decimals="-3" id="f-444" unitRef="usd">234000</goss:AccruedAccountingFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-445" unitRef="usd">311000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-446" unitRef="usd">854000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-447" unitRef="usd">15186000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-448" unitRef="usd">26680000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-449">Fair Value Measurements and Available for Sale Investments&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its cash equivalents and available-for-sale investments within Level&#160;1 or Level&#160;2. The fair value of the Company&#x2019;s investment grade corporate debt securities and commercial paper classified as Level 2 is determined using proprietary valuation models and analytical tools, which utilize market pricing or prices for similar instruments that are both objective and publicly available, such as matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and offers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the hierarchy for assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Market&lt;br/&gt;Prices for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&#160;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the carrying amounts of the Company&#x2019;s financial instruments, which include cash, prepaid and other current assets, interest receivable, accrued research and development expenses, accounts payable and accrued expenses and other current liabilities, approximate fair values because of their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $0.2 million interest receivable as of December&#160;31, 2024. There was no significant interest receivable as of December 31, 2023. Interest receivable is recorded as a component of prepaid expenses and other current assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023 the fair value of the Company's 2027 Notes was $110.0 million and $74.9 million, respectively. The fair value was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available for Sale Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in U.S. Treasury and agency securities, corporate debt securities, and commercial paper, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below.&#160;The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded in other income, net in the Company's consolidated statements of operations and comprehensive loss. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recover of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in marketable securities&#160;as of&#160;December&#160;31, 2024 and 2023 are as follows&#160;(in thousands except securities amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and December&#160;31, 2023, the Company classified $25.3 million and $25.2 million, respectively, of assets with original maturities of 90 days or less as cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Factors considered when evaluating available-for-sale investments for impairment include the severity of the impairment, changes in underlying credit ratings, the financial condition of the issuer, the probability that the scheduled cash payments will continue to be made and the Company&#x2019;s intent and ability to hold the investment until recovery of the amortized cost basis. The Company intends and has the ability to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. As of December&#160;31, 2024 and 2023, there were no material declines in the market value of the Company's available-for-sale investments due to credit-related factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of available-for-sale debt securities, as of December&#160;31, 2024, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the hierarchy for assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Market&lt;br/&gt;Prices for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&#160;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-451" unitRef="usd">25264000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-452" unitRef="usd">25264000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-454" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-73" decimals="-3" id="f-455" unitRef="usd">56900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-74" decimals="-3" id="f-456" unitRef="usd">56900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-75" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-76" decimals="-3" id="f-458" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-77" decimals="-3" id="f-459" unitRef="usd">188653000</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-78" decimals="-3" id="f-460" unitRef="usd">0</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-79" decimals="-3" id="f-461" unitRef="usd">188653000</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-80" decimals="-3" id="f-462" unitRef="usd">0</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="-3" id="f-463" unitRef="usd">19963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="-3" id="f-465" unitRef="usd">19963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="-3" id="f-466" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-467" unitRef="usd">25222000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-468" unitRef="usd">25222000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-470" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-3" id="f-471" unitRef="usd">92309000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-3" id="f-472" unitRef="usd">92309000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-93" decimals="-3" id="f-475" unitRef="usd">168534000</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-94" decimals="-3" id="f-476" unitRef="usd">0</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-95" decimals="-3" id="f-477" unitRef="usd">168534000</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="c-96" decimals="-3" id="f-478" unitRef="usd">0</goss:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-97" decimals="-3" id="f-479" unitRef="usd">3473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-98" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-99" decimals="-3" id="f-481" unitRef="usd">3473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-100" decimals="-3" id="f-482" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivableCurrent contextRef="c-5" decimals="-5" id="f-483" unitRef="usd">200000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c-6" decimals="-5" id="f-484" unitRef="usd">0</us-gaap:InterestReceivableCurrent>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-101" decimals="-5" id="f-485" unitRef="usd">110000000.0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-102" decimals="-5" id="f-486" unitRef="usd">74900000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-487">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in marketable securities&#160;as of&#160;December&#160;31, 2024 and 2023 are as follows&#160;(in thousands except securities amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;U.S. Treasury and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-103" decimals="-3" id="f-488" unitRef="usd">56875000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-103" decimals="-3" id="f-489" unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-103" decimals="-3" id="f-490" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-103" decimals="-3" id="f-491" unitRef="usd">56900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-104" decimals="-3" id="f-492" unitRef="usd">19950000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-104" decimals="-3" id="f-493" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-104" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-104" decimals="-3" id="f-495" unitRef="usd">19963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-105" decimals="-3" id="f-496" unitRef="usd">188537000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-105" decimals="-3" id="f-497" unitRef="usd">142000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-105" decimals="-3" id="f-498" unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-105" decimals="-3" id="f-499" unitRef="usd">188653000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-500" unitRef="usd">265362000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-3" id="f-501" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-3" id="f-502" unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-503" unitRef="usd">265516000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions contextRef="c-5" decimals="0" id="f-504" unitRef="security">5</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-106" decimals="-3" id="f-505" unitRef="usd">92294000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-106" decimals="-3" id="f-506" unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-106" decimals="-3" id="f-507" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="-3" id="f-508" unitRef="usd">92309000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-107" decimals="-3" id="f-509" unitRef="usd">3467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-107" decimals="-3" id="f-510" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-107" decimals="-3" id="f-511" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-107" decimals="-3" id="f-512" unitRef="usd">3473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-108" decimals="-3" id="f-513" unitRef="usd">168488000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-108" decimals="-3" id="f-514" unitRef="usd">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-108" decimals="-3" id="f-515" unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-108" decimals="-3" id="f-516" unitRef="usd">168534000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-6" decimals="-3" id="f-517" unitRef="usd">264249000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-6" decimals="-3" id="f-518" unitRef="usd">102000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-6" decimals="-3" id="f-519" unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="-3" id="f-520" unitRef="usd">264316000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions contextRef="c-6" decimals="0" id="f-521" unitRef="security">12</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-522" unitRef="usd">25300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-523" unitRef="usd">25200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of available-for-sale debt securities, as of December&#160;31, 2024, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-5" decimals="-3" id="f-525" unitRef="usd">265516000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <goss:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue contextRef="c-5" decimals="-3" id="f-526" unitRef="usd">0</goss:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-527" unitRef="usd">265516000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-528">Indebtedness&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 2, 2019, the Company entered into a credit, guaranty and security agreement, as amended on September 18, 2019, July 2, 2020, December 7, 2022 and February 14, 2023 (the &#x201c;Credit Facility&#x201d;), with MidCap Financial Trust (&#x201c;MidCap&#x201d;), as agent and lender, and the additional lenders party thereto from time to time (together with MidCap, the &#x201c;Lenders&#x201d;), pursuant to which the Lenders, agreed to make term loans available to the Company for working capital and general business purposes, in a principal amount of up to $150.0&#160;million in term loan commitments, including a $30.0&#160;million term loan that was funded at the closing date, with the ability to access the remaining $120.0&#160;million in two additional tranches (each $60.0&#160;million), subject to specified availability periods, the achievement of certain clinical development milestones, minimum cash requirements and other customary conditions. On May 3, 2024, the Credit Facility was terminated and the Company recorded a $7.7&#160;million payment of the outstanding debt balance in full and discharged, which released the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from the obligations under the Credit Facility, and Lenders&#x2019; security interests in the Company&#x2019;s assets and property were released. Unamortized debt discount and issuance costs were written off and recorded in interest expense on the consolidated statements of operations and comprehensive loss. Since the Credit Facility was terminated, there was no debt outstanding as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;5.00% Convertible Senior Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 21, 2020, the Company issued $200.0&#160;million aggregate principal amount of 5.00% convertible senior notes due 2027 in a public offering (the "2027 Notes"). The 2027 Notes were registered pursuant to the Company&#x2019;s shelf registration statement on Form S-3 filed with the SEC on April 10, 2020. The interest rate on the 2027 Notes is fixed at 5.00% per annum. Interest is payable semi-annually in arrears on June 1 and December 1 of each year, commencing on December 1, 2020. The 2027 Notes will mature on June 1, 2027. The net proceeds from the offering, after deducting the underwriting discounts and commissions and other offering costs, were approximately $193.6 million. The 2027 Notes may be settled in cash, shares of the Company&#x2019;s common stock, or a combination thereof, solely at the Company&#x2019;s election. The initial conversion rate of the 2027 Notes is&#160;61.6095&#160;shares per&#160;$1,000&#160;principal amount, which is equivalent to a conversion price of approximately&#160;$16.23&#160;per share, subject to adjustments.&#160;In addition, following certain corporate events that occur prior to the maturity date or if the Company issues a notice of redemption, the Company will increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event during the related redemption period in certain circumstances.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Notes are senior unsecured obligations of the Company, ranking senior in right of payment to any of the Company&#x2019;s indebtedness that is expressly subordinated in right of payment to the 2027 Notes, and are effectively subordinated to the Company&#x2019;s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their notes at their option only in the following circumstances: (1) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2020, if the last reported sale price per share of the Company&#x2019;s common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company&#x2019;s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company&#x2019;s common stock; (4) if the Company calls such notes for redemption; and (5) at any time from, and including, March 1, 2027 until the close of business on the scheduled trading day immediately before the maturity date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have the right to redeem the 2027 Notes prior to June 6, 2024. As of December&#160;31, 2024, the Company has not redeemed the 2027 Notes. On or after June 6, 2024 and on or before the 50th scheduled trading day immediately before the maturity date, the Company may redeem the 2027 Notes, in whole or in part, if the last reported sale price of the Company&#x2019;s common stock has been at least 130% of the conversion price then in effect on (1) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. In the case of any optional redemption, the Company will redeem the 2027 Notes at a redemption price equal to 100% of the principal amount of such Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a fundamental change prior to the maturity date of the 2027 Notes, holders of the 2027 Notes may require the Company to repurchase for cash all or part of their 2027 Notes at a repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indenture governing the 2027 Notes provides for customary terms and covenants, including that upon certain events of default, either the trustee or the holders of not less than 25% in aggregate principal amount of the 2027 Notes then outstanding may declare the unpaid principal amount of the 2027 Notes and accrued and unpaid interest, if any, thereon immediately due and payable. As of December&#160;31, 2024, the Company was in compliance with these covenants. In the case of certain events of bankruptcy, insolvency or reorganization, the principal amount of the 2027 Notes together with accrued and unpaid interest, if any, thereon will automatically become and be immediately due and payable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, there were no events or market conditions that would allow holders to convert the 2027 Notes.&#160;When the 2027 Notes become convertible within 12 months of the balance sheet date, the carrying value of the 2027 Notes will be reclassified to short-term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for the 2027 Notes as a single liability measured at amortized cost. As the equity component is no longer required to be split into a separate component, the Company recorded an adjustment to reflect this update.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded&#160;$0.4&#160;million of the debt issuance costs related to the 2027 Notes as a reduction to the liability and amortizes these costs to interest expense over the term of the 2027 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the 2027 Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the interest expense recognized related to the 2027 Notes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense related to the 2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-109" decimals="-5" id="f-529" unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-110" decimals="-5" id="f-530" unitRef="usd">30000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-109" decimals="-5" id="f-531" unitRef="usd">120000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <goss:NumberOfAdditionalTranches
      contextRef="c-109"
      decimals="0"
      id="f-532"
      unitRef="tranche">2</goss:NumberOfAdditionalTranches>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-111" decimals="-5" id="f-533" unitRef="usd">60000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-112" decimals="-5" id="f-534" unitRef="usd">60000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-113" decimals="-5" id="f-535" unitRef="usd">7700000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LineOfCredit contextRef="c-114" decimals="INF" id="f-536" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-115" decimals="4" id="f-537" unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <goss:DebtInstrumentAggregatePrincipalAmount contextRef="c-116" decimals="-5" id="f-538" unitRef="usd">200000000</goss:DebtInstrumentAggregatePrincipalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-115" decimals="4" id="f-539" unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-115" decimals="4" id="f-540" unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-116" decimals="-5" id="f-541" unitRef="usd">193600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-115"
      decimals="2"
      id="f-542"
      unitRef="usdPerShare">16.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <goss:DebtInstrumentConvertibleConversionPricePercentage contextRef="c-116" decimals="2" id="f-543" unitRef="number">1.30</goss:DebtInstrumentConvertibleConversionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-117"
      decimals="0"
      id="f-544"
      unitRef="tradingday">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-118"
      decimals="0"
      id="f-545"
      unitRef="tradingday">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-119"
      decimals="0"
      id="f-546"
      unitRef="tradingday">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-120"
      decimals="0"
      id="f-547"
      unitRef="tradingday">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-120"
      decimals="0"
      id="f-548"
      unitRef="tradingday">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <goss:DebtInstrumentConvertibleConversionLastReportedSalePricePercentage contextRef="c-121" decimals="2" id="f-549" unitRef="number">0.98</goss:DebtInstrumentConvertibleConversionLastReportedSalePricePercentage>
    <goss:DebtInstrumentRedemptionTermThresholdTradingDays contextRef="c-116" id="f-550">P50D</goss:DebtInstrumentRedemptionTermThresholdTradingDays>
    <goss:DebtInstrumentConvertibleConversionPricePercentage contextRef="c-116" decimals="2" id="f-551" unitRef="number">1.30</goss:DebtInstrumentConvertibleConversionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-117"
      decimals="0"
      id="f-552"
      unitRef="tradingday">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-118"
      decimals="0"
      id="f-553"
      unitRef="tradingday">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-116" decimals="2" id="f-554" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <goss:PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes contextRef="c-116" decimals="2" id="f-555" unitRef="number">1</goss:PercentageOfRepurchasePriceIsEqualToPrincipalAmountOfConvertibleNotes>
    <goss:LongTermDebtPercentageInAggregatePrincipalAmount contextRef="c-116" decimals="2" id="f-556" unitRef="number">0.25</goss:LongTermDebtPercentageInAggregatePrincipalAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-115" decimals="-5" id="f-557" unitRef="usd">400000</us-gaap:DeferredFinanceCostsNet>
    <goss:ScheduleOfNotesTableTableTextBlock contextRef="c-1" id="f-558">&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the 2027 Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</goss:ScheduleOfNotesTableTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-122" decimals="-3" id="f-559" unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-123" decimals="-3" id="f-560" unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-122" decimals="-3" id="f-561" unitRef="usd">2321000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-123" decimals="-3" id="f-562" unitRef="usd">3194000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-122" decimals="-3" id="f-563" unitRef="usd">156000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-123" decimals="-3" id="f-564" unitRef="usd">215000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-122" decimals="-3" id="f-565" unitRef="usd">197523000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-123" decimals="-3" id="f-566" unitRef="usd">196591000</us-gaap:LongTermDebt>
    <goss:ScheduleOfInterestExpenseRecognizedTableTableTextBlock contextRef="c-1" id="f-567">&lt;div style="margin-top:5pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the interest expense recognized related to the 2027 Notes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense related to the 2027 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</goss:ScheduleOfInterestExpenseRecognizedTableTableTextBlock>
    <goss:ContractualInterestExpense contextRef="c-124" decimals="-3" id="f-568" unitRef="usd">10000000</goss:ContractualInterestExpense>
    <goss:ContractualInterestExpense contextRef="c-125" decimals="-3" id="f-569" unitRef="usd">10000000</goss:ContractualInterestExpense>
    <goss:ContractualInterestExpense contextRef="c-126" decimals="-3" id="f-570" unitRef="usd">10000000</goss:ContractualInterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-124" decimals="-3" id="f-571" unitRef="usd">873000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-125" decimals="-3" id="f-572" unitRef="usd">826000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-126" decimals="-3" id="f-573" unitRef="usd">782000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-124" decimals="-3" id="f-574" unitRef="usd">59000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-125" decimals="-3" id="f-575" unitRef="usd">56000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-126" decimals="-3" id="f-576" unitRef="usd">53000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-124" decimals="-3" id="f-577" unitRef="usd">10932000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-125" decimals="-3" id="f-578" unitRef="usd">10882000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-126" decimals="-3" id="f-579" unitRef="usd">10835000</us-gaap:InterestExpenseDebt>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-581">Licenses, Asset Acquisitions and Contingent Consideration&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following purchased assets were accounted for as asset acquisitions as substantially all of the fair value of the assets acquired were concentrated in a group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of employees and early stage of development. Because the assets had not yet received regulatory approval, the fair value attributable to these assets was recorded as in process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License from Pulmokine, Inc. (Seralutinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;2, 2017, the Company entered into a license agreement with Pulmokine, Inc. under which it was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine to develop and commercialize seralutinib and certain backup compounds for the treatment, prevention and diagnosis of any and all disease or conditions. On November 26, 2024, Pulmokine became a wholly-owned subsidiary of XOMA Royalty Corporation. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The assets acquired are in the early stages of the FDA approval process, and the Company intends to further develop the assets acquired through potential FDA approval as evidenced by the milestone arrangement in the contract. The development activities cannot be performed without significant cost and effort by the Company. The agreement will remain in effect from the effective date, unless terminated earlier, until, on a licensed product-by-licensed product and country-by-country basis, the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product or specified regulatory exclusivity for the licensed product in such country. The Company is obligated to make future development and regulatory milestone payments of up to $48.0 million, which includes a payment of $5.0 million due upon initiation of a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 3 clinical trial in a second indication, commercial milestone payments of up to $45.0 million, and sales milestone payments of up to $190.0 million. The Company is also obligated to pay tiered royalties on sales for each licensed product, at percentages ranging from the mid-single digits to the high single-digits. In addition, if the Company chooses to sublicense or assign to any third parties its rights under the agreement with respect to a licensed product, or the Company&#x2019;s seralutinib operating subsidiary undergoes a change of control, the Company must pay to Pulmokine a specified percentage of all revenue to be received in connection with such transaction. The Company made an upfront payment of $5.5 million in October 2017. The Company made a milestone payment of $5.0&#160;million in connection with the initiation of the first Phase 2 clinical trial of seralutinib in January 2021 and made a milestone payment of $10.0&#160;million, which was accrued in 2023, in connection with the initiation of the Phase 3 clinical trial of seralutinib in January 2024. The Company recognized these milestone payments as research and development expense on its consolidated statements of operations and comprehensive loss. As of December&#160;31, 2024, no other milestones had been accrued as the underlying contingencies had not yet been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following IPR&amp;amp;D expense on the consolidated statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Seralutinib&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Terminated programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total in process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <goss:ProductLicenseTerm contextRef="c-127" id="f-582">P10Y</goss:ProductLicenseTerm>
    <goss:BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable contextRef="c-128" decimals="-5" id="f-583" unitRef="usd">48000000.0</goss:BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable>
    <goss:BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable contextRef="c-128" decimals="-5" id="f-584" unitRef="usd">5000000.0</goss:BusinessCombinationContingentConsiderationInitialPhaseThreeClinicalPaymentsPayable>
    <goss:BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable contextRef="c-128" decimals="-5" id="f-585" unitRef="usd">45000000.0</goss:BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable>
    <goss:BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable contextRef="c-128" decimals="-5" id="f-586" unitRef="usd">190000000.0</goss:BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable>
    <goss:UpfrontPayment contextRef="c-129" decimals="-5" id="f-587" unitRef="usd">5500000</goss:UpfrontPayment>
    <us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized contextRef="c-130" decimals="-5" id="f-588" unitRef="usd">5000000</us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized contextRef="c-131" decimals="-5" id="f-589" unitRef="usd">10000000</us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized contextRef="c-132" decimals="0" id="f-590" unitRef="usd">0</us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized>
    <goss:InProcessResearchAndDevelopmentExpensesTableTextBlock contextRef="c-1" id="f-591">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following IPR&amp;amp;D expense on the consolidated statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Seralutinib&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Terminated programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total in process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</goss:InProcessResearchAndDevelopmentExpensesTableTextBlock>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-133" decimals="-3" id="f-592" unitRef="usd">0</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-134" decimals="-3" id="f-593" unitRef="usd">10000000</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-135" decimals="-3" id="f-594" unitRef="usd">0</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-136" decimals="-3" id="f-595" unitRef="usd">0</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-137" decimals="-3" id="f-596" unitRef="usd">0</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-138" decimals="-3" id="f-597" unitRef="usd">65000</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-1" decimals="-3" id="f-598" unitRef="usd">0</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-13" decimals="-3" id="f-599" unitRef="usd">10000000</goss:ResearchAndDevelopmentInProcessExpenses>
    <goss:ResearchAndDevelopmentInProcessExpenses contextRef="c-14" decimals="-3" id="f-600" unitRef="usd">65000</goss:ResearchAndDevelopmentInProcessExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-601">Income Taxes&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of net loss before taxes for the years ended December&#160;31, 2024, 2023, and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;229,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense for the years ended December 31, 2024, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets and liabilities at December&#160;31, 2024, 2023 and 2022 are shown below. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced. The change in the valuation allowance for the year ended December&#160;31, 2024 was an increase of $7.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 174 capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;229,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(228,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(221,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(204,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had federal and state NOL carryforwards of approximately $398.1 million and $3.3 million, respectively. The federal NOL carryforwards can be carried forward indefinitely and be available to offset up to 80% of future taxable income each year. The California NOL carryforwards begin to expire in 2036. As of December&#160;31, 2024, the Company also has Irish NOL carryforwards of approximately $113.0 million, which can be carried forward indefinitely. In the current year, the Company removed federal and foreign NOL carryforwards of $141.0 million and $0.4 million, respectively, as a result of mergers and liquidations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company also had orphan drug credit and federal research tax credit carryforwards of approximately $48.2 million and California research tax credits of $13.2 million. The federal research tax credit carryforwards begin to expire in 2038, and the California research tax credit carryforward does not expire and can be carried forward indefinitely until utilized. In the current year, the Company removed federal and California credit carryforwards of $9.7 million and $0.4 million, respectively, as a result of mergers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and experimentation credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nondeductible interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic/Foreign Restructuring Impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax respectively. In general, an ownership change as defined by Sections 382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over a three-year period. The Company had an ownership change with the IPO in February of 2019 which resulted in no forfeiture of NOLs or credits.  The Company had an additional ownership change in July of 2023, which resulted in a significant limitation on the Company's utilization of its NOLs and is expected to result in forfeiture of some or all of the federal credits. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company's effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the United States, California, Florida, Ireland, and Luxembourg. Due to the Company&#x2019;s losses incurred, the Company is subject to the income tax examination by authorities since inception. The Company&#x2019;s policy is to recognize interest expense and penalties related to income tax matters as tax expense. For the years ended December&#160;31, 2024, 2023 and 2022 and as of December 31, 2024 and 2023, there were no accruals for interest related to unrecognized tax benefits or tax penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2024, 2023, and 2022, excluding interest and penalties, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits at December&#160;31, 2024 is $13.9 million that, if recognized, would not impact the Company&#x2019;s income tax benefit or effective tax rate as long as the Company's deferred tax asset remains subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company's unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-602">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of net loss before taxes for the years ended December&#160;31, 2024, 2023, and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;229,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-603" unitRef="usd">-32178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-3" id="f-604" unitRef="usd">-134073000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-14" decimals="-3" id="f-605" unitRef="usd">-175777000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-606" unitRef="usd">-23457000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-3" id="f-607" unitRef="usd">-45736000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-14" decimals="-3" id="f-608" unitRef="usd">-53593000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes contextRef="c-1" decimals="-3" id="f-609" unitRef="usd">-55635000</goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes>
    <goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes contextRef="c-13" decimals="-3" id="f-610" unitRef="usd">-179809000</goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes>
    <goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes contextRef="c-14" decimals="-3" id="f-611" unitRef="usd">-229370000</goss:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForTaxPurposes>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-612">&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense for the years ended December 31, 2024, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-613" unitRef="usd">886000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-614" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-616" unitRef="usd">7000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-617" unitRef="usd">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-618" unitRef="usd">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-619" unitRef="usd">893000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-620" unitRef="usd">8000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-621" unitRef="usd">8000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-622" unitRef="usd">7400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-623">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 174 capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;229,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;205,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(228,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(221,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(204,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-624" unitRef="usd">97940000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-625" unitRef="usd">122987000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-32" decimals="-3" id="f-626" unitRef="usd">128989000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="c-5" decimals="-3" id="f-627" unitRef="usd">10575000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="c-6" decimals="-3" id="f-628" unitRef="usd">0</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="c-32" decimals="-3" id="f-629" unitRef="usd">0</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-5" decimals="-3" id="f-630" unitRef="usd">20348000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-6" decimals="-3" id="f-631" unitRef="usd">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-32" decimals="-3" id="f-632" unitRef="usd">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-633" unitRef="usd">44803000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-6" decimals="-3" id="f-634" unitRef="usd">45445000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-32" decimals="-3" id="f-635" unitRef="usd">34193000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-636" unitRef="usd">2646000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-6" decimals="-3" id="f-637" unitRef="usd">6919000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-32" decimals="-3" id="f-638" unitRef="usd">8487000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-639" unitRef="usd">10984000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-640" unitRef="usd">9886000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-32" decimals="-3" id="f-641" unitRef="usd">8445000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <goss:DeferredTaxAssetsLeaseLiability contextRef="c-5" decimals="-3" id="f-642" unitRef="usd">1135000</goss:DeferredTaxAssetsLeaseLiability>
    <goss:DeferredTaxAssetsLeaseLiability contextRef="c-6" decimals="-3" id="f-643" unitRef="usd">726000</goss:DeferredTaxAssetsLeaseLiability>
    <goss:DeferredTaxAssetsLeaseLiability contextRef="c-32" decimals="-3" id="f-644" unitRef="usd">1354000</goss:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-5" decimals="-3" id="f-645" unitRef="usd">547000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-6" decimals="-3" id="f-646" unitRef="usd">1887000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-32" decimals="-3" id="f-647" unitRef="usd">2514000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-648" unitRef="usd">35715000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-649" unitRef="usd">34268000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-32" decimals="-3" id="f-650" unitRef="usd">21840000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-651" unitRef="usd">5076000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-652" unitRef="usd">43000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-32" decimals="-3" id="f-653" unitRef="usd">37000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-654" unitRef="usd">229769000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-655" unitRef="usd">222161000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-32" decimals="-3" id="f-656" unitRef="usd">205859000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-3" id="f-657" unitRef="usd">3000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-6" decimals="-3" id="f-658" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-32" decimals="-3" id="f-659" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <goss:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-5" decimals="-3" id="f-660" unitRef="usd">1083000</goss:DeferredTaxLiabilitiesRightOfUseAsset>
    <goss:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-6" decimals="-3" id="f-661" unitRef="usd">660000</goss:DeferredTaxLiabilitiesRightOfUseAsset>
    <goss:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-32" decimals="-3" id="f-662" unitRef="usd">1244000</goss:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-663" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-664" unitRef="usd">108000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-32" decimals="-3" id="f-665" unitRef="usd">565000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-666" unitRef="usd">1086000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-667" unitRef="usd">768000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-32" decimals="-3" id="f-668" unitRef="usd">1809000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-669" unitRef="usd">228683000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-670" unitRef="usd">221393000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-32" decimals="-3" id="f-671" unitRef="usd">204050000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-672" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-673" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-32" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-139" decimals="-5" id="f-675" unitRef="usd">398100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-140" decimals="-5" id="f-676" unitRef="usd">3300000</us-gaap:OperatingLossCarryforwards>
    <goss:NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage contextRef="c-141" decimals="2" id="f-677" unitRef="number">0.80</goss:NetOperatingLossesCarryforwardAvailableToOffsetFutureFederalTaxableIncomePercentage>
    <us-gaap:OperatingLossCarryforwards contextRef="c-142" decimals="-5" id="f-678" unitRef="usd">113000000.0</us-gaap:OperatingLossCarryforwards>
    <goss:OperatingLossCarryforwardsReductionDueToMergerAndLiquidation contextRef="c-143" decimals="-5" id="f-679" unitRef="usd">141000000.0</goss:OperatingLossCarryforwardsReductionDueToMergerAndLiquidation>
    <goss:OperatingLossCarryforwardsReductionDueToMergerAndLiquidation contextRef="c-144" decimals="-5" id="f-680" unitRef="usd">400000</goss:OperatingLossCarryforwardsReductionDueToMergerAndLiquidation>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-139" decimals="-5" id="f-681" unitRef="usd">48200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-140" decimals="-5" id="f-682" unitRef="usd">13200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <goss:TaxCreditCarryforwardsReductionDueToMerger contextRef="c-143" decimals="-5" id="f-683" unitRef="usd">9700000</goss:TaxCreditCarryforwardsReductionDueToMerger>
    <goss:TaxCreditCarryforwardsReductionDueToMerger contextRef="c-145" decimals="-5" id="f-684" unitRef="usd">400000</goss:TaxCreditCarryforwardsReductionDueToMerger>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-685">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and experimentation credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nondeductible interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic/Foreign Restructuring Impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="4" id="f-686" unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="4" id="f-687" unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-14" decimals="4" id="f-688" unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="4" id="f-689" unitRef="number">-0.1238</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="4" id="f-690" unitRef="number">-0.0873</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="4" id="f-691" unitRef="number">-0.2025</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="4" id="f-692" unitRef="number">-0.0303</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-13" decimals="4" id="f-693" unitRef="number">-0.0569</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-14" decimals="4" id="f-694" unitRef="number">-0.0339</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="4" id="f-695" unitRef="number">-0.0375</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-13" decimals="4" id="f-696" unitRef="number">-0.0213</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-14" decimals="4" id="f-697" unitRef="number">-0.0188</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-1" decimals="4" id="f-698" unitRef="number">-0.0472</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-13" decimals="4" id="f-699" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-14" decimals="4" id="f-700" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="4" id="f-701" unitRef="number">-0.0461</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="4" id="f-702" unitRef="number">-0.0144</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-14" decimals="4" id="f-703" unitRef="number">-0.0090</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent contextRef="c-1" decimals="4" id="f-704" unitRef="number">-0.0413</goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent>
    <goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent contextRef="c-13" decimals="4" id="f-705" unitRef="number">-0.0127</goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent>
    <goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent contextRef="c-14" decimals="4" id="f-706" unitRef="number">-0.0099</goss:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges contextRef="c-1" decimals="4" id="f-707" unitRef="number">0.0252</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges contextRef="c-13" decimals="4" id="f-708" unitRef="number">-0.1249</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges contextRef="c-14" decimals="4" id="f-709" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="4" id="f-710" unitRef="number">0.0144</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-13" decimals="4" id="f-711" unitRef="number">-0.0062</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-14" decimals="4" id="f-712" unitRef="number">-0.0037</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="4" id="f-713" unitRef="number">-0.0160</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="4" id="f-714" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-14" decimals="4" id="f-715" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-716">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2024, 2023, and 2022, excluding interest and penalties, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-717" unitRef="usd">13654000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-32" decimals="-3" id="f-718" unitRef="usd">10572000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-19" decimals="-3" id="f-719" unitRef="usd">7551000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-720" unitRef="usd">2028000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-721" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-14" decimals="-3" id="f-722" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-723" unitRef="usd">2293000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-724" unitRef="usd">3082000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-14" decimals="-3" id="f-725" unitRef="usd">3021000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-726" unitRef="usd">13919000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-727" unitRef="usd">13654000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-32" decimals="-3" id="f-728" unitRef="usd">10572000</us-gaap:UnrecognizedTaxBenefits>
    <goss:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate contextRef="c-5" decimals="-5" id="f-729" unitRef="usd">13900000</goss:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-730">Stockholders&#x2019; Equity&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock is entitled to one vote. Common stock owners are entitled to dividends when funds are legally available and declared by the Company's board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statement and Stock Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 10, 2020, the Company filed a universal shelf registration statement on Form S-3, covering the offering from time to time of common stock, preferred stock, debt securities, warrants and units, which registration statement became automatically effective on April 10, 2020 (the &#x201c;Shelf Registration Statement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 21, 2020, the Company completed a public offering of 9,433,963 shares of its common stock at a public offering price of $13.25 per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering costs, were approximately $117.1&#160;million. The shares sold in the offering were registered pursuant to the Company&#x2019;s Shelf Registration Statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Private Placement Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company completed a private placement of 16,649,365 shares of the Company's common stock at purchase price of $7.21 per share. The gross proceeds for the private placement were $120.1&#160;million, before deducting offering expenses, which equaled $0.2&#160;million. On August 9, 2022, the Company filed a registration statement on Form S-3 registering the shares of common stock issued in the private placement, which registration statement became automatically effective on August 9, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 24, 2023, the Company completed a private placement of 129,869,440 shares of the Company&#x2019;s common stock and accompanying warrants to purchase up to 32,467,360 shares of the Company's common stock at a combined &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purchase price of $1.63125 per share and accompanying warrant, or with respect to any purchaser that was an officer, director, employee or consultant of the Company $1.85125, per share and accompanying warrant. Each warrant has an exercise price per share of $2.04, was immediately exercisable on the date of issuance and will expire five years from the closing of the private placement. The aggregate gross proceeds for the private placement were $212.1&#160;million, before deducting offering expenses, which equaled $10.8&#160;million. On August 18, 2023, the Company filed a registration statement on Form S-3 registering the shares of common stock and shares of common stock issuable upon the exercise of warrants issued in the private placement, which registration statement was declared effective on August 28, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shares of Common Stock Subject to Repurchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;3, 2015, the Company issued 9,160,888 shares of common stock as founder shares for services rendered to the Company, valued at $0.0001 par value per share, for a total of approximately $4,100 (the &#x201c;founder shares&#x201d;). On January&#160;4, 2018, incremental vesting conditions were placed on the previously issued founder shares. Fifty percent of the previously issued founder shares vested on January&#160;4, 2018, and the remaining founder shares are subject to vesting restrictions over a period of five years. These shares are subject to repurchase by the Company upon a founder's termination of employment or service to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the employment agreements with the Company&#x2019;s founders executed January 4, 2018, the Company provided for certain potential additional issuances of common stock (the &#x201c;anti-dilution shares&#x201d;) to each of the founders to ensure the total number of shares of common stock held by them and their affiliates (inclusive of any shares subject to equity awards granted by the Company) would represent 15% of the Company&#x2019;s fully-diluted capitalization until such time as the Company raised $300.0 million in equity capital, including the capital raised in the Series&#160;A financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In furtherance of this obligation, on May 21, 2018, the Company issued 251,547 shares of common stock to the founders for services rendered to the Company, valued at $2.61 per share with an additional 251,547&#160;shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. In addition, on September 6, 2018, the Company issued 1,795,023 shares of common stock to the founders for services rendered to the Company, valued at $9.63 per share, with an additional 1,795,023 shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest. As such, the Company recognizes the measurement date fair value of the restricted stock over the vesting period as compensation expense. As of December&#160;31, 2024, there were no shares of common stock subject to repurchase by the Company. The unvested stock liability related to these awards is immaterial to all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Chiesi Equity Option&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 3, 2024, pursuant to the Chiesi Collaboration Agreement (as defined in Note 12 below) the Company granted to Chiesi (as defined in Note 12 below) an option to purchase directly from the Company, on one or more occasions, up to an aggregate number of shares of the Company&#x2019;s common stock (the "Equity Option") such that immediately following such issuance, Chiesi&#x2019;s beneficial ownership of the Company&#x2019;s common stock shall not exceed 9.9% of the total number of issued and outstanding shares of the Company&#x2019;s common stock. The Equity Option shall be exercisable by Chiesi, in whole or in part, at any time prior to the earliest to occur of the date on which (a) the last patient is last dosed in either (i) the PROSERA Phase 3 study for PAH or (ii) a Phase 3 clinical trial for the PH-ILD Indication, (b) any third party commences a tender offer or exchange offer for more than 50% of the outstanding shares of the Company&#x2019;s common stock, and (c) the Company publicly announces its intent to consummate a GB002, Inc. change of control. The purchase price of each share the Company&#x2019;s common stock subject to the Equity Option shall be equal to 107.5% of the daily volume-weighted average per share price of the Company&#x2019;s common stock on The Nasdaq Stock Market over the 30-trading day period ending on and including the last trading day prior to the date on which Chiesi delivers an exercise notice to the Company; provided that such purchase price shall be no less than $1.63 per share. The shares of the Company&#x2019;s common stock to be issued will be issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions by an issuer not involving any public offering, pursuant to the terms of a stock issuance agreement to be entered into between the Company and Chiesi in connection with each such exercise of the Equity Option. The Company evaluated the Equity Option granted to Chiesi as consideration payable to a customer and determined it qualified under ASC 718. Due to the market condition included in the Equity Option, the Company used the Geometric Brownian Motion/Monte Carlo model to determine fair market value. The value of the Equity Option is $0.5&#160;million, which is included in additional paid-in capital on the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <goss:CommonStockVotingRightsNumberOfVotesPerShare contextRef="c-1" decimals="INF" id="f-731" unitRef="vote">1</goss:CommonStockVotingRightsNumberOfVotesPerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-146"
      decimals="INF"
      id="f-732"
      unitRef="shares">9433963</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-147"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">13.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-146" decimals="-5" id="f-734" unitRef="usd">117100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-148"
      decimals="INF"
      id="f-735"
      unitRef="shares">16649365</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-149"
      decimals="2"
      id="f-736"
      unitRef="usdPerShare">7.21</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-148" decimals="-5" id="f-737" unitRef="usd">120100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-150" decimals="-5" id="f-738" unitRef="usd">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-151"
      decimals="INF"
      id="f-739"
      unitRef="shares">129869440</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-152"
      decimals="INF"
      id="f-740"
      unitRef="shares">32467360</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-153"
      decimals="5"
      id="f-741"
      unitRef="usdPerShare">1.63125</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-154"
      decimals="INF"
      id="f-742"
      unitRef="usdPerShare">1.85125</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-153"
      decimals="INF"
      id="f-743"
      unitRef="usdPerShare">2.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-153" id="f-744">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-155" decimals="-5" id="f-745" unitRef="usd">212100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-151" decimals="-5" id="f-746" unitRef="usd">10800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-156"
      decimals="INF"
      id="f-747"
      unitRef="shares">9160888</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-157"
      decimals="INF"
      id="f-748"
      unitRef="usdPerShare">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-156" decimals="0" id="f-749" unitRef="usd">4100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <goss:CommonStockVestingPercentage contextRef="c-158" decimals="2" id="f-750" unitRef="number">0.50</goss:CommonStockVestingPercentage>
    <goss:CommonStockVestingPeriod contextRef="c-159" id="f-751">P5Y</goss:CommonStockVestingPeriod>
    <goss:PercentageOfFullyDilutedShareCapital contextRef="c-160" decimals="2" id="f-752" unitRef="number">0.15</goss:PercentageOfFullyDilutedShareCapital>
    <goss:IncreasedInEquityCapitalAmount contextRef="c-160" decimals="-5" id="f-753" unitRef="usd">300000000.0</goss:IncreasedInEquityCapitalAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-161"
      decimals="INF"
      id="f-754"
      unitRef="shares">251547</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-162"
      decimals="2"
      id="f-755"
      unitRef="usdPerShare">2.61</us-gaap:SharesIssuedPricePerShare>
    <goss:IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting
      contextRef="c-161"
      decimals="INF"
      id="f-756"
      unitRef="shares">251547</goss:IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-163"
      decimals="INF"
      id="f-757"
      unitRef="shares">1795023</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-164"
      decimals="2"
      id="f-758"
      unitRef="usdPerShare">9.63</us-gaap:SharesIssuedPricePerShare>
    <goss:IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting
      contextRef="c-163"
      decimals="INF"
      id="f-759"
      unitRef="shares">1795023</goss:IncrementalCommonSharesAttributableToRestrictedStockSubjectToVesting>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares contextRef="c-5" decimals="INF" id="f-760" unitRef="shares">0</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage
      contextRef="c-165"
      decimals="INF"
      id="f-761"
      unitRef="number">0.099</goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPercentage>
    <goss:CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding
      contextRef="c-166"
      decimals="INF"
      id="f-762"
      unitRef="number">0.50</goss:CollaborationAgreementEquityOptionOwnedByCounterpartyTenderOfferOrExchangeOfferPercentageOfSharesOutstanding>
    <goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice
      contextRef="c-166"
      decimals="INF"
      id="f-763"
      unitRef="number">1.075</goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePricePercentageOfCommonStocksAveragePerSharePrice>
    <goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays contextRef="c-166" decimals="INF" id="f-764" unitRef="day">30</goss:CollaborationAgreementEquityOptionOwnedByCounterpartyPurchasePriceNumberOfTradingDays>
    <goss:CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice contextRef="c-166" decimals="2" id="f-765" unitRef="number">1.63</goss:CollaborationAgreementEquityOptionOwnedByCounterpartyMinimumPurchasePrice>
    <goss:ContractWithCustomerLiabilityFairValueOfEquityOption contextRef="c-166" decimals="-5" id="f-766" unitRef="usd">500000</goss:ContractWithCustomerLiabilityFairValueOfEquityOption>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-767">Equity Incentive Plans&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Equity Inducement Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company approved the 2023 Employment Inducement Incentive Plan (the "2023 Inducement Plan"). The terms of the 2023 Inducement Plan are substantially similar to the terms of the Company&#x2019;s 2019 Incentive Award Plan (as described below) with the exception that incentive stock options may not be issued under the 2023 Inducement Plan and awards under the 2023 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq rules. The 2023 Inducement Plan was adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under the 2023 Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors of the Company or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The Company has initially reserved 6,762,279 shares of the Company&#x2019;s common stock for issuance pursuant to awards granted under the 2023 Inducement Plan. As of December&#160;31, 2024, an aggregate of 4,152,779 shares of common stock were available for issuance under the 2023 Inducement Plan, and 2,609,500 shares of common stock were subject to outstanding awards under the 2023 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2019, the Company&#x2019;s board of directors and stockholders approved and adopted the 2019 Incentive Award Plan (the &#x201c;2019 Plan&#x201d;). The 2019 Plan became effective on February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock or cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#x2019;s subsidiaries. A total of 5,750,000 shares of common stock were approved to be initially reserved for issuance under the 2019 Plan. The number of shares that remained available for issuance under the 2017 Plan (as defined below) as of the effective date of the 2019 Plan were, and shares subject to outstanding awards under the 2017 Plan as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 5% of the outstanding number of shares of the Company&#x2019;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors. As of December&#160;31, 2024, an aggregate of 2,308,197 shares of common stock were available for issuance under the 2019 Plan and 29,747,623 shares of common stock were subject to outstanding awards under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2019, the Company&#x2019;s board of directors and stockholders approved and adopted the 2019 Employee Stock Purchase Plan (the "ESPP"). The ESPP became effective as of February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 700,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#x2019;s common stock on December&#160;31 of the preceding calendar year or such lesser amount as determined by the Company&#x2019;s board of directors. During the years ended December&#160;31, 2024 and 2023, 767,125 shares and 336,795 shares were issued pursuant to the ESPP, respectively. As of December&#160;31, 2024, an aggregate of 4,545,812 shares of common stock were available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) permitted the granting of incentive stock options, non-statutory stock options, restricted stock, restricted stock units and other stock-based awards. Subsequent to the adoption of the 2019 Plan, no additional equity awards can be made under the 2017 Plan. As of December&#160;31, 2024, 2,059,214 shares of common stock were subject to outstanding options under the 2017 Plan, and no shares of restricted stock awards granted under the 2017 Plan were unvested.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each employee and non-employee time-vested stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company uses its own volatility to the extent it has sufficient trading history, and for awards in which sufficient trading history is not available, a peer group is used to calculate the expected volatility. Due to the lack of historical exercise history, the expected term of the Company&#x2019;s stock options for employees has been determined utilizing the &#x201c;simplified&#x201d; method for awards. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S.&#160;Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2023, the Company granted to its Chairman and Chief Executive Officer 750,000 options with an exercise price of $1.36 per share. This grant contains both service and market based vesting conditions. The awards vest on the later of the date of achievement and the one-year anniversary of the grant date. The market condition becomes satisfied in 50%, 25% and 25% tranches upon achieving the average per-share closing price of the Company's common stock over any 30 consecutive calendar days following the grant date equal to or exceeding $5.00, $7.50 and $10.00, respectively. In the event a stock price tranche has not vested prior to the fourth anniversary of the grant date, any portion of the option attributable to such tranche will be forfeited. Due to the market condition included in this grant, the Company used the Geometric Brownian Motion/Monte Carlo model to value this award. The total stock-based compensation expense related to this award is $0.4&#160;million, which is included in general and administrative expense on the consolidated statements of operations and comprehensive loss. The Company expects to recognize this expense over a weighted average period of approximately 2.2 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective May 5, 2023, and in accordance with the terms of the 2019 Plan, the Company's board of directors approved a stock option repricing (the &#x201c;Option Repricing&#x201d;) whereby the exercise price of each Eligible Option (as defined below) was immediately reduced to $1.36 per share, the closing stock price on May 5, 2023. For purposes of the Option Repricing, &#x201c;Eligible Options&#x201d; are 6,817,057 outstanding stock options as of May 5, 2023 (vested or unvested) granted under the 2019 Plan prior to November 30, 2022 and held by those eligible employees of the Company identified by the Company's board of directors, including the Company&#x2019;s executive officers, except for the Company&#x2019;s Chairman and Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The participation of the executive officers of the Company in the Option Repricing was subject to their agreement to cancel a portion of their Eligible Options effective immediately (the &#x201c;Cancelled Options&#x201d;). Each executive was required to agree to cancel one-third of his or her Eligible Options, on a grant-by-grant basis. The Cancelled Options were deducted proportionately from the vested and unvested portions of each Repriced Option grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent an Eligible Option is exercised prior to the Premium End Date (as defined below), or the eligible employee&#x2019;s employment terminates prior to the Premium End Date, the eligible employee will be required to pay the original exercise price per share of the Eligible Options in connection with any exercise of the Eligible Option. The &#x201c;Premium End Date&#x201d; means the earliest of (i) May 5, 2024, (ii) the date of a change in control, (iii) the eligible employee&#x2019;s death or disability, or (iv) if an eligible employee is an executive subject to the cancellation of a portion of Eligible Options and is terminated under circumstances giving rise to severance under his or her employment agreement, the date of such termination. Except for the reduction in the exercise prices of the Eligible Options as described above, the Eligible Options will retain their existing terms and conditions as set forth in the 2019 Plan and the applicable award agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The repricing resulted in $3.4&#160;million of incremental cost, which was calculated using the Black-Scholes option-pricing model, of which $2.0&#160;million of the incremental cost was recognized immediately, and $1.4&#160;million of the incremental cost will be recognized on the straight-line basis over the remaining vesting period of the repriced options. The incremental cost is included in general and administrative expense and research and development expense on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to estimate the fair value of stock option awards granted to employees under the Company&#x2019;s equity incentive plans and the shares purchasable under the ESPP during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.195%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.59% - 4.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.36% - 4.73%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.31% - 4.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100.72% - 104.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.01% - 170.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.10% - 89.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.88% -5.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.87% - 5.47%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.60% - 3.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83.96% - 151.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115.19% - 216.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.98% - 121.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&#160;Subject&#160;to&lt;br/&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:41pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,434,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,271,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(270,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(948,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,487,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,159,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,020,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,626,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,006,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,216,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,416,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,416,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,126,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value per share for the stock options granted during the year ended December&#160;31, 2024, 2023 and 2022 was $0.78, $3.88 and $4.77, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate fair value of stock options that vested during the years ended December&#160;31, 2024, 2023 and 2022 was $15.7 million, $22.7 million and $20.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value in the above table is calculated as the difference between fair value of the Company&#x2019;s common stock price and the exercise price of the stock options. There were no options exercised during the years ended December&#160;31, 2024 and 2023. The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2022 was $1.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 24, 2023, the Company completed a private placement of 129,869,440 shares of the Company&#x2019;s common stock and accompanying warrants to purchase up to 32,467,360 shares of the Company's common stock at a combined purchase price of $1.63125 per share and accompanying warrant, or with respect to any purchaser that was an officer, director, employee or consultant of the Company, $1.85125 per share and accompanying warrant. Each warrant has an exercise price per share of $2.04, was immediately exercisable on the date of issuance and will expire five years from the closing of the private placement. Given that the warrants are indexed to the Company's shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company's consolidated balance sheets. As of December&#160;31, 2024, there were 32,467,360 warrants outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The summary of the Company&#x2019;s restricted stock activity during the years ended December&#160;31, 2024, 2023 and 2022 is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Restricted&lt;br/&gt;Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,561,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;572,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,592,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(191,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,350,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(779,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(142,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(427,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there was no unrecognized stock-based compensation expense related to the unvested restricted stock awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense has been reported in the Company&#x2019;s consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, the total unrecognized compensation related to unvested stock option awards granted was $14.0 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, total unrecognized compensation expense related to the ESPP was $0.8 million, which the Company expects to recognize over a weighted-average period of approximately 0.8 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-167"
      decimals="INF"
      id="f-768"
      unitRef="shares">6762279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-168"
      decimals="INF"
      id="f-769"
      unitRef="shares">4152779</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <goss:SharesReservedForIssuanceOnGrantingOfOutstandingAwards
      contextRef="c-168"
      decimals="INF"
      id="f-770"
      unitRef="shares">2609500</goss:SharesReservedForIssuanceOnGrantingOfOutstandingAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c-169" decimals="0" id="f-771" unitRef="shares">5750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-170" id="f-772">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-170" decimals="2" id="f-773" unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-171" decimals="0" id="f-774" unitRef="shares">2308197</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-171" decimals="0" id="f-775" unitRef="shares">29747623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-172" decimals="2" id="f-776" unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c-173" decimals="0" id="f-777" unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-174" id="f-778">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-174" decimals="2" id="f-779" unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued contextRef="c-175" decimals="0" id="f-780" unitRef="shares">767125</goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued>
    <goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued contextRef="c-176" decimals="0" id="f-781" unitRef="shares">336795</goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-177" decimals="0" id="f-782" unitRef="shares">4545812</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-178" decimals="0" id="f-783" unitRef="shares">2059214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c-179" decimals="0" id="f-784" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-180" decimals="0" id="f-785" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-181"
      decimals="INF"
      id="f-786"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-181"
      decimals="INF"
      id="f-787"
      unitRef="usdPerShare">1.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-182" id="f-788">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-183"
      decimals="INF"
      id="f-789"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-184"
      decimals="INF"
      id="f-790"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-185"
      decimals="INF"
      id="f-791"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays contextRef="c-182" id="f-792">P30D</goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdConsecutiveDays>
    <goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice
      contextRef="c-183"
      decimals="2"
      id="f-793"
      unitRef="usdPerShare">5.00</goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice>
    <goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice
      contextRef="c-184"
      decimals="2"
      id="f-794"
      unitRef="usdPerShare">7.50</goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice>
    <goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice
      contextRef="c-185"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">10.00</goss:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsThresholdSharePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-182" decimals="-5" id="f-796" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-182" id="f-797">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-186"
      decimals="INF"
      id="f-798"
      unitRef="usdPerShare">1.36</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-186"
      decimals="INF"
      id="f-799"
      unitRef="shares">6817057</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-181" decimals="-5" id="f-800" unitRef="usd">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-181" decimals="-5" id="f-801" unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-186" decimals="-5" id="f-802" unitRef="usd">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c-1" id="f-803">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to estimate the fair value of stock option awards granted to employees under the Company&#x2019;s equity incentive plans and the shares purchasable under the ESPP during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.195%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.59% - 4.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.36% - 4.73%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.31% - 4.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100.72% - 104.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.01% - 170.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.10% - 89.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.88% -5.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.87% - 5.47%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.60% - 3.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83.96% - 151.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115.19% - 216.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.98% - 121.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-187" id="f-804">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-188" id="f-805">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-189" id="f-806">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-190" id="f-807">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-191" id="f-808">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-192" id="f-809">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-180" decimals="4" id="f-810" unitRef="number">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-180" decimals="4" id="f-811" unitRef="number">0.0450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-193" decimals="4" id="f-812" unitRef="number">0.0336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-193" decimals="4" id="f-813" unitRef="number">0.0473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-194" decimals="4" id="f-814" unitRef="number">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-194" decimals="4" id="f-815" unitRef="number">0.0435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-180" decimals="4" id="f-816" unitRef="number">1.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-180" decimals="4" id="f-817" unitRef="number">1.0451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-193" decimals="4" id="f-818" unitRef="number">0.7001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-193" decimals="4" id="f-819" unitRef="number">1.7069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-194" decimals="4" id="f-820" unitRef="number">0.7110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-194" decimals="4" id="f-821" unitRef="number">0.8987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-180"
      decimals="INF"
      id="f-822"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-193"
      decimals="INF"
      id="f-823"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-194"
      decimals="INF"
      id="f-824"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-195" id="f-825">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-196" id="f-826">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-197" id="f-827">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-198" id="f-828">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-199" id="f-829">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-200" id="f-830">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-201" decimals="4" id="f-831" unitRef="number">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-201" decimals="4" id="f-832" unitRef="number">0.0527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-202" decimals="4" id="f-833" unitRef="number">0.0487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-202" decimals="4" id="f-834" unitRef="number">0.0547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-203" decimals="4" id="f-835" unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-203" decimals="4" id="f-836" unitRef="number">0.0351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-201" decimals="4" id="f-837" unitRef="number">0.8396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-201" decimals="4" id="f-838" unitRef="number">1.5154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-202" decimals="4" id="f-839" unitRef="number">1.1519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-202" decimals="4" id="f-840" unitRef="number">2.1645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-203" decimals="4" id="f-841" unitRef="number">0.6498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-203" decimals="4" id="f-842" unitRef="number">1.2143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-201"
      decimals="INF"
      id="f-843"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-202"
      decimals="INF"
      id="f-844"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-203"
      decimals="INF"
      id="f-845"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-846">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&#160;Subject&#160;to&lt;br/&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:41pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,434,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,271,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(270,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(948,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,487,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,159,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,020,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,626,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,006,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,216,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,416,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,416,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,126,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-19" decimals="0" id="f-847" unitRef="shares">9434660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-19"
      decimals="2"
      id="f-848"
      unitRef="usdPerShare">12.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-20" id="f-849">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-19" decimals="-3" id="f-850" unitRef="usd">15822000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-14" decimals="0" id="f-851" unitRef="shares">9271272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-14"
      decimals="2"
      id="f-852"
      unitRef="usdPerShare">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-14" decimals="0" id="f-853" unitRef="shares">270707</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-14"
      decimals="2"
      id="f-854"
      unitRef="usdPerShare">6.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-14" decimals="0" id="f-855" unitRef="shares">948060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-14"
      decimals="2"
      id="f-856"
      unitRef="usdPerShare">15.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-32" decimals="0" id="f-857" unitRef="shares">17487165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-32"
      decimals="2"
      id="f-858"
      unitRef="usdPerShare">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-14" id="f-859">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-32" decimals="-3" id="f-860" unitRef="usd">47000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-13" decimals="0" id="f-861" unitRef="shares">17159617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-13" decimals="0" id="f-863" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-864"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-13" decimals="0" id="f-865" unitRef="shares">11020667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-866"
      unitRef="usdPerShare">11.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="0" id="f-867" unitRef="shares">23626115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-868"
      unitRef="usdPerShare">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-13" id="f-869">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-870" unitRef="usd">369000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="0" id="f-871" unitRef="shares">13006228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-872"
      unitRef="usdPerShare">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="0" id="f-873" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-874"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="0" id="f-875" unitRef="shares">2216006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-876"
      unitRef="usdPerShare">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="0" id="f-877" unitRef="shares">34416337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-878"
      unitRef="usdPerShare">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-879">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-880" unitRef="usd">598000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-5" decimals="0" id="f-881" unitRef="shares">34416337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-882"
      unitRef="usdPerShare">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-883">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-884" unitRef="usd">598000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-5" decimals="0" id="f-885" unitRef="shares">14126062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-886"
      unitRef="usdPerShare">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-887">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-888" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c-180"
      decimals="2"
      id="f-889"
      unitRef="usdPerShare">0.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c-193"
      decimals="2"
      id="f-890"
      unitRef="usdPerShare">3.88</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c-194"
      decimals="2"
      id="f-891"
      unitRef="usdPerShare">4.77</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-180" decimals="-5" id="f-892" unitRef="usd">15700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-193" decimals="-5" id="f-893" unitRef="usd">22700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-194" decimals="-5" id="f-894" unitRef="usd">20700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-180" decimals="-5" id="f-895" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-193" decimals="-5" id="f-896" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-194" decimals="-5" id="f-897" unitRef="usd">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-151"
      decimals="INF"
      id="f-898"
      unitRef="shares">129869440</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-152"
      decimals="INF"
      id="f-899"
      unitRef="shares">32467360</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-153"
      decimals="INF"
      id="f-900"
      unitRef="usdPerShare">1.63125</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-154"
      decimals="INF"
      id="f-901"
      unitRef="usdPerShare">1.85125</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-153"
      decimals="INF"
      id="f-902"
      unitRef="usdPerShare">2.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-204" id="f-903">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-5" decimals="INF" id="f-904" unitRef="shares">32467360</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-905">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The summary of the Company&#x2019;s restricted stock activity during the years ended December&#160;31, 2024, 2023 and 2022 is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Restricted&lt;br/&gt;Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,561,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;572,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,592,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(191,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,350,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(779,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(142,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(427,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-205" decimals="0" id="f-906" unitRef="shares">2561219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-205"
      decimals="2"
      id="f-907"
      unitRef="usdPerShare">8.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-206" decimals="0" id="f-908" unitRef="shares">572901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-206"
      decimals="2"
      id="f-909"
      unitRef="usdPerShare">11.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-206" decimals="0" id="f-910" unitRef="shares">1592588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-206"
      decimals="2"
      id="f-911"
      unitRef="usdPerShare">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-206" decimals="0" id="f-912" unitRef="shares">191497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-206"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-207" decimals="0" id="f-914" unitRef="shares">1350035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-207"
      decimals="2"
      id="f-915"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-208" decimals="0" id="f-916" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-208"
      decimals="2"
      id="f-917"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-208" decimals="0" id="f-918" unitRef="shares">779900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-208"
      decimals="2"
      id="f-919"
      unitRef="usdPerShare">10.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-208" decimals="0" id="f-920" unitRef="shares">142437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-208"
      decimals="2"
      id="f-921"
      unitRef="usdPerShare">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-209" decimals="0" id="f-922" unitRef="shares">427698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-209"
      decimals="2"
      id="f-923"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-210" decimals="0" id="f-924" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-210"
      decimals="2"
      id="f-925"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-210" decimals="0" id="f-926" unitRef="shares">427698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-210"
      decimals="2"
      id="f-927"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-210" decimals="0" id="f-928" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-210"
      decimals="2"
      id="f-929"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-211" decimals="0" id="f-930" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-211"
      decimals="2"
      id="f-931"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-211" decimals="-5" id="f-932" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-933">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense has been reported in the Company&#x2019;s consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-3" id="f-934" unitRef="usd">10172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-3" id="f-935" unitRef="usd">15871000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-214" decimals="-3" id="f-936" unitRef="usd">24415000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-215" decimals="-3" id="f-937" unitRef="usd">10447000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-216" decimals="-3" id="f-938" unitRef="usd">12647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-217" decimals="-3" id="f-939" unitRef="usd">18138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-940" unitRef="usd">20619000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-941" unitRef="usd">28518000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-942" unitRef="usd">42553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-218" decimals="-5" id="f-943" unitRef="usd">14000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-180" id="f-944">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-177" decimals="-5" id="f-945" unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-175" id="f-946">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-948">Property and Equipment, Net&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 was approximately $0.8 million, $1.6 million and $1.8 million, respectively, and was recorded in general and administrative expense and research and development expense, respectively, on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-949">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-219" id="f-950">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-220" id="f-951">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-221" decimals="-3" id="f-952" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-222" decimals="-3" id="f-953" unitRef="usd">1097000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-223" id="f-954">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-223" decimals="-3" id="f-955" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-224" decimals="-3" id="f-956" unitRef="usd">123000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-225" id="f-957">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-225" decimals="-3" id="f-958" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-226" decimals="-3" id="f-959" unitRef="usd">52000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-227" id="f-960">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-228" id="f-961">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-229" decimals="-3" id="f-962" unitRef="usd">193000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-230" decimals="-3" id="f-963" unitRef="usd">3246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-231" id="f-964">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-232" id="f-965">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-233" decimals="-3" id="f-966" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-234" decimals="-3" id="f-967" unitRef="usd">2562000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-968" unitRef="usd">193000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-969" unitRef="usd">7080000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-970" unitRef="usd">183000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-971" unitRef="usd">5432000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-972" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-973" unitRef="usd">1648000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-974" unitRef="usd">800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-975" unitRef="usd">1600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-976" unitRef="usd">1800000</us-gaap:Depreciation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-977">Commitments and Contingencies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously leased certain office and laboratory space under a non-cancelable operating lease which expired in January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 9, 2024, the Company entered into a lease agreement for office space located at 3115 Merryfield Row, Suite 120, San Diego, CA 92121, consisting of approximately 18,421 square feet. The term of the lease is 63 months commencing on August 1, 2024. The base rent is $109,605 per month effective October 1, 2024, and it is subject to a 3% annual increase every October. The lease expires on October 31, 2029 with an option for a &lt;span style="-sec-ix-hidden:f-982"&gt;one&lt;/span&gt;-year extension and an option to terminate on December 1, 2027 with the payment of a termination fee equal to four months of the then-current base rent upon the termination date. As of December 31, 2024, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monthly rent expense is recognized on a straight-line basis over the term of the leases. The operating leases are included in the consolidated balance sheets at the present value of the lease payments at an incremental borrowing rate of 7% for each of the initial leased space and expansion space expiring in January 2025 and 12.4% for the office lease commenced on August 1, 2024 using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the leases do not provide an implicit rate. As of December&#160;31, 2024, the weighted average remaining lease term was 4.7 years, and weighted-average discount rate was 12.4%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs were comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities as of December&#160;31, 2024 and 2023 was $3.8 million and $3.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross future minimum annual rental commitments as of December&#160;31, 2024, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted&#160;Rent&lt;br/&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted rent payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <goss:LeaseeOperatingLeaseLeasedArea contextRef="c-235" decimals="INF" id="f-978" unitRef="sqft">18421</goss:LeaseeOperatingLeaseLeasedArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-235" id="f-979">P63M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <goss:LesseeOperatingLeaseBaseRent contextRef="c-236" decimals="-3" id="f-980" unitRef="usd">109605000</goss:LesseeOperatingLeaseBaseRent>
    <goss:LesseeOperatingLeaseBaseRentAnnualIncreasePercentage
      contextRef="c-236"
      decimals="INF"
      id="f-981"
      unitRef="number">0.03</goss:LesseeOperatingLeaseBaseRentAnnualIncreasePercentage>
    <goss:LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent
      contextRef="c-237"
      decimals="INF"
      id="f-983"
      unitRef="month">4</goss:LesseeOperatingLeaseTerminationFeeNumberOfMonthsOfBaseRent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-238" decimals="2" id="f-984" unitRef="number">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-239" decimals="3" id="f-985" unitRef="number">0.124</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-986">P4Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-987" unitRef="number">0.124</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-988">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs were comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-989" unitRef="usd">3706000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-3" id="f-990" unitRef="usd">3114000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-3" id="f-991" unitRef="usd">3097000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-992" unitRef="usd">48000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-13" decimals="-3" id="f-993" unitRef="usd">52000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-14" decimals="-3" id="f-994" unitRef="usd">45000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-995" unitRef="usd">3754000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-13" decimals="-3" id="f-996" unitRef="usd">3166000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-14" decimals="-3" id="f-997" unitRef="usd">3142000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-998" unitRef="usd">3800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-5" id="f-999" unitRef="usd">3300000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1000">&lt;div style="margin-top:10pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross future minimum annual rental commitments as of December&#160;31, 2024, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted&#160;Rent&lt;br/&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted rent payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-1001" unitRef="usd">1550000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-1002" unitRef="usd">1417000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-1003" unitRef="usd">1406000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-1004" unitRef="usd">1448000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-1005" unitRef="usd">1237000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-1006" unitRef="usd">7058000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-1007" unitRef="usd">1699000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-1008" unitRef="usd">5359000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1009" unitRef="usd">961000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1010" unitRef="usd">4398000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-1011" unitRef="usd">5359000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-1012">Significant Agreements and Contracts&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 3, 2024, the Company, GB002, Inc., a Delaware corporation and wholly-owned subsidiary of the Company and Gossamer Bio 002 Ltd., a corporation organized and existing under the laws of Ireland and indirect wholly-owned subsidiary of the Company, entered into a global collaboration and license agreement (the &#x201c;Chiesi Collaboration Agreement&#x201d;) with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, &#x201c;Chiesi&#x201d;). The Company concluded that there were four distinct performance obligations under the Chiesi Collaboration Agreement: the U.S. Territory license (as defined below), the ROW Territory license (as defined below), and the research and development services of both PAH and PH-ILD clinical development. Revenue associated with the licenses was recognized upon delivery in May 2024. In addition, the Company granted to Chiesi an option to purchase the Equity Option, as described in Note 8, "Stockholders Equity."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds (&#x201c;Licensed Products&#x201d;) in the U.S. (&#x201c;U.S. Territory&#x201d;) and the rest of the world (&#x201c;ROW Territory&#x201d;), for therapeutic, prophylactic and diagnostic uses in humans and animals, for the treatment of PAH and PH-ILD and other indications, as may be permitted under the Chiesi Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Chiesi Collaboration Agreement, the Company granted two exclusive, sublicensable (with the Company&#x2019;s consent required in the U.S. Territory for third party sublicenses) licenses to Chiesi under intellectual property rights controlled by the Company relating to seralutinib and Licensed Products, for the worldwide development, manufacture and commercialization of seralutinib and Licensed Products. The licenses granted to Chiesi are subject to retained rights of the Company for the worldwide development and manufacture of seralutinib and Licensed Products, commercialization of Licensed Products in the U.S. Territory, and performance of its obligations and exercise of its rights that may be set forth in the global development plan and US commercialization plan, in each case in accordance with the Chiesi Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The parties agreed to use commercially reasonable efforts to conduct development and commercialization activities in relation to seralutinib and Licensed Products, under the global development plan and US commercialization plan in accordance with the timelines therein. The Company will continue to lead global development of seralutinib in PAH and PH-ILD, and the parties will equally share the costs for the activities included in the global development plan for all Licensed Products, with the exception of the PROSERA Phase 3 study, which the Company will be solely responsible for conducting at the Company&#x2019;s own cost and expense. With respect to each country in the ROW Territory, such obligation to equally share such development costs shall end when regulatory approval is received for a Licensed Product in such country. With respect to U.S. Territory, the development costs incurred following regulatory approval shall continue to be shared equally. The Company will lead potential commercialization for PAH and PH-ILD in the US, with both parties contributing 50 percent of commercial efforts, including performing 50 percent of the commercialization activities. Chiesi will lead potential commercialization in the US Territory in any additional indications, and Chiesi will have the exclusive right to commercialize Licensed Products in the ROW Territory. Chiesi further agreed to use commercially reasonable efforts to commercialize Licensed Products in certain specified countries in the ROW Territory following receipt of regulatory approvals. Generally, the Company will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products for the U.S. Territory for PAH and PH-ILD, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and, subject to any existing obligations of the Company to third party manufacturers, Chiesi will have the right to lead in manufacturing commercial supply of seralutinib and Licensed Products in the ROW Territory, in each case in accordance with the Chiesi Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Chiesi Collaboration Agreement, neither party nor its affiliates is permitted to develop or commercialize any compound or product throughout the term whose primary mechanism of action is inhibition of a tyrosine kinase for the treatment of PAH or PH-ILD in the U.S. Territory or ROW Territory, subject to certain restrictions for the EU and UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration and as reimbursement for the Company&#x2019;s development costs, Chiesi agreed to pay the Company an up-front, nonrefundable payment of $160&#160;million. Additionally, the Company will be eligible to receive up to $146&#160;million in regulatory milestones and $180&#160;million in sales milestones. In the U.S. Territory, the parties agreed to share commercial profits and losses equally. In the ROW Territory, Chiesi will pay the Company an escalating mid-to-high teens percentage royalty on net sales of Licensed Product for PAH and additional indications on a Licensed Product-by-Licensed Product and country-by-country basis with such payment obligations beginning on the first commercial sale of Licensed Product in such country and expiring on a country-by-country basis on the latest of (a) the expiration of a valid claim to a the Company patent right in such country, (b) the expiration of regulatory exclusivity, and (c) the date that is 10 years after the first commercial sale of such Licensed Product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as regulatory and commercial milestones, development costs, and profit sharing U.S. Territory will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the Chiesi Collaboration Agreement will remain in force until no Licensed Products are being developed or commercialized in the US Territory and in the ROW Territory, on a country-by-country basis, until no royalty terms are in effect for all countries. Either party may terminate the Chiesi Collaboration Agreement for the other party&#x2019;s material breach, subject to a specified notice and cure periods, or due to an insolvency event of the other party. In lieu of termination upon a party&#x2019;s material breach due to non-payment of development costs within a specified time the non-breaching party may elect an alternative remedy which may involve modifications to their performance and payment obligations. The Company has the right to terminate by providing written notice in the event Chiesi or its affiliates or sublicensee brings a patent challenge and Chiesi does not take certain steps to withdraw from or cease supporting such challenge. Chiesi may terminate the Chiesi Collaboration Agreement without cause upon prior written notice to the Company, subject to a notice period in which all rights to Licensed Products and Licensed Compounds will revert back to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that progress towards completion of the research and development services performance obligation related to the Chiesi Collaboration Agreement is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#x2019;s estimates have no impact on the Company&#x2019;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. The transaction price to be recognized as revenue from sale of licenses and revenue from contracts with collaborators under the Chiesi Collaboration Agreement consists of the one-time non-refundable and non-creditable development cost reimbursement payment and research and development costs. The transaction price was reduced by the fair value of the Equity Option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the transaction price pursuant to the Chiesi Collaboration Agreement is equal to the one-time development cost reimbursement payment of $160.0&#160;million less the fair market value of the Equity Option of $0.5&#160;million. The price allocated for the Equity Option was determined to be at fair market value utilizing the Geometric Brownian Motion/Monte Carlo model and was considered a reduction in the transaction price. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each distinct performance obligation. In estimating the stand-alone selling price for each distinct performance obligation, the Company developed assumptions that require judgment and included forecasted revenues or costs, expected development timelines, discount rates and probabilities of technical and regulatory success. A description of the distinct performance obligations identified under the Chiesi Collaboration Agreement, as well as the amount of revenue allocated to each distinct significant performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The licenses to the Company&#x2019;s intellectual properties, bundled with the associated know-how, represents two distinct performance obligations. The licenses and associated know-how were transferred to Chiesi in June 2024, therefore the Company recognized the full revenue related to these distinct performance obligations in the amount of $90.7&#160;million during the year ended December 31, 2024 as revenue from sale of licenses on its consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The progress towards completion of the two distinct performance obligations related to PAH and PH-ILD research and development services for the Licensed Products is measured in an amount proportional to the research and development expenses incurred and the total estimated PAH and PH-ILD research and development expenses. In addition, the Company and Chiesi share equally in the costs of ongoing global seralutinib clinical development, with the exception of the PROSERA Phase 3 study, and the costs of commercialization in the US. The Company records the revenue from performing research and development services and the cost-sharing payments due from Chiesi as revenue from contracts with collaborators on its consolidated statements of operations and comprehensive loss. For the year ended December&#160;31, 2024, the Company recognized $24.1 million for the PAH and PH-ILD research and development performance obligations and commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company determined that as of December&#160;31, 2024, it is not probable that a significant revenue reversal will not occur related to the potential milestone payments as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the sales and usage based royalty exception. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. No milestone payments were recognized during the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As the licenses are deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's contract liabilities related to the Chiesi Collaboration Agreement (recorded as contract liabilities on the balance sheet) during the year ended December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from sale of US license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(78,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from sale of ROW license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH research and development service performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD research and development service performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the contract liability amount of $55.9 million represents the aggregate transaction price allocated to performance obligations that are unsatisfied under the Chiesi Collaboration Agreement. This amount is expected to be recognized over 4.0 years, which represents the remaining research period under the Chiesi Collaboration Agreement. As of December&#160;31, 2024, the current contract liability balance of $17.1 million is classified as a current liability since the rights to the research and development service are expected to be satisfied within one year, and the remaining contract liability balance of $38.9 million is classified as a long-term liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company recorded $5.3 million in accounts receivable associated with the Chiesi Collaboration Agreement. The payments are typically due 30 days after quarterly invoices are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our contract revenues from Chiesi Collaboration Agreement disaggregated by timing of revenue recognition and excluding royalty revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from Chiesi Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US License&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH research and development service performance obligation satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD research and development service performance obligation satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH research and development costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD research and development costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH commercial costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD commercial costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rate changes on revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue from Chiesi Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <goss:NumberOfDistinctPerformanceObligations
      contextRef="c-166"
      decimals="INF"
      id="f-1013"
      unitRef="performanceobligation">4</goss:NumberOfDistinctPerformanceObligations>
    <goss:NumberOfLicensesGranted
      contextRef="c-166"
      decimals="INF"
      id="f-1014"
      unitRef="license">2</goss:NumberOfLicensesGranted>
    <goss:RevenuePerformanceObligationCommercialEffortsContributionPercentage
      contextRef="c-166"
      decimals="INF"
      id="f-1015"
      unitRef="number">0.50</goss:RevenuePerformanceObligationCommercialEffortsContributionPercentage>
    <goss:RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage
      contextRef="c-166"
      decimals="INF"
      id="f-1016"
      unitRef="number">0.50</goss:RevenuePerformanceObligationCommercializationActivitiesPerformancePercentage>
    <goss:RevenuePerformanceObligationUpfrontNonrefundableAmountReceived contextRef="c-166" decimals="-6" id="f-1017" unitRef="usd">160000000</goss:RevenuePerformanceObligationUpfrontNonrefundableAmountReceived>
    <goss:RevenuePerformanceObligationRegulatoryMilestonesAmount contextRef="c-165" decimals="-6" id="f-1018" unitRef="usd">146000000</goss:RevenuePerformanceObligationRegulatoryMilestonesAmount>
    <goss:RevenuePerformanceObligationSalesMilestonesAmount contextRef="c-165" decimals="-6" id="f-1019" unitRef="usd">180000000</goss:RevenuePerformanceObligationSalesMilestonesAmount>
    <goss:RevenueLoyaltyReceivableExpirationPeriod contextRef="c-240" id="f-1020">P10Y</goss:RevenueLoyaltyReceivableExpirationPeriod>
    <goss:ContractWithCustomerLiabilityDevelopmentCost contextRef="c-166" decimals="-5" id="f-1021" unitRef="usd">160000000</goss:ContractWithCustomerLiabilityDevelopmentCost>
    <goss:ContractWithCustomerLiabilityFairValueOfEquityOption contextRef="c-166" decimals="-5" id="f-1022" unitRef="usd">500000</goss:ContractWithCustomerLiabilityFairValueOfEquityOption>
    <goss:NumberOfDistinctPerformanceObligations
      contextRef="c-241"
      decimals="INF"
      id="f-1023"
      unitRef="performanceobligation">2</goss:NumberOfDistinctPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-242" decimals="-5" id="f-1024" unitRef="usd">90700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <goss:NumberOfDistinctPerformanceObligations
      contextRef="c-243"
      decimals="INF"
      id="f-1025"
      unitRef="performanceobligation">2</goss:NumberOfDistinctPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-244" decimals="-5" id="f-1026" unitRef="usd">24100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-1027">&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's contract liabilities related to the Chiesi Collaboration Agreement (recorded as contract liabilities on the balance sheet) during the year ended December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from sale of US license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(78,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from sale of ROW license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH research and development service performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD research and development service performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-245" decimals="-3" id="f-1028" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <goss:ContractWithCustomerLiabilityUpfrontPaymentReceived contextRef="c-246" decimals="-3" id="f-1029" unitRef="usd">159536000</goss:ContractWithCustomerLiabilityUpfrontPaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-247" decimals="-3" id="f-1030" unitRef="usd">78947000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-248" decimals="-3" id="f-1031" unitRef="usd">11721000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-249" decimals="-3" id="f-1032" unitRef="usd">9555000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-250" decimals="-3" id="f-1033" unitRef="usd">1291000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <goss:ContractWithCustomerLiabilityEffectOfChangeInExchangeRate contextRef="c-246" decimals="-3" id="f-1034" unitRef="usd">2103000</goss:ContractWithCustomerLiabilityEffectOfChangeInExchangeRate>
    <us-gaap:ContractWithCustomerLiability contextRef="c-251" decimals="-3" id="f-1035" unitRef="usd">55919000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-251" decimals="-5" id="f-1036" unitRef="usd">55900000</us-gaap:ContractWithCustomerLiability>
    <goss:ContractWithCustomerRevenueRecognitionPeriod contextRef="c-251" id="f-1037">P4Y</goss:ContractWithCustomerRevenueRecognitionPeriod>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-5" id="f-1038" unitRef="usd">17100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-5" id="f-1039" unitRef="usd">38900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-251" decimals="-5" id="f-1040" unitRef="usd">5300000</us-gaap:AccountsReceivableNetCurrent>
    <goss:AccountReceivablePaymentTerm contextRef="c-246" id="f-1041">P30D</goss:AccountReceivablePaymentTerm>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-1042">&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our contract revenues from Chiesi Collaboration Agreement disaggregated by timing of revenue recognition and excluding royalty revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from Chiesi Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US License&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH research and development service performance obligation satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD research and development service performance obligation satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH research and development costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD research and development costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PAH commercial costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from PH-ILD commercial costs subject to reimbursement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rate changes on revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue from Chiesi Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-252" decimals="-3" id="f-1043" unitRef="usd">78947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-253" decimals="-3" id="f-1044" unitRef="usd">11721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-254" decimals="-3" id="f-1045" unitRef="usd">9555000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-255" decimals="-3" id="f-1046" unitRef="usd">1291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-256" decimals="-3" id="f-1047" unitRef="usd">10246000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-257" decimals="-3" id="f-1048" unitRef="usd">2380000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-258" decimals="-3" id="f-1049" unitRef="usd">538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-259" decimals="-3" id="f-1050" unitRef="usd">116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-260" decimals="-3" id="f-1051" unitRef="usd">-93000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-246" decimals="-3" id="f-1052" unitRef="usd">114701000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1053">Segment Information&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the CODM in making decisions regarding the allocation of resources and assessing performance. The Company's CODM is its chief executive officer. The Company views its operations and manages its business as one operating segment. The Company's operating segment derives its revenues from its collaboration agreement with Chiesi and is wholly attributable to the United States. The CODM assesses performance for the Company's single operating segment and decides how to allocate resources based on research and development expenses incurred, which is a component of the Company's consolidated net loss as reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Further, segment depreciation expense and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. The CODM uses research and development expenses and results of clinical trial activities completed to date to evaluate how to allocate the Company's resources to advance seralutinib.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Seralutinib&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(179,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(229,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other segment items include R&amp;amp;D expenses for other terminated programs. These costs include employee expenses, as well as allocations of consolidated overhead and stock compensation. Further, general and administrative expenses are also provided to the CODM regularly, but are included within other segment items as they are not utilized as part of the decision making process as it relates to the allocation of resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1054"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1055">&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Seralutinib&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(179,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(229,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other segment items include R&amp;amp;D expenses for other terminated programs. These costs include employee expenses, as well as allocations of consolidated overhead and stock compensation. Further, general and administrative expenses are also provided to the CODM regularly, but are included within other segment items as they are not utilized as part of the decision making process as it relates to the allocation of resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-261" decimals="-3" id="f-1056" unitRef="usd">114701000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-262" decimals="-3" id="f-1057" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-263" decimals="-3" id="f-1058" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-261" decimals="-3" id="f-1059" unitRef="usd">129247000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-262" decimals="-3" id="f-1060" unitRef="usd">103158000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-263" decimals="-3" id="f-1061" unitRef="usd">63048000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-261" decimals="-3" id="f-1062" unitRef="usd">45373000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-262" decimals="-3" id="f-1063" unitRef="usd">80601000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-263" decimals="-3" id="f-1064" unitRef="usd">155545000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:InvestmentIncomeInterest contextRef="c-261" decimals="-3" id="f-1065" unitRef="usd">1779000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-262" decimals="-3" id="f-1066" unitRef="usd">1997000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-263" decimals="-3" id="f-1067" unitRef="usd">1583000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-261" decimals="-3" id="f-1068" unitRef="usd">11517000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-262" decimals="-3" id="f-1069" unitRef="usd">13511000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-263" decimals="-3" id="f-1070" unitRef="usd">13880000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-261" decimals="-3" id="f-1071" unitRef="usd">14022000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-262" decimals="-3" id="f-1072" unitRef="usd">15456000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-263" decimals="-3" id="f-1073" unitRef="usd">1512000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-261" decimals="-3" id="f-1074" unitRef="usd">893000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-262" decimals="-3" id="f-1075" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-263" decimals="-3" id="f-1076" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-261" decimals="-3" id="f-1077" unitRef="usd">-56528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-262" decimals="-3" id="f-1078" unitRef="usd">-179817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-263" decimals="-3" id="f-1079" unitRef="usd">-229378000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1080">&lt;div style="margin-top:11pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Subsequent events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated all subsequent events and transactions through the filing date. There were no material events that impacted the audited consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
